{
  "entities": [
    {
      "entity_id": "ent:4900f32b9fab",
      "entity_type": "PROTEIN",
      "name": "MAOA",
      "normalized_id": "N/A",
      "aliases": [
        "MAOA"
      ],
      "description": "MAOA is described as the enzyme that mediates dopamine degradation, challenging the traditional belief that MAOB performs this function."
    },
    {
      "entity_id": "ent:b3040f3e67f7",
      "entity_type": "PROTEIN",
      "name": "MAOB",
      "normalized_id": "N/A",
      "aliases": [
        "MAOB",
        "Monoamine oxidase B",
        "Monoamine oxidase-B"
      ],
      "description": "Monoamine oxidase-B (MAOB) is described as an enzyme that mediates the aberrant synthesis of GABA and hydrogen peroxide in reactive astrocytes of Parkinson's disease, and its expression increases with aging and in neurodegenerative conditions."
    },
    {
      "entity_id": "ent:fef68ab52f09",
      "entity_type": "DISEASE",
      "name": "Parkinson's disease",
      "normalized_id": "N/A",
      "aliases": [
        "Parkinson's Disease",
        "PD"
      ],
      "description": "A disease where reactive astrocytes in the substantia nigra pars compacta show increased MAOB expression, and astrocytic GABA suppresses dopaminergic neuronal activity while H2O2 aggravates neuronal death."
    },
    {
      "entity_id": "ent:321cb81eaff9",
      "entity_type": "MECHANISM",
      "name": "aberrant suppression and deterioration of dopaminergic neurons",
      "normalized_id": "N/A",
      "aliases": [
        "aberrant tonic inhibition"
      ],
      "description": "Role of MAOB through excessive GABA and H2O2 synthesis in reactive astrocytes."
    },
    {
      "entity_id": "ent:4c577291e98b",
      "entity_type": "MECHANISM",
      "name": "excessive GABA and H2O2 synthesis",
      "normalized_id": "N/A",
      "aliases": [
        "astrocytic GABA production"
      ],
      "description": "Process in reactive astrocytes linked to MAOB's role in Parkinson's disease."
    },
    {
      "entity_id": "ent:ba5ffc952c8d",
      "entity_type": "MECHANISM",
      "name": "degradation of monoamine neurotransmitters",
      "normalized_id": "N/A",
      "aliases": [
        "DA deamination",
        "DA degradation",
        "excessive DA degradation"
      ],
      "description": "Process traditionally believed to be mediated by MAOB for neurotransmitters like dopamine."
    },
    {
      "entity_id": "ent:f71c64e8baa2",
      "entity_type": "MECHANISM",
      "name": "tonically suppresses the dopaminergic neuronal activity",
      "normalized_id": "N/A",
      "aliases": [
        "tonic inhibition"
      ],
      "description": "Mechanism by which astrocytic GABA affects dopaminergic neurons."
    },
    {
      "entity_id": "ent:552e9b7e03b8",
      "entity_type": "MECHANISM",
      "name": "oxidatively deaminated",
      "normalized_id": "N/A",
      "aliases": [
        "deaminated"
      ],
      "description": "Process distinguishing MAO from other enzymes acting on diamines."
    },
    {
      "entity_id": "ent:9d3a0abef6cd",
      "entity_type": "MECHANISM",
      "name": "catalyzes the oxidation of monoamines",
      "normalized_id": "N/A",
      "aliases": [
        "catalyzes"
      ],
      "description": "Enzymatic function of monoamine oxidase (MAO) family at mitochondrial outer membranes."
    },
    {
      "entity_id": "ent:e83c02822576",
      "entity_type": "MECHANISM",
      "name": "contribute to the progression and maintenance of neuroinflammation and neurodegeneration",
      "normalized_id": "N/A",
      "aliases": [
        "neurodegenerative diseases",
        "reactive astrogliosis"
      ],
      "description": "Suggested role of increased MAOB expression with reactive astrogliosis in diseases."
    },
    {
      "entity_id": "ent:d6f79d9a562d",
      "entity_type": "SYMPTOM",
      "name": "motor dysfunction",
      "normalized_id": "N/A",
      "aliases": [
        "motor dysfunction"
      ],
      "description": "Motor dysfunction is mentioned as part of the toxicity caused by MPTP in Parkinson's disease."
    },
    {
      "entity_id": "ent:d19390680e91",
      "entity_type": "TREATMENT",
      "name": "selegiline administration",
      "normalized_id": "N/A",
      "aliases": [
        "selegiline"
      ],
      "description": "A post-treatment regime starting 3 days after MPTP administration that significantly alleviated MPTP-induced PD-like pathology and motor symptoms in a mouse model."
    },
    {
      "entity_id": "ent:a5a6d3dcf4c7",
      "entity_type": "DISEASE",
      "name": "PD-like pathology",
      "normalized_id": "N/A",
      "aliases": [
        "parkinsonian motor symptoms",
        "parkinsonian symptoms",
        "PD",
        "PD pathology"
      ],
      "description": "Pathology alleviated by post-treatment selegiline administration in the MPTP mouse model."
    },
    {
      "entity_id": "ent:1c7f8cffc70f",
      "entity_type": "MECHANISM",
      "name": "DA metabolism",
      "normalized_id": "N/A",
      "aliases": [
        "DA metabolism"
      ],
      "description": "The chemical processes involving dopamine, mentioned as a role of MAOB to be excluded in PD pathology."
    },
    {
      "entity_id": "ent:8302356fd02a",
      "entity_type": "MECHANISM",
      "name": "metabolized",
      "normalized_id": "N/A",
      "aliases": [
        "conversion",
        "metabolism",
        "metabolize",
        "metabolized",
        "MPP+ conversion"
      ],
      "description": "Process of chemical transformation, specifically MPTP being converted to the toxic MPP+ by MAOB in astrocytes."
    },
    {
      "entity_id": "ent:0be353b57618",
      "entity_type": "MECHANISM",
      "name": "DA degradation",
      "normalized_id": "N/A",
      "aliases": [
        "DA degradation",
        "degradation"
      ],
      "description": "Process involving the breakdown of dopamine, discussed in the context of MAOB's role in vitro and in the living brain."
    },
    {
      "entity_id": "ent:950560577b26",
      "entity_type": "MECHANISM",
      "name": "deaminated",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Chemical process of removing an amine group, specifically described as how MAOB acts on dopamine after it enters astrocytes."
    },
    {
      "entity_id": "ent:918cfcf6fd4e",
      "entity_type": "MECHANISM",
      "name": "GABA synthesis",
      "normalized_id": "N/A",
      "aliases": [
        "synthesis",
        "synthesize",
        "synthesized",
        "synthesizing"
      ],
      "description": "Biosynthetic process for producing GABA, identified as a critical enzymatic role for MAOB in astrocytes under physiological conditions."
    },
    {
      "entity_id": "ent:a980819c9600",
      "entity_type": "MECHANISM",
      "name": "aberrant suppression",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Abnormal inhibitory process leading to decreased activity of dopaminergic neurons in the SNpc, caused by excessive GABA."
    },
    {
      "entity_id": "ent:599cd7cac967",
      "entity_type": "MECHANISM",
      "name": "aberrant synthesis of GABA and hydrogen peroxide",
      "normalized_id": "N/A",
      "aliases": [
        "aberrant GABA synthesis",
        "aberrant synthesis of GABA and hydrogen peroxide"
      ],
      "description": "Abnormal production of GABA, identified as the mechanism through which astrocytic MAOB substantially contributes to PD pathology."
    },
    {
      "entity_id": "ent:81c7b6f5b981",
      "entity_type": "MECHANISM",
      "name": "tonically inhibit",
      "normalized_id": "N/A",
      "aliases": [
        "tonic inhibition"
      ],
      "description": "Continuous inhibitory action, where astrocytic GABA binds to extrasynaptic GABA_A receptors to suppress neighboring neuronal activity."
    },
    {
      "entity_id": "ent:434e480a4a35",
      "entity_type": "TREATMENT",
      "name": "irreversible MAOB inhibitors",
      "normalized_id": "N/A",
      "aliases": [
        "irreversible inhibitors",
        "irreversible MAOB inhibitors",
        "MAOB inhibitors"
      ],
      "description": "Inhibitors of monoamine oxidase B that are described as having shortcomings in the context of Alzheimer's disease treatment."
    },
    {
      "entity_id": "ent:0443ec4ba5ea",
      "entity_type": "DISEASE",
      "name": "Alzheimer's disease",
      "normalized_id": "N/A",
      "aliases": [
        "AD",
        "Alzheimer's disease"
      ],
      "description": "A disease mentioned in mouse models where GABA from reactive astrocytes impairs memory."
    },
    {
      "entity_id": "ent:6ea68b38485f",
      "entity_type": "MECHANISM",
      "name": "reactive astrogliosis",
      "normalized_id": "N/A",
      "aliases": [
        "reactive astrogliosis"
      ],
      "description": "A process prevented by inhibition of monoamine oxidase B in a stab wound injury model according to the text."
    },
    {
      "entity_id": "ent:bb47817e0ed3",
      "entity_type": "TREATMENT",
      "name": "deprenyl (selegiline)",
      "normalized_id": "N/A",
      "aliases": [
        "deprenyl",
        "selegiline"
      ],
      "description": "A medication referred to as deprenyl with the synonym selegiline, studied for its effect on the natural history of Parkinson's disease."
    },
    {
      "entity_id": "ent:f82f40b55d07",
      "entity_type": "PROTEIN",
      "name": "MAO-B",
      "normalized_id": "N/A",
      "aliases": [
        "MAO-B",
        "MAOB"
      ],
      "description": "Enzyme demonstrated in brain astrocytes and serotonergic neurons, showing differential age-related changes in mouse brain and peripheral organs, with age-related increases in human brain."
    },
    {
      "entity_id": "ent:be73eaf37479",
      "entity_type": "PROTEIN",
      "name": "monoamine oxidase",
      "normalized_id": "N/A",
      "aliases": [
        "A type monoamine oxidase",
        "MAO",
        "monoamine oxidase",
        "type A",
        "type B",
        "types A",
        "tyramine oxidase"
      ],
      "description": "Enzyme discussed in relation to genes and behavior in the cited annual review of neuroscience."
    },
    {
      "entity_id": "ent:51da53feedad",
      "entity_type": "PROTEIN",
      "name": "monoamine oxidase A",
      "normalized_id": "N/A",
      "aliases": [
        "MAO-A",
        "monoamine oxidase A"
      ],
      "description": "Enzyme form immunocytochemically localized in human peripheral tissues and brain along with monoamine oxidase B."
    },
    {
      "entity_id": "ent:a501715cbb98",
      "entity_type": "PATHWAY",
      "name": "maintain the homeostasis of monoamine neurotransmitters and metabolites",
      "normalized_id": "N/A",
      "aliases": [
        "catecholamine metabolism",
        "maintain the homeostasis of monoamine neurotransmitters and metabolites"
      ],
      "description": "Described as a contemporary view with implications for physiology and medicine in the referenced article."
    },
    {
      "entity_id": "ent:bb3a46e0e21d",
      "entity_type": "TREATMENT",
      "name": "deprenyl",
      "normalized_id": "N/A",
      "aliases": [
        "deprenyl"
      ],
      "description": "A monoamine oxidase B inhibitor that potentiates phenylethylamine behaviour in rats."
    },
    {
      "entity_id": "ent:5a2b7b45c8ef",
      "entity_type": "DISEASE",
      "name": "Parkinson disease",
      "normalized_id": "N/A",
      "aliases": [
        "Parkinson disease"
      ],
      "description": "A condition treated by rasagiline, described as a novel, second-generation propargylamine."
    },
    {
      "entity_id": "ent:5a8bc6738968",
      "entity_type": "MECHANISM",
      "name": "tonic GABA synthesis",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Process described as being mediated by MAO-B according to the text."
    },
    {
      "entity_id": "ent:fe6ed4e43233",
      "entity_type": "MECHANISM",
      "name": "dopamine degradation",
      "normalized_id": "N/A",
      "aliases": [
        "dopamine degradation"
      ],
      "description": "Process described as involving MAO-A according to the text."
    },
    {
      "entity_id": "ent:88c9aad95028",
      "entity_type": "MECHANISM",
      "name": "tonic inhibition",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Inhibition described as being mediated by glial GABA synthesized by monoamine oxidase B."
    },
    {
      "entity_id": "ent:ca4e431b9f00",
      "entity_type": "MECHANISM",
      "name": "deamination",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Process described for dopamine by an A type monoamine oxidase in rat brain."
    },
    {
      "entity_id": "ent:66bc3475ca3b",
      "entity_type": "OTHER",
      "name": "Substrate specificity",
      "normalized_id": "N/A",
      "aliases": [
        "substrate selectivity"
      ],
      "description": "Property of brain amine oxidase of several mammals being investigated in a 1960 project report."
    },
    {
      "entity_id": "ent:f3005c947def",
      "entity_type": "OTHER",
      "name": "Preferential deamination",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Deamination process described as preferentially affecting dopamine by an A type monoamine oxidase in rat brain."
    },
    {
      "entity_id": "ent:e36da1ad0150",
      "entity_type": "OTHER",
      "name": "Specificity of endogenous substrates",
      "normalized_id": "N/A",
      "aliases": [
        "distinct substrate selectivity"
      ],
      "description": "Specificity for types A and B monoamine oxidase in rat striatum, as studied in neurochemical research."
    },
    {
      "entity_id": "ent:2b3c854b7989",
      "entity_type": "PROTEIN",
      "name": "MAO-A",
      "normalized_id": "N/A",
      "aliases": [
        "MAO-A"
      ],
      "description": "An enzyme described as having a differential role in dopamine degradation according to the document."
    },
    {
      "entity_id": "ent:67569d977eed",
      "entity_type": "PROTEIN",
      "name": "amine oxidase",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "An enzyme from brain described with substrate specificity in several mammals according to the document."
    },
    {
      "entity_id": "ent:9ad1f6609c5c",
      "entity_type": "PROTEIN",
      "name": "monoamine oxidase type B",
      "normalized_id": "N/A",
      "aliases": [
        "MAO-B",
        "monoamine oxidase B",
        "monoamine oxidase-B"
      ],
      "description": "An enzyme questioned for its role in dopaminergic nerve cell death in Parkinson's disease according to the document."
    },
    {
      "entity_id": "ent:d9ea6bb0a2ea",
      "entity_type": "DRUG",
      "name": "L-DOPA",
      "normalized_id": "N/A",
      "aliases": [
        "L-DOPA"
      ],
      "description": "Compound described as a source of dopamine following selective MAO-A or -B inhibition in rat striatum."
    },
    {
      "entity_id": "ent:2850aed3f2da",
      "entity_type": "PROTEIN",
      "name": "monoamine oxidase-B",
      "normalized_id": "N/A",
      "aliases": [
        "MAO-B"
      ],
      "description": "Enzyme described as being inhibited by deprenyl, which potentiates neuronal responses to dopamine agonists in the rat striatum."
    },
    {
      "entity_id": "ent:831a57626092",
      "entity_type": "MECHANISM",
      "name": "Inhibition of monoamine oxidase-B",
      "normalized_id": "N/A",
      "aliases": [
        "MAO-A inhibition",
        "MAO-B inhibition",
        "selective MAO-A or -B inhibition"
      ],
      "description": "Inhibition of monoamine oxidase-B potentiates neuronal responses to dopamine agonists but does not inhibit dopamine catabolism in the rat striatum."
    },
    {
      "entity_id": "ent:f2b818e7ec8a",
      "entity_type": "MECHANISM",
      "name": "Complexity of dopamine metabolism",
      "normalized_id": "N/A",
      "aliases": [
        "Complexity of dopamine metabolism",
        "dopamine catabolism",
        "dopamine metabolism"
      ],
      "description": "Dopamine catabolism in the rat striatum is not inhibited by monoamine oxidase-B inhibition according to the study."
    },
    {
      "entity_id": "ent:7b2bcc8e7cdc",
      "entity_type": "MECHANISM",
      "name": "metabolism of dopamine",
      "normalized_id": "N/A",
      "aliases": [
        "dopamine metabolism"
      ],
      "description": "The metabolism of dopamine by both forms of monoamine oxidase in the rat brain and its inhibition by cimoxatone is described."
    },
    {
      "entity_id": "ent:8741409191ee",
      "entity_type": "MECHANISM",
      "name": "H_{2}O_{2} production",
      "normalized_id": "N/A",
      "aliases": [
        "hydrogen peroxide production"
      ],
      "description": "Severe reactive astrocytes precipitate pathological hallmarks of Alzheimer's disease via H_{2}O_{2} production."
    },
    {
      "entity_id": "ent:ada7a45aeaed",
      "entity_type": "TREATMENT",
      "name": "Selective inhibitors of monoamine oxidase type B",
      "normalized_id": "N/A",
      "aliases": [
        "MAO-B inhibitors",
        "monoamine oxidase type-B inhibitors",
        "monoamine oxidase-B (MAO-B) inhibitors",
        "Monoamine Oxidase-B Inhibitors"
      ],
      "description": "Pharmacologic agents that specifically target MAO-B enzymes, discussed in relation to the \"cheese effect\" side effect."
    },
    {
      "entity_id": "ent:3313f2168e89",
      "entity_type": "TREATMENT",
      "name": "Monoamine Oxidase Inhibitors",
      "normalized_id": "N/A",
      "aliases": [
        "MAO inhibitors"
      ],
      "description": "A class of drugs reviewed for their anti-inflammatory therapeutic potential and mechanisms of action."
    },
    {
      "entity_id": "ent:57c4eeaf3392",
      "entity_type": "TREATMENT",
      "name": "treated with l-deprenyl",
      "normalized_id": "N/A",
      "aliases": [
        "selegiline treatment"
      ],
      "description": "Therapeutic administration of l-deprenyl to parkinsonian patients to study monoamine oxidase activity and metabolism."
    },
    {
      "entity_id": "ent:83a23102f697",
      "entity_type": "MECHANISM",
      "name": "neuroprotective activity",
      "normalized_id": "N/A",
      "aliases": [
        "neuroprotection",
        "neuroprotective activity",
        "neuroprotective capacity"
      ],
      "description": "An effect provided by safinamide in the 6-hydroxydopamine model of Parkinson's disease."
    },
    {
      "entity_id": "ent:83a05372da2a",
      "entity_type": "DRUG",
      "name": "selegiline",
      "normalized_id": "N/A",
      "aliases": [
        "deprenyl",
        "l-deprenyl",
        "selegiline"
      ],
      "description": "Drug described as a selective MAO-B inhibitor in formulations that bypass first-pass metabolism and also inhibit MAO-A in the human brain."
    },
    {
      "entity_id": "ent:1c3341f3966f",
      "entity_type": "DRUG",
      "name": "rasagiline",
      "normalized_id": "N/A",
      "aliases": [
        "Azilect",
        "rasagiline"
      ],
      "description": "Drug described as an anti-Parkinson drug with pharmacological properties modifying endogenous brain amines, reserpine reversal, serotonergic and dopaminergic behaviours."
    },
    {
      "entity_id": "ent:d7eb2f78f5ad",
      "entity_type": "MECHANISM",
      "name": "apoptosis",
      "normalized_id": "N/A",
      "aliases": [
        "apoptosis"
      ],
      "description": "A process that STC2 prevents, as it facilitates cells dealing with stress conditions."
    },
    {
      "entity_id": "ent:0ccca2500cf5",
      "entity_type": "TREATMENT",
      "name": "radiotherapy",
      "normalized_id": "N/A",
      "aliases": [
        "treatment"
      ],
      "description": "Treatment mentioned as remaining one of the most effective treatments for patients with local prostate cancer tumours."
    },
    {
      "entity_id": "ent:4cb806fad36b",
      "entity_type": "GENE",
      "name": "Stanniocalcin 2",
      "normalized_id": "N/A",
      "aliases": [
        "Stanniocalcin",
        "Stanniocalcin 2",
        "STC2"
      ],
      "description": "Gene with elevated levels in gastric cancer compared to normal tissues, correlated with tumour invasion, lymphatic metastasis and poor prognosis."
    },
    {
      "entity_id": "ent:58535bff9017",
      "entity_type": "DISEASE",
      "name": "cancers",
      "normalized_id": "N/A",
      "aliases": [
        "cancers"
      ],
      "description": "N/A"
    },
    {
      "entity_id": "ent:c18707e2df04",
      "entity_type": "DISEASE",
      "name": "lymphatic metastasis",
      "normalized_id": "N/A",
      "aliases": [
        "metastasis"
      ],
      "description": "A factor correlated with elevated STC2 expression in gastric cancer."
    },
    {
      "entity_id": "ent:68ea0cbbaad0",
      "entity_type": "DISEASE",
      "name": "tumours",
      "normalized_id": "N/A",
      "aliases": [
        "tumour",
        "tumour cells",
        "tumour development",
        "tumour growth",
        "tumour progression",
        "tumour tissues",
        "tumours"
      ],
      "description": "N/A"
    },
    {
      "entity_id": "ent:3973c7a8b0e1",
      "entity_type": "DISEASE",
      "name": "metastatic lesions",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Conditions diagnosed in approximately 30% of RCC patients at first visit."
    },
    {
      "entity_id": "ent:a4bb2da43561",
      "entity_type": "DISEASE",
      "name": "metastasis",
      "normalized_id": "N/A",
      "aliases": [
        "metastasis"
      ],
      "description": "A condition some RCC patients develop even after removal of local tumours."
    },
    {
      "entity_id": "ent:6f714ddc8aa8",
      "entity_type": "TREATMENT",
      "name": "adjuvant chemotherapy",
      "normalized_id": "N/A",
      "aliases": [
        "adjuvant chemotherapy",
        "adjuvant therapy"
      ],
      "description": "A therapy mentioned as having its therapeutic efficacy evaluated by detecting antitumor immune response."
    },
    {
      "entity_id": "ent:3f9116ddb795",
      "entity_type": "GENE",
      "name": "HIF-1",
      "normalized_id": "N/A",
      "aliases": [
        "HIF",
        "HIF-1",
        "HIF-1 heterodimer",
        "Hypoxia-inducible factor"
      ],
      "description": "A signaling pathway activated by bevacizumab to induce STC2 expression in orthotopic human colon cancer xenografts."
    },
    {
      "entity_id": "ent:5cc76b733bd7",
      "entity_type": "TREATMENT",
      "name": "chemo- and radio- therapies",
      "normalized_id": "N/A",
      "aliases": [
        "Cancer therapy",
        "chemo- and radio- therapies",
        "chemotherapies"
      ],
      "description": "Treatments mentioned in the context of inducing immunogenic cell death to facilitate therapeutic vaccine development."
    },
    {
      "entity_id": "ent:9e91135bbf60",
      "entity_type": "MECHANISM",
      "name": "ER stress",
      "normalized_id": "N/A",
      "aliases": [
        "ER stress"
      ],
      "description": "A characteristic of immunogenic cell death, which regulates the expression of immune-relevant metagenes."
    },
    {
      "entity_id": "ent:1696cdf36823",
      "entity_type": "DISEASE",
      "name": "osteosarcoma",
      "normalized_id": "N/A",
      "aliases": [
        "osteosarcoma"
      ],
      "description": "Described in patients where STC2 can be grouped with glycolytic genes to assess prognosis."
    },
    {
      "entity_id": "ent:e89a92f88c14",
      "entity_type": "DISEASE",
      "name": "nasopharyngeal carcinoma",
      "normalized_id": "N/A",
      "aliases": [
        "nasopharyngeal carcinoma"
      ],
      "description": "Described in CNE2 cells where glucose-deprivation can induce STC2 at protein levels."
    },
    {
      "entity_id": "ent:c42258ce34c8",
      "entity_type": "DISEASE",
      "name": "tumour progression",
      "normalized_id": "N/A",
      "aliases": [
        "tumour progression"
      ],
      "description": "Described as a process during which STC2 has biological functions in metabolic reprogramming."
    },
    {
      "entity_id": "ent:0eca83d57246",
      "entity_type": "DISEASE",
      "name": "human cancers",
      "normalized_id": "N/A",
      "aliases": [
        "cancer",
        "cancers",
        "carcinoma",
        "human cancers",
        "tumour",
        "tumours"
      ],
      "description": "Described as having metabolic reprogramming as an emerging hallmark, with characteristics including Warburg effect and active glutaminolysis."
    },
    {
      "entity_id": "ent:6f608b9b1cb8",
      "entity_type": "DISEASE",
      "name": "cervical cancer",
      "normalized_id": "N/A",
      "aliases": [
        "cervical cancer"
      ],
      "description": "Described in cisplatin-resistant cells that demonstrate increased STC2 mRNA and protein levels."
    },
    {
      "entity_id": "ent:fc370882bdd3",
      "entity_type": "MECHANISM",
      "name": "invasion",
      "normalized_id": "N/A",
      "aliases": [
        "invasion"
      ],
      "description": "Aspect of tumour biology regulated by STC2, associated with tumour phenotypes and disease stages."
    },
    {
      "entity_id": "ent:91817c886025",
      "entity_type": "MECHANISM",
      "name": "cell proliferation",
      "normalized_id": "N/A",
      "aliases": [
        "cell proliferation",
        "proliferation"
      ],
      "description": "Aspect of tumour biology regulated by STC2, associated with tumour phenotypes and disease stages."
    },
    {
      "entity_id": "ent:b26ae4f28d7a",
      "entity_type": "OTHER",
      "name": "stress conditions",
      "normalized_id": "N/A",
      "aliases": [
        "stress conditions"
      ],
      "description": "Solid tumour cells are described as commonly encountering stress conditions which selectively activate corresponding signaling pathways."
    },
    {
      "entity_id": "ent:fa2b5659e346",
      "entity_type": "OTHER",
      "name": "recurrence",
      "normalized_id": "N/A",
      "aliases": [
        "relapse"
      ],
      "description": "Serum STC2 levels are described as potentially being utilized to assess recurrence in patients with various types of cancers."
    },
    {
      "entity_id": "ent:ffd3536de9bc",
      "entity_type": "OTHER",
      "name": "disease stages",
      "normalized_id": "N/A",
      "aliases": [
        "disease stage"
      ],
      "description": "Cell proliferation, invasion and metastasis regulated by STC2 are described as being associated with disease stages."
    },
    {
      "entity_id": "ent:fb90ba00e932",
      "entity_type": "PROTEIN",
      "name": "GCN2",
      "normalized_id": "N/A",
      "aliases": [
        "GCN2",
        "General control nonderepressible 2"
      ],
      "description": "General control nonderepressible 2, listed in the abbreviations section."
    },
    {
      "entity_id": "ent:b2611505203d",
      "entity_type": "PROTEIN",
      "name": "PKR",
      "normalized_id": "N/A",
      "aliases": [
        "MAO",
        "PKR",
        "Protein R kinase (=Eukaryotic Translation Initiation Factor 2 Alpha Kinase 2)"
      ],
      "description": "Protein R kinase, also known as Eukaryotic Translation Initiation Factor 2 Alpha Kinase 2, listed in the abbreviations section."
    },
    {
      "entity_id": "ent:8fc07bdac764",
      "entity_type": "BIOMARKER",
      "name": "GABA",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "A neurotransmitter synthesized by MAOB in reactive astrocytes, which tonically suppresses dopaminergic neuronal activity in Parkinson's disease."
    },
    {
      "entity_id": "ent:87ed17dc8b72",
      "entity_type": "BIOMARKER",
      "name": "H2O2",
      "normalized_id": "N/A",
      "aliases": [
        "hydrogen peroxide"
      ],
      "description": "A compound synthesized by MAOB in reactive astrocytes, which aggravates astrocytic reactivity and dopaminergic neuronal death in Parkinson's disease."
    },
    {
      "entity_id": "ent:4b068b460831",
      "entity_type": "BIOMARKER",
      "name": "dopamine",
      "normalized_id": "N/A",
      "aliases": [
        "DA"
      ],
      "description": "A monoamine neurotransmitter whose degradation is mediated by MAOA, and whose neuronal activity is suppressed by astrocytic GABA in Parkinson's disease."
    },
    {
      "entity_id": "ent:7c8cc56c4e64",
      "entity_type": "BIOMARKER",
      "name": "PET",
      "normalized_id": "N/A",
      "aliases": [
        "positron emission tomography"
      ],
      "description": "An imaging technique used for molecular imaging of MAOB in living human brains to measure its levels."
    },
    {
      "entity_id": "ent:ef19292214bb",
      "entity_type": "MECHANISM",
      "name": "aggravates astrocytic reactivity and dopaminergic neuronal death",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Mechanism by which H2O2 contributes to Parkinson's disease progression."
    },
    {
      "entity_id": "ent:5118fd790378",
      "entity_type": "MECHANISM",
      "name": "reduce reactive astrogliosis and restore dopaminergic neuronal activity",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Mechanism of action for reversible MAOB inhibitors in alleviating PD symptoms."
    },
    {
      "entity_id": "ent:70a100599ee8",
      "entity_type": "MECHANISM",
      "name": "oxidize catecholamines",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Function discovered for MAO in the brain regarding neurotransmitters like dopamine."
    },
    {
      "entity_id": "ent:9808347fe412",
      "entity_type": "MECHANISM",
      "name": "contribute to brain aging",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Potential role of age-related increase in astrocytic MAOB expression."
    },
    {
      "entity_id": "ent:99497d5f5bd9",
      "entity_type": "PATHWAY",
      "name": "putrescine degradation route",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "A route involved in astrocytic GABA production, specifically involving MAOB according to recent investigations."
    },
    {
      "entity_id": "ent:c7f5ccc4d424",
      "entity_type": "DRUG",
      "name": "levodopa",
      "normalized_id": "N/A",
      "aliases": [
        "levodopa"
      ],
      "description": "Described as the most popular therapeutic agent for Parkinson's disease."
    },
    {
      "entity_id": "ent:9d620848cc35",
      "entity_type": "DRUG",
      "name": "clorgiline",
      "normalized_id": "N/A",
      "aliases": [
        "clorgiline"
      ],
      "description": "Described as the first-generation specific inhibitor of MAOA developed in the 1960s."
    },
    {
      "entity_id": "ent:53b8485f6257",
      "entity_type": "SYMPTOM",
      "name": "bradykinesia",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Included as part of the motor dysfunction characterizing Parkinson's disease."
    },
    {
      "entity_id": "ent:2c286a4ae090",
      "entity_type": "SYMPTOM",
      "name": "resting tremor",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Included as part of the motor dysfunction characterizing Parkinson's disease."
    },
    {
      "entity_id": "ent:758a9926d9e7",
      "entity_type": "SYMPTOM",
      "name": "gait disturbance",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Included as part of the motor dysfunction characterizing Parkinson's disease."
    },
    {
      "entity_id": "ent:22dfdcc45ce9",
      "entity_type": "SYMPTOM",
      "name": "postural instability",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Included as part of the motor dysfunction characterizing Parkinson's disease."
    },
    {
      "entity_id": "ent:352e32fda357",
      "entity_type": "TREATMENT",
      "name": "selective inhibitors against MAOA and MAOB",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Described as being used in several in vivo studies that demonstrated DA is much preferentially degraded by MAOA compared to MAOB in the rat brain."
    },
    {
      "entity_id": "ent:74ae36586264",
      "entity_type": "MECHANISM",
      "name": "nigrostriatal DA depletion",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Described as the cause of Parkinson's disease, specifically nigrostriatal DA depletion."
    },
    {
      "entity_id": "ent:20f70fded358",
      "entity_type": "MECHANISM",
      "name": "differential cellular localization",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "A distinct physiological and pathological role factor for MAO isoenzymes due to their differential cellular localization."
    },
    {
      "entity_id": "ent:cd91478f2e84",
      "entity_type": "MECHANISM",
      "name": "metabolism",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "MAOA is primarily responsible for the metabolism of epinephrine, norepinephrine, melatonin, and serotonin."
    },
    {
      "entity_id": "ent:67c464075e30",
      "entity_type": "MECHANISM",
      "name": "degradation",
      "normalized_id": "N/A",
      "aliases": [
        "degradation",
        "degraded"
      ],
      "description": "MAOB is responsible for the degradation of phenylethylamine and benzylamine."
    },
    {
      "entity_id": "ent:7248c30733ea",
      "entity_type": "MECHANISM",
      "name": "blockade of DA degradation",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "The therapeutic efficacy of MAOB inhibitors for PD is not attributed to a blockade of DA degradation."
    },
    {
      "entity_id": "ent:70547b872a76",
      "entity_type": "MECHANISM",
      "name": "blockade of the excessive astrocytic GABA synthesis",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "The therapeutic efficacy of MAOB inhibitors for PD is attributed to a blockade of the excessive astrocytic GABA synthesis."
    },
    {
      "entity_id": "ent:db1bf5cb52a7",
      "entity_type": "OTHER",
      "name": "early monotherapy",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "A treatment approach mentioned as one way irreversible MAOB inhibitors are prescribed for Parkinson's disease patients."
    },
    {
      "entity_id": "ent:d88315582b02",
      "entity_type": "OTHER",
      "name": "add-on",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "A supplementary treatment mentioned as one way irreversible MAOB inhibitors are prescribed alongside other medications for Parkinson's disease."
    },
    {
      "entity_id": "ent:adb9fd3bdb2e",
      "entity_type": "OTHER",
      "name": "clinical effects",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Outcomes or impacts observed in a clinical setting, with some reports demonstrating discouraging ones for irreversible MAOB inhibitors."
    },
    {
      "entity_id": "ent:6bf20272ff9e",
      "entity_type": "OTHER",
      "name": "cellular localization",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "The specific cellular location of MAO isoenzymes, cited as a reason for their distinct physiological and pathological roles."
    },
    {
      "entity_id": "ent:437a61f6f218",
      "entity_type": "OTHER",
      "name": "enzymatic properties",
      "normalized_id": "N/A",
      "aliases": [
        "enzymatic activities"
      ],
      "description": "Characteristics related to enzyme function, revealed by cDNA cloning and peptide sequencing of human MAOA and MAOB."
    },
    {
      "entity_id": "ent:a04466f40050",
      "entity_type": "OTHER",
      "name": "cDNA cloning",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "A molecular biology technique used to reveal molecular differences in the enzymatic properties of human MAOA and MAOB."
    },
    {
      "entity_id": "ent:e0bc2bee9945",
      "entity_type": "OTHER",
      "name": "peptide sequencing",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "A technique used to reveal molecular differences in the enzymatic properties of human MAOA and MAOB."
    },
    {
      "entity_id": "ent:a92a0463740a",
      "entity_type": "OTHER",
      "name": "pathophysiology",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "The functional changes associated with a disease, specifically Parkinson's disease, which MAOB has long been believed to contribute to."
    },
    {
      "entity_id": "ent:2b73d3bc7d38",
      "entity_type": "OTHER",
      "name": "clinical efficacy",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "The effectiveness of a treatment in a clinical setting, described as positive but limited for irreversible MAOB inhibitors like selegiline and rasagiline."
    },
    {
      "entity_id": "ent:064cb5671e6e",
      "entity_type": "OTHER",
      "name": "traditional views",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Established perspectives that the review summarizes, specifically regarding the pathological role of MAOB in Parkinson's disease."
    },
    {
      "entity_id": "ent:69a05a3717ef",
      "entity_type": "OTHER",
      "name": "recent perspectives",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Newer viewpoints that the review summarizes in an attempt to redefine the pathological role of MAOB in Parkinson's disease."
    },
    {
      "entity_id": "ent:fa961fe31875",
      "entity_type": "OTHER",
      "name": "in vivo studies",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Research conducted in living organisms, specifically mentioned in the context of studies with selective inhibitors against MAOA and MAOB in rat brains."
    },
    {
      "entity_id": "ent:a8ab7689d790",
      "entity_type": "OTHER",
      "name": "selective inhibitors",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Compounds that target specific enzymes, used in in vivo studies against MAOA and MAOB to investigate DA metabolism."
    },
    {
      "entity_id": "ent:01c83e309f41",
      "entity_type": "OTHER",
      "name": "affinity",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "The strength of binding, specifically mentioned regarding DA deamination being 2.5-fold higher to MAOA than to MAOB."
    },
    {
      "entity_id": "ent:c9196084e0a7",
      "entity_type": "OTHER",
      "name": "tissue homogenates",
      "normalized_id": "N/A",
      "aliases": [
        "homogenates"
      ],
      "description": "Uniform mixtures of blended tissue, used to measure enzymatic activities of MAOA and MAOB, though noted as potentially different from the intact brain."
    },
    {
      "entity_id": "ent:abad6f96a955",
      "entity_type": "OTHER",
      "name": "intact brain",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "The brain in its whole, undamaged state, noted as potentially different from tissue homogenates in terms of MAO enzymatic activities."
    },
    {
      "entity_id": "ent:4858196d9876",
      "entity_type": "OTHER",
      "name": "controversies",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Disagreements or debates, specifically regarding the contributions of MAOA and MAOB to DA degradation."
    },
    {
      "entity_id": "ent:65b47528787c",
      "entity_type": "PATHWAY",
      "name": "nigrostriatal DA pathway",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Pathway mentioned in the context of low DAT expression in astrocytes."
    },
    {
      "entity_id": "ent:3dd64ffce8e4",
      "entity_type": "TREATMENT",
      "name": "KDS2010",
      "normalized_id": "N/A",
      "aliases": [
        "KDS2010"
      ],
      "description": "Described as a newly developed potent, reversible, and selective MAOB inhibitor used in a study to circumvent limitations of irreversible inhibitors."
    },
    {
      "entity_id": "ent:d591e95de1ac",
      "entity_type": "MECHANISM",
      "name": "binds to and activates DA receptors",
      "normalized_id": "N/A",
      "aliases": [
        "receptor activation"
      ],
      "description": "DA binds to and activates DA receptors after release from presynaptic terminals."
    },
    {
      "entity_id": "ent:25c0eba75237",
      "entity_type": "MECHANISM",
      "name": "absorbed back into the presynaptic neurons through the DA transporter (DAT)",
      "normalized_id": "N/A",
      "aliases": [
        "reuptake"
      ],
      "description": "DA is taken back into presynaptic neurons via the DA transporter after unbinding from receptors."
    },
    {
      "entity_id": "ent:6369720feb94",
      "entity_type": "MECHANISM",
      "name": "metabolic pathways for degrading DA",
      "normalized_id": "N/A",
      "aliases": [
        "DA degradation",
        "DA degradation pathway",
        "DA metabolism",
        "DA-degradation pathway",
        "regulating DA levels"
      ],
      "description": "Two main pathways exist for the degradation of dopamine."
    },
    {
      "entity_id": "ent:d4d5d47b7e55",
      "entity_type": "MECHANISM",
      "name": "MAO catalyzes the conversion of DA to 3,4-dihydroxyphenylacetaldehyde (DOPAL)",
      "normalized_id": "N/A",
      "aliases": [
        "MAO converts DA to 3,4-dihydroxyphenylacetaldehyde (DOPAL)",
        "MAO-mediated DA degradation"
      ],
      "description": "MAO enzyme catalyzes the first step in one DA degradation pathway, converting DA to DOPAL."
    },
    {
      "entity_id": "ent:3e32a999904f",
      "entity_type": "MECHANISM",
      "name": "metabolized into 3,4-dihydroxyphenylacetic acid (DOPAC) by aldehyde dehydrogenase (ALDH)",
      "normalized_id": "N/A",
      "aliases": [
        "converted to 3,4-dihydroxyphenylacetic acid (DOPAC) by aldehyde dehydrogenases (ALDH)"
      ],
      "description": "DOPAL is metabolized into DOPAC by the enzyme aldehyde dehydrogenase."
    },
    {
      "entity_id": "ent:a3485f397947",
      "entity_type": "MECHANISM",
      "name": "decomposed into an inert metabolite homovanillic acid (HVA) by catechol-o-methyltransferase (COMT)",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "DOPAC is decomposed into the final inert metabolite HVA by the enzyme COMT."
    },
    {
      "entity_id": "ent:90fdd7653b0f",
      "entity_type": "MECHANISM",
      "name": "COMT catalyzes the conversion of DA to 3-methoxytyramine (3-MT)",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "COMT enzyme catalyzes the conversion of DA to 3-MT in the second degradation pathway."
    },
    {
      "entity_id": "ent:a4cbf3bbfc58",
      "entity_type": "MECHANISM",
      "name": "metabolized into 3-methoxy-4-hydroxyphenylacetaldehyde (MHPA) by MAO",
      "normalized_id": "N/A",
      "aliases": [
        "converted to 3-methoxy-4-hydroxyphenylacetaldehyde (MHPA) by MAO"
      ],
      "description": "3-MT is metabolized into MHPA by the MAO enzyme."
    },
    {
      "entity_id": "ent:784af089dfb4",
      "entity_type": "MECHANISM",
      "name": "decomposed into the final product HVA via ALDH",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "MHPA is decomposed into the final product HVA by ALDH."
    },
    {
      "entity_id": "ent:83bb5662b998",
      "entity_type": "MECHANISM",
      "name": "augmented MAOB-mediated DA degradation",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Increased degradation of DA mediated by MAOB enzyme, reported to contribute to PD pathology."
    },
    {
      "entity_id": "ent:f735eeac579f",
      "entity_type": "MECHANISM",
      "name": "H_{2}O_{2} is believed to be produced during the MAOB-mediated DA degradation",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Hydrogen peroxide production is associated with MAOB-mediated dopamine degradation."
    },
    {
      "entity_id": "ent:f25bf79d4715",
      "entity_type": "MECHANISM",
      "name": "metabolized into homovanillic acid (HVA) through two different pathways",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "DA taken up via DAT is metabolized into HVA via two distinct enzymatic pathways."
    },
    {
      "entity_id": "ent:20b7d866a8b8",
      "entity_type": "MECHANISM",
      "name": "converted to HVA through catechol-o-methyltransferase (COMT)",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "DOPAC is finally converted to HVA by the enzyme COMT."
    },
    {
      "entity_id": "ent:bcbea8acd8df",
      "entity_type": "MECHANISM",
      "name": "COMT converts DA to 3-methoxytyramine (3-MT)",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "COMT enzyme converts dopamine to 3-MT in the second degradation pathway."
    },
    {
      "entity_id": "ent:25324c31ee2d",
      "entity_type": "MECHANISM",
      "name": "converted to HVA by ALDH",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "MHPA is finally converted to HVA by the enzyme ALDH."
    },
    {
      "entity_id": "ent:21dab3814f34",
      "entity_type": "MECHANISM",
      "name": "DA is degraded by MAOA and MAOB",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "It has been assumed dopamine degradation involves both MAOA and MAOB enzymes in neurons and astrocytes."
    },
    {
      "entity_id": "ent:e850c7972ca3",
      "entity_type": "MECHANISM",
      "name": "reduced DA metabolism",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Acute pharmacological inhibition of MAOA with clorgiline reduces dopamine metabolism."
    },
    {
      "entity_id": "ent:f04fb49b8069",
      "entity_type": "MECHANISM",
      "name": "blocked DA degradation",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "MAOA inhibition, not MAOB inhibition, dramatically blocked dopamine degradation in rat PD models."
    },
    {
      "entity_id": "ent:f1db3fa087d4",
      "entity_type": "MECHANISM",
      "name": "participate in DA degradation",
      "normalized_id": "N/A",
      "aliases": [
        "contributes to DA metabolism",
        "engaged in DA degradation"
      ],
      "description": "MAOB is less likely to participate in dopamine degradation in humans, based on gene deficiency phenotypes."
    },
    {
      "entity_id": "ent:2832974dab07",
      "entity_type": "MECHANISM",
      "name": "contributes to in vivo DA metabolism",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Both phasic and basal DA levels were affected only by MAOA inhibition, indicating MAOA contributes to in vivo DA metabolism."
    },
    {
      "entity_id": "ent:dfac6cb33a0d",
      "entity_type": "PROTEIN",
      "name": "DA receptors",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Receptors that DA binds to and activates after release from presynaptic terminals."
    },
    {
      "entity_id": "ent:1eb2920c871a",
      "entity_type": "PROTEIN",
      "name": "DA transporter",
      "normalized_id": "N/A",
      "aliases": [
        "DAT",
        "DATs"
      ],
      "description": "Transporter that absorbs DA back into presynaptic neurons after receptor activation."
    },
    {
      "entity_id": "ent:70cbdacce540",
      "entity_type": "PROTEIN",
      "name": "MAO",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Enzyme that catalyzes the conversion of DA to DOPAL in the first metabolic pathway."
    },
    {
      "entity_id": "ent:f7823e36c3f1",
      "entity_type": "PROTEIN",
      "name": "catechol-o-methyltransferase",
      "normalized_id": "N/A",
      "aliases": [
        "COMT"
      ],
      "description": "Enzyme that decomposes DOPAC into homovanillic acid (HVA) in the first pathway."
    },
    {
      "entity_id": "ent:bc111e3ad6e9",
      "entity_type": "PROTEIN",
      "name": "aldehyde dehydrogenases",
      "normalized_id": "N/A",
      "aliases": [
        "aldehyde dehydrogenase",
        "ALDH"
      ],
      "description": "Enzymes that convert DOPAL to DOPAC in the first DA degradation pathway."
    },
    {
      "entity_id": "ent:162ead085d84",
      "entity_type": "TREATMENT",
      "name": "pharmacological blockade of MAOB inhibitors",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "A pharmacological blockade described as being well documented to prevent MPTP-induced PD pathology and parkinsonian motor symptoms."
    },
    {
      "entity_id": "ent:0fdb9c2e9b44",
      "entity_type": "GENE",
      "name": "DAT",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Protein with relatively low expression in astrocytes but mainly expressed in DAergic neurons, involved in the uptake of MPP+."
    },
    {
      "entity_id": "ent:e6eac44af5b7",
      "entity_type": "PROTEIN",
      "name": "Bestrophin-1",
      "normalized_id": "N/A",
      "aliases": [
        "Best1"
      ],
      "description": "Ca2+-activated anion channel through which astrocytic GABA is tonically released."
    },
    {
      "entity_id": "ent:d2ff732091cc",
      "entity_type": "PROTEIN",
      "name": "tyrosine hydroxylase",
      "normalized_id": "N/A",
      "aliases": [
        "TH",
        "tyrosine hydroxylase"
      ],
      "description": "Key DA-synthesizing enzyme whose reduction in level is caused by aberrant suppression of DAergic neuronal activity."
    },
    {
      "entity_id": "ent:b592b4ef77cd",
      "entity_type": "SYMPTOM",
      "name": "parkinsonian motor symptoms",
      "normalized_id": "N/A",
      "aliases": [
        "motor symptoms",
        "parkinsonian",
        "parkinsonian models",
        "parkinsonian motor symptoms",
        "parkinsonian symptoms",
        "PD",
        "PD pathology",
        "PD-like pathology"
      ],
      "description": "Motor symptoms associated with Parkinson's disease that can be prevented by pharmacological blockade of MAOB inhibitors in MPTP-induced pathology."
    },
    {
      "entity_id": "ent:671f04b3ac60",
      "entity_type": "DISEASE",
      "name": "AD",
      "normalized_id": "N/A",
      "aliases": [
        "AD"
      ],
      "description": "Condition in which brains show higher MAOB expression and astrocytic GABA in reactive astrocytes in the hippocampus."
    },
    {
      "entity_id": "ent:6caef06f89d8",
      "entity_type": "MECHANISM",
      "name": "taken up",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Cellular uptake process, specifically MPP+ being transported into dopaminergic neurons via DAT."
    },
    {
      "entity_id": "ent:030bb795057b",
      "entity_type": "MECHANISM",
      "name": "destroys",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Process of causing damage or death, specifically MPP+ destroying dopaminergic neurons after uptake."
    },
    {
      "entity_id": "ent:534c54c8183a",
      "entity_type": "MECHANISM",
      "name": "pharmacological blockade",
      "normalized_id": "N/A",
      "aliases": [
        "MAOB inhibition",
        "pharmacological blockade"
      ],
      "description": "Inhibition by drugs, specifically of MAOB to prevent MPTP-induced PD pathology and symptoms."
    },
    {
      "entity_id": "ent:065377ecb72e",
      "entity_type": "MECHANISM",
      "name": "blocking the conversion",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Inhibitory action preventing the chemical transformation of MPTP to MPP+, a proposed action of selegiline."
    },
    {
      "entity_id": "ent:348b3ea5065e",
      "entity_type": "PATHWAY",
      "name": "putrescine degradation pathway",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "A pathway where MAOB catalyzes the conversion of N-acetylputrescine to N-acetyl--aminobutyraldehyde, producing H2O2 as a byproduct."
    },
    {
      "entity_id": "ent:786030932da4",
      "entity_type": "PATHWAY",
      "name": "compensatory astrocytic GABA-synthesizing pathway",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "A pathway containing diamine oxidase that is turned on after long-term treatment with irreversible MAOB inhibitors like selegiline."
    },
    {
      "entity_id": "ent:0cb7b2560702",
      "entity_type": "PROTEIN",
      "name": "putrescine aminotransferase",
      "normalized_id": "N/A",
      "aliases": [
        "PAT"
      ],
      "description": "Enzyme that converts putrescine to N-acetylputrescine."
    },
    {
      "entity_id": "ent:f46fd76014ec",
      "entity_type": "PROTEIN",
      "name": "Bestrophin 1",
      "normalized_id": "N/A",
      "aliases": [
        "BEST1"
      ],
      "description": "Protein from astrocytes via which GABA is released."
    },
    {
      "entity_id": "ent:d5ce123ab32a",
      "entity_type": "SYMPTOM",
      "name": "cognitive impairment",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Reported to be caused by MAOB-mediated H2O2 in AD, as mentioned in the document."
    },
    {
      "entity_id": "ent:a0c5f9a01bdf",
      "entity_type": "SYMPTOM",
      "name": "motor fluctuations",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Mentioned as potentially being reduced by MAOB inhibitors in PD patients."
    },
    {
      "entity_id": "ent:45adadce7f4d",
      "entity_type": "GENE",
      "name": "A53T",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "A mutation mentioned in the context of alpha-synuclein in a mouse model of PD."
    },
    {
      "entity_id": "ent:a74f6d97947f",
      "entity_type": "GENE",
      "name": "-synuclein",
      "normalized_id": "N/A",
      "aliases": [
        "alpha-synuclein"
      ],
      "description": "A protein whose misfolded accumulation in reactive astrocytes could be linked to increased putrescine levels under PD pathogenesis."
    },
    {
      "entity_id": "ent:d9aae2d21475",
      "entity_type": "DISEASE",
      "name": "tauopathy",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Reported to be caused by MAOB-mediated H2O2 in AD."
    },
    {
      "entity_id": "ent:f2ec3cb3760f",
      "entity_type": "DISEASE",
      "name": "brain atrophy",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Reported to be caused by MAOB-mediated H2O2 in AD."
    },
    {
      "entity_id": "ent:3f1cc2760e94",
      "entity_type": "DISEASE",
      "name": "PD",
      "normalized_id": "N/A",
      "aliases": [
        "Parkinson's disease"
      ],
      "description": "Pathology exacerbated by astrocytic MAOB-dependent H2O2."
    },
    {
      "entity_id": "ent:e6eb434c811a",
      "entity_type": "DISEASE",
      "name": "neurodegeneration",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Promoted by astrocytic H2O2 exacerbating astrocytic reactivity."
    },
    {
      "entity_id": "ent:74edf173aac6",
      "entity_type": "DISEASE",
      "name": "PD pathophysiology",
      "normalized_id": "N/A",
      "aliases": [
        "PD pathology"
      ],
      "description": "Contributed to by astrocytic H2O2 promoting neurodegeneration in PD animal models and patients."
    },
    {
      "entity_id": "ent:9e040f0f05d7",
      "entity_type": "DISEASE",
      "name": "PD-related neurodegeneration",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Possibility of direct involvement of MAOB-dependent H2O2 needs future testing."
    },
    {
      "entity_id": "ent:f2fa7ea6929e",
      "entity_type": "DISEASE",
      "name": "DAergic neuron degeneration",
      "normalized_id": "N/A",
      "aliases": [
        "DAergic neuronal death",
        "neuronal death",
        "neuronal degeneration"
      ],
      "description": "MAOB inhibitors have been shown to prevent this."
    },
    {
      "entity_id": "ent:6702d0aa76c6",
      "entity_type": "DISEASE",
      "name": "PD patients",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "MAOB inhibitors may reduce motor fluctuations in these individuals."
    },
    {
      "entity_id": "ent:be70a669d4e2",
      "entity_type": "TREATMENT",
      "name": "gene-silencing",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "A method tested in rodent models of PD, including the MPTP mouse model, 6-OHDA rat model, and viral overexpression of A53T-mutated alpha-synuclein mouse model."
    },
    {
      "entity_id": "ent:80d745f4a04b",
      "entity_type": "TREATMENT",
      "name": "genetic ablation",
      "normalized_id": "N/A",
      "aliases": [
        "genetic ablation",
        "silencing"
      ],
      "description": "A method tested in rodent models of PD, including the MPTP mouse model, 6-OHDA rat model, and viral overexpression of A53T-mutated alpha-synuclein mouse model."
    },
    {
      "entity_id": "ent:c3c7b3bf175d",
      "entity_type": "TREATMENT",
      "name": "MAOB inhibitors",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Recent discoveries delineate their new mode of action in the treatment of PD as blocking astrocytic GABA and H2O2 synthesis."
    },
    {
      "entity_id": "ent:a0513094fd31",
      "entity_type": "TREATMENT",
      "name": "reversible inhibitors",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "A category of MAOB inhibitors that includes safinamide and KDS2010."
    },
    {
      "entity_id": "ent:db6fc7703586",
      "entity_type": "TREATMENT",
      "name": "safinamide",
      "normalized_id": "N/A",
      "aliases": [
        "safinamide",
        "Xadago"
      ],
      "description": "A reversible MAOB inhibitor."
    },
    {
      "entity_id": "ent:87df3377a13e",
      "entity_type": "TREATMENT",
      "name": "reversible MAOB inhibitors",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Such as safinamide and KDS2010 do not turn on the compensatory GABA-synthetic mechanism even under long-term treatment."
    },
    {
      "entity_id": "ent:5fe20bdcddc9",
      "entity_type": "TREATMENT",
      "name": "Eldepryl",
      "normalized_id": "N/A",
      "aliases": [
        "selegiline hydrochloride",
        "Zelapar"
      ],
      "description": "A MAOB inhibitor used to treat PD, also known as selegiline hydrochloride or Zelapar."
    },
    {
      "entity_id": "ent:b1942f58bf63",
      "entity_type": "MECHANISM",
      "name": "H_{2}O_{2} synthesis",
      "normalized_id": "N/A",
      "aliases": [
        "H_{2}O_{2} production",
        "H_{2}O_{2} synthesis"
      ],
      "description": "Process in which MAOB is critically engaged, producing H_{2}O_{2} as a byproduct during the conversion of N-acetylputrescine to N-acetyl--aminobutyraldehyde."
    },
    {
      "entity_id": "ent:6b3664c6f141",
      "entity_type": "MECHANISM",
      "name": "conversion of N-acetylputrescine to N-acetyl--aminobutyraldehyde",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Catalytic reaction in the putrescine degradation pathway performed by MAOB, which produces H_{2}O_{2} as a byproduct."
    },
    {
      "entity_id": "ent:3ba56d1fd515",
      "entity_type": "MECHANISM",
      "name": "astrocytic MAOB-dependent H_{2}O_{2}",
      "normalized_id": "N/A",
      "aliases": [
        "MAOB-dependent H_{2}O_{2}"
      ],
      "description": "Mechanism suggested to be critical for PD pathology, where MAOB overexpression in astrocytes increases H_{2}O_{2} level and exacerbates pathology."
    },
    {
      "entity_id": "ent:1173bf9d000d",
      "entity_type": "MECHANISM",
      "name": "H_{2}O_{2} scavenger",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Property of AAD2004, a compound with significant neuroprotective effect on the SNpc of the MPTP mouse model."
    },
    {
      "entity_id": "ent:15a7cbda5e94",
      "entity_type": "MECHANISM",
      "name": "astrocytic reactivity",
      "normalized_id": "N/A",
      "aliases": [
        "glial activation"
      ],
      "description": "Process that can be exacerbated by astrocytic H_{2}O_{2}, promoting neurodegeneration and contributing to PD pathophysiology."
    },
    {
      "entity_id": "ent:d0b33ea7d880",
      "entity_type": "MECHANISM",
      "name": "astrocytic GABA synthesis",
      "normalized_id": "N/A",
      "aliases": [
        "GABA synthesis"
      ],
      "description": "Process blocked by MAOB inhibition in PD models, along with blocking aberrant tonic inhibition of DAergic neurons, TH expression, and parkinsonian motor symptoms."
    },
    {
      "entity_id": "ent:e4042a234068",
      "entity_type": "MECHANISM",
      "name": "aberrant tonic inhibition of DAergic neurons",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Process blocked by MAOB inhibition in PD models, along with blocking astrocytic GABA synthesis, TH expression, and parkinsonian motor symptoms."
    },
    {
      "entity_id": "ent:048b7170d04a",
      "entity_type": "MECHANISM",
      "name": "mode of action",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "New delineated mechanism of MAOB inhibitors in PD treatment as blocking astrocytic GABA and H_{2}O_{2} synthesis."
    },
    {
      "entity_id": "ent:327c8f1e704c",
      "entity_type": "MECHANISM",
      "name": "blocking astrocytic GABA and H_{2}O_{2} synthesis",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "New mode of action of MAOB inhibitors in the treatment of PD, as delineated by recent discoveries."
    },
    {
      "entity_id": "ent:4cae3aea4dc3",
      "entity_type": "MECHANISM",
      "name": "DA metabolism to HVA",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Process for which MAOA, not MAOB, is responsible according to recent discoveries."
    },
    {
      "entity_id": "ent:af7c28bf0fce",
      "entity_type": "MECHANISM",
      "name": "accumulation of misfolded -synuclein",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Process to which increased putrescine level in reactive astrocytes under PD pathogenesis could be linked."
    },
    {
      "entity_id": "ent:a71684a1e1e8",
      "entity_type": "MECHANISM",
      "name": "converted to N-acetylputrescine",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Process performed by putrescine aminotransferase (PAT) on putrescine."
    },
    {
      "entity_id": "ent:fdf6be25e435",
      "entity_type": "MECHANISM",
      "name": "converts the N-acetylputrescine to N-acetyl--aminobutyraldehyde",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Action performed by MAOB, producing H_{2}O_{2} as a byproduct."
    },
    {
      "entity_id": "ent:984f14162c54",
      "entity_type": "MECHANISM",
      "name": "produces H_{2}O_{2} as a byproduct",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Outcome of MAOB converting N-acetylputrescine to N-acetyl--aminobutyraldehyde."
    },
    {
      "entity_id": "ent:c578661f5b62",
      "entity_type": "MECHANISM",
      "name": "converted to N-acetyl--aminobutyrate and GABA",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Sequential conversion process of N-acetyl--aminobutyraldehyde."
    },
    {
      "entity_id": "ent:621250144e6e",
      "entity_type": "MECHANISM",
      "name": "inhibits the excitability of neighboring DAergic neurons",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Action of GABA released via Bestrophin 1 (BEST1) from astrocytes."
    },
    {
      "entity_id": "ent:09bf91810ba6",
      "entity_type": "MECHANISM",
      "name": "exacerbates DAergic neuronal degeneration",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Action of H_{2}O_{2} on the other hand, following GABA's inhibition of neuronal excitability."
    },
    {
      "entity_id": "ent:2ff59df5c9c9",
      "entity_type": "MECHANISM",
      "name": "aberrant suppression and deterioration of DAergic neurons",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Process leading to reduced expression of tyrosine hydroxylase (TH) and DA deficiency."
    },
    {
      "entity_id": "ent:cd246da965b1",
      "entity_type": "MECHANISM",
      "name": "reduced expression of tyrosine hydroxylase (TH)",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Outcome of the aberrant suppression and deterioration of DAergic neurons, leading to DA deficiency."
    },
    {
      "entity_id": "ent:7618d6b4c164",
      "entity_type": "MECHANISM",
      "name": "DA deficiency",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Result of reduced expression of tyrosine hydroxylase (TH) due to aberrant suppression and deterioration of DAergic neurons."
    },
    {
      "entity_id": "ent:323b8b288a81",
      "entity_type": "MECHANISM",
      "name": "neuroprotective effects",
      "normalized_id": "N/A",
      "aliases": [
        "neuroprotective effect"
      ],
      "description": "Effects shown by MAOB inhibitors to prevent DAergic neuron degeneration and decrease parkinsonian symptoms, especially in early phase patients."
    },
    {
      "entity_id": "ent:7daeaa201e94",
      "entity_type": "MECHANISM",
      "name": "prevent DAergic neuron degeneration",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Effect shown by MAOB inhibitors, along with having neuroprotective effects and decreasing parkinsonian symptoms."
    },
    {
      "entity_id": "ent:01dd5927c4b2",
      "entity_type": "MECHANISM",
      "name": "decrease parkinsonian symptoms",
      "normalized_id": "N/A",
      "aliases": [
        "reduce the motor fluctuations"
      ],
      "description": "Effect shown by MAOB inhibitors, along with having neuroprotective effects and preventing DAergic neuron degeneration."
    },
    {
      "entity_id": "ent:4099afe8c131",
      "entity_type": "MECHANISM",
      "name": "low selectivity-induced undesirable effects",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Drawback of conventional irreversible MAOB inhibitors, such as the cheese effect, that reversible inhibitors can circumvent."
    },
    {
      "entity_id": "ent:6fdda079b06e",
      "entity_type": "MECHANISM",
      "name": "cheese effect",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Example of a low selectivity-induced undesirable effect of conventional irreversible MAOB inhibitors."
    },
    {
      "entity_id": "ent:ca4e00d2c52c",
      "entity_type": "MECHANISM",
      "name": "short-lived action",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Drawback of conventional irreversible MAOB inhibitors that reversible inhibitors can circumvent."
    },
    {
      "entity_id": "ent:bfc002f7cebe",
      "entity_type": "TREATMENT",
      "name": "monotherapy",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "A treatment approach used in the early phase of Parkinson's disease, as described for selegiline."
    },
    {
      "entity_id": "ent:975c4a8d97bf",
      "entity_type": "TREATMENT",
      "name": "combination therapy",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "A treatment approach used with levodopa in more advanced Parkinson's disease states, as described for selegiline."
    },
    {
      "entity_id": "ent:f22ff4ee44c2",
      "entity_type": "TREATMENT",
      "name": "levodopa treatment",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "A treatment that selegiline has been shown to delay the time point for, according to the document."
    },
    {
      "entity_id": "ent:766d35489b24",
      "entity_type": "TREATMENT",
      "name": "long-term treatment",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "A treatment approach with selegiline suggested to delay the progression of Parkinson's disease signs and symptoms."
    },
    {
      "entity_id": "ent:d381f3dd452c",
      "entity_type": "TREATMENT",
      "name": "add-on therapy",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "A treatment approach used in more advanced Parkinson's disease, as described for rasagiline."
    },
    {
      "entity_id": "ent:853ef08fbe2e",
      "entity_type": "TREATMENT",
      "name": "gene therapy",
      "normalized_id": "N/A",
      "aliases": [
        "gene therapy"
      ],
      "description": "A technology mentioned as being developed for genetic manipulation in the treatment of Parkinson's disease."
    },
    {
      "entity_id": "ent:27ee4ab6b31d",
      "entity_type": "TREATMENT",
      "name": "genetic manipulation",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "An approach mentioned as a potential safe target for treatment in Parkinson's disease using MAOB."
    },
    {
      "entity_id": "ent:22997b413ae0",
      "entity_type": "DISEASE",
      "name": "dyskinesia",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Most common adverse event reported in clinical trials of safinamide."
    },
    {
      "entity_id": "ent:50cacde9afd2",
      "entity_type": "DISEASE",
      "name": "hypertension",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Severe condition that rasagiline may cause according to FDA label warnings."
    },
    {
      "entity_id": "ent:60f9025a409c",
      "entity_type": "DISEASE",
      "name": "hypotension",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Condition that rasagiline may cause according to FDA label warnings."
    },
    {
      "entity_id": "ent:812bf1c924ef",
      "entity_type": "DISEASE",
      "name": "hallucinations",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Condition that rasagiline may cause according to FDA label warnings."
    },
    {
      "entity_id": "ent:3e2137ed32dd",
      "entity_type": "OTHER",
      "name": "clinical trials",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Studies mentioned in the context of providing evidence for disease-modifying effects of selegiline."
    },
    {
      "entity_id": "ent:c00620e69c7f",
      "entity_type": "OTHER",
      "name": "head-to-head trials",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Clinical studies mentioned as needed to compare rasagiline with selegiline or other inhibitors."
    },
    {
      "entity_id": "ent:1cd82360ad96",
      "entity_type": "OTHER",
      "name": "off-target effects",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Undesirable properties mentioned as a disadvantage suffered by safinamide."
    },
    {
      "entity_id": "ent:bfd976a7df4f",
      "entity_type": "OTHER",
      "name": "adverse effects",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Negative outcomes mentioned as a disadvantage suffered by safinamide."
    },
    {
      "entity_id": "ent:8e3613e97a6a",
      "entity_type": "OTHER",
      "name": "therapeutic strategy",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "An approach mentioned as promising for next-generation treatment of early Parkinson's disease patients."
    },
    {
      "entity_id": "ent:9642f29b2cfb",
      "entity_type": "MECHANISM",
      "name": "MAOB inhibition",
      "normalized_id": "N/A",
      "aliases": [
        "selective, irreversible MAOB inhibitor"
      ],
      "description": "Described as the mechanism of action for selegiline, used in Parkinson's disease treatment."
    },
    {
      "entity_id": "ent:9bef84d72967",
      "entity_type": "MECHANISM",
      "name": "anti-apoptotic effects",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Potential effects of rasagiline observed in in vitro and in vivo parkinsonian models."
    },
    {
      "entity_id": "ent:7d72e67ffa29",
      "entity_type": "MECHANISM",
      "name": "inhibits voltage-gated sodium and N-type calcium channels",
      "normalized_id": "N/A",
      "aliases": [
        "ion channel blocking activity"
      ],
      "description": "Undesirable property of safinamide that modulates glutamate release."
    },
    {
      "entity_id": "ent:53e97b261bee",
      "entity_type": "MECHANISM",
      "name": "modulating glutamate release",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Effect resulting from safinamide's inhibition of voltage-gated sodium and N-type calcium channels."
    },
    {
      "entity_id": "ent:88437b3f39cf",
      "entity_type": "MECHANISM",
      "name": "neuroprotective properties",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Properties of safinamide thought to be related to MAOB inhibition and ion channel blocking activity."
    },
    {
      "entity_id": "ent:8adc0aedac66",
      "entity_type": "MECHANISM",
      "name": "excessive astrocytic GABA",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "PD-like pathology alleviated by KDS2010 in multiple rodent models of PD."
    },
    {
      "entity_id": "ent:1b49691f5ee9",
      "entity_type": "MECHANISM",
      "name": "nigrostriatal DAergic neuronal loss",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "PD-like pathology alleviated by KDS2010 in multiple rodent models of PD."
    },
    {
      "entity_id": "ent:739aee243b00",
      "entity_type": "MECHANISM",
      "name": "excessive GABA synthesis",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Process for which MAOB is responsible in reactive astrocytes of rodent PD models, leading to aberrant suppression of DAergic neurons."
    },
    {
      "entity_id": "ent:f1b9f45b5f0e",
      "entity_type": "PROTEIN",
      "name": "tyramine oxidase",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "A new enzyme system in liver described in reference 1."
    },
    {
      "entity_id": "ent:d399d77bc79c",
      "entity_type": "PROTEIN",
      "name": "monoamine oxidases A and B",
      "normalized_id": "N/A",
      "aliases": [
        "MAO",
        "MAO-A",
        "MAO-A and MAO-B",
        "MAO-B",
        "monoamine oxidase",
        "monoamine oxidase A",
        "monoamine oxidase B",
        "monoamine oxidase proteins",
        "monoamine oxidases"
      ],
      "description": "Enzymes whose developmental expression in mouse nervous systems is studied in reference 7."
    },
    {
      "entity_id": "ent:3788f2c479ae",
      "entity_type": "TREATMENT",
      "name": "reversible MAO-B inhibitor",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "A newly developed reversible inhibitor of monoamine oxidase B that is described as circumventing the shortcomings of irreversible inhibitors in Alzheimer's disease."
    },
    {
      "entity_id": "ent:29fa43362442",
      "entity_type": "MECHANISM",
      "name": "scar formation",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "A process prevented by inhibition of monoamine oxidase B in a stab wound injury model according to the text."
    },
    {
      "entity_id": "ent:80deca0424b0",
      "entity_type": "MECHANISM",
      "name": "neurotoxicity",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "A molecular pathway involved with 6-OHDA, dopamine and MPTP contributing to the apoptotic theory in Parkinson's disease."
    },
    {
      "entity_id": "ent:13a8b7b93f67",
      "entity_type": "MECHANISM",
      "name": "apoptotic theory",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "A theory in Parkinson's disease to which molecular pathways involving neurotoxicity contribute according to the text."
    },
    {
      "entity_id": "ent:934a250a1c4d",
      "entity_type": "DISEASE",
      "name": "Major Depressive Disorder",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "A disorder studied in relation to monoamine oxidase B total distribution volume in the prefrontal cortex."
    },
    {
      "entity_id": "ent:e639eca39780",
      "entity_type": "DISEASE",
      "name": "Parkinsonism",
      "normalized_id": "N/A",
      "aliases": [
        "Parkinson",
        "Parkinsonism"
      ],
      "description": "A condition where the pathological role of astrocytic MAOB is revealed by genetic studies."
    },
    {
      "entity_id": "ent:77a0a9f19ae9",
      "entity_type": "DISEASE",
      "name": "subcortical Stroke",
      "normalized_id": "N/A",
      "aliases": [
        "Stroke"
      ],
      "description": "A condition mentioned in the context of cortical hypometabolism and impeded functional recovery after its occurrence."
    },
    {
      "entity_id": "ent:84e2b5353e4b",
      "entity_type": "MECHANISM",
      "name": "inhibition",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Process described as necessary for increased functional activity of dopamine and 5-hydroxytryptamine."
    },
    {
      "entity_id": "ent:bdae51ed6cfe",
      "entity_type": "MECHANISM",
      "name": "oxidation",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Process described for dopamine and its inhibition by deprenyl in man."
    },
    {
      "entity_id": "ent:5ddc76f0336a",
      "entity_type": "OTHER",
      "name": "effective therapeutic candidate",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Description applied to KDS2010, a newly developed reversible MAO-B inhibitor, for Parkinson's Disease."
    },
    {
      "entity_id": "ent:6b7190f25743",
      "entity_type": "OTHER",
      "name": "phenylethylamine behaviour",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Behavior in rats that is potentiated by the monoamine oxidase B inhibitor deprenyl without inhibition of catecholamine metabolite formation."
    },
    {
      "entity_id": "ent:cdd8db06c38f",
      "entity_type": "OTHER",
      "name": "increased functional activity",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Activity of dopamine and 5-hydroxytryptamine that requires a certain degree of inhibition of monoamine oxidase enzymes."
    },
    {
      "entity_id": "ent:a1aecd802cf3",
      "entity_type": "OTHER",
      "name": "Species differences",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Differences in the deamination of dopamine and other substrates for monoamine oxidase in brain across species."
    },
    {
      "entity_id": "ent:d0d7cb64a9d4",
      "entity_type": "OTHER",
      "name": "Allotopic properties",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Properties of human brain monoamine oxidase discussed in a 1973 Nature New Biology publication."
    },
    {
      "entity_id": "ent:80db3a48898d",
      "entity_type": "OTHER",
      "name": "reservoir for L-DOPA",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Function attributed to striatal astrocytes in a 2014 PLoS ONE study."
    },
    {
      "entity_id": "ent:c8bf72d1086b",
      "entity_type": "OTHER",
      "name": "contemporary view",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "View of catecholamine metabolism with implications for physiology and medicine as presented in a pharmacology review."
    },
    {
      "entity_id": "ent:5a72b46266d4",
      "entity_type": "OTHER",
      "name": "sensitive two-photon probe",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Probe developed to selectively detect monoamine oxidase B activity in Parkinson's disease models."
    },
    {
      "entity_id": "ent:f23bfe8d09c7",
      "entity_type": "OTHER",
      "name": "dopaminergic nerve cell death",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Cell death process in Parkinson's disease investigated for potential involvement of monoamine oxidase type B."
    },
    {
      "entity_id": "ent:a73147c9c735",
      "entity_type": "OTHER",
      "name": "brain dialysis study",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Study method used to examine striatal dopamine metabolism in monoamine oxidase B-deficient mice."
    },
    {
      "entity_id": "ent:657fab43cea6",
      "entity_type": "OTHER",
      "name": "nigro-striatal lesions",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Lesions in rats used to study the effects of monoamine oxidase B inhibition on dopamine metabolism."
    },
    {
      "entity_id": "ent:fdf3d1eddd1f",
      "entity_type": "DRUG",
      "name": "cimoxatone",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Drug described as inhibiting the metabolism of dopamine by both forms of monoamine oxidase in rat brain."
    },
    {
      "entity_id": "ent:c58c5fbae281",
      "entity_type": "DRUG",
      "name": "meperidine",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Drug mentioned as having analogues that cause chronic Parkinsonism when injected intravenously."
    },
    {
      "entity_id": "ent:2eeb3d55ee5c",
      "entity_type": "DRUG",
      "name": "MPTP",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Toxin described in a mouse model of Parkinson's disease and noted for its binding and conversion in human brain."
    },
    {
      "entity_id": "ent:a02a65cb5200",
      "entity_type": "DISEASE",
      "name": "parkinsonian",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Term used to describe substantial nigra in relation to MPTP binding and toxin conversion."
    },
    {
      "entity_id": "ent:f904253205c6",
      "entity_type": "MECHANISM",
      "name": "deamination of dopamine",
      "normalized_id": "N/A",
      "aliases": [
        "dopamine deamination"
      ],
      "description": "The deamination of dopamine by human brain monoamine oxidase with specificity for the two enzyme forms in seven brain regions."
    },
    {
      "entity_id": "ent:dfb611151f62",
      "entity_type": "MECHANISM",
      "name": "extraneuronal toxin conversion",
      "normalized_id": "N/A",
      "aliases": [
        "toxin conversion"
      ],
      "description": "Evidence for extraneuronal toxin conversion in human brain is mentioned in the context of MPTP binding in parkinsonian substantia nigra."
    },
    {
      "entity_id": "ent:e76d9dba1250",
      "entity_type": "MECHANISM",
      "name": "Channel-mediated tonic GABA release",
      "normalized_id": "N/A",
      "aliases": [
        "GABA release",
        "tonic GABA release"
      ],
      "description": "Channel-mediated tonic GABA release from glia is described as a mechanism in the referenced study."
    },
    {
      "entity_id": "ent:c3adf0985045",
      "entity_type": "MECHANISM",
      "name": "Astrocytic urea cycle",
      "normalized_id": "N/A",
      "aliases": [
        "urea cycle"
      ],
      "description": "Astrocytic urea cycle detoxifies A-derived ammonia while impairing memory in Alzheimer's disease."
    },
    {
      "entity_id": "ent:181b9c5c4fd3",
      "entity_type": "MECHANISM",
      "name": "glutamate release",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Safinamide inhibits in vivo glutamate release in a rat model of Parkinson's disease according to the study."
    },
    {
      "entity_id": "ent:3508bd43f3ce",
      "entity_type": "TREATMENT",
      "name": "MPTP mouse model",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "An experimental protocol used to model Parkinson's disease in mice through neurotoxin administration."
    },
    {
      "entity_id": "ent:920e70e15bfa",
      "entity_type": "TREATMENT",
      "name": "therapy",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Treatment approaches for Parkinson's disease mentioned in the context of MPTP toxicity mechanisms."
    },
    {
      "entity_id": "ent:1bd5a2f4f2c8",
      "entity_type": "TREATMENT",
      "name": "anti-Parkinson drug",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Medications like safinamide developed for treating Parkinson's disease symptoms and pathology."
    },
    {
      "entity_id": "ent:ba7af383f574",
      "entity_type": "TREATMENT",
      "name": "MAO-B mouse model",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "An inducible experimental model of Parkinson's disease used to study basic mechanisms and develop therapeutics."
    },
    {
      "entity_id": "ent:19cab9ad7474",
      "entity_type": "TREATMENT",
      "name": "developing novel therapeutics",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "The process of creating new treatments for Parkinson's disease using experimental models."
    },
    {
      "entity_id": "ent:fcc88978986b",
      "entity_type": "TREATMENT",
      "name": "dopamine agonists",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "A class of Parkinson's disease medications compared with monoamine oxidase type-B inhibitors in effectiveness studies."
    },
    {
      "entity_id": "ent:254b905784ad",
      "entity_type": "TREATMENT",
      "name": "anti-inflammatory therapeutic",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Potential medical applications of monoamine oxidase inhibitors beyond their neurological effects."
    },
    {
      "entity_id": "ent:627b95546e41",
      "entity_type": "TREATMENT",
      "name": "disease-modification",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Therapeutic approaches aimed at altering the progression of Parkinson's disease rather than just treating symptoms."
    },
    {
      "entity_id": "ent:736789816dcd",
      "entity_type": "GENE",
      "name": "A53T-SNCA",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "A genetic variant (A53T) of the SNCA gene associated with Parkinson's disease pathology in an overexpression-induced model studied using CRISPR-Cas9 gene editing."
    },
    {
      "entity_id": "ent:8d14d88cfb8b",
      "entity_type": "DISEASE",
      "name": "aluminium induced neurotoxicity",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "N/A"
    },
    {
      "entity_id": "ent:6e425cc63a1d",
      "entity_type": "MECHANISM",
      "name": "oxidative damage",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "A process against which the aged substantia nigra is protected by deprenyl according to the cited study."
    },
    {
      "entity_id": "ent:5bc4f51890c3",
      "entity_type": "MECHANISM",
      "name": "antiapoptotic new protein synthesis",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "A process induced by propargylamines in serum- and nerve growth factor-withdrawn, NGF-differentiated PC-12 cells."
    },
    {
      "entity_id": "ent:167a63227ea1",
      "entity_type": "MECHANISM",
      "name": "first-pass metabolism",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "A metabolic process that certain formulations of selegiline bypass according to the evidence presented."
    },
    {
      "entity_id": "ent:9cdbd86f9782",
      "entity_type": "DRUG",
      "name": "Propargylamines",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Compounds described as inducing antiapoptotic new protein synthesis in serum- and nerve growth factor-withdrawn, NGF-differentiated PC-12 cells."
    },
    {
      "entity_id": "ent:e5ad530db782",
      "entity_type": "TREATMENT",
      "name": "Antisense Oligonucleotides",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Molecular mechanisms of these therapeutic agents are discussed in the context of nucleic acid therapy."
    },
    {
      "entity_id": "ent:2280dbc53a93",
      "entity_type": "TREATMENT",
      "name": "CRISPR-Cas9 Gene Editing",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Described as protecting from the A53T-SNCA overexpression-induced pathology of Parkinson's Disease In Vivo."
    },
    {
      "entity_id": "ent:0ca2fd9c234b",
      "entity_type": "MECHANISM",
      "name": "hypoxia",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "A stress condition under which STC2 expression is significantly stimulated."
    },
    {
      "entity_id": "ent:2c4f8bd577e3",
      "entity_type": "MECHANISM",
      "name": "nutrient deprivation",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "A stress condition under which STC2 expression is significantly stimulated."
    },
    {
      "entity_id": "ent:0ed8e9415cff",
      "entity_type": "MECHANISM",
      "name": "acquired resistance",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "A development promoted by STC2, specifically to chemo- and radio- therapies."
    },
    {
      "entity_id": "ent:275204214514",
      "entity_type": "MECHANISM",
      "name": "migration",
      "normalized_id": "N/A",
      "aliases": [
        "migration"
      ],
      "description": "A process promoted by STC2 overexpression according to multiple groups."
    },
    {
      "entity_id": "ent:9a21813f3861",
      "entity_type": "MECHANISM",
      "name": "immune response",
      "normalized_id": "N/A",
      "aliases": [
        "immune response"
      ],
      "description": "A process promoted by STC2 overexpression according to multiple groups."
    },
    {
      "entity_id": "ent:af7c6a514b63",
      "entity_type": "MECHANISM",
      "name": "tumour growth",
      "normalized_id": "N/A",
      "aliases": [
        "tumour growth"
      ],
      "description": "A process positively correlated with STC2 overexpression."
    },
    {
      "entity_id": "ent:3c10d6c3b551",
      "entity_type": "DISEASE",
      "name": "breast cancer",
      "normalized_id": "N/A",
      "aliases": [
        "Breast cancer"
      ],
      "description": "A human tumour where STC2 is broadly upregulated according to the text."
    },
    {
      "entity_id": "ent:23590a452689",
      "entity_type": "DISEASE",
      "name": "colorectal cancer",
      "normalized_id": "N/A",
      "aliases": [
        "Colorectal cancer"
      ],
      "description": "A human tumour where STC2 is broadly upregulated according to the text."
    },
    {
      "entity_id": "ent:24f7983a6a7f",
      "entity_type": "DISEASE",
      "name": "gastric cancer",
      "normalized_id": "N/A",
      "aliases": [
        "Gastric cancer"
      ],
      "description": "A human tumour where STC2 is broadly upregulated according to the text."
    },
    {
      "entity_id": "ent:31e561727b94",
      "entity_type": "DISEASE",
      "name": "esophageal squamous cell carcinoma",
      "normalized_id": "N/A",
      "aliases": [
        "ESCC",
        "Esophageal squamous cell carcinoma"
      ],
      "description": "A human tumour where STC2 is broadly upregulated according to the text."
    },
    {
      "entity_id": "ent:fdeaffb9a71e",
      "entity_type": "DISEASE",
      "name": "prostate cancer",
      "normalized_id": "N/A",
      "aliases": [
        "Prostate cancer"
      ],
      "description": "A human tumour where STC2 is broadly upregulated according to the text."
    },
    {
      "entity_id": "ent:fbab9237a0dc",
      "entity_type": "DISEASE",
      "name": "renal cell carcinoma",
      "normalized_id": "N/A",
      "aliases": [
        "RCC",
        "Renal cell carcinoma"
      ],
      "description": "A human tumour where STC2 is broadly upregulated according to the text."
    },
    {
      "entity_id": "ent:53c80f427cd0",
      "entity_type": "DISEASE",
      "name": "head and neck squamous cell carcinoma",
      "normalized_id": "N/A",
      "aliases": [
        "head and neck squamous cell carcinoma",
        "HNSC",
        "HNSCC"
      ],
      "description": "A human tumour where STC2 is broadly upregulated according to the text."
    },
    {
      "entity_id": "ent:7355b15f5f8e",
      "entity_type": "DISEASE",
      "name": "hepatocellular carcinoma",
      "normalized_id": "N/A",
      "aliases": [
        "HCC"
      ],
      "description": "A human tumour where STC2 is broadly upregulated according to the text."
    },
    {
      "entity_id": "ent:c63c8184ec05",
      "entity_type": "DISEASE",
      "name": "ovarian cancer",
      "normalized_id": "N/A",
      "aliases": [
        "Ovarian cancer"
      ],
      "description": "A human tumour where STC2 is broadly upregulated according to the text."
    },
    {
      "entity_id": "ent:a0ddd4c429f0",
      "entity_type": "DISEASE",
      "name": "lung cancer",
      "normalized_id": "N/A",
      "aliases": [
        "Lung cancer"
      ],
      "description": "A human tumour where STC2 is broadly upregulated according to the text."
    },
    {
      "entity_id": "ent:10cedd056771",
      "entity_type": "DISEASE",
      "name": "pancreatic cancer",
      "normalized_id": "N/A",
      "aliases": [
        "Pancreatic Cancer"
      ],
      "description": "A human tumour where STC2 is broadly upregulated according to the text."
    },
    {
      "entity_id": "ent:220d447e472d",
      "entity_type": "DISEASE",
      "name": "endometrial cancer",
      "normalized_id": "N/A",
      "aliases": [
        "Endometrial cancer"
      ],
      "description": "A human tumour where STC2 is broadly upregulated according to the text."
    },
    {
      "entity_id": "ent:19d2a32a9547",
      "entity_type": "DISEASE",
      "name": "neuroblastoma",
      "normalized_id": "N/A",
      "aliases": [
        "Neuroblastoma"
      ],
      "description": "A human tumour where STC2 is broadly upregulated according to the text."
    },
    {
      "entity_id": "ent:0b7c6805078b",
      "entity_type": "DISEASE",
      "name": "gallbladder cancer",
      "normalized_id": "N/A",
      "aliases": [
        "Gallbladder cancer"
      ],
      "description": "A human tumour where STC2 is broadly upregulated according to the text."
    },
    {
      "entity_id": "ent:de93663feb80",
      "entity_type": "DISEASE",
      "name": "cholangiocarcinoma",
      "normalized_id": "N/A",
      "aliases": [
        "CHOL",
        "Cholangiocarcinoma"
      ],
      "description": "A human tumour where STC2 is broadly upregulated according to the text."
    },
    {
      "entity_id": "ent:d01d6472060f",
      "entity_type": "DISEASE",
      "name": "acute myeloid leukemia",
      "normalized_id": "N/A",
      "aliases": [
        "acute Myeloid Leukemia",
        "LAML"
      ],
      "description": "A human tumour where STC2 expression is lower than in normal counterparts according to the text."
    },
    {
      "entity_id": "ent:fcf6cd64c58f",
      "entity_type": "DISEASE",
      "name": "skin cutaneous melanoma",
      "normalized_id": "N/A",
      "aliases": [
        "SKCM",
        "skin cutaneous melanoma"
      ],
      "description": "A human tumour where STC2 expression is lower than in normal counterparts according to the text."
    },
    {
      "entity_id": "ent:d935f1ac237f",
      "entity_type": "OTHER",
      "name": "Detection Methods",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Column header in a table listing various methods used to detect or measure biological markers in tumor studies."
    },
    {
      "entity_id": "ent:92949b18d058",
      "entity_type": "OTHER",
      "name": "Clinical Importance",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Column header in a table describing the clinical significance or relevance of findings from tumor studies."
    },
    {
      "entity_id": "ent:1578c0a72f80",
      "entity_type": "OTHER",
      "name": "qRT-PCR",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "A detection method used to measure mRNA levels, as indicated in studies of breast cancer and other tumors."
    },
    {
      "entity_id": "ent:71035bc2e106",
      "entity_type": "OTHER",
      "name": "FISH",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "A detection method used to assess STC2 expression in breast cancer studies."
    },
    {
      "entity_id": "ent:66b32be089aa",
      "entity_type": "OTHER",
      "name": "IHC",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "A detection method used to evaluate STC2 expression and its relationship with survival outcomes in various cancers."
    },
    {
      "entity_id": "ent:963fac1d13bb",
      "entity_type": "OTHER",
      "name": "Microarray",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "A detection method used to measure STC2 levels in breast cancer studies, correlating with prognosis."
    },
    {
      "entity_id": "ent:cfdb2f1b1892",
      "entity_type": "OTHER",
      "name": "RNA-Seq",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "A detection method used to assess STC2 expression levels and their association with prognosis in various cancers."
    },
    {
      "entity_id": "ent:1f30b07cc14b",
      "entity_type": "BIOMARKER",
      "name": "STC2 IHC staining score",
      "normalized_id": "N/A",
      "aliases": [
        "Blood STC2 levels",
        "cytosolic STC2 staining",
        "STC2",
        "STC2 expression",
        "STC2 levels",
        "STC2 mRNA",
        "STC2 mRNA expression",
        "STC2 mRNA levels",
        "STC2 staining"
      ],
      "description": "STC2 IHC staining score is correlated with high Gleason scores in prostate cancer as stated in the text."
    },
    {
      "entity_id": "ent:35110d20daa5",
      "entity_type": "DISEASE",
      "name": "ESCC",
      "normalized_id": "N/A",
      "aliases": [
        "ESCC"
      ],
      "description": "Condition where elevated STC2 mRNA levels are associated with lymph node metastasis and poor prognosis."
    },
    {
      "entity_id": "ent:43b66291a272",
      "entity_type": "DISEASE",
      "name": "clear cell RCC",
      "normalized_id": "N/A",
      "aliases": [
        "papillary RCC",
        "RCC"
      ],
      "description": "Type of RCC where patients with high cytosolic STC2 staining have poor prognosis compared to those with low expression."
    },
    {
      "entity_id": "ent:9e5c946017ad",
      "entity_type": "DISEASE",
      "name": "HNSCC",
      "normalized_id": "N/A",
      "aliases": [
        "HNSCC"
      ],
      "description": "Condition where elevated STC2 expression is correlated with poor outcome and high STC2 expression is significantly associated with poor survival."
    },
    {
      "entity_id": "ent:2532c00492a0",
      "entity_type": "DISEASE",
      "name": "HCC",
      "normalized_id": "N/A",
      "aliases": [
        "HCC"
      ],
      "description": "Cancer where STC2 expression is associated with poor survival, correlated with poor prognosis, and can predict overall survival."
    },
    {
      "entity_id": "ent:62093514f4b4",
      "entity_type": "TREATMENT",
      "name": "anti-estrogen therapy",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Described as a standard treatment for patients with estrogen receptor-positive breast cancers."
    },
    {
      "entity_id": "ent:714288d937cc",
      "entity_type": "PROTEIN",
      "name": "estrogen receptor",
      "normalized_id": "N/A",
      "aliases": [
        "Er"
      ],
      "description": "Receptor described as positive in most breast cancers and interacting with circulatory estrogens, with its constitutive activation leading to hyper-activation of downstream survival signaling."
    },
    {
      "entity_id": "ent:3f9158614d65",
      "entity_type": "PROTEIN",
      "name": "human epidermal growth factor receptor 2",
      "normalized_id": "N/A",
      "aliases": [
        "ErbB2"
      ],
      "description": "Receptor described as demonstrating amplification and/or overexpression in approximately 15-20% breast cancer patients, which can form homodimers or heterodimers with other ErbB family members."
    },
    {
      "entity_id": "ent:5313787d30a4",
      "entity_type": "MECHANISM",
      "name": "proliferation",
      "normalized_id": "N/A",
      "aliases": [
        "proliferation"
      ],
      "description": "A cellular process that STC2 is reported to control, along with migration and immune response."
    },
    {
      "entity_id": "ent:87ba11a0f112",
      "entity_type": "MECHANISM",
      "name": "activation",
      "normalized_id": "N/A",
      "aliases": [
        "activation"
      ],
      "description": "Constitutive activation of Er signaling leads to hyper-activation of downstream survival signaling."
    },
    {
      "entity_id": "ent:ea7c3ed59686",
      "entity_type": "MECHANISM",
      "name": "signaling",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Er signaling, when constitutively activated, leads to hyper-activation of downstream survival signaling."
    },
    {
      "entity_id": "ent:bf7569086e49",
      "entity_type": "MECHANISM",
      "name": "cell growth",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Downstream survival signaling promoted by constitutive Er activation promotes cell growth and inhibits apoptosis."
    },
    {
      "entity_id": "ent:67cded7528c8",
      "entity_type": "MECHANISM",
      "name": "survival",
      "normalized_id": "N/A",
      "aliases": [
        "survival"
      ],
      "description": "Downstream signaling activated by ErbB2 enhances survival and proliferation of oncogenic cells."
    },
    {
      "entity_id": "ent:f2bccbfda20f",
      "entity_type": "DISEASE",
      "name": "colon adenocarcinoma",
      "normalized_id": "N/A",
      "aliases": [
        "COAD"
      ],
      "description": "A type of human tumour mentioned in the comparison of STC2 expression between tumours and normal tissues."
    },
    {
      "entity_id": "ent:397688ce2cba",
      "entity_type": "DISEASE",
      "name": "esophageal carcinoma",
      "normalized_id": "N/A",
      "aliases": [
        "ESCA"
      ],
      "description": "A type of human tumour mentioned in the comparison of STC2 expression between tumours and normal tissues."
    },
    {
      "entity_id": "ent:91e3fabb72fc",
      "entity_type": "DISEASE",
      "name": "glioblastoma multiforme",
      "normalized_id": "N/A",
      "aliases": [
        "GBM"
      ],
      "description": "A type of human tumour mentioned in the comparison of STC2 expression between tumours and normal tissues."
    },
    {
      "entity_id": "ent:3bfc47b22efd",
      "entity_type": "DISEASE",
      "name": "kidney renal clear cell carcinoma",
      "normalized_id": "N/A",
      "aliases": [
        "KIRC"
      ],
      "description": "A type of human tumour mentioned in the comparison of STC2 expression between tumours and normal tissues."
    },
    {
      "entity_id": "ent:771f62db4f1c",
      "entity_type": "DISEASE",
      "name": "brain lower grade glioma",
      "normalized_id": "N/A",
      "aliases": [
        "LGG"
      ],
      "description": "A type of human tumour mentioned in the comparison of STC2 expression between tumours and normal tissues."
    },
    {
      "entity_id": "ent:15fe14fcee6f",
      "entity_type": "DISEASE",
      "name": "ovarian serous cystadenocarcinoma",
      "normalized_id": "N/A",
      "aliases": [
        "OV"
      ],
      "description": "A type of human tumour mentioned in the comparison of STC2 expression between tumours and normal tissues."
    },
    {
      "entity_id": "ent:5558c8e7249e",
      "entity_type": "DISEASE",
      "name": "rectum adenocarcinoma",
      "normalized_id": "N/A",
      "aliases": [
        "READ"
      ],
      "description": "A type of human tumour mentioned in the comparison of STC2 expression between tumours and normal tissues."
    },
    {
      "entity_id": "ent:b358be8a154f",
      "entity_type": "DISEASE",
      "name": "uterine corpus endometrial carcinoma",
      "normalized_id": "N/A",
      "aliases": [
        "UCEC"
      ],
      "description": "A type of human tumour mentioned in the comparison of STC2 expression between tumours and normal tissues."
    },
    {
      "entity_id": "ent:31d57c4427fc",
      "entity_type": "DISEASE",
      "name": "uterine carcinosarcoma",
      "normalized_id": "N/A",
      "aliases": [
        "UCS"
      ],
      "description": "A type of human tumour mentioned in the comparison of STC2 expression between tumours and normal tissues."
    },
    {
      "entity_id": "ent:fb0f767385ef",
      "entity_type": "DISEASE",
      "name": "Adrenocortical carcinoma",
      "normalized_id": "N/A",
      "aliases": [
        "ACC"
      ],
      "description": "A type of human tumour mentioned in the comparison of STC2 expression between tumours and normal tissues."
    },
    {
      "entity_id": "ent:385bf21bc588",
      "entity_type": "DISEASE",
      "name": "Cervical squamous cell carcinoma and endocervical adenocarcinoma",
      "normalized_id": "N/A",
      "aliases": [
        "CESC"
      ],
      "description": "A type of human tumour mentioned in the comparison of STC2 expression between tumours and normal tissues."
    },
    {
      "entity_id": "ent:dbf9ed602283",
      "entity_type": "DISEASE",
      "name": "Lymphoid Neoplasm Diffuse Large B-cell Lymphoma",
      "normalized_id": "N/A",
      "aliases": [
        "DLBC"
      ],
      "description": "A type of human tumour mentioned in the comparison of STC2 expression between tumours and normal tissues."
    },
    {
      "entity_id": "ent:14d8234f25e5",
      "entity_type": "DISEASE",
      "name": "Kidney Chromophobe",
      "normalized_id": "N/A",
      "aliases": [
        "KICH"
      ],
      "description": "A type of human tumour mentioned in the comparison of STC2 expression between tumours and normal tissues."
    },
    {
      "entity_id": "ent:f7cdf4c75d65",
      "entity_type": "DISEASE",
      "name": "Liver hepatocellular carcinoma",
      "normalized_id": "N/A",
      "aliases": [
        "LIHC"
      ],
      "description": "A type of human tumour mentioned in the comparison of STC2 expression between tumours and normal tissues."
    },
    {
      "entity_id": "ent:96cf25b394ba",
      "entity_type": "DISEASE",
      "name": "Lung squamous cell carcinoma",
      "normalized_id": "N/A",
      "aliases": [
        "LUSC"
      ],
      "description": "A type of human tumour mentioned in the comparison of STC2 expression between tumours and normal tissues."
    },
    {
      "entity_id": "ent:2ad447516ae5",
      "entity_type": "DISEASE",
      "name": "Pheochromocytoma and Paraganglioma",
      "normalized_id": "N/A",
      "aliases": [
        "PCPG"
      ],
      "description": "A type of human tumour mentioned in the comparison of STC2 expression between tumours and normal tissues."
    },
    {
      "entity_id": "ent:ce8c7f70561e",
      "entity_type": "DISEASE",
      "name": "Sarcoma",
      "normalized_id": "N/A",
      "aliases": [
        "SARC"
      ],
      "description": "A type of human tumour mentioned in the comparison of STC2 expression between tumours and normal tissues."
    },
    {
      "entity_id": "ent:8fd49161d452",
      "entity_type": "DISEASE",
      "name": "Stomach adenocarcinoma",
      "normalized_id": "N/A",
      "aliases": [
        "STAD"
      ],
      "description": "A type of human tumour mentioned in the comparison of STC2 expression between tumours and normal tissues."
    },
    {
      "entity_id": "ent:a019420e94bc",
      "entity_type": "DISEASE",
      "name": "Testicular Germ Cell Tumours",
      "normalized_id": "N/A",
      "aliases": [
        "TGCT"
      ],
      "description": "A type of human tumour mentioned in the comparison of STC2 expression between tumours and normal tissues."
    },
    {
      "entity_id": "ent:2177d318ce40",
      "entity_type": "DISEASE",
      "name": "Thymoma",
      "normalized_id": "N/A",
      "aliases": [
        "THYM"
      ],
      "description": "A type of human tumour mentioned in the comparison of STC2 expression between tumours and normal tissues."
    },
    {
      "entity_id": "ent:7794e3c7aae2",
      "entity_type": "DISEASE",
      "name": "Bladder Urothelial Carcinoma",
      "normalized_id": "N/A",
      "aliases": [
        "BLCA"
      ],
      "description": "A type of human tumour mentioned in the comparison of STC2 expression between tumours and normal tissues."
    },
    {
      "entity_id": "ent:8cc25f3b8f9c",
      "entity_type": "DISEASE",
      "name": "Breast invasive carcinoma",
      "normalized_id": "N/A",
      "aliases": [
        "BRCA"
      ],
      "description": "A type of human tumour mentioned in the comparison of STC2 expression between tumours and normal tissues."
    },
    {
      "entity_id": "ent:330b2216dbaf",
      "entity_type": "DISEASE",
      "name": "Kidney renal papillary cell carcinoma",
      "normalized_id": "N/A",
      "aliases": [
        "KIRP"
      ],
      "description": "A type of human tumour mentioned in the comparison of STC2 expression between tumours and normal tissues."
    },
    {
      "entity_id": "ent:afcb148dae91",
      "entity_type": "DISEASE",
      "name": "Lung adenocarcinoma",
      "normalized_id": "N/A",
      "aliases": [
        "LUAD"
      ],
      "description": "A type of human tumour mentioned in the comparison of STC2 expression between tumours and normal tissues."
    },
    {
      "entity_id": "ent:fa003968f5bc",
      "entity_type": "DISEASE",
      "name": "Pancreatic adenocarcinoma",
      "normalized_id": "N/A",
      "aliases": [
        "PAAD"
      ],
      "description": "A type of human tumour mentioned in the comparison of STC2 expression between tumours and normal tissues."
    },
    {
      "entity_id": "ent:d86b9a9a35fb",
      "entity_type": "DISEASE",
      "name": "Prostate adenocarcinoma",
      "normalized_id": "N/A",
      "aliases": [
        "PRAD"
      ],
      "description": "A type of human tumour mentioned in the comparison of STC2 expression between tumours and normal tissues."
    },
    {
      "entity_id": "ent:9ba3ebf8f7c0",
      "entity_type": "DISEASE",
      "name": "Thyroid carcinoma",
      "normalized_id": "N/A",
      "aliases": [
        "THCA"
      ],
      "description": "A type of human tumour mentioned in the comparison of STC2 expression between tumours and normal tissues."
    },
    {
      "entity_id": "ent:2fe9fbecdcd1",
      "entity_type": "DISEASE",
      "name": "breast cancers",
      "normalized_id": "N/A",
      "aliases": [
        "breast cancer",
        "breast cancers"
      ],
      "description": "Most (~70%) are positive for estrogen receptor (Er), and anti-estrogen therapy is a standard treatment for patients with Er-positive breast cancers."
    },
    {
      "entity_id": "ent:663bcbfe890e",
      "entity_type": "MECHANISM",
      "name": "stress response factor",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "STC2 is described as a stress response factor that may reduce cell proliferation when nutrient is limited."
    },
    {
      "entity_id": "ent:739cd79f99ee",
      "entity_type": "TREATMENT",
      "name": "surgery",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Treatment mentioned as remaining one of the most effective treatments for patients with local prostate cancer tumours."
    },
    {
      "entity_id": "ent:42decf6ec30a",
      "entity_type": "TREATMENT",
      "name": "medical androgen ablation",
      "normalized_id": "N/A",
      "aliases": [
        "castration"
      ],
      "description": "Treatment mentioned as something the majority of relapsed prostate cancer patients still demonstrate acceptable response to."
    },
    {
      "entity_id": "ent:198096b450c2",
      "entity_type": "TREATMENT",
      "name": "radical nephrectomy",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Surgical procedure mentioned in relation to survival rates for renal cell carcinoma patients."
    },
    {
      "entity_id": "ent:910d9b3ed16c",
      "entity_type": "DISEASE",
      "name": "advanced stage gastric cancer",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "A condition where patients often first visit with an advanced stage, and postoperative adjuvant chemotherapy assists prognosis improvement."
    },
    {
      "entity_id": "ent:5c1af8103579",
      "entity_type": "DISEASE",
      "name": "tumour invasion",
      "normalized_id": "N/A",
      "aliases": [
        "tumour invasion"
      ],
      "description": "A factor correlated with elevated STC2 expression in gastric cancer."
    },
    {
      "entity_id": "ent:87d641a65ed4",
      "entity_type": "DISEASE",
      "name": "poor prognosis",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "A condition correlated with elevated STC2 expression in gastric cancer and ESCC."
    },
    {
      "entity_id": "ent:6396f29391e0",
      "entity_type": "DISEASE",
      "name": "lymphatic invasion",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "A factor correlated with STC2 levels in ESCC patients."
    },
    {
      "entity_id": "ent:fb0c177cc351",
      "entity_type": "DISEASE",
      "name": "lymph node metastasis",
      "normalized_id": "N/A",
      "aliases": [
        "lymph node metastasis"
      ],
      "description": "A factor correlated with STC2 levels in ESCC patients."
    },
    {
      "entity_id": "ent:75ac61b8b416",
      "entity_type": "DISEASE",
      "name": "cancer-related death",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "N/A"
    },
    {
      "entity_id": "ent:895aaafcb46f",
      "entity_type": "DISEASE",
      "name": "castration-resistant prostate cancer",
      "normalized_id": "N/A",
      "aliases": [
        "CRPC"
      ],
      "description": "A condition where tumours become castration-resistant and more aggressive, with increased STC2 mRNA levels in cells."
    },
    {
      "entity_id": "ent:0175c710c0c2",
      "entity_type": "DISEASE",
      "name": "aggressive prostate cancer",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "A condition for which STC2 may serve as a novel diagnostic biomarker."
    },
    {
      "entity_id": "ent:bf1620ad5b42",
      "entity_type": "DISEASE",
      "name": "kidney tumours",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "N/A"
    },
    {
      "entity_id": "ent:b214803b97f8",
      "entity_type": "DISEASE",
      "name": "metastatic RCC",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "A condition for which there is no effective treatment, making search for novel therapeutic targets critical."
    },
    {
      "entity_id": "ent:0107b8509188",
      "entity_type": "TREATMENT",
      "name": "therapeutic treatment",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "The text mentions therapeutic treatment as something that, along with some compounds, can trigger ER stress."
    },
    {
      "entity_id": "ent:94f30b5d604d",
      "entity_type": "TREATMENT",
      "name": "tunicamycin",
      "normalized_id": "N/A",
      "aliases": [
        "an inhibitor of N-linked glycosylation"
      ],
      "description": "Described as an inhibitor of N-linked glycosylation used in treatment to induce the expression of factors like STC2."
    },
    {
      "entity_id": "ent:c7e694f8a620",
      "entity_type": "TREATMENT",
      "name": "thapsigargin",
      "normalized_id": "N/A",
      "aliases": [
        "an inhibitor of sarco- (endo-) plasmic reticulum Ca^{2+}-ATPase"
      ],
      "description": "Described as an inhibitor of sarco-(endo-)plasmic reticulum Ca^{2+}-ATPase used in treatment to induce the expression of factors like STC2."
    },
    {
      "entity_id": "ent:2ebc820e0c5a",
      "entity_type": "PATHWAY",
      "name": "ER stress response",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "A response triggered by hypoxia, nutrient depletion, ATP depletion, oxidative stress, or compounds disrupting ER functions, leading to the sequestration of BiP and activation of transcription factors."
    },
    {
      "entity_id": "ent:6ff56b0d344a",
      "entity_type": "PATHWAY",
      "name": "JNK/NF-B and CHOP pathways",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Pathways activated by severe and prolonged ER stress that promote apoptosis."
    },
    {
      "entity_id": "ent:1894a5e2b44a",
      "entity_type": "PATHWAY",
      "name": "p-eIF2a-ATF4 axis",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Serves as a modulator of the severity of ER stress response by activating three downstream stress genes under moderate stress conditions."
    },
    {
      "entity_id": "ent:ab7653a16064",
      "entity_type": "PATHWAY",
      "name": "integrated stress response (IRS)",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "A critical role mediated by ATF4, activated by stress conditions in the tumor microenvironment like uneven oxygen levels and insufficient nutrient supply."
    },
    {
      "entity_id": "ent:e97cd9054487",
      "entity_type": "PATHWAY",
      "name": "unfold protein response (UPR)",
      "normalized_id": "N/A",
      "aliases": [
        "ER stress",
        "unfold protein response",
        "UPR"
      ],
      "description": "An evolutionarily conserved response activated by ER stress that disrupts protein maturation and accumulates unfolded or misfolded proteins."
    },
    {
      "entity_id": "ent:b4dc81e7d670",
      "entity_type": "PATHWAY",
      "name": "ATF4 pathway",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "A pathway on which ER stress-induced STC2 expression depends, but not on XBP-1 and ATF6."
    },
    {
      "entity_id": "ent:bf5fe76ae03f",
      "entity_type": "MECHANISM",
      "name": "oxidative stress",
      "normalized_id": "N/A",
      "aliases": [
        "oxidative stress"
      ],
      "description": "A condition that, along with hypoxia and nutrient depletion, triggers ER stress."
    },
    {
      "entity_id": "ent:b50d18d196c3",
      "entity_type": "MECHANISM",
      "name": "inflammatory response",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "A process whose involved genes are transcriptionally upregulated by activation of ATF6, ATF4 and XBP1 under ER stress conditions."
    },
    {
      "entity_id": "ent:7a73765039ae",
      "entity_type": "MECHANISM",
      "name": "protein folding",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "A process whose involved genes are transcriptionally upregulated by activation of ATF6, ATF4 and XBP1 under ER stress conditions."
    },
    {
      "entity_id": "ent:eb0026137d17",
      "entity_type": "MECHANISM",
      "name": "cell survival",
      "normalized_id": "N/A",
      "aliases": [
        "cell survival"
      ],
      "description": "A process promoted by STC2 modulation of ER stress response severity under moderate stress conditions."
    },
    {
      "entity_id": "ent:37f4945dfc3b",
      "entity_type": "MECHANISM",
      "name": "signal transduction",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "N/A"
    },
    {
      "entity_id": "ent:0b6f6d62aef8",
      "entity_type": "MECHANISM",
      "name": "receptor binding",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "N/A"
    },
    {
      "entity_id": "ent:80cdd561481b",
      "entity_type": "MECHANISM",
      "name": "dephosphorylation",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "N/A"
    },
    {
      "entity_id": "ent:98a96a3b9d57",
      "entity_type": "DISEASE",
      "name": "laryngeal cancer",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "A condition where STC2 has been detected in the sera of patients."
    },
    {
      "entity_id": "ent:3f233242093c",
      "entity_type": "DISEASE",
      "name": "glioma",
      "normalized_id": "N/A",
      "aliases": [
        "glioma"
      ],
      "description": "A tumor type from which STC2 is detected in the culture medium of derived cell lines."
    },
    {
      "entity_id": "ent:78dada768e89",
      "entity_type": "DISEASE",
      "name": "fibrosarcoma",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "A tumor type from which STC2 is detected in the culture medium of derived cell lines and where STC2 has been reported to be phosphorylated in human cells."
    },
    {
      "entity_id": "ent:e4172399a7e1",
      "entity_type": "DISEASE",
      "name": "tumor",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "A condition where it is promising to investigate the clinicopathological importance of serum STC2 levels in diagnosis and evaluating patients' prognosis."
    },
    {
      "entity_id": "ent:e4fe1de20815",
      "entity_type": "GENE",
      "name": "ATF6",
      "normalized_id": "N/A",
      "aliases": [
        "activating transcription factor 6",
        "ATF6"
      ],
      "description": "A negative regulator of ER stress whose activation leads to transcriptional upregulation of genes involved in ER homeostasis and other processes."
    },
    {
      "entity_id": "ent:6d170aeb0950",
      "entity_type": "GENE",
      "name": "PERK",
      "normalized_id": "N/A",
      "aliases": [
        "PERK",
        "PKR-like ER kinase"
      ],
      "description": "A factor that can be activated through the loss of interaction with Bip and/or direct binding with unfolded or misfolded proteins during ER stress."
    },
    {
      "entity_id": "ent:1d85301cd59c",
      "entity_type": "GENE",
      "name": "IRE1",
      "normalized_id": "N/A",
      "aliases": [
        "inositol-requiring protein 1",
        "IRE1"
      ],
      "description": "A factor that can be activated through the loss of interaction with Bip and/or direct binding with unfolded or misfolded proteins during ER stress."
    },
    {
      "entity_id": "ent:e7b0433b4833",
      "entity_type": "GENE",
      "name": "ATF4",
      "normalized_id": "N/A",
      "aliases": [
        "Activating transcription factor",
        "activating transcription factor 4",
        "ATF",
        "ATF4"
      ],
      "description": "A transcription factor whose activation leads to transcriptional upregulation of genes, and ER stress-induced STC2 expression depends on its pathway."
    },
    {
      "entity_id": "ent:b2ed84f7c1ee",
      "entity_type": "GENE",
      "name": "XBP1",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "A gene whose activation leads to transcriptional upregulation of genes involved in ER homeostasis and other processes."
    },
    {
      "entity_id": "ent:157f8be80f3a",
      "entity_type": "GENE",
      "name": "JNK",
      "normalized_id": "N/A",
      "aliases": [
        "JNK"
      ],
      "description": "Part of a pathway (JNK/NF-B) that is activated by severe and prolonged ER stress and promotes apoptosis."
    },
    {
      "entity_id": "ent:0a78999db51f",
      "entity_type": "GENE",
      "name": "NF-B",
      "normalized_id": "N/A",
      "aliases": [
        "NF-B"
      ],
      "description": "Part of a pathway (JNK/NF-B) that is activated by severe and prolonged ER stress and promotes apoptosis."
    },
    {
      "entity_id": "ent:3b017d5e45bf",
      "entity_type": "GENE",
      "name": "eIF2a",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "A factor dephosphorylated by GADD34 to attenuate ATF4-mediated stress response under moderate ER stress conditions."
    },
    {
      "entity_id": "ent:6522f966f7f7",
      "entity_type": "GENE",
      "name": "GADD34",
      "normalized_id": "N/A",
      "aliases": [
        "CHOP",
        "GADD34"
      ],
      "description": "A phosphoprotein phosphatase that directly dephosphorylates eIF2a to attenuate ATF4-mediated stress response under moderate ER stress."
    },
    {
      "entity_id": "ent:951580d4e4d5",
      "entity_type": "GENE",
      "name": "IRE1",
      "normalized_id": "N/A",
      "aliases": [
        "IRE1",
        "IRE1",
        "IRE1"
      ],
      "description": "Activated by aluminium toxicity-induced ER stress, leading to apoptosis associated with clinical stages."
    },
    {
      "entity_id": "ent:1b1363047762",
      "entity_type": "GENE",
      "name": "XBP-1",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "A pathway on which ER stress-induced STC2 expression does not depend, according to the document."
    },
    {
      "entity_id": "ent:7d8768c91951",
      "entity_type": "PROTEIN",
      "name": "BiP",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Negative regulator of ATF6, PERK and IRE1 that is sequestrated by misfolded proteins accumulated in the ER lumen during ER stress."
    },
    {
      "entity_id": "ent:08e6d97ee8f5",
      "entity_type": "PROTEIN",
      "name": "p-eIF2a",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Part of the p-eIF2a-ATF4 axis that serves as a modulator of the severity of ER stress response under moderate stress conditions."
    },
    {
      "entity_id": "ent:8008836cbf19",
      "entity_type": "PROTEIN",
      "name": "calcineurin",
      "normalized_id": "N/A",
      "aliases": [
        "calcineurin"
      ],
      "description": "Calcium and calmodulin dependent serine/threonine protein phosphatase that STC2 performs its function through affecting."
    },
    {
      "entity_id": "ent:4cfab6ef9c6e",
      "entity_type": "PROTEIN",
      "name": "casein kinase",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Phosphorylates STC2 between Serine-285 and Serine-298 in the C-terminal region in human fibrosarcoma cells."
    },
    {
      "entity_id": "ent:f840d0fe94d3",
      "entity_type": "PATHWAY",
      "name": "CHOP and JNK/NF-B pathways",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Pathways described as being cooperatively triggered by ER stress-responsive arms ATF4, ATF6 and IRE1 to induce apoptosis."
    },
    {
      "entity_id": "ent:b6aa731efbfe",
      "entity_type": "PATHWAY",
      "name": "ATF4-dependent adaptive pathway",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Pathway described as being regulated by STC2 through unknown mechanisms, with ATF4 expression upregulated despite PERK suppression."
    },
    {
      "entity_id": "ent:3acca5c1922f",
      "entity_type": "PATHWAY",
      "name": "ATF4 signaling",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Signaling described as being modulated by STC2 to limit the severity of ER stress, demonstrating protective effects."
    },
    {
      "entity_id": "ent:890a724213a0",
      "entity_type": "PATHWAY",
      "name": "eIF2-ATF4 axis",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Axis described as being activated by stress-activated kinases GCN2, PKR and HRI to facilitate cellular homeostasis and adaptation to stress conditions."
    },
    {
      "entity_id": "ent:2a580964940a",
      "entity_type": "PATHWAY",
      "name": "pentose pathway",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Pathway described as being inhibited during glucose deprivation, causing intracellular redox imbalance and leading to oxidative stress."
    },
    {
      "entity_id": "ent:3b75e47e24ac",
      "entity_type": "PATHWAY",
      "name": "hypoxic response",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Response described as evolutionarily conserved and activated by tumour cells under hypoxic conditions through stabilizing HIF-1."
    },
    {
      "entity_id": "ent:4cc9213c27e3",
      "entity_type": "GENE",
      "name": "CHOP",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "CHOP is involved in apoptosis pathways triggered by ER stress along with JNK/NF-B."
    },
    {
      "entity_id": "ent:ac2c7d568b1a",
      "entity_type": "GENE",
      "name": "calnexin",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Calnexin is mentioned as a Ca^{2+}-binding chaperone, part of the UPR genes whose transcription is suppressed."
    },
    {
      "entity_id": "ent:2e01276f1ef3",
      "entity_type": "GENE",
      "name": "calreticulin",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Calreticulin is mentioned as a Ca^{2+}-binding chaperone, part of the UPR genes whose transcription is suppressed."
    },
    {
      "entity_id": "ent:b2275ca3f598",
      "entity_type": "GENE",
      "name": "HRI",
      "normalized_id": "N/A",
      "aliases": [
        "Heme-Regulated Inhibitor (=Eukaryotic Translation Initiation Factor 2 Alpha Kinase 1)",
        "HRI"
      ],
      "description": "HRI is a stress-activated kinase that can activate the eIF2-ATF4 axis under various stress conditions."
    },
    {
      "entity_id": "ent:a62a5dc65fcc",
      "entity_type": "GENE",
      "name": "eIF2",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "eIF2 is part of the eIF2-ATF4 axis; its phosphorylation inhibits global translation but promotes ATF4 translation."
    },
    {
      "entity_id": "ent:2c830a4e1d8d",
      "entity_type": "GENE",
      "name": "HIF-1",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "HIF-1 is stabilized under hypoxic conditions and interacts with HIF-1 to form the HIF-1 heterodimer."
    },
    {
      "entity_id": "ent:dbe433230462",
      "entity_type": "GENE",
      "name": "HIF-1",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "HIF-1 interacts with HIF-1 to form the HIF-1 heterodimer under hypoxic conditions."
    },
    {
      "entity_id": "ent:6f5e2e8560bc",
      "entity_type": "GENE",
      "name": "CBP",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "CBP is mentioned as binding with HIF-1 in the nucleus to form a transcription complex that induces STC2 expression."
    },
    {
      "entity_id": "ent:5a287b219f76",
      "entity_type": "GENE",
      "name": "N-cadherin",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "N-cadherin is upregulated by STC2 as a mesenchymal marker during epithelial-mesenchymal transition (EMT)."
    },
    {
      "entity_id": "ent:ee274cba4b7d",
      "entity_type": "GENE",
      "name": "vimentin",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Vimentin is upregulated by STC2 as a mesenchymal marker during epithelial-mesenchymal transition (EMT)."
    },
    {
      "entity_id": "ent:b66f007e4d34",
      "entity_type": "GENE",
      "name": "E-cadherin",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "E-cadherin is downregulated by STC2 during epithelial-mesenchymal transition (EMT)."
    },
    {
      "entity_id": "ent:7ae390bfbc6e",
      "entity_type": "GENE",
      "name": "MMP",
      "normalized_id": "N/A",
      "aliases": [
        "matrix metalloproteinase",
        "MMP"
      ],
      "description": "MMP, specifically MMP-2 and -9, is upregulated by STC2 to drive cell migration and invasion."
    },
    {
      "entity_id": "ent:4786511cee73",
      "entity_type": "MECHANISM",
      "name": "cellular adaptation",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "A process facilitated by the conserved response upon moderate ER stress to enhance survival."
    },
    {
      "entity_id": "ent:382f5b176671",
      "entity_type": "MECHANISM",
      "name": "activating ER stress",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "A mechanism by which aluminium induces apoptosis as a cytotoxic reagent."
    },
    {
      "entity_id": "ent:1f76b87cfdeb",
      "entity_type": "MECHANISM",
      "name": "cellular homeostasis",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "A state facilitated by stress-activated kinases activating the eIF2-ATF4 axis under stress conditions."
    },
    {
      "entity_id": "ent:9a7f198a70c9",
      "entity_type": "MECHANISM",
      "name": "adaptation to stress conditions",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "A process facilitated by stress-activated kinases activating the eIF2-ATF4 axis under conditions like proteotoxicity and nutrient withdrawal."
    },
    {
      "entity_id": "ent:55a4b999a0ec",
      "entity_type": "MECHANISM",
      "name": "proteotoxicity",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "A stress condition under which stress-activated kinases can activate the eIF2-ATF4 axis."
    },
    {
      "entity_id": "ent:86fbd195dae9",
      "entity_type": "MECHANISM",
      "name": "nutrient withdrawal",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "A stress condition under which stress-activated kinases can activate the eIF2-ATF4 axis."
    },
    {
      "entity_id": "ent:aeddfdd75374",
      "entity_type": "MECHANISM",
      "name": "viral infection",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "A stress condition under which stress-activated kinases can activate the eIF2-ATF4 axis."
    },
    {
      "entity_id": "ent:dd7cd2ae4a15",
      "entity_type": "MECHANISM",
      "name": "phosphorylated eIF2 inhibits global protein translation",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "A mechanism under stress conditions where phosphorylated eIF2 inhibits global protein translation but selectively promotes translation of proteins like ATF4."
    },
    {
      "entity_id": "ent:1794c9f62ad2",
      "entity_type": "MECHANISM",
      "name": "stress response",
      "normalized_id": "N/A",
      "aliases": [
        "stress response"
      ],
      "description": "A critical function for cell survival where proteins like ATF4 are selectively translated under stress conditions."
    },
    {
      "entity_id": "ent:1bc07d4cccdf",
      "entity_type": "MECHANISM",
      "name": "phosphorylation of eIF2",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "A process promoted by glutamine deprivation through amino acids deprivation triggered GCN2 activation."
    },
    {
      "entity_id": "ent:a36ce08e88fe",
      "entity_type": "MECHANISM",
      "name": "GCN2 activation",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "An activation triggered by amino acids deprivation that promotes phosphorylation of eIF2 during glutamine deprivation."
    },
    {
      "entity_id": "ent:cd403280c92c",
      "entity_type": "MECHANISM",
      "name": "glucose deprivation impairs ATP production",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "A mechanism by which glucose deprivation triggers ER stress."
    },
    {
      "entity_id": "ent:4606b937ae69",
      "entity_type": "MECHANISM",
      "name": "inhibited pentose pathway causes intracellular redox imbalance",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "A mechanism leading to oxidative stress during glucose deprivation, which triggers ER stress."
    },
    {
      "entity_id": "ent:9ccc6ffade0a",
      "entity_type": "MECHANISM",
      "name": "low glucose also suppresses protein glycosylation",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "A mechanism during glucose deprivation that results in protein unfolding/misfolding, triggering ER stress."
    },
    {
      "entity_id": "ent:fc943a67d75e",
      "entity_type": "MECHANISM",
      "name": "protein unfolding/misfolding",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "A result of suppressed protein glycosylation due to low glucose, which triggers ER stress."
    },
    {
      "entity_id": "ent:29e8725cd435",
      "entity_type": "MECHANISM",
      "name": "adaptation of cells to various types of stresses",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "A process mediated by STC2 as a general stress-responsive factor through ATF4-dependent induction."
    },
    {
      "entity_id": "ent:1d1998360a8b",
      "entity_type": "MECHANISM",
      "name": "cell cycle progression",
      "normalized_id": "N/A",
      "aliases": [
        "cell cycle progression"
      ],
      "description": "A process promoted by STC2 under hypoxic conditions through enhancing cyclin D expression and Rb phosphorylation."
    },
    {
      "entity_id": "ent:24e37830b964",
      "entity_type": "MECHANISM",
      "name": "epithelial-mesenchymal transition (EMT)",
      "normalized_id": "N/A",
      "aliases": [
        "EMT"
      ],
      "description": "A process induced by STC2 under hypoxic conditions through upregulating mesenchymal markers and downregulating E-cadherin."
    },
    {
      "entity_id": "ent:b33d4fc68bb1",
      "entity_type": "MECHANISM",
      "name": "cell migration and invasion",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Processes driven by STC2 under hypoxic conditions through the upregulation of matrix metalloproteinase (MMP)-2 and -9."
    },
    {
      "entity_id": "ent:8521f646d630",
      "entity_type": "MECHANISM",
      "name": "adaptive response",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "A response mediated by genes whose expression is enhanced by HIF-1 binding to HRE under hypoxic conditions."
    },
    {
      "entity_id": "ent:020301f9939a",
      "entity_type": "PROTEIN",
      "name": "JNK/NF-B",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "A pathway via which the three ER stress-triggered responsive arms ATF4, ATF6 and IRE1 may cooperatively trigger apoptosis upon persisting and severe ER stress."
    },
    {
      "entity_id": "ent:324af0aa7d91",
      "entity_type": "PROTEIN",
      "name": "BiP/Grp78",
      "normalized_id": "N/A",
      "aliases": [
        "BiP",
        "Grp78"
      ],
      "description": "A molecular chaperone and UPR gene whose transcription is suppressed by aluminium glycinate."
    },
    {
      "entity_id": "ent:1f114e5c1735",
      "entity_type": "PROTEIN",
      "name": "CBP/p300",
      "normalized_id": "N/A",
      "aliases": [
        "CBP/p300",
        "p300"
      ],
      "description": "A transcription complex component that HIF-1 binds to in the nucleus to induce the expression of STC2 under hypoxic conditions."
    },
    {
      "entity_id": "ent:f66ea0eed00c",
      "entity_type": "PROTEIN",
      "name": "cyclin D",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "A protein whose expression is enhanced by STC2 to promote cell cycle progression under hypoxic conditions."
    },
    {
      "entity_id": "ent:3d6256a36491",
      "entity_type": "PROTEIN",
      "name": "Rb",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "A protein whose phosphorylation is enhanced by STC2 to promote cell cycle progression under hypoxic conditions."
    },
    {
      "entity_id": "ent:8917d5aec9aa",
      "entity_type": "PROTEIN",
      "name": "matrix metalloproteinase (MMP)-2",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "A protein upregulated by STC2 to drive cell migration and invasion under hypoxic conditions."
    },
    {
      "entity_id": "ent:c5d625a9ca94",
      "entity_type": "PROTEIN",
      "name": "matrix metalloproteinase (MMP)-9",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "A protein upregulated by STC2 to drive cell migration and invasion under hypoxic conditions."
    },
    {
      "entity_id": "ent:c96b7ae81d2f",
      "entity_type": "BIOMARKER",
      "name": "STC2 mRNA",
      "normalized_id": "N/A",
      "aliases": [
        "STC2"
      ],
      "description": "N/A"
    },
    {
      "entity_id": "ent:823b1851aacd",
      "entity_type": "PROTEIN",
      "name": "HMGA2",
      "normalized_id": "N/A",
      "aliases": [
        "High-mobility gene group A2",
        "HMGA2"
      ],
      "description": "A non-histone chromatin factor and oncofetal protein that regulates cell growth, differentiation, and migration, and can transcriptionally upregulate STC2 during fetal development and oncogenesis."
    },
    {
      "entity_id": "ent:e993fd630e27",
      "entity_type": "PROTEIN",
      "name": "HMGA",
      "normalized_id": "N/A",
      "aliases": [
        "High Mobility Group A"
      ],
      "description": "A family of non-histone chromatin factors that possess transcriptional activities, with three members: HMGA1a, HMGA1b, and HMGA2."
    },
    {
      "entity_id": "ent:bd6e96111104",
      "entity_type": "PROTEIN",
      "name": "AhR",
      "normalized_id": "N/A",
      "aliases": [
        "AhR",
        "Aryl hydrocarbon receptor"
      ],
      "description": "A transcription factor that acts as an environmental sensor, with STC2 identified as a putative downstream target in hepatocytes, and its agonists can block STC2 expression."
    },
    {
      "entity_id": "ent:24424170339e",
      "entity_type": "PROTEIN",
      "name": "Sp1",
      "normalized_id": "N/A",
      "aliases": [
        "Sp1",
        "Specificity protein 1"
      ],
      "description": "A transactivation molecule that belongs to the Sp or Krppel-like factor protein family, promotes oncogene activities, and directly regulates STC2 by altering its promoter activity and protein levels."
    },
    {
      "entity_id": "ent:bb824a4749f6",
      "entity_type": "GENE",
      "name": "HIF-1 ",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "The constitutively active form (AdCA5) of this protein upregulates STC2 expression at mRNA and protein levels."
    },
    {
      "entity_id": "ent:b69c90b613c6",
      "entity_type": "GENE",
      "name": "HMGA1a",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "A member of the HMGA protein family, which are non-histone chromatin factors with transcriptional activities."
    },
    {
      "entity_id": "ent:b5fdaf2fac19",
      "entity_type": "GENE",
      "name": "HMGA1b",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "A member of the HMGA protein family, which are non-histone chromatin factors with transcriptional activities."
    },
    {
      "entity_id": "ent:1a8c07468561",
      "entity_type": "MECHANISM",
      "name": "hypoxia induces the expression of STC2",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Hypoxia induces STC2 expression in proximal tubular epithelial cells, with longer exposure leading to higher mRNA levels."
    },
    {
      "entity_id": "ent:13900a42cfcd",
      "entity_type": "MECHANISM",
      "name": "HIF-1 directly binds to HRE binding motifs",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "HIF-1 directly binds to conserved HRE binding motifs in the STC2 promoter, as shown by electrophoretic mobility shift assay."
    },
    {
      "entity_id": "ent:3ef980fc9e8a",
      "entity_type": "MECHANISM",
      "name": "methylation of CpG islands compromises STC2 expression",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Methylation of CpG islands in the STC2 promoter region compromises STC2 expression in cancer cells but not normal epithelial cells."
    },
    {
      "entity_id": "ent:b6f87cff8785",
      "entity_type": "MECHANISM",
      "name": "5-aza-2-deoxycytidine induces STC2 expression",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "DNA methylation inhibitor 5-aza-2'-deoxycytidine induces STC2 expression by inhibiting methylation."
    },
    {
      "entity_id": "ent:8050493ccc82",
      "entity_type": "MECHANISM",
      "name": "chetomin reverses hypoxia-induced STC2 expression",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Chetomin, a p300 inhibitor, reverses hypoxia-induced STC2 expression, highlighting CBP/p300 as co-activators of HIF-1."
    },
    {
      "entity_id": "ent:d1950f33c4f8",
      "entity_type": "MECHANISM",
      "name": "CBP/p300 are indispensable co-activators of HIF-1 for STC2 upregulation",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "CBP/p300 are described as indispensable co-activators of HIF-1 for STC2 upregulation during hypoxia."
    },
    {
      "entity_id": "ent:3ae811f0d46a",
      "entity_type": "MECHANISM",
      "name": "STC2 facilitates cell survival, proliferation and migration",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "STC2 facilitates cell survival, proliferation and migration under low oxygen conditions as a direct HIF-1 target."
    },
    {
      "entity_id": "ent:baafe4adc229",
      "entity_type": "MECHANISM",
      "name": "HMGA2 regulates cell growth, differentiation and migration",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "HMGA2 regulates cell growth, differentiation and migration according to the text."
    },
    {
      "entity_id": "ent:d57f2b2cf503",
      "entity_type": "MECHANISM",
      "name": "ectopic HMGA2 expression enhances luciferase activity mediated by STC2 promoter",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Ectopic HMGA2 expression enhances STC2 promoter-mediated luciferase activity dose-dependently, suggesting transcriptional induction."
    },
    {
      "entity_id": "ent:08523c9212ea",
      "entity_type": "MECHANISM",
      "name": "HMGA2 upregulates STC2",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "HMGA2 transcriptionally upregulates STC2 during fetal development and oncogenesis as an oncofetal protein."
    },
    {
      "entity_id": "ent:589a3de6ee48",
      "entity_type": "MECHANISM",
      "name": "AhR agonists block STC2 expression",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "AhR agonists block STC2 expression, indicating STC2 is an AhR-dependent gene."
    },
    {
      "entity_id": "ent:0ea5687ace19",
      "entity_type": "MECHANISM",
      "name": "cinnabarinic acid leads to acetylation of lysine residue in histone H4 and transcription of STC2 gene",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Metastasis-associated protein 2 recruitment to STC2 promoter leads to histone H4 acetylation and STC2 transcription upon cinnabarinic acid treatment."
    },
    {
      "entity_id": "ent:0861b82e0ea9",
      "entity_type": "MECHANISM",
      "name": "STC2 protects cells from various stress conditions",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "STC2 protects cells from stress conditions including ER stress induced by H2O2, thapsigargin and ethanol."
    },
    {
      "entity_id": "ent:acee77f63af6",
      "entity_type": "MECHANISM",
      "name": "Sp1 functions to promote the activities of oncogenes for cell survival, tumour progression and metastasis",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Sp1 promotes oncogene activities for cell survival, tumour progression and metastasis according to the text."
    },
    {
      "entity_id": "ent:c43089de4965",
      "entity_type": "MECHANISM",
      "name": "genetic manipulation of Sp1 alters STC2 promoter-mediated luciferase activity",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Genetic manipulation of Sp1 alters STC2 promoter-mediated luciferase activity dose-dependently in colorectal cancer cells."
    },
    {
      "entity_id": "ent:f91229812a85",
      "entity_type": "MECHANISM",
      "name": "ectopic expression or knockdown of Sp1 alters STC2 protein levels",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Ectopic expression or knockdown of Sp1 alters STC2 protein levels, indicating direct regulation."
    },
    {
      "entity_id": "ent:1c9065ac8466",
      "entity_type": "PATHWAY",
      "name": "PI3K-Akt signaling",
      "normalized_id": "N/A",
      "aliases": [
        "PI3K-Akt signaling"
      ],
      "description": "A signaling pathway activated by HOTAIR to induce STC2 expression, enhancing cell proliferation, migration and invasion in HNSCC."
    },
    {
      "entity_id": "ent:d267117f453d",
      "entity_type": "PATHWAY",
      "name": "FAK-PI3K-Akt-mTOR signaling pathway",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "A signaling pathway regulated by STC2 to antagonize the inhibiting activity of miR-381 in HNSCC cells."
    },
    {
      "entity_id": "ent:0623c2160b44",
      "entity_type": "GENE",
      "name": "miR-206",
      "normalized_id": "N/A",
      "aliases": [
        "miR-206"
      ],
      "description": "A microRNA located on human chromosome 6p12.2 that demonstrates tumour-suppressor activities and regulates STC2 expression in gastric cancer and HNSCC."
    },
    {
      "entity_id": "ent:7c47c64195ff",
      "entity_type": "GENE",
      "name": "LINC00460",
      "normalized_id": "N/A",
      "aliases": [
        "LINC00460",
        "long intergenic nonprotein coding RNA 460"
      ],
      "description": "A long non-coding RNA that can antagonize miR-206 function and upregulate STC2 expression, inhibiting autophagy and suppressing apoptosis."
    },
    {
      "entity_id": "ent:a3c75c246457",
      "entity_type": "GENE",
      "name": "HOTAIR",
      "normalized_id": "N/A",
      "aliases": [
        "homeobox transcript antisense RNA",
        "HOTAIR"
      ],
      "description": "A long non-coding RNA that functions as a sponge to antagonize miR-206 activity, inducing STC2 expression to enhance cell proliferation, migration and invasion."
    },
    {
      "entity_id": "ent:c3031a2ae174",
      "entity_type": "GENE",
      "name": "miR-485-5p",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "A microRNA significantly downregulated in human HCC samples, with bioinformatic prediction suggesting STC2 is its target."
    },
    {
      "entity_id": "ent:4ef05019688a",
      "entity_type": "GENE",
      "name": "miR-184",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "A microRNA with levels reversely correlated with STC2 mRNA in glioblastoma tissues, shown to downregulate STC2 through direct interaction with its 3'-UTR."
    },
    {
      "entity_id": "ent:54a7eb4673d9",
      "entity_type": "GENE",
      "name": "miR-190",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "A microRNA with a binding sequence in the 3'-UTR of STC2 mRNA, directly regulating STC2 and affecting EMT and angiogenesis in breast cancer cells."
    },
    {
      "entity_id": "ent:e65312f3644a",
      "entity_type": "GENE",
      "name": "miR-381",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "A microRNA that inhibits cell proliferation, migration and invasion in HNSCC cells, with STC2 identified as its direct target through bioinformatic analysis and luciferase assays."
    },
    {
      "entity_id": "ent:c156beed3d6b",
      "entity_type": "BIOMARKER",
      "name": "miRNA",
      "normalized_id": "N/A",
      "aliases": [
        "microRNA"
      ],
      "description": "Small, single-stranded non-coding RNA about 22 nucleotides in length that mediates post-transcriptional gene repression or mRNA degradation."
    },
    {
      "entity_id": "ent:1c578fcfacf4",
      "entity_type": "BIOMARKER",
      "name": "lncRNAs",
      "normalized_id": "N/A",
      "aliases": [
        "long non-coding RNAs"
      ],
      "description": "Long non-coding RNAs that perform functions through transcriptional regulation and act as molecular scaffolds for interactions between mRNAs, miRNAs, DNAs, and proteins."
    },
    {
      "entity_id": "ent:f88b18fb3478",
      "entity_type": "MECHANISM",
      "name": "post-transcriptional gene repression",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "A biological process mediated by miRNAs that involves repression of genes after transcription."
    },
    {
      "entity_id": "ent:46394e9fb20c",
      "entity_type": "MECHANISM",
      "name": "mRNA degradation",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "A process mediated by miRNAs that involves breaking down messenger RNA molecules."
    },
    {
      "entity_id": "ent:245cb8fa873d",
      "entity_type": "MECHANISM",
      "name": "transcriptional regulation",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "A functional mechanism through which lncRNAs perform their functions, either in cis or trans manner."
    },
    {
      "entity_id": "ent:974c2da8e680",
      "entity_type": "MECHANISM",
      "name": "molecular scaffolds",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "A functional role of lncRNAs that facilitates interactions between mRNAs, miRNAs, DNAs and relevant proteins."
    },
    {
      "entity_id": "ent:a882fe04ae79",
      "entity_type": "MECHANISM",
      "name": "inhibits autophagy",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "A process where STC2 expression suppresses autophagy through downregulating Beclin-1."
    },
    {
      "entity_id": "ent:932beef05ed4",
      "entity_type": "MECHANISM",
      "name": "suppresses apoptosis",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "A process where STC2 expression inhibits apoptosis by activating Erk and Akt signaling."
    },
    {
      "entity_id": "ent:676b2c556d24",
      "entity_type": "MECHANISM",
      "name": "activating Erk and Akt signaling",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "A signaling mechanism activated by STC2 expression that suppresses apoptosis."
    },
    {
      "entity_id": "ent:4c52a37a83c1",
      "entity_type": "MECHANISM",
      "name": "functions as a sponge",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "A mechanism where HOTAIR antagonizes miR-206 activity by acting as a molecular sponge."
    },
    {
      "entity_id": "ent:097cd5d8e7de",
      "entity_type": "MECHANISM",
      "name": "activating PI3K-Akt signaling",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "A signaling pathway activated by STC2 expression to enhance cell proliferation, migration and invasion."
    },
    {
      "entity_id": "ent:f00e9a174ea9",
      "entity_type": "MECHANISM",
      "name": "direct interaction",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "A mechanism where miR-184 downregulates STC2 expression through binding to the 3'-UTR of STC2 mRNA."
    },
    {
      "entity_id": "ent:2bcb2d208d73",
      "entity_type": "MECHANISM",
      "name": "direct regulation",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "A mechanism where miR-190 directly regulates STC2, as shown by luciferase reporter assay."
    },
    {
      "entity_id": "ent:e0073e0dd1c2",
      "entity_type": "MECHANISM",
      "name": "regulates epithelial-mesenchymal transition (EMT)",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "A process where miR-190 regulates EMT through altering Erk and Akt signaling in an STC2-dependent manner."
    },
    {
      "entity_id": "ent:8ae156ee4fd2",
      "entity_type": "MECHANISM",
      "name": "regulating the FAK-PI3K-Akt-mTOR signaling pathway",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "A mechanism where STC2 antagonizes miR-381's inhibiting activity in HNSCC cells through pathway regulation."
    },
    {
      "entity_id": "ent:17a5eb344646",
      "entity_type": "DISEASE",
      "name": "tumorigenesis",
      "normalized_id": "N/A",
      "aliases": [
        "tumorigenesis"
      ],
      "description": "A biological process related to miRNAs regulating cell differentiation, maturation, proliferation, survival and immune response."
    },
    {
      "entity_id": "ent:207e9010014e",
      "entity_type": "DISEASE",
      "name": "tumour metastasis",
      "normalized_id": "N/A",
      "aliases": [
        "metastasis",
        "tumour metastasis"
      ],
      "description": "A process related to tumour progression that miRNAs can regulate through cell differentiation, maturation, proliferation, survival and immune response."
    },
    {
      "entity_id": "ent:90d97d7a89e0",
      "entity_type": "DISEASE",
      "name": "disease stage",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "A condition in gastric cancer that is inversely correlated with increased miR-206 levels."
    },
    {
      "entity_id": "ent:32a062f5a464",
      "entity_type": "DISEASE",
      "name": "tumour stage",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "A condition in HNSCC that is negatively associated with miR-206 expression."
    },
    {
      "entity_id": "ent:95225858316f",
      "entity_type": "DISEASE",
      "name": "autophagy",
      "normalized_id": "N/A",
      "aliases": [
        "autophagy"
      ],
      "description": "A process inhibited by STC2 upregulation through downregulating Beclin-1."
    },
    {
      "entity_id": "ent:c2bb7c987181",
      "entity_type": "DISEASE",
      "name": "glioblastoma",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "A condition where a reverse correlation between miR-184 and STC2 mRNA levels was illustrated in human tissues."
    },
    {
      "entity_id": "ent:6c49c95ec56f",
      "entity_type": "PATHWAY",
      "name": "Akt signaling",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "A signaling pathway described as being activated, leading to the suppression of apoptosis and autophagy."
    },
    {
      "entity_id": "ent:e4cfed15cbd9",
      "entity_type": "PATHWAY",
      "name": "EMT",
      "normalized_id": "N/A",
      "aliases": [
        "epithelial-mesenchymal transition"
      ],
      "description": "A process correlated with LINC00460 expression and described as involving downregulation of epithelial markers and upregulation of mesenchymal markers to increase cell motility."
    },
    {
      "entity_id": "ent:a6caeb5b2eab",
      "entity_type": "GENE",
      "name": "Chromosome 13q33.2",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "A chromosomal region where LINC00460 is located."
    },
    {
      "entity_id": "ent:d8fb17d14255",
      "entity_type": "GENE",
      "name": "ROR1-AS1",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "A lncRNA reported to regulate STC2 expression by sponging miR-670-3p that suppresses STC2 expression in cervical cancer."
    },
    {
      "entity_id": "ent:665fa9ca10b5",
      "entity_type": "GENE",
      "name": "miR-670-3p",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "A microRNA that suppresses STC2 expression and is sponged by ROR1-AS1 in cervical cancer."
    },
    {
      "entity_id": "ent:d08e9fa0bf7c",
      "entity_type": "GENE",
      "name": "SNHG17",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "A lncRNA reported to regulate STC2 expression."
    },
    {
      "entity_id": "ent:1f374a27e83d",
      "entity_type": "PROTEIN",
      "name": "Akt",
      "normalized_id": "N/A",
      "aliases": [
        "Akt"
      ],
      "description": "Signaling protein described as being activated by STC2 upregulation, which suppresses apoptosis and autophagy."
    },
    {
      "entity_id": "ent:ba01c315e1e4",
      "entity_type": "MECHANISM",
      "name": "oncogenic properties",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Properties described as being demonstrated by LINC00460 when upregulated in human cancers."
    },
    {
      "entity_id": "ent:cb13698d2b40",
      "entity_type": "MECHANISM",
      "name": "sponge",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Mechanism described where LINC00460 works to compromise miR-206 function."
    },
    {
      "entity_id": "ent:466c37332856",
      "entity_type": "MECHANISM",
      "name": "activation of Akt signaling",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Process described as being activated, leading to the suppression of apoptosis and autophagy."
    },
    {
      "entity_id": "ent:f1d5382e5e09",
      "entity_type": "MECHANISM",
      "name": "suppresses apoptosis and autophagy",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Action described as a result of Akt signaling activation."
    },
    {
      "entity_id": "ent:8b20d80d0e85",
      "entity_type": "MECHANISM",
      "name": "functioning as a sponge",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Mechanism described for HOTAIR to promote STC2 expression by sponging miR-206."
    },
    {
      "entity_id": "ent:ccdc3f19fb37",
      "entity_type": "MECHANISM",
      "name": "inhibits apoptosis",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Action described for STC2 overexpression in response to thapsigargin."
    },
    {
      "entity_id": "ent:801fc5254a09",
      "entity_type": "MECHANISM",
      "name": "protects cells from necrosis and apoptosis",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Action described for STC2 in a cerulein-induced pancreatitis model in transgenic mice."
    },
    {
      "entity_id": "ent:0f47df5cd3cd",
      "entity_type": "MECHANISM",
      "name": "driving cell proliferation",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Result described from STC2 upregulation under hypoxia, leading to cyclin D induction and Rb hyper-phosphorylation."
    },
    {
      "entity_id": "ent:b6771414f114",
      "entity_type": "MECHANISM",
      "name": "promotes tumour metastasis",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Action described for STC2 through promoting EMT and upregulating MMP-2 and -9."
    },
    {
      "entity_id": "ent:4edd1ed11d11",
      "entity_type": "MECHANISM",
      "name": "promoting EMT",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Mechanism described for how STC2 enhances tumour metastasis."
    },
    {
      "entity_id": "ent:9477631c28a7",
      "entity_type": "MECHANISM",
      "name": "upregulating MMP -2 and -9",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Mechanism described for how STC2 enhances tumour metastasis."
    },
    {
      "entity_id": "ent:4bbfe38fd09d",
      "entity_type": "MECHANISM",
      "name": "facilitate the degradation of ECM",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Action described for MMP-2 and -9 when upregulated by ectopic STC2 expression."
    },
    {
      "entity_id": "ent:8139712b2751",
      "entity_type": "MECHANISM",
      "name": "enhances the invasive ability",
      "normalized_id": "N/A",
      "aliases": [
        "enhances the invasion"
      ],
      "description": "Action described for STC2 overexpression in neuroblastoma cells, associated with upregulating MMP-2 expression."
    },
    {
      "entity_id": "ent:62a9097af315",
      "entity_type": "DISEASE",
      "name": "RCC",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Described as a cancer where LINC00460 is upregulated to drive development, and where elevated STC2 levels are associated with invasiveness and metastasis."
    },
    {
      "entity_id": "ent:698fd5ff1abf",
      "entity_type": "DISEASE",
      "name": "thyroid cancer",
      "normalized_id": "N/A",
      "aliases": [
        "thyroid cancer"
      ],
      "description": "Described as a cancer where LINC00460 is upregulated to drive development."
    },
    {
      "entity_id": "ent:7d3161f43dfb",
      "entity_type": "DISEASE",
      "name": "meningioma",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Described as a cancer where LINC00460 is upregulated to drive development."
    },
    {
      "entity_id": "ent:9e4d4f02be06",
      "entity_type": "DISEASE",
      "name": "necrosis",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Described as being protected against by STC2 in a pancreatitis model-induced by cerulein in transgenic mice."
    },
    {
      "entity_id": "ent:c99fecc036c3",
      "entity_type": "DISEASE",
      "name": "pancreatitis",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Described as a model induced by cerulein in transgenic mice where STC2 protects cells from necrosis and apoptosis."
    },
    {
      "entity_id": "ent:0519d7f6de6a",
      "entity_type": "OTHER",
      "name": "patients' prognosis",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "A clinical factor correlated with the expression of LINC00460."
    },
    {
      "entity_id": "ent:c4f6cce88178",
      "entity_type": "OTHER",
      "name": "therapeutical approaches",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "New doors opened for targeting STC2, as per the discovery of non-coding RNA-mediated regulation."
    },
    {
      "entity_id": "ent:527f249a582c",
      "entity_type": "OTHER",
      "name": "biological roles",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Described roles of STC2 in human cancers, as indicated by the section heading."
    },
    {
      "entity_id": "ent:4abd246b2b1c",
      "entity_type": "OTHER",
      "name": "tumour cell survival",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "A role of STC2, as indicated by the section heading 'STC2 promotes tumour cell survival and tumour growth'."
    },
    {
      "entity_id": "ent:6e76234e85e2",
      "entity_type": "OTHER",
      "name": "hypoxic conditions",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Conditions under which STC2 is upregulated in SKOV3 and MCF-7 cells, leading to cyclin D induction and Rb hyper-phosphorylation."
    },
    {
      "entity_id": "ent:29e3089d438e",
      "entity_type": "OTHER",
      "name": "colony formation",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "A cellular process compromised by knockdown of STC2 in PC-3 cells and also compromised by overexpression of STC2 in breast cancer cells."
    },
    {
      "entity_id": "ent:b7c5fa7ffe5a",
      "entity_type": "OTHER",
      "name": "tumour size",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Correlated with elevated STC2 levels in colorectal cancer."
    },
    {
      "entity_id": "ent:6a44c5b20ade",
      "entity_type": "OTHER",
      "name": "chorioallantoic membrane of chicken embryo assay",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "An assay that revealed ectopic expression of STC2 enhances the growth of tumour xenografts."
    },
    {
      "entity_id": "ent:15021b2d71a4",
      "entity_type": "OTHER",
      "name": "tumour xenografts",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "The growth of which is enhanced by ectopic expression of STC2, as revealed by an assay."
    },
    {
      "entity_id": "ent:d6269657cde4",
      "entity_type": "OTHER",
      "name": "tumour suppressor-like activities",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Activities possessed by STC2 in breast cancer, where its overexpression compromises cell proliferation and colony formation."
    },
    {
      "entity_id": "ent:fa136d4fea9c",
      "entity_type": "OTHER",
      "name": "context-dependent manner",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "The manner in which STC2 performs its roles, as indicated by findings showing both promoting and compromising effects on proliferation."
    },
    {
      "entity_id": "ent:4cb61d899d84",
      "entity_type": "OTHER",
      "name": "metastatic phenotype",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Acquired by tumour cells as the first major step in tumour metastasis."
    },
    {
      "entity_id": "ent:a72be1285513",
      "entity_type": "OTHER",
      "name": "cell--cell adhesion",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Reduced in tumour cells undergoing EMT as part of acquiring a metastatic phenotype."
    },
    {
      "entity_id": "ent:6d3aad617c6c",
      "entity_type": "OTHER",
      "name": "apical-basolateral polarity",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Reduced in tumour cells undergoing EMT as part of acquiring a metastatic phenotype."
    },
    {
      "entity_id": "ent:fdac8f392cb6",
      "entity_type": "OTHER",
      "name": "increased motility",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Occurs in tumour cells undergoing EMT as part of acquiring a metastatic phenotype."
    },
    {
      "entity_id": "ent:c4607bd23423",
      "entity_type": "OTHER",
      "name": "intravasation",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "The third major step in tumour metastasis, where tumour cells migrate, penetrate blood vessel walls, and become circulating tumour cells."
    },
    {
      "entity_id": "ent:2772544abf71",
      "entity_type": "OTHER",
      "name": "extravasation",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Part of the fourth major step in tumour metastasis, where circulating tumour cells invade through blood vessel walls."
    },
    {
      "entity_id": "ent:d55c2335af6e",
      "entity_type": "OTHER",
      "name": "metastatic tumours",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Formed in the fourth major step of tumour metastasis after extravasation and residing in distal tissues or organs."
    },
    {
      "entity_id": "ent:ab45b16b5aff",
      "entity_type": "OTHER",
      "name": "Transwell assay",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "An assay that revealed overexpression of STC2 enhances the invasion of ovarian cancer cells through matrigel or HUVEC-coated wells."
    },
    {
      "entity_id": "ent:dd0a04cf5860",
      "entity_type": "OTHER",
      "name": "invasive ability",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Enhanced by overexpression of STC2 in neuroblastoma cells, which also upregulates MMP-2 expression."
    },
    {
      "entity_id": "ent:4295006a80d3",
      "entity_type": "OTHER",
      "name": "invasiveness",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Associated with elevated STC2 levels in human tumours like ESCC, gastric cancer, colorectal cancer, RCC, and neuroblastoma."
    },
    {
      "entity_id": "ent:f8fe176c0d6d",
      "entity_type": "OTHER",
      "name": "cellular response to nutrient-deprivation",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "A process regulated by STC2, as indicated by the section heading."
    },
    {
      "entity_id": "ent:4219aafdfa43",
      "entity_type": "PATHWAY",
      "name": "glycolysis",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "A process where tumour cells utilize glucose, even in the presence of oxygen, as part of the Warburg effect in cancer metabolism."
    },
    {
      "entity_id": "ent:aacdc6a5684d",
      "entity_type": "PATHWAY",
      "name": "Warburg effect",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "A characteristic of cancer metabolism where tumour cells utilize glucose through glycolysis even in the presence of oxygen."
    },
    {
      "entity_id": "ent:aceb02e4e994",
      "entity_type": "PATHWAY",
      "name": "glutaminolysis",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "A characteristic of cancer metabolism involving the conversion of glutamine to glutamate, catalyzed by glutaminase."
    },
    {
      "entity_id": "ent:c250a65fea0d",
      "entity_type": "PATHWAY",
      "name": "glycolytic genes",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Genes associated with glycolysis, used with STC2 to assess prognosis in osteosarcoma patients and whose expression is induced by STC2."
    },
    {
      "entity_id": "ent:710315a2494c",
      "entity_type": "PATHWAY",
      "name": "HIF-1 signaling",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "A signaling pathway activated by bevacizumab that induces STC2 expression in orthotopic human colon cancer xenografts."
    },
    {
      "entity_id": "ent:a61318429a4b",
      "entity_type": "GENE",
      "name": "Glucose Transporter 1",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "A glycolytic gene whose expression is induced by STC2 to promote glucose utilization in tumour cells."
    },
    {
      "entity_id": "ent:74c77969155f",
      "entity_type": "GENE",
      "name": "Lactate Dehydrogenase A",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "A glycolytic gene whose expression is induced by STC2 to promote glucose utilization in tumour cells."
    },
    {
      "entity_id": "ent:e1b0ca7eb0a2",
      "entity_type": "GENE",
      "name": "VEGF",
      "normalized_id": "N/A",
      "aliases": [
        "Vascular endothelial growth factor",
        "VEGF"
      ],
      "description": "Vascular endothelial growth factor, targeted by the anti-VEGF antibody bevacizumab in chemotherapeutic treatments."
    },
    {
      "entity_id": "ent:3655c26ea07d",
      "entity_type": "TREATMENT",
      "name": "anti-vascular endothelial growth factor (VEGF) antibody",
      "normalized_id": "N/A",
      "aliases": [
        "anti-VEGF antibody"
      ],
      "description": "A chemotherapeutic treatment exposure that upregulates STC2, as mentioned in the text."
    },
    {
      "entity_id": "ent:d0c589bd471d",
      "entity_type": "TREATMENT",
      "name": "cisplatin",
      "normalized_id": "N/A",
      "aliases": [
        "cisplatin"
      ],
      "description": "A chemotherapeutic treatment exposure that upregulates STC2, as mentioned in the text."
    },
    {
      "entity_id": "ent:be83536bcf21",
      "entity_type": "TREATMENT",
      "name": "oxaliplatin",
      "normalized_id": "N/A",
      "aliases": [
        "oxaliplatin"
      ],
      "description": "A chemotherapeutic treatment exposure that upregulates STC2, as mentioned in the text."
    },
    {
      "entity_id": "ent:5e1173717cec",
      "entity_type": "TREATMENT",
      "name": "tyrosine kinase inhibitors (TKIs)",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "A chemotherapeutic treatment exposure that upregulates STC2, as mentioned in the text."
    },
    {
      "entity_id": "ent:93c4228acd20",
      "entity_type": "TREATMENT",
      "name": "bevacizumab",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Described as an anti-VEGF antibody application that inhibits tumor growth and induces STC2 expression."
    },
    {
      "entity_id": "ent:2d770f6f8f7b",
      "entity_type": "TREATMENT",
      "name": "anti-VEGF treatment",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "A treatment to which STC2 may contribute to the development of acquired resistance."
    },
    {
      "entity_id": "ent:00c0adb7c676",
      "entity_type": "BIOMARKER",
      "name": "metagenes",
      "normalized_id": "N/A",
      "aliases": [
        "immune-relevant transcripts or gene sets"
      ],
      "description": "Immune-relevant transcripts or gene sets that characterize immunogenic cell death, with STC2 identified as one demonstrating negative correlation with immune-associated metagenes in breast cancer."
    },
    {
      "entity_id": "ent:7eda936a1df0",
      "entity_type": "BIOMARKER",
      "name": "heme oxygenase 1",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "An enzyme whose activity is altered by STC2 interaction, compromising the activity of IFN--producing CD8+ Tc1 cells."
    },
    {
      "entity_id": "ent:c91dc08b76ac",
      "entity_type": "BIOMARKER",
      "name": "histidine-rich glycoprotein",
      "normalized_id": "N/A",
      "aliases": [
        "HRG"
      ],
      "description": "A plasma glycoprotein that controls macrophage phenotypic switching, with STC2 identified as its binding partner to modulate immune response."
    },
    {
      "entity_id": "ent:ec5780b581ff",
      "entity_type": "BIOMARKER",
      "name": "STC2-HRG complex",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "A complex formed between STC2 and HRG that modulates the immune response of inflammatory cells, though its in vivo importance requires further study."
    },
    {
      "entity_id": "ent:2d073bdebec4",
      "entity_type": "MECHANISM",
      "name": "Metabolic reprogramming",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Described as an emerging hallmark of human cancers, involving unique metabolism of glucose and glutamine."
    },
    {
      "entity_id": "ent:cca845e47c42",
      "entity_type": "MECHANISM",
      "name": "immunogenic cell death",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Characterized by ER stress and autophagy that regulates the expression of immune-relevant metagenes, induced by chemotherapies."
    },
    {
      "entity_id": "ent:4d99e4a0b1c2",
      "entity_type": "PROTEIN",
      "name": "glutaminase",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Enzyme described as catalyzing the conversion of glutamine to glutamate in the process of glutaminolysis."
    },
    {
      "entity_id": "ent:519111893361",
      "entity_type": "DISEASE",
      "name": "colon cancer",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Described in human xenografts where bevacizumab application successfully inhibits growth through blocking cell cycle and inducing apoptosis."
    },
    {
      "entity_id": "ent:214455000cbc",
      "entity_type": "DISEASE",
      "name": "colorectal carcinoma",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Described in human liver metastatic tumours where STC2 is overexpressed in those treated with bevacizumab."
    },
    {
      "entity_id": "ent:ba96e149b262",
      "entity_type": "PATHWAY",
      "name": "c-Jun signaling",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "STC2 enhances the activation of c-Jun singling, the transcription of AXL and the activation of Erk pathway."
    },
    {
      "entity_id": "ent:d79d8888c609",
      "entity_type": "PATHWAY",
      "name": "Erk pathway",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "STC2 enhances the activation of c-Jun singling, the transcription of AXL and the activation of Erk pathway."
    },
    {
      "entity_id": "ent:85da2f3faa54",
      "entity_type": "BIOMARKER",
      "name": "Erk",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "A signaling molecule whose phosphorylation is increased in resistant cells and can be reversed by STC2 knockdown."
    },
    {
      "entity_id": "ent:c3bc54c41427",
      "entity_type": "BIOMARKER",
      "name": "p38",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "A signaling molecule whose phosphorylation is increased in resistant cells and can be reversed by STC2 knockdown."
    },
    {
      "entity_id": "ent:a9cf4e76e5aa",
      "entity_type": "BIOMARKER",
      "name": "PI3K-Akt",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "A signaling pathway that STC2 can promote the activation of to induce P-glycoprotein expression."
    },
    {
      "entity_id": "ent:ea892c89297e",
      "entity_type": "BIOMARKER",
      "name": "P-glycoprotein",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "A protein induced by STC2 via PI3K-Akt signaling, involved in chemical compound handling and regarded as a primary factor for acquired resistance to oxaliplatin."
    },
    {
      "entity_id": "ent:f77177a96075",
      "entity_type": "BIOMARKER",
      "name": "Bcl2",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "A protein upregulated by STC2 to compromise paclitaxel-induced apoptosis in human HCC cells."
    },
    {
      "entity_id": "ent:c8046b722671",
      "entity_type": "BIOMARKER",
      "name": "AXL",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "A gene whose transcription is enhanced by STC2 to mediate TKI resistance in lung cancer."
    },
    {
      "entity_id": "ent:b129f04c5585",
      "entity_type": "GENE",
      "name": "PI3K",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Part of the PI3K-Akt signaling pathway that STC2 can promote the activation of to induce P-glycoprotein expression."
    },
    {
      "entity_id": "ent:e0276bdeecf2",
      "entity_type": "GENE",
      "name": "c-Jun",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "STC2 enhances the activation of c-Jun signaling, which is part of the mechanism in TKI resistance according to the document."
    },
    {
      "entity_id": "ent:732d37b209d3",
      "entity_type": "PROTEIN",
      "name": "epidermal growth factor receptor",
      "normalized_id": "N/A",
      "aliases": [
        "EGFR"
      ],
      "description": "Hyperactivation of its signaling is a critical contributor to lung cancer development and progression."
    },
    {
      "entity_id": "ent:caa82193fea1",
      "entity_type": "TREATMENT",
      "name": "paclitaxel",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "A drug whose induced apoptosis is compromised by ectopic STC2 expression in human HCC cells through upregulation of P-glycoprotein and Bcl2."
    },
    {
      "entity_id": "ent:c0aad3b0ace7",
      "entity_type": "TREATMENT",
      "name": "TKIs",
      "normalized_id": "N/A",
      "aliases": [
        "TKI"
      ],
      "description": "Tyrosine kinase inhibitors widely applied to treat non-small cell lung cancer with hyperactivated EGFR signaling, though some tumours develop acquired resistance."
    },
    {
      "entity_id": "ent:86fd9ed17f34",
      "entity_type": "TREATMENT",
      "name": "radiation therapy",
      "normalized_id": "N/A",
      "aliases": [
        "radiotherapy",
        "Radiotherapy"
      ],
      "description": "Includes external beam, internal beam and systemic radiation like radioactive iodine for thyroid cancer, and molecular radiotherapy for advanced prostate cancer and gastroenteropancreatic neuroendocrine tumour."
    },
    {
      "entity_id": "ent:26f080c4682e",
      "entity_type": "TREATMENT",
      "name": "external beam radiotherapy",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Widely applied to treat many different tumours including breast cancer, colorectal cancer, esophageal cancer, HNSCC, NSCLC, skin squamous cell carcinoma, prostate cancer, and brain tumours."
    },
    {
      "entity_id": "ent:f1441474e056",
      "entity_type": "TREATMENT",
      "name": "internal beam therapy",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Normally used to treat HNSCC, breast cancer, cervical cancer, prostate cancer and tumours from the eye."
    },
    {
      "entity_id": "ent:97f38133ecc8",
      "entity_type": "TREATMENT",
      "name": "intensity-modulated radiotherapy",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "A treatment given to patients with human nasopharyngeal carcinomas, after which STC2 levels are correlated with tumour response."
    },
    {
      "entity_id": "ent:7c240e189077",
      "entity_type": "TREATMENT",
      "name": "radiation",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "A treatment that induces colony formation in human CNE2 nasopharyngeal carcinoma cells, an effect compromised by STC2 knockout."
    },
    {
      "entity_id": "ent:8d1663b1471e",
      "entity_type": "DISEASE",
      "name": "non-small cell lung cancer",
      "normalized_id": "N/A",
      "aliases": [
        "NSCLC"
      ],
      "description": "A type of lung cancer treated with TKIs, where some tumors develop acquired resistance."
    },
    {
      "entity_id": "ent:3155a28dfecd",
      "entity_type": "DISEASE",
      "name": "gastroenteropancreatic neuroendocrine tumour",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "A tumour type mentioned as an example where molecular radiotherapy is applied."
    },
    {
      "entity_id": "ent:d31f22110c40",
      "entity_type": "DISEASE",
      "name": "esophageal cancer",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "A tumour type mentioned as being widely treated with external beam radiotherapy."
    },
    {
      "entity_id": "ent:19ba7aac7c82",
      "entity_type": "DISEASE",
      "name": "skin squamous cell carcinoma",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "A tumour type mentioned as being widely treated with external beam radiotherapy."
    },
    {
      "entity_id": "ent:0db91928d568",
      "entity_type": "DISEASE",
      "name": "brain tumours",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Tumour type mentioned as being widely treated with external beam radiotherapy."
    },
    {
      "entity_id": "ent:814da34b3cf3",
      "entity_type": "DISEASE",
      "name": "nasopharyngeal carcinomas",
      "normalized_id": "N/A",
      "aliases": [
        "nasopharyngeal carcinoma"
      ],
      "description": "A type of human cancer studied in relation to STC2 levels and response to intensity-modulated radiotherapy."
    },
    {
      "entity_id": "ent:1aee051abe29",
      "entity_type": "MECHANISM",
      "name": "phosphorylation",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Increased phosphorylation of Erk, JNK and p38 is demonstrated in resistant cells and can be reversed by STC2 knockdown."
    },
    {
      "entity_id": "ent:8af5aab0e797",
      "entity_type": "MECHANISM",
      "name": "paracrine mechanism",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "STC2 performs its biological functions at least partially through a paracrine mechanism."
    },
    {
      "entity_id": "ent:f9b4c5abb206",
      "entity_type": "MECHANISM",
      "name": "expression",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "STC2 can promote the activation of PI3K-Akt signaling to induce the expression of P-glycoprotein."
    },
    {
      "entity_id": "ent:ee882a1dc9ab",
      "entity_type": "MECHANISM",
      "name": "absorption",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "P-glycoprotein involves in the absorption, distribution and excretion of chemical compounds."
    },
    {
      "entity_id": "ent:d422f1fd5ed6",
      "entity_type": "MECHANISM",
      "name": "distribution",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "P-glycoprotein involves in the absorption, distribution and excretion of chemical compounds."
    },
    {
      "entity_id": "ent:9f7e548c1308",
      "entity_type": "MECHANISM",
      "name": "excretion",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "P-glycoprotein involves in the absorption, distribution and excretion of chemical compounds."
    },
    {
      "entity_id": "ent:4063290c9460",
      "entity_type": "MECHANISM",
      "name": "upregulating",
      "normalized_id": "N/A",
      "aliases": [
        "upregulation"
      ],
      "description": "Ectopic expression of STC2 compromises paclitaxel-induced apoptosis through upregulating P-glycoprotein and Bcl2."
    },
    {
      "entity_id": "ent:dd5ba559faa7",
      "entity_type": "MECHANISM",
      "name": "Hyperactivation",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Hyperactivation of epidermal growth factor receptor (EGFR) signaling is a critical contributor for the development and progression of lung cancer."
    },
    {
      "entity_id": "ent:50e4d5985b54",
      "entity_type": "MECHANISM",
      "name": "transcription",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "STC2 enhances the activation of c-Jun singling, the transcription of AXL and the activation of Erk pathway."
    },
    {
      "entity_id": "ent:d0f302749b7e",
      "entity_type": "MECHANISM",
      "name": "DNA damage-induced cell death",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Mechanistically, radiation causes DNA damage-induced cell death, and finally suppresses tumour growth."
    },
    {
      "entity_id": "ent:8a64aefabacd",
      "entity_type": "MECHANISM",
      "name": "cell cycle arrest",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "STC2 knockout not only promotes cell cycle arrest in G_{2}-M phase, but also suppresses cell migration and invasion."
    },
    {
      "entity_id": "ent:dd55cf7fd1f1",
      "entity_type": "MECHANISM",
      "name": "cell migration",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "STC2 knockout not only promotes cell cycle arrest in G_{2}-M phase, but also suppresses cell migration and invasion."
    },
    {
      "entity_id": "ent:ab3ee9d4a6cd",
      "entity_type": "BIOMARKER",
      "name": "serum STC2 levels",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Levels of STC2 in serum that can be easily monitored and are investigated as a practical biomarker for assessing prognosis or recurrence in cancer patients."
    },
    {
      "entity_id": "ent:2c60ecb4eed6",
      "entity_type": "MECHANISM",
      "name": "signal transduction pathway",
      "normalized_id": "N/A",
      "aliases": [
        "signaling pathways"
      ],
      "description": "Pathway associated with STC2 that requires identification of its receptor to be better understood."
    },
    {
      "entity_id": "ent:0ad104f0436a",
      "entity_type": "MECHANISM",
      "name": "mechanisms of action",
      "normalized_id": "N/A",
      "aliases": [
        "mechanism of action",
        "MOA"
      ],
      "description": "Associated with STC2's signal transduction pathway, requiring better understanding through receptor identification."
    },
    {
      "entity_id": "ent:1451079efbe9",
      "entity_type": "OTHER",
      "name": "biomarker",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Serum STC2 levels are described as potentially being utilized as a practical biomarker to assess prognosis or recurrence in patients with various types of cancers."
    },
    {
      "entity_id": "ent:b15e773260ce",
      "entity_type": "OTHER",
      "name": "prognosis",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Serum STC2 levels are described as potentially being utilized to assess prognosis in patients with various types of cancers."
    },
    {
      "entity_id": "ent:637ea8c9650d",
      "entity_type": "OTHER",
      "name": "tumour phenotypes",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Cell proliferation, invasion and metastasis regulated by STC2 are described as being associated with tumour phenotypes."
    },
    {
      "entity_id": "ent:a34a71f1dbb8",
      "entity_type": "OTHER",
      "name": "targeted therapies",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "STC2 is described as a potential candidate for developing targeted therapies, particularly for patients with late-stage diseases."
    },
    {
      "entity_id": "ent:c5a1c65df177",
      "entity_type": "OTHER",
      "name": "combined therapies",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Late-stage diseases are described as usually requiring combined therapies."
    },
    {
      "entity_id": "ent:ce9110fdb3e5",
      "entity_type": "OTHER",
      "name": "therapeutic target",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "Further investigation into STC2's mechanism of action may facilitate its clinical utilization as a novel therapeutic target."
    },
    {
      "entity_id": "ent:72ca6af3dcaf",
      "entity_type": "PROTEIN",
      "name": "EGFR",
      "normalized_id": "N/A",
      "aliases": [
        "Epidermal growth factor receptor",
        "ErbB"
      ],
      "description": "Epidermal growth factor receptor, listed in the abbreviations section."
    },
    {
      "entity_id": "ent:56e40d589185",
      "entity_type": "PROTEIN",
      "name": "HDAC",
      "normalized_id": "N/A",
      "aliases": [
        "Histone deacetylase"
      ],
      "description": "Histone deacetylase, listed in the abbreviations section."
    },
    {
      "entity_id": "ent:c1a143b6e2be",
      "entity_type": "PROTEIN",
      "name": "HRG",
      "normalized_id": "N/A",
      "aliases": [
        "Histidine-rich glycoprotein"
      ],
      "description": "Histidine-rich glycoprotein, listed in the abbreviations section."
    },
    {
      "entity_id": "ent:ceb73a8e75a9",
      "entity_type": "PROTEIN",
      "name": "STC",
      "normalized_id": "N/A",
      "aliases": [
        "Stanniocalcin"
      ],
      "description": "Stanniocalcin, listed in the abbreviations section."
    }
  ],
  "relations": [
    {
      "head": "MAOB",
      "relation": "mediate",
      "tail": "degradation of monoamine neurotransmitters",
      "relation_type": null,
      "confidence": [
        0.2,
        0.0
      ],
      "evidence": [
        "Monoamine oxidase-B (MAOB) has been believed to mediate the degradation of monoamine neurotransmitters such as dopamine.",
        "However, this traditional belief has been challenged by demonstrating that it is not MAOB but MAOA which mediates dopamine degradation."
      ],
      "mechanism": "unknown",
      "source": "ocr_result_1_0",
      "subject": {
        "entity_id": "ent:b3040f3e67f7",
        "entity_type": "PROTEIN",
        "name": "MAOB",
        "normalized_id": "N/A",
        "aliases": [
          "MAOB",
          "Monoamine oxidase B",
          "Monoamine oxidase-B"
        ],
        "description": "Monoamine oxidase-B (MAOB) is described as an enzyme that mediates the aberrant synthesis of GABA and hydrogen peroxide in reactive astrocytes of Parkinson's disease, and its expression increases with aging and in neurodegenerative conditions."
      },
      "object": {
        "entity_id": "ent:ba5ffc952c8d",
        "entity_type": "MECHANISM",
        "name": "degradation of monoamine neurotransmitters",
        "normalized_id": "N/A",
        "aliases": [
          "DA deamination",
          "DA degradation",
          "excessive DA degradation"
        ],
        "description": "Process traditionally believed to be mediated by MAOB for neurotransmitters like dopamine."
      },
      "time_info": null
    },
    {
      "head": "MAOB",
      "relation": "mediate",
      "tail": "aberrant synthesis of GABA and hydrogen peroxide",
      "relation_type": null,
      "confidence": [
        0.9,
        0.1
      ],
      "evidence": [
        "Instead, MAOB mediates the aberrant synthesis of GABA and hydrogen peroxide (HO) in reactive astrocytes of Parkinson's disease (PD).",
        "In this perspective, we redefine the role of MAOB for the aberrant suppression and deterioration of dopaminergic neurons through excessive GABA and HO synthesis of reactive astrocytes in PD."
      ],
      "mechanism": "unknown",
      "source": "ocr_result_1_0",
      "subject": {
        "entity_id": "ent:b3040f3e67f7",
        "entity_type": "PROTEIN",
        "name": "MAOB",
        "normalized_id": "N/A",
        "aliases": [
          "MAOB",
          "Monoamine oxidase B",
          "Monoamine oxidase-B"
        ],
        "description": "Monoamine oxidase-B (MAOB) is described as an enzyme that mediates the aberrant synthesis of GABA and hydrogen peroxide in reactive astrocytes of Parkinson's disease, and its expression increases with aging and in neurodegenerative conditions."
      },
      "object": {
        "entity_id": "ent:599cd7cac967",
        "entity_type": "MECHANISM",
        "name": "aberrant synthesis of GABA and hydrogen peroxide",
        "normalized_id": "N/A",
        "aliases": [
          "aberrant GABA synthesis",
          "aberrant synthesis of GABA and hydrogen peroxide"
        ],
        "description": "Abnormal production of GABA, identified as the mechanism through which astrocytic MAOB substantially contributes to PD pathology."
      },
      "time_info": null
    },
    {
      "head": "GABA",
      "relation": "tonically suppresses",
      "tail": "reduce reactive astrogliosis and restore dopaminergic neuronal activity",
      "relation_type": null,
      "confidence": [
        0.85,
        0.15
      ],
      "evidence": [
        "Astrocytic GABA tonically suppresses the dopaminergic neuronal activity",
        "we redefine the role of MAOB for the aberrant suppression and deterioration of dopaminergic neurons through excessive GABA and HO synthesis of reactive astrocytes in PD."
      ],
      "mechanism": "unknown",
      "source": "ocr_result_1_0",
      "subject": {
        "entity_id": "ent:8fc07bdac764",
        "entity_type": "BIOMARKER",
        "name": "GABA",
        "normalized_id": "N/A",
        "aliases": [],
        "description": "A neurotransmitter synthesized by MAOB in reactive astrocytes, which tonically suppresses dopaminergic neuronal activity in Parkinson's disease."
      },
      "object": {
        "entity_id": "ent:5118fd790378",
        "entity_type": "MECHANISM",
        "name": "reduce reactive astrogliosis and restore dopaminergic neuronal activity",
        "normalized_id": "N/A",
        "aliases": [],
        "description": "Mechanism of action for reversible MAOB inhibitors in alleviating PD symptoms."
      },
      "time_info": null
    },
    {
      "head": "excessive GABA and H2O2 synthesis",
      "relation": "aggravates",
      "tail": "aggravates astrocytic reactivity and dopaminergic neuronal death",
      "relation_type": null,
      "confidence": [
        0.8,
        0.3
      ],
      "evidence": [
        "whereas HO aggravates astrocytic reactivity and dopaminergic neuronal death."
      ],
      "mechanism": "unknown",
      "source": "ocr_result_1_0",
      "subject": {
        "entity_id": "ent:4c577291e98b",
        "entity_type": "MECHANISM",
        "name": "excessive GABA and H2O2 synthesis",
        "normalized_id": "N/A",
        "aliases": [
          "astrocytic GABA production"
        ],
        "description": "Process in reactive astrocytes linked to MAOB's role in Parkinson's disease."
      },
      "object": {
        "entity_id": "ent:ef19292214bb",
        "entity_type": "MECHANISM",
        "name": "aggravates astrocytic reactivity and dopaminergic neuronal death",
        "normalized_id": "N/A",
        "aliases": [],
        "description": "Mechanism by which H2O2 contributes to Parkinson's disease progression."
      },
      "time_info": null
    },
    {
      "head": "excessive GABA and H2O2 synthesis",
      "relation": "aggravates",
      "tail": "aggravates astrocytic reactivity and dopaminergic neuronal death",
      "relation_type": null,
      "confidence": [
        0.85,
        0.1
      ],
      "evidence": [
        "whereas HO aggravates astrocytic reactivity and dopaminergic neuronal death."
      ],
      "mechanism": "unknown",
      "source": "ocr_result_1_0",
      "subject": {
        "entity_id": "ent:4c577291e98b",
        "entity_type": "MECHANISM",
        "name": "excessive GABA and H2O2 synthesis",
        "normalized_id": "N/A",
        "aliases": [
          "astrocytic GABA production"
        ],
        "description": "Process in reactive astrocytes linked to MAOB's role in Parkinson's disease."
      },
      "object": {
        "entity_id": "ent:ef19292214bb",
        "entity_type": "MECHANISM",
        "name": "aggravates astrocytic reactivity and dopaminergic neuronal death",
        "normalized_id": "N/A",
        "aliases": [],
        "description": "Mechanism by which H2O2 contributes to Parkinson's disease progression."
      },
      "time_info": null
    },
    {
      "head": "MAOB",
      "relation": "reduce",
      "tail": "reduce reactive astrogliosis and restore dopaminergic neuronal activity",
      "relation_type": null,
      "confidence": [
        0.75,
        0.1
      ],
      "evidence": [
        "Recently discovered reversible MAOB inhibitors reduce reactive astrogliosis and restore dopaminergic neuronal activity to alleviate PD symptoms in rodents."
      ],
      "mechanism": "unknown",
      "source": "ocr_result_1_0",
      "subject": {
        "entity_id": "ent:b3040f3e67f7",
        "entity_type": "PROTEIN",
        "name": "MAOB",
        "normalized_id": "N/A",
        "aliases": [
          "MAOB",
          "Monoamine oxidase B",
          "Monoamine oxidase-B"
        ],
        "description": "Monoamine oxidase-B (MAOB) is described as an enzyme that mediates the aberrant synthesis of GABA and hydrogen peroxide in reactive astrocytes of Parkinson's disease, and its expression increases with aging and in neurodegenerative conditions."
      },
      "object": {
        "entity_id": "ent:5118fd790378",
        "entity_type": "MECHANISM",
        "name": "reduce reactive astrogliosis and restore dopaminergic neuronal activity",
        "normalized_id": "N/A",
        "aliases": [],
        "description": "Mechanism of action for reversible MAOB inhibitors in alleviating PD symptoms."
      },
      "time_info": null
    },
    {
      "head": "MAOB",
      "relation": "restore",
      "tail": "reduce reactive astrogliosis and restore dopaminergic neuronal activity",
      "relation_type": null,
      "confidence": [
        0.75,
        0.1
      ],
      "evidence": [
        "Recently discovered reversible MAOB inhibitors reduce reactive astrogliosis and restore dopaminergic neuronal activity to alleviate PD symptoms in rodents."
      ],
      "mechanism": "unknown",
      "source": "ocr_result_1_0",
      "subject": {
        "entity_id": "ent:b3040f3e67f7",
        "entity_type": "PROTEIN",
        "name": "MAOB",
        "normalized_id": "N/A",
        "aliases": [
          "MAOB",
          "Monoamine oxidase B",
          "Monoamine oxidase-B"
        ],
        "description": "Monoamine oxidase-B (MAOB) is described as an enzyme that mediates the aberrant synthesis of GABA and hydrogen peroxide in reactive astrocytes of Parkinson's disease, and its expression increases with aging and in neurodegenerative conditions."
      },
      "object": {
        "entity_id": "ent:5118fd790378",
        "entity_type": "MECHANISM",
        "name": "reduce reactive astrogliosis and restore dopaminergic neuronal activity",
        "normalized_id": "N/A",
        "aliases": [],
        "description": "Mechanism of action for reversible MAOB inhibitors in alleviating PD symptoms."
      },
      "time_info": null
    },
    {
      "head": "MAOB",
      "relation": "alleviate",
      "tail": "Parkinson's disease",
      "relation_type": null,
      "confidence": [
        0.7,
        0.05
      ],
      "evidence": [
        "Recently discovered reversible MAOB inhibitors reduce reactive astrogliosis and restore dopaminergic neuronal activity to alleviate PD symptoms in rodents."
      ],
      "mechanism": "unknown",
      "source": "ocr_result_1_0",
      "subject": {
        "entity_id": "ent:b3040f3e67f7",
        "entity_type": "PROTEIN",
        "name": "MAOB",
        "normalized_id": "N/A",
        "aliases": [
          "MAOB",
          "Monoamine oxidase B",
          "Monoamine oxidase-B"
        ],
        "description": "Monoamine oxidase-B (MAOB) is described as an enzyme that mediates the aberrant synthesis of GABA and hydrogen peroxide in reactive astrocytes of Parkinson's disease, and its expression increases with aging and in neurodegenerative conditions."
      },
      "object": {
        "entity_id": "ent:fef68ab52f09",
        "entity_type": "DISEASE",
        "name": "Parkinson's disease",
        "normalized_id": "N/A",
        "aliases": [
          "Parkinson's Disease",
          "PD"
        ],
        "description": "A disease where reactive astrocytes in the substantia nigra pars compacta show increased MAOB expression, and astrocytic GABA suppresses dopaminergic neuronal activity while H2O2 aggravates neuronal death."
      },
      "time_info": null
    },
    {
      "head": "contribute to brain aging",
      "relation": "increase",
      "tail": "MAOB",
      "relation_type": null,
      "confidence": [
        0.9,
        0.2
      ],
      "evidence": [
        "Interestingly, MAOB expression is clearly increased with aging in most structures of rodent brains, including the cortex, hippocampus, and striatum",
        "Furthermore, human brain tissue shows a delayed but significant age-related increase in MAOB, which starts at the age of 50-60 years",
        "another study using molecular imaging of MAOB with [C] L-deprenyl-D2 and positron emission tomography (PET) imaging in the living human brains demonstrated that MAOB level was increased in all brain regions examined, except the cingulate gyrus, along with aging"
      ],
      "mechanism": "unknown",
      "source": "ocr_result_1_0",
      "subject": {
        "entity_id": "ent:9808347fe412",
        "entity_type": "MECHANISM",
        "name": "contribute to brain aging",
        "normalized_id": "N/A",
        "aliases": [],
        "description": "Potential role of age-related increase in astrocytic MAOB expression."
      },
      "object": {
        "entity_id": "ent:b3040f3e67f7",
        "entity_type": "PROTEIN",
        "name": "MAOB",
        "normalized_id": "N/A",
        "aliases": [
          "MAOB",
          "Monoamine oxidase B",
          "Monoamine oxidase-B"
        ],
        "description": "Monoamine oxidase-B (MAOB) is described as an enzyme that mediates the aberrant synthesis of GABA and hydrogen peroxide in reactive astrocytes of Parkinson's disease, and its expression increases with aging and in neurodegenerative conditions."
      },
      "time_info": null
    },
    {
      "head": "reduce reactive astrogliosis and restore dopaminergic neuronal activity",
      "relation": "associate with",
      "tail": "MAOB",
      "relation_type": null,
      "confidence": [
        0.85,
        0.85
      ],
      "evidence": [
        "In addition, MAOB expression is significantly increased in the neuroinflammatory and neurodegenerative conditions, which is associated with reactive astrogliosis",
        "MAOB expression is significantly increased in the reactive astrocytes of the substantia nigra pars compacta (SNpc)"
      ],
      "mechanism": "unknown",
      "source": "ocr_result_1_0",
      "subject": {
        "entity_id": "ent:5118fd790378",
        "entity_type": "MECHANISM",
        "name": "reduce reactive astrogliosis and restore dopaminergic neuronal activity",
        "normalized_id": "N/A",
        "aliases": [],
        "description": "Mechanism of action for reversible MAOB inhibitors in alleviating PD symptoms."
      },
      "object": {
        "entity_id": "ent:b3040f3e67f7",
        "entity_type": "PROTEIN",
        "name": "MAOB",
        "normalized_id": "N/A",
        "aliases": [
          "MAOB",
          "Monoamine oxidase B",
          "Monoamine oxidase-B"
        ],
        "description": "Monoamine oxidase-B (MAOB) is described as an enzyme that mediates the aberrant synthesis of GABA and hydrogen peroxide in reactive astrocytes of Parkinson's disease, and its expression increases with aging and in neurodegenerative conditions."
      },
      "time_info": null
    },
    {
      "head": "MAOB",
      "relation": "contribute to",
      "tail": "contribute to brain aging",
      "relation_type": null,
      "confidence": [
        0.65,
        0.1
      ],
      "evidence": [
        "Based on the exclusive expression of MAOB in astrocytes, the age-related increase in MAOB expression in astrocytes could contribute to brain aging."
      ],
      "mechanism": "unknown",
      "source": "ocr_result_1_0",
      "subject": {
        "entity_id": "ent:b3040f3e67f7",
        "entity_type": "PROTEIN",
        "name": "MAOB",
        "normalized_id": "N/A",
        "aliases": [
          "MAOB",
          "Monoamine oxidase B",
          "Monoamine oxidase-B"
        ],
        "description": "Monoamine oxidase-B (MAOB) is described as an enzyme that mediates the aberrant synthesis of GABA and hydrogen peroxide in reactive astrocytes of Parkinson's disease, and its expression increases with aging and in neurodegenerative conditions."
      },
      "object": {
        "entity_id": "ent:9808347fe412",
        "entity_type": "MECHANISM",
        "name": "contribute to brain aging",
        "normalized_id": "N/A",
        "aliases": [],
        "description": "Potential role of age-related increase in astrocytic MAOB expression."
      },
      "time_info": null
    },
    {
      "head": "MAOB",
      "relation": "contribute to",
      "tail": "contribute to the progression and maintenance of neuroinflammation and neurodegeneration",
      "relation_type": null,
      "confidence": [
        0.75,
        0.2
      ],
      "evidence": [
        "These emerging lines of evidence have suggested that the increased MAOB expression along with reactive astrogliosis could contribute to the progression and maintenance of neuroinflammation and neurodegeneration."
      ],
      "mechanism": "unknown",
      "source": "ocr_result_1_0",
      "subject": {
        "entity_id": "ent:b3040f3e67f7",
        "entity_type": "PROTEIN",
        "name": "MAOB",
        "normalized_id": "N/A",
        "aliases": [
          "MAOB",
          "Monoamine oxidase B",
          "Monoamine oxidase-B"
        ],
        "description": "Monoamine oxidase-B (MAOB) is described as an enzyme that mediates the aberrant synthesis of GABA and hydrogen peroxide in reactive astrocytes of Parkinson's disease, and its expression increases with aging and in neurodegenerative conditions."
      },
      "object": {
        "entity_id": "ent:e83c02822576",
        "entity_type": "MECHANISM",
        "name": "contribute to the progression and maintenance of neuroinflammation and neurodegeneration",
        "normalized_id": "N/A",
        "aliases": [
          "neurodegenerative diseases",
          "reactive astrogliosis"
        ],
        "description": "Suggested role of increased MAOB expression with reactive astrogliosis in diseases."
      },
      "time_info": null
    },
    {
      "head": "MAOB",
      "relation": "increase with",
      "tail": "contribute to brain aging",
      "relation_type": null,
      "confidence": [
        0.9,
        0.2
      ],
      "evidence": [
        "Interestingly, MAOB expression is clearly increased with aging in most structures of rodent brains",
        "Furthermore, human brain tissue shows a delayed but significant age-related increase in MAOB",
        "MAOB level was increased in all brain regions examined, except the cingulate gyrus, along with aging"
      ],
      "mechanism": "unknown",
      "source": "ocr_result_1_0",
      "subject": {
        "entity_id": "ent:b3040f3e67f7",
        "entity_type": "PROTEIN",
        "name": "MAOB",
        "normalized_id": "N/A",
        "aliases": [
          "MAOB",
          "Monoamine oxidase B",
          "Monoamine oxidase-B"
        ],
        "description": "Monoamine oxidase-B (MAOB) is described as an enzyme that mediates the aberrant synthesis of GABA and hydrogen peroxide in reactive astrocytes of Parkinson's disease, and its expression increases with aging and in neurodegenerative conditions."
      },
      "object": {
        "entity_id": "ent:9808347fe412",
        "entity_type": "MECHANISM",
        "name": "contribute to brain aging",
        "normalized_id": "N/A",
        "aliases": [],
        "description": "Potential role of age-related increase in astrocytic MAOB expression."
      },
      "time_info": null
    },
    {
      "head": "selective inhibitors against MAOA and MAOB",
      "relation": "upregulate in",
      "tail": "Parkinson's disease",
      "relation_type": null,
      "confidence": [
        0.85,
        0.05
      ],
      "evidence": [
        "Notably, MAOB is known to be upregulated in PD patients' brains [34].",
        "Moreover, MAOB has recently received special attention due to its increased level along with reactive astrogliosis in neurodegenerative diseases, including PD [15,16,17,18,21,22,38,41]."
      ],
      "mechanism": "unknown",
      "source": "ocr_result_1_1",
      "subject": {
        "entity_id": "ent:352e32fda357",
        "entity_type": "TREATMENT",
        "name": "selective inhibitors against MAOA and MAOB",
        "normalized_id": "N/A",
        "aliases": [],
        "description": "Described as being used in several in vivo studies that demonstrated DA is much preferentially degraded by MAOA compared to MAOB in the rat brain."
      },
      "object": {
        "entity_id": "ent:fef68ab52f09",
        "entity_type": "DISEASE",
        "name": "Parkinson's disease",
        "normalized_id": "N/A",
        "aliases": [
          "Parkinson's Disease",
          "PD"
        ],
        "description": "A disease where reactive astrocytes in the substantia nigra pars compacta show increased MAOB expression, and astrocytic GABA suppresses dopaminergic neuronal activity while H2O2 aggravates neuronal death."
      },
      "time_info": null
    },
    {
      "head": "selective inhibitors against MAOA and MAOB",
      "relation": "contribute to",
      "tail": "Parkinson's disease",
      "relation_type": null,
      "confidence": [
        0.75,
        0.1
      ],
      "evidence": [
        "Therefore, MAOB has long been believed to contribute to PD pathophysiology through excessive DA degradation [35].",
        "These recent discoveries on the pathological role of astrocytic MAOB led us to revisit the MAOB's role in PD pathophysiology."
      ],
      "mechanism": "unknown",
      "source": "ocr_result_1_1",
      "subject": {
        "entity_id": "ent:352e32fda357",
        "entity_type": "TREATMENT",
        "name": "selective inhibitors against MAOA and MAOB",
        "normalized_id": "N/A",
        "aliases": [],
        "description": "Described as being used in several in vivo studies that demonstrated DA is much preferentially degraded by MAOA compared to MAOB in the rat brain."
      },
      "object": {
        "entity_id": "ent:fef68ab52f09",
        "entity_type": "DISEASE",
        "name": "Parkinson's disease",
        "normalized_id": "N/A",
        "aliases": [
          "Parkinson's Disease",
          "PD"
        ],
        "description": "A disease where reactive astrocytes in the substantia nigra pars compacta show increased MAOB expression, and astrocytic GABA suppresses dopaminergic neuronal activity while H2O2 aggravates neuronal death."
      },
      "time_info": null
    },
    {
      "head": "selective inhibitors against MAOA and MAOB",
      "relation": "involve in",
      "tail": "excessive GABA and H2O2 synthesis",
      "relation_type": null,
      "confidence": [
        0.9,
        0.05
      ],
      "evidence": [
        "Since 2014, several investigations have begun to emphasize the specific involvement of MAOB, but not MAOA, in astrocytic GABA production via the putrescine degradation route [15,16,21,38,39,40], which has been overlooked in the brain for decades."
      ],
      "mechanism": "unknown",
      "source": "ocr_result_1_1",
      "subject": {
        "entity_id": "ent:352e32fda357",
        "entity_type": "TREATMENT",
        "name": "selective inhibitors against MAOA and MAOB",
        "normalized_id": "N/A",
        "aliases": [],
        "description": "Described as being used in several in vivo studies that demonstrated DA is much preferentially degraded by MAOA compared to MAOB in the rat brain."
      },
      "object": {
        "entity_id": "ent:4c577291e98b",
        "entity_type": "MECHANISM",
        "name": "excessive GABA and H2O2 synthesis",
        "normalized_id": "N/A",
        "aliases": [
          "astrocytic GABA production"
        ],
        "description": "Process in reactive astrocytes linked to MAOB's role in Parkinson's disease."
      },
      "time_info": null
    },
    {
      "head": "irreversible MAOB inhibitors",
      "relation": "block",
      "tail": "blockade of the excessive astrocytic GABA synthesis",
      "relation_type": null,
      "confidence": [
        0.8,
        0.05
      ],
      "evidence": [
        "The therapeutic efficacy of MAOB inhibitors for PD is not attributed to a blockade of DA degradation. Instead, it is attributed to a blockade of the excessive astrocytic GABA synthesis and the aberrant tonic inhibition of DAergic neurons in the SNpc."
      ],
      "mechanism": "unknown",
      "source": "ocr_result_1_1",
      "subject": {
        "entity_id": "ent:434e480a4a35",
        "entity_type": "TREATMENT",
        "name": "irreversible MAOB inhibitors",
        "normalized_id": "N/A",
        "aliases": [
          "irreversible inhibitors",
          "irreversible MAOB inhibitors",
          "MAOB inhibitors"
        ],
        "description": "Inhibitors of monoamine oxidase B that are described as having shortcomings in the context of Alzheimer's disease treatment."
      },
      "object": {
        "entity_id": "ent:70547b872a76",
        "entity_type": "MECHANISM",
        "name": "blockade of the excessive astrocytic GABA synthesis",
        "normalized_id": "N/A",
        "aliases": [],
        "description": "The therapeutic efficacy of MAOB inhibitors for PD is attributed to a blockade of the excessive astrocytic GABA synthesis."
      },
      "time_info": null
    },
    {
      "head": "levodopa",
      "relation": "treat",
      "tail": "Parkinson's disease",
      "relation_type": null,
      "confidence": [
        0.95,
        0.01
      ],
      "evidence": [
        "Apart from levodopa, which is the most popular therapeutic agent for PD, several irreversible MAOB inhibitors have been widely prescribed for PD patients as an early monotherapy or an add-on to other medications"
      ],
      "mechanism": "unknown",
      "source": "ocr_result_1_1",
      "subject": {
        "entity_id": "ent:c7f5ccc4d424",
        "entity_type": "DRUG",
        "name": "levodopa",
        "normalized_id": "N/A",
        "aliases": [
          "levodopa"
        ],
        "description": "Described as the most popular therapeutic agent for Parkinson's disease."
      },
      "object": {
        "entity_id": "ent:fef68ab52f09",
        "entity_type": "DISEASE",
        "name": "Parkinson's disease",
        "normalized_id": "N/A",
        "aliases": [
          "Parkinson's Disease",
          "PD"
        ],
        "description": "A disease where reactive astrocytes in the substantia nigra pars compacta show increased MAOB expression, and astrocytic GABA suppresses dopaminergic neuronal activity while H2O2 aggravates neuronal death."
      },
      "time_info": null
    },
    {
      "head": "irreversible MAOB inhibitors",
      "relation": "treat",
      "tail": "Parkinson's disease",
      "relation_type": null,
      "confidence": [
        0.85,
        0.01
      ],
      "evidence": [
        "several irreversible MAOB inhibitors have been widely prescribed for PD patients as an early monotherapy or an add-on to other medications",
        "This belief was further supported by a positive but limited clinical efficacy of irreversible MAOB inhibitors such as selegiline and rasagiline for PD patients [36,37]."
      ],
      "mechanism": "unknown",
      "source": "ocr_result_1_1",
      "subject": {
        "entity_id": "ent:434e480a4a35",
        "entity_type": "TREATMENT",
        "name": "irreversible MAOB inhibitors",
        "normalized_id": "N/A",
        "aliases": [
          "irreversible inhibitors",
          "irreversible MAOB inhibitors",
          "MAOB inhibitors"
        ],
        "description": "Inhibitors of monoamine oxidase B that are described as having shortcomings in the context of Alzheimer's disease treatment."
      },
      "object": {
        "entity_id": "ent:fef68ab52f09",
        "entity_type": "DISEASE",
        "name": "Parkinson's disease",
        "normalized_id": "N/A",
        "aliases": [
          "Parkinson's Disease",
          "PD"
        ],
        "description": "A disease where reactive astrocytes in the substantia nigra pars compacta show increased MAOB expression, and astrocytic GABA suppresses dopaminergic neuronal activity while H2O2 aggravates neuronal death."
      },
      "time_info": null
    },
    {
      "head": "selegiline administration",
      "relation": "treat",
      "tail": "Parkinson's disease",
      "relation_type": null,
      "confidence": [
        0.85,
        0.01
      ],
      "evidence": [
        "This belief was further supported by a positive but limited clinical efficacy of irreversible MAOB inhibitors such as selegiline and rasagiline for PD patients [36,37]."
      ],
      "mechanism": "unknown",
      "source": "ocr_result_1_1",
      "subject": {
        "entity_id": "ent:d19390680e91",
        "entity_type": "TREATMENT",
        "name": "selegiline administration",
        "normalized_id": "N/A",
        "aliases": [
          "selegiline"
        ],
        "description": "A post-treatment regime starting 3 days after MPTP administration that significantly alleviated MPTP-induced PD-like pathology and motor symptoms in a mouse model."
      },
      "object": {
        "entity_id": "ent:fef68ab52f09",
        "entity_type": "DISEASE",
        "name": "Parkinson's disease",
        "normalized_id": "N/A",
        "aliases": [
          "Parkinson's Disease",
          "PD"
        ],
        "description": "A disease where reactive astrocytes in the substantia nigra pars compacta show increased MAOB expression, and astrocytic GABA suppresses dopaminergic neuronal activity while H2O2 aggravates neuronal death."
      },
      "time_info": null
    },
    {
      "head": "rasagiline",
      "relation": "treat",
      "tail": "Parkinson's disease",
      "relation_type": null,
      "confidence": [
        0.85,
        0.01
      ],
      "evidence": [
        "This belief was further supported by a positive but limited clinical efficacy of irreversible MAOB inhibitors such as selegiline and rasagiline for PD patients [36,37]."
      ],
      "mechanism": "unknown",
      "source": "ocr_result_1_1",
      "subject": {
        "entity_id": "ent:1c3341f3966f",
        "entity_type": "DRUG",
        "name": "rasagiline",
        "normalized_id": "N/A",
        "aliases": [
          "Azilect",
          "rasagiline"
        ],
        "description": "Drug described as an anti-Parkinson drug with pharmacological properties modifying endogenous brain amines, reserpine reversal, serotonergic and dopaminergic behaviours."
      },
      "object": {
        "entity_id": "ent:fef68ab52f09",
        "entity_type": "DISEASE",
        "name": "Parkinson's disease",
        "normalized_id": "N/A",
        "aliases": [
          "Parkinson's Disease",
          "PD"
        ],
        "description": "A disease where reactive astrocytes in the substantia nigra pars compacta show increased MAOB expression, and astrocytic GABA suppresses dopaminergic neuronal activity while H2O2 aggravates neuronal death."
      },
      "time_info": null
    },
    {
      "head": "nigrostriatal DA depletion",
      "relation": "cause",
      "tail": "Parkinson's disease",
      "relation_type": null,
      "confidence": [
        0.9,
        0.7
      ],
      "evidence": [
        "PD is the most prevalent neurodegenerative motor disorder, which is caused by nigrostriatal DA depletion [23]."
      ],
      "mechanism": "unknown",
      "source": "ocr_result_1_1",
      "subject": {
        "entity_id": "ent:74ae36586264",
        "entity_type": "MECHANISM",
        "name": "nigrostriatal DA depletion",
        "normalized_id": "N/A",
        "aliases": [],
        "description": "Described as the cause of Parkinson's disease, specifically nigrostriatal DA depletion."
      },
      "object": {
        "entity_id": "ent:fef68ab52f09",
        "entity_type": "DISEASE",
        "name": "Parkinson's disease",
        "normalized_id": "N/A",
        "aliases": [
          "Parkinson's Disease",
          "PD"
        ],
        "description": "A disease where reactive astrocytes in the substantia nigra pars compacta show increased MAOB expression, and astrocytic GABA suppresses dopaminergic neuronal activity while H2O2 aggravates neuronal death."
      },
      "time_info": null
    },
    {
      "head": "selective inhibitors against MAOA and MAOB",
      "relation": "catalyze",
      "tail": "degradation of monoamine neurotransmitters",
      "relation_type": null,
      "confidence": [
        0.65,
        0.05
      ],
      "evidence": [
        "DA is traditionally known to be degraded by both MAOA and MAOB.",
        "On the other hand, some other studies using selegiline also demonstrated that MAOB catalyzes DA as a substrate in rats [45,46,47].",
        "Notably, an investigation with the homogenates of brain tissues from various species by Garrick and Murphy demonstrated that DA was found to be deaminated largely by MAOA in the rat brains, whereas by MAOB in the brains of humans and vervet [46].",
        "Despite the controversies on the contributions of MAOA and MAOB to DA degradation, it has been traditionally and until now generally believed that both MAOA and MAOB are equally active towards DA degradation [35,48,49,50,51]."
      ],
      "mechanism": "unknown",
      "source": "ocr_result_1_1",
      "subject": {
        "entity_id": "ent:352e32fda357",
        "entity_type": "TREATMENT",
        "name": "selective inhibitors against MAOA and MAOB",
        "normalized_id": "N/A",
        "aliases": [],
        "description": "Described as being used in several in vivo studies that demonstrated DA is much preferentially degraded by MAOA compared to MAOB in the rat brain."
      },
      "object": {
        "entity_id": "ent:ba5ffc952c8d",
        "entity_type": "MECHANISM",
        "name": "degradation of monoamine neurotransmitters",
        "normalized_id": "N/A",
        "aliases": [
          "DA deamination",
          "DA degradation",
          "excessive DA degradation"
        ],
        "description": "Process traditionally believed to be mediated by MAOB for neurotransmitters like dopamine."
      },
      "time_info": null
    },
    {
      "head": "MAOB",
      "relation": "utilize",
      "tail": "DA metabolism",
      "relation_type": null,
      "confidence": [
        0.85,
        0.05
      ],
      "evidence": [
        "Several in vitro studies demonstrated that MAOB also utilizes DA as a substrate in both rats (Km = ~340 M) [67] and humans (Km = ~210--230 M) [68], indicating the capability of MAOB in DA degradation in vitro."
      ],
      "mechanism": "unknown",
      "source": "ocr_result_1_3",
      "subject": {
        "entity_id": "ent:b3040f3e67f7",
        "entity_type": "PROTEIN",
        "name": "MAOB",
        "normalized_id": "N/A",
        "aliases": [
          "MAOB",
          "Monoamine oxidase B",
          "Monoamine oxidase-B"
        ],
        "description": "Monoamine oxidase-B (MAOB) is described as an enzyme that mediates the aberrant synthesis of GABA and hydrogen peroxide in reactive astrocytes of Parkinson's disease, and its expression increases with aging and in neurodegenerative conditions."
      },
      "object": {
        "entity_id": "ent:1c7f8cffc70f",
        "entity_type": "MECHANISM",
        "name": "DA metabolism",
        "normalized_id": "N/A",
        "aliases": [
          "DA metabolism"
        ],
        "description": "The chemical processes involving dopamine, mentioned as a role of MAOB to be excluded in PD pathology."
      },
      "time_info": null
    },
    {
      "head": "MAOB",
      "relation": "deaminate",
      "tail": "DA metabolism",
      "relation_type": null,
      "confidence": [
        0.4,
        0.05
      ],
      "evidence": [
        "In the living brain, however, DA needs to first enter the astrocytes, where MAOB is mainly localized, for being deaminated by MAOB.",
        "Consequently, regardless of MAOB's ability to metabolize DA in vitro, the contribution of astrocytic MAOB to DA degradation is negligible in the living brain."
      ],
      "mechanism": "unknown",
      "source": "ocr_result_1_3",
      "subject": {
        "entity_id": "ent:b3040f3e67f7",
        "entity_type": "PROTEIN",
        "name": "MAOB",
        "normalized_id": "N/A",
        "aliases": [
          "MAOB",
          "Monoamine oxidase B",
          "Monoamine oxidase-B"
        ],
        "description": "Monoamine oxidase-B (MAOB) is described as an enzyme that mediates the aberrant synthesis of GABA and hydrogen peroxide in reactive astrocytes of Parkinson's disease, and its expression increases with aging and in neurodegenerative conditions."
      },
      "object": {
        "entity_id": "ent:1c7f8cffc70f",
        "entity_type": "MECHANISM",
        "name": "DA metabolism",
        "normalized_id": "N/A",
        "aliases": [
          "DA metabolism"
        ],
        "description": "The chemical processes involving dopamine, mentioned as a role of MAOB to be excluded in PD pathology."
      },
      "time_info": null
    },
    {
      "head": "MAOB",
      "relation": "prevent",
      "tail": "parkinsonian motor symptoms",
      "relation_type": null,
      "confidence": [
        0.9,
        0.1
      ],
      "evidence": [
        "Moreover, pharmacological blockade of MAOB inhibitors has been well documented to prevent MPTP-induced PD pathology and parkinsonian motor symptoms [36,73]."
      ],
      "mechanism": "unknown",
      "source": "ocr_result_1_3",
      "subject": {
        "entity_id": "ent:b3040f3e67f7",
        "entity_type": "PROTEIN",
        "name": "MAOB",
        "normalized_id": "N/A",
        "aliases": [
          "MAOB",
          "Monoamine oxidase B",
          "Monoamine oxidase-B"
        ],
        "description": "Monoamine oxidase-B (MAOB) is described as an enzyme that mediates the aberrant synthesis of GABA and hydrogen peroxide in reactive astrocytes of Parkinson's disease, and its expression increases with aging and in neurodegenerative conditions."
      },
      "object": {
        "entity_id": "ent:b592b4ef77cd",
        "entity_type": "SYMPTOM",
        "name": "parkinsonian motor symptoms",
        "normalized_id": "N/A",
        "aliases": [
          "motor symptoms",
          "parkinsonian",
          "parkinsonian models",
          "parkinsonian motor symptoms",
          "parkinsonian symptoms",
          "PD",
          "PD pathology",
          "PD-like pathology"
        ],
        "description": "Motor symptoms associated with Parkinson's disease that can be prevented by pharmacological blockade of MAOB inhibitors in MPTP-induced pathology."
      },
      "time_info": null
    },
    {
      "head": "selegiline administration",
      "relation": "alleviate",
      "tail": "PD-like pathology",
      "relation_type": null,
      "confidence": [
        0.75,
        0.05
      ],
      "evidence": [
        "On the other hand, in the MPTP mouse model, it was recently demonstrated that the post-treatment regime of selegiline administration, which starts 3 days after MPTP, significantly alleviated MPTP-induced PD-like pathology and motor symptoms [38]."
      ],
      "mechanism": "unknown",
      "source": "ocr_result_1_3",
      "subject": {
        "entity_id": "ent:d19390680e91",
        "entity_type": "TREATMENT",
        "name": "selegiline administration",
        "normalized_id": "N/A",
        "aliases": [
          "selegiline"
        ],
        "description": "A post-treatment regime starting 3 days after MPTP administration that significantly alleviated MPTP-induced PD-like pathology and motor symptoms in a mouse model."
      },
      "object": {
        "entity_id": "ent:a5a6d3dcf4c7",
        "entity_type": "DISEASE",
        "name": "PD-like pathology",
        "normalized_id": "N/A",
        "aliases": [
          "parkinsonian motor symptoms",
          "parkinsonian symptoms",
          "PD",
          "PD pathology"
        ],
        "description": "Pathology alleviated by post-treatment selegiline administration in the MPTP mouse model."
      },
      "time_info": null
    },
    {
      "head": "selegiline administration",
      "relation": "alleviate",
      "tail": "motor dysfunction",
      "relation_type": null,
      "confidence": [
        0.75,
        0.05
      ],
      "evidence": [
        "On the other hand, in the MPTP mouse model, it was recently demonstrated that the post-treatment regime of selegiline administration, which starts 3 days after MPTP, significantly alleviated MPTP-induced PD-like pathology and motor symptoms [38]."
      ],
      "mechanism": "unknown",
      "source": "ocr_result_1_3",
      "subject": {
        "entity_id": "ent:d19390680e91",
        "entity_type": "TREATMENT",
        "name": "selegiline administration",
        "normalized_id": "N/A",
        "aliases": [
          "selegiline"
        ],
        "description": "A post-treatment regime starting 3 days after MPTP administration that significantly alleviated MPTP-induced PD-like pathology and motor symptoms in a mouse model."
      },
      "object": {
        "entity_id": "ent:d6f79d9a562d",
        "entity_type": "SYMPTOM",
        "name": "motor dysfunction",
        "normalized_id": "N/A",
        "aliases": [
          "motor dysfunction"
        ],
        "description": "Motor dysfunction is mentioned as part of the toxicity caused by MPTP in Parkinson's disease."
      },
      "time_info": null
    },
    {
      "head": "MAOB",
      "relation": "synthesize",
      "tail": "aberrant synthesis of GABA and hydrogen peroxide",
      "relation_type": null,
      "confidence": [
        0.95,
        0.05
      ],
      "evidence": [
        "MAOB has been demonstrated as a critical enzyme for astrocytic GABA synthesis in several brain areas under physiological conditions, including the cerebellum [40,75] and striatum [39].",
        "Previous reports have revealed that astrocytic GABA is synthesized from putrescine through several steps of enzymatic actions, including MAOB [15,40]."
      ],
      "mechanism": "unknown",
      "source": "ocr_result_1_3",
      "subject": {
        "entity_id": "ent:b3040f3e67f7",
        "entity_type": "PROTEIN",
        "name": "MAOB",
        "normalized_id": "N/A",
        "aliases": [
          "MAOB",
          "Monoamine oxidase B",
          "Monoamine oxidase-B"
        ],
        "description": "Monoamine oxidase-B (MAOB) is described as an enzyme that mediates the aberrant synthesis of GABA and hydrogen peroxide in reactive astrocytes of Parkinson's disease, and its expression increases with aging and in neurodegenerative conditions."
      },
      "object": {
        "entity_id": "ent:599cd7cac967",
        "entity_type": "MECHANISM",
        "name": "aberrant synthesis of GABA and hydrogen peroxide",
        "normalized_id": "N/A",
        "aliases": [
          "aberrant GABA synthesis",
          "aberrant synthesis of GABA and hydrogen peroxide"
        ],
        "description": "Abnormal production of GABA, identified as the mechanism through which astrocytic MAOB substantially contributes to PD pathology."
      },
      "time_info": null
    },
    {
      "head": "pharmacological blockade",
      "relation": "prevent",
      "tail": "parkinsonian motor symptoms",
      "relation_type": null,
      "confidence": [
        0.9,
        0.1
      ],
      "evidence": [
        "Moreover, pharmacological blockade of MAOB inhibitors has been well documented to prevent MPTP-induced PD pathology and parkinsonian motor symptoms [36,73]."
      ],
      "mechanism": "unknown",
      "source": "ocr_result_1_3",
      "subject": {
        "entity_id": "ent:534c54c8183a",
        "entity_type": "MECHANISM",
        "name": "pharmacological blockade",
        "normalized_id": "N/A",
        "aliases": [
          "MAOB inhibition",
          "pharmacological blockade"
        ],
        "description": "Inhibition by drugs, specifically of MAOB to prevent MPTP-induced PD pathology and symptoms."
      },
      "object": {
        "entity_id": "ent:b592b4ef77cd",
        "entity_type": "SYMPTOM",
        "name": "parkinsonian motor symptoms",
        "normalized_id": "N/A",
        "aliases": [
          "motor symptoms",
          "parkinsonian",
          "parkinsonian models",
          "parkinsonian motor symptoms",
          "parkinsonian symptoms",
          "PD",
          "PD pathology",
          "PD-like pathology"
        ],
        "description": "Motor symptoms associated with Parkinson's disease that can be prevented by pharmacological blockade of MAOB inhibitors in MPTP-induced pathology."
      },
      "time_info": null
    },
    {
      "head": "MAOB",
      "relation": "reduce",
      "tail": "tyrosine hydroxylase",
      "relation_type": null,
      "confidence": [
        0.65,
        0.1
      ],
      "evidence": [
        "The aberrant suppression of DAergic neuronal activity leads to a substantial decrease in tyrosine hydroxylase (TH), the key DA-synthesizing enzyme.",
        "Notably, the reduction of TH level could be reversible when the DAergic neurons are aberrantly suppressed but still alive."
      ],
      "mechanism": "unknown",
      "source": "ocr_result_1_3",
      "subject": {
        "entity_id": "ent:b3040f3e67f7",
        "entity_type": "PROTEIN",
        "name": "MAOB",
        "normalized_id": "N/A",
        "aliases": [
          "MAOB",
          "Monoamine oxidase B",
          "Monoamine oxidase-B"
        ],
        "description": "Monoamine oxidase-B (MAOB) is described as an enzyme that mediates the aberrant synthesis of GABA and hydrogen peroxide in reactive astrocytes of Parkinson's disease, and its expression increases with aging and in neurodegenerative conditions."
      },
      "object": {
        "entity_id": "ent:d2ff732091cc",
        "entity_type": "PROTEIN",
        "name": "tyrosine hydroxylase",
        "normalized_id": "N/A",
        "aliases": [
          "TH",
          "tyrosine hydroxylase"
        ],
        "description": "Key DA-synthesizing enzyme whose reduction in level is caused by aberrant suppression of DAergic neuronal activity."
      },
      "time_info": null
    },
    {
      "head": "aberrant suppression",
      "relation": "lead to",
      "tail": "tyrosine hydroxylase",
      "relation_type": null,
      "confidence": [
        0.8,
        0.15
      ],
      "evidence": [
        "The aberrant suppression of DAergic neuronal activity leads to a substantial decrease in tyrosine hydroxylase (TH), the key DA-synthesizing enzyme.",
        "Notably, the reduction of TH level could be reversible when the DAergic neurons are aberrantly suppressed but still alive."
      ],
      "mechanism": "unknown",
      "source": "ocr_result_1_3",
      "subject": {
        "entity_id": "ent:a980819c9600",
        "entity_type": "MECHANISM",
        "name": "aberrant suppression",
        "normalized_id": "N/A",
        "aliases": [],
        "description": "Abnormal inhibitory process leading to decreased activity of dopaminergic neurons in the SNpc, caused by excessive GABA."
      },
      "object": {
        "entity_id": "ent:d2ff732091cc",
        "entity_type": "PROTEIN",
        "name": "tyrosine hydroxylase",
        "normalized_id": "N/A",
        "aliases": [
          "TH",
          "tyrosine hydroxylase"
        ],
        "description": "Key DA-synthesizing enzyme whose reduction in level is caused by aberrant suppression of DAergic neuronal activity."
      },
      "time_info": null
    },
    {
      "head": "monoamine oxidase A",
      "relation": "increase",
      "tail": "reactive astrogliosis",
      "relation_type": null,
      "confidence": [
        0.75,
        0.15
      ],
      "evidence": [
        "MAO-B elevation in mouse brain astrocytes results in Parkinson's pathology.",
        "Inhibition of monoamine oxidase B prevents reactive astrogliosis and scar formation in stab wound injury model."
      ],
      "mechanism": "unknown",
      "source": "ocr_result_1_7",
      "subject": {
        "entity_id": "ent:51da53feedad",
        "entity_type": "PROTEIN",
        "name": "monoamine oxidase A",
        "normalized_id": "N/A",
        "aliases": [
          "MAO-A",
          "monoamine oxidase A"
        ],
        "description": "Enzyme form immunocytochemically localized in human peripheral tissues and brain along with monoamine oxidase B."
      },
      "object": {
        "entity_id": "ent:6ea68b38485f",
        "entity_type": "MECHANISM",
        "name": "reactive astrogliosis",
        "normalized_id": "N/A",
        "aliases": [
          "reactive astrogliosis"
        ],
        "description": "A process prevented by inhibition of monoamine oxidase B in a stab wound injury model according to the text."
      },
      "time_info": null
    },
    {
      "head": "monoamine oxidase A",
      "relation": "increase",
      "tail": "scar formation",
      "relation_type": null,
      "confidence": [
        0.7,
        0.1
      ],
      "evidence": [
        "Inhibition of monoamine oxidase B prevents reactive astrogliosis and scar formation in stab wound injury model."
      ],
      "mechanism": "unknown",
      "source": "ocr_result_1_7",
      "subject": {
        "entity_id": "ent:51da53feedad",
        "entity_type": "PROTEIN",
        "name": "monoamine oxidase A",
        "normalized_id": "N/A",
        "aliases": [
          "MAO-A",
          "monoamine oxidase A"
        ],
        "description": "Enzyme form immunocytochemically localized in human peripheral tissues and brain along with monoamine oxidase B."
      },
      "object": {
        "entity_id": "ent:29fa43362442",
        "entity_type": "MECHANISM",
        "name": "scar formation",
        "normalized_id": "N/A",
        "aliases": [],
        "description": "A process prevented by inhibition of monoamine oxidase B in a stab wound injury model according to the text."
      },
      "time_info": null
    },
    {
      "head": "monoamine oxidase A",
      "relation": "result in",
      "tail": "Parkinson's disease",
      "relation_type": null,
      "confidence": [
        0.65,
        0.05
      ],
      "evidence": [
        "MAO-B elevation in mouse brain astrocytes results in Parkinson's pathology.",
        "The Pathological Role of Astrocytic MAOB in Parkinsonism Revealed by Genetic Ablation and Over-expression of MAOB."
      ],
      "mechanism": "unknown",
      "source": "ocr_result_1_7",
      "subject": {
        "entity_id": "ent:51da53feedad",
        "entity_type": "PROTEIN",
        "name": "monoamine oxidase A",
        "normalized_id": "N/A",
        "aliases": [
          "MAO-A",
          "monoamine oxidase A"
        ],
        "description": "Enzyme form immunocytochemically localized in human peripheral tissues and brain along with monoamine oxidase B."
      },
      "object": {
        "entity_id": "ent:fef68ab52f09",
        "entity_type": "DISEASE",
        "name": "Parkinson's disease",
        "normalized_id": "N/A",
        "aliases": [
          "Parkinson's Disease",
          "PD"
        ],
        "description": "A disease where reactive astrocytes in the substantia nigra pars compacta show increased MAOB expression, and astrocytic GABA suppresses dopaminergic neuronal activity while H2O2 aggravates neuronal death."
      },
      "time_info": null
    },
    {
      "head": "MAO-B",
      "relation": "circumvent",
      "tail": "irreversible MAOB inhibitors",
      "relation_type": null,
      "confidence": [
        0.85,
        0.1
      ],
      "evidence": [
        "Newly developed reversible MAO-B inhibitor circumvents the shortcomings of irreversible inhibitors in Alzheimer's disease."
      ],
      "mechanism": "unknown",
      "source": "ocr_result_1_7",
      "subject": {
        "entity_id": "ent:f82f40b55d07",
        "entity_type": "PROTEIN",
        "name": "MAO-B",
        "normalized_id": "N/A",
        "aliases": [
          "MAO-B",
          "MAOB"
        ],
        "description": "Enzyme demonstrated in brain astrocytes and serotonergic neurons, showing differential age-related changes in mouse brain and peripheral organs, with age-related increases in human brain."
      },
      "object": {
        "entity_id": "ent:434e480a4a35",
        "entity_type": "TREATMENT",
        "name": "irreversible MAOB inhibitors",
        "normalized_id": "N/A",
        "aliases": [
          "irreversible inhibitors",
          "irreversible MAOB inhibitors",
          "MAOB inhibitors"
        ],
        "description": "Inhibitors of monoamine oxidase B that are described as having shortcomings in the context of Alzheimer's disease treatment."
      },
      "time_info": null
    },
    {
      "head": "deprenyl (selegiline)",
      "relation": "inhibit",
      "tail": "monoamine oxidase A",
      "relation_type": null,
      "confidence": [
        0.95,
        0.05
      ],
      "evidence": [
        "The effect of deprenyl (selegiline) on the natural history of Parkinson's disease.",
        "Comparison of Early-Phase 11C-Deuterium-l-Deprenyl and 11C-Pittsburgh Compound B PET for Assessing Brain Perfusion in Alzheimer Disease."
      ],
      "mechanism": "unknown",
      "source": "ocr_result_1_7",
      "subject": {
        "entity_id": "ent:bb47817e0ed3",
        "entity_type": "TREATMENT",
        "name": "deprenyl (selegiline)",
        "normalized_id": "N/A",
        "aliases": [
          "deprenyl",
          "selegiline"
        ],
        "description": "A medication referred to as deprenyl with the synonym selegiline, studied for its effect on the natural history of Parkinson's disease."
      },
      "object": {
        "entity_id": "ent:51da53feedad",
        "entity_type": "PROTEIN",
        "name": "monoamine oxidase A",
        "normalized_id": "N/A",
        "aliases": [
          "MAO-A",
          "monoamine oxidase A"
        ],
        "description": "Enzyme form immunocytochemically localized in human peripheral tissues and brain along with monoamine oxidase B."
      },
      "time_info": null
    },
    {
      "head": "monoamine oxidase A",
      "relation": "prevent",
      "tail": "reactive astrogliosis",
      "relation_type": null,
      "confidence": [
        0.8,
        0.1
      ],
      "evidence": [
        "Inhibition of monoamine oxidase B prevents reactive astrogliosis and scar formation in stab wound injury model."
      ],
      "mechanism": "unknown",
      "source": "ocr_result_1_7",
      "subject": {
        "entity_id": "ent:51da53feedad",
        "entity_type": "PROTEIN",
        "name": "monoamine oxidase A",
        "normalized_id": "N/A",
        "aliases": [
          "MAO-A",
          "monoamine oxidase A"
        ],
        "description": "Enzyme form immunocytochemically localized in human peripheral tissues and brain along with monoamine oxidase B."
      },
      "object": {
        "entity_id": "ent:6ea68b38485f",
        "entity_type": "MECHANISM",
        "name": "reactive astrogliosis",
        "normalized_id": "N/A",
        "aliases": [
          "reactive astrogliosis"
        ],
        "description": "A process prevented by inhibition of monoamine oxidase B in a stab wound injury model according to the text."
      },
      "time_info": null
    },
    {
      "head": "monoamine oxidase A",
      "relation": "prevent",
      "tail": "scar formation",
      "relation_type": null,
      "confidence": [
        0.8,
        0.1
      ],
      "evidence": [
        "Inhibition of monoamine oxidase B prevents reactive astrogliosis and scar formation in stab wound injury model."
      ],
      "mechanism": "unknown",
      "source": "ocr_result_1_7",
      "subject": {
        "entity_id": "ent:51da53feedad",
        "entity_type": "PROTEIN",
        "name": "monoamine oxidase A",
        "normalized_id": "N/A",
        "aliases": [
          "MAO-A",
          "monoamine oxidase A"
        ],
        "description": "Enzyme form immunocytochemically localized in human peripheral tissues and brain along with monoamine oxidase B."
      },
      "object": {
        "entity_id": "ent:29fa43362442",
        "entity_type": "MECHANISM",
        "name": "scar formation",
        "normalized_id": "N/A",
        "aliases": [],
        "description": "A process prevented by inhibition of monoamine oxidase B in a stab wound injury model according to the text."
      },
      "time_info": null
    },
    {
      "head": "deprenyl (selegiline)",
      "relation": "affect",
      "tail": "Parkinson's disease",
      "relation_type": null,
      "confidence": [
        0.9,
        0.05
      ],
      "evidence": [
        "The effect of deprenyl (selegiline) on the natural history of Parkinson's disease.",
        "Different Generations of Type-B Monoamine Oxidase Inhibitors in Parkinson's Disease: From Bench to Bedside."
      ],
      "mechanism": "unknown",
      "source": "ocr_result_1_7",
      "subject": {
        "entity_id": "ent:bb47817e0ed3",
        "entity_type": "TREATMENT",
        "name": "deprenyl (selegiline)",
        "normalized_id": "N/A",
        "aliases": [
          "deprenyl",
          "selegiline"
        ],
        "description": "A medication referred to as deprenyl with the synonym selegiline, studied for its effect on the natural history of Parkinson's disease."
      },
      "object": {
        "entity_id": "ent:fef68ab52f09",
        "entity_type": "DISEASE",
        "name": "Parkinson's disease",
        "normalized_id": "N/A",
        "aliases": [
          "Parkinson's Disease",
          "PD"
        ],
        "description": "A disease where reactive astrocytes in the substantia nigra pars compacta show increased MAOB expression, and astrocytic GABA suppresses dopaminergic neuronal activity while H2O2 aggravates neuronal death."
      },
      "time_info": null
    },
    {
      "head": "rasagiline",
      "relation": "inhibit",
      "tail": "monoamine oxidase type B",
      "relation_type": null,
      "confidence": [
        0.95,
        0.05
      ],
      "evidence": [
        "Weinreb, O.; Amit, T.; Bar-Am, O.; Youdim, M.B. Rasagiline: A novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity. Prog. Neurobiol. 2010, 92, 330--344.",
        "Chen, J.J.; Swope, D.M. Clinical pharmacology of rasagiline: A novel, second-generation propargylamine for the treatment of Parkinson disease. J. Clin. Pharmacol. 2005, 45, 878--894."
      ],
      "mechanism": "unknown",
      "source": "ocr_result_1_8",
      "subject": {
        "entity_id": "ent:1c3341f3966f",
        "entity_type": "DRUG",
        "name": "rasagiline",
        "normalized_id": "N/A",
        "aliases": [
          "Azilect",
          "rasagiline"
        ],
        "description": "Drug described as an anti-Parkinson drug with pharmacological properties modifying endogenous brain amines, reserpine reversal, serotonergic and dopaminergic behaviours."
      },
      "object": {
        "entity_id": "ent:9ad1f6609c5c",
        "entity_type": "PROTEIN",
        "name": "monoamine oxidase type B",
        "normalized_id": "N/A",
        "aliases": [
          "MAO-B",
          "monoamine oxidase B",
          "monoamine oxidase-B"
        ],
        "description": "An enzyme questioned for its role in dopaminergic nerve cell death in Parkinson's disease according to the document."
      },
      "time_info": null
    },
    {
      "head": "monoamine oxidase type B",
      "relation": "synthesize",
      "tail": "tonic GABA synthesis",
      "relation_type": null,
      "confidence": [
        0.85,
        0.1
      ],
      "evidence": [
        "Cho, H.U.; Kim, S.; Sim, J.; Yang, S.; An, H.; Nam, M.H.; Jang, D.P.; Lee, C.J. Redefining differential roles of MAO-A in dopamine degradation and MAO-B in tonic GABA synthesis. Exp. Mol. Med. 2021, 53, 1148--1158.",
        "Yoon, B.E.; Woo, J.; Chun, Y.E.; Chun, H.; Jo, S.; Bae, J.Y.; An, H.; Min, J.O.; Oh, S.J.; Han, K.S.; et al. Glial GABA, synthesized by monoamine oxidase B, mediates tonic inhibition. J. Physiol. 2014, 592, 4951--4968."
      ],
      "mechanism": "unknown",
      "source": "ocr_result_1_8",
      "subject": {
        "entity_id": "ent:9ad1f6609c5c",
        "entity_type": "PROTEIN",
        "name": "monoamine oxidase type B",
        "normalized_id": "N/A",
        "aliases": [
          "MAO-B",
          "monoamine oxidase B",
          "monoamine oxidase-B"
        ],
        "description": "An enzyme questioned for its role in dopaminergic nerve cell death in Parkinson's disease according to the document."
      },
      "object": {
        "entity_id": "ent:5a8bc6738968",
        "entity_type": "MECHANISM",
        "name": "tonic GABA synthesis",
        "normalized_id": "N/A",
        "aliases": [],
        "description": "Process described as being mediated by MAO-B according to the text."
      },
      "time_info": null
    },
    {
      "head": "KDS2010",
      "relation": "inhibit",
      "tail": "monoamine oxidase type B",
      "relation_type": null,
      "confidence": [
        0.9,
        0.05
      ],
      "evidence": [
        "Nam, M.H.; Park, J.H.; Song, H.J.; Choi, J.W.; Kim, S.; Jang, B.K.; Yoon, H.H.; Heo, J.Y.; Lee, H.; An, H.; et al. KDS2010, a Newly Developed Reversible MAO-B Inhibitor, as an Effective Therapeutic Candidate for Parkinson's Disease. Neurotherapeutics 2021, 18, 1729--1747."
      ],
      "mechanism": "unknown",
      "source": "ocr_result_1_8",
      "subject": {
        "entity_id": "ent:3dd64ffce8e4",
        "entity_type": "TREATMENT",
        "name": "KDS2010",
        "normalized_id": "N/A",
        "aliases": [
          "KDS2010"
        ],
        "description": "Described as a newly developed potent, reversible, and selective MAOB inhibitor used in a study to circumvent limitations of irreversible inhibitors."
      },
      "object": {
        "entity_id": "ent:9ad1f6609c5c",
        "entity_type": "PROTEIN",
        "name": "monoamine oxidase type B",
        "normalized_id": "N/A",
        "aliases": [
          "MAO-B",
          "monoamine oxidase B",
          "monoamine oxidase-B"
        ],
        "description": "An enzyme questioned for its role in dopaminergic nerve cell death in Parkinson's disease according to the document."
      },
      "time_info": null
    },
    {
      "head": "deprenyl",
      "relation": "inhibit",
      "tail": "monoamine oxidase type B",
      "relation_type": null,
      "confidence": [
        0.97,
        0.05
      ],
      "evidence": [
        "Braestrup, C.; Andersen, H.; Randrup, A. The monoamine oxidase B inhibitor deprenyl potentiates phenylethylamine behaviour in rats without inhibition of catecholamine metabolite formation. Eur. J. Pharmacol. 1975, 34, 181--187.",
        "Glover, V.; Elsworth, J.D.; Sandler, M. Dopamine oxidation and its inhibition by- deprenyl in man. J. Neural. Transm. Suppl. 1980, 16, 163--172.",
        "Robakis, D.; Fahn, S. Defining the Role of the Monoamine Oxidase-B Inhibitors for Parkinson's Disease. CNS Drugs 2015, 29, 433--441."
      ],
      "mechanism": "unknown",
      "source": "ocr_result_1_8",
      "subject": {
        "entity_id": "ent:bb3a46e0e21d",
        "entity_type": "TREATMENT",
        "name": "deprenyl",
        "normalized_id": "N/A",
        "aliases": [
          "deprenyl"
        ],
        "description": "A monoamine oxidase B inhibitor that potentiates phenylethylamine behaviour in rats."
      },
      "object": {
        "entity_id": "ent:9ad1f6609c5c",
        "entity_type": "PROTEIN",
        "name": "monoamine oxidase type B",
        "normalized_id": "N/A",
        "aliases": [
          "MAO-B",
          "monoamine oxidase B",
          "monoamine oxidase-B"
        ],
        "description": "An enzyme questioned for its role in dopaminergic nerve cell death in Parkinson's disease according to the document."
      },
      "time_info": null
    },
    {
      "head": "MAO-A",
      "relation": "deaminate",
      "tail": "dopamine degradation",
      "relation_type": null,
      "confidence": [
        0.8,
        0.15
      ],
      "evidence": [
        "Cho, H.U.; Kim, S.; Sim, J.; Yang, S.; An, H.; Nam, M.H.; Jang, D.P.; Lee, C.J. Redefining differential roles of MAO-A in dopamine degradation and MAO-B in tonic GABA synthesis. Exp. Mol. Med. 2021, 53, 1148--1158.",
        "Waldmeier, P.C.; Delini-Stula, A.; Maitre, L. Preferential deamination of dopamine by an A type monoamine oxidase in rat brain. Naunyn-Schmiedebergs Arch. Pharmacol. 1976, 292, 9--14.",
        "Green, A.R.; Mitchell, B.D.; Tordoff, A.F.; Youdim, M.B. Evidence for dopamine deamination by both type A and type B monoamine oxidase in rat brain in vivo and for the degree of inhibition of enzyme necessary for increased functional activity of dopamine and 5-hydroxytryptamine. Br. J. Pharmacol. 1977, 60, 343--349."
      ],
      "mechanism": "unknown",
      "source": "ocr_result_1_8",
      "subject": {
        "entity_id": "ent:2b3c854b7989",
        "entity_type": "PROTEIN",
        "name": "MAO-A",
        "normalized_id": "N/A",
        "aliases": [
          "MAO-A"
        ],
        "description": "An enzyme described as having a differential role in dopamine degradation according to the document."
      },
      "object": {
        "entity_id": "ent:fe6ed4e43233",
        "entity_type": "MECHANISM",
        "name": "dopamine degradation",
        "normalized_id": "N/A",
        "aliases": [
          "dopamine degradation"
        ],
        "description": "Process described as involving MAO-A according to the text."
      },
      "time_info": null
    },
    {
      "head": "monoamine oxidase type B",
      "relation": "deaminate",
      "tail": "dopamine degradation",
      "relation_type": null,
      "confidence": [
        0.7,
        0.15
      ],
      "evidence": [
        "Green, A.R.; Mitchell, B.D.; Tordoff, A.F.; Youdim, M.B. Evidence for dopamine deamination by both type A and type B monoamine oxidase in rat brain in vivo and for the degree of inhibition of enzyme necessary for increased functional activity of dopamine and 5-hydroxytryptamine. Br. J. Pharmacol. 1977, 60, 343--349.",
        "Schoepp, D.D.; Azzaro, A.J. Specificity of endogenous substrates for types A and B monoamine oxidase in rat striatum. J. Neurochem. 1981, 36, 2025--2031.",
        "Roth, J.A.; Feor, K. Deamination of dopamine and its 3-O-methylated derivative by human brain monoamine oxidase. Biochem. Pharmacol. 1978, 27, 1606--1608."
      ],
      "mechanism": "unknown",
      "source": "ocr_result_1_8",
      "subject": {
        "entity_id": "ent:9ad1f6609c5c",
        "entity_type": "PROTEIN",
        "name": "monoamine oxidase type B",
        "normalized_id": "N/A",
        "aliases": [
          "MAO-B",
          "monoamine oxidase B",
          "monoamine oxidase-B"
        ],
        "description": "An enzyme questioned for its role in dopaminergic nerve cell death in Parkinson's disease according to the document."
      },
      "object": {
        "entity_id": "ent:fe6ed4e43233",
        "entity_type": "MECHANISM",
        "name": "dopamine degradation",
        "normalized_id": "N/A",
        "aliases": [
          "dopamine degradation"
        ],
        "description": "Process described as involving MAO-A according to the text."
      },
      "time_info": null
    },
    {
      "head": "deprenyl",
      "relation": "inhibit",
      "tail": "oxidation",
      "relation_type": null,
      "confidence": [
        0.88,
        0.05
      ],
      "evidence": [
        "Glover, V.; Elsworth, J.D.; Sandler, M. Dopamine oxidation and its inhibition by- deprenyl in man. J. Neural. Transm. Suppl. 1980, 16, 163--172."
      ],
      "mechanism": "unknown",
      "source": "ocr_result_1_8",
      "subject": {
        "entity_id": "ent:bb3a46e0e21d",
        "entity_type": "TREATMENT",
        "name": "deprenyl",
        "normalized_id": "N/A",
        "aliases": [
          "deprenyl"
        ],
        "description": "A monoamine oxidase B inhibitor that potentiates phenylethylamine behaviour in rats."
      },
      "object": {
        "entity_id": "ent:bdae51ed6cfe",
        "entity_type": "MECHANISM",
        "name": "oxidation",
        "normalized_id": "N/A",
        "aliases": [],
        "description": "Process described for dopamine and its inhibition by deprenyl in man."
      },
      "time_info": null
    },
    {
      "head": "monoamine oxidase type B",
      "relation": "oxidize",
      "tail": "dopamine degradation",
      "relation_type": null,
      "confidence": [
        0.75,
        0.15
      ],
      "evidence": [
        "Glover, V.; Elsworth, J.D.; Sandler, M. Dopamine oxidation and its inhibition by- deprenyl in man. J. Neural. Transm. Suppl. 1980, 16, 163--172.",
        "Green, A.R.; Mitchell, B.D.; Tordoff, A.F.; Youdim, M.B. Evidence for dopamine deamination by both type A and type B monoamine oxidase in rat brain in vivo and for the degree of inhibition of enzyme necessary for increased functional activity of dopamine and 5-hydroxytryptamine. Br. J. Pharmacol. 1977, 60, 343--349.",
        "Roth, J.A.; Feor, K. Deamination of dopamine and its 3-O-methylated derivative by human brain monoamine oxidase. Biochem. Pharmacol. 1978, 27, 1606--1608."
      ],
      "mechanism": "unknown",
      "source": "ocr_result_1_8",
      "subject": {
        "entity_id": "ent:9ad1f6609c5c",
        "entity_type": "PROTEIN",
        "name": "monoamine oxidase type B",
        "normalized_id": "N/A",
        "aliases": [
          "MAO-B",
          "monoamine oxidase B",
          "monoamine oxidase-B"
        ],
        "description": "An enzyme questioned for its role in dopaminergic nerve cell death in Parkinson's disease according to the document."
      },
      "object": {
        "entity_id": "ent:fe6ed4e43233",
        "entity_type": "MECHANISM",
        "name": "dopamine degradation",
        "normalized_id": "N/A",
        "aliases": [
          "dopamine degradation"
        ],
        "description": "Process described as involving MAO-A according to the text."
      },
      "time_info": null
    },
    {
      "head": "selegiline",
      "relation": "inhibit",
      "tail": "Inhibition of monoamine oxidase-B",
      "relation_type": null,
      "confidence": [
        0.95,
        0.05
      ],
      "evidence": [
        "Inhibition of monoamine oxidase-B by-deprenyl potentiates neuronal responses to dopamine agonists but does not inhibit dopamine catabolism in the rat striatum.",
        "Monoamine oxidase-B (MAO-B) inhibitors: Implications for disease-modification in Parkinson's disease.",
        "Selegiline's neuroprotective capacity revisited."
      ],
      "mechanism": "unknown",
      "source": "ocr_result_1_9",
      "subject": {
        "entity_id": "ent:83a05372da2a",
        "entity_type": "DRUG",
        "name": "selegiline",
        "normalized_id": "N/A",
        "aliases": [
          "deprenyl",
          "l-deprenyl",
          "selegiline"
        ],
        "description": "Drug described as a selective MAO-B inhibitor in formulations that bypass first-pass metabolism and also inhibit MAO-A in the human brain."
      },
      "object": {
        "entity_id": "ent:831a57626092",
        "entity_type": "MECHANISM",
        "name": "Inhibition of monoamine oxidase-B",
        "normalized_id": "N/A",
        "aliases": [
          "MAO-A inhibition",
          "MAO-B inhibition",
          "selective MAO-A or -B inhibition"
        ],
        "description": "Inhibition of monoamine oxidase-B potentiates neuronal responses to dopamine agonists but does not inhibit dopamine catabolism in the rat striatum."
      },
      "time_info": null
    },
    {
      "head": "cimoxatone",
      "relation": "inhibit",
      "tail": "Selective inhibitors of monoamine oxidase type B",
      "relation_type": null,
      "confidence": [
        0.85,
        0.05
      ],
      "evidence": [
        "The metabolism of dopamine by both forms of monoamine oxidase in the rat brain and its inhibition by cimoxatone."
      ],
      "mechanism": "unknown",
      "source": "ocr_result_1_9",
      "subject": {
        "entity_id": "ent:fdf3d1eddd1f",
        "entity_type": "DRUG",
        "name": "cimoxatone",
        "normalized_id": "N/A",
        "aliases": [],
        "description": "Drug described as inhibiting the metabolism of dopamine by both forms of monoamine oxidase in rat brain."
      },
      "object": {
        "entity_id": "ent:ada7a45aeaed",
        "entity_type": "TREATMENT",
        "name": "Selective inhibitors of monoamine oxidase type B",
        "normalized_id": "N/A",
        "aliases": [
          "MAO-B inhibitors",
          "monoamine oxidase type-B inhibitors",
          "monoamine oxidase-B (MAO-B) inhibitors",
          "Monoamine Oxidase-B Inhibitors"
        ],
        "description": "Pharmacologic agents that specifically target MAO-B enzymes, discussed in relation to the \"cheese effect\" side effect."
      },
      "time_info": null
    },
    {
      "head": "safinamide",
      "relation": "inhibit",
      "tail": "glutamate release",
      "relation_type": null,
      "confidence": [
        0.8,
        0.05
      ],
      "evidence": [
        "Safinamide inhibits in vivo glutamate release in a rat model of Parkinson's disease."
      ],
      "mechanism": "unknown",
      "source": "ocr_result_1_9",
      "subject": {
        "entity_id": "ent:db6fc7703586",
        "entity_type": "TREATMENT",
        "name": "safinamide",
        "normalized_id": "N/A",
        "aliases": [
          "safinamide",
          "Xadago"
        ],
        "description": "A reversible MAOB inhibitor."
      },
      "object": {
        "entity_id": "ent:181b9c5c4fd3",
        "entity_type": "MECHANISM",
        "name": "glutamate release",
        "normalized_id": "N/A",
        "aliases": [],
        "description": "Safinamide inhibits in vivo glutamate release in a rat model of Parkinson's disease according to the study."
      },
      "time_info": null
    },
    {
      "head": "selegiline",
      "relation": "slow",
      "tail": "Parkinson's disease",
      "relation_type": null,
      "confidence": [
        0.9,
        0.1
      ],
      "evidence": [
        "Selegiline slows the progression of the symptoms of Parkinson disease.",
        "Monoamine oxidase-B (MAO-B) inhibitors: Implications for disease-modification in Parkinson's disease.",
        "Selegiline's neuroprotective capacity revisited."
      ],
      "mechanism": "unknown",
      "source": "ocr_result_1_9",
      "subject": {
        "entity_id": "ent:83a05372da2a",
        "entity_type": "DRUG",
        "name": "selegiline",
        "normalized_id": "N/A",
        "aliases": [
          "deprenyl",
          "l-deprenyl",
          "selegiline"
        ],
        "description": "Drug described as a selective MAO-B inhibitor in formulations that bypass first-pass metabolism and also inhibit MAO-A in the human brain."
      },
      "object": {
        "entity_id": "ent:fef68ab52f09",
        "entity_type": "DISEASE",
        "name": "Parkinson's disease",
        "normalized_id": "N/A",
        "aliases": [
          "Parkinson's Disease",
          "PD"
        ],
        "description": "A disease where reactive astrocytes in the substantia nigra pars compacta show increased MAOB expression, and astrocytic GABA suppresses dopaminergic neuronal activity while H2O2 aggravates neuronal death."
      },
      "time_info": null
    },
    {
      "head": "deprenyl",
      "relation": "protect",
      "tail": "oxidative damage",
      "relation_type": null,
      "confidence": [
        0.85,
        0.05
      ],
      "evidence": [
        "Protection of the aged substantia nigra of the rat against oxidative damage by-deprenyl.",
        "-Deprenyl protects human dopaminergic neuroblastoma SH-SY5Y cells from apoptosis induced by peroxynitrite and nitric oxide."
      ],
      "mechanism": "unknown",
      "source": "ocr_result_1_10",
      "subject": {
        "entity_id": "ent:bb3a46e0e21d",
        "entity_type": "TREATMENT",
        "name": "deprenyl",
        "normalized_id": "N/A",
        "aliases": [
          "deprenyl"
        ],
        "description": "A monoamine oxidase B inhibitor that potentiates phenylethylamine behaviour in rats."
      },
      "object": {
        "entity_id": "ent:6e425cc63a1d",
        "entity_type": "MECHANISM",
        "name": "oxidative damage",
        "normalized_id": "N/A",
        "aliases": [],
        "description": "A process against which the aged substantia nigra is protected by deprenyl according to the cited study."
      },
      "time_info": null
    },
    {
      "head": "deprenyl",
      "relation": "attenuate",
      "tail": "aluminium induced neurotoxicity",
      "relation_type": null,
      "confidence": [
        0.8,
        0.05
      ],
      "evidence": [
        "deprenyl attenuates aluminium induced neurotoxicity in primary cortical cultures."
      ],
      "mechanism": "unknown",
      "source": "ocr_result_1_10",
      "subject": {
        "entity_id": "ent:bb3a46e0e21d",
        "entity_type": "TREATMENT",
        "name": "deprenyl",
        "normalized_id": "N/A",
        "aliases": [
          "deprenyl"
        ],
        "description": "A monoamine oxidase B inhibitor that potentiates phenylethylamine behaviour in rats."
      },
      "object": {
        "entity_id": "ent:8d14d88cfb8b",
        "entity_type": "DISEASE",
        "name": "aluminium induced neurotoxicity",
        "normalized_id": "N/A",
        "aliases": [],
        "description": "N/A"
      },
      "time_info": null
    },
    {
      "head": "deprenyl",
      "relation": "protect",
      "tail": "apoptosis",
      "relation_type": null,
      "confidence": [
        0.82,
        0.05
      ],
      "evidence": [
        "-Deprenyl protects human dopaminergic neuroblastoma SH-SY5Y cells from apoptosis induced by peroxynitrite and nitric oxide."
      ],
      "mechanism": "unknown",
      "source": "ocr_result_1_10",
      "subject": {
        "entity_id": "ent:bb3a46e0e21d",
        "entity_type": "TREATMENT",
        "name": "deprenyl",
        "normalized_id": "N/A",
        "aliases": [
          "deprenyl"
        ],
        "description": "A monoamine oxidase B inhibitor that potentiates phenylethylamine behaviour in rats."
      },
      "object": {
        "entity_id": "ent:d7eb2f78f5ad",
        "entity_type": "MECHANISM",
        "name": "apoptosis",
        "normalized_id": "N/A",
        "aliases": [
          "apoptosis"
        ],
        "description": "A process that STC2 prevents, as it facilitates cells dealing with stress conditions."
      },
      "time_info": null
    },
    {
      "head": "Propargylamines",
      "relation": "induce",
      "tail": "antiapoptotic new protein synthesis",
      "relation_type": null,
      "confidence": [
        0.78,
        0.05
      ],
      "evidence": [
        "Propargylamines induce antiapoptotic new protein synthesis in serum- and nerve growth factor (NGF)-withdrawn, NGF-differentiated PC-12 cells."
      ],
      "mechanism": "unknown",
      "source": "ocr_result_1_10",
      "subject": {
        "entity_id": "ent:9cdbd86f9782",
        "entity_type": "DRUG",
        "name": "Propargylamines",
        "normalized_id": "N/A",
        "aliases": [],
        "description": "Compounds described as inducing antiapoptotic new protein synthesis in serum- and nerve growth factor-withdrawn, NGF-differentiated PC-12 cells."
      },
      "object": {
        "entity_id": "ent:5bc4f51890c3",
        "entity_type": "MECHANISM",
        "name": "antiapoptotic new protein synthesis",
        "normalized_id": "N/A",
        "aliases": [],
        "description": "A process induced by propargylamines in serum- and nerve growth factor-withdrawn, NGF-differentiated PC-12 cells."
      },
      "time_info": null
    },
    {
      "head": "selegiline",
      "relation": "inhibit",
      "tail": "MAO-A",
      "relation_type": null,
      "confidence": [
        0.7,
        0.05
      ],
      "evidence": [
        "Evidence that formulations of the selective MAO-B inhibitor, selegiline, which bypass first-pass metabolism, also inhibit MAO-A in the human brain."
      ],
      "mechanism": "unknown",
      "source": "ocr_result_1_10",
      "subject": {
        "entity_id": "ent:83a05372da2a",
        "entity_type": "DRUG",
        "name": "selegiline",
        "normalized_id": "N/A",
        "aliases": [
          "deprenyl",
          "l-deprenyl",
          "selegiline"
        ],
        "description": "Drug described as a selective MAO-B inhibitor in formulations that bypass first-pass metabolism and also inhibit MAO-A in the human brain."
      },
      "object": {
        "entity_id": "ent:2b3c854b7989",
        "entity_type": "PROTEIN",
        "name": "MAO-A",
        "normalized_id": "N/A",
        "aliases": [
          "MAO-A"
        ],
        "description": "An enzyme described as having a differential role in dopamine degradation according to the document."
      },
      "time_info": null
    },
    {
      "head": "selegiline",
      "relation": "inhibit",
      "tail": "MAO-B",
      "relation_type": null,
      "confidence": [
        0.95,
        0.05
      ],
      "evidence": [
        "Evidence that formulations of the selective MAO-B inhibitor, selegiline, which bypass first-pass metabolism, also inhibit MAO-A in the human brain."
      ],
      "mechanism": "unknown",
      "source": "ocr_result_1_10",
      "subject": {
        "entity_id": "ent:83a05372da2a",
        "entity_type": "DRUG",
        "name": "selegiline",
        "normalized_id": "N/A",
        "aliases": [
          "deprenyl",
          "l-deprenyl",
          "selegiline"
        ],
        "description": "Drug described as a selective MAO-B inhibitor in formulations that bypass first-pass metabolism and also inhibit MAO-A in the human brain."
      },
      "object": {
        "entity_id": "ent:f82f40b55d07",
        "entity_type": "PROTEIN",
        "name": "MAO-B",
        "normalized_id": "N/A",
        "aliases": [
          "MAO-B",
          "MAOB"
        ],
        "description": "Enzyme demonstrated in brain astrocytes and serotonergic neurons, showing differential age-related changes in mouse brain and peripheral organs, with age-related increases in human brain."
      },
      "time_info": null
    },
    {
      "head": "rasagiline",
      "relation": "reverse",
      "tail": "first-pass metabolism",
      "relation_type": null,
      "confidence": [
        0.1,
        0.05
      ],
      "evidence": [
        "Evidence that formulations of the selective MAO-B inhibitor, selegiline, which bypass first-pass metabolism, also inhibit MAO-A in the human brain."
      ],
      "mechanism": "unknown",
      "source": "ocr_result_1_10",
      "subject": {
        "entity_id": "ent:1c3341f3966f",
        "entity_type": "DRUG",
        "name": "rasagiline",
        "normalized_id": "N/A",
        "aliases": [
          "Azilect",
          "rasagiline"
        ],
        "description": "Drug described as an anti-Parkinson drug with pharmacological properties modifying endogenous brain amines, reserpine reversal, serotonergic and dopaminergic behaviours."
      },
      "object": {
        "entity_id": "ent:167a63227ea1",
        "entity_type": "MECHANISM",
        "name": "first-pass metabolism",
        "normalized_id": "N/A",
        "aliases": [],
        "description": "A metabolic process that certain formulations of selegiline bypass according to the evidence presented."
      },
      "time_info": null
    },
    {
      "head": "safinamide",
      "relation": "protect",
      "tail": "Parkinson's disease",
      "relation_type": null,
      "confidence": [
        0.75,
        0.05
      ],
      "evidence": [
        "Neuroprotection by safinamide in the 6-hydroxydopamine model of Parkinson's disease.",
        "The safety and efficacy of safinamide mesylate for the treatment of Parkinson's disease.",
        "Pharmacokinetics and pharmacodynamics of safinamide, a neuroprotectant with antiparkinsonian and anticonvulsant activity."
      ],
      "mechanism": "unknown",
      "source": "ocr_result_1_10",
      "subject": {
        "entity_id": "ent:db6fc7703586",
        "entity_type": "TREATMENT",
        "name": "safinamide",
        "normalized_id": "N/A",
        "aliases": [
          "safinamide",
          "Xadago"
        ],
        "description": "A reversible MAOB inhibitor."
      },
      "object": {
        "entity_id": "ent:fef68ab52f09",
        "entity_type": "DISEASE",
        "name": "Parkinson's disease",
        "normalized_id": "N/A",
        "aliases": [
          "Parkinson's Disease",
          "PD"
        ],
        "description": "A disease where reactive astrocytes in the substantia nigra pars compacta show increased MAOB expression, and astrocytic GABA suppresses dopaminergic neuronal activity while H2O2 aggravates neuronal death."
      },
      "time_info": null
    },
    {
      "head": "CRISPR-Cas9 Gene Editing",
      "relation": "protect",
      "tail": "Parkinson's disease",
      "relation_type": null,
      "confidence": [
        0.82,
        0.05
      ],
      "evidence": [
        "CRISPR-Cas9 Gene Editing Protects from the A53T-SNCA Overexpression-Induced Pathology of Parkinson's Disease In Vivo."
      ],
      "mechanism": "unknown",
      "source": "ocr_result_1_10",
      "subject": {
        "entity_id": "ent:2280dbc53a93",
        "entity_type": "TREATMENT",
        "name": "CRISPR-Cas9 Gene Editing",
        "normalized_id": "N/A",
        "aliases": [],
        "description": "Described as protecting from the A53T-SNCA overexpression-induced pathology of Parkinson's Disease In Vivo."
      },
      "object": {
        "entity_id": "ent:fef68ab52f09",
        "entity_type": "DISEASE",
        "name": "Parkinson's disease",
        "normalized_id": "N/A",
        "aliases": [
          "Parkinson's Disease",
          "PD"
        ],
        "description": "A disease where reactive astrocytes in the substantia nigra pars compacta show increased MAOB expression, and astrocytic GABA suppresses dopaminergic neuronal activity while H2O2 aggravates neuronal death."
      },
      "time_info": null
    },
    {
      "head": "ER stress",
      "relation": "stimulate",
      "tail": "Stanniocalcin 2",
      "relation_type": null,
      "confidence": [
        0.85,
        0.05
      ],
      "evidence": [
        "The expression of STC2 is regulated at both transcriptional and post-transcriptional levels; particularly, STC2 is significantly stimulated under various stress conditions like ER stress, hypoxia and nutrient deprivation."
      ],
      "mechanism": "unknown",
      "source": "ocr_result_2_0",
      "subject": {
        "entity_id": "ent:9e91135bbf60",
        "entity_type": "MECHANISM",
        "name": "ER stress",
        "normalized_id": "N/A",
        "aliases": [
          "ER stress"
        ],
        "description": "A characteristic of immunogenic cell death, which regulates the expression of immune-relevant metagenes."
      },
      "object": {
        "entity_id": "ent:4cb806fad36b",
        "entity_type": "GENE",
        "name": "Stanniocalcin 2",
        "normalized_id": "N/A",
        "aliases": [
          "Stanniocalcin",
          "Stanniocalcin 2",
          "STC2"
        ],
        "description": "Gene with elevated levels in gastric cancer compared to normal tissues, correlated with tumour invasion, lymphatic metastasis and poor prognosis."
      },
      "time_info": null
    },
    {
      "head": "hypoxia",
      "relation": "stimulate",
      "tail": "Stanniocalcin 2",
      "relation_type": null,
      "confidence": [
        0.85,
        0.05
      ],
      "evidence": [
        "The expression of STC2 is regulated at both transcriptional and post-transcriptional levels; particularly, STC2 is significantly stimulated under various stress conditions like ER stress, hypoxia and nutrient deprivation."
      ],
      "mechanism": "unknown",
      "source": "ocr_result_2_0",
      "subject": {
        "entity_id": "ent:0ca2fd9c234b",
        "entity_type": "MECHANISM",
        "name": "hypoxia",
        "normalized_id": "N/A",
        "aliases": [],
        "description": "A stress condition under which STC2 expression is significantly stimulated."
      },
      "object": {
        "entity_id": "ent:4cb806fad36b",
        "entity_type": "GENE",
        "name": "Stanniocalcin 2",
        "normalized_id": "N/A",
        "aliases": [
          "Stanniocalcin",
          "Stanniocalcin 2",
          "STC2"
        ],
        "description": "Gene with elevated levels in gastric cancer compared to normal tissues, correlated with tumour invasion, lymphatic metastasis and poor prognosis."
      },
      "time_info": null
    },
    {
      "head": "nutrient deprivation",
      "relation": "stimulate",
      "tail": "Stanniocalcin 2",
      "relation_type": null,
      "confidence": [
        0.85,
        0.05
      ],
      "evidence": [
        "The expression of STC2 is regulated at both transcriptional and post-transcriptional levels; particularly, STC2 is significantly stimulated under various stress conditions like ER stress, hypoxia and nutrient deprivation."
      ],
      "mechanism": "unknown",
      "source": "ocr_result_2_0",
      "subject": {
        "entity_id": "ent:2c4f8bd577e3",
        "entity_type": "MECHANISM",
        "name": "nutrient deprivation",
        "normalized_id": "N/A",
        "aliases": [],
        "description": "A stress condition under which STC2 expression is significantly stimulated."
      },
      "object": {
        "entity_id": "ent:4cb806fad36b",
        "entity_type": "GENE",
        "name": "Stanniocalcin 2",
        "normalized_id": "N/A",
        "aliases": [
          "Stanniocalcin",
          "Stanniocalcin 2",
          "STC2"
        ],
        "description": "Gene with elevated levels in gastric cancer compared to normal tissues, correlated with tumour invasion, lymphatic metastasis and poor prognosis."
      },
      "time_info": null
    },
    {
      "head": "Stanniocalcin 2",
      "relation": "facilitate",
      "tail": "stress conditions",
      "relation_type": null,
      "confidence": [
        0.75,
        0.1
      ],
      "evidence": [
        "Biologically, STC2 facilitates cells dealing with stress conditions and prevents apoptosis."
      ],
      "mechanism": "unknown",
      "source": "ocr_result_2_0",
      "subject": {
        "entity_id": "ent:4cb806fad36b",
        "entity_type": "GENE",
        "name": "Stanniocalcin 2",
        "normalized_id": "N/A",
        "aliases": [
          "Stanniocalcin",
          "Stanniocalcin 2",
          "STC2"
        ],
        "description": "Gene with elevated levels in gastric cancer compared to normal tissues, correlated with tumour invasion, lymphatic metastasis and poor prognosis."
      },
      "object": {
        "entity_id": "ent:b26ae4f28d7a",
        "entity_type": "OTHER",
        "name": "stress conditions",
        "normalized_id": "N/A",
        "aliases": [
          "stress conditions"
        ],
        "description": "Solid tumour cells are described as commonly encountering stress conditions which selectively activate corresponding signaling pathways."
      },
      "time_info": null
    },
    {
      "head": "Stanniocalcin 2",
      "relation": "prevent",
      "tail": "apoptosis",
      "relation_type": null,
      "confidence": [
        0.8,
        0.05
      ],
      "evidence": [
        "Biologically, STC2 facilitates cells dealing with stress conditions and prevents apoptosis."
      ],
      "mechanism": "unknown",
      "source": "ocr_result_2_0",
      "subject": {
        "entity_id": "ent:4cb806fad36b",
        "entity_type": "GENE",
        "name": "Stanniocalcin 2",
        "normalized_id": "N/A",
        "aliases": [
          "Stanniocalcin",
          "Stanniocalcin 2",
          "STC2"
        ],
        "description": "Gene with elevated levels in gastric cancer compared to normal tissues, correlated with tumour invasion, lymphatic metastasis and poor prognosis."
      },
      "object": {
        "entity_id": "ent:d7eb2f78f5ad",
        "entity_type": "MECHANISM",
        "name": "apoptosis",
        "normalized_id": "N/A",
        "aliases": [
          "apoptosis"
        ],
        "description": "A process that STC2 prevents, as it facilitates cells dealing with stress conditions."
      },
      "time_info": null
    },
    {
      "head": "Stanniocalcin 2",
      "relation": "promote",
      "tail": "acquired resistance",
      "relation_type": null,
      "confidence": [
        0.82,
        0.05
      ],
      "evidence": [
        "Importantly, STC2 also promotes the development of acquired resistance to chemo- and radio- therapies."
      ],
      "mechanism": "unknown",
      "source": "ocr_result_2_0",
      "subject": {
        "entity_id": "ent:4cb806fad36b",
        "entity_type": "GENE",
        "name": "Stanniocalcin 2",
        "normalized_id": "N/A",
        "aliases": [
          "Stanniocalcin",
          "Stanniocalcin 2",
          "STC2"
        ],
        "description": "Gene with elevated levels in gastric cancer compared to normal tissues, correlated with tumour invasion, lymphatic metastasis and poor prognosis."
      },
      "object": {
        "entity_id": "ent:0ed8e9415cff",
        "entity_type": "MECHANISM",
        "name": "acquired resistance",
        "normalized_id": "N/A",
        "aliases": [],
        "description": "A development promoted by STC2, specifically to chemo- and radio- therapies."
      },
      "time_info": null
    },
    {
      "head": "Stanniocalcin 2",
      "relation": "promote",
      "tail": "cell proliferation",
      "relation_type": null,
      "confidence": [
        0.78,
        0.05
      ],
      "evidence": [
        "In addition, multiple groups have reported that STC2 overexpression promotes cell proliferation, migration and immune response."
      ],
      "mechanism": "unknown",
      "source": "ocr_result_2_0",
      "subject": {
        "entity_id": "ent:4cb806fad36b",
        "entity_type": "GENE",
        "name": "Stanniocalcin 2",
        "normalized_id": "N/A",
        "aliases": [
          "Stanniocalcin",
          "Stanniocalcin 2",
          "STC2"
        ],
        "description": "Gene with elevated levels in gastric cancer compared to normal tissues, correlated with tumour invasion, lymphatic metastasis and poor prognosis."
      },
      "object": {
        "entity_id": "ent:91817c886025",
        "entity_type": "MECHANISM",
        "name": "cell proliferation",
        "normalized_id": "N/A",
        "aliases": [
          "cell proliferation",
          "proliferation"
        ],
        "description": "Aspect of tumour biology regulated by STC2, associated with tumour phenotypes and disease stages."
      },
      "time_info": null
    },
    {
      "head": "Stanniocalcin 2",
      "relation": "promote",
      "tail": "migration",
      "relation_type": null,
      "confidence": [
        0.78,
        0.05
      ],
      "evidence": [
        "In addition, multiple groups have reported that STC2 overexpression promotes cell proliferation, migration and immune response."
      ],
      "mechanism": "unknown",
      "source": "ocr_result_2_0",
      "subject": {
        "entity_id": "ent:4cb806fad36b",
        "entity_type": "GENE",
        "name": "Stanniocalcin 2",
        "normalized_id": "N/A",
        "aliases": [
          "Stanniocalcin",
          "Stanniocalcin 2",
          "STC2"
        ],
        "description": "Gene with elevated levels in gastric cancer compared to normal tissues, correlated with tumour invasion, lymphatic metastasis and poor prognosis."
      },
      "object": {
        "entity_id": "ent:275204214514",
        "entity_type": "MECHANISM",
        "name": "migration",
        "normalized_id": "N/A",
        "aliases": [
          "migration"
        ],
        "description": "A process promoted by STC2 overexpression according to multiple groups."
      },
      "time_info": null
    },
    {
      "head": "Stanniocalcin 2",
      "relation": "promote",
      "tail": "immune response",
      "relation_type": null,
      "confidence": [
        0.7,
        0.05
      ],
      "evidence": [
        "In addition, multiple groups have reported that STC2 overexpression promotes cell proliferation, migration and immune response."
      ],
      "mechanism": "unknown",
      "source": "ocr_result_2_0",
      "subject": {
        "entity_id": "ent:4cb806fad36b",
        "entity_type": "GENE",
        "name": "Stanniocalcin 2",
        "normalized_id": "N/A",
        "aliases": [
          "Stanniocalcin",
          "Stanniocalcin 2",
          "STC2"
        ],
        "description": "Gene with elevated levels in gastric cancer compared to normal tissues, correlated with tumour invasion, lymphatic metastasis and poor prognosis."
      },
      "object": {
        "entity_id": "ent:9a21813f3861",
        "entity_type": "MECHANISM",
        "name": "immune response",
        "normalized_id": "N/A",
        "aliases": [
          "immune response"
        ],
        "description": "A process promoted by STC2 overexpression according to multiple groups."
      },
      "time_info": null
    },
    {
      "head": "Stanniocalcin 2",
      "relation": "correlate with",
      "tail": "tumour growth",
      "relation_type": null,
      "confidence": [
        0.75,
        0.1
      ],
      "evidence": [
        "Therefore, the overexpression of STC2 is positively correlated with tumour growth, invasion, metastasis and patients' prognosis, highlighting its potential as a biomarker and a therapeutic target."
      ],
      "mechanism": "unknown",
      "source": "ocr_result_2_0",
      "subject": {
        "entity_id": "ent:4cb806fad36b",
        "entity_type": "GENE",
        "name": "Stanniocalcin 2",
        "normalized_id": "N/A",
        "aliases": [
          "Stanniocalcin",
          "Stanniocalcin 2",
          "STC2"
        ],
        "description": "Gene with elevated levels in gastric cancer compared to normal tissues, correlated with tumour invasion, lymphatic metastasis and poor prognosis."
      },
      "object": {
        "entity_id": "ent:af7c6a514b63",
        "entity_type": "MECHANISM",
        "name": "tumour growth",
        "normalized_id": "N/A",
        "aliases": [
          "tumour growth"
        ],
        "description": "A process positively correlated with STC2 overexpression."
      },
      "time_info": null
    },
    {
      "head": "Stanniocalcin 2",
      "relation": "correlate with",
      "tail": "invasion",
      "relation_type": null,
      "confidence": [
        0.75,
        0.1
      ],
      "evidence": [
        "Therefore, the overexpression of STC2 is positively correlated with tumour growth, invasion, metastasis and patients' prognosis, highlighting its potential as a biomarker and a therapeutic target."
      ],
      "mechanism": "unknown",
      "source": "ocr_result_2_0",
      "subject": {
        "entity_id": "ent:4cb806fad36b",
        "entity_type": "GENE",
        "name": "Stanniocalcin 2",
        "normalized_id": "N/A",
        "aliases": [
          "Stanniocalcin",
          "Stanniocalcin 2",
          "STC2"
        ],
        "description": "Gene with elevated levels in gastric cancer compared to normal tissues, correlated with tumour invasion, lymphatic metastasis and poor prognosis."
      },
      "object": {
        "entity_id": "ent:fc370882bdd3",
        "entity_type": "MECHANISM",
        "name": "invasion",
        "normalized_id": "N/A",
        "aliases": [
          "invasion"
        ],
        "description": "Aspect of tumour biology regulated by STC2, associated with tumour phenotypes and disease stages."
      },
      "time_info": null
    },
    {
      "head": "Stanniocalcin 2",
      "relation": "correlate with",
      "tail": "lymphatic metastasis",
      "relation_type": null,
      "confidence": [
        0.75,
        0.1
      ],
      "evidence": [
        "Therefore, the overexpression of STC2 is positively correlated with tumour growth, invasion, metastasis and patients' prognosis, highlighting its potential as a biomarker and a therapeutic target."
      ],
      "mechanism": "unknown",
      "source": "ocr_result_2_0",
      "subject": {
        "entity_id": "ent:4cb806fad36b",
        "entity_type": "GENE",
        "name": "Stanniocalcin 2",
        "normalized_id": "N/A",
        "aliases": [
          "Stanniocalcin",
          "Stanniocalcin 2",
          "STC2"
        ],
        "description": "Gene with elevated levels in gastric cancer compared to normal tissues, correlated with tumour invasion, lymphatic metastasis and poor prognosis."
      },
      "object": {
        "entity_id": "ent:c18707e2df04",
        "entity_type": "DISEASE",
        "name": "lymphatic metastasis",
        "normalized_id": "N/A",
        "aliases": [
          "metastasis"
        ],
        "description": "A factor correlated with elevated STC2 expression in gastric cancer."
      },
      "time_info": null
    },
    {
      "head": "Stanniocalcin 2",
      "relation": "correlate with",
      "tail": "tumour invasion",
      "relation_type": null,
      "confidence": [
        0.85,
        0.15
      ],
      "evidence": [
        "elevated STC2 expression is correlated with tumour invasion, lymphatic metastasis and poor prognosis [62, 63]."
      ],
      "mechanism": "unknown",
      "source": "ocr_result_2_4",
      "subject": {
        "entity_id": "ent:4cb806fad36b",
        "entity_type": "GENE",
        "name": "Stanniocalcin 2",
        "normalized_id": "N/A",
        "aliases": [
          "Stanniocalcin",
          "Stanniocalcin 2",
          "STC2"
        ],
        "description": "Gene with elevated levels in gastric cancer compared to normal tissues, correlated with tumour invasion, lymphatic metastasis and poor prognosis."
      },
      "object": {
        "entity_id": "ent:5c1af8103579",
        "entity_type": "DISEASE",
        "name": "tumour invasion",
        "normalized_id": "N/A",
        "aliases": [
          "tumour invasion"
        ],
        "description": "A factor correlated with elevated STC2 expression in gastric cancer."
      },
      "time_info": null
    },
    {
      "head": "Stanniocalcin 2",
      "relation": "correlate with",
      "tail": "metastasis",
      "relation_type": null,
      "confidence": [
        0.85,
        0.15
      ],
      "evidence": [
        "elevated STC2 expression is correlated with tumour invasion, lymphatic metastasis and poor prognosis [62, 63].",
        "Further clinicopathological analyses demonstrated STC2 levels are correlated with lymphatic invasion, lymph node metastasis, and poor prognosis in ESCC patients"
      ],
      "mechanism": "unknown",
      "source": "ocr_result_2_4",
      "subject": {
        "entity_id": "ent:4cb806fad36b",
        "entity_type": "GENE",
        "name": "Stanniocalcin 2",
        "normalized_id": "N/A",
        "aliases": [
          "Stanniocalcin",
          "Stanniocalcin 2",
          "STC2"
        ],
        "description": "Gene with elevated levels in gastric cancer compared to normal tissues, correlated with tumour invasion, lymphatic metastasis and poor prognosis."
      },
      "object": {
        "entity_id": "ent:a4bb2da43561",
        "entity_type": "DISEASE",
        "name": "metastasis",
        "normalized_id": "N/A",
        "aliases": [
          "metastasis"
        ],
        "description": "A condition some RCC patients develop even after removal of local tumours."
      },
      "time_info": null
    },
    {
      "head": "Stanniocalcin 2",
      "relation": "correlate with",
      "tail": "poor prognosis",
      "relation_type": null,
      "confidence": [
        0.88,
        0.1
      ],
      "evidence": [
        "elevated STC2 expression is correlated with tumour invasion, lymphatic metastasis and poor prognosis [62, 63].",
        "Further clinicopathological analyses demonstrated STC2 levels are correlated with lymphatic invasion, lymph node metastasis, and poor prognosis in ESCC patients",
        "The expression of STC2 is correlated with the aggressiveness of primary RCC and the survival rates post radical nephrectomy [37]."
      ],
      "mechanism": "unknown",
      "source": "ocr_result_2_4",
      "subject": {
        "entity_id": "ent:4cb806fad36b",
        "entity_type": "GENE",
        "name": "Stanniocalcin 2",
        "normalized_id": "N/A",
        "aliases": [
          "Stanniocalcin",
          "Stanniocalcin 2",
          "STC2"
        ],
        "description": "Gene with elevated levels in gastric cancer compared to normal tissues, correlated with tumour invasion, lymphatic metastasis and poor prognosis."
      },
      "object": {
        "entity_id": "ent:87d641a65ed4",
        "entity_type": "DISEASE",
        "name": "poor prognosis",
        "normalized_id": "N/A",
        "aliases": [],
        "description": "A condition correlated with elevated STC2 expression in gastric cancer and ESCC."
      },
      "time_info": null
    },
    {
      "head": "Stanniocalcin 2",
      "relation": "correlate with",
      "tail": "lymphatic invasion",
      "relation_type": null,
      "confidence": [
        0.82,
        0.15
      ],
      "evidence": [
        "Further clinicopathological analyses demonstrated STC2 levels are correlated with lymphatic invasion, lymph node metastasis, and poor prognosis in ESCC patients"
      ],
      "mechanism": "unknown",
      "source": "ocr_result_2_4",
      "subject": {
        "entity_id": "ent:4cb806fad36b",
        "entity_type": "GENE",
        "name": "Stanniocalcin 2",
        "normalized_id": "N/A",
        "aliases": [
          "Stanniocalcin",
          "Stanniocalcin 2",
          "STC2"
        ],
        "description": "Gene with elevated levels in gastric cancer compared to normal tissues, correlated with tumour invasion, lymphatic metastasis and poor prognosis."
      },
      "object": {
        "entity_id": "ent:6396f29391e0",
        "entity_type": "DISEASE",
        "name": "lymphatic invasion",
        "normalized_id": "N/A",
        "aliases": [],
        "description": "A factor correlated with STC2 levels in ESCC patients."
      },
      "time_info": null
    },
    {
      "head": "Stanniocalcin 2",
      "relation": "correlate with",
      "tail": "metastasis",
      "relation_type": null,
      "confidence": [
        0.85,
        0.15
      ],
      "evidence": [
        "Further clinicopathological analyses demonstrated STC2 levels are correlated with lymphatic invasion, lymph node metastasis, and poor prognosis in ESCC patients"
      ],
      "mechanism": "unknown",
      "source": "ocr_result_2_4",
      "subject": {
        "entity_id": "ent:4cb806fad36b",
        "entity_type": "GENE",
        "name": "Stanniocalcin 2",
        "normalized_id": "N/A",
        "aliases": [
          "Stanniocalcin",
          "Stanniocalcin 2",
          "STC2"
        ],
        "description": "Gene with elevated levels in gastric cancer compared to normal tissues, correlated with tumour invasion, lymphatic metastasis and poor prognosis."
      },
      "object": {
        "entity_id": "ent:a4bb2da43561",
        "entity_type": "DISEASE",
        "name": "metastasis",
        "normalized_id": "N/A",
        "aliases": [
          "metastasis"
        ],
        "description": "A condition some RCC patients develop even after removal of local tumours."
      },
      "time_info": null
    },
    {
      "head": "Stanniocalcin 2",
      "relation": "correlate with",
      "tail": "renal cell carcinoma",
      "relation_type": null,
      "confidence": [
        0.8,
        0.15
      ],
      "evidence": [
        "The expression of STC2 is correlated with the aggressiveness of primary RCC and the survival rates post radical nephrectomy [37]."
      ],
      "mechanism": "unknown",
      "source": "ocr_result_2_4",
      "subject": {
        "entity_id": "ent:4cb806fad36b",
        "entity_type": "GENE",
        "name": "Stanniocalcin 2",
        "normalized_id": "N/A",
        "aliases": [
          "Stanniocalcin",
          "Stanniocalcin 2",
          "STC2"
        ],
        "description": "Gene with elevated levels in gastric cancer compared to normal tissues, correlated with tumour invasion, lymphatic metastasis and poor prognosis."
      },
      "object": {
        "entity_id": "ent:fbab9237a0dc",
        "entity_type": "DISEASE",
        "name": "renal cell carcinoma",
        "normalized_id": "N/A",
        "aliases": [
          "RCC",
          "Renal cell carcinoma"
        ],
        "description": "A human tumour where STC2 is broadly upregulated according to the text."
      },
      "time_info": null
    },
    {
      "head": "Stanniocalcin 2",
      "relation": "correlate with",
      "tail": "radical nephrectomy",
      "relation_type": null,
      "confidence": [
        0.78,
        0.1
      ],
      "evidence": [
        "The expression of STC2 is correlated with the aggressiveness of primary RCC and the survival rates post radical nephrectomy [37]."
      ],
      "mechanism": "unknown",
      "source": "ocr_result_2_4",
      "subject": {
        "entity_id": "ent:4cb806fad36b",
        "entity_type": "GENE",
        "name": "Stanniocalcin 2",
        "normalized_id": "N/A",
        "aliases": [
          "Stanniocalcin",
          "Stanniocalcin 2",
          "STC2"
        ],
        "description": "Gene with elevated levels in gastric cancer compared to normal tissues, correlated with tumour invasion, lymphatic metastasis and poor prognosis."
      },
      "object": {
        "entity_id": "ent:198096b450c2",
        "entity_type": "TREATMENT",
        "name": "radical nephrectomy",
        "normalized_id": "N/A",
        "aliases": [],
        "description": "Surgical procedure mentioned in relation to survival rates for renal cell carcinoma patients."
      },
      "time_info": null
    },
    {
      "head": "Stanniocalcin 2",
      "relation": "correlate with",
      "tail": "tumour progression",
      "relation_type": null,
      "confidence": [
        0.75,
        0.15
      ],
      "evidence": [
        "In brief, elevated STC2 levels are correlated with tumour progression, disease stage and patients' prognosis."
      ],
      "mechanism": "unknown",
      "source": "ocr_result_2_4",
      "subject": {
        "entity_id": "ent:4cb806fad36b",
        "entity_type": "GENE",
        "name": "Stanniocalcin 2",
        "normalized_id": "N/A",
        "aliases": [
          "Stanniocalcin",
          "Stanniocalcin 2",
          "STC2"
        ],
        "description": "Gene with elevated levels in gastric cancer compared to normal tissues, correlated with tumour invasion, lymphatic metastasis and poor prognosis."
      },
      "object": {
        "entity_id": "ent:c42258ce34c8",
        "entity_type": "DISEASE",
        "name": "tumour progression",
        "normalized_id": "N/A",
        "aliases": [
          "tumour progression"
        ],
        "description": "Described as a process during which STC2 has biological functions in metabolic reprogramming."
      },
      "time_info": null
    },
    {
      "head": "Stanniocalcin 2",
      "relation": "correlate with",
      "tail": "disease stages",
      "relation_type": null,
      "confidence": [
        0.75,
        0.15
      ],
      "evidence": [
        "In brief, elevated STC2 levels are correlated with tumour progression, disease stage and patients' prognosis."
      ],
      "mechanism": "unknown",
      "source": "ocr_result_2_4",
      "subject": {
        "entity_id": "ent:4cb806fad36b",
        "entity_type": "GENE",
        "name": "Stanniocalcin 2",
        "normalized_id": "N/A",
        "aliases": [
          "Stanniocalcin",
          "Stanniocalcin 2",
          "STC2"
        ],
        "description": "Gene with elevated levels in gastric cancer compared to normal tissues, correlated with tumour invasion, lymphatic metastasis and poor prognosis."
      },
      "object": {
        "entity_id": "ent:ffd3536de9bc",
        "entity_type": "OTHER",
        "name": "disease stages",
        "normalized_id": "N/A",
        "aliases": [
          "disease stage"
        ],
        "description": "Cell proliferation, invasion and metastasis regulated by STC2 are described as being associated with disease stages."
      },
      "time_info": null
    },
    {
      "head": "Stanniocalcin 2",
      "relation": "correlate with",
      "tail": "ovarian cancer",
      "relation_type": null,
      "confidence": [
        0.7,
        0.15
      ],
      "evidence": [
        "The expression of STC2 in vascular cells is correlated with decreased DFS in ovarian cancer [42]."
      ],
      "mechanism": "unknown",
      "source": "ocr_result_2_4",
      "subject": {
        "entity_id": "ent:4cb806fad36b",
        "entity_type": "GENE",
        "name": "Stanniocalcin 2",
        "normalized_id": "N/A",
        "aliases": [
          "Stanniocalcin",
          "Stanniocalcin 2",
          "STC2"
        ],
        "description": "Gene with elevated levels in gastric cancer compared to normal tissues, correlated with tumour invasion, lymphatic metastasis and poor prognosis."
      },
      "object": {
        "entity_id": "ent:c63c8184ec05",
        "entity_type": "DISEASE",
        "name": "ovarian cancer",
        "normalized_id": "N/A",
        "aliases": [
          "Ovarian cancer"
        ],
        "description": "A human tumour where STC2 is broadly upregulated according to the text."
      },
      "time_info": null
    },
    {
      "head": "Stanniocalcin 2",
      "relation": "enhance",
      "tail": "tumour invasion",
      "relation_type": null,
      "confidence": [
        0.65,
        0.1
      ],
      "evidence": [
        "Ectopic expression of STC2 enhances the proliferation and invasiveness of ESCC cells; while knockdown of STC2 compromises the proliferation of ESCC cells with high STC2 levels [35]."
      ],
      "mechanism": "unknown",
      "source": "ocr_result_2_4",
      "subject": {
        "entity_id": "ent:4cb806fad36b",
        "entity_type": "GENE",
        "name": "Stanniocalcin 2",
        "normalized_id": "N/A",
        "aliases": [
          "Stanniocalcin",
          "Stanniocalcin 2",
          "STC2"
        ],
        "description": "Gene with elevated levels in gastric cancer compared to normal tissues, correlated with tumour invasion, lymphatic metastasis and poor prognosis."
      },
      "object": {
        "entity_id": "ent:5c1af8103579",
        "entity_type": "DISEASE",
        "name": "tumour invasion",
        "normalized_id": "N/A",
        "aliases": [
          "tumour invasion"
        ],
        "description": "A factor correlated with elevated STC2 expression in gastric cancer."
      },
      "time_info": null
    },
    {
      "head": "STC2-HRG complex",
      "relation": "induce",
      "tail": "glycolytic genes",
      "relation_type": null,
      "confidence": [
        0.75,
        0.05
      ],
      "evidence": [
        "Mechanistically, STC2 promotes glucose utilization though inducing the expression of glycolytic genes including Glucose Transporter 1 and Lactate Dehydrogenase A [41]."
      ],
      "mechanism": "unknown",
      "source": "ocr_result_2_10",
      "subject": {
        "entity_id": "ent:ec5780b581ff",
        "entity_type": "BIOMARKER",
        "name": "STC2-HRG complex",
        "normalized_id": "N/A",
        "aliases": [],
        "description": "A complex formed between STC2 and HRG that modulates the immune response of inflammatory cells, though its in vivo importance requires further study."
      },
      "object": {
        "entity_id": "ent:c250a65fea0d",
        "entity_type": "PATHWAY",
        "name": "glycolytic genes",
        "normalized_id": "N/A",
        "aliases": [],
        "description": "Genes associated with glycolysis, used with STC2 to assess prognosis in osteosarcoma patients and whose expression is induced by STC2."
      },
      "time_info": null
    },
    {
      "head": "bevacizumab",
      "relation": "induce",
      "tail": "Stanniocalcin 2",
      "relation_type": null,
      "confidence": [
        0.82,
        0.05
      ],
      "evidence": [
        "cDNA microarray revealed bevacizumab induces STC2 expression through activating HIF-1 signaling in orthotopic human colon cancer xenografts [161].",
        "STC2 is upregulated upon exposure to several chemotherapeutic treatments, such as, anti-vascular endothelial growth factor (VEGF) antibody, cisplatin, oxaliplatin and tyrosine kinase inhibitors (TKIs), highlighting its potential in mediating the development of acquired resistance to chemotherapies (Table 3)."
      ],
      "mechanism": "unknown",
      "source": "ocr_result_2_10",
      "subject": {
        "entity_id": "ent:93c4228acd20",
        "entity_type": "TREATMENT",
        "name": "bevacizumab",
        "normalized_id": "N/A",
        "aliases": [],
        "description": "Described as an anti-VEGF antibody application that inhibits tumor growth and induces STC2 expression."
      },
      "object": {
        "entity_id": "ent:4cb806fad36b",
        "entity_type": "GENE",
        "name": "Stanniocalcin 2",
        "normalized_id": "N/A",
        "aliases": [
          "Stanniocalcin",
          "Stanniocalcin 2",
          "STC2"
        ],
        "description": "Gene with elevated levels in gastric cancer compared to normal tissues, correlated with tumour invasion, lymphatic metastasis and poor prognosis."
      },
      "time_info": null
    },
    {
      "head": "bevacizumab",
      "relation": "activate",
      "tail": "HIF-1",
      "relation_type": null,
      "confidence": [
        0.78,
        0.05
      ],
      "evidence": [
        "cDNA microarray revealed bevacizumab induces STC2 expression through activating HIF-1 signaling in orthotopic human colon cancer xenografts [161]."
      ],
      "mechanism": "unknown",
      "source": "ocr_result_2_10",
      "subject": {
        "entity_id": "ent:93c4228acd20",
        "entity_type": "TREATMENT",
        "name": "bevacizumab",
        "normalized_id": "N/A",
        "aliases": [],
        "description": "Described as an anti-VEGF antibody application that inhibits tumor growth and induces STC2 expression."
      },
      "object": {
        "entity_id": "ent:3f9116ddb795",
        "entity_type": "GENE",
        "name": "HIF-1",
        "normalized_id": "N/A",
        "aliases": [
          "HIF",
          "HIF-1",
          "HIF-1 heterodimer",
          "Hypoxia-inducible factor"
        ],
        "description": "A signaling pathway activated by bevacizumab to induce STC2 expression in orthotopic human colon cancer xenografts."
      },
      "time_info": null
    },
    {
      "head": "Stanniocalcin 2",
      "relation": "drive",
      "tail": "cell cycle progression",
      "relation_type": null,
      "confidence": [
        0.7,
        0.1
      ],
      "evidence": [
        "Since STC2 drives cell proliferation and migration under hypoxic conditions; it is not surprised that STC2 is overexpressed in liver metastatic tumours of human colorectal carcinoma treated with bevacizumab relative to those without treatment, indicating STC2 may contribute to the development of acquired resistance to anti-VEGF treatment."
      ],
      "mechanism": "unknown",
      "source": "ocr_result_2_10",
      "subject": {
        "entity_id": "ent:4cb806fad36b",
        "entity_type": "GENE",
        "name": "Stanniocalcin 2",
        "normalized_id": "N/A",
        "aliases": [
          "Stanniocalcin",
          "Stanniocalcin 2",
          "STC2"
        ],
        "description": "Gene with elevated levels in gastric cancer compared to normal tissues, correlated with tumour invasion, lymphatic metastasis and poor prognosis."
      },
      "object": {
        "entity_id": "ent:1d1998360a8b",
        "entity_type": "MECHANISM",
        "name": "cell cycle progression",
        "normalized_id": "N/A",
        "aliases": [
          "cell cycle progression"
        ],
        "description": "A process promoted by STC2 under hypoxic conditions through enhancing cyclin D expression and Rb phosphorylation."
      },
      "time_info": null
    },
    {
      "head": "Stanniocalcin 2",
      "relation": "compromise",
      "tail": "cell cycle progression",
      "relation_type": null,
      "confidence": [
        0.85,
        0.05
      ],
      "evidence": [
        "Cisplatin-resistant cervical cancer cells demonstrate increased STC2 mRNA and protein levels, while knockdown of STC2 effectively compromise cell proliferation and induce apoptosis in resistant cells [150], indicating"
      ],
      "mechanism": "unknown",
      "source": "ocr_result_2_10",
      "subject": {
        "entity_id": "ent:4cb806fad36b",
        "entity_type": "GENE",
        "name": "Stanniocalcin 2",
        "normalized_id": "N/A",
        "aliases": [
          "Stanniocalcin",
          "Stanniocalcin 2",
          "STC2"
        ],
        "description": "Gene with elevated levels in gastric cancer compared to normal tissues, correlated with tumour invasion, lymphatic metastasis and poor prognosis."
      },
      "object": {
        "entity_id": "ent:1d1998360a8b",
        "entity_type": "MECHANISM",
        "name": "cell cycle progression",
        "normalized_id": "N/A",
        "aliases": [
          "cell cycle progression"
        ],
        "description": "A process promoted by STC2 under hypoxic conditions through enhancing cyclin D expression and Rb phosphorylation."
      },
      "time_info": null
    },
    {
      "head": "Stanniocalcin 2",
      "relation": "induce",
      "tail": "apoptosis",
      "relation_type": null,
      "confidence": [
        0.85,
        0.05
      ],
      "evidence": [
        "Cisplatin-resistant cervical cancer cells demonstrate increased STC2 mRNA and protein levels, while knockdown of STC2 effectively compromise cell proliferation and induce apoptosis in resistant cells [150], indicating"
      ],
      "mechanism": "unknown",
      "source": "ocr_result_2_10",
      "subject": {
        "entity_id": "ent:4cb806fad36b",
        "entity_type": "GENE",
        "name": "Stanniocalcin 2",
        "normalized_id": "N/A",
        "aliases": [
          "Stanniocalcin",
          "Stanniocalcin 2",
          "STC2"
        ],
        "description": "Gene with elevated levels in gastric cancer compared to normal tissues, correlated with tumour invasion, lymphatic metastasis and poor prognosis."
      },
      "object": {
        "entity_id": "ent:d7eb2f78f5ad",
        "entity_type": "MECHANISM",
        "name": "apoptosis",
        "normalized_id": "N/A",
        "aliases": [
          "apoptosis"
        ],
        "description": "A process that STC2 prevents, as it facilitates cells dealing with stress conditions."
      },
      "time_info": null
    },
    {
      "head": "STC2-HRG complex",
      "relation": "interact",
      "tail": "heme oxygenase 1",
      "relation_type": null,
      "confidence": [
        0.65,
        0.6
      ],
      "evidence": [
        "Moreover, STC2 can modulate the immunomodulatory properties of mesenchymal stem cells, which compromise the activity of IFN--producing CD8^{+} Tc1 cells through interacting and altering the activity of heme oxygenase 1 (Table 2) [152]."
      ],
      "mechanism": "unknown",
      "source": "ocr_result_2_10",
      "subject": {
        "entity_id": "ent:ec5780b581ff",
        "entity_type": "BIOMARKER",
        "name": "STC2-HRG complex",
        "normalized_id": "N/A",
        "aliases": [],
        "description": "A complex formed between STC2 and HRG that modulates the immune response of inflammatory cells, though its in vivo importance requires further study."
      },
      "object": {
        "entity_id": "ent:7eda936a1df0",
        "entity_type": "BIOMARKER",
        "name": "heme oxygenase 1",
        "normalized_id": "N/A",
        "aliases": [],
        "description": "An enzyme whose activity is altered by STC2 interaction, compromising the activity of IFN--producing CD8+ Tc1 cells."
      },
      "time_info": null
    },
    {
      "head": "STC2-HRG complex",
      "relation": "bind",
      "tail": "STC2-HRG complex",
      "relation_type": null,
      "confidence": [
        0.6,
        0.6
      ],
      "evidence": [
        "Unbiased analysis identified as a binding partner of HRG, STC2 can modulate the immune response of inflammatory cells [160]; however, the in vivo biological importance of STC2-HRG complex remains to be further dissected."
      ],
      "mechanism": "unknown",
      "source": "ocr_result_2_10",
      "subject": {
        "entity_id": "ent:ec5780b581ff",
        "entity_type": "BIOMARKER",
        "name": "STC2-HRG complex",
        "normalized_id": "N/A",
        "aliases": [],
        "description": "A complex formed between STC2 and HRG that modulates the immune response of inflammatory cells, though its in vivo importance requires further study."
      },
      "object": {
        "entity_id": "ent:ec5780b581ff",
        "entity_type": "BIOMARKER",
        "name": "STC2-HRG complex",
        "normalized_id": "N/A",
        "aliases": [],
        "description": "A complex formed between STC2 and HRG that modulates the immune response of inflammatory cells, though its in vivo importance requires further study."
      },
      "time_info": null
    },
    {
      "head": "bevacizumab",
      "relation": "inhibit",
      "tail": "anti-vascular endothelial growth factor (VEGF) antibody",
      "relation_type": null,
      "confidence": [
        0.88,
        0.05
      ],
      "evidence": [
        "The application of bevacizumab, the anti-VEGF antibody, successfully inhibits the growth of human colon cancer xenografts through blocking cell cycle progression at early stage and inducing apoptosis at late stage."
      ],
      "mechanism": "unknown",
      "source": "ocr_result_2_10",
      "subject": {
        "entity_id": "ent:93c4228acd20",
        "entity_type": "TREATMENT",
        "name": "bevacizumab",
        "normalized_id": "N/A",
        "aliases": [],
        "description": "Described as an anti-VEGF antibody application that inhibits tumor growth and induces STC2 expression."
      },
      "object": {
        "entity_id": "ent:3655c26ea07d",
        "entity_type": "TREATMENT",
        "name": "anti-vascular endothelial growth factor (VEGF) antibody",
        "normalized_id": "N/A",
        "aliases": [
          "anti-VEGF antibody"
        ],
        "description": "A chemotherapeutic treatment exposure that upregulates STC2, as mentioned in the text."
      },
      "time_info": null
    },
    {
      "head": "bevacizumab",
      "relation": "block",
      "tail": "cell cycle progression",
      "relation_type": null,
      "confidence": [
        0.8,
        0.05
      ],
      "evidence": [
        "The application of bevacizumab, the anti-VEGF antibody, successfully inhibits the growth of human colon cancer xenografts through blocking cell cycle progression at early stage and inducing apoptosis at late stage."
      ],
      "mechanism": "unknown",
      "source": "ocr_result_2_10",
      "subject": {
        "entity_id": "ent:93c4228acd20",
        "entity_type": "TREATMENT",
        "name": "bevacizumab",
        "normalized_id": "N/A",
        "aliases": [],
        "description": "Described as an anti-VEGF antibody application that inhibits tumor growth and induces STC2 expression."
      },
      "object": {
        "entity_id": "ent:1d1998360a8b",
        "entity_type": "MECHANISM",
        "name": "cell cycle progression",
        "normalized_id": "N/A",
        "aliases": [
          "cell cycle progression"
        ],
        "description": "A process promoted by STC2 under hypoxic conditions through enhancing cyclin D expression and Rb phosphorylation."
      },
      "time_info": null
    },
    {
      "head": "STC",
      "relation": "regulate",
      "tail": "cell proliferation",
      "relation_type": null,
      "confidence": [
        0.75,
        0.15
      ],
      "evidence": [
        "STC2 regulates various aspects of tumour biology like cell proliferation, invasion and metastasis that are associated with tumour phenotypes and disease stages."
      ],
      "mechanism": "unknown",
      "source": "ocr_result_2_12",
      "subject": {
        "entity_id": "ent:ceb73a8e75a9",
        "entity_type": "PROTEIN",
        "name": "STC",
        "normalized_id": "N/A",
        "aliases": [
          "Stanniocalcin"
        ],
        "description": "Stanniocalcin, listed in the abbreviations section."
      },
      "object": {
        "entity_id": "ent:91817c886025",
        "entity_type": "MECHANISM",
        "name": "cell proliferation",
        "normalized_id": "N/A",
        "aliases": [
          "cell proliferation",
          "proliferation"
        ],
        "description": "Aspect of tumour biology regulated by STC2, associated with tumour phenotypes and disease stages."
      },
      "time_info": null
    },
    {
      "head": "STC",
      "relation": "regulate",
      "tail": "invasion",
      "relation_type": null,
      "confidence": [
        0.75,
        0.15
      ],
      "evidence": [
        "STC2 regulates various aspects of tumour biology like cell proliferation, invasion and metastasis that are associated with tumour phenotypes and disease stages."
      ],
      "mechanism": "unknown",
      "source": "ocr_result_2_12",
      "subject": {
        "entity_id": "ent:ceb73a8e75a9",
        "entity_type": "PROTEIN",
        "name": "STC",
        "normalized_id": "N/A",
        "aliases": [
          "Stanniocalcin"
        ],
        "description": "Stanniocalcin, listed in the abbreviations section."
      },
      "object": {
        "entity_id": "ent:fc370882bdd3",
        "entity_type": "MECHANISM",
        "name": "invasion",
        "normalized_id": "N/A",
        "aliases": [
          "invasion"
        ],
        "description": "Aspect of tumour biology regulated by STC2, associated with tumour phenotypes and disease stages."
      },
      "time_info": null
    },
    {
      "head": "STC",
      "relation": "regulate",
      "tail": "metastasis",
      "relation_type": null,
      "confidence": [
        0.75,
        0.15
      ],
      "evidence": [
        "STC2 regulates various aspects of tumour biology like cell proliferation, invasion and metastasis that are associated with tumour phenotypes and disease stages."
      ],
      "mechanism": "unknown",
      "source": "ocr_result_2_12",
      "subject": {
        "entity_id": "ent:ceb73a8e75a9",
        "entity_type": "PROTEIN",
        "name": "STC",
        "normalized_id": "N/A",
        "aliases": [
          "Stanniocalcin"
        ],
        "description": "Stanniocalcin, listed in the abbreviations section."
      },
      "object": {
        "entity_id": "ent:a4bb2da43561",
        "entity_type": "DISEASE",
        "name": "metastasis",
        "normalized_id": "N/A",
        "aliases": [
          "metastasis"
        ],
        "description": "A condition some RCC patients develop even after removal of local tumours."
      },
      "time_info": null
    },
    {
      "head": "stress conditions",
      "relation": "activate",
      "tail": "signal transduction pathway",
      "relation_type": null,
      "confidence": [
        0.85,
        0.05
      ],
      "evidence": [
        "Solid tumour cells commonly encounter stress conditions which selectively activate corresponding signaling pathways to reprogram metabolism, adjust tumour cell survival, proliferation, invasion and migration."
      ],
      "mechanism": "unknown",
      "source": "ocr_result_2_12",
      "subject": {
        "entity_id": "ent:b26ae4f28d7a",
        "entity_type": "OTHER",
        "name": "stress conditions",
        "normalized_id": "N/A",
        "aliases": [
          "stress conditions"
        ],
        "description": "Solid tumour cells are described as commonly encountering stress conditions which selectively activate corresponding signaling pathways."
      },
      "object": {
        "entity_id": "ent:2c60ecb4eed6",
        "entity_type": "MECHANISM",
        "name": "signal transduction pathway",
        "normalized_id": "N/A",
        "aliases": [
          "signaling pathways"
        ],
        "description": "Pathway associated with STC2 that requires identification of its receptor to be better understood."
      },
      "time_info": null
    },
    {
      "head": "stress conditions",
      "relation": "upregulate",
      "tail": "STC",
      "relation_type": null,
      "confidence": [
        0.8,
        0.1
      ],
      "evidence": [
        "STC2 is upregulated in many tumour cells under multiple stress conditions which activate ATF4, HIF-1 or both, strongly suggesting that STC2 participates in the evolutionarily conserved response under stress conditions."
      ],
      "mechanism": "unknown",
      "source": "ocr_result_2_12",
      "subject": {
        "entity_id": "ent:b26ae4f28d7a",
        "entity_type": "OTHER",
        "name": "stress conditions",
        "normalized_id": "N/A",
        "aliases": [
          "stress conditions"
        ],
        "description": "Solid tumour cells are described as commonly encountering stress conditions which selectively activate corresponding signaling pathways."
      },
      "object": {
        "entity_id": "ent:ceb73a8e75a9",
        "entity_type": "PROTEIN",
        "name": "STC",
        "normalized_id": "N/A",
        "aliases": [
          "Stanniocalcin"
        ],
        "description": "Stanniocalcin, listed in the abbreviations section."
      },
      "time_info": null
    },
    {
      "head": "stress conditions",
      "relation": "activate",
      "tail": "ATF4",
      "relation_type": null,
      "confidence": [
        0.7,
        0.1
      ],
      "evidence": [
        "STC2 is upregulated in many tumour cells under multiple stress conditions which activate ATF4, HIF-1 or both, strongly suggesting that STC2 participates in the evolutionarily conserved response under stress conditions."
      ],
      "mechanism": "unknown",
      "source": "ocr_result_2_12",
      "subject": {
        "entity_id": "ent:b26ae4f28d7a",
        "entity_type": "OTHER",
        "name": "stress conditions",
        "normalized_id": "N/A",
        "aliases": [
          "stress conditions"
        ],
        "description": "Solid tumour cells are described as commonly encountering stress conditions which selectively activate corresponding signaling pathways."
      },
      "object": {
        "entity_id": "ent:e7b0433b4833",
        "entity_type": "GENE",
        "name": "ATF4",
        "normalized_id": "N/A",
        "aliases": [
          "Activating transcription factor",
          "activating transcription factor 4",
          "ATF",
          "ATF4"
        ],
        "description": "A transcription factor whose activation leads to transcriptional upregulation of genes, and ER stress-induced STC2 expression depends on its pathway."
      },
      "time_info": null
    },
    {
      "head": "stress conditions",
      "relation": "activate",
      "tail": "HIF-1",
      "relation_type": null,
      "confidence": [
        0.7,
        0.1
      ],
      "evidence": [
        "STC2 is upregulated in many tumour cells under multiple stress conditions which activate ATF4, HIF-1 or both, strongly suggesting that STC2 participates in the evolutionarily conserved response under stress conditions."
      ],
      "mechanism": "unknown",
      "source": "ocr_result_2_12",
      "subject": {
        "entity_id": "ent:b26ae4f28d7a",
        "entity_type": "OTHER",
        "name": "stress conditions",
        "normalized_id": "N/A",
        "aliases": [
          "stress conditions"
        ],
        "description": "Solid tumour cells are described as commonly encountering stress conditions which selectively activate corresponding signaling pathways."
      },
      "object": {
        "entity_id": "ent:3f9116ddb795",
        "entity_type": "GENE",
        "name": "HIF-1",
        "normalized_id": "N/A",
        "aliases": [
          "HIF",
          "HIF-1",
          "HIF-1 heterodimer",
          "Hypoxia-inducible factor"
        ],
        "description": "A signaling pathway activated by bevacizumab to induce STC2 expression in orthotopic human colon cancer xenografts."
      },
      "time_info": null
    },
    {
      "head": "STC",
      "relation": "participate in",
      "tail": "stress conditions",
      "relation_type": null,
      "confidence": [
        0.8,
        0.05
      ],
      "evidence": [
        "STC2 is upregulated in many tumour cells under multiple stress conditions which activate ATF4, HIF-1 or both, strongly suggesting that STC2 participates in the evolutionarily conserved response under stress conditions."
      ],
      "mechanism": "unknown",
      "source": "ocr_result_2_12",
      "subject": {
        "entity_id": "ent:ceb73a8e75a9",
        "entity_type": "PROTEIN",
        "name": "STC",
        "normalized_id": "N/A",
        "aliases": [
          "Stanniocalcin"
        ],
        "description": "Stanniocalcin, listed in the abbreviations section."
      },
      "object": {
        "entity_id": "ent:b26ae4f28d7a",
        "entity_type": "OTHER",
        "name": "stress conditions",
        "normalized_id": "N/A",
        "aliases": [
          "stress conditions"
        ],
        "description": "Solid tumour cells are described as commonly encountering stress conditions which selectively activate corresponding signaling pathways."
      },
      "time_info": null
    }
  ],
  "subgraphs": {
    "ocr_result_1_0": {
      "id": "ocr_result_1_0",
      "name": "",
      "meta": {
        "text": "#\n\nInternational Journal of\n\nMolecular Sciences\n\nMDPI\n\n# Review\n\n# Revisiting the Role of Astrocytic MAOB in Parkinson's Disease\n\nMin-Ho Nam  $^{1,2,*,\\dagger}$ , Moonsun Sa  $^{3,4,\\dagger}$ , Yeon Ha Ju  $^{1}$ , Mingu Gordon Park  $^{3,4}$  and C. Justin Lee  $^{3,4,*}$\n\n$^{1}$  Brain Science Institute, Korea Institute of Science and Technology, Seoul 02792, Korea; yeonha92@kist.re.kr\n$^{2}$  Department of KHU-KIST Convergence Science and Technology, Kyung Hee University, Seoul 02453, Korea\n3 KU-KIST Graduate School of Converging Science and Technology, Korea University, Seoul 02841, Korea; moonsun@ibs.re.kr (M.S.); mgpark@ibs.re.kr (M.G.P.)\n4 Center for Cognition and Sociality, Institute for Basic Science, Daejeon 34126, Korea\n* Correspondence: dr.namminho@kist.re.kr (M.-H.N.); cjl@ibs.re.kr (C.J.L.)\nThese authors contributed equally to this work.\n\nAbstract: Monoamine oxidase-B (MAOB) has been believed to mediate the degradation of monoamine neurotransmitters such as dopamine. However, this traditional belief has been challenged by demonstrating that it is not MAOB but MAOA which mediates dopamine degradation. Instead, MAOB mediates the aberrant synthesis of GABA and hydrogen peroxide  $(\\mathrm{H}_2\\mathrm{O}_2)$  in reactive astrocytes of Parkinson's disease (PD). Astrocytic GABA tonically suppresses the dopaminergic neuronal activity, whereas  $\\mathrm{H}_2\\mathrm{O}_2$  aggravates astrocytic reactivity and dopaminergic neuronal death. Recently discovered reversible MAOB inhibitors reduce reactive astrogliosis and restore dopaminergic neuronal activity to alleviate PD symptoms in rodents. In this perspective, we redefine the role of MAOB for the aberrant suppression and deterioration of dopaminergic neurons through excessive GABA and  $\\mathrm{H}_2\\mathrm{O}_2$  synthesis of reactive astrocytes in PD.\n\nKeywords: astrocyte; Parkinson's disease; MAOB; GABA;  $\\mathrm{H}_2\\mathrm{O}_2$ ; dopamine\n\n# check for updates\n\nCitation: Nam, M.-H.; Sa, M.; Ju, Y.H.; Park, M.G.; Lee, C.J. Revisiting the Role of Astrocytic MAOB in Parkinson's Disease. Int. J. Mol. Sci. 2022, 23, 4453. https://doi.org/10.3390/ijms23084453\n\nAcademic Editor: Chakraborty Ashok\n\nReceived: 24 March 2022\n\nAccepted: 16 April 2022\n\nPublished: 18 April 2022\n\nPublisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.\n\n# C\n\nCopyright:  2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).\n\n# 1. MAOB Expression in the Brain\n\nMonoamine oxidase B (MAOB) is a class of monoamine oxidase (MAO), a family of enzymes that catalyzes the oxidation of monoamines at the outer membrane of mitochondria. MAO was first discovered in the liver and named tyramine oxidase by Mary Bernheim in 1928 [1]. After a decade, it was renamed MAO to distinguish it from oxidatively deaminated diamines. In the 1950s, this enzyme was identified in the brain and discovered to oxidize catecholamines, such as dopamine (DA), adrenaline, and noradrenaline [2-4]. Nowadays, MAO is believed to maintain the homeostasis of monoamine neurotransmitters and metabolites in the brain [5].\n\nMAOB is expressed throughout the whole brain, including the cerebral cortex, cerebellum, hippocampus, and midbrain [6,7]. Among several types of brain cells, a series of previous immunohistochemical and in situ hybridization studies demonstrated that MAOB is preferentially placed in astrocytes of both rodent and human brains [8-10]. In addition to astrocytes, several reports demonstrated that MAOB is also expressed in serotonergic and histaminergic neurons [8]. However, except in a few specific brain regions, such as the dorsal raphe and tuberomammillary nucleus, MAOB is exclusively expressed within astrocytes in most brain regions [8-10]. Therefore, the physiological role of MAOB in the brain is most likely attributed to astrocytes.\n\nInterestingly, MAOB expression is clearly increased with aging in most structures of rodent brains, including the cortex, hippocampus, and striatum [11,12]. This age-related increase in MAOB starts right after birth and continues for more than one year [11,12]. Furthermore, human brain tissue shows a delayed but significant age-related increase in MAOB, which starts at the age of 50-60 years [13]. Another study using molecular imaging of MAOB with  $\\left[{ }^{11} \\mathrm{C}\\right]$  L-deprenyl-D2 and positron emission tomography (PET)\n\nInt. J. Mol. Sci. 2022, 23, 4453. https://doi.org/10.3390/ijms23084453\n\nhttps://www.mdpi.com/journal/ijms\n\nimaging in the living human brains demonstrated that MAOB level was increased in all brain regions examined, except the cingulate gyrus, along with aging [14]. Based on the exclusive expression of MAOB in astrocytes, the age-related increase in MAOB expression in astrocytes could contribute to brain aging.\n\nIn addition, MAOB expression is significantly increased in the neuroinflammatory and neurodegenerative conditions, which is associated with reactive astrogliosis [15,16,17,18,19,20]. For example, several studies using various techniques, including immunohistochemistry, enzyme activity assay, and molecular PET imaging, have shown that MAOB expression is significantly increased in the reactive astrocytes of the hippocampus and frontal cortex of the brains with Alzheimer's disease (AD) [15,16,17,19,20]. In Parkinson's disease (PD), MAOB expression is significantly increased in the reactive astrocytes of the substantia nigra pars compacta (SNpc) [18,21,22]. These emerging lines of evidence have suggested that the increased MAOB expression along with reactive astrogliosis could contribute to the progression and maintenance of neuroinflammation and neurodegeneration.",
        "source": "ocr_result_1"
      },
      "entities": [
        {
          "entity_id": "ent:0da0981b2564",
          "entity_type": "DISEASE",
          "name": "Parkinson's disease",
          "normalized_id": "N/A",
          "aliases": [
            "PD"
          ],
          "description": "A disease where reactive astrocytes in the substantia nigra pars compacta show increased MAOB expression, and astrocytic GABA suppresses dopaminergic neuronal activity while H2O2 aggravates neuronal death."
        },
        {
          "entity_id": "ent:c2f76a150273",
          "entity_type": "DISEASE",
          "name": "Alzheimer's disease",
          "normalized_id": "N/A",
          "aliases": [
            "AD"
          ],
          "description": "A condition where MAOB expression is significantly increased in the reactive astrocytes of the hippocampus and frontal cortex."
        },
        {
          "entity_id": "ent:b9c77630ce9d",
          "entity_type": "PROTEIN",
          "name": "MAOB",
          "normalized_id": "N/A",
          "aliases": [
            "monoamine oxidase B",
            "Monoamine oxidase B",
            "Monoamine oxidase-B"
          ],
          "description": "Monoamine oxidase-B (MAOB) is described as an enzyme that mediates the aberrant synthesis of GABA and hydrogen peroxide in reactive astrocytes of Parkinson's disease, and its expression increases with aging and in neurodegenerative conditions."
        },
        {
          "entity_id": "ent:17e8a4ffd9ec",
          "entity_type": "PROTEIN",
          "name": "MAOA",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "MAOA is described as the enzyme that mediates dopamine degradation, challenging the traditional belief that MAOB performs this function."
        },
        {
          "entity_id": "ent:58b22f5d611d",
          "entity_type": "PROTEIN",
          "name": "monoamine oxidase",
          "normalized_id": "N/A",
          "aliases": [
            "MAO"
          ],
          "description": "Monoamine oxidase (MAO) is described as a family of enzymes that catalyzes the oxidation of monoamines at the outer membrane of mitochondria and is believed to maintain homeostasis of monoamine neurotransmitters in the brain."
        },
        {
          "entity_id": "ent:bdb75e153017",
          "entity_type": "PROTEIN",
          "name": "tyramine oxidase",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Tyramine oxidase is described as the original name for monoamine oxidase (MAO) when it was first discovered in the liver by Mary Bernheim in 1928."
        },
        {
          "entity_id": "ent:9f3e57461507",
          "entity_type": "BIOMARKER",
          "name": "GABA",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A neurotransmitter synthesized by MAOB in reactive astrocytes, which tonically suppresses dopaminergic neuronal activity in Parkinson's disease."
        },
        {
          "entity_id": "ent:32bb9dc9fe58",
          "entity_type": "BIOMARKER",
          "name": "H2O2",
          "normalized_id": "N/A",
          "aliases": [
            "hydrogen peroxide"
          ],
          "description": "A compound synthesized by MAOB in reactive astrocytes, which aggravates astrocytic reactivity and dopaminergic neuronal death in Parkinson's disease."
        },
        {
          "entity_id": "ent:8af66cb2eeba",
          "entity_type": "BIOMARKER",
          "name": "dopamine",
          "normalized_id": "N/A",
          "aliases": [
            "DA"
          ],
          "description": "A monoamine neurotransmitter whose degradation is mediated by MAOA, and whose neuronal activity is suppressed by astrocytic GABA in Parkinson's disease."
        },
        {
          "entity_id": "ent:b7cebb5b16bb",
          "entity_type": "BIOMARKER",
          "name": "PET",
          "normalized_id": "N/A",
          "aliases": [
            "positron emission tomography"
          ],
          "description": "An imaging technique used for molecular imaging of MAOB in living human brains to measure its levels."
        },
        {
          "entity_id": "ent:1706e10b3438",
          "entity_type": "MECHANISM",
          "name": "degradation of monoamine neurotransmitters",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Process traditionally believed to be mediated by MAOB for neurotransmitters like dopamine."
        },
        {
          "entity_id": "ent:2ba0cafc389b",
          "entity_type": "MECHANISM",
          "name": "dopamine degradation",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Process described as being mediated by MAOA, not MAOB."
        },
        {
          "entity_id": "ent:4d574fb64211",
          "entity_type": "MECHANISM",
          "name": "aberrant synthesis of GABA and hydrogen peroxide",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Process mediated by MAOB in reactive astrocytes of Parkinson's disease."
        },
        {
          "entity_id": "ent:d7933eae15a6",
          "entity_type": "MECHANISM",
          "name": "tonically suppresses the dopaminergic neuronal activity",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Mechanism by which astrocytic GABA affects dopaminergic neurons."
        },
        {
          "entity_id": "ent:1567639f4cfa",
          "entity_type": "MECHANISM",
          "name": "aggravates astrocytic reactivity and dopaminergic neuronal death",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Mechanism by which H2O2 contributes to Parkinson's disease progression."
        },
        {
          "entity_id": "ent:39d388ae4175",
          "entity_type": "MECHANISM",
          "name": "reduce reactive astrogliosis and restore dopaminergic neuronal activity",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Mechanism of action for reversible MAOB inhibitors in alleviating PD symptoms."
        },
        {
          "entity_id": "ent:b5725f0f5a69",
          "entity_type": "MECHANISM",
          "name": "aberrant suppression and deterioration of dopaminergic neurons",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Role of MAOB through excessive GABA and H2O2 synthesis in reactive astrocytes."
        },
        {
          "entity_id": "ent:b0d44ea5de70",
          "entity_type": "MECHANISM",
          "name": "excessive GABA and H2O2 synthesis",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Process in reactive astrocytes linked to MAOB's role in Parkinson's disease."
        },
        {
          "entity_id": "ent:49d941816dbd",
          "entity_type": "MECHANISM",
          "name": "catalyzes the oxidation of monoamines",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Enzymatic function of monoamine oxidase (MAO) family at mitochondrial outer membranes."
        },
        {
          "entity_id": "ent:102fb1dfef68",
          "entity_type": "MECHANISM",
          "name": "oxidatively deaminated",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Process distinguishing MAO from other enzymes acting on diamines."
        },
        {
          "entity_id": "ent:552634a6d0e7",
          "entity_type": "MECHANISM",
          "name": "oxidize catecholamines",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Function discovered for MAO in the brain regarding neurotransmitters like dopamine."
        },
        {
          "entity_id": "ent:ede5fce3b5af",
          "entity_type": "MECHANISM",
          "name": "maintain the homeostasis of monoamine neurotransmitters and metabolites",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Current believed role of MAO in the brain."
        },
        {
          "entity_id": "ent:86e42b12f3ec",
          "entity_type": "MECHANISM",
          "name": "contribute to brain aging",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Potential role of age-related increase in astrocytic MAOB expression."
        },
        {
          "entity_id": "ent:59567678c41b",
          "entity_type": "MECHANISM",
          "name": "contribute to the progression and maintenance of neuroinflammation and neurodegeneration",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Suggested role of increased MAOB expression with reactive astrogliosis in diseases."
        }
      ],
      "relations": [
        {
          "head": "MAOB",
          "relation": "mediate",
          "tail": "degradation of monoamine neurotransmitters",
          "relation_type": "UNKNOWN",
          "confidence": [
            0.2,
            0.0
          ],
          "evidence": [
            "Monoamine oxidase-B (MAOB) has been believed to mediate the degradation of monoamine neurotransmitters such as dopamine.",
            "However, this traditional belief has been challenged by demonstrating that it is not MAOB but MAOA which mediates dopamine degradation."
          ],
          "mechanism": "unknown",
          "source": "ocr_result_1_0",
          "subject": {
            "entity_id": "ent:b9c77630ce9d",
            "entity_type": "PROTEIN",
            "name": "MAOB",
            "normalized_id": "N/A",
            "aliases": [
              "monoamine oxidase B",
              "Monoamine oxidase B",
              "Monoamine oxidase-B"
            ],
            "description": "Monoamine oxidase-B (MAOB) is described as an enzyme that mediates the aberrant synthesis of GABA and hydrogen peroxide in reactive astrocytes of Parkinson's disease, and its expression increases with aging and in neurodegenerative conditions."
          },
          "object": {
            "entity_id": "ent:1706e10b3438",
            "entity_type": "MECHANISM",
            "name": "degradation of monoamine neurotransmitters",
            "normalized_id": "N/A",
            "aliases": [],
            "description": "Process traditionally believed to be mediated by MAOB for neurotransmitters like dopamine."
          },
          "time_info": null
        },
        {
          "head": "MAOB",
          "relation": "mediate",
          "tail": "aberrant synthesis of GABA and hydrogen peroxide",
          "relation_type": "UNKNOWN",
          "confidence": [
            0.9,
            0.1
          ],
          "evidence": [
            "Instead, MAOB mediates the aberrant synthesis of GABA and hydrogen peroxide (HO) in reactive astrocytes of Parkinson's disease (PD).",
            "In this perspective, we redefine the role of MAOB for the aberrant suppression and deterioration of dopaminergic neurons through excessive GABA and HO synthesis of reactive astrocytes in PD."
          ],
          "mechanism": "unknown",
          "source": "ocr_result_1_0",
          "subject": {
            "entity_id": "ent:b9c77630ce9d",
            "entity_type": "PROTEIN",
            "name": "MAOB",
            "normalized_id": "N/A",
            "aliases": [
              "monoamine oxidase B",
              "Monoamine oxidase B",
              "Monoamine oxidase-B"
            ],
            "description": "Monoamine oxidase-B (MAOB) is described as an enzyme that mediates the aberrant synthesis of GABA and hydrogen peroxide in reactive astrocytes of Parkinson's disease, and its expression increases with aging and in neurodegenerative conditions."
          },
          "object": {
            "entity_id": "ent:4d574fb64211",
            "entity_type": "MECHANISM",
            "name": "aberrant synthesis of GABA and hydrogen peroxide",
            "normalized_id": "N/A",
            "aliases": [],
            "description": "Process mediated by MAOB in reactive astrocytes of Parkinson's disease."
          },
          "time_info": null
        },
        {
          "head": "astrocytic GABA",
          "relation": "tonically suppresses",
          "tail": "dopaminergic neuronal activity",
          "relation_type": "UNKNOWN",
          "confidence": [
            0.85,
            0.15
          ],
          "evidence": [
            "Astrocytic GABA tonically suppresses the dopaminergic neuronal activity",
            "we redefine the role of MAOB for the aberrant suppression and deterioration of dopaminergic neurons through excessive GABA and HO synthesis of reactive astrocytes in PD."
          ],
          "mechanism": "unknown",
          "source": "ocr_result_1_0",
          "subject": {
            "entity_id": "ent:9f3e57461507",
            "entity_type": "BIOMARKER",
            "name": "GABA",
            "normalized_id": "N/A",
            "aliases": [],
            "description": "A neurotransmitter synthesized by MAOB in reactive astrocytes, which tonically suppresses dopaminergic neuronal activity in Parkinson's disease."
          },
          "object": {
            "entity_id": "ent:39d388ae4175",
            "entity_type": "MECHANISM",
            "name": "reduce reactive astrogliosis and restore dopaminergic neuronal activity",
            "normalized_id": "N/A",
            "aliases": [],
            "description": "Mechanism of action for reversible MAOB inhibitors in alleviating PD symptoms."
          },
          "time_info": null
        },
        {
          "head": "H2O2",
          "relation": "aggravates",
          "tail": "astrocytic reactivity",
          "relation_type": "UNKNOWN",
          "confidence": [
            0.8,
            0.3
          ],
          "evidence": [
            "whereas HO aggravates astrocytic reactivity and dopaminergic neuronal death."
          ],
          "mechanism": "unknown",
          "source": "ocr_result_1_0",
          "subject": {
            "entity_id": "ent:b0d44ea5de70",
            "entity_type": "MECHANISM",
            "name": "excessive GABA and H2O2 synthesis",
            "normalized_id": "N/A",
            "aliases": [],
            "description": "Process in reactive astrocytes linked to MAOB's role in Parkinson's disease."
          },
          "object": {
            "entity_id": "ent:1567639f4cfa",
            "entity_type": "MECHANISM",
            "name": "aggravates astrocytic reactivity and dopaminergic neuronal death",
            "normalized_id": "N/A",
            "aliases": [],
            "description": "Mechanism by which H2O2 contributes to Parkinson's disease progression."
          },
          "time_info": null
        },
        {
          "head": "H2O2",
          "relation": "aggravates",
          "tail": "dopaminergic neuronal death",
          "relation_type": "UNKNOWN",
          "confidence": [
            0.85,
            0.1
          ],
          "evidence": [
            "whereas HO aggravates astrocytic reactivity and dopaminergic neuronal death."
          ],
          "mechanism": "unknown",
          "source": "ocr_result_1_0",
          "subject": {
            "entity_id": "ent:b0d44ea5de70",
            "entity_type": "MECHANISM",
            "name": "excessive GABA and H2O2 synthesis",
            "normalized_id": "N/A",
            "aliases": [],
            "description": "Process in reactive astrocytes linked to MAOB's role in Parkinson's disease."
          },
          "object": {
            "entity_id": "ent:1567639f4cfa",
            "entity_type": "MECHANISM",
            "name": "aggravates astrocytic reactivity and dopaminergic neuronal death",
            "normalized_id": "N/A",
            "aliases": [],
            "description": "Mechanism by which H2O2 contributes to Parkinson's disease progression."
          },
          "time_info": null
        },
        {
          "head": "reversible MAOB inhibitors",
          "relation": "reduce",
          "tail": "reactive astrogliosis",
          "relation_type": "UNKNOWN",
          "confidence": [
            0.75,
            0.1
          ],
          "evidence": [
            "Recently discovered reversible MAOB inhibitors reduce reactive astrogliosis and restore dopaminergic neuronal activity to alleviate PD symptoms in rodents."
          ],
          "mechanism": "unknown",
          "source": "ocr_result_1_0",
          "subject": {
            "entity_id": "ent:b9c77630ce9d",
            "entity_type": "PROTEIN",
            "name": "MAOB",
            "normalized_id": "N/A",
            "aliases": [
              "monoamine oxidase B",
              "Monoamine oxidase B",
              "Monoamine oxidase-B"
            ],
            "description": "Monoamine oxidase-B (MAOB) is described as an enzyme that mediates the aberrant synthesis of GABA and hydrogen peroxide in reactive astrocytes of Parkinson's disease, and its expression increases with aging and in neurodegenerative conditions."
          },
          "object": {
            "entity_id": "ent:39d388ae4175",
            "entity_type": "MECHANISM",
            "name": "reduce reactive astrogliosis and restore dopaminergic neuronal activity",
            "normalized_id": "N/A",
            "aliases": [],
            "description": "Mechanism of action for reversible MAOB inhibitors in alleviating PD symptoms."
          },
          "time_info": null
        },
        {
          "head": "reversible MAOB inhibitors",
          "relation": "restore",
          "tail": "dopaminergic neuronal activity",
          "relation_type": "UNKNOWN",
          "confidence": [
            0.75,
            0.1
          ],
          "evidence": [
            "Recently discovered reversible MAOB inhibitors reduce reactive astrogliosis and restore dopaminergic neuronal activity to alleviate PD symptoms in rodents."
          ],
          "mechanism": "unknown",
          "source": "ocr_result_1_0",
          "subject": {
            "entity_id": "ent:b9c77630ce9d",
            "entity_type": "PROTEIN",
            "name": "MAOB",
            "normalized_id": "N/A",
            "aliases": [
              "monoamine oxidase B",
              "Monoamine oxidase B",
              "Monoamine oxidase-B"
            ],
            "description": "Monoamine oxidase-B (MAOB) is described as an enzyme that mediates the aberrant synthesis of GABA and hydrogen peroxide in reactive astrocytes of Parkinson's disease, and its expression increases with aging and in neurodegenerative conditions."
          },
          "object": {
            "entity_id": "ent:39d388ae4175",
            "entity_type": "MECHANISM",
            "name": "reduce reactive astrogliosis and restore dopaminergic neuronal activity",
            "normalized_id": "N/A",
            "aliases": [],
            "description": "Mechanism of action for reversible MAOB inhibitors in alleviating PD symptoms."
          },
          "time_info": null
        },
        {
          "head": "reversible MAOB inhibitors",
          "relation": "alleviate",
          "tail": "Parkinson's disease",
          "relation_type": "UNKNOWN",
          "confidence": [
            0.7,
            0.05
          ],
          "evidence": [
            "Recently discovered reversible MAOB inhibitors reduce reactive astrogliosis and restore dopaminergic neuronal activity to alleviate PD symptoms in rodents."
          ],
          "mechanism": "unknown",
          "source": "ocr_result_1_0",
          "subject": {
            "entity_id": "ent:b9c77630ce9d",
            "entity_type": "PROTEIN",
            "name": "MAOB",
            "normalized_id": "N/A",
            "aliases": [
              "monoamine oxidase B",
              "Monoamine oxidase B",
              "Monoamine oxidase-B"
            ],
            "description": "Monoamine oxidase-B (MAOB) is described as an enzyme that mediates the aberrant synthesis of GABA and hydrogen peroxide in reactive astrocytes of Parkinson's disease, and its expression increases with aging and in neurodegenerative conditions."
          },
          "object": {
            "entity_id": "ent:0da0981b2564",
            "entity_type": "DISEASE",
            "name": "Parkinson's disease",
            "normalized_id": "N/A",
            "aliases": [
              "PD"
            ],
            "description": "A disease where reactive astrocytes in the substantia nigra pars compacta show increased MAOB expression, and astrocytic GABA suppresses dopaminergic neuronal activity while H2O2 aggravates neuronal death."
          },
          "time_info": null
        },
        {
          "head": "aging",
          "relation": "increase",
          "tail": "MAOB expression",
          "relation_type": "UNKNOWN",
          "confidence": [
            0.9,
            0.2
          ],
          "evidence": [
            "Interestingly, MAOB expression is clearly increased with aging in most structures of rodent brains, including the cortex, hippocampus, and striatum",
            "Furthermore, human brain tissue shows a delayed but significant age-related increase in MAOB, which starts at the age of 50-60 years",
            "another study using molecular imaging of MAOB with [C] L-deprenyl-D2 and positron emission tomography (PET) imaging in the living human brains demonstrated that MAOB level was increased in all brain regions examined, except the cingulate gyrus, along with aging"
          ],
          "mechanism": "unknown",
          "source": "ocr_result_1_0",
          "subject": {
            "entity_id": "ent:86e42b12f3ec",
            "entity_type": "MECHANISM",
            "name": "contribute to brain aging",
            "normalized_id": "N/A",
            "aliases": [],
            "description": "Potential role of age-related increase in astrocytic MAOB expression."
          },
          "object": {
            "entity_id": "ent:b9c77630ce9d",
            "entity_type": "PROTEIN",
            "name": "MAOB",
            "normalized_id": "N/A",
            "aliases": [
              "monoamine oxidase B",
              "Monoamine oxidase B",
              "Monoamine oxidase-B"
            ],
            "description": "Monoamine oxidase-B (MAOB) is described as an enzyme that mediates the aberrant synthesis of GABA and hydrogen peroxide in reactive astrocytes of Parkinson's disease, and its expression increases with aging and in neurodegenerative conditions."
          },
          "time_info": null
        },
        {
          "head": "reactive astrogliosis",
          "relation": "associate with",
          "tail": "MAOB expression",
          "relation_type": "UNKNOWN",
          "confidence": [
            0.85,
            0.85
          ],
          "evidence": [
            "In addition, MAOB expression is significantly increased in the neuroinflammatory and neurodegenerative conditions, which is associated with reactive astrogliosis",
            "MAOB expression is significantly increased in the reactive astrocytes of the substantia nigra pars compacta (SNpc)"
          ],
          "mechanism": "unknown",
          "source": "ocr_result_1_0",
          "subject": {
            "entity_id": "ent:39d388ae4175",
            "entity_type": "MECHANISM",
            "name": "reduce reactive astrogliosis and restore dopaminergic neuronal activity",
            "normalized_id": "N/A",
            "aliases": [],
            "description": "Mechanism of action for reversible MAOB inhibitors in alleviating PD symptoms."
          },
          "object": {
            "entity_id": "ent:b9c77630ce9d",
            "entity_type": "PROTEIN",
            "name": "MAOB",
            "normalized_id": "N/A",
            "aliases": [
              "monoamine oxidase B",
              "Monoamine oxidase B",
              "Monoamine oxidase-B"
            ],
            "description": "Monoamine oxidase-B (MAOB) is described as an enzyme that mediates the aberrant synthesis of GABA and hydrogen peroxide in reactive astrocytes of Parkinson's disease, and its expression increases with aging and in neurodegenerative conditions."
          },
          "time_info": null
        },
        {
          "head": "MAOB",
          "relation": "contribute to",
          "tail": "brain aging",
          "relation_type": "UNKNOWN",
          "confidence": [
            0.65,
            0.1
          ],
          "evidence": [
            "Based on the exclusive expression of MAOB in astrocytes, the age-related increase in MAOB expression in astrocytes could contribute to brain aging."
          ],
          "mechanism": "unknown",
          "source": "ocr_result_1_0",
          "subject": {
            "entity_id": "ent:b9c77630ce9d",
            "entity_type": "PROTEIN",
            "name": "MAOB",
            "normalized_id": "N/A",
            "aliases": [
              "monoamine oxidase B",
              "Monoamine oxidase B",
              "Monoamine oxidase-B"
            ],
            "description": "Monoamine oxidase-B (MAOB) is described as an enzyme that mediates the aberrant synthesis of GABA and hydrogen peroxide in reactive astrocytes of Parkinson's disease, and its expression increases with aging and in neurodegenerative conditions."
          },
          "object": {
            "entity_id": "ent:86e42b12f3ec",
            "entity_type": "MECHANISM",
            "name": "contribute to brain aging",
            "normalized_id": "N/A",
            "aliases": [],
            "description": "Potential role of age-related increase in astrocytic MAOB expression."
          },
          "time_info": null
        },
        {
          "head": "increased MAOB expression",
          "relation": "contribute to",
          "tail": "progression and maintenance of neuroinflammation and neurodegeneration",
          "relation_type": "UNKNOWN",
          "confidence": [
            0.75,
            0.2
          ],
          "evidence": [
            "These emerging lines of evidence have suggested that the increased MAOB expression along with reactive astrogliosis could contribute to the progression and maintenance of neuroinflammation and neurodegeneration."
          ],
          "mechanism": "unknown",
          "source": "ocr_result_1_0",
          "subject": {
            "entity_id": "ent:b9c77630ce9d",
            "entity_type": "PROTEIN",
            "name": "MAOB",
            "normalized_id": "N/A",
            "aliases": [
              "monoamine oxidase B",
              "Monoamine oxidase B",
              "Monoamine oxidase-B"
            ],
            "description": "Monoamine oxidase-B (MAOB) is described as an enzyme that mediates the aberrant synthesis of GABA and hydrogen peroxide in reactive astrocytes of Parkinson's disease, and its expression increases with aging and in neurodegenerative conditions."
          },
          "object": {
            "entity_id": "ent:59567678c41b",
            "entity_type": "MECHANISM",
            "name": "contribute to the progression and maintenance of neuroinflammation and neurodegeneration",
            "normalized_id": "N/A",
            "aliases": [],
            "description": "Suggested role of increased MAOB expression with reactive astrogliosis in diseases."
          },
          "time_info": null
        },
        {
          "head": "MAOB",
          "relation": "increase with",
          "tail": "aging",
          "relation_type": "UNKNOWN",
          "confidence": [
            0.9,
            0.2
          ],
          "evidence": [
            "Interestingly, MAOB expression is clearly increased with aging in most structures of rodent brains",
            "Furthermore, human brain tissue shows a delayed but significant age-related increase in MAOB",
            "MAOB level was increased in all brain regions examined, except the cingulate gyrus, along with aging"
          ],
          "mechanism": "unknown",
          "source": "ocr_result_1_0",
          "subject": {
            "entity_id": "ent:b9c77630ce9d",
            "entity_type": "PROTEIN",
            "name": "MAOB",
            "normalized_id": "N/A",
            "aliases": [
              "monoamine oxidase B",
              "Monoamine oxidase B",
              "Monoamine oxidase-B"
            ],
            "description": "Monoamine oxidase-B (MAOB) is described as an enzyme that mediates the aberrant synthesis of GABA and hydrogen peroxide in reactive astrocytes of Parkinson's disease, and its expression increases with aging and in neurodegenerative conditions."
          },
          "object": {
            "entity_id": "ent:86e42b12f3ec",
            "entity_type": "MECHANISM",
            "name": "contribute to brain aging",
            "normalized_id": "N/A",
            "aliases": [],
            "description": "Potential role of age-related increase in astrocytic MAOB expression."
          },
          "time_info": null
        }
      ]
    },
    "ocr_result_1_1": {
      "id": "ocr_result_1_1",
      "name": "",
      "meta": {
        "text": "## 2. Challenges for Defining the Role of MAOB in Parkinson's Disease\n\nPD is the most prevalent neurodegenerative motor disorder, which is caused by nigrostriatal DA depletion [23]. It is characterized by remarkable motor dysfunction, including bradykinesia, resting tremor, gait disturbance, and postural instability [24]. Apart from levodopa, which is the most popular therapeutic agent for PD, several irreversible MAOB inhibitors have been widely prescribed for PD patients as an early monotherapy or an add-on to other medications, despite some reports demonstrating their discouraging clinical effects [25,26].\n\nThere are two isoenzymes of MAO: MAOA and MAOB. While both isoenzymes are mitochondria-bound flavoenzymes [27], their physiological and pathological roles are distinct due to their differential cellular localization [28] and distinct substrate selectivity. First, MAOA is mainly localized in the nigrostriatal DAergic axon terminals [28,29,30], whereas MAOB is located exclusively in astrocytes and serotonergic neurons [29,30]. Second, they have distinct molecular differences in enzymatic properties revealed by cDNA cloning and peptide sequencing of human MAOA and MAOB [31,32], allowing their differential substrate selectivity. In particular, MAOA is primarily responsible for the metabolism of epinephrine, norepinephrine, melatonin, and serotonin, whereas MAOB is responsible for the degradation of phenylethylamine and benzylamine [33]. Notably, DA is traditionally known to be degraded by both MAOA and MAOB. Particularly, MAOB is known to be upregulated in PD patients' brains [34]. Therefore, MAOB has long been believed to contribute to PD pathophysiology through excessive DA degradation [35]. This belief was further supported by a positive but limited clinical efficacy of irreversible MAOB inhibitors such as selegiline and rasagiline for PD patients [36,37].\n\nSince 2014, several investigations have begun to emphasize the specific involvement of MAOB, but not MAOA, in astrocytic GABA production via the putrescine degradation route [15,16,21,38,39,40], which has been overlooked in the brain for decades. Moreover, MAOB has recently received special attention due to its increased level along with reactive astrogliosis in neurodegenerative diseases, including PD [15,16,17,18,21,22,38,41]. These recent discoveries on the pathological role of astrocytic MAOB led us to revisit the MAOB's role in PD pathophysiology. The therapeutic efficacy of MAOB inhibitors for PD is not attributed to a blockade of DA degradation. Instead, it is attributed to a blockade of the excessive astrocytic GABA synthesis and the aberrant tonic inhibition of DAergic neurons in the SNpc. In this review, we summarize the traditional views and recent perspectives in an attempt to redefine the pathological role of MAOB in PD pathophysiology.\n\n2.1. Traditional Views on MAOB as a DA-Metabolizing Enzyme\n\nAs described above, MAOA and MAOB have differential substrate selectivity. In particular, epinephrine, norepinephrine, melatonin, and serotonin are known to be metabolized by MAOA, whereas phenylethylamine and benzylamine are known to be degraded by MAOB [33]. Among several various monoamines, DA has been one of the most well-known substrates for MAO for the past six decades ago [42]. Since the first-generation specific inhibitors of MAOA and MAOB, clorgiline, and selegiline, respectively, were developed in the 1960s, researchers started to investigate which isoenzyme was responsible for DA metabolism in the 1970s. Several in vivo studies with selective inhibitors against MAOA and MAOB demonstrated that DA is much preferentially degraded by MAOA compared to MAOB in the rat brain [43,44]. On the other hand, some other studies using selegiline also demonstrated that MAOB catalyzes DA as a substrate in rats [45,46,47]. These conflicting results could be partially attributed to the low selectivity of selegiline to MAOB over MAOA (~150-fold difference). Indeed, the affinity of DA deamination was 2.5-fold higher to MAOA than MAOB [47]. Notably, an investigation with the homogenates of brain tissues from various species by Garrick and Murphy demonstrated that DA was found to be deaminated largely by MAOA in the rat brains, whereas by MAOB in the brains of humans and vervet [46]. However, this pivotal finding was limited by the fact that the enzymatic activities of MAOA and MAOB were measured with tissue homogenates which could be different from the intact brain. Despite the controversies on the contributions of MAOA and MAOB to DA degradation, it has been traditionally and until now generally believed that both MAOA and MAOB are equally active towards DA degradation [35,48,49,50,51].",
        "source": "ocr_result_1"
      },
      "entities": [
        {
          "entity_id": "ent:bd6e4e2a7ccf",
          "entity_type": "PATHWAY",
          "name": "putrescine degradation route",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A route involved in astrocytic GABA production, specifically involving MAOB according to recent investigations."
        },
        {
          "entity_id": "ent:4ecb24b2e330",
          "entity_type": "GENE",
          "name": "MAOB",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "An isoenzyme of MAO located exclusively in astrocytes and serotonergic neurons, responsible for degrading phenylethylamine and benzylamine, and upregulated in PD patients' brains."
        },
        {
          "entity_id": "ent:eb3f3e38d77d",
          "entity_type": "GENE",
          "name": "MAOA",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "An isoenzyme of MAO mainly localized in nigrostriatal DAergic axon terminals, primarily responsible for metabolizing epinephrine, norepinephrine, melatonin, and serotonin."
        },
        {
          "entity_id": "ent:e6e8799f2979",
          "entity_type": "PROTEIN",
          "name": "MAO",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Refers to monoamine oxidase, with two isoenzymes (MAOA and MAOB) that are mitochondria-bound flavoenzymes with differential cellular localization and substrate selectivity."
        },
        {
          "entity_id": "ent:c876cfe5153f",
          "entity_type": "DRUG",
          "name": "levodopa",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Described as the most popular therapeutic agent for Parkinson's disease."
        },
        {
          "entity_id": "ent:82fb4cdbc0f1",
          "entity_type": "DRUG",
          "name": "selegiline",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Described as an irreversible MAOB inhibitor with positive but limited clinical efficacy for Parkinson's disease patients."
        },
        {
          "entity_id": "ent:a48a954a3c52",
          "entity_type": "DRUG",
          "name": "rasagiline",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Described as an irreversible MAOB inhibitor with positive but limited clinical efficacy for Parkinson's disease patients."
        },
        {
          "entity_id": "ent:e1de62b4d7d2",
          "entity_type": "DRUG",
          "name": "clorgiline",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Described as the first-generation specific inhibitor of MAOA developed in the 1960s."
        },
        {
          "entity_id": "ent:4683f251fbed",
          "entity_type": "SYMPTOM",
          "name": "motor dysfunction",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A remarkable characteristic of Parkinson's disease, as described in the text."
        },
        {
          "entity_id": "ent:af662044fecc",
          "entity_type": "SYMPTOM",
          "name": "bradykinesia",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Included as part of the motor dysfunction characterizing Parkinson's disease."
        },
        {
          "entity_id": "ent:225305c1c133",
          "entity_type": "SYMPTOM",
          "name": "resting tremor",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Included as part of the motor dysfunction characterizing Parkinson's disease."
        },
        {
          "entity_id": "ent:e8b146a17361",
          "entity_type": "SYMPTOM",
          "name": "gait disturbance",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Included as part of the motor dysfunction characterizing Parkinson's disease."
        },
        {
          "entity_id": "ent:280928dfbcf1",
          "entity_type": "SYMPTOM",
          "name": "postural instability",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Included as part of the motor dysfunction characterizing Parkinson's disease."
        },
        {
          "entity_id": "ent:cd96e2edb784",
          "entity_type": "DISEASE",
          "name": "Parkinson's Disease",
          "normalized_id": "N/A",
          "aliases": [
            "PD"
          ],
          "description": "Described as the most prevalent neurodegenerative motor disorder, characterized by motor dysfunction and caused by nigrostriatal dopamine depletion."
        },
        {
          "entity_id": "ent:4dccca3c35de",
          "entity_type": "DISEASE",
          "name": "neurodegenerative diseases",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Described as conditions where reactive astrogliosis occurs, with Parkinson's Disease listed as an example."
        },
        {
          "entity_id": "ent:868f31807433",
          "entity_type": "TREATMENT",
          "name": "irreversible MAOB inhibitors",
          "normalized_id": "N/A",
          "aliases": [
            "MAOB inhibitors"
          ],
          "description": "Described as being widely prescribed for PD patients as an early monotherapy or an add-on to other medications."
        },
        {
          "entity_id": "ent:8b2f04546fd8",
          "entity_type": "TREATMENT",
          "name": "selective inhibitors against MAOA and MAOB",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Described as being used in several in vivo studies that demonstrated DA is much preferentially degraded by MAOA compared to MAOB in the rat brain."
        },
        {
          "entity_id": "ent:c0c759a4bb48",
          "entity_type": "MECHANISM",
          "name": "nigrostriatal DA depletion",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Described as the cause of Parkinson's disease, specifically nigrostriatal DA depletion."
        },
        {
          "entity_id": "ent:11d42348bcb5",
          "entity_type": "MECHANISM",
          "name": "differential cellular localization",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A distinct physiological and pathological role factor for MAO isoenzymes due to their differential cellular localization."
        },
        {
          "entity_id": "ent:8c0ad29aae85",
          "entity_type": "MECHANISM",
          "name": "distinct substrate selectivity",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A distinct physiological and pathological role factor for MAO isoenzymes due to their distinct substrate selectivity."
        },
        {
          "entity_id": "ent:f5a15b641e2f",
          "entity_type": "MECHANISM",
          "name": "metabolism",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "MAOA is primarily responsible for the metabolism of epinephrine, norepinephrine, melatonin, and serotonin."
        },
        {
          "entity_id": "ent:29b680483e8e",
          "entity_type": "MECHANISM",
          "name": "degradation",
          "normalized_id": "N/A",
          "aliases": [
            "degraded"
          ],
          "description": "MAOB is responsible for the degradation of phenylethylamine and benzylamine."
        },
        {
          "entity_id": "ent:9d6f7764d7f7",
          "entity_type": "MECHANISM",
          "name": "excessive DA degradation",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "MAOB has long been believed to contribute to PD pathophysiology through excessive DA degradation."
        },
        {
          "entity_id": "ent:6b62c000294a",
          "entity_type": "MECHANISM",
          "name": "astrocytic GABA production",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "The specific involvement of MAOB in astrocytic GABA production via the putrescine degradation route."
        },
        {
          "entity_id": "ent:6f8a67888b27",
          "entity_type": "MECHANISM",
          "name": "reactive astrogliosis",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "MAOB has recently received special attention due to its increased level along with reactive astrogliosis in neurodegenerative diseases."
        },
        {
          "entity_id": "ent:ec09b7f811dd",
          "entity_type": "MECHANISM",
          "name": "blockade of DA degradation",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "The therapeutic efficacy of MAOB inhibitors for PD is not attributed to a blockade of DA degradation."
        },
        {
          "entity_id": "ent:0d40e71352c3",
          "entity_type": "MECHANISM",
          "name": "blockade of the excessive astrocytic GABA synthesis",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "The therapeutic efficacy of MAOB inhibitors for PD is attributed to a blockade of the excessive astrocytic GABA synthesis."
        },
        {
          "entity_id": "ent:1b18fa08fa0e",
          "entity_type": "MECHANISM",
          "name": "aberrant tonic inhibition",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "The therapeutic efficacy of MAOB inhibitors for PD is attributed to a blockade of the aberrant tonic inhibition of DAergic neurons."
        },
        {
          "entity_id": "ent:e23b214a9f4e",
          "entity_type": "MECHANISM",
          "name": "metabolized",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Epinephrine, norepinephrine, melatonin, and serotonin are known to be metabolized by MAOA."
        },
        {
          "entity_id": "ent:92bded174bee",
          "entity_type": "MECHANISM",
          "name": "DA metabolism",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Researchers started to investigate which isoenzyme was responsible for DA metabolism in the 1970s."
        },
        {
          "entity_id": "ent:0d5a025daa33",
          "entity_type": "MECHANISM",
          "name": "catalyzes",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Some studies using selegiline demonstrated that MAOB catalyzes DA as a substrate in rats."
        },
        {
          "entity_id": "ent:9d29d3782591",
          "entity_type": "MECHANISM",
          "name": "DA deamination",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "The affinity of DA deamination was 2.5-fold higher to MAOA than MAOB."
        },
        {
          "entity_id": "ent:d8069daedbe7",
          "entity_type": "MECHANISM",
          "name": "deaminated",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "DA was found to be deaminated largely by MAOA in the rat brains, whereas by MAOB in the brains of humans and vervet."
        },
        {
          "entity_id": "ent:8a56f8d1077b",
          "entity_type": "MECHANISM",
          "name": "DA degradation",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "It has been traditionally and until now generally believed that both MAOA and MAOB are equally active towards DA degradation."
        },
        {
          "entity_id": "ent:9831b9ba4e09",
          "entity_type": "OTHER",
          "name": "early monotherapy",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A treatment approach mentioned as one way irreversible MAOB inhibitors are prescribed for Parkinson's disease patients."
        },
        {
          "entity_id": "ent:ab7e32bc6740",
          "entity_type": "OTHER",
          "name": "add-on",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A supplementary treatment mentioned as one way irreversible MAOB inhibitors are prescribed alongside other medications for Parkinson's disease."
        },
        {
          "entity_id": "ent:e4b18613939b",
          "entity_type": "OTHER",
          "name": "clinical effects",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Outcomes or impacts observed in a clinical setting, with some reports demonstrating discouraging ones for irreversible MAOB inhibitors."
        },
        {
          "entity_id": "ent:724cb6c3b60e",
          "entity_type": "OTHER",
          "name": "cellular localization",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "The specific cellular location of MAO isoenzymes, cited as a reason for their distinct physiological and pathological roles."
        },
        {
          "entity_id": "ent:212605757955",
          "entity_type": "OTHER",
          "name": "substrate selectivity",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "The property of enzymes to preferentially act on specific substrates, mentioned as distinct between MAOA and MAOB."
        },
        {
          "entity_id": "ent:689f007697db",
          "entity_type": "OTHER",
          "name": "enzymatic properties",
          "normalized_id": "N/A",
          "aliases": [
            "enzymatic activities"
          ],
          "description": "Characteristics related to enzyme function, revealed by cDNA cloning and peptide sequencing of human MAOA and MAOB."
        },
        {
          "entity_id": "ent:a1c592b68bae",
          "entity_type": "OTHER",
          "name": "cDNA cloning",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A molecular biology technique used to reveal molecular differences in the enzymatic properties of human MAOA and MAOB."
        },
        {
          "entity_id": "ent:3152b6cb8d27",
          "entity_type": "OTHER",
          "name": "peptide sequencing",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A technique used to reveal molecular differences in the enzymatic properties of human MAOA and MAOB."
        },
        {
          "entity_id": "ent:51f6397444b3",
          "entity_type": "OTHER",
          "name": "pathophysiology",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "The functional changes associated with a disease, specifically Parkinson's disease, which MAOB has long been believed to contribute to."
        },
        {
          "entity_id": "ent:b0e5feb6d260",
          "entity_type": "OTHER",
          "name": "clinical efficacy",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "The effectiveness of a treatment in a clinical setting, described as positive but limited for irreversible MAOB inhibitors like selegiline and rasagiline."
        },
        {
          "entity_id": "ent:9ade75d3a354",
          "entity_type": "OTHER",
          "name": "tonic inhibition",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A persistent form of neuronal inhibition, described as aberrant and targeting dopaminergic neurons in the SNpc, which MAOB inhibitor efficacy may block."
        },
        {
          "entity_id": "ent:f8cdf00b3b9b",
          "entity_type": "OTHER",
          "name": "traditional views",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Established perspectives that the review summarizes, specifically regarding the pathological role of MAOB in Parkinson's disease."
        },
        {
          "entity_id": "ent:ef50d44cd91e",
          "entity_type": "OTHER",
          "name": "recent perspectives",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Newer viewpoints that the review summarizes in an attempt to redefine the pathological role of MAOB in Parkinson's disease."
        },
        {
          "entity_id": "ent:5a9da84334d2",
          "entity_type": "OTHER",
          "name": "in vivo studies",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Research conducted in living organisms, specifically mentioned in the context of studies with selective inhibitors against MAOA and MAOB in rat brains."
        },
        {
          "entity_id": "ent:2bbc7204d58c",
          "entity_type": "OTHER",
          "name": "selective inhibitors",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Compounds that target specific enzymes, used in in vivo studies against MAOA and MAOB to investigate DA metabolism."
        },
        {
          "entity_id": "ent:b61d427de4fb",
          "entity_type": "OTHER",
          "name": "affinity",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "The strength of binding, specifically mentioned regarding DA deamination being 2.5-fold higher to MAOA than to MAOB."
        },
        {
          "entity_id": "ent:60812d7d2fce",
          "entity_type": "OTHER",
          "name": "tissue homogenates",
          "normalized_id": "N/A",
          "aliases": [
            "homogenates"
          ],
          "description": "Uniform mixtures of blended tissue, used to measure enzymatic activities of MAOA and MAOB, though noted as potentially different from the intact brain."
        },
        {
          "entity_id": "ent:63cfef12787a",
          "entity_type": "OTHER",
          "name": "intact brain",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "The brain in its whole, undamaged state, noted as potentially different from tissue homogenates in terms of MAO enzymatic activities."
        },
        {
          "entity_id": "ent:4f50169dba3b",
          "entity_type": "OTHER",
          "name": "controversies",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Disagreements or debates, specifically regarding the contributions of MAOA and MAOB to DA degradation."
        }
      ],
      "relations": [
        {
          "head": "MAOB",
          "relation": "upregulate in",
          "tail": "Parkinson's Disease",
          "relation_type": "UNKNOWN",
          "confidence": [
            0.85,
            0.05
          ],
          "evidence": [
            "Notably, MAOB is known to be upregulated in PD patients' brains [34].",
            "Moreover, MAOB has recently received special attention due to its increased level along with reactive astrogliosis in neurodegenerative diseases, including PD [15,16,17,18,21,22,38,41]."
          ],
          "mechanism": "unknown",
          "source": "ocr_result_1_1",
          "subject": {
            "entity_id": "ent:8b2f04546fd8",
            "entity_type": "TREATMENT",
            "name": "selective inhibitors against MAOA and MAOB",
            "normalized_id": "N/A",
            "aliases": [],
            "description": "Described as being used in several in vivo studies that demonstrated DA is much preferentially degraded by MAOA compared to MAOB in the rat brain."
          },
          "object": {
            "entity_id": "ent:cd96e2edb784",
            "entity_type": "DISEASE",
            "name": "Parkinson's Disease",
            "normalized_id": "N/A",
            "aliases": [
              "PD"
            ],
            "description": "Described as the most prevalent neurodegenerative motor disorder, characterized by motor dysfunction and caused by nigrostriatal dopamine depletion."
          },
          "time_info": null
        },
        {
          "head": "MAOB",
          "relation": "contribute to",
          "tail": "Parkinson's Disease",
          "relation_type": "UNKNOWN",
          "confidence": [
            0.75,
            0.1
          ],
          "evidence": [
            "Therefore, MAOB has long been believed to contribute to PD pathophysiology through excessive DA degradation [35].",
            "These recent discoveries on the pathological role of astrocytic MAOB led us to revisit the MAOB's role in PD pathophysiology."
          ],
          "mechanism": "unknown",
          "source": "ocr_result_1_1",
          "subject": {
            "entity_id": "ent:8b2f04546fd8",
            "entity_type": "TREATMENT",
            "name": "selective inhibitors against MAOA and MAOB",
            "normalized_id": "N/A",
            "aliases": [],
            "description": "Described as being used in several in vivo studies that demonstrated DA is much preferentially degraded by MAOA compared to MAOB in the rat brain."
          },
          "object": {
            "entity_id": "ent:cd96e2edb784",
            "entity_type": "DISEASE",
            "name": "Parkinson's Disease",
            "normalized_id": "N/A",
            "aliases": [
              "PD"
            ],
            "description": "Described as the most prevalent neurodegenerative motor disorder, characterized by motor dysfunction and caused by nigrostriatal dopamine depletion."
          },
          "time_info": null
        },
        {
          "head": "MAOB",
          "relation": "involve in",
          "tail": "astrocytic GABA production",
          "relation_type": "UNKNOWN",
          "confidence": [
            0.9,
            0.05
          ],
          "evidence": [
            "Since 2014, several investigations have begun to emphasize the specific involvement of MAOB, but not MAOA, in astrocytic GABA production via the putrescine degradation route [15,16,21,38,39,40], which has been overlooked in the brain for decades."
          ],
          "mechanism": "unknown",
          "source": "ocr_result_1_1",
          "subject": {
            "entity_id": "ent:8b2f04546fd8",
            "entity_type": "TREATMENT",
            "name": "selective inhibitors against MAOA and MAOB",
            "normalized_id": "N/A",
            "aliases": [],
            "description": "Described as being used in several in vivo studies that demonstrated DA is much preferentially degraded by MAOA compared to MAOB in the rat brain."
          },
          "object": {
            "entity_id": "ent:6b62c000294a",
            "entity_type": "MECHANISM",
            "name": "astrocytic GABA production",
            "normalized_id": "N/A",
            "aliases": [],
            "description": "The specific involvement of MAOB in astrocytic GABA production via the putrescine degradation route."
          },
          "time_info": null
        },
        {
          "head": "irreversible MAOB inhibitors",
          "relation": "block",
          "tail": "excessive astrocytic GABA synthesis",
          "relation_type": "UNKNOWN",
          "confidence": [
            0.8,
            0.05
          ],
          "evidence": [
            "The therapeutic efficacy of MAOB inhibitors for PD is not attributed to a blockade of DA degradation. Instead, it is attributed to a blockade of the excessive astrocytic GABA synthesis and the aberrant tonic inhibition of DAergic neurons in the SNpc."
          ],
          "mechanism": "unknown",
          "source": "ocr_result_1_1",
          "subject": {
            "entity_id": "ent:868f31807433",
            "entity_type": "TREATMENT",
            "name": "irreversible MAOB inhibitors",
            "normalized_id": "N/A",
            "aliases": [
              "MAOB inhibitors"
            ],
            "description": "Described as being widely prescribed for PD patients as an early monotherapy or an add-on to other medications."
          },
          "object": {
            "entity_id": "ent:0d40e71352c3",
            "entity_type": "MECHANISM",
            "name": "blockade of the excessive astrocytic GABA synthesis",
            "normalized_id": "N/A",
            "aliases": [],
            "description": "The therapeutic efficacy of MAOB inhibitors for PD is attributed to a blockade of the excessive astrocytic GABA synthesis."
          },
          "time_info": null
        },
        {
          "head": "levodopa",
          "relation": "treat",
          "tail": "Parkinson's Disease",
          "relation_type": "UNKNOWN",
          "confidence": [
            0.95,
            0.01
          ],
          "evidence": [
            "Apart from levodopa, which is the most popular therapeutic agent for PD, several irreversible MAOB inhibitors have been widely prescribed for PD patients as an early monotherapy or an add-on to other medications"
          ],
          "mechanism": "unknown",
          "source": "ocr_result_1_1",
          "subject": {
            "entity_id": "ent:c876cfe5153f",
            "entity_type": "DRUG",
            "name": "levodopa",
            "normalized_id": "N/A",
            "aliases": [],
            "description": "Described as the most popular therapeutic agent for Parkinson's disease."
          },
          "object": {
            "entity_id": "ent:cd96e2edb784",
            "entity_type": "DISEASE",
            "name": "Parkinson's Disease",
            "normalized_id": "N/A",
            "aliases": [
              "PD"
            ],
            "description": "Described as the most prevalent neurodegenerative motor disorder, characterized by motor dysfunction and caused by nigrostriatal dopamine depletion."
          },
          "time_info": null
        },
        {
          "head": "irreversible MAOB inhibitors",
          "relation": "treat",
          "tail": "Parkinson's Disease",
          "relation_type": "UNKNOWN",
          "confidence": [
            0.85,
            0.01
          ],
          "evidence": [
            "several irreversible MAOB inhibitors have been widely prescribed for PD patients as an early monotherapy or an add-on to other medications",
            "This belief was further supported by a positive but limited clinical efficacy of irreversible MAOB inhibitors such as selegiline and rasagiline for PD patients [36,37]."
          ],
          "mechanism": "unknown",
          "source": "ocr_result_1_1",
          "subject": {
            "entity_id": "ent:868f31807433",
            "entity_type": "TREATMENT",
            "name": "irreversible MAOB inhibitors",
            "normalized_id": "N/A",
            "aliases": [
              "MAOB inhibitors"
            ],
            "description": "Described as being widely prescribed for PD patients as an early monotherapy or an add-on to other medications."
          },
          "object": {
            "entity_id": "ent:cd96e2edb784",
            "entity_type": "DISEASE",
            "name": "Parkinson's Disease",
            "normalized_id": "N/A",
            "aliases": [
              "PD"
            ],
            "description": "Described as the most prevalent neurodegenerative motor disorder, characterized by motor dysfunction and caused by nigrostriatal dopamine depletion."
          },
          "time_info": null
        },
        {
          "head": "selegiline",
          "relation": "treat",
          "tail": "Parkinson's Disease",
          "relation_type": "UNKNOWN",
          "confidence": [
            0.85,
            0.01
          ],
          "evidence": [
            "This belief was further supported by a positive but limited clinical efficacy of irreversible MAOB inhibitors such as selegiline and rasagiline for PD patients [36,37]."
          ],
          "mechanism": "unknown",
          "source": "ocr_result_1_1",
          "subject": {
            "entity_id": "ent:82fb4cdbc0f1",
            "entity_type": "DRUG",
            "name": "selegiline",
            "normalized_id": "N/A",
            "aliases": [],
            "description": "Described as an irreversible MAOB inhibitor with positive but limited clinical efficacy for Parkinson's disease patients."
          },
          "object": {
            "entity_id": "ent:cd96e2edb784",
            "entity_type": "DISEASE",
            "name": "Parkinson's Disease",
            "normalized_id": "N/A",
            "aliases": [
              "PD"
            ],
            "description": "Described as the most prevalent neurodegenerative motor disorder, characterized by motor dysfunction and caused by nigrostriatal dopamine depletion."
          },
          "time_info": null
        },
        {
          "head": "rasagiline",
          "relation": "treat",
          "tail": "Parkinson's Disease",
          "relation_type": "UNKNOWN",
          "confidence": [
            0.85,
            0.01
          ],
          "evidence": [
            "This belief was further supported by a positive but limited clinical efficacy of irreversible MAOB inhibitors such as selegiline and rasagiline for PD patients [36,37]."
          ],
          "mechanism": "unknown",
          "source": "ocr_result_1_1",
          "subject": {
            "entity_id": "ent:a48a954a3c52",
            "entity_type": "DRUG",
            "name": "rasagiline",
            "normalized_id": "N/A",
            "aliases": [],
            "description": "Described as an irreversible MAOB inhibitor with positive but limited clinical efficacy for Parkinson's disease patients."
          },
          "object": {
            "entity_id": "ent:cd96e2edb784",
            "entity_type": "DISEASE",
            "name": "Parkinson's Disease",
            "normalized_id": "N/A",
            "aliases": [
              "PD"
            ],
            "description": "Described as the most prevalent neurodegenerative motor disorder, characterized by motor dysfunction and caused by nigrostriatal dopamine depletion."
          },
          "time_info": null
        },
        {
          "head": "DA depletion",
          "relation": "cause",
          "tail": "Parkinson's Disease",
          "relation_type": "UNKNOWN",
          "confidence": [
            0.9,
            0.7
          ],
          "evidence": [
            "PD is the most prevalent neurodegenerative motor disorder, which is caused by nigrostriatal DA depletion [23]."
          ],
          "mechanism": "unknown",
          "source": "ocr_result_1_1",
          "subject": {
            "entity_id": "ent:c0c759a4bb48",
            "entity_type": "MECHANISM",
            "name": "nigrostriatal DA depletion",
            "normalized_id": "N/A",
            "aliases": [],
            "description": "Described as the cause of Parkinson's disease, specifically nigrostriatal DA depletion."
          },
          "object": {
            "entity_id": "ent:cd96e2edb784",
            "entity_type": "DISEASE",
            "name": "Parkinson's Disease",
            "normalized_id": "N/A",
            "aliases": [
              "PD"
            ],
            "description": "Described as the most prevalent neurodegenerative motor disorder, characterized by motor dysfunction and caused by nigrostriatal dopamine depletion."
          },
          "time_info": null
        },
        {
          "head": "MAOB",
          "relation": "catalyze",
          "tail": "DA deamination",
          "relation_type": "UNKNOWN",
          "confidence": [
            0.65,
            0.05
          ],
          "evidence": [
            "DA is traditionally known to be degraded by both MAOA and MAOB.",
            "On the other hand, some other studies using selegiline also demonstrated that MAOB catalyzes DA as a substrate in rats [45,46,47].",
            "Notably, an investigation with the homogenates of brain tissues from various species by Garrick and Murphy demonstrated that DA was found to be deaminated largely by MAOA in the rat brains, whereas by MAOB in the brains of humans and vervet [46].",
            "Despite the controversies on the contributions of MAOA and MAOB to DA degradation, it has been traditionally and until now generally believed that both MAOA and MAOB are equally active towards DA degradation [35,48,49,50,51]."
          ],
          "mechanism": "unknown",
          "source": "ocr_result_1_1",
          "subject": {
            "entity_id": "ent:8b2f04546fd8",
            "entity_type": "TREATMENT",
            "name": "selective inhibitors against MAOA and MAOB",
            "normalized_id": "N/A",
            "aliases": [],
            "description": "Described as being used in several in vivo studies that demonstrated DA is much preferentially degraded by MAOA compared to MAOB in the rat brain."
          },
          "object": {
            "entity_id": "ent:9d29d3782591",
            "entity_type": "MECHANISM",
            "name": "DA deamination",
            "normalized_id": "N/A",
            "aliases": [],
            "description": "The affinity of DA deamination was 2.5-fold higher to MAOA than MAOB."
          },
          "time_info": null
        }
      ]
    },
    "ocr_result_1_2": {
      "id": "ocr_result_1_2",
      "name": "",
      "meta": {
        "text": "Once DA is released from the DAergic presynaptic terminals, it binds to and activates DA receptors. After the receptor activation, DA quickly becomes unbound from its receptors and is absorbed back into the presynaptic neurons through the DA transporter (DAT) [52]. There are two main metabolic pathways for degrading DA. First, MAO catalyzes the conversion of DA to 3,4-dihydroxyphenylacetaldehyde (DOPAL), which is, in turn, metabolized into 3,4-dihydroxyphenylacetic acid (DOPAC) by aldehyde dehydrogenase (ALDH). Finally, DOPAC is decomposed into an inert metabolite homovanillic acid (HVA) by catechol-o-methyltransferase (COMT) [53,54]. Second, COMT catalyzes the conversion of DA to 3-methoxytyramine (3-MT), which is, in turn, metabolized into 3-methoxy-4-hydroxyphenylacetaldehyde (MHPA) by MAO. Finally, MHPA is also decomposed into the final product HVA via ALDH [53,54] (Figure 1). The enzymes in the DA-degradation pathway are expressed in both DAergic presynaptic neurons and astrocytes. However, DATs are differentially expressed in DAergic presynaptic neurons and astrocytes: high in neurons but low in astrocytes [55,56]. This paradoxical low expression of DAT in the astrocytes of the nigrostriatal DA pathway [55,56] has implicated the limited participation of astrocytes in DA degradation in various brain regions, including the striatum, nucleus accumbens, and substantia nigra.\n\nDA degradation is particularly important in the pathophysiology of PD, in which DA deficiency is the key etiology. Among the DA-degrading enzymes, MAOB expression has been reported to be increased in PD patients, while MAOA expression has not [57,58,59]. Therefore, the augmented MAOB-mediated DA degradation has been accepted to contribute to PD pathology [51]. Moreover, H_{2}O_{2} is believed to be produced during the MAOB-mediated DA degradation, which could also exacerbate DAergic neuronal dysfunction and degeneration in PD [34,59]. These findings have been somewhat supported by a positive but limited clinical efficacy of irreversible MAOB inhibitors such as selegiline and rasagiline [36,37,60], while the controversies on whether MAOB is responsible for PD pathology through DA degradation in vivo have been left unresolved.\n\nInt.J.Mol.Sci.2022,23,4453\n\n![img-0.jpeg](img-0.jpeg)\nFigure 1. The traditional view on MAOB as a DA- and MPTP-metabolizing enzyme. MAOA and MAOB have been traditionally believed to be responsible for dopamine (DA) metabolism. DA taken up via DA transporter (DAT) is known to be metabolized into homovanillic acid (HVA) through two different pathways. First, MAO converts DA to 3,4-dihydroxyphenylacetaldehyde (DOPAL), which is then converted to 3,4-dihydroxyphenylacetic acid (DOPAC) by aldehyde dehydrogenases (ALDH). DOPAC is finally converted to HVA through catechol-o-methyltransferase (COMT). Second, COMT converts DA to 3-methoxytyramine (3-MT), which is then converted to 3-methoxy-4-hydroxyphenylacetaldehyde (MHPA) by MAO. Then, MHPA is finally converted to HVA by ALDH. Due to the presence of these enzymes in both DAergic presynaptic terminals and astrocytes, it has been assumed that DA is degraded by MAOA and MAOB in both cell types.\n\n# 2.2. Past and Recent Discoveries against the Belief of MAOB as a DA-Degrading Enzyme\n\nIn rodents, accumulating lines of evidence have demonstrated that MAOB is not engaged in regulating DA levels in vivo. Fornai et al. showed that there was no difference in striatal DA levels between MAOB-deficient and wild-type mice [61], implicating that MAOB does not contribute to DA metabolism in the striatum. Consistently, the administration of MAOB inhibitors such as selegiline has been reported to be unable to alter the efflux of DA in the striatum and nucleus accumbens of rats [62-64]. On the other hand, acute pharmacological inhibition of MAOA with clorgiline reduced DA metabolism [62,64]. Moreover, another study reported that it was not MAOB inhibition but MAOA inhibition that dramatically blocked DA degradation in rat models of PD [65]. These results imply that it is not MAOB but MAOA which contributes to DA metabolism. Furthermore, people deficient in the MAOB gene show no apparent phenotypes, whereas people deficient in the MAOA gene display severe mental retardation and psychological defects [66], suggesting that MAOB is less likely to participate in DA degradation in humans.\n\nIn support of these previous reports, a recent report, employing the latest technologies, provided more compelling lines of evidence demonstrating that not MAOB but MAOA is critically engaged in DA degradation, at least in rodents [39]. Cho et al. utilized fast cyclic voltammetry (FSCV) and multiple trains of five cyclic square wave voltammetry (M-CSWV) to electrochemically monitor the phasic and tonic DA currents evoked by electrical stimulation of the nigrostriatal pathway in the in vivo rat striatum, respectively. Both phasic and basal DA levels were only affected by MAOA inhibition but not by MAOB inhibition, indicating that not MAOB but MAOA contributes to in vivo DA metabolism [39]. This study also adopted a newly developed potent, reversible, and selective MAOB inhibitor, KDS2010 [16], which could circumvent the limitations of previous studies using the irreversible MAOB inhibitor, selegiline. These findings were also confirmed by ex vivo DA imaging using the latest GRABDA2m sensor [39].",
        "source": "ocr_result_1"
      },
      "entities": [
        {
          "entity_id": "ent:fbd15b66f781",
          "entity_type": "GENE",
          "name": "MAOB",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "N/A"
        },
        {
          "entity_id": "ent:4340c40414b5",
          "entity_type": "GENE",
          "name": "MAOA",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "N/A"
        },
        {
          "entity_id": "ent:e88a80192248",
          "entity_type": "PATHWAY",
          "name": "nigrostriatal DA pathway",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Pathway mentioned in the context of low DAT expression in astrocytes."
        },
        {
          "entity_id": "ent:174e8f4dc004",
          "entity_type": "DISEASE",
          "name": "Parkinson's disease",
          "normalized_id": "N/A",
          "aliases": [
            "PD"
          ],
          "description": "A condition described as having DA deficiency as its key etiology, with pathophysiology involving DA degradation and MAOB expression changes."
        },
        {
          "entity_id": "ent:526c1aea41db",
          "entity_type": "TREATMENT",
          "name": "selegiline",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Described as an irreversible MAOB inhibitor with positive but limited clinical efficacy in PD, and used in studies to examine DA efflux."
        },
        {
          "entity_id": "ent:9eac5c3c60d3",
          "entity_type": "TREATMENT",
          "name": "rasagiline",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Described as an irreversible MAOB inhibitor with positive but limited clinical efficacy in PD."
        },
        {
          "entity_id": "ent:74a134e4459c",
          "entity_type": "TREATMENT",
          "name": "clorgiline",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Described as an acute pharmacological inhibitor of MAOA that reduced DA metabolism in studies."
        },
        {
          "entity_id": "ent:338d1acd0d34",
          "entity_type": "TREATMENT",
          "name": "KDS2010",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Described as a newly developed potent, reversible, and selective MAOB inhibitor used in a study to circumvent limitations of irreversible inhibitors."
        },
        {
          "entity_id": "ent:696e6a9560c0",
          "entity_type": "MECHANISM",
          "name": "binds to and activates DA receptors",
          "normalized_id": "N/A",
          "aliases": [
            "receptor activation"
          ],
          "description": "DA binds to and activates DA receptors after release from presynaptic terminals."
        },
        {
          "entity_id": "ent:ee703170e0fd",
          "entity_type": "MECHANISM",
          "name": "absorbed back into the presynaptic neurons through the DA transporter (DAT)",
          "normalized_id": "N/A",
          "aliases": [
            "reuptake"
          ],
          "description": "DA is taken back into presynaptic neurons via the DA transporter after unbinding from receptors."
        },
        {
          "entity_id": "ent:fc1ace017a01",
          "entity_type": "MECHANISM",
          "name": "metabolic pathways for degrading DA",
          "normalized_id": "N/A",
          "aliases": [
            "DA degradation",
            "DA degradation pathway",
            "DA metabolism",
            "DA-degradation pathway",
            "regulating DA levels"
          ],
          "description": "Two main pathways exist for the degradation of dopamine."
        },
        {
          "entity_id": "ent:0fa19650986a",
          "entity_type": "MECHANISM",
          "name": "MAO catalyzes the conversion of DA to 3,4-dihydroxyphenylacetaldehyde (DOPAL)",
          "normalized_id": "N/A",
          "aliases": [
            "MAO converts DA to 3,4-dihydroxyphenylacetaldehyde (DOPAL)",
            "MAO-mediated DA degradation"
          ],
          "description": "MAO enzyme catalyzes the first step in one DA degradation pathway, converting DA to DOPAL."
        },
        {
          "entity_id": "ent:a2d86d265057",
          "entity_type": "MECHANISM",
          "name": "metabolized into 3,4-dihydroxyphenylacetic acid (DOPAC) by aldehyde dehydrogenase (ALDH)",
          "normalized_id": "N/A",
          "aliases": [
            "converted to 3,4-dihydroxyphenylacetic acid (DOPAC) by aldehyde dehydrogenases (ALDH)"
          ],
          "description": "DOPAL is metabolized into DOPAC by the enzyme aldehyde dehydrogenase."
        },
        {
          "entity_id": "ent:4cd3003f48a9",
          "entity_type": "MECHANISM",
          "name": "decomposed into an inert metabolite homovanillic acid (HVA) by catechol-o-methyltransferase (COMT)",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "DOPAC is decomposed into the final inert metabolite HVA by the enzyme COMT."
        },
        {
          "entity_id": "ent:0719a2681e94",
          "entity_type": "MECHANISM",
          "name": "COMT catalyzes the conversion of DA to 3-methoxytyramine (3-MT)",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "COMT enzyme catalyzes the conversion of DA to 3-MT in the second degradation pathway."
        },
        {
          "entity_id": "ent:7c4034cd6d36",
          "entity_type": "MECHANISM",
          "name": "metabolized into 3-methoxy-4-hydroxyphenylacetaldehyde (MHPA) by MAO",
          "normalized_id": "N/A",
          "aliases": [
            "converted to 3-methoxy-4-hydroxyphenylacetaldehyde (MHPA) by MAO"
          ],
          "description": "3-MT is metabolized into MHPA by the MAO enzyme."
        },
        {
          "entity_id": "ent:05269dba9f42",
          "entity_type": "MECHANISM",
          "name": "decomposed into the final product HVA via ALDH",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "MHPA is decomposed into the final product HVA by ALDH."
        },
        {
          "entity_id": "ent:d8bcfc852f50",
          "entity_type": "MECHANISM",
          "name": "augmented MAOB-mediated DA degradation",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Increased degradation of DA mediated by MAOB enzyme, reported to contribute to PD pathology."
        },
        {
          "entity_id": "ent:3dcd95ce5fb2",
          "entity_type": "MECHANISM",
          "name": "H_{2}O_{2} is believed to be produced during the MAOB-mediated DA degradation",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Hydrogen peroxide production is associated with MAOB-mediated dopamine degradation."
        },
        {
          "entity_id": "ent:82be94fab14e",
          "entity_type": "MECHANISM",
          "name": "metabolized into homovanillic acid (HVA) through two different pathways",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "DA taken up via DAT is metabolized into HVA via two distinct enzymatic pathways."
        },
        {
          "entity_id": "ent:facce41b2da2",
          "entity_type": "MECHANISM",
          "name": "converted to HVA through catechol-o-methyltransferase (COMT)",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "DOPAC is finally converted to HVA by the enzyme COMT."
        },
        {
          "entity_id": "ent:afd4ddc89e96",
          "entity_type": "MECHANISM",
          "name": "COMT converts DA to 3-methoxytyramine (3-MT)",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "COMT enzyme converts dopamine to 3-MT in the second degradation pathway."
        },
        {
          "entity_id": "ent:7732af422d76",
          "entity_type": "MECHANISM",
          "name": "converted to HVA by ALDH",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "MHPA is finally converted to HVA by the enzyme ALDH."
        },
        {
          "entity_id": "ent:04bdd13524d0",
          "entity_type": "MECHANISM",
          "name": "DA is degraded by MAOA and MAOB",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "It has been assumed dopamine degradation involves both MAOA and MAOB enzymes in neurons and astrocytes."
        },
        {
          "entity_id": "ent:76b0c7bc7f78",
          "entity_type": "MECHANISM",
          "name": "reduced DA metabolism",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Acute pharmacological inhibition of MAOA with clorgiline reduces dopamine metabolism."
        },
        {
          "entity_id": "ent:6e45dcd612d2",
          "entity_type": "MECHANISM",
          "name": "blocked DA degradation",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "MAOA inhibition, not MAOB inhibition, dramatically blocked dopamine degradation in rat PD models."
        },
        {
          "entity_id": "ent:f7e110997300",
          "entity_type": "MECHANISM",
          "name": "participate in DA degradation",
          "normalized_id": "N/A",
          "aliases": [
            "contributes to DA metabolism",
            "engaged in DA degradation"
          ],
          "description": "MAOB is less likely to participate in dopamine degradation in humans, based on gene deficiency phenotypes."
        },
        {
          "entity_id": "ent:f5a8417509e8",
          "entity_type": "MECHANISM",
          "name": "contributes to in vivo DA metabolism",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Both phasic and basal DA levels were affected only by MAOA inhibition, indicating MAOA contributes to in vivo DA metabolism."
        },
        {
          "entity_id": "ent:24cfbd2539f1",
          "entity_type": "PROTEIN",
          "name": "DA receptors",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Receptors that DA binds to and activates after release from presynaptic terminals."
        },
        {
          "entity_id": "ent:40a2622e6fc4",
          "entity_type": "PROTEIN",
          "name": "DA transporter",
          "normalized_id": "N/A",
          "aliases": [
            "DAT",
            "DATs"
          ],
          "description": "Transporter that absorbs DA back into presynaptic neurons after receptor activation."
        },
        {
          "entity_id": "ent:a3105fc8b290",
          "entity_type": "PROTEIN",
          "name": "MAO",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Enzyme that catalyzes the conversion of DA to DOPAL in the first metabolic pathway."
        },
        {
          "entity_id": "ent:ef678d69e1e1",
          "entity_type": "PROTEIN",
          "name": "catechol-o-methyltransferase",
          "normalized_id": "N/A",
          "aliases": [
            "COMT"
          ],
          "description": "Enzyme that decomposes DOPAC into homovanillic acid (HVA) in the first pathway."
        },
        {
          "entity_id": "ent:ae484a5e2a6c",
          "entity_type": "PROTEIN",
          "name": "aldehyde dehydrogenases",
          "normalized_id": "N/A",
          "aliases": [
            "aldehyde dehydrogenase",
            "ALDH"
          ],
          "description": "Enzymes that convert DOPAL to DOPAC in the first DA degradation pathway."
        }
      ],
      "relations": []
    },
    "ocr_result_1_3": {
      "id": "ocr_result_1_3",
      "name": "",
      "meta": {
        "text": "The contribution of MAOB to DA degradation in the brain could be ascribed to the difference in the experimental conditions, depending on whether an experiment is performed in vitro or in vivo. Several in vitro studies demonstrated that MAOB also utilizes DA as a substrate in both rats (Km = ~340 M) [67] and humans (Km = ~210--230 M) [68], indicating the capability of MAOB in DA degradation in vitro. In the living brain, however, DA needs to first enter the astrocytes, where MAOB is mainly localized, for being deaminated by MAOB. However, DAT expression is relatively low in the astrocytes of various brain regions, including the striatum, nucleus accumbens, and SNpc [55,56], whereas DAT is mainly expressed in the DAergic neurons. Consequently, regardless of MAOB's ability to metabolize DA in vitro, the contribution of astrocytic MAOB to DA degradation is negligible in the living brain. Taken together, the accumulating lines of evidence call for redefining the role of MAOB in the brain by excluding DA metabolism in the PD pathology.\n\n### 2.3. Traditional Views on MAOB as an MPTP-Metabolizing Enzyme\n\nAnother traditional view of MAOB's action originates from an unfortunate accident. The neurotoxicity of MPTP has been known since 1976 when Barry Kidston, a graduate student in chemistry, self-administered MPTP and began to show parkinsonian symptoms within three days. The autopsy of his brain further revealed the disruption of DAergic neurons and the existence of Lewy bodies in the SNpc [69]. Since MPTP was first reported to cause PD in humans [69], fundamental mechanisms have been studied on how MPTP causes toxicity and motor dysfunction in PD. Now the MPTP-induced mouse model is one of the most widely utilized PD models [70].\n\nMPTP has long been recognized to be a non-toxic substance. However, once MPTP enters the brain, it is believed to be metabolized to a toxic cation MPP+ through MAOB in astrocytes [71]. MPP+ is thought to be taken up by DAergic neurons through DAT and destroys them [72] (Figure 1). Moreover, pharmacological blockade of MAOB inhibitors has been well documented to prevent MPTP-induced PD pathology and parkinsonian motor symptoms [36,73]. These findings led researchers to pay attention only to the MAOB's role in the conversion of MPTP to MPP+ in the MPTP model, while other possible actions of MAOB in the MPTP-mediated PD-like pathology have been overlooked.\n\nOn the other hand, in the MPTP mouse model, it was recently demonstrated that the post-treatment regime of selegiline administration, which starts 3 days after MPTP, significantly alleviated MPTP-induced PD-like pathology and motor symptoms [38]. Since MPTP is known to be converted to MPP+ within 3 days [74], any alleviating effect by selegiline should not be attributed to MAOB's action of MPP+ conversion. This finding suggests that selegiline may act in ways other than blocking the conversion of MPTP to MPP+.\n\n3. Recent Discoveries on MAOB as the Astrocytic GABA- and H_{2}O_{2}-Synthesizing Enzyme\n\nIn contrast to the traditional view on the role of MAOB via DA degradation and MPTP conversion in the pathophysiology of PD, MAOB has been demonstrated as a critical enzyme for astrocytic GABA synthesis in several brain areas under physiological conditions, including the cerebellum [40,75] and striatum [39]. Previous reports have revealed that astrocytic GABA is synthesized from putrescine through several steps of enzymatic actions, including MAOB [15,40]. The astrocytic GABA is tonically released through a Ca2+-activated anion channel Bestrophin-1 (Best1) [76] and binds to extrasynaptic GABA_{A} receptors to tonically inhibit the neighboring neuronal activity [21,38,40,76]. The physiological level of MAOB-mediated tonic inhibition varies by brain region, with high levels in the cerebellum and striatum and low levels in the cortex and hippocampus [77]. Notably, MAOA was not responsible for astrocytic GABA-mediated tonic inhibition in the striatum [39]. These new discoveries highlight the distinct role of MAOB, but not MAOA, in the astrocytic GABA synthesis and tonic inhibition of neurons under physiological conditions.\n\nUnder pathological conditions, including reactive astrogliosis, which is frequently seen in the brains with PD, SNpc reactive astrocytes show high expression of MAOB [21,22,41]. In detail, reactive astrocytes aberrantly synthesize GABA through the enzymatic action of MAOB, leading to excessive tonic inhibition of neighboring DAergic neurons in the SNpc. The aberrant suppression of DAergic neuronal activity leads to a substantial decrease in tyrosine hydroxylase (TH), the key DA-synthesizing enzyme. Notably, the reduction of TH level could be reversible when the DAergic neurons are aberrantly suppressed but still alive. The reduced TH expression causes a deficiency of DA synthesis, which can lead to parkinsonian motor symptoms (Figure 2) [21]. A similar phenomenon of higher MAOB expression and astrocytic GABA in reactive astrocytes has also been reported in the hippocampus of AD brains [15,16,78,79]. These recent discoveries underscore the substantial contribution of astrocytic MAOB in PD pathology through aberrant GABA synthesis.",
        "source": "ocr_result_1"
      },
      "entities": [
        {
          "entity_id": "ent:1c13ff924d3f",
          "entity_type": "TREATMENT",
          "name": "pharmacological blockade of MAOB inhibitors",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A pharmacological blockade described as being well documented to prevent MPTP-induced PD pathology and parkinsonian motor symptoms."
        },
        {
          "entity_id": "ent:e6a70fe46bd0",
          "entity_type": "TREATMENT",
          "name": "selegiline administration",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A post-treatment regime starting 3 days after MPTP administration that significantly alleviated MPTP-induced PD-like pathology and motor symptoms in a mouse model."
        },
        {
          "entity_id": "ent:1b34d319268f",
          "entity_type": "GENE",
          "name": "MAOB",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Enzyme described as contributing to DA degradation in the brain, localized mainly in astrocytes, and involved in MPTP metabolism and astrocytic GABA synthesis."
        },
        {
          "entity_id": "ent:6d79b738329a",
          "entity_type": "GENE",
          "name": "DAT",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Protein with relatively low expression in astrocytes but mainly expressed in DAergic neurons, involved in the uptake of MPP+."
        },
        {
          "entity_id": "ent:7b050232663a",
          "entity_type": "GENE",
          "name": "MAOA",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Enzyme noted as not responsible for astrocytic GABA-mediated tonic inhibition in the striatum."
        },
        {
          "entity_id": "ent:f33241cb235b",
          "entity_type": "PROTEIN",
          "name": "Bestrophin-1",
          "normalized_id": "N/A",
          "aliases": [
            "Best1"
          ],
          "description": "Ca2+-activated anion channel through which astrocytic GABA is tonically released."
        },
        {
          "entity_id": "ent:d65ad5dbdde6",
          "entity_type": "PROTEIN",
          "name": "tyrosine hydroxylase",
          "normalized_id": "N/A",
          "aliases": [
            "TH"
          ],
          "description": "Key DA-synthesizing enzyme whose reduction in level is caused by aberrant suppression of DAergic neuronal activity."
        },
        {
          "entity_id": "ent:278c211767cd",
          "entity_type": "SYMPTOM",
          "name": "motor dysfunction",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Motor dysfunction is mentioned as part of the toxicity caused by MPTP in Parkinson's disease."
        },
        {
          "entity_id": "ent:35552a408dee",
          "entity_type": "SYMPTOM",
          "name": "parkinsonian motor symptoms",
          "normalized_id": "N/A",
          "aliases": [
            "motor symptoms",
            "parkinsonian symptoms",
            "PD",
            "PD pathology",
            "PD-like pathology"
          ],
          "description": "Motor symptoms associated with Parkinson's disease that can be prevented by pharmacological blockade of MAOB inhibitors in MPTP-induced pathology."
        },
        {
          "entity_id": "ent:d62f37a1635f",
          "entity_type": "DISEASE",
          "name": "PD-like pathology",
          "normalized_id": "N/A",
          "aliases": [
            "parkinsonian motor symptoms",
            "parkinsonian symptoms",
            "PD",
            "PD pathology"
          ],
          "description": "Pathology alleviated by post-treatment selegiline administration in the MPTP mouse model."
        },
        {
          "entity_id": "ent:f9c154374a1d",
          "entity_type": "DISEASE",
          "name": "AD",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Condition in which brains show higher MAOB expression and astrocytic GABA in reactive astrocytes in the hippocampus."
        },
        {
          "entity_id": "ent:f1e37c2e4678",
          "entity_type": "MECHANISM",
          "name": "DA degradation",
          "normalized_id": "N/A",
          "aliases": [
            "degradation"
          ],
          "description": "Process involving the breakdown of dopamine, discussed in the context of MAOB's role in vitro and in the living brain."
        },
        {
          "entity_id": "ent:6251b566bcc9",
          "entity_type": "MECHANISM",
          "name": "deaminated",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Chemical process of removing an amine group, specifically described as how MAOB acts on dopamine after it enters astrocytes."
        },
        {
          "entity_id": "ent:0402bc63bf6f",
          "entity_type": "MECHANISM",
          "name": "DA metabolism",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "The chemical processes involving dopamine, mentioned as a role of MAOB to be excluded in PD pathology."
        },
        {
          "entity_id": "ent:89fda2b6831c",
          "entity_type": "MECHANISM",
          "name": "metabolized",
          "normalized_id": "N/A",
          "aliases": [
            "conversion",
            "metabolism",
            "metabolize",
            "MPP+ conversion"
          ],
          "description": "Process of chemical transformation, specifically MPTP being converted to the toxic MPP+ by MAOB in astrocytes."
        },
        {
          "entity_id": "ent:40a89776e556",
          "entity_type": "MECHANISM",
          "name": "taken up",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Cellular uptake process, specifically MPP+ being transported into dopaminergic neurons via DAT."
        },
        {
          "entity_id": "ent:331988bbeeb3",
          "entity_type": "MECHANISM",
          "name": "destroys",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Process of causing damage or death, specifically MPP+ destroying dopaminergic neurons after uptake."
        },
        {
          "entity_id": "ent:1c2ac5147c3c",
          "entity_type": "MECHANISM",
          "name": "pharmacological blockade",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Inhibition by drugs, specifically of MAOB to prevent MPTP-induced PD pathology and symptoms."
        },
        {
          "entity_id": "ent:9aae8623d5d7",
          "entity_type": "MECHANISM",
          "name": "blocking the conversion",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Inhibitory action preventing the chemical transformation of MPTP to MPP+, a proposed action of selegiline."
        },
        {
          "entity_id": "ent:674c5ee16cc2",
          "entity_type": "MECHANISM",
          "name": "GABA synthesis",
          "normalized_id": "N/A",
          "aliases": [
            "synthesis",
            "synthesize",
            "synthesized",
            "synthesizing"
          ],
          "description": "Biosynthetic process for producing GABA, identified as a critical enzymatic role for MAOB in astrocytes under physiological conditions."
        },
        {
          "entity_id": "ent:bdd05ac4eac7",
          "entity_type": "MECHANISM",
          "name": "tonically inhibit",
          "normalized_id": "N/A",
          "aliases": [
            "tonic inhibition"
          ],
          "description": "Continuous inhibitory action, where astrocytic GABA binds to extrasynaptic GABA_A receptors to suppress neighboring neuronal activity."
        },
        {
          "entity_id": "ent:0944d9619277",
          "entity_type": "MECHANISM",
          "name": "aberrant suppression",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Abnormal inhibitory process leading to decreased activity of dopaminergic neurons in the SNpc, caused by excessive GABA."
        },
        {
          "entity_id": "ent:19d56a8ea9b0",
          "entity_type": "MECHANISM",
          "name": "aberrant GABA synthesis",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Abnormal production of GABA, identified as the mechanism through which astrocytic MAOB substantially contributes to PD pathology."
        }
      ],
      "relations": [
        {
          "head": "MAOB",
          "relation": "utilize",
          "tail": "DA",
          "relation_type": "UNKNOWN",
          "confidence": [
            0.85,
            0.05
          ],
          "evidence": [
            "Several in vitro studies demonstrated that MAOB also utilizes DA as a substrate in both rats (Km = ~340 M) [67] and humans (Km = ~210--230 M) [68], indicating the capability of MAOB in DA degradation in vitro."
          ],
          "mechanism": "unknown",
          "source": "ocr_result_1_3",
          "subject": {
            "entity_id": "ent:1b34d319268f",
            "entity_type": "GENE",
            "name": "MAOB",
            "normalized_id": "N/A",
            "aliases": [],
            "description": "Enzyme described as contributing to DA degradation in the brain, localized mainly in astrocytes, and involved in MPTP metabolism and astrocytic GABA synthesis."
          },
          "object": {
            "entity_id": "ent:0402bc63bf6f",
            "entity_type": "MECHANISM",
            "name": "DA metabolism",
            "normalized_id": "N/A",
            "aliases": [],
            "description": "The chemical processes involving dopamine, mentioned as a role of MAOB to be excluded in PD pathology."
          },
          "time_info": null
        },
        {
          "head": "MAOB",
          "relation": "deaminate",
          "tail": "DA",
          "relation_type": "UNKNOWN",
          "confidence": [
            0.4,
            0.05
          ],
          "evidence": [
            "In the living brain, however, DA needs to first enter the astrocytes, where MAOB is mainly localized, for being deaminated by MAOB.",
            "Consequently, regardless of MAOB's ability to metabolize DA in vitro, the contribution of astrocytic MAOB to DA degradation is negligible in the living brain."
          ],
          "mechanism": "unknown",
          "source": "ocr_result_1_3",
          "subject": {
            "entity_id": "ent:1b34d319268f",
            "entity_type": "GENE",
            "name": "MAOB",
            "normalized_id": "N/A",
            "aliases": [],
            "description": "Enzyme described as contributing to DA degradation in the brain, localized mainly in astrocytes, and involved in MPTP metabolism and astrocytic GABA synthesis."
          },
          "object": {
            "entity_id": "ent:0402bc63bf6f",
            "entity_type": "MECHANISM",
            "name": "DA metabolism",
            "normalized_id": "N/A",
            "aliases": [],
            "description": "The chemical processes involving dopamine, mentioned as a role of MAOB to be excluded in PD pathology."
          },
          "time_info": null
        },
        {
          "head": "MAOB inhibitors",
          "relation": "prevent",
          "tail": "parkinsonian motor symptoms",
          "relation_type": "UNKNOWN",
          "confidence": [
            0.9,
            0.1
          ],
          "evidence": [
            "Moreover, pharmacological blockade of MAOB inhibitors has been well documented to prevent MPTP-induced PD pathology and parkinsonian motor symptoms [36,73]."
          ],
          "mechanism": "unknown",
          "source": "ocr_result_1_3",
          "subject": {
            "entity_id": "ent:1b34d319268f",
            "entity_type": "GENE",
            "name": "MAOB",
            "normalized_id": "N/A",
            "aliases": [],
            "description": "Enzyme described as contributing to DA degradation in the brain, localized mainly in astrocytes, and involved in MPTP metabolism and astrocytic GABA synthesis."
          },
          "object": {
            "entity_id": "ent:35552a408dee",
            "entity_type": "SYMPTOM",
            "name": "parkinsonian motor symptoms",
            "normalized_id": "N/A",
            "aliases": [
              "motor symptoms",
              "parkinsonian symptoms",
              "PD",
              "PD pathology",
              "PD-like pathology"
            ],
            "description": "Motor symptoms associated with Parkinson's disease that can be prevented by pharmacological blockade of MAOB inhibitors in MPTP-induced pathology."
          },
          "time_info": null
        },
        {
          "head": "selegiline administration",
          "relation": "alleviate",
          "tail": "MPTP-induced PD-like pathology",
          "relation_type": "UNKNOWN",
          "confidence": [
            0.75,
            0.05
          ],
          "evidence": [
            "On the other hand, in the MPTP mouse model, it was recently demonstrated that the post-treatment regime of selegiline administration, which starts 3 days after MPTP, significantly alleviated MPTP-induced PD-like pathology and motor symptoms [38]."
          ],
          "mechanism": "unknown",
          "source": "ocr_result_1_3",
          "subject": {
            "entity_id": "ent:e6a70fe46bd0",
            "entity_type": "TREATMENT",
            "name": "selegiline administration",
            "normalized_id": "N/A",
            "aliases": [],
            "description": "A post-treatment regime starting 3 days after MPTP administration that significantly alleviated MPTP-induced PD-like pathology and motor symptoms in a mouse model."
          },
          "object": {
            "entity_id": "ent:d62f37a1635f",
            "entity_type": "DISEASE",
            "name": "PD-like pathology",
            "normalized_id": "N/A",
            "aliases": [
              "parkinsonian motor symptoms",
              "parkinsonian symptoms",
              "PD",
              "PD pathology"
            ],
            "description": "Pathology alleviated by post-treatment selegiline administration in the MPTP mouse model."
          },
          "time_info": null
        },
        {
          "head": "selegiline administration",
          "relation": "alleviate",
          "tail": "motor dysfunction",
          "relation_type": "UNKNOWN",
          "confidence": [
            0.75,
            0.05
          ],
          "evidence": [
            "On the other hand, in the MPTP mouse model, it was recently demonstrated that the post-treatment regime of selegiline administration, which starts 3 days after MPTP, significantly alleviated MPTP-induced PD-like pathology and motor symptoms [38]."
          ],
          "mechanism": "unknown",
          "source": "ocr_result_1_3",
          "subject": {
            "entity_id": "ent:e6a70fe46bd0",
            "entity_type": "TREATMENT",
            "name": "selegiline administration",
            "normalized_id": "N/A",
            "aliases": [],
            "description": "A post-treatment regime starting 3 days after MPTP administration that significantly alleviated MPTP-induced PD-like pathology and motor symptoms in a mouse model."
          },
          "object": {
            "entity_id": "ent:278c211767cd",
            "entity_type": "SYMPTOM",
            "name": "motor dysfunction",
            "normalized_id": "N/A",
            "aliases": [],
            "description": "Motor dysfunction is mentioned as part of the toxicity caused by MPTP in Parkinson's disease."
          },
          "time_info": null
        },
        {
          "head": "MAOB",
          "relation": "synthesize",
          "tail": "GABA",
          "relation_type": "UNKNOWN",
          "confidence": [
            0.95,
            0.05
          ],
          "evidence": [
            "MAOB has been demonstrated as a critical enzyme for astrocytic GABA synthesis in several brain areas under physiological conditions, including the cerebellum [40,75] and striatum [39].",
            "Previous reports have revealed that astrocytic GABA is synthesized from putrescine through several steps of enzymatic actions, including MAOB [15,40]."
          ],
          "mechanism": "unknown",
          "source": "ocr_result_1_3",
          "subject": {
            "entity_id": "ent:1b34d319268f",
            "entity_type": "GENE",
            "name": "MAOB",
            "normalized_id": "N/A",
            "aliases": [],
            "description": "Enzyme described as contributing to DA degradation in the brain, localized mainly in astrocytes, and involved in MPTP metabolism and astrocytic GABA synthesis."
          },
          "object": {
            "entity_id": "ent:19d56a8ea9b0",
            "entity_type": "MECHANISM",
            "name": "aberrant GABA synthesis",
            "normalized_id": "N/A",
            "aliases": [],
            "description": "Abnormal production of GABA, identified as the mechanism through which astrocytic MAOB substantially contributes to PD pathology."
          },
          "time_info": null
        },
        {
          "head": "pharmacological blockade of MAOB inhibitors",
          "relation": "prevent",
          "tail": "parkinsonian motor symptoms",
          "relation_type": "UNKNOWN",
          "confidence": [
            0.9,
            0.1
          ],
          "evidence": [
            "Moreover, pharmacological blockade of MAOB inhibitors has been well documented to prevent MPTP-induced PD pathology and parkinsonian motor symptoms [36,73]."
          ],
          "mechanism": "unknown",
          "source": "ocr_result_1_3",
          "subject": {
            "entity_id": "ent:1c2ac5147c3c",
            "entity_type": "MECHANISM",
            "name": "pharmacological blockade",
            "normalized_id": "N/A",
            "aliases": [],
            "description": "Inhibition by drugs, specifically of MAOB to prevent MPTP-induced PD pathology and symptoms."
          },
          "object": {
            "entity_id": "ent:35552a408dee",
            "entity_type": "SYMPTOM",
            "name": "parkinsonian motor symptoms",
            "normalized_id": "N/A",
            "aliases": [
              "motor symptoms",
              "parkinsonian symptoms",
              "PD",
              "PD pathology",
              "PD-like pathology"
            ],
            "description": "Motor symptoms associated with Parkinson's disease that can be prevented by pharmacological blockade of MAOB inhibitors in MPTP-induced pathology."
          },
          "time_info": null
        },
        {
          "head": "MAOB",
          "relation": "reduce",
          "tail": "TH",
          "relation_type": "UNKNOWN",
          "confidence": [
            0.65,
            0.1
          ],
          "evidence": [
            "The aberrant suppression of DAergic neuronal activity leads to a substantial decrease in tyrosine hydroxylase (TH), the key DA-synthesizing enzyme.",
            "Notably, the reduction of TH level could be reversible when the DAergic neurons are aberrantly suppressed but still alive."
          ],
          "mechanism": "unknown",
          "source": "ocr_result_1_3",
          "subject": {
            "entity_id": "ent:1b34d319268f",
            "entity_type": "GENE",
            "name": "MAOB",
            "normalized_id": "N/A",
            "aliases": [],
            "description": "Enzyme described as contributing to DA degradation in the brain, localized mainly in astrocytes, and involved in MPTP metabolism and astrocytic GABA synthesis."
          },
          "object": {
            "entity_id": "ent:d65ad5dbdde6",
            "entity_type": "PROTEIN",
            "name": "tyrosine hydroxylase",
            "normalized_id": "N/A",
            "aliases": [
              "TH"
            ],
            "description": "Key DA-synthesizing enzyme whose reduction in level is caused by aberrant suppression of DAergic neuronal activity."
          },
          "time_info": null
        },
        {
          "head": "aberrant suppression",
          "relation": "lead to",
          "tail": "decrease in TH",
          "relation_type": "UNKNOWN",
          "confidence": [
            0.8,
            0.15
          ],
          "evidence": [
            "The aberrant suppression of DAergic neuronal activity leads to a substantial decrease in tyrosine hydroxylase (TH), the key DA-synthesizing enzyme.",
            "Notably, the reduction of TH level could be reversible when the DAergic neurons are aberrantly suppressed but still alive."
          ],
          "mechanism": "unknown",
          "source": "ocr_result_1_3",
          "subject": {
            "entity_id": "ent:0944d9619277",
            "entity_type": "MECHANISM",
            "name": "aberrant suppression",
            "normalized_id": "N/A",
            "aliases": [],
            "description": "Abnormal inhibitory process leading to decreased activity of dopaminergic neurons in the SNpc, caused by excessive GABA."
          },
          "object": {
            "entity_id": "ent:d65ad5dbdde6",
            "entity_type": "PROTEIN",
            "name": "tyrosine hydroxylase",
            "normalized_id": "N/A",
            "aliases": [
              "TH"
            ],
            "description": "Key DA-synthesizing enzyme whose reduction in level is caused by aberrant suppression of DAergic neuronal activity."
          },
          "time_info": null
        }
      ]
    },
    "ocr_result_1_4": {
      "id": "ocr_result_1_4",
      "name": "",
      "meta": {
        "text": "In addition to GABA, MAOB is critically engaged in H_{2}O_{2} synthesis. While MAOB catalyzes the conversion of N-acetylputresicne to N-acetyl--aminobutyraldehyde in the putrescine degradation pathway, H_{2}O_{2} is produced (Figure 2). In AD, MAOB-mediated H_{2}O_{2} is reported to cause glial activation, tauopathy, neuronal death, brain atrophy, and cognitive impairment [78]. A previous report suggested that astrocytic MAOB-dependent H_{2}O_{2} could be critical for PD pathology by demonstrating that MAOB overexpression in astrocytes increased the H_{2}O_{2} level and exacerbated the PD pathology [18,80]. This finding was recapitulated by a recent report demonstrating that AAD2004, a potent H_{2}O_{2} scavenger, has a significant neuroprotective effect on SNpc of the MPTP mouse model [21]. These reports raise the possibility that MAOB-dependent H_{2}O_{2} directly causes DAergic neuronal death in the MPTP model. The astrocytic H_{2}O_{2} can exacerbate the astrocytic reactivity and promote neurodegeneration [78], which can largely contribute to PD pathophysiology not only in PD animal models but also in patients. This intriguing possibility of the direct involvement of MAOB-dependent H_{2}O_{2} in PD-related neurodegeneration needs to be tested in future investigations.\n\nIn this regard, astrocytic MAOB could be the therapeutic target for alleviating PD pathology and the related motor symptoms. This possibility has been tested in the rodent models of PD, including the MPTP mouse model, 6-OHDA rat model, and viral overexpression of A53T-mutated alpha-synuclein mouse model by a pharmacological blockade, gene-silencing, and genetic ablation of MAOB [21,22,41]. MAOB inhibition in these PD models blocked astrocytic GABA synthesis, aberrant tonic inhibition of DAergic neurons, TH expression, and parkinsonian motor symptoms. These recent discoveries delineate the new mode of action of MAOB inhibitors in the treatment of PD as blocking astrocytic GABA and H_{2}O_{2} synthesis.\n\n##\n\nInt.J.Mol.Sci.2022,23,4453\n\n![img-1.jpeg](img-1.jpeg)\nFigure 2. The recent findings on MAOB as a GABA- and  $\\mathrm{H}_2\\mathrm{O}_2$  -synthesizing enzyme. According to recent discoveries, it is not MAOB but MAOA that is responsible for dopamine (DA) metabolism to HVA. Instead, MAOB is responsible for astrocytic GABA and  $\\mathrm{H}_2\\mathrm{O}_2$  synthesis. In detail, under the PD pathogenesis, the putrescine level in reactive astrocytes is increased, which could be linked to the accumulation of misfolded  $\\alpha$  -synuclein. Putrescine is converted to N-acetylputrescine by putrescine aminotransferase (PAT). MAOB converts the N-acetylputrescine to N-acetyl-  $\\gamma$  -aminobutyraldehyde and produces  $\\mathrm{H}_2\\mathrm{O}_2$  as a byproduct. N-acetyl-  $\\gamma$  -aminobutyraldehyde is sequentially converted to N-acetyl-  $\\gamma$  -aminobutyrate and GABA. GABA, released via Bestrophin 1 (BEST1) from astrocytes, inhibits the excitability of neighboring DAergic neurons. On the other hand,  $\\mathrm{H}_2\\mathrm{O}_2$  exacerbates DAergic neuronal degeneration. The aberrant suppression and deterioration of DAergic neurons lead to reduced expression of tyrosine hydroxylase (TH) and DA deficiency.\n\n# 4. MAOB as a Therapeutic Target for PD\n\nMAOB inhibitors are categorized into two classes: irreversible inhibitors, including selegiline and rasagiline, and reversible inhibitors, including safinamide and KDS2010 [16]. For the past several decades, the irreversible MAOB inhibitors have been widely utilized in both clinics and animal studies due to their high potency  $(\\mathrm{IC}50 = \\sim 10\\mathrm{nM})$ . However, these irreversible inhibitors have a critical drawback which is the low selectivity (selegiline,  $\\sim 150$ -fold; rasagiline,  $\\sim 52$ -fold) [41], thereby losing their MAOB selectivity at higher doses. The low selectivity of these irreversible inhibitors could have caused the misinterpretation about the role of MAOB in DA degradation because most of the past studies investigating the role of MAOB utilized selegiline and rasagiline.\n\nAlso, irreversible inhibitors have limitations as therapeutic agents because their action is short-lived. The long-term treatment (over 2 weeks) of selegiline lost its effect on blocking astrocytic GABA synthesis by turning on a compensatory astrocytic GABA-synthesizing pathway which contains diamine oxidase [15,16]. On the other hand, reversible MAOB inhibitors such as safinamide and KDS2010 do not turn on the compensatory GABA-synthetic mechanism even under the long-term treatment condition.\n\nMAOB inhibitors have been shown to have neuroprotective effects, prevent DAergic neuron degeneration, and decrease parkinsonian symptoms, especially when it is applied to the early phase patients [26,81,82,83,84]. MAOB inhibitors may also reduce the motor fluctuations in PD patients [85]. Up to date, several different MAOB inhibitors are used to treat PD, including Eldepryl or Zelapar (selegiline hydrochloride), Azilect (rasagiline), and Xadago (safinamide). Taken together, reversible MAOB inhibitors can circumvent the drawbacks of conventional irreversible MAOB inhibitors, including low selectivity-induced undesirable effects such as the cheese effect [86] and its short-lived action. Each MAOB inhibitor has been described below.\n\n### 4.1. Selegiline",
        "source": "ocr_result_1"
      },
      "entities": [
        {
          "entity_id": "ent:1674344d1a32",
          "entity_type": "PATHWAY",
          "name": "putrescine degradation pathway",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A pathway where MAOB catalyzes the conversion of N-acetylputrescine to N-acetyl--aminobutyraldehyde, producing H2O2 as a byproduct."
        },
        {
          "entity_id": "ent:e25783ef423c",
          "entity_type": "PATHWAY",
          "name": "compensatory astrocytic GABA-synthesizing pathway",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A pathway containing diamine oxidase that is turned on after long-term treatment with irreversible MAOB inhibitors like selegiline."
        },
        {
          "entity_id": "ent:6dfd506b6f1d",
          "entity_type": "PROTEIN",
          "name": "MAOB",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Enzyme critically engaged in H2O2 synthesis, catalyzes conversion of N-acetylputrescine to N-acetyl--aminobutyraldehyde, and is responsible for astrocytic GABA and H2O2 synthesis."
        },
        {
          "entity_id": "ent:f003ca34f3da",
          "entity_type": "PROTEIN",
          "name": "MAOA",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Enzyme described as responsible for dopamine (DA) metabolism to HVA."
        },
        {
          "entity_id": "ent:329a2cb13ab7",
          "entity_type": "PROTEIN",
          "name": "putrescine aminotransferase",
          "normalized_id": "N/A",
          "aliases": [
            "PAT"
          ],
          "description": "Enzyme that converts putrescine to N-acetylputrescine."
        },
        {
          "entity_id": "ent:34acc41466e4",
          "entity_type": "PROTEIN",
          "name": "Bestrophin 1",
          "normalized_id": "N/A",
          "aliases": [
            "BEST1"
          ],
          "description": "Protein from astrocytes via which GABA is released."
        },
        {
          "entity_id": "ent:9964bdf89db1",
          "entity_type": "PROTEIN",
          "name": "tyrosine hydroxylase",
          "normalized_id": "N/A",
          "aliases": [
            "TH"
          ],
          "description": "Enzyme whose reduced expression is linked to DA deficiency from aberrant suppression of DAergic neurons."
        },
        {
          "entity_id": "ent:f3862803b71e",
          "entity_type": "SYMPTOM",
          "name": "cognitive impairment",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Reported to be caused by MAOB-mediated H2O2 in AD, as mentioned in the document."
        },
        {
          "entity_id": "ent:b5e43b5884b2",
          "entity_type": "SYMPTOM",
          "name": "parkinsonian motor symptoms",
          "normalized_id": "N/A",
          "aliases": [
            "motor symptoms",
            "parkinsonian symptoms"
          ],
          "description": "Described as being blocked by MAOB inhibition in PD models according to the text."
        },
        {
          "entity_id": "ent:376bc6bfad28",
          "entity_type": "SYMPTOM",
          "name": "motor fluctuations",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Mentioned as potentially being reduced by MAOB inhibitors in PD patients."
        },
        {
          "entity_id": "ent:7401a2509e6f",
          "entity_type": "GENE",
          "name": "A53T",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A mutation mentioned in the context of alpha-synuclein in a mouse model of PD."
        },
        {
          "entity_id": "ent:9f4521daf150",
          "entity_type": "GENE",
          "name": "-synuclein",
          "normalized_id": "N/A",
          "aliases": [
            "alpha-synuclein"
          ],
          "description": "A protein whose misfolded accumulation in reactive astrocytes could be linked to increased putrescine levels under PD pathogenesis."
        },
        {
          "entity_id": "ent:8a9fd2a6b38d",
          "entity_type": "DISEASE",
          "name": "AD",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "N/A"
        },
        {
          "entity_id": "ent:5c1c0b9ab2d7",
          "entity_type": "DISEASE",
          "name": "tauopathy",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Reported to be caused by MAOB-mediated H2O2 in AD."
        },
        {
          "entity_id": "ent:ad2030e4f044",
          "entity_type": "DISEASE",
          "name": "brain atrophy",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Reported to be caused by MAOB-mediated H2O2 in AD."
        },
        {
          "entity_id": "ent:3a794af32136",
          "entity_type": "DISEASE",
          "name": "PD",
          "normalized_id": "N/A",
          "aliases": [
            "Parkinson's disease"
          ],
          "description": "Pathology exacerbated by astrocytic MAOB-dependent H2O2."
        },
        {
          "entity_id": "ent:ecdc6e9e410f",
          "entity_type": "DISEASE",
          "name": "neurodegeneration",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Promoted by astrocytic H2O2 exacerbating astrocytic reactivity."
        },
        {
          "entity_id": "ent:9c3a8eacc692",
          "entity_type": "DISEASE",
          "name": "PD pathophysiology",
          "normalized_id": "N/A",
          "aliases": [
            "PD pathology"
          ],
          "description": "Contributed to by astrocytic H2O2 promoting neurodegeneration in PD animal models and patients."
        },
        {
          "entity_id": "ent:1f46763096d0",
          "entity_type": "DISEASE",
          "name": "PD-related neurodegeneration",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Possibility of direct involvement of MAOB-dependent H2O2 needs future testing."
        },
        {
          "entity_id": "ent:8ca1799e504e",
          "entity_type": "DISEASE",
          "name": "DAergic neuron degeneration",
          "normalized_id": "N/A",
          "aliases": [
            "DAergic neuronal death",
            "neuronal death",
            "neuronal degeneration"
          ],
          "description": "MAOB inhibitors have been shown to prevent this."
        },
        {
          "entity_id": "ent:644c5e22b489",
          "entity_type": "DISEASE",
          "name": "PD patients",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "MAOB inhibitors may reduce motor fluctuations in these individuals."
        },
        {
          "entity_id": "ent:1d48f5e7c23a",
          "entity_type": "TREATMENT",
          "name": "pharmacological blockade",
          "normalized_id": "N/A",
          "aliases": [
            "MAOB inhibition"
          ],
          "description": "A method tested in rodent models of PD, including the MPTP mouse model, 6-OHDA rat model, and viral overexpression of A53T-mutated alpha-synuclein mouse model."
        },
        {
          "entity_id": "ent:ac19d9664d9c",
          "entity_type": "TREATMENT",
          "name": "gene-silencing",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A method tested in rodent models of PD, including the MPTP mouse model, 6-OHDA rat model, and viral overexpression of A53T-mutated alpha-synuclein mouse model."
        },
        {
          "entity_id": "ent:8ad8ae5c73cf",
          "entity_type": "TREATMENT",
          "name": "genetic ablation",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A method tested in rodent models of PD, including the MPTP mouse model, 6-OHDA rat model, and viral overexpression of A53T-mutated alpha-synuclein mouse model."
        },
        {
          "entity_id": "ent:41ac1fc8ad28",
          "entity_type": "TREATMENT",
          "name": "MAOB inhibitors",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Recent discoveries delineate their new mode of action in the treatment of PD as blocking astrocytic GABA and H2O2 synthesis."
        },
        {
          "entity_id": "ent:ab665c9f917b",
          "entity_type": "TREATMENT",
          "name": "irreversible inhibitors",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A category of MAOB inhibitors that includes selegiline and rasagiline, widely utilized in both clinics and animal studies due to high potency."
        },
        {
          "entity_id": "ent:820cbc6b07cd",
          "entity_type": "TREATMENT",
          "name": "selegiline",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "An irreversible MAOB inhibitor with high potency but low selectivity, used in clinics and animal studies."
        },
        {
          "entity_id": "ent:ce65d3ffdbaf",
          "entity_type": "TREATMENT",
          "name": "rasagiline",
          "normalized_id": "N/A",
          "aliases": [
            "Azilect"
          ],
          "description": "An irreversible MAOB inhibitor with high potency but low selectivity, used in clinics and animal studies."
        },
        {
          "entity_id": "ent:6335afcadb85",
          "entity_type": "TREATMENT",
          "name": "reversible inhibitors",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A category of MAOB inhibitors that includes safinamide and KDS2010."
        },
        {
          "entity_id": "ent:b9bf5641659f",
          "entity_type": "TREATMENT",
          "name": "safinamide",
          "normalized_id": "N/A",
          "aliases": [
            "Xadago"
          ],
          "description": "A reversible MAOB inhibitor."
        },
        {
          "entity_id": "ent:3531248a8204",
          "entity_type": "TREATMENT",
          "name": "KDS2010",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A reversible MAOB inhibitor."
        },
        {
          "entity_id": "ent:850a6bde4488",
          "entity_type": "TREATMENT",
          "name": "irreversible MAOB inhibitors",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Have been widely utilized in both clinics and animal studies due to their high potency."
        },
        {
          "entity_id": "ent:0d75ac1a300e",
          "entity_type": "TREATMENT",
          "name": "reversible MAOB inhibitors",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Such as safinamide and KDS2010 do not turn on the compensatory GABA-synthetic mechanism even under long-term treatment."
        },
        {
          "entity_id": "ent:a0518625a6b3",
          "entity_type": "TREATMENT",
          "name": "Eldepryl",
          "normalized_id": "N/A",
          "aliases": [
            "selegiline hydrochloride",
            "Zelapar"
          ],
          "description": "A MAOB inhibitor used to treat PD, also known as selegiline hydrochloride or Zelapar."
        },
        {
          "entity_id": "ent:e517d081e235",
          "entity_type": "MECHANISM",
          "name": "H_{2}O_{2} synthesis",
          "normalized_id": "N/A",
          "aliases": [
            "H_{2}O_{2} production"
          ],
          "description": "Process in which MAOB is critically engaged, producing H_{2}O_{2} as a byproduct during the conversion of N-acetylputrescine to N-acetyl--aminobutyraldehyde."
        },
        {
          "entity_id": "ent:872e74b6e07e",
          "entity_type": "MECHANISM",
          "name": "conversion of N-acetylputrescine to N-acetyl--aminobutyraldehyde",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Catalytic reaction in the putrescine degradation pathway performed by MAOB, which produces H_{2}O_{2} as a byproduct."
        },
        {
          "entity_id": "ent:6cd9f3c347d7",
          "entity_type": "MECHANISM",
          "name": "astrocytic MAOB-dependent H_{2}O_{2}",
          "normalized_id": "N/A",
          "aliases": [
            "MAOB-dependent H_{2}O_{2}"
          ],
          "description": "Mechanism suggested to be critical for PD pathology, where MAOB overexpression in astrocytes increases H_{2}O_{2} level and exacerbates pathology."
        },
        {
          "entity_id": "ent:92d1903a380c",
          "entity_type": "MECHANISM",
          "name": "H_{2}O_{2} scavenger",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Property of AAD2004, a compound with significant neuroprotective effect on the SNpc of the MPTP mouse model."
        },
        {
          "entity_id": "ent:30d192e6a29e",
          "entity_type": "MECHANISM",
          "name": "astrocytic reactivity",
          "normalized_id": "N/A",
          "aliases": [
            "glial activation"
          ],
          "description": "Process that can be exacerbated by astrocytic H_{2}O_{2}, promoting neurodegeneration and contributing to PD pathophysiology."
        },
        {
          "entity_id": "ent:327baf1e341f",
          "entity_type": "MECHANISM",
          "name": "astrocytic GABA synthesis",
          "normalized_id": "N/A",
          "aliases": [
            "GABA synthesis"
          ],
          "description": "Process blocked by MAOB inhibition in PD models, along with blocking aberrant tonic inhibition of DAergic neurons, TH expression, and parkinsonian motor symptoms."
        },
        {
          "entity_id": "ent:34c7826b90d4",
          "entity_type": "MECHANISM",
          "name": "aberrant tonic inhibition of DAergic neurons",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Process blocked by MAOB inhibition in PD models, along with blocking astrocytic GABA synthesis, TH expression, and parkinsonian motor symptoms."
        },
        {
          "entity_id": "ent:d1fe67f9c463",
          "entity_type": "MECHANISM",
          "name": "mode of action",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "New delineated mechanism of MAOB inhibitors in PD treatment as blocking astrocytic GABA and H_{2}O_{2} synthesis."
        },
        {
          "entity_id": "ent:855af55c0632",
          "entity_type": "MECHANISM",
          "name": "blocking astrocytic GABA and H_{2}O_{2} synthesis",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "New mode of action of MAOB inhibitors in the treatment of PD, as delineated by recent discoveries."
        },
        {
          "entity_id": "ent:f8facd4b3937",
          "entity_type": "MECHANISM",
          "name": "DA metabolism to HVA",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Process for which MAOA, not MAOB, is responsible according to recent discoveries."
        },
        {
          "entity_id": "ent:4e32be749e83",
          "entity_type": "MECHANISM",
          "name": "accumulation of misfolded -synuclein",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Process to which increased putrescine level in reactive astrocytes under PD pathogenesis could be linked."
        },
        {
          "entity_id": "ent:0141307f7d83",
          "entity_type": "MECHANISM",
          "name": "converted to N-acetylputrescine",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Process performed by putrescine aminotransferase (PAT) on putrescine."
        },
        {
          "entity_id": "ent:920dfc964b68",
          "entity_type": "MECHANISM",
          "name": "converts the N-acetylputrescine to N-acetyl--aminobutyraldehyde",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Action performed by MAOB, producing H_{2}O_{2} as a byproduct."
        },
        {
          "entity_id": "ent:29bcdb855675",
          "entity_type": "MECHANISM",
          "name": "produces H_{2}O_{2} as a byproduct",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Outcome of MAOB converting N-acetylputrescine to N-acetyl--aminobutyraldehyde."
        },
        {
          "entity_id": "ent:3661fbbbbd61",
          "entity_type": "MECHANISM",
          "name": "converted to N-acetyl--aminobutyrate and GABA",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Sequential conversion process of N-acetyl--aminobutyraldehyde."
        },
        {
          "entity_id": "ent:736f1f8a04ef",
          "entity_type": "MECHANISM",
          "name": "inhibits the excitability of neighboring DAergic neurons",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Action of GABA released via Bestrophin 1 (BEST1) from astrocytes."
        },
        {
          "entity_id": "ent:6c317113545f",
          "entity_type": "MECHANISM",
          "name": "exacerbates DAergic neuronal degeneration",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Action of H_{2}O_{2} on the other hand, following GABA's inhibition of neuronal excitability."
        },
        {
          "entity_id": "ent:cfccea2d4f57",
          "entity_type": "MECHANISM",
          "name": "aberrant suppression and deterioration of DAergic neurons",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Process leading to reduced expression of tyrosine hydroxylase (TH) and DA deficiency."
        },
        {
          "entity_id": "ent:532f679f8ede",
          "entity_type": "MECHANISM",
          "name": "reduced expression of tyrosine hydroxylase (TH)",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Outcome of the aberrant suppression and deterioration of DAergic neurons, leading to DA deficiency."
        },
        {
          "entity_id": "ent:d3aa6507063c",
          "entity_type": "MECHANISM",
          "name": "DA deficiency",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Result of reduced expression of tyrosine hydroxylase (TH) due to aberrant suppression and deterioration of DAergic neurons."
        },
        {
          "entity_id": "ent:291a19f5c25f",
          "entity_type": "MECHANISM",
          "name": "neuroprotective effects",
          "normalized_id": "N/A",
          "aliases": [
            "neuroprotective effect"
          ],
          "description": "Effects shown by MAOB inhibitors to prevent DAergic neuron degeneration and decrease parkinsonian symptoms, especially in early phase patients."
        },
        {
          "entity_id": "ent:f6961ce2b903",
          "entity_type": "MECHANISM",
          "name": "prevent DAergic neuron degeneration",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Effect shown by MAOB inhibitors, along with having neuroprotective effects and decreasing parkinsonian symptoms."
        },
        {
          "entity_id": "ent:3a6c3714043f",
          "entity_type": "MECHANISM",
          "name": "decrease parkinsonian symptoms",
          "normalized_id": "N/A",
          "aliases": [
            "reduce the motor fluctuations"
          ],
          "description": "Effect shown by MAOB inhibitors, along with having neuroprotective effects and preventing DAergic neuron degeneration."
        },
        {
          "entity_id": "ent:e057d5e3a166",
          "entity_type": "MECHANISM",
          "name": "low selectivity-induced undesirable effects",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Drawback of conventional irreversible MAOB inhibitors, such as the cheese effect, that reversible inhibitors can circumvent."
        },
        {
          "entity_id": "ent:e6538490ab58",
          "entity_type": "MECHANISM",
          "name": "cheese effect",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Example of a low selectivity-induced undesirable effect of conventional irreversible MAOB inhibitors."
        },
        {
          "entity_id": "ent:071f23a3c0ae",
          "entity_type": "MECHANISM",
          "name": "short-lived action",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Drawback of conventional irreversible MAOB inhibitors that reversible inhibitors can circumvent."
        }
      ],
      "relations": []
    },
    "ocr_result_1_5": {
      "id": "ocr_result_1_5",
      "name": "",
      "meta": {
        "text": "The first MAOB inhibitor was selegiline, synthesized by Zoltan Ecseri in 1962, patented as an antidepressant in 1965, and developed by Jozsef Knoll as a psychic energizer [87]. Selegiline is a selective, irreversible MAOB inhibitor, which is used as monotherapy in the early phase of PD or as a combination therapy with levodopa in more advanced PD states. Selegiline has been shown to delay the time point of levodopa treatment [88,89]. Furthermore, a study of 157 de novo patients suggested that long-term treatment of selegiline delays the progression of the signs and symptoms of PD [90]. However, there is no conclusive evidence from clinical trials to prove that selegiline has disease-modifying effects [91,92,93,94]. Moreover, selegiline has been reported to lose its selectivity to MAOB at high doses (10 mg/kg) [95]. Furthermore, selegiline is metabolized into amphetamine and methamphetamine metabolites, which may cause deleterious effects [96].\n\n### 4.2. Rasagiline\n\nRasagiline is a second-generation propargylamine-based selective, irreversible MAOB inhibitor. Rasagiline is used as monotherapy to treat early PD or as add-on therapy in more advanced PD. Rasagiline and selegiline are currently licensed in Europe and North America for the symptomatic improvement of early PD. Unlike selegiline, rasagiline has no methamphetamine and amphetamine metabolites. Furthermore, it was shown to have potential anti-apoptotic effects in in vitro and in vivo parkinsonian models [37,60,97]. Although some clinical studies found that rasagiline showed clinical efficacy in both early monotherapy and in advanced PD with levodopa, head-to-head trials comparing rasagiline with selegiline or other inhibitors are needed to test whether rasagiline is superior or not. Furthermore, the FDA label contains warnings that rasagiline may cause severe hypertension or hypotension, worsen the movements in some people, or cause hallucinations [98].\n\n### 4.3. Safinamide\n\nSafinamide is a reversible and selective MAOB inhibitor, approved in March 2017 by the US Food and Drug Administration (FDA) for the treatment of PD patients. Safinamide has undesirable properties in that it also inhibits voltage-gated sodium and N-type calcium channels, modulating glutamate release [73]. It is shown that safinamide has neuroprotective properties thought to be related to MAOB inhibition and ion channel blocking activity [99]. Safinamide was generally well tolerated in clinical trials, but dyskinesia was the most common adverse event [100]. Despite the advantage of being a reversible inhibitor, safinamide suffers from several off-target effects and some adverse effects [101].\n\n### 4.4. KDS2010\n\nA recently developed KDS2010, which is ~12,500-fold more selective to MAOB than MAOA, differentiates the role of MAOB from MAOA and reports that MAOB does not contribute to DA degradation [39]. KDS2010 is a potent (IC50 = 7.6 nM), and selective MAOB inhibitor named shows no known off-target effect (no other enzymes or channels causing >40% inhibition) or toxicity for 4 weeks of repeated dosing in non-human primates [16,41]. KDS2010 was turned out to be highly effective for alleviating the PD-related motor symptoms and PD-like pathology, including reactive astrogliosis, excessive astrocytic\n\nGABA, and nigrostriatal DAergic neuronal loss in multiple rodent models of PD [41]. Its clinical efficacy is still waiting to be tested in future studies.\n\nIn addition to pharmacology, genetic ablation or silencing of astrocytic MAOB has been reported to alleviate parkinsonian motor symptoms [21,22]. Since MAOB deficiency does not exhibit any abnormalities in humans [66], MAOB might also be used as a safe target for genetic manipulation in the treatment of PD. Recent studies have developed several technologies for gene therapy, including small-interfering RNA (siRNA), short-hairpin RNA (shRNA), an antisense oligonucleotide (ASO), and CRISPR-Cas9, which could be delivered in vivo by an adeno-associated virus (AAV) or nanoparticles [102,103,104]. These genetic manipulations may have a one-off potential for long-term benefits. The genetic ablation of MAOB using these approaches might be considered a promising next-generation therapeutic strategy for early PD patients in the future.\n\n## 5. Concluding Remarks\n\nIn this review, we have comprehensively reviewed how recognition of the MAOB's role in PD pathology has evolved over time, from its traditional role as a DA-degrading enzyme to the recent findings as a critical enzyme regulating astrocytic reactivity. Accumulating lines of evidence have indicated that MAOA, not MAOB, is mainly responsible for mediating DA degradation. On the other hand, MAOB is responsible for the aberrant suppression and deterioration of DAergic neurons through excessive GABA and H_{2}O_{2} synthesis in reactive astrocytes of the rodent PD models. A better understanding of the pathogenic role of MAOB in PD will aid in better deciding when MAOB inhibitors are used to improve the efficacy. Furthermore, redefining the MAOB's role and the mode of action of MAOB inhibitors will spur the new development of innovative therapeutic techniques to fine-control the MAOB's activity or gene expression.",
        "source": "ocr_result_1"
      },
      "entities": [
        {
          "entity_id": "ent:93b328dab0a3",
          "entity_type": "GENE",
          "name": "MAOB",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Monoamine oxidase B enzyme described as a target for inhibitors like selegiline and rasagiline in Parkinson's disease treatment."
        },
        {
          "entity_id": "ent:fd545e5e9eac",
          "entity_type": "GENE",
          "name": "MAOA",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Monoamine oxidase A enzyme described as mainly responsible for mediating dopamine degradation according to the review."
        },
        {
          "entity_id": "ent:612b1b9eb52e",
          "entity_type": "DRUG",
          "name": "selegiline",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A selective, irreversible MAOB inhibitor used as monotherapy in early PD or in combination with levodopa in advanced PD, metabolized into amphetamine and methamphetamine metabolites."
        },
        {
          "entity_id": "ent:fc4e0e422917",
          "entity_type": "DRUG",
          "name": "levodopa",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A drug used in combination therapy with selegiline for more advanced Parkinson's disease states."
        },
        {
          "entity_id": "ent:16e0c2f3ae05",
          "entity_type": "DRUG",
          "name": "rasagiline",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A second-generation propargylamine-based selective, irreversible MAOB inhibitor used as monotherapy for early PD or as add-on therapy in advanced PD."
        },
        {
          "entity_id": "ent:8a0c191cda91",
          "entity_type": "DRUG",
          "name": "safinamide",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A reversible and selective MAOB inhibitor approved by the FDA for treating PD patients, which also inhibits voltage-gated sodium and N-type calcium channels."
        },
        {
          "entity_id": "ent:d1b89a7e52fc",
          "entity_type": "DRUG",
          "name": "KDS2010",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A recently developed potent and selective MAOB inhibitor with no known off-target effects or toxicity in non-human primates, effective in alleviating PD-related symptoms in rodent models."
        },
        {
          "entity_id": "ent:c364163bc1a7",
          "entity_type": "TREATMENT",
          "name": "monotherapy",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A treatment approach used in the early phase of Parkinson's disease, as described for selegiline."
        },
        {
          "entity_id": "ent:715ac83a1100",
          "entity_type": "TREATMENT",
          "name": "combination therapy",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A treatment approach used with levodopa in more advanced Parkinson's disease states, as described for selegiline."
        },
        {
          "entity_id": "ent:ff72a5c0e1e9",
          "entity_type": "TREATMENT",
          "name": "levodopa treatment",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A treatment that selegiline has been shown to delay the time point for, according to the document."
        },
        {
          "entity_id": "ent:c502ad5892ba",
          "entity_type": "TREATMENT",
          "name": "long-term treatment",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A treatment approach with selegiline suggested to delay the progression of Parkinson's disease signs and symptoms."
        },
        {
          "entity_id": "ent:6eee6848642f",
          "entity_type": "TREATMENT",
          "name": "add-on therapy",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A treatment approach used in more advanced Parkinson's disease, as described for rasagiline."
        },
        {
          "entity_id": "ent:844d6132e92f",
          "entity_type": "TREATMENT",
          "name": "gene therapy",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A technology mentioned as being developed for genetic manipulation in the treatment of Parkinson's disease."
        },
        {
          "entity_id": "ent:eedd40123184",
          "entity_type": "TREATMENT",
          "name": "genetic manipulation",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "An approach mentioned as a potential safe target for treatment in Parkinson's disease using MAOB."
        },
        {
          "entity_id": "ent:74b9718775bf",
          "entity_type": "DISEASE",
          "name": "parkinsonian motor symptoms",
          "normalized_id": "N/A",
          "aliases": [
            "parkinsonian",
            "parkinsonian models",
            "PD",
            "PD-like pathology"
          ],
          "description": "Symptoms alleviated by genetic ablation or silencing of astrocytic MAOB according to reports."
        },
        {
          "entity_id": "ent:411e0cd3a325",
          "entity_type": "DISEASE",
          "name": "dyskinesia",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Most common adverse event reported in clinical trials of safinamide."
        },
        {
          "entity_id": "ent:56932941c035",
          "entity_type": "DISEASE",
          "name": "hypertension",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Severe condition that rasagiline may cause according to FDA label warnings."
        },
        {
          "entity_id": "ent:14b3c05cbde1",
          "entity_type": "DISEASE",
          "name": "hypotension",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Condition that rasagiline may cause according to FDA label warnings."
        },
        {
          "entity_id": "ent:bac60251872c",
          "entity_type": "DISEASE",
          "name": "hallucinations",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Condition that rasagiline may cause according to FDA label warnings."
        },
        {
          "entity_id": "ent:f88a6204ac7a",
          "entity_type": "OTHER",
          "name": "clinical trials",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Studies mentioned in the context of providing evidence for disease-modifying effects of selegiline."
        },
        {
          "entity_id": "ent:a2a2d50b8ae1",
          "entity_type": "OTHER",
          "name": "head-to-head trials",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Clinical studies mentioned as needed to compare rasagiline with selegiline or other inhibitors."
        },
        {
          "entity_id": "ent:148014ea5591",
          "entity_type": "OTHER",
          "name": "off-target effects",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Undesirable properties mentioned as a disadvantage suffered by safinamide."
        },
        {
          "entity_id": "ent:8823145e5d11",
          "entity_type": "OTHER",
          "name": "adverse effects",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Negative outcomes mentioned as a disadvantage suffered by safinamide."
        },
        {
          "entity_id": "ent:8c9ac10ff8e9",
          "entity_type": "OTHER",
          "name": "therapeutic strategy",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "An approach mentioned as promising for next-generation treatment of early Parkinson's disease patients."
        },
        {
          "entity_id": "ent:7f75d427aac1",
          "entity_type": "MECHANISM",
          "name": "MAOB inhibition",
          "normalized_id": "N/A",
          "aliases": [
            "selective, irreversible MAOB inhibitor"
          ],
          "description": "Described as the mechanism of action for selegiline, used in Parkinson's disease treatment."
        },
        {
          "entity_id": "ent:766b68e07350",
          "entity_type": "MECHANISM",
          "name": "anti-apoptotic effects",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Potential effects of rasagiline observed in in vitro and in vivo parkinsonian models."
        },
        {
          "entity_id": "ent:7fd043613a56",
          "entity_type": "MECHANISM",
          "name": "inhibits voltage-gated sodium and N-type calcium channels",
          "normalized_id": "N/A",
          "aliases": [
            "ion channel blocking activity"
          ],
          "description": "Undesirable property of safinamide that modulates glutamate release."
        },
        {
          "entity_id": "ent:788578b094d2",
          "entity_type": "MECHANISM",
          "name": "modulating glutamate release",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Effect resulting from safinamide's inhibition of voltage-gated sodium and N-type calcium channels."
        },
        {
          "entity_id": "ent:cd1521007874",
          "entity_type": "MECHANISM",
          "name": "neuroprotective properties",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Properties of safinamide thought to be related to MAOB inhibition and ion channel blocking activity."
        },
        {
          "entity_id": "ent:17916d7b924a",
          "entity_type": "MECHANISM",
          "name": "DA degradation",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Reported that MAOB does not contribute to this process according to KDS2010 studies."
        },
        {
          "entity_id": "ent:070a28f263f3",
          "entity_type": "MECHANISM",
          "name": "reactive astrogliosis",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "PD-like pathology alleviated by KDS2010 in multiple rodent models of PD."
        },
        {
          "entity_id": "ent:54baadac3f9c",
          "entity_type": "MECHANISM",
          "name": "excessive astrocytic GABA",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "PD-like pathology alleviated by KDS2010 in multiple rodent models of PD."
        },
        {
          "entity_id": "ent:2bd0ae7232b5",
          "entity_type": "MECHANISM",
          "name": "nigrostriatal DAergic neuronal loss",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "PD-like pathology alleviated by KDS2010 in multiple rodent models of PD."
        },
        {
          "entity_id": "ent:1f589bdef8e5",
          "entity_type": "MECHANISM",
          "name": "genetic ablation",
          "normalized_id": "N/A",
          "aliases": [
            "silencing"
          ],
          "description": "Reported to alleviate parkinsonian motor symptoms when applied to astrocytic MAOB."
        },
        {
          "entity_id": "ent:82489db8fb57",
          "entity_type": "MECHANISM",
          "name": "excessive GABA synthesis",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Process for which MAOB is responsible in reactive astrocytes of rodent PD models, leading to aberrant suppression of DAergic neurons."
        },
        {
          "entity_id": "ent:2c22f2fb0049",
          "entity_type": "MECHANISM",
          "name": "H_{2}O_{2} synthesis",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Process for which MAOB is responsible in reactive astrocytes of rodent PD models, leading to deterioration of DAergic neurons."
        }
      ],
      "relations": []
    },
    "ocr_result_1_6": {
      "id": "ocr_result_1_6",
      "name": "",
      "meta": {
        "text": "Conceptualization, M.-H.N. M.S. and C.J.L.; writingoriginal draft preparation, M.-H.N. M.S. Y.H.J. and C.J.L.; writingreview and editing, M.-H.N. M.S. Y.H.J. and C.J.L.; visualization, M.S. and M.G.P.; supervision, C.J.L.; project administration, M.-H.N. and C.J.L.; funding acquisition, M.-H.N. and C.J.L. All authors have read and agreed to the published version of the manuscript.\n\nThis research was funded by the Institute for Basic Science (IBS), Center for Cognition and Sociality (IBS-R001-D2) to C.J.L. and Brain Research Program through the National Research Foundation of Korea (NRF), funded by the Ministry of Science and ICT (2018M3C7A1056897 and 2022R1C1C1006167) to M.-H.N.\n\nThe authors declare no conflict of interest.\n\n1. Hare, M.L. Tyramine oxidase: A new enzyme system in liver. Biochem. J. 1928, 22, 968--979. [CrossRef] [PubMed]\n2. Rebhun, J.; Feinberg, S.M.; Zeller, E.A. Potentiating effect of iproniazid on action of some sympathicomimetic amines. Proc. Soc. Exp. Biol. Med. 1954, 87, 218--220. [CrossRef] [PubMed]\n3. Gorkin, V.Z. On certain properties of monoaminoxidase in liver and brain mitochondria in rats. Biokhimiia 1959, 24, 826--832. [PubMed]\n4. Nagatsu, T. Progress in monoamine oxidase (MAO) research in relation to genetic engineering. Neurotoxicology 2004, 25, 11--20. [CrossRef]\n5. Youdim, M.B.; Edmondson, D.; Tipton, K.F. The therapeutic potential of monoamine oxidase inhibitors. Nat. Rev. Neurosci. 2006, 7, 295--309. [CrossRef]\n6. Tong, J.; Meyer, J.H.; Furukawa, Y.; Boileau, I.; Chang, L.J.; Wilson, A.A.; Houle, S.; Kish, S.J. Distribution of monoamine oxidase proteins in human brain: Implications for brain imaging studies. J. Cereb. Blood. Flow. Metab. 2013, 33, 863--871. [CrossRef]\n7. Vitalis, T.; Fouquet, C.; Alvarez, C.; Seif, I.; Price, D.; Gaspar, P.; Cases, O. Developmental expression of monoamine oxidases A and B in the central and peripheral nervous systems of the mouse. J. Comp. Neurol. 2002, 442, 331--347. [CrossRef]\n8. Luque, J.M.; Kwan, S.W.; Abell, C.W.; Da Prada, M.; Richards, J.G. Cellular expression of mRNAs encoding monoamine oxidases A and B in the rat central nervous system. J. Comp. Neurol. 1995, 363, 665--680. [CrossRef]\n9. Riederer, P.; Konradi, C.; Schay, V.; Kienzl, E.; Birkmayer, G.; Danielczyk, W.; Sofic, E.; Youdim, M.B. Localization of MAO-A and MAO-B in human brain: A step in understanding the therapeutic action of L-deprenyl. Adv. Neurol. 1987, 45, 111--118.",
        "source": "ocr_result_1"
      },
      "entities": [
        {
          "entity_id": "ent:8de82009f12e",
          "entity_type": "PROTEIN",
          "name": "tyramine oxidase",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A new enzyme system in liver described in reference 1."
        },
        {
          "entity_id": "ent:17a8527f786b",
          "entity_type": "PROTEIN",
          "name": "monoamine oxidases A and B",
          "normalized_id": "N/A",
          "aliases": [
            "MAO",
            "MAO-A",
            "MAO-A and MAO-B",
            "MAO-B",
            "monoamine oxidase",
            "monoamine oxidase A",
            "monoamine oxidase B",
            "monoamine oxidase proteins",
            "monoamine oxidases"
          ],
          "description": "Enzymes whose developmental expression in mouse nervous systems is studied in reference 7."
        }
      ],
      "relations": []
    },
    "ocr_result_1_7": {
      "id": "ocr_result_1_7",
      "name": "",
      "meta": {
        "text": "10. Levitt, P.; Pintar, J.E.; Breakefield, X.O. Immunocytochemical demonstration of monoamine oxidase B in brain astrocytes and serotonergic neurons. Proc. Natl. Acad. Sci. USA 1982, 79, 6385--6389. [CrossRef]\n11. Saura, J.; Richards, J.G.; Mahy, N. Differential age-related changes of MAO-A and MAO-B in mouse brain and peripheral organs. Neurobiol. Aging 1994, 15, 399--408. [CrossRef]\n12. Clarke, L.E.; Liddelow, S.A.; Chakraborty, C.; Munch, A.E.; Heiman, M.; Barres, B.A. Normal aging induces A1-like astrocyte reactivity. Proc. Natl. Acad. Sci. USA 2018, 115, E1896--E1905. [CrossRef] [PubMed]\n13. Mahy, N.; Andres, N.; Andrade, C.; Saura, J. Age-related changes of MAO-A and -B distribution in human and mouse brain. Neurobiology 2000, 8, 47--54. [PubMed]\n14. Fowler, J.S.; Volkow, N.D.; Wang, G.J.; Logan, J.; Pappas, N.; Shea, C.; MacGregor, R. Age-related increases in brain monoamine oxidase B in living healthy human subjects. Neurobiol. Aging 1997, 18, 431--435. [CrossRef]\n15. Jo, S.; Yarishkin, O.; Hwang, Y.J.; Chun, Y.E.; Park, M.; Woo, D.H.; Bae, J.Y.; Kim, T.; Lee, J.; Chun, H.; et al. GABA from reactive astrocytes impairs memory in mouse models of Alzheimer's disease. Nat. Med. 2014, 20, 886--896. [CrossRef]\n16. Park, J.H.; Ju, Y.H.; Choi, J.W.; Song, H.J.; Jang, B.K.; Woo, J.; Chun, H.; Kim, H.J.; Shin, S.J.; Yarishkin, O.; et al. Newly developed reversible MAO-B inhibitor circumvents the shortcomings of irreversible inhibitors in Alzheimer's disease. Sci. Adv. 2019, 5, eaav0316. [CrossRef]\n17. Chun, H.; Lim, J.; Park, K.D.; Lee, C.J. Inhibition of monoamine oxidase B prevents reactive astrogliosis and scar formation in stab wound injury model. Glia 2022, 70, 354--367. [CrossRef]\n18. Mallajosyula, J.K.; Kaur, D.; Chinta, S.J.; Rajagopalan, S.; Rane, A.; Nicholls, D.G.; Di Monte, D.A.; Macarthur, H.; Andersen, J.K. MAO-B elevation in mouse brain astrocytes results in Parkinson's pathology. PLoS ONE 2008, 3, e1616. [CrossRef]\n19. Moriguchi, S.; Wilson, A.A.; Miler, L.; Rusjan, P.M.; Vasdev, N.; Kish, S.J.; Rajkowska, G.; Wang, J.; Bagby, M.; Mizrahi, R.; et al. Monoamine Oxidase B Total Distribution Volume in the Prefrontal Cortex of Major Depressive Disorder: An [11C]SL25.1188 Positron Emission Tomography Study. JAMA Psychiatry 2019, 76, 634--641. [CrossRef]\n20. Rodriguez-Vieitez, E.; Carter, S.F.; Chiotis, K.; Saint-Aubert, L.; Leuzy, A.; Scholl, M.; Almkvist, O.; Wall, A.; Langstrom, B.; Nordberg, A. Comparison of Early-Phase 11C-Deuterium-l-Deprenyl and 11C-Pittsburgh Compound B PET for Assessing Brain Perfusion in Alzheimer Disease. J. Nucl. Med. 2016, 57, 1071--1077. [CrossRef]\n21. Heo, J.Y.; Nam, M.H.; Yoon, H.H.; Kim, J.; Hwang, Y.J.; Won, W.; Woo, D.H.; Lee, J.A.; Park, H.J.; Jo, S.; et al. Aberrant Tonic Inhibition of Dopaminergic Neuronal Activity Causes Motor Symptoms in Animal Models of Parkinson's Disease. Curr. Biol. 2020, 30, 276--291.e9. [CrossRef] [PubMed]\n22. An, H.; Heo, J.Y.; Lee, C.J.; Nam, M.H. The Pathological Role of Astrocytic MAOB in Parkinsonism Revealed by Genetic Ablation and Over-expression of MAOB. Exp. Neurobiol. 2021, 30, 113--119. [CrossRef] [PubMed]\n23. Blum, D.; Torch, S.; Lambeng, N.; Nissou, M.; Benabid, A.L.; Sadoul, R.; Verna, J.M. Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: Contribution to the apoptotic theory in Parkinson's disease. Prog. Neurobiol. 2001, 65, 135--172. [CrossRef]\n24. Jankovic, J. Parkinson's disease: Clinical features and diagnosis. J. Neurol. Neurosurg. Psychiatry 2008, 79, 368--376. [CrossRef]\n25. Armstrong, M.J.; Okun, M.S. Diagnosis and Treatment of Parkinson Disease: A Review. JAMA 2020, 323, 548--560. [CrossRef]\n26. Alborghetti, M.; Nicoletti, F. Different Generations of Type-B Monoamine Oxidase Inhibitors in Parkinson's Disease: From Bench to Bedside. Curr. Neuropharmacol. 2019, 17, 861--873. [CrossRef]\n27. Shih, J.C.; Chen, K.; Ridd, M.J. Monoamine oxidase: From genes to behavior. Annu. Rev. Neurosci. 1999, 22, 197--217. [CrossRef]\n28. Westlund, K.N.; Denney, R.M.; Rose, R.M.; Abell, C.W. Localization of distinct monoamine oxidase A and monoamine oxidase B cell populations in human brainstem. Neuroscience 1988, 25, 439--456. [CrossRef]\n29. Thorpe, L.W.; Westlund, K.N.; Kochersperger, L.M.; Abell, C.W.; Denney, R.M. Immunocytochemical localization of monoamine oxidases A and B in human peripheral tissues and brain. J. Histochem. Cytochem. 1987, 35, 23--32. [CrossRef]\n30. Fagervall, I.; Ross, S.B. A and B forms of monoamine oxidase within the monoaminergic neurons of the rat brain. J. Neurochem. 1986, 47, 569--576. [CrossRef]\n31. Bach, A.W.; Lan, N.C.; Johnson, D.L.; Abell, C.W.; Bembenek, M.E.; Kwan, S.W.; Seeburg, P.H.; Shih, J.C. cDNA cloning of human liver monoamine oxidase A and B: Molecular basis of differences in enzymatic properties. Proc. Natl. Acad. Sci. USA 1988, 85, 4934--4938. [CrossRef] [PubMed]\n32. Hsu, Y.P.; Weyler, W.; Chen, S.; Sims, K.B.; Rinehart, W.B.; Utterback, M.C.; Powell, J.F.; Breakefield, X.O. Structural features of human monoamine oxidase A elucidated from cDNA and peptide sequences. J. Neurochem. 1988, 51, 1321--1324. [CrossRef] [PubMed]\n33. Brannan, T.; Prikhojan, A.; Martinez-Tica, J.; Yahr, M.D. In vivo comparison of the effects of inhibition of MAO-A versus MAO-B on striatal L-DOPA and dopamine metabolism. J. Neural. Transm. Park Dis. Dement. Sect. 1995, 10, 79--89. [CrossRef] [PubMed]\n34. Tong, J.; Rathitharan, G.; Meyer, J.H.; Furukawa, Y.; Ang, L.C.; Boileau, I.; Guttman, M.; Hornykiewicz, O.; Kish, S.J. Brain monoamine oxidase B and A in human parkinsonian dopamine deficiency disorders. Brain 2017, 140, 2460--2474. [CrossRef]\n35. Glover, V.; Sandler, M.; Owen, F.; Riley, G.J. Dopamine is a monoamine oxidase B substrate in man. Nature 1977, 265, 80--81. [CrossRef]\n36. Tetrud, J.W.; Langston, J.W. The effect of deprenyl (selegiline) on the natural history of Parkinson's disease. Science 1989, 245, 519--522. [CrossRef]",
        "source": "ocr_result_1"
      },
      "entities": [
        {
          "entity_id": "ent:1134b1a59d14",
          "entity_type": "TREATMENT",
          "name": "reversible MAO-B inhibitor",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A newly developed reversible inhibitor of monoamine oxidase B that is described as circumventing the shortcomings of irreversible inhibitors in Alzheimer's disease."
        },
        {
          "entity_id": "ent:462e0511509f",
          "entity_type": "TREATMENT",
          "name": "irreversible inhibitors",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Inhibitors of monoamine oxidase B that are described as having shortcomings in the context of Alzheimer's disease treatment."
        },
        {
          "entity_id": "ent:0856e782c875",
          "entity_type": "TREATMENT",
          "name": "deprenyl (selegiline)",
          "normalized_id": "N/A",
          "aliases": [
            "deprenyl",
            "selegiline"
          ],
          "description": "A medication referred to as deprenyl with the synonym selegiline, studied for its effect on the natural history of Parkinson's disease."
        },
        {
          "entity_id": "ent:e1fbbd878a1d",
          "entity_type": "MECHANISM",
          "name": "reactive astrogliosis",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A process prevented by inhibition of monoamine oxidase B in a stab wound injury model according to the text."
        },
        {
          "entity_id": "ent:df6730274dbb",
          "entity_type": "MECHANISM",
          "name": "scar formation",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A process prevented by inhibition of monoamine oxidase B in a stab wound injury model according to the text."
        },
        {
          "entity_id": "ent:c9bc9c94bc6f",
          "entity_type": "MECHANISM",
          "name": "neurotoxicity",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A molecular pathway involved with 6-OHDA, dopamine and MPTP contributing to the apoptotic theory in Parkinson's disease."
        },
        {
          "entity_id": "ent:9f929fc8cada",
          "entity_type": "MECHANISM",
          "name": "apoptotic theory",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A theory in Parkinson's disease to which molecular pathways involving neurotoxicity contribute according to the text."
        },
        {
          "entity_id": "ent:2e4e9b8bab05",
          "entity_type": "DISEASE",
          "name": "Alzheimer's disease",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A disease mentioned in mouse models where GABA from reactive astrocytes impairs memory."
        },
        {
          "entity_id": "ent:d48e5d5ce7a9",
          "entity_type": "DISEASE",
          "name": "Parkinson's disease",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A disease mentioned in the context of MAO-B elevation in mouse brain astrocytes resulting in its pathology."
        },
        {
          "entity_id": "ent:e954ebca551b",
          "entity_type": "DISEASE",
          "name": "Major Depressive Disorder",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A disorder studied in relation to monoamine oxidase B total distribution volume in the prefrontal cortex."
        },
        {
          "entity_id": "ent:1338729ecfde",
          "entity_type": "DISEASE",
          "name": "Alzheimer's disease",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A disease for which early-phase PET tracers are compared for assessing brain perfusion."
        },
        {
          "entity_id": "ent:ce2c7954e579",
          "entity_type": "DISEASE",
          "name": "Parkinsonism",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A condition where the pathological role of astrocytic MAOB is revealed by genetic studies."
        },
        {
          "entity_id": "ent:9ec073085dfc",
          "entity_type": "DISEASE",
          "name": "Parkinson's disease",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A disease reviewed for its diagnosis and treatment."
        },
        {
          "entity_id": "ent:8d2e0b3b2eaa",
          "entity_type": "PROTEIN",
          "name": "MAO-B",
          "normalized_id": "N/A",
          "aliases": [
            "MAO-B",
            "MAOB"
          ],
          "description": "Enzyme demonstrated in brain astrocytes and serotonergic neurons, showing differential age-related changes in mouse brain and peripheral organs, with age-related increases in human brain."
        },
        {
          "entity_id": "ent:c377f9041217",
          "entity_type": "PROTEIN",
          "name": "monoamine oxidase",
          "normalized_id": "N/A",
          "aliases": [
            "MAO"
          ],
          "description": "Enzyme discussed in relation to genes and behavior in the cited annual review of neuroscience."
        },
        {
          "entity_id": "ent:f4f6d8dd583f",
          "entity_type": "PROTEIN",
          "name": "monoamine oxidase A",
          "normalized_id": "N/A",
          "aliases": [
            "MAO-A",
            "monoamine oxidase A"
          ],
          "description": "Enzyme form immunocytochemically localized in human peripheral tissues and brain along with monoamine oxidase B."
        }
      ],
      "relations": [
        {
          "head": "monoamine oxidase B",
          "relation": "increase",
          "tail": "reactive astrogliosis",
          "relation_type": "UNKNOWN",
          "confidence": [
            0.75,
            0.15
          ],
          "evidence": [
            "MAO-B elevation in mouse brain astrocytes results in Parkinson's pathology.",
            "Inhibition of monoamine oxidase B prevents reactive astrogliosis and scar formation in stab wound injury model."
          ],
          "mechanism": "unknown",
          "source": "ocr_result_1_7",
          "subject": {
            "entity_id": "ent:f4f6d8dd583f",
            "entity_type": "PROTEIN",
            "name": "monoamine oxidase A",
            "normalized_id": "N/A",
            "aliases": [
              "MAO-A",
              "monoamine oxidase A"
            ],
            "description": "Enzyme form immunocytochemically localized in human peripheral tissues and brain along with monoamine oxidase B."
          },
          "object": {
            "entity_id": "ent:e1fbbd878a1d",
            "entity_type": "MECHANISM",
            "name": "reactive astrogliosis",
            "normalized_id": "N/A",
            "aliases": [],
            "description": "A process prevented by inhibition of monoamine oxidase B in a stab wound injury model according to the text."
          },
          "time_info": null
        },
        {
          "head": "monoamine oxidase B",
          "relation": "increase",
          "tail": "scar formation",
          "relation_type": "UNKNOWN",
          "confidence": [
            0.7,
            0.1
          ],
          "evidence": [
            "Inhibition of monoamine oxidase B prevents reactive astrogliosis and scar formation in stab wound injury model."
          ],
          "mechanism": "unknown",
          "source": "ocr_result_1_7",
          "subject": {
            "entity_id": "ent:f4f6d8dd583f",
            "entity_type": "PROTEIN",
            "name": "monoamine oxidase A",
            "normalized_id": "N/A",
            "aliases": [
              "MAO-A",
              "monoamine oxidase A"
            ],
            "description": "Enzyme form immunocytochemically localized in human peripheral tissues and brain along with monoamine oxidase B."
          },
          "object": {
            "entity_id": "ent:df6730274dbb",
            "entity_type": "MECHANISM",
            "name": "scar formation",
            "normalized_id": "N/A",
            "aliases": [],
            "description": "A process prevented by inhibition of monoamine oxidase B in a stab wound injury model according to the text."
          },
          "time_info": null
        },
        {
          "head": "monoamine oxidase B",
          "relation": "result in",
          "tail": "Parkinson's disease",
          "relation_type": "UNKNOWN",
          "confidence": [
            0.65,
            0.05
          ],
          "evidence": [
            "MAO-B elevation in mouse brain astrocytes results in Parkinson's pathology.",
            "The Pathological Role of Astrocytic MAOB in Parkinsonism Revealed by Genetic Ablation and Over-expression of MAOB."
          ],
          "mechanism": "unknown",
          "source": "ocr_result_1_7",
          "subject": {
            "entity_id": "ent:f4f6d8dd583f",
            "entity_type": "PROTEIN",
            "name": "monoamine oxidase A",
            "normalized_id": "N/A",
            "aliases": [
              "MAO-A",
              "monoamine oxidase A"
            ],
            "description": "Enzyme form immunocytochemically localized in human peripheral tissues and brain along with monoamine oxidase B."
          },
          "object": {
            "entity_id": "ent:9ec073085dfc",
            "entity_type": "DISEASE",
            "name": "Parkinson's disease",
            "normalized_id": "N/A",
            "aliases": [],
            "description": "A disease reviewed for its diagnosis and treatment."
          },
          "time_info": null
        },
        {
          "head": "reversible MAO-B inhibitor",
          "relation": "circumvent",
          "tail": "irreversible inhibitors",
          "relation_type": "UNKNOWN",
          "confidence": [
            0.85,
            0.1
          ],
          "evidence": [
            "Newly developed reversible MAO-B inhibitor circumvents the shortcomings of irreversible inhibitors in Alzheimer's disease."
          ],
          "mechanism": "unknown",
          "source": "ocr_result_1_7",
          "subject": {
            "entity_id": "ent:8d2e0b3b2eaa",
            "entity_type": "PROTEIN",
            "name": "MAO-B",
            "normalized_id": "N/A",
            "aliases": [
              "MAO-B",
              "MAOB"
            ],
            "description": "Enzyme demonstrated in brain astrocytes and serotonergic neurons, showing differential age-related changes in mouse brain and peripheral organs, with age-related increases in human brain."
          },
          "object": {
            "entity_id": "ent:462e0511509f",
            "entity_type": "TREATMENT",
            "name": "irreversible inhibitors",
            "normalized_id": "N/A",
            "aliases": [],
            "description": "Inhibitors of monoamine oxidase B that are described as having shortcomings in the context of Alzheimer's disease treatment."
          },
          "time_info": null
        },
        {
          "head": "deprenyl (selegiline)",
          "relation": "inhibit",
          "tail": "monoamine oxidase B",
          "relation_type": "UNKNOWN",
          "confidence": [
            0.95,
            0.05
          ],
          "evidence": [
            "The effect of deprenyl (selegiline) on the natural history of Parkinson's disease.",
            "Comparison of Early-Phase 11C-Deuterium-l-Deprenyl and 11C-Pittsburgh Compound B PET for Assessing Brain Perfusion in Alzheimer Disease."
          ],
          "mechanism": "unknown",
          "source": "ocr_result_1_7",
          "subject": {
            "entity_id": "ent:0856e782c875",
            "entity_type": "TREATMENT",
            "name": "deprenyl (selegiline)",
            "normalized_id": "N/A",
            "aliases": [
              "deprenyl",
              "selegiline"
            ],
            "description": "A medication referred to as deprenyl with the synonym selegiline, studied for its effect on the natural history of Parkinson's disease."
          },
          "object": {
            "entity_id": "ent:f4f6d8dd583f",
            "entity_type": "PROTEIN",
            "name": "monoamine oxidase A",
            "normalized_id": "N/A",
            "aliases": [
              "MAO-A",
              "monoamine oxidase A"
            ],
            "description": "Enzyme form immunocytochemically localized in human peripheral tissues and brain along with monoamine oxidase B."
          },
          "time_info": null
        },
        {
          "head": "Inhibition of monoamine oxidase B",
          "relation": "prevent",
          "tail": "reactive astrogliosis",
          "relation_type": "UNKNOWN",
          "confidence": [
            0.8,
            0.1
          ],
          "evidence": [
            "Inhibition of monoamine oxidase B prevents reactive astrogliosis and scar formation in stab wound injury model."
          ],
          "mechanism": "unknown",
          "source": "ocr_result_1_7",
          "subject": {
            "entity_id": "ent:f4f6d8dd583f",
            "entity_type": "PROTEIN",
            "name": "monoamine oxidase A",
            "normalized_id": "N/A",
            "aliases": [
              "MAO-A",
              "monoamine oxidase A"
            ],
            "description": "Enzyme form immunocytochemically localized in human peripheral tissues and brain along with monoamine oxidase B."
          },
          "object": {
            "entity_id": "ent:e1fbbd878a1d",
            "entity_type": "MECHANISM",
            "name": "reactive astrogliosis",
            "normalized_id": "N/A",
            "aliases": [],
            "description": "A process prevented by inhibition of monoamine oxidase B in a stab wound injury model according to the text."
          },
          "time_info": null
        },
        {
          "head": "Inhibition of monoamine oxidase B",
          "relation": "prevent",
          "tail": "scar formation",
          "relation_type": "UNKNOWN",
          "confidence": [
            0.8,
            0.1
          ],
          "evidence": [
            "Inhibition of monoamine oxidase B prevents reactive astrogliosis and scar formation in stab wound injury model."
          ],
          "mechanism": "unknown",
          "source": "ocr_result_1_7",
          "subject": {
            "entity_id": "ent:f4f6d8dd583f",
            "entity_type": "PROTEIN",
            "name": "monoamine oxidase A",
            "normalized_id": "N/A",
            "aliases": [
              "MAO-A",
              "monoamine oxidase A"
            ],
            "description": "Enzyme form immunocytochemically localized in human peripheral tissues and brain along with monoamine oxidase B."
          },
          "object": {
            "entity_id": "ent:df6730274dbb",
            "entity_type": "MECHANISM",
            "name": "scar formation",
            "normalized_id": "N/A",
            "aliases": [],
            "description": "A process prevented by inhibition of monoamine oxidase B in a stab wound injury model according to the text."
          },
          "time_info": null
        },
        {
          "head": "deprenyl (selegiline)",
          "relation": "affect",
          "tail": "Parkinson's disease",
          "relation_type": "UNKNOWN",
          "confidence": [
            0.9,
            0.05
          ],
          "evidence": [
            "The effect of deprenyl (selegiline) on the natural history of Parkinson's disease.",
            "Different Generations of Type-B Monoamine Oxidase Inhibitors in Parkinson's Disease: From Bench to Bedside."
          ],
          "mechanism": "unknown",
          "source": "ocr_result_1_7",
          "subject": {
            "entity_id": "ent:0856e782c875",
            "entity_type": "TREATMENT",
            "name": "deprenyl (selegiline)",
            "normalized_id": "N/A",
            "aliases": [
              "deprenyl",
              "selegiline"
            ],
            "description": "A medication referred to as deprenyl with the synonym selegiline, studied for its effect on the natural history of Parkinson's disease."
          },
          "object": {
            "entity_id": "ent:9ec073085dfc",
            "entity_type": "DISEASE",
            "name": "Parkinson's disease",
            "normalized_id": "N/A",
            "aliases": [],
            "description": "A disease reviewed for its diagnosis and treatment."
          },
          "time_info": null
        }
      ]
    },
    "ocr_result_1_8": {
      "id": "ocr_result_1_8",
      "name": "",
      "meta": {
        "text": "37. Weinreb, O.; Amit, T.; Bar-Am, O.; Youdim, M.B. Rasagiline: A novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity. Prog. Neurobiol. 2010, 92, 330--344. [CrossRef]\n38. Nam, M.H.; Cho, J.; Kwon, D.H.; Park, J.Y.; Woo, J.; Lee, J.M.; Lee, S.; Ko, H.Y.; Won, W.; Kim, R.G.; et al. Excessive Astrocytic GABA Causes Cortical Hypometabolism and Impedes Functional Recovery after Subcortical Stroke. Cell Rep. 2020, 32, 107975. [CrossRef]\n39. Cho, H.U.; Kim, S.; Sim, J.; Yang, S.; An, H.; Nam, M.H.; Jang, D.P.; Lee, C.J. Redefining differential roles of MAO-A in dopamine degradation and MAO-B in tonic GABA synthesis. Exp. Mol. Med. 2021, 53, 1148--1158. [CrossRef]\n40. Yoon, B.E.; Woo, J.; Chun, Y.E.; Chun, H.; Jo, S.; Bae, J.Y.; An, H.; Min, J.O.; Oh, S.J.; Han, K.S.; et al. Glial GABA, synthesized by monoamine oxidase B, mediates tonic inhibition. J. Physiol. 2014, 592, 4951--4968. [CrossRef]\n41. Nam, M.H.; Park, J.H.; Song, H.J.; Choi, J.W.; Kim, S.; Jang, B.K.; Yoon, H.H.; Heo, J.Y.; Lee, H.; An, H.; et al. KDS2010, a Newly Developed Reversible MAO-B Inhibitor, as an Effective Therapeutic Candidate for Parkinson's Disease. Neurotherapeutics 2021, 18, 1729--1747. [CrossRef] [PubMed]\n42. Weiner, N. Substrate specificity of brain amine oxidase of several mammals. Proj. Rep. USAF Sch. Aviat. Med. 1960, 60, 1--8. [CrossRef]\n43. Braestrup, C.; Andersen, H.; Randrup, A. The monoamine oxidase B inhibitor deprenyl potentiates phenylethylamine behaviour in rats without inhibition of catecholamine metabolite formation. Eur. J. Pharmacol. 1975, 34, 181--187. [CrossRef]\n44. Waldmeier, P.C.; Delini-Stula, A.; Maitre, L. Preferential deamination of dopamine by an A type monoamine oxidase in rat brain. Naunyn-Schmiedebergs Arch. Pharmacol. 1976, 292, 9--14. [CrossRef] [PubMed]\n45. Green, A.R.; Mitchell, B.D.; Tordoff, A.F.; Youdim, M.B. Evidence for dopamine deamination by both type A and type B monoamine oxidase in rat brain in vivo and for the degree of inhibition of enzyme necessary for increased functional activity of dopamine and 5-hydroxytryptamine. Br. J. Pharmacol. 1977, 60, 343--349. [CrossRef] [PubMed]\n46. Garrick, N.A.; Murphy, D.L. Species differences in the deamination of dopamine and other substrates for monoamine oxidase in brain. Psychopharmacology 1980, 72, 27--33. [CrossRef] [PubMed]\n47. Schoepp, D.D.; Azzaro, A.J. Specificity of endogenous substrates for types A and B monoamine oxidase in rat striatum. J. Neurochem. 1981, 36, 2025--2031. [CrossRef]\n48. Roth, J.A.; Feor, K. Deamination of dopamine and its 3-O-methylated derivative by human brain monoamine oxidase. Biochem. Pharmacol. 1978, 27, 1606--1608. [CrossRef]\n49. Glover, V.; Elsworth, J.D.; Sandler, M. Dopamine oxidation and its inhibition by- deprenyl in man. J. Neural. Transm. Suppl. 1980, 16, 163--172.\n50. Tipton, K.F.; Houslay, M.D.; Garrett, N.J. Allotopic properties of human brain monoamine oxidase. Nat. New Biol. 1973, 246, 213--214. [CrossRef]\n51. Robakis, D.; Fahn, S. Defining the Role of the Monoamine Oxidase-B Inhibitors for Parkinson's Disease. CNS Drugs 2015, 29, 433--441. [CrossRef]\n52. Asanuma, M.; Miyazaki, I.; Murakami, S.; Diaz-Corrales, F.J.; Ogawa, N. Striatal astrocytes act as a reservoir for L-DOPA. PLoS ONE 2014, 9, e106362. [CrossRef] [PubMed]\n53. Eisenhofer, G.; Kopin, I.J.; Goldstein, D.S. Catecholamine metabolism: A contemporary view with implications for physiology and medicine. Pharmacol. Rev. 2004, 56, 331--349. [CrossRef] [PubMed]\n54. Meiser, J.; Weindl, D.; Hiller, K. Complexity of dopamine metabolism. Cell Commun. Signal. 2013, 11, 34. [CrossRef] [PubMed]\n55. Nirenberg, M.J.; Vaughan, R.A.; Uhl, G.R.; Kuhar, M.J.; Pickel, V.M. The dopamine transporter is localized to dendritic and axonal plasma membranes of nigrostriatal dopaminergic neurons. J. Neurosci. 1996, 16, 436--447. [CrossRef] [PubMed]\n56. Nirenberg, M.J.; Chan, J.; Pohorille, A.; Vaughan, R.A.; Uhl, G.R.; Kuhar, M.J.; Pickel, V.M. The dopamine transporter: Comparative ultrastructure of dopaminergic axons in limbic and motor compartments of the nucleus accumbens. J. Neurosci. 1997, 17, 6899--6907. [CrossRef]\n57. Li, L.; Zhang, C.W.; Chen, G.Y.; Zhu, B.; Chai, C.; Xu, Q.H.; Tan, E.K.; Zhu, Q.; Lim, K.L.; Yao, S.Q. A sensitive two-photon probe to selectively detect monoamine oxidase B activity in Parkinson's disease models. Nat. Commun. 2014, 5, 3276. [CrossRef]\n58. Nicotra, A.; Pierucci, F.; Parvez, H.; Senatori, O. Monoamine oxidase expression during development and aging. Neurotoxicology 2004, 25, 155--165. [CrossRef]\n59. Damier, P.; Kastner, A.; Agid, Y.; Hirsch, E.C. Does monoamine oxidase type B play a role in dopaminergic nerve cell death in Parkinson's disease? Neurology 1996, 46, 1262--1269. [CrossRef]\n60. Chen, J.J.; Swope, D.M. Clinical pharmacology of rasagiline: A novel, second-generation propargylamine for the treatment of Parkinson disease. J. Clin. Pharmacol. 2005, 45, 878--894. [CrossRef]\n61. Fornai, F.; Chen, K.; Giorgi, F.S.; Gesi, M.; Alessandri, M.G.; Shih, J.C. Striatal dopamine metabolism in monoamine oxidase B-deficient mice: A brain dialysis study. J. Neurochem. 1999, 73, 2434--2440. [CrossRef] [PubMed]\n62. Butcher, S.P.; Fairbrother, I.S.; Kelly, J.S.; Arbuthnott, G.W. Effects of selective monoamine oxidase inhibitors on the in vivo release and metabolism of dopamine in the rat striatum. J. Neurochem. 1990, 55, 981--988. [CrossRef] [PubMed]\n63. Scarr, E.; Wingerchuk, D.M.; Juorio, A.V.; Paterson, I.A. The effects of monoamine oxidase B inhibition on dopamine metabolism in rats with nigro-striatal lesions. Neurochem. Res. 1994, 19, 153--159. [CrossRef] [PubMed]",
        "source": "ocr_result_1"
      },
      "entities": [
        {
          "entity_id": "ent:648bfbd70daf",
          "entity_type": "PATHWAY",
          "name": "catecholamine metabolism",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Described as a contemporary view with implications for physiology and medicine in the referenced article."
        },
        {
          "entity_id": "ent:3bd811d2535d",
          "entity_type": "TREATMENT",
          "name": "Rasagiline",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity."
        },
        {
          "entity_id": "ent:614fe34fcd95",
          "entity_type": "TREATMENT",
          "name": "KDS2010",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A newly developed reversible MAO-B inhibitor described as an effective therapeutic candidate for Parkinson's Disease."
        },
        {
          "entity_id": "ent:353654a4ddf7",
          "entity_type": "TREATMENT",
          "name": "deprenyl",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A monoamine oxidase B inhibitor that potentiates phenylethylamine behaviour in rats."
        },
        {
          "entity_id": "ent:2ac7a4576b87",
          "entity_type": "DRUG",
          "name": "L-DOPA",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Striatal astrocytes act as a reservoir for L-DOPA according to the cited study."
        },
        {
          "entity_id": "ent:8fce394d7761",
          "entity_type": "DISEASE",
          "name": "Parkinson's disease",
          "normalized_id": "N/A",
          "aliases": [
            "Parkinson's disease"
          ],
          "description": "A condition mentioned as the target for novel anti-Parkinsonian monoamine oxidase-B inhibitors and other therapeutic candidates."
        },
        {
          "entity_id": "ent:741084e793b1",
          "entity_type": "DISEASE",
          "name": "subcortical Stroke",
          "normalized_id": "N/A",
          "aliases": [
            "Stroke"
          ],
          "description": "A condition mentioned in the context of cortical hypometabolism and impeded functional recovery after its occurrence."
        },
        {
          "entity_id": "ent:c82775eda705",
          "entity_type": "DISEASE",
          "name": "Parkinson disease",
          "normalized_id": "N/A",
          "aliases": [
            "Parkinson disease"
          ],
          "description": "A condition treated by rasagiline, described as a novel, second-generation propargylamine."
        },
        {
          "entity_id": "ent:c745d0183f70",
          "entity_type": "MECHANISM",
          "name": "neuroprotective activity",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Activity described for rasagiline as a novel anti-Parkinsonian monoamine oxidase-B inhibitor."
        },
        {
          "entity_id": "ent:ba6e7c6fe9c9",
          "entity_type": "MECHANISM",
          "name": "tonic GABA synthesis",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Process described as being mediated by MAO-B according to the text."
        },
        {
          "entity_id": "ent:279100aadc9a",
          "entity_type": "MECHANISM",
          "name": "tonic inhibition",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Inhibition described as being mediated by glial GABA synthesized by monoamine oxidase B."
        },
        {
          "entity_id": "ent:b51fbcce41f8",
          "entity_type": "MECHANISM",
          "name": "dopamine degradation",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Process described as involving MAO-A according to the text."
        },
        {
          "entity_id": "ent:1480e309f2c2",
          "entity_type": "MECHANISM",
          "name": "deamination",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Process described for dopamine by an A type monoamine oxidase in rat brain."
        },
        {
          "entity_id": "ent:840de798fe91",
          "entity_type": "MECHANISM",
          "name": "inhibition",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Process described as necessary for increased functional activity of dopamine and 5-hydroxytryptamine."
        },
        {
          "entity_id": "ent:f8c8d33c5229",
          "entity_type": "MECHANISM",
          "name": "oxidation",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Process described for dopamine and its inhibition by deprenyl in man."
        },
        {
          "entity_id": "ent:22fa7f50168d",
          "entity_type": "OTHER",
          "name": "effective therapeutic candidate",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Description applied to KDS2010, a newly developed reversible MAO-B inhibitor, for Parkinson's Disease."
        },
        {
          "entity_id": "ent:1b28af4fb0bf",
          "entity_type": "OTHER",
          "name": "Substrate specificity",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Property of brain amine oxidase of several mammals being investigated in a 1960 project report."
        },
        {
          "entity_id": "ent:0ea758a50e76",
          "entity_type": "OTHER",
          "name": "phenylethylamine behaviour",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Behavior in rats that is potentiated by the monoamine oxidase B inhibitor deprenyl without inhibition of catecholamine metabolite formation."
        },
        {
          "entity_id": "ent:1ca7b1bf6d46",
          "entity_type": "OTHER",
          "name": "Preferential deamination",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Deamination process described as preferentially affecting dopamine by an A type monoamine oxidase in rat brain."
        },
        {
          "entity_id": "ent:49142387c0fb",
          "entity_type": "OTHER",
          "name": "increased functional activity",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Activity of dopamine and 5-hydroxytryptamine that requires a certain degree of inhibition of monoamine oxidase enzymes."
        },
        {
          "entity_id": "ent:5ae450739520",
          "entity_type": "OTHER",
          "name": "Species differences",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Differences in the deamination of dopamine and other substrates for monoamine oxidase in brain across species."
        },
        {
          "entity_id": "ent:db89a628f80b",
          "entity_type": "OTHER",
          "name": "Specificity of endogenous substrates",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Specificity for types A and B monoamine oxidase in rat striatum, as studied in neurochemical research."
        },
        {
          "entity_id": "ent:161384fff50c",
          "entity_type": "OTHER",
          "name": "Allotopic properties",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Properties of human brain monoamine oxidase discussed in a 1973 Nature New Biology publication."
        },
        {
          "entity_id": "ent:c24de4bb31cd",
          "entity_type": "OTHER",
          "name": "reservoir for L-DOPA",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Function attributed to striatal astrocytes in a 2014 PLoS ONE study."
        },
        {
          "entity_id": "ent:736205db0df5",
          "entity_type": "OTHER",
          "name": "contemporary view",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "View of catecholamine metabolism with implications for physiology and medicine as presented in a pharmacology review."
        },
        {
          "entity_id": "ent:b43e480dc6e3",
          "entity_type": "OTHER",
          "name": "Complexity of dopamine metabolism",
          "normalized_id": "N/A",
          "aliases": [
            "dopamine metabolism"
          ],
          "description": "Concept discussed in a 2013 Cell Communication and Signaling article focusing on dopamine metabolic pathways."
        },
        {
          "entity_id": "ent:67b8eff0d325",
          "entity_type": "OTHER",
          "name": "sensitive two-photon probe",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Probe developed to selectively detect monoamine oxidase B activity in Parkinson's disease models."
        },
        {
          "entity_id": "ent:dafd16fa5a2a",
          "entity_type": "OTHER",
          "name": "dopaminergic nerve cell death",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Cell death process in Parkinson's disease investigated for potential involvement of monoamine oxidase type B."
        },
        {
          "entity_id": "ent:32638b658e3a",
          "entity_type": "OTHER",
          "name": "brain dialysis study",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Study method used to examine striatal dopamine metabolism in monoamine oxidase B-deficient mice."
        },
        {
          "entity_id": "ent:4b1844ceb204",
          "entity_type": "OTHER",
          "name": "nigro-striatal lesions",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Lesions in rats used to study the effects of monoamine oxidase B inhibition on dopamine metabolism."
        },
        {
          "entity_id": "ent:54d2bebc226d",
          "entity_type": "PROTEIN",
          "name": "MAO-A",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "An enzyme described as having a differential role in dopamine degradation according to the document."
        },
        {
          "entity_id": "ent:8fde78fdafaf",
          "entity_type": "PROTEIN",
          "name": "amine oxidase",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "An enzyme from brain described with substrate specificity in several mammals according to the document."
        },
        {
          "entity_id": "ent:86ad740427f6",
          "entity_type": "PROTEIN",
          "name": "monoamine oxidase",
          "normalized_id": "N/A",
          "aliases": [
            "type A",
            "types A",
            "A type monoamine oxidase",
            "type B"
          ],
          "description": "An enzyme described as preferentially deaminating dopamine in rat brain according to the document."
        },
        {
          "entity_id": "ent:e44f671ea1c6",
          "entity_type": "PROTEIN",
          "name": "monoamine oxidase type B",
          "normalized_id": "N/A",
          "aliases": [
            "MAO-B",
            "monoamine oxidase B",
            "monoamine oxidase-B"
          ],
          "description": "An enzyme questioned for its role in dopaminergic nerve cell death in Parkinson's disease according to the document."
        }
      ],
      "relations": [
        {
          "head": "Rasagiline",
          "relation": "inhibit",
          "tail": "monoamine oxidase type B",
          "relation_type": "UNKNOWN",
          "confidence": [
            0.95,
            0.05
          ],
          "evidence": [
            "Weinreb, O.; Amit, T.; Bar-Am, O.; Youdim, M.B. Rasagiline: A novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity. Prog. Neurobiol. 2010, 92, 330--344.",
            "Chen, J.J.; Swope, D.M. Clinical pharmacology of rasagiline: A novel, second-generation propargylamine for the treatment of Parkinson disease. J. Clin. Pharmacol. 2005, 45, 878--894."
          ],
          "mechanism": "unknown",
          "source": "ocr_result_1_8",
          "subject": {
            "entity_id": "ent:3bd811d2535d",
            "entity_type": "TREATMENT",
            "name": "Rasagiline",
            "normalized_id": "N/A",
            "aliases": [],
            "description": "A novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity."
          },
          "object": {
            "entity_id": "ent:e44f671ea1c6",
            "entity_type": "PROTEIN",
            "name": "monoamine oxidase type B",
            "normalized_id": "N/A",
            "aliases": [
              "MAO-B",
              "monoamine oxidase B",
              "monoamine oxidase-B"
            ],
            "description": "An enzyme questioned for its role in dopaminergic nerve cell death in Parkinson's disease according to the document."
          },
          "time_info": null
        },
        {
          "head": "monoamine oxidase type B",
          "relation": "synthesize",
          "tail": "tonic GABA synthesis",
          "relation_type": "UNKNOWN",
          "confidence": [
            0.85,
            0.1
          ],
          "evidence": [
            "Cho, H.U.; Kim, S.; Sim, J.; Yang, S.; An, H.; Nam, M.H.; Jang, D.P.; Lee, C.J. Redefining differential roles of MAO-A in dopamine degradation and MAO-B in tonic GABA synthesis. Exp. Mol. Med. 2021, 53, 1148--1158.",
            "Yoon, B.E.; Woo, J.; Chun, Y.E.; Chun, H.; Jo, S.; Bae, J.Y.; An, H.; Min, J.O.; Oh, S.J.; Han, K.S.; et al. Glial GABA, synthesized by monoamine oxidase B, mediates tonic inhibition. J. Physiol. 2014, 592, 4951--4968."
          ],
          "mechanism": "unknown",
          "source": "ocr_result_1_8",
          "subject": {
            "entity_id": "ent:e44f671ea1c6",
            "entity_type": "PROTEIN",
            "name": "monoamine oxidase type B",
            "normalized_id": "N/A",
            "aliases": [
              "MAO-B",
              "monoamine oxidase B",
              "monoamine oxidase-B"
            ],
            "description": "An enzyme questioned for its role in dopaminergic nerve cell death in Parkinson's disease according to the document."
          },
          "object": {
            "entity_id": "ent:ba6e7c6fe9c9",
            "entity_type": "MECHANISM",
            "name": "tonic GABA synthesis",
            "normalized_id": "N/A",
            "aliases": [],
            "description": "Process described as being mediated by MAO-B according to the text."
          },
          "time_info": null
        },
        {
          "head": "KDS2010",
          "relation": "inhibit",
          "tail": "monoamine oxidase type B",
          "relation_type": "UNKNOWN",
          "confidence": [
            0.9,
            0.05
          ],
          "evidence": [
            "Nam, M.H.; Park, J.H.; Song, H.J.; Choi, J.W.; Kim, S.; Jang, B.K.; Yoon, H.H.; Heo, J.Y.; Lee, H.; An, H.; et al. KDS2010, a Newly Developed Reversible MAO-B Inhibitor, as an Effective Therapeutic Candidate for Parkinson's Disease. Neurotherapeutics 2021, 18, 1729--1747."
          ],
          "mechanism": "unknown",
          "source": "ocr_result_1_8",
          "subject": {
            "entity_id": "ent:614fe34fcd95",
            "entity_type": "TREATMENT",
            "name": "KDS2010",
            "normalized_id": "N/A",
            "aliases": [],
            "description": "A newly developed reversible MAO-B inhibitor described as an effective therapeutic candidate for Parkinson's Disease."
          },
          "object": {
            "entity_id": "ent:e44f671ea1c6",
            "entity_type": "PROTEIN",
            "name": "monoamine oxidase type B",
            "normalized_id": "N/A",
            "aliases": [
              "MAO-B",
              "monoamine oxidase B",
              "monoamine oxidase-B"
            ],
            "description": "An enzyme questioned for its role in dopaminergic nerve cell death in Parkinson's disease according to the document."
          },
          "time_info": null
        },
        {
          "head": "deprenyl",
          "relation": "inhibit",
          "tail": "monoamine oxidase type B",
          "relation_type": "UNKNOWN",
          "confidence": [
            0.97,
            0.05
          ],
          "evidence": [
            "Braestrup, C.; Andersen, H.; Randrup, A. The monoamine oxidase B inhibitor deprenyl potentiates phenylethylamine behaviour in rats without inhibition of catecholamine metabolite formation. Eur. J. Pharmacol. 1975, 34, 181--187.",
            "Glover, V.; Elsworth, J.D.; Sandler, M. Dopamine oxidation and its inhibition by- deprenyl in man. J. Neural. Transm. Suppl. 1980, 16, 163--172.",
            "Robakis, D.; Fahn, S. Defining the Role of the Monoamine Oxidase-B Inhibitors for Parkinson's Disease. CNS Drugs 2015, 29, 433--441."
          ],
          "mechanism": "unknown",
          "source": "ocr_result_1_8",
          "subject": {
            "entity_id": "ent:353654a4ddf7",
            "entity_type": "TREATMENT",
            "name": "deprenyl",
            "normalized_id": "N/A",
            "aliases": [],
            "description": "A monoamine oxidase B inhibitor that potentiates phenylethylamine behaviour in rats."
          },
          "object": {
            "entity_id": "ent:e44f671ea1c6",
            "entity_type": "PROTEIN",
            "name": "monoamine oxidase type B",
            "normalized_id": "N/A",
            "aliases": [
              "MAO-B",
              "monoamine oxidase B",
              "monoamine oxidase-B"
            ],
            "description": "An enzyme questioned for its role in dopaminergic nerve cell death in Parkinson's disease according to the document."
          },
          "time_info": null
        },
        {
          "head": "MAO-A",
          "relation": "deaminate",
          "tail": "dopamine degradation",
          "relation_type": "UNKNOWN",
          "confidence": [
            0.8,
            0.15
          ],
          "evidence": [
            "Cho, H.U.; Kim, S.; Sim, J.; Yang, S.; An, H.; Nam, M.H.; Jang, D.P.; Lee, C.J. Redefining differential roles of MAO-A in dopamine degradation and MAO-B in tonic GABA synthesis. Exp. Mol. Med. 2021, 53, 1148--1158.",
            "Waldmeier, P.C.; Delini-Stula, A.; Maitre, L. Preferential deamination of dopamine by an A type monoamine oxidase in rat brain. Naunyn-Schmiedebergs Arch. Pharmacol. 1976, 292, 9--14.",
            "Green, A.R.; Mitchell, B.D.; Tordoff, A.F.; Youdim, M.B. Evidence for dopamine deamination by both type A and type B monoamine oxidase in rat brain in vivo and for the degree of inhibition of enzyme necessary for increased functional activity of dopamine and 5-hydroxytryptamine. Br. J. Pharmacol. 1977, 60, 343--349."
          ],
          "mechanism": "unknown",
          "source": "ocr_result_1_8",
          "subject": {
            "entity_id": "ent:54d2bebc226d",
            "entity_type": "PROTEIN",
            "name": "MAO-A",
            "normalized_id": "N/A",
            "aliases": [],
            "description": "An enzyme described as having a differential role in dopamine degradation according to the document."
          },
          "object": {
            "entity_id": "ent:b51fbcce41f8",
            "entity_type": "MECHANISM",
            "name": "dopamine degradation",
            "normalized_id": "N/A",
            "aliases": [],
            "description": "Process described as involving MAO-A according to the text."
          },
          "time_info": null
        },
        {
          "head": "monoamine oxidase type B",
          "relation": "deaminate",
          "tail": "dopamine degradation",
          "relation_type": "UNKNOWN",
          "confidence": [
            0.7,
            0.15
          ],
          "evidence": [
            "Green, A.R.; Mitchell, B.D.; Tordoff, A.F.; Youdim, M.B. Evidence for dopamine deamination by both type A and type B monoamine oxidase in rat brain in vivo and for the degree of inhibition of enzyme necessary for increased functional activity of dopamine and 5-hydroxytryptamine. Br. J. Pharmacol. 1977, 60, 343--349.",
            "Schoepp, D.D.; Azzaro, A.J. Specificity of endogenous substrates for types A and B monoamine oxidase in rat striatum. J. Neurochem. 1981, 36, 2025--2031.",
            "Roth, J.A.; Feor, K. Deamination of dopamine and its 3-O-methylated derivative by human brain monoamine oxidase. Biochem. Pharmacol. 1978, 27, 1606--1608."
          ],
          "mechanism": "unknown",
          "source": "ocr_result_1_8",
          "subject": {
            "entity_id": "ent:e44f671ea1c6",
            "entity_type": "PROTEIN",
            "name": "monoamine oxidase type B",
            "normalized_id": "N/A",
            "aliases": [
              "MAO-B",
              "monoamine oxidase B",
              "monoamine oxidase-B"
            ],
            "description": "An enzyme questioned for its role in dopaminergic nerve cell death in Parkinson's disease according to the document."
          },
          "object": {
            "entity_id": "ent:b51fbcce41f8",
            "entity_type": "MECHANISM",
            "name": "dopamine degradation",
            "normalized_id": "N/A",
            "aliases": [],
            "description": "Process described as involving MAO-A according to the text."
          },
          "time_info": null
        },
        {
          "head": "deprenyl",
          "relation": "inhibit",
          "tail": "dopamine oxidation",
          "relation_type": "UNKNOWN",
          "confidence": [
            0.88,
            0.05
          ],
          "evidence": [
            "Glover, V.; Elsworth, J.D.; Sandler, M. Dopamine oxidation and its inhibition by- deprenyl in man. J. Neural. Transm. Suppl. 1980, 16, 163--172."
          ],
          "mechanism": "unknown",
          "source": "ocr_result_1_8",
          "subject": {
            "entity_id": "ent:353654a4ddf7",
            "entity_type": "TREATMENT",
            "name": "deprenyl",
            "normalized_id": "N/A",
            "aliases": [],
            "description": "A monoamine oxidase B inhibitor that potentiates phenylethylamine behaviour in rats."
          },
          "object": {
            "entity_id": "ent:f8c8d33c5229",
            "entity_type": "MECHANISM",
            "name": "oxidation",
            "normalized_id": "N/A",
            "aliases": [],
            "description": "Process described for dopamine and its inhibition by deprenyl in man."
          },
          "time_info": null
        },
        {
          "head": "monoamine oxidase type B",
          "relation": "oxidize",
          "tail": "dopamine degradation",
          "relation_type": "UNKNOWN",
          "confidence": [
            0.75,
            0.15
          ],
          "evidence": [
            "Glover, V.; Elsworth, J.D.; Sandler, M. Dopamine oxidation and its inhibition by- deprenyl in man. J. Neural. Transm. Suppl. 1980, 16, 163--172.",
            "Green, A.R.; Mitchell, B.D.; Tordoff, A.F.; Youdim, M.B. Evidence for dopamine deamination by both type A and type B monoamine oxidase in rat brain in vivo and for the degree of inhibition of enzyme necessary for increased functional activity of dopamine and 5-hydroxytryptamine. Br. J. Pharmacol. 1977, 60, 343--349.",
            "Roth, J.A.; Feor, K. Deamination of dopamine and its 3-O-methylated derivative by human brain monoamine oxidase. Biochem. Pharmacol. 1978, 27, 1606--1608."
          ],
          "mechanism": "unknown",
          "source": "ocr_result_1_8",
          "subject": {
            "entity_id": "ent:e44f671ea1c6",
            "entity_type": "PROTEIN",
            "name": "monoamine oxidase type B",
            "normalized_id": "N/A",
            "aliases": [
              "MAO-B",
              "monoamine oxidase B",
              "monoamine oxidase-B"
            ],
            "description": "An enzyme questioned for its role in dopaminergic nerve cell death in Parkinson's disease according to the document."
          },
          "object": {
            "entity_id": "ent:b51fbcce41f8",
            "entity_type": "MECHANISM",
            "name": "dopamine degradation",
            "normalized_id": "N/A",
            "aliases": [],
            "description": "Process described as involving MAO-A according to the text."
          },
          "time_info": null
        }
      ]
    },
    "ocr_result_1_9": {
      "id": "ocr_result_1_9",
      "name": "",
      "meta": {
        "text": "^{64} Paterson, I.A.; Juorio, A.V.; Berry, M.D.; Zhu, M.Y. Inhibition of monoamine oxidase-B by-deprenyl potentiates neuronal responses to dopamine agonists but does not inhibit dopamine catabolism in the rat striatum. J. Pharmacol. Exp. Ther. 1991, 258, 1019--1026.\n- (65) Sader-Mazbar, O.; Loboda, Y.; Rabey, M.J.; Finberg, J.P. Increased L-DOPA-derived dopamine following selective MAO-A or -B inhibition in rat striatum depleted of dopaminergic and serotonergic innervation. Br. J. Pharmacol. 2013, 170, 999--1013. [CrossRef]\n- (66) Lenders, J.W.; Eisenhofer, G.; Abeling, N.G.; Berger, W.; Murphy, D.L.; Konings, C.H.; Wagemakers, L.M.; Kopin, I.J.; Karoum, F.; van Gennip, A.H.; et al. Specific genetic deficiencies of the A and B isoenzymes of monoamine oxidase are characterized by distinct neurochemical and clinical phenotypes. J. Clin. Investig. 1996, 97, 1010--1019. [CrossRef]\n- (67) Fowler, C.J.; Benedetti, M.S. The metabolism of dopamine by both forms of monoamine oxidase in the rat brain and its inhibition by cimoxatone. J. Neurochem. 1983, 40, 1534--1541. [CrossRef]\n- (68) O'Carroll, A.M.; Fowler, C.J.; Phillips, J.P.; Tobbia, I.; Tipton, K.F. The deamination of dopamine by human brain monoamine oxidase. Specificity for the two enzyme forms in seven brain regions. Naunyn. Schmiedebergs. Arch. Pharmacol. 1983, 322, 198--202. [CrossRef]\n- (69) Davis, G.C.; Williams, A.C.; Markey, S.P.; Ebert, M.H.; Caine, E.D.; Reichert, C.M.; Kopin, I.J. Chronic Parkinsonism secondary to intravenous injection of meperidine analogues. Psychiatry Res. 1979, 1, 249--254. [CrossRef]\n- (70) Jackson-Lewis, V.; Przedborski, S. Protocol for the MPTP mouse model of Parkinson's disease. Nat. Protoc. 2007, 2, 141--151. [CrossRef]\n- (71) Uhl, G.R.; Javitch, J.A.; Snyder, S.H. Normal MPTP binding in parkinsonian substantial nigra: Evidence for extraneuronal toxin conversion in human brain. Lancet 1985, 1, 956--957. [CrossRef]\n- (72) Watanabe, Y.; Himeda, T.; Araki, T. Mechanisms of MPTP toxicity and their implications for therapy of Parkinson's disease. Med. Sci. Monit. 2005, 11, RA17--RA23. [PubMed]\n- (73) Caccia, C.; Maj, R.; Calabresi, M.; Maestroni, S.; Faravelli, L.; Curatolo, L.; Salvati, P.; Fariello, R.G. Safinamide: From molecular targets to a new anti-Parkinson drug. Neurology 2006, 67 (7 Suppl. 2), S18--S23. [CrossRef]\n- (74) Sundstrom, E.; Luthman, J.; Goldstein, M.; Jonsson, G. Time course of MPTP-induced degeneration of the nigrostriatal dopamine system in C57 BL/6 mice. Brain Res Bull 1988, 21, 257--263. [CrossRef]\n- (75) Woo, J.; Min, J.O.; Kang, D.S.; Kim, Y.S.; Jung, G.H.; Park, H.J.; Kim, S.; An, H.; Kwon, J.; Kim, J.; et al. Control of motor coordination by astrocytic tonic GABA release through modulation of excitation/inhibition balance in cerebellum. Proc. Natl. Acad. Sci. USA 2018, 115, 5004--5009. [CrossRef]\n- (76) Lee, S.; Yoon, B.E.; Berglund, K.; Oh, S.J.; Park, H.; Shin, H.S.; Augustine, G.J.; Lee, C.J. Channel-mediated tonic GABA release from glia. Science 2010, 330, 790--796. [CrossRef]\n- (77) Yoon, B.E.; Jo, S.; Woo, J.; Lee, J.H.; Kim, T.; Kim, D.; Lee, C.J. The amount of astrocytic GABA positively correlates with the degree of tonic inhibition in hippocampal CA1 and cerebellum. Mol. Brain. 2011, 4, 42. [CrossRef]\n- (78) Chun, H.; Im, H.; Kang, Y.J.; Kim, Y.; Shin, J.H.; Won, W.; Lim, J.; Ju, Y.; Park, Y.M.; Kim, S.; et al. Severe reactive astrocytes precipitate pathological hallmarks of Alzheimer's disease via H_{2}O_{2} production. Nat. Neurosci. 2020, 23, 1555--1566. [CrossRef]\n- (79) Ju, Y.H.; Bhalla, M.; Hyeon, S.J.; Oh, J.E.; Yoo, S.; Chae, U.; Kwon, J.; Koh, W.; Lim, J.; Park, Y.M.; et al. Astrocytic urea cycle detoxifies A-derived ammonia while impairing memory in Alzheimer's disease. bioRxiv 2021, arXiv:15.464517. [CrossRef]\n- (80) Chamoli, M.; Chinta, S.J.; Andersen, J.K. An inducible MAO-B mouse model of Parkinson's disease: A tool towards better understanding basic disease mechanisms and developing novel therapeutics. J. Neural. Transm. 2018, 125, 1651--1658. [CrossRef]\n- (81) Tan, Y.Y.; Jenner, P.; Chen, S.D. Monoamine Oxidase-B Inhibitors for the Treatment of Parkinson's Disease: Past, Present, and Future. J. Parkinsons Dis. 2022, 12, 477--493. [CrossRef] [PubMed]\n- (82) Binde, C.D.; Tvete, I.F.; Gasemyr, J.I.; Natvig, B.; Klemp, M. Comparative effectiveness of dopamine agonists and monoamine oxidase type-B inhibitors for Parkinson's disease: A multiple treatment comparison meta-analysis. Eur. J. Clin. Pharmacol. 2020, 76, 1731--1743. [CrossRef] [PubMed]\n- (83) Ostadkarampour, M.; Putnins, E.E. Monoamine Oxidase Inhibitors: A Review of Their Anti-Inflammatory Therapeutic Potential and Mechanisms of Action. Front Pharmacol. 2021, 12, 676239. [CrossRef] [PubMed]\n- (84) Pisano, C.A.; Brugnoli, A.; Novello, S.; Caccia, C.; Keywood, C.; Melloni, E.; Vailati, S.; Padoani, G.; Morari, M. Safinamide inhibits in vivo glutamate release in a rat model of Parkinson's disease. Neuropharmacology 2020, 167, 108006. [CrossRef] [PubMed]\n- (85) Teo, K.C.; Ho, S.L. Monoamine oxidase-B (MAO-B) inhibitors: Implications for disease-modification in Parkinson's disease. Transl. Neurodegener. 2013, 2, 19. [CrossRef] [PubMed]\n- (86) Finberg, J.P.; Gillman, K. Selective inhibitors of monoamine oxidase type B and the cheese effect. Int. Rev. Neurobiol. 2011, 100, 169--190.\n- (87) Knoll, J.; Ecseri, Z.; Kelemen, K.; Nievel, J.; Knoll, B. Phenylisopropylmethylpropinylamine (E-250), a new spectrum psychic energizer. Arch. Int. Pharmacodyn. Ther. 1965, 155, 154--164.\n- (88) Riederer, P.; Youdim, M.B. Monoamine oxidase activity and monoamine metabolism in brains of parkinsonian patients treated with l-deprenyl. J. Neurochem. 1986, 46, 1359--1365. [CrossRef]\n- (89) Riederer, P.; Lachenmayer, L. Selegiline's neuroprotective capacity revisited. J. Neural Transm. 2003, 110, 1273--1278. [CrossRef]\n- (90) Palhagen, S.; Heinonen, E.; Hagglund, J.; Kaugesaar, T.; Maki-Ikola, O.; Palm, R.; Swedish Parkinson Study, G. Selegiline slows the progression of the symptoms of Parkinson disease. Neurology 2006, 66, 1200--1206. [CrossRef]",
        "source": "ocr_result_1"
      },
      "entities": [
        {
          "entity_id": "ent:bff39a19a8e8",
          "entity_type": "PROTEIN",
          "name": "monoamine oxidase-B",
          "normalized_id": "N/A",
          "aliases": [
            "MAO-B"
          ],
          "description": "Enzyme described as being inhibited by deprenyl, which potentiates neuronal responses to dopamine agonists in the rat striatum."
        },
        {
          "entity_id": "ent:e9b94210cd3f",
          "entity_type": "PROTEIN",
          "name": "MAO-A",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Isoenzyme of monoamine oxidase described as being selectively inhibited, leading to increased L-DOPA-derived dopamine in rat striatum."
        },
        {
          "entity_id": "ent:aa7e5c0341c6",
          "entity_type": "PROTEIN",
          "name": "monoamine oxidase",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Enzyme described as having A and B isoenzymes with specific genetic deficiencies characterized by distinct neurochemical and clinical phenotypes."
        },
        {
          "entity_id": "ent:5e647d1b5c27",
          "entity_type": "DRUG",
          "name": "L-DOPA",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Compound described as a source of dopamine following selective MAO-A or -B inhibition in rat striatum."
        },
        {
          "entity_id": "ent:89d08c7a6828",
          "entity_type": "DRUG",
          "name": "cimoxatone",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Drug described as inhibiting the metabolism of dopamine by both forms of monoamine oxidase in rat brain."
        },
        {
          "entity_id": "ent:c6017d340808",
          "entity_type": "DRUG",
          "name": "meperidine",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Drug mentioned as having analogues that cause chronic Parkinsonism when injected intravenously."
        },
        {
          "entity_id": "ent:63a1a8bd33ec",
          "entity_type": "DRUG",
          "name": "MPTP",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Toxin described in a mouse model of Parkinson's disease and noted for its binding and conversion in human brain."
        },
        {
          "entity_id": "ent:fe3a4aea216f",
          "entity_type": "DRUG",
          "name": "Safinamide",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Drug described as a new anti-Parkinson agent that inhibits in vivo glutamate release in rat models."
        },
        {
          "entity_id": "ent:c8026e41e1e1",
          "entity_type": "DRUG",
          "name": "Selegiline",
          "normalized_id": "N/A",
          "aliases": [
            "deprenyl",
            "l-deprenyl"
          ],
          "description": "Drug noted for its neuroprotective capacity and for slowing symptom progression in Parkinson's disease."
        },
        {
          "entity_id": "ent:37005fa157f8",
          "entity_type": "DISEASE",
          "name": "Parkinsonism",
          "normalized_id": "N/A",
          "aliases": [
            "Parkinson"
          ],
          "description": "Condition described as chronic and secondary to intravenous injection of meperidine analogues."
        },
        {
          "entity_id": "ent:7034bc4157ba",
          "entity_type": "DISEASE",
          "name": "Parkinson's disease",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Disease for which the MPTP mouse model protocol is described."
        },
        {
          "entity_id": "ent:8ff83938e559",
          "entity_type": "DISEASE",
          "name": "parkinsonian",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Term used to describe substantial nigra in relation to MPTP binding and toxin conversion."
        },
        {
          "entity_id": "ent:ee709b4c0aa7",
          "entity_type": "DISEASE",
          "name": "Alzheimer's disease",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Disease where severe reactive astrocytes precipitate pathological hallmarks via HO production."
        },
        {
          "entity_id": "ent:eaee2392f832",
          "entity_type": "DISEASE",
          "name": "Parkinson disease",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Disease whose symptom progression is slowed by selegiline according to the Swedish Parkinson Study Group."
        },
        {
          "entity_id": "ent:2cb0e97f3d2e",
          "entity_type": "MECHANISM",
          "name": "Inhibition of monoamine oxidase-B",
          "normalized_id": "N/A",
          "aliases": [
            "MAO-A inhibition",
            "MAO-B inhibition",
            "selective MAO-A or -B inhibition"
          ],
          "description": "Inhibition of monoamine oxidase-B potentiates neuronal responses to dopamine agonists but does not inhibit dopamine catabolism in the rat striatum."
        },
        {
          "entity_id": "ent:6915408f8e55",
          "entity_type": "MECHANISM",
          "name": "dopamine catabolism",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Dopamine catabolism in the rat striatum is not inhibited by monoamine oxidase-B inhibition according to the study."
        },
        {
          "entity_id": "ent:d9247696c877",
          "entity_type": "MECHANISM",
          "name": "metabolism of dopamine",
          "normalized_id": "N/A",
          "aliases": [
            "dopamine metabolism"
          ],
          "description": "The metabolism of dopamine by both forms of monoamine oxidase in the rat brain and its inhibition by cimoxatone is described."
        },
        {
          "entity_id": "ent:7a2775e5d9ce",
          "entity_type": "MECHANISM",
          "name": "deamination of dopamine",
          "normalized_id": "N/A",
          "aliases": [
            "dopamine deamination"
          ],
          "description": "The deamination of dopamine by human brain monoamine oxidase with specificity for the two enzyme forms in seven brain regions."
        },
        {
          "entity_id": "ent:a5481106313c",
          "entity_type": "MECHANISM",
          "name": "extraneuronal toxin conversion",
          "normalized_id": "N/A",
          "aliases": [
            "toxin conversion"
          ],
          "description": "Evidence for extraneuronal toxin conversion in human brain is mentioned in the context of MPTP binding in parkinsonian substantia nigra."
        },
        {
          "entity_id": "ent:75f0cde952b6",
          "entity_type": "MECHANISM",
          "name": "Channel-mediated tonic GABA release",
          "normalized_id": "N/A",
          "aliases": [
            "GABA release",
            "tonic GABA release"
          ],
          "description": "Channel-mediated tonic GABA release from glia is described as a mechanism in the referenced study."
        },
        {
          "entity_id": "ent:c9907d238b42",
          "entity_type": "MECHANISM",
          "name": "H_{2}O_{2} production",
          "normalized_id": "N/A",
          "aliases": [
            "hydrogen peroxide production"
          ],
          "description": "Severe reactive astrocytes precipitate pathological hallmarks of Alzheimer's disease via H_{2}O_{2} production."
        },
        {
          "entity_id": "ent:153849672d1f",
          "entity_type": "MECHANISM",
          "name": "Astrocytic urea cycle",
          "normalized_id": "N/A",
          "aliases": [
            "urea cycle"
          ],
          "description": "Astrocytic urea cycle detoxifies A-derived ammonia while impairing memory in Alzheimer's disease."
        },
        {
          "entity_id": "ent:245c85f4a106",
          "entity_type": "MECHANISM",
          "name": "glutamate release",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Safinamide inhibits in vivo glutamate release in a rat model of Parkinson's disease according to the study."
        },
        {
          "entity_id": "ent:a1372e0b2371",
          "entity_type": "TREATMENT",
          "name": "MPTP mouse model",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "An experimental protocol used to model Parkinson's disease in mice through neurotoxin administration."
        },
        {
          "entity_id": "ent:11b068718194",
          "entity_type": "TREATMENT",
          "name": "therapy",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Treatment approaches for Parkinson's disease mentioned in the context of MPTP toxicity mechanisms."
        },
        {
          "entity_id": "ent:aeac225f2be0",
          "entity_type": "TREATMENT",
          "name": "anti-Parkinson drug",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Medications like safinamide developed for treating Parkinson's disease symptoms and pathology."
        },
        {
          "entity_id": "ent:9792f2163367",
          "entity_type": "TREATMENT",
          "name": "MAO-B mouse model",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "An inducible experimental model of Parkinson's disease used to study basic mechanisms and develop therapeutics."
        },
        {
          "entity_id": "ent:075fe16fe4c2",
          "entity_type": "TREATMENT",
          "name": "developing novel therapeutics",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "The process of creating new treatments for Parkinson's disease using experimental models."
        },
        {
          "entity_id": "ent:cfcd54cd829c",
          "entity_type": "TREATMENT",
          "name": "treatment",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Therapeutic approaches for Parkinson's disease involving various pharmacological interventions."
        },
        {
          "entity_id": "ent:fa5f8e2b61f5",
          "entity_type": "TREATMENT",
          "name": "dopamine agonists",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A class of Parkinson's disease medications compared with monoamine oxidase type-B inhibitors in effectiveness studies."
        },
        {
          "entity_id": "ent:f0f7b2500bf1",
          "entity_type": "TREATMENT",
          "name": "Monoamine Oxidase Inhibitors",
          "normalized_id": "N/A",
          "aliases": [
            "MAO inhibitors"
          ],
          "description": "A class of drugs reviewed for their anti-inflammatory therapeutic potential and mechanisms of action."
        },
        {
          "entity_id": "ent:76536ad3403d",
          "entity_type": "TREATMENT",
          "name": "anti-inflammatory therapeutic",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Potential medical applications of monoamine oxidase inhibitors beyond their neurological effects."
        },
        {
          "entity_id": "ent:4cbedc41325f",
          "entity_type": "TREATMENT",
          "name": "disease-modification",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Therapeutic approaches aimed at altering the progression of Parkinson's disease rather than just treating symptoms."
        },
        {
          "entity_id": "ent:8b82e4f8bdcd",
          "entity_type": "TREATMENT",
          "name": "Selective inhibitors of monoamine oxidase type B",
          "normalized_id": "N/A",
          "aliases": [
            "MAO-B inhibitors",
            "monoamine oxidase type-B inhibitors",
            "monoamine oxidase-B (MAO-B) inhibitors",
            "Monoamine Oxidase-B Inhibitors"
          ],
          "description": "Pharmacologic agents that specifically target MAO-B enzymes, discussed in relation to the \"cheese effect\" side effect."
        },
        {
          "entity_id": "ent:b90180e99bfc",
          "entity_type": "TREATMENT",
          "name": "treated with l-deprenyl",
          "normalized_id": "N/A",
          "aliases": [
            "selegiline treatment"
          ],
          "description": "Therapeutic administration of l-deprenyl to parkinsonian patients to study monoamine oxidase activity and metabolism."
        },
        {
          "entity_id": "ent:1618d04b838c",
          "entity_type": "TREATMENT",
          "name": "neuroprotective capacity",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Therapeutic property of selegiline that may protect neurons from damage in Parkinson's disease."
        }
      ],
      "relations": [
        {
          "head": "Selegiline",
          "relation": "inhibit",
          "tail": "monoamine oxidase-B",
          "relation_type": "UNKNOWN",
          "confidence": [
            0.95,
            0.05
          ],
          "evidence": [
            "Inhibition of monoamine oxidase-B by-deprenyl potentiates neuronal responses to dopamine agonists but does not inhibit dopamine catabolism in the rat striatum.",
            "Monoamine oxidase-B (MAO-B) inhibitors: Implications for disease-modification in Parkinson's disease.",
            "Selegiline's neuroprotective capacity revisited."
          ],
          "mechanism": "unknown",
          "source": "ocr_result_1_9",
          "subject": {
            "entity_id": "ent:c8026e41e1e1",
            "entity_type": "DRUG",
            "name": "Selegiline",
            "normalized_id": "N/A",
            "aliases": [
              "deprenyl",
              "l-deprenyl"
            ],
            "description": "Drug noted for its neuroprotective capacity and for slowing symptom progression in Parkinson's disease."
          },
          "object": {
            "entity_id": "ent:2cb0e97f3d2e",
            "entity_type": "MECHANISM",
            "name": "Inhibition of monoamine oxidase-B",
            "normalized_id": "N/A",
            "aliases": [
              "MAO-A inhibition",
              "MAO-B inhibition",
              "selective MAO-A or -B inhibition"
            ],
            "description": "Inhibition of monoamine oxidase-B potentiates neuronal responses to dopamine agonists but does not inhibit dopamine catabolism in the rat striatum."
          },
          "time_info": null
        },
        {
          "head": "cimoxatone",
          "relation": "inhibit",
          "tail": "monoamine oxidase",
          "relation_type": "UNKNOWN",
          "confidence": [
            0.85,
            0.05
          ],
          "evidence": [
            "The metabolism of dopamine by both forms of monoamine oxidase in the rat brain and its inhibition by cimoxatone."
          ],
          "mechanism": "unknown",
          "source": "ocr_result_1_9",
          "subject": {
            "entity_id": "ent:89d08c7a6828",
            "entity_type": "DRUG",
            "name": "cimoxatone",
            "normalized_id": "N/A",
            "aliases": [],
            "description": "Drug described as inhibiting the metabolism of dopamine by both forms of monoamine oxidase in rat brain."
          },
          "object": {
            "entity_id": "ent:8b82e4f8bdcd",
            "entity_type": "TREATMENT",
            "name": "Selective inhibitors of monoamine oxidase type B",
            "normalized_id": "N/A",
            "aliases": [
              "MAO-B inhibitors",
              "monoamine oxidase type-B inhibitors",
              "monoamine oxidase-B (MAO-B) inhibitors",
              "Monoamine Oxidase-B Inhibitors"
            ],
            "description": "Pharmacologic agents that specifically target MAO-B enzymes, discussed in relation to the \"cheese effect\" side effect."
          },
          "time_info": null
        },
        {
          "head": "Safinamide",
          "relation": "inhibit",
          "tail": "glutamate release",
          "relation_type": "UNKNOWN",
          "confidence": [
            0.8,
            0.05
          ],
          "evidence": [
            "Safinamide inhibits in vivo glutamate release in a rat model of Parkinson's disease."
          ],
          "mechanism": "unknown",
          "source": "ocr_result_1_9",
          "subject": {
            "entity_id": "ent:fe3a4aea216f",
            "entity_type": "DRUG",
            "name": "Safinamide",
            "normalized_id": "N/A",
            "aliases": [],
            "description": "Drug described as a new anti-Parkinson agent that inhibits in vivo glutamate release in rat models."
          },
          "object": {
            "entity_id": "ent:245c85f4a106",
            "entity_type": "MECHANISM",
            "name": "glutamate release",
            "normalized_id": "N/A",
            "aliases": [],
            "description": "Safinamide inhibits in vivo glutamate release in a rat model of Parkinson's disease according to the study."
          },
          "time_info": null
        },
        {
          "head": "Selegiline",
          "relation": "slow",
          "tail": "Parkinson's disease",
          "relation_type": "UNKNOWN",
          "confidence": [
            0.9,
            0.1
          ],
          "evidence": [
            "Selegiline slows the progression of the symptoms of Parkinson disease.",
            "Monoamine oxidase-B (MAO-B) inhibitors: Implications for disease-modification in Parkinson's disease.",
            "Selegiline's neuroprotective capacity revisited."
          ],
          "mechanism": "unknown",
          "source": "ocr_result_1_9",
          "subject": {
            "entity_id": "ent:c8026e41e1e1",
            "entity_type": "DRUG",
            "name": "Selegiline",
            "normalized_id": "N/A",
            "aliases": [
              "deprenyl",
              "l-deprenyl"
            ],
            "description": "Drug noted for its neuroprotective capacity and for slowing symptom progression in Parkinson's disease."
          },
          "object": {
            "entity_id": "ent:7034bc4157ba",
            "entity_type": "DISEASE",
            "name": "Parkinson's disease",
            "normalized_id": "N/A",
            "aliases": [],
            "description": "Disease for which the MPTP mouse model protocol is described."
          },
          "time_info": null
        }
      ]
    },
    "ocr_result_1_10": {
      "id": "ocr_result_1_10",
      "name": "",
      "meta": {
        "text": "91. De la Cruz, C.P.; Revilla, E.; Steffen, V.; Rodriguez-Gomez, J.A.; Cano, J.; Machado, A. Protection of the aged substantia nigra of the rat against oxidative damage by-deprenyl. Br. J. Pharmacol. 1996, 117, 1756--1760. [CrossRef] [PubMed]\n\n92. Munirathinam, S.; Lakshmana, M.K.; Raju, T.R. deprenyl attenuates aluminium induced neurotoxicity in primary cortical cultures. Neurodegeneration 1996, 5, 161--167. [CrossRef] [PubMed]\n\n93. Maruyama, W.; Takahashi, T.; Naoi, M. -Deprenyl protects human dopaminergic neuroblastoma SH-SY5Y cells from apoptosis induced by peroxynitrite and nitric oxide. J. Neurochem. 1998, 70, 2510--2515. [CrossRef] [PubMed]\n\n94. Tatton, W.G.; Chalmers-Redman, R.M.; Ju, W.J.; Mammen, M.; Carlile, G.W.; Pong, A.W.; Tatton, N.A. Propargylamines induce antiapoptotic new protein synthesis in serum- and nerve growth factor (NGF)-withdrawn, NGF-differentiated PC-12 cells. J. Pharmacol. Exp. Ther. 2002, 301, 753--764. [CrossRef]\n\n95. Fowler, J.S.; Logan, J.; Volkow, N.D.; Shumay, E.; McCall-Perez, F.; Jayne, M.; Wang, G.J.; Alexoff, D.L.; Apelskog-Torres, K.; Hubbard, B.; et al. Evidence that formulations of the selective MAO-B inhibitor, selegiline, which bypass first-pass metabolism, also inhibit MAO-A in the human brain. Neuropsychopharmacology 2015, 40, 650--657. [CrossRef]\n\n96. Maurer, H.H.; Kraemer, T. Toxicological detection of selegiline and its metabolites in urine using fluorescence polarization immunoassay (FPIA) and gas chromatography-mass spectrometry (GC-MS) and differentiation by enantioselective GC-MS of the intake of selegiline from abuse of methamphetamine or amphetamine. Arch. Toxicol. 1992, 66, 675--678.\n\n97. Finberg, J.P.; Youdim, M.B. Pharmacological properties of the anti-Parkinson drug rasagiline; modification of endogenous brain amines, reserpine reversal, serotonergic and dopaminergic behaviours. Neuropharmacology 2002, 43, 1110--1118. [CrossRef]\n\n98. Kamakura, K.; Mochizuki, H.; Kaida, K.; Hirata, A.; Kanzaki, M.; Masaki, T.; Nakamura, R.; Motoyoshi, K. Therapeutic factors causing hallucination in Parkinson's disease patients, especially those given selegiline. Parkinsonism Relat. Disord. 2004, 10, 235--242. [CrossRef]\n\n99. Sadeghian, M.; Mullali, G.; Pocock, J.M.; Piers, T.; Roach, A.; Smith, K.J. Neuroprotection by safinamide in the 6-hydroxydopamine model of Parkinson's disease. Neuropathol. Appl. Neurobiol. 2016, 42, 423--435. [CrossRef]\n\n100. Perez-Lloret, S.; Rascol, O. The safety and efficacy of safinamide mesylate for the treatment of Parkinson's disease. Expert. Rev. Neurother. 2016, 16, 245--258. [CrossRef]\n\n101. Marzo, A.; Dal Bo, L.; Monti, N.C.; Crivelli, F.; Ismaili, S.; Caccia, C.; Cattaneo, C.; Fariello, R.G. Pharmacokinetics and pharmacodynamics of safinamide, a neuroprotectant with antiparkinsonian and anticonvulsant activity. Pharmacol. Res. 2004, 50, 77--85. [CrossRef] [PubMed]\n\n102. Bulaklak, K.; Gersbach, C.A. The once and future gene therapy. Nat. Commun. 2020, 11, 5820. [CrossRef]\n\n103. Crooke, S.T. Molecular Mechanisms of Antisense Oligonucleotides. Nucleic Acid. Ther. 2017, 27, 70--77. [CrossRef] [PubMed]\n\n104. Yoon, H.H.; Ye, S.; Lim, S.; Jo, A.; Lee, H.; Hong, F.; Lee, S.E.; Oh, S.J.; Kim, N.R.; Kim, K.; et al. CRISPR-Cas9 Gene Editing Protects from the A53T-SNCA Overexpression-Induced Pathology of Parkinson's Disease In Vivo. CRISPR J. 2022, 5, 95--108. [CrossRef] [PubMed]",
        "source": "ocr_result_1"
      },
      "entities": [
        {
          "entity_id": "ent:3904efca6a0a",
          "entity_type": "GENE",
          "name": "A53T-SNCA",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A genetic variant (A53T) of the SNCA gene associated with Parkinson's disease pathology in an overexpression-induced model studied using CRISPR-Cas9 gene editing."
        },
        {
          "entity_id": "ent:7eec4c2bdf1c",
          "entity_type": "PROTEIN",
          "name": "MAO-B",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Enzyme described as a selective inhibitor target of selegiline formulations that bypass first-pass metabolism."
        },
        {
          "entity_id": "ent:9eb46c4092e9",
          "entity_type": "PROTEIN",
          "name": "MAO-A",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Enzyme described as being inhibited in the human brain by formulations of the selective MAO-B inhibitor selegiline that bypass first-pass metabolism."
        },
        {
          "entity_id": "ent:2a3828125d8f",
          "entity_type": "DISEASE",
          "name": "aluminium induced neurotoxicity",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "N/A"
        },
        {
          "entity_id": "ent:31268a57fd65",
          "entity_type": "DISEASE",
          "name": "apoptosis",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "N/A"
        },
        {
          "entity_id": "ent:f6c4f83730a0",
          "entity_type": "DISEASE",
          "name": "Parkinson's disease",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "N/A"
        },
        {
          "entity_id": "ent:73360d1e8693",
          "entity_type": "MECHANISM",
          "name": "oxidative damage",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A process against which the aged substantia nigra is protected by deprenyl according to the cited study."
        },
        {
          "entity_id": "ent:20defcc14a2a",
          "entity_type": "MECHANISM",
          "name": "antiapoptotic new protein synthesis",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A process induced by propargylamines in serum- and nerve growth factor-withdrawn, NGF-differentiated PC-12 cells."
        },
        {
          "entity_id": "ent:7ab508dc72d1",
          "entity_type": "MECHANISM",
          "name": "first-pass metabolism",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A metabolic process that certain formulations of selegiline bypass according to the evidence presented."
        },
        {
          "entity_id": "ent:2dce450b9171",
          "entity_type": "MECHANISM",
          "name": "neuroprotection",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "An effect provided by safinamide in the 6-hydroxydopamine model of Parkinson's disease."
        },
        {
          "entity_id": "ent:61b6bd4b4a41",
          "entity_type": "DRUG",
          "name": "deprenyl",
          "normalized_id": "N/A",
          "aliases": [
            "deprenyl"
          ],
          "description": "Drug described as protecting human dopaminergic neuroblastoma SH-SY5Y cells from apoptosis induced by peroxynitrite and nitric oxide."
        },
        {
          "entity_id": "ent:7a49e9b8e453",
          "entity_type": "DRUG",
          "name": "Propargylamines",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Compounds described as inducing antiapoptotic new protein synthesis in serum- and nerve growth factor-withdrawn, NGF-differentiated PC-12 cells."
        },
        {
          "entity_id": "ent:42f388b4924a",
          "entity_type": "DRUG",
          "name": "selegiline",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Drug described as a selective MAO-B inhibitor in formulations that bypass first-pass metabolism and also inhibit MAO-A in the human brain."
        },
        {
          "entity_id": "ent:fffabe1f29a9",
          "entity_type": "DRUG",
          "name": "rasagiline",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Drug described as an anti-Parkinson drug with pharmacological properties modifying endogenous brain amines, reserpine reversal, serotonergic and dopaminergic behaviours."
        },
        {
          "entity_id": "ent:23042f2dcbf6",
          "entity_type": "DRUG",
          "name": "safinamide",
          "normalized_id": "N/A",
          "aliases": [
            "safinamide"
          ],
          "description": "Drug described for the treatment of Parkinson's disease, with discussion of its safety and efficacy."
        },
        {
          "entity_id": "ent:1c7071ca4fda",
          "entity_type": "TREATMENT",
          "name": "gene therapy",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Referred to as 'the once and future' approach in a communication about genetic interventions."
        },
        {
          "entity_id": "ent:d953ab7ea02a",
          "entity_type": "TREATMENT",
          "name": "Antisense Oligonucleotides",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Molecular mechanisms of these therapeutic agents are discussed in the context of nucleic acid therapy."
        },
        {
          "entity_id": "ent:1f04302c5a5d",
          "entity_type": "TREATMENT",
          "name": "CRISPR-Cas9 Gene Editing",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Described as protecting from the A53T-SNCA overexpression-induced pathology of Parkinson's Disease In Vivo."
        }
      ],
      "relations": [
        {
          "head": "-Deprenyl",
          "relation": "protect",
          "tail": "oxidative damage",
          "relation_type": "UNKNOWN",
          "confidence": [
            0.85,
            0.05
          ],
          "evidence": [
            "Protection of the aged substantia nigra of the rat against oxidative damage by-deprenyl.",
            "-Deprenyl protects human dopaminergic neuroblastoma SH-SY5Y cells from apoptosis induced by peroxynitrite and nitric oxide."
          ],
          "mechanism": "unknown",
          "source": "ocr_result_1_10",
          "subject": {
            "entity_id": "ent:61b6bd4b4a41",
            "entity_type": "DRUG",
            "name": "deprenyl",
            "normalized_id": "N/A",
            "aliases": [
              "deprenyl"
            ],
            "description": "Drug described as protecting human dopaminergic neuroblastoma SH-SY5Y cells from apoptosis induced by peroxynitrite and nitric oxide."
          },
          "object": {
            "entity_id": "ent:73360d1e8693",
            "entity_type": "MECHANISM",
            "name": "oxidative damage",
            "normalized_id": "N/A",
            "aliases": [],
            "description": "A process against which the aged substantia nigra is protected by deprenyl according to the cited study."
          },
          "time_info": null
        },
        {
          "head": "-Deprenyl",
          "relation": "attenuate",
          "tail": "neurotoxicity",
          "relation_type": "UNKNOWN",
          "confidence": [
            0.8,
            0.05
          ],
          "evidence": [
            "deprenyl attenuates aluminium induced neurotoxicity in primary cortical cultures."
          ],
          "mechanism": "unknown",
          "source": "ocr_result_1_10",
          "subject": {
            "entity_id": "ent:61b6bd4b4a41",
            "entity_type": "DRUG",
            "name": "deprenyl",
            "normalized_id": "N/A",
            "aliases": [
              "deprenyl"
            ],
            "description": "Drug described as protecting human dopaminergic neuroblastoma SH-SY5Y cells from apoptosis induced by peroxynitrite and nitric oxide."
          },
          "object": {
            "entity_id": "ent:2a3828125d8f",
            "entity_type": "DISEASE",
            "name": "aluminium induced neurotoxicity",
            "normalized_id": "N/A",
            "aliases": [],
            "description": "N/A"
          },
          "time_info": null
        },
        {
          "head": "-Deprenyl",
          "relation": "protect",
          "tail": "apoptosis",
          "relation_type": "UNKNOWN",
          "confidence": [
            0.82,
            0.05
          ],
          "evidence": [
            "-Deprenyl protects human dopaminergic neuroblastoma SH-SY5Y cells from apoptosis induced by peroxynitrite and nitric oxide."
          ],
          "mechanism": "unknown",
          "source": "ocr_result_1_10",
          "subject": {
            "entity_id": "ent:61b6bd4b4a41",
            "entity_type": "DRUG",
            "name": "deprenyl",
            "normalized_id": "N/A",
            "aliases": [
              "deprenyl"
            ],
            "description": "Drug described as protecting human dopaminergic neuroblastoma SH-SY5Y cells from apoptosis induced by peroxynitrite and nitric oxide."
          },
          "object": {
            "entity_id": "ent:31268a57fd65",
            "entity_type": "DISEASE",
            "name": "apoptosis",
            "normalized_id": "N/A",
            "aliases": [],
            "description": "N/A"
          },
          "time_info": null
        },
        {
          "head": "Propargylamines",
          "relation": "induce",
          "tail": "antiapoptotic new protein synthesis",
          "relation_type": "UNKNOWN",
          "confidence": [
            0.78,
            0.05
          ],
          "evidence": [
            "Propargylamines induce antiapoptotic new protein synthesis in serum- and nerve growth factor (NGF)-withdrawn, NGF-differentiated PC-12 cells."
          ],
          "mechanism": "unknown",
          "source": "ocr_result_1_10",
          "subject": {
            "entity_id": "ent:7a49e9b8e453",
            "entity_type": "DRUG",
            "name": "Propargylamines",
            "normalized_id": "N/A",
            "aliases": [],
            "description": "Compounds described as inducing antiapoptotic new protein synthesis in serum- and nerve growth factor-withdrawn, NGF-differentiated PC-12 cells."
          },
          "object": {
            "entity_id": "ent:20defcc14a2a",
            "entity_type": "MECHANISM",
            "name": "antiapoptotic new protein synthesis",
            "normalized_id": "N/A",
            "aliases": [],
            "description": "A process induced by propargylamines in serum- and nerve growth factor-withdrawn, NGF-differentiated PC-12 cells."
          },
          "time_info": null
        },
        {
          "head": "selegiline",
          "relation": "inhibit",
          "tail": "MAO-A",
          "relation_type": "UNKNOWN",
          "confidence": [
            0.7,
            0.05
          ],
          "evidence": [
            "Evidence that formulations of the selective MAO-B inhibitor, selegiline, which bypass first-pass metabolism, also inhibit MAO-A in the human brain."
          ],
          "mechanism": "unknown",
          "source": "ocr_result_1_10",
          "subject": {
            "entity_id": "ent:42f388b4924a",
            "entity_type": "DRUG",
            "name": "selegiline",
            "normalized_id": "N/A",
            "aliases": [],
            "description": "Drug described as a selective MAO-B inhibitor in formulations that bypass first-pass metabolism and also inhibit MAO-A in the human brain."
          },
          "object": {
            "entity_id": "ent:9eb46c4092e9",
            "entity_type": "PROTEIN",
            "name": "MAO-A",
            "normalized_id": "N/A",
            "aliases": [],
            "description": "Enzyme described as being inhibited in the human brain by formulations of the selective MAO-B inhibitor selegiline that bypass first-pass metabolism."
          },
          "time_info": null
        },
        {
          "head": "selegiline",
          "relation": "inhibit",
          "tail": "MAO-B",
          "relation_type": "UNKNOWN",
          "confidence": [
            0.95,
            0.05
          ],
          "evidence": [
            "Evidence that formulations of the selective MAO-B inhibitor, selegiline, which bypass first-pass metabolism, also inhibit MAO-A in the human brain."
          ],
          "mechanism": "unknown",
          "source": "ocr_result_1_10",
          "subject": {
            "entity_id": "ent:42f388b4924a",
            "entity_type": "DRUG",
            "name": "selegiline",
            "normalized_id": "N/A",
            "aliases": [],
            "description": "Drug described as a selective MAO-B inhibitor in formulations that bypass first-pass metabolism and also inhibit MAO-A in the human brain."
          },
          "object": {
            "entity_id": "ent:7eec4c2bdf1c",
            "entity_type": "PROTEIN",
            "name": "MAO-B",
            "normalized_id": "N/A",
            "aliases": [],
            "description": "Enzyme described as a selective inhibitor target of selegiline formulations that bypass first-pass metabolism."
          },
          "time_info": null
        },
        {
          "head": "rasagiline",
          "relation": "reverse",
          "tail": "first-pass metabolism",
          "relation_type": "UNKNOWN",
          "confidence": [
            0.1,
            0.05
          ],
          "evidence": [
            "Evidence that formulations of the selective MAO-B inhibitor, selegiline, which bypass first-pass metabolism, also inhibit MAO-A in the human brain."
          ],
          "mechanism": "unknown",
          "source": "ocr_result_1_10",
          "subject": {
            "entity_id": "ent:fffabe1f29a9",
            "entity_type": "DRUG",
            "name": "rasagiline",
            "normalized_id": "N/A",
            "aliases": [],
            "description": "Drug described as an anti-Parkinson drug with pharmacological properties modifying endogenous brain amines, reserpine reversal, serotonergic and dopaminergic behaviours."
          },
          "object": {
            "entity_id": "ent:7ab508dc72d1",
            "entity_type": "MECHANISM",
            "name": "first-pass metabolism",
            "normalized_id": "N/A",
            "aliases": [],
            "description": "A metabolic process that certain formulations of selegiline bypass according to the evidence presented."
          },
          "time_info": null
        },
        {
          "head": "safinamide mesylate",
          "relation": "protect",
          "tail": "Parkinson's disease",
          "relation_type": "UNKNOWN",
          "confidence": [
            0.75,
            0.05
          ],
          "evidence": [
            "Neuroprotection by safinamide in the 6-hydroxydopamine model of Parkinson's disease.",
            "The safety and efficacy of safinamide mesylate for the treatment of Parkinson's disease.",
            "Pharmacokinetics and pharmacodynamics of safinamide, a neuroprotectant with antiparkinsonian and anticonvulsant activity."
          ],
          "mechanism": "unknown",
          "source": "ocr_result_1_10",
          "subject": {
            "entity_id": "ent:23042f2dcbf6",
            "entity_type": "DRUG",
            "name": "safinamide",
            "normalized_id": "N/A",
            "aliases": [
              "safinamide"
            ],
            "description": "Drug described for the treatment of Parkinson's disease, with discussion of its safety and efficacy."
          },
          "object": {
            "entity_id": "ent:f6c4f83730a0",
            "entity_type": "DISEASE",
            "name": "Parkinson's disease",
            "normalized_id": "N/A",
            "aliases": [],
            "description": "N/A"
          },
          "time_info": null
        },
        {
          "head": "CRISPR-Cas9 Gene Editing",
          "relation": "protect",
          "tail": "Parkinson's disease",
          "relation_type": "UNKNOWN",
          "confidence": [
            0.82,
            0.05
          ],
          "evidence": [
            "CRISPR-Cas9 Gene Editing Protects from the A53T-SNCA Overexpression-Induced Pathology of Parkinson's Disease In Vivo."
          ],
          "mechanism": "unknown",
          "source": "ocr_result_1_10",
          "subject": {
            "entity_id": "ent:1f04302c5a5d",
            "entity_type": "TREATMENT",
            "name": "CRISPR-Cas9 Gene Editing",
            "normalized_id": "N/A",
            "aliases": [],
            "description": "Described as protecting from the A53T-SNCA overexpression-induced pathology of Parkinson's Disease In Vivo."
          },
          "object": {
            "entity_id": "ent:f6c4f83730a0",
            "entity_type": "DISEASE",
            "name": "Parkinson's disease",
            "normalized_id": "N/A",
            "aliases": [],
            "description": "N/A"
          },
          "time_info": null
        }
      ]
    },
    "ocr_result_2_0": {
      "id": "ocr_result_2_0",
      "name": "",
      "meta": {
        "text": "Qie and Sang J Exp Clin Cancer Res (2022) 41:161\nhttps://doi.org/10.1186/s13046-022-02370-w\n\nJournal of Experimental &amp; Clinical Cancer Research\n\n# REVIEW\n\n# Open Access\n\n# Stanniocalcin 2 (STC2): a universal tumour biomarker and a potential therapeutical target\n\nShuo Qie $^{1,2,3,4*}$  and Nianli Sang $^{5*}$\n\n# Abstract\n\nStanniocalcin 2 (STC2) is a glycoprotein which is expressed in a broad spectrum of tumour cells and tumour tissues derived from human breast, colorectum, stomach, esophagus, prostate, kidney, liver, bone, ovary, lung and so forth. The expression of STC2 is regulated at both transcriptional and post-transcriptional levels; particularly, STC2 is significantly stimulated under various stress conditions like ER stress, hypoxia and nutrient deprivation. Biologically, STC2 facilitates cells dealing with stress conditions and prevents apoptosis. Importantly, STC2 also promotes the development of acquired resistance to chemo- and radio- therapies. In addition, multiple groups have reported that STC2 overexpression promotes cell proliferation, migration and immune response. Therefore, the overexpression of STC2 is positively correlated with tumour growth, invasion, metastasis and patients' prognosis, highlighting its potential as a biomarker and a therapeutic target. This review focuses on discussing the regulation, biological functions and clinical importance of STC2 in human cancers. Future perspectives in this field will also be discussed.\n\nKeywords: Stanniocalcin 2, Stress Response, Tumorigenesis, Tumour progression, Prognosis, Cancer therapy\n\n# Background\n\nSTC2 belongs to a highly conserved, secreted glycoprotein hormone family. The term \"stanniocalcin\" (STC) derives from the corpuscles of Stannius, the endocrine glands that are ventrally located on the surface of the fish kidney [1]. STC was initially reported to lower the intracellular calcium concentrations through compromising  $\\mathrm{Ca^{2+}}$  influx in fish [2-4]. Two isoforms of human STC have been identified: STC1 and STC2 [5, 6]. STC1, the human ortholog of fish STC, was identified through the differential display of genes related to cellular immortalization and the random sequencing of a fetal lung DNA library [7-11]. Human STC2, a paralog of STC1, was identified by searching the STC1 related Expressed Sequence Tag database [12-14]. STC2 shows  $34\\%$  identity with human STC1 and eel STC based on sequencing\n\nanalysis [14]. Phylogenetically, STC2 is highly conserved in vertebrates, including the most common animal models Danio rerio, Xenopus tropicalis, Mus musculus, and Rattus norvegicus (Fig. 1), suggesting a biologically important role of STC2 in species preservation during evolution and highlighting the animal models to study STC2.\n\nHuman STC1, a protein with 247 amino acids [15], is broadly expressed in a series of human tissues including kidney [16], ovary [17], bone [18], prostate [18], thyroid [18], neuron [19], muscle [20], etc. Biologically, STC1 is involved in physiological processes such as intestinal  $\\mathrm{Ca^{2+}}$  transport and organogenesis [9, 21-24], suggesting STC1 plays similar functions like its fish ortholog.\n\nHuman STC2 is a 302-amino acid (aa) protein, with aa1-24 as signal peptide for ER transportation. Considering its mRNA levels, STC2 is highly expressed in tissues of breast, muscle, heart, testis and pancreas under physiological conditions as indicated by The Human Protein Atlas [14], which is consistent with the RNA expression in normal human tissues (Fig. 2). Although STC1 has been reported to regulate multiple processes during\n\n*Correspondence: shuoqie@tmu.edu.cn; nianli.sang@drexel.edu\n\n^{1}\n Department of Pathology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China\n\n^{5}\n Department of Biology, Drexel University, PA, Philadelphia, USA Full list of author information is available at the end of the article\n\nBMC\n\n The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.\n\nQie and Sang J Exp Clin Cancer Res (2022) 41:161\n\n![img-0.jpeg](img-0.jpeg)\nFig. 1 The comparison of STC2 protein sequences among indicated species. It suggests highly phylogenetic conservation in different vertebrates\n\ntumour development and progression [15, 25-28], the different expression pattern of STC1 and STC2 indicates they may have different roles under physiological or pathological conditions.",
        "source": "ocr_result_2"
      },
      "entities": [
        {
          "entity_id": "ent:2dbb68fbc092",
          "entity_type": "TREATMENT",
          "name": "chemo- and radio- therapies",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Therapies to which STC2 promotes the development of acquired resistance, as mentioned in the abstract."
        },
        {
          "entity_id": "ent:ba8e328de0ee",
          "entity_type": "TREATMENT",
          "name": "Cancer therapy",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A keyword listed in the article's keywords section, indicating a general therapeutic approach discussed in the context of STC2."
        },
        {
          "entity_id": "ent:f79164325c1c",
          "entity_type": "BIOMARKER",
          "name": "Stanniocalcin 2",
          "normalized_id": "N/A",
          "aliases": [
            "STC2"
          ],
          "description": "A glycoprotein expressed in a broad spectrum of tumour cells and tissues, with overexpression positively correlated with tumour growth, invasion, metastasis and patients' prognosis, highlighting its potential as a biomarker."
        },
        {
          "entity_id": "ent:b8f43b436b78",
          "entity_type": "DISEASE",
          "name": "tumour",
          "normalized_id": "N/A",
          "aliases": [
            "tumour",
            "tumour cells",
            "tumour tissues",
            "tumour growth",
            "tumour development",
            "tumour progression"
          ],
          "description": "Described as cells and tissues derived from various human organs, with STC2 expression positively correlated with growth, invasion, metastasis, and patient prognosis."
        },
        {
          "entity_id": "ent:09c62a5bec9c",
          "entity_type": "DISEASE",
          "name": "cancers",
          "normalized_id": "N/A",
          "aliases": [
            "cancers"
          ],
          "description": "Human cancers are the focus of the review discussing STC2's regulation, biological functions, and clinical importance."
        },
        {
          "entity_id": "ent:8d327767b802",
          "entity_type": "MECHANISM",
          "name": "apoptosis",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A process that STC2 prevents, as it facilitates cells dealing with stress conditions."
        },
        {
          "entity_id": "ent:729959de711f",
          "entity_type": "MECHANISM",
          "name": "ER stress",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A stress condition under which STC2 expression is significantly stimulated."
        },
        {
          "entity_id": "ent:d4a6ed9cfbf4",
          "entity_type": "MECHANISM",
          "name": "hypoxia",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A stress condition under which STC2 expression is significantly stimulated."
        },
        {
          "entity_id": "ent:8dbbb980913f",
          "entity_type": "MECHANISM",
          "name": "nutrient deprivation",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A stress condition under which STC2 expression is significantly stimulated."
        },
        {
          "entity_id": "ent:8e94b217755d",
          "entity_type": "MECHANISM",
          "name": "stress conditions",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Conditions like ER stress, hypoxia, and nutrient deprivation under which STC2 expression is stimulated and which STC2 helps cells deal with."
        },
        {
          "entity_id": "ent:3b126514638e",
          "entity_type": "MECHANISM",
          "name": "acquired resistance",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A development promoted by STC2, specifically to chemo- and radio- therapies."
        },
        {
          "entity_id": "ent:64b41bedef19",
          "entity_type": "MECHANISM",
          "name": "cell proliferation",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A process promoted by STC2 overexpression according to multiple groups."
        },
        {
          "entity_id": "ent:a0ef43343475",
          "entity_type": "MECHANISM",
          "name": "migration",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A process promoted by STC2 overexpression according to multiple groups."
        },
        {
          "entity_id": "ent:88a575e9319d",
          "entity_type": "MECHANISM",
          "name": "immune response",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A process promoted by STC2 overexpression according to multiple groups."
        },
        {
          "entity_id": "ent:87b358ffeadb",
          "entity_type": "MECHANISM",
          "name": "tumour growth",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A process positively correlated with STC2 overexpression."
        },
        {
          "entity_id": "ent:d2eaca1cd087",
          "entity_type": "MECHANISM",
          "name": "invasion",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A process positively correlated with STC2 overexpression."
        },
        {
          "entity_id": "ent:b9b750868a17",
          "entity_type": "MECHANISM",
          "name": "metastasis",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A process positively correlated with STC2 overexpression."
        }
      ],
      "relations": [
        {
          "head": "ER stress",
          "relation": "stimulate",
          "tail": "Stanniocalcin 2",
          "relation_type": "UNKNOWN",
          "confidence": [
            0.85,
            0.05
          ],
          "evidence": [
            "The expression of STC2 is regulated at both transcriptional and post-transcriptional levels; particularly, STC2 is significantly stimulated under various stress conditions like ER stress, hypoxia and nutrient deprivation."
          ],
          "mechanism": "unknown",
          "source": "ocr_result_2_0",
          "subject": {
            "entity_id": "ent:729959de711f",
            "entity_type": "MECHANISM",
            "name": "ER stress",
            "normalized_id": "N/A",
            "aliases": [],
            "description": "A stress condition under which STC2 expression is significantly stimulated."
          },
          "object": {
            "entity_id": "ent:f79164325c1c",
            "entity_type": "BIOMARKER",
            "name": "Stanniocalcin 2",
            "normalized_id": "N/A",
            "aliases": [
              "STC2"
            ],
            "description": "A glycoprotein expressed in a broad spectrum of tumour cells and tissues, with overexpression positively correlated with tumour growth, invasion, metastasis and patients' prognosis, highlighting its potential as a biomarker."
          },
          "time_info": null
        },
        {
          "head": "hypoxia",
          "relation": "stimulate",
          "tail": "Stanniocalcin 2",
          "relation_type": "UNKNOWN",
          "confidence": [
            0.85,
            0.05
          ],
          "evidence": [
            "The expression of STC2 is regulated at both transcriptional and post-transcriptional levels; particularly, STC2 is significantly stimulated under various stress conditions like ER stress, hypoxia and nutrient deprivation."
          ],
          "mechanism": "unknown",
          "source": "ocr_result_2_0",
          "subject": {
            "entity_id": "ent:d4a6ed9cfbf4",
            "entity_type": "MECHANISM",
            "name": "hypoxia",
            "normalized_id": "N/A",
            "aliases": [],
            "description": "A stress condition under which STC2 expression is significantly stimulated."
          },
          "object": {
            "entity_id": "ent:f79164325c1c",
            "entity_type": "BIOMARKER",
            "name": "Stanniocalcin 2",
            "normalized_id": "N/A",
            "aliases": [
              "STC2"
            ],
            "description": "A glycoprotein expressed in a broad spectrum of tumour cells and tissues, with overexpression positively correlated with tumour growth, invasion, metastasis and patients' prognosis, highlighting its potential as a biomarker."
          },
          "time_info": null
        },
        {
          "head": "nutrient deprivation",
          "relation": "stimulate",
          "tail": "Stanniocalcin 2",
          "relation_type": "UNKNOWN",
          "confidence": [
            0.85,
            0.05
          ],
          "evidence": [
            "The expression of STC2 is regulated at both transcriptional and post-transcriptional levels; particularly, STC2 is significantly stimulated under various stress conditions like ER stress, hypoxia and nutrient deprivation."
          ],
          "mechanism": "unknown",
          "source": "ocr_result_2_0",
          "subject": {
            "entity_id": "ent:8dbbb980913f",
            "entity_type": "MECHANISM",
            "name": "nutrient deprivation",
            "normalized_id": "N/A",
            "aliases": [],
            "description": "A stress condition under which STC2 expression is significantly stimulated."
          },
          "object": {
            "entity_id": "ent:f79164325c1c",
            "entity_type": "BIOMARKER",
            "name": "Stanniocalcin 2",
            "normalized_id": "N/A",
            "aliases": [
              "STC2"
            ],
            "description": "A glycoprotein expressed in a broad spectrum of tumour cells and tissues, with overexpression positively correlated with tumour growth, invasion, metastasis and patients' prognosis, highlighting its potential as a biomarker."
          },
          "time_info": null
        },
        {
          "head": "Stanniocalcin 2",
          "relation": "facilitate",
          "tail": "stress conditions",
          "relation_type": "UNKNOWN",
          "confidence": [
            0.75,
            0.1
          ],
          "evidence": [
            "Biologically, STC2 facilitates cells dealing with stress conditions and prevents apoptosis."
          ],
          "mechanism": "unknown",
          "source": "ocr_result_2_0",
          "subject": {
            "entity_id": "ent:f79164325c1c",
            "entity_type": "BIOMARKER",
            "name": "Stanniocalcin 2",
            "normalized_id": "N/A",
            "aliases": [
              "STC2"
            ],
            "description": "A glycoprotein expressed in a broad spectrum of tumour cells and tissues, with overexpression positively correlated with tumour growth, invasion, metastasis and patients' prognosis, highlighting its potential as a biomarker."
          },
          "object": {
            "entity_id": "ent:8e94b217755d",
            "entity_type": "MECHANISM",
            "name": "stress conditions",
            "normalized_id": "N/A",
            "aliases": [],
            "description": "Conditions like ER stress, hypoxia, and nutrient deprivation under which STC2 expression is stimulated and which STC2 helps cells deal with."
          },
          "time_info": null
        },
        {
          "head": "Stanniocalcin 2",
          "relation": "prevent",
          "tail": "apoptosis",
          "relation_type": "UNKNOWN",
          "confidence": [
            0.8,
            0.05
          ],
          "evidence": [
            "Biologically, STC2 facilitates cells dealing with stress conditions and prevents apoptosis."
          ],
          "mechanism": "unknown",
          "source": "ocr_result_2_0",
          "subject": {
            "entity_id": "ent:f79164325c1c",
            "entity_type": "BIOMARKER",
            "name": "Stanniocalcin 2",
            "normalized_id": "N/A",
            "aliases": [
              "STC2"
            ],
            "description": "A glycoprotein expressed in a broad spectrum of tumour cells and tissues, with overexpression positively correlated with tumour growth, invasion, metastasis and patients' prognosis, highlighting its potential as a biomarker."
          },
          "object": {
            "entity_id": "ent:8d327767b802",
            "entity_type": "MECHANISM",
            "name": "apoptosis",
            "normalized_id": "N/A",
            "aliases": [],
            "description": "A process that STC2 prevents, as it facilitates cells dealing with stress conditions."
          },
          "time_info": null
        },
        {
          "head": "Stanniocalcin 2",
          "relation": "promote",
          "tail": "acquired resistance",
          "relation_type": "UNKNOWN",
          "confidence": [
            0.82,
            0.05
          ],
          "evidence": [
            "Importantly, STC2 also promotes the development of acquired resistance to chemo- and radio- therapies."
          ],
          "mechanism": "unknown",
          "source": "ocr_result_2_0",
          "subject": {
            "entity_id": "ent:f79164325c1c",
            "entity_type": "BIOMARKER",
            "name": "Stanniocalcin 2",
            "normalized_id": "N/A",
            "aliases": [
              "STC2"
            ],
            "description": "A glycoprotein expressed in a broad spectrum of tumour cells and tissues, with overexpression positively correlated with tumour growth, invasion, metastasis and patients' prognosis, highlighting its potential as a biomarker."
          },
          "object": {
            "entity_id": "ent:3b126514638e",
            "entity_type": "MECHANISM",
            "name": "acquired resistance",
            "normalized_id": "N/A",
            "aliases": [],
            "description": "A development promoted by STC2, specifically to chemo- and radio- therapies."
          },
          "time_info": null
        },
        {
          "head": "Stanniocalcin 2",
          "relation": "promote",
          "tail": "cell proliferation",
          "relation_type": "UNKNOWN",
          "confidence": [
            0.78,
            0.05
          ],
          "evidence": [
            "In addition, multiple groups have reported that STC2 overexpression promotes cell proliferation, migration and immune response."
          ],
          "mechanism": "unknown",
          "source": "ocr_result_2_0",
          "subject": {
            "entity_id": "ent:f79164325c1c",
            "entity_type": "BIOMARKER",
            "name": "Stanniocalcin 2",
            "normalized_id": "N/A",
            "aliases": [
              "STC2"
            ],
            "description": "A glycoprotein expressed in a broad spectrum of tumour cells and tissues, with overexpression positively correlated with tumour growth, invasion, metastasis and patients' prognosis, highlighting its potential as a biomarker."
          },
          "object": {
            "entity_id": "ent:64b41bedef19",
            "entity_type": "MECHANISM",
            "name": "cell proliferation",
            "normalized_id": "N/A",
            "aliases": [],
            "description": "A process promoted by STC2 overexpression according to multiple groups."
          },
          "time_info": null
        },
        {
          "head": "Stanniocalcin 2",
          "relation": "promote",
          "tail": "migration",
          "relation_type": "UNKNOWN",
          "confidence": [
            0.78,
            0.05
          ],
          "evidence": [
            "In addition, multiple groups have reported that STC2 overexpression promotes cell proliferation, migration and immune response."
          ],
          "mechanism": "unknown",
          "source": "ocr_result_2_0",
          "subject": {
            "entity_id": "ent:f79164325c1c",
            "entity_type": "BIOMARKER",
            "name": "Stanniocalcin 2",
            "normalized_id": "N/A",
            "aliases": [
              "STC2"
            ],
            "description": "A glycoprotein expressed in a broad spectrum of tumour cells and tissues, with overexpression positively correlated with tumour growth, invasion, metastasis and patients' prognosis, highlighting its potential as a biomarker."
          },
          "object": {
            "entity_id": "ent:a0ef43343475",
            "entity_type": "MECHANISM",
            "name": "migration",
            "normalized_id": "N/A",
            "aliases": [],
            "description": "A process promoted by STC2 overexpression according to multiple groups."
          },
          "time_info": null
        },
        {
          "head": "Stanniocalcin 2",
          "relation": "promote",
          "tail": "immune response",
          "relation_type": "UNKNOWN",
          "confidence": [
            0.7,
            0.05
          ],
          "evidence": [
            "In addition, multiple groups have reported that STC2 overexpression promotes cell proliferation, migration and immune response."
          ],
          "mechanism": "unknown",
          "source": "ocr_result_2_0",
          "subject": {
            "entity_id": "ent:f79164325c1c",
            "entity_type": "BIOMARKER",
            "name": "Stanniocalcin 2",
            "normalized_id": "N/A",
            "aliases": [
              "STC2"
            ],
            "description": "A glycoprotein expressed in a broad spectrum of tumour cells and tissues, with overexpression positively correlated with tumour growth, invasion, metastasis and patients' prognosis, highlighting its potential as a biomarker."
          },
          "object": {
            "entity_id": "ent:88a575e9319d",
            "entity_type": "MECHANISM",
            "name": "immune response",
            "normalized_id": "N/A",
            "aliases": [],
            "description": "A process promoted by STC2 overexpression according to multiple groups."
          },
          "time_info": null
        },
        {
          "head": "Stanniocalcin 2",
          "relation": "correlate with",
          "tail": "tumour growth",
          "relation_type": "UNKNOWN",
          "confidence": [
            0.75,
            0.1
          ],
          "evidence": [
            "Therefore, the overexpression of STC2 is positively correlated with tumour growth, invasion, metastasis and patients' prognosis, highlighting its potential as a biomarker and a therapeutic target."
          ],
          "mechanism": "unknown",
          "source": "ocr_result_2_0",
          "subject": {
            "entity_id": "ent:f79164325c1c",
            "entity_type": "BIOMARKER",
            "name": "Stanniocalcin 2",
            "normalized_id": "N/A",
            "aliases": [
              "STC2"
            ],
            "description": "A glycoprotein expressed in a broad spectrum of tumour cells and tissues, with overexpression positively correlated with tumour growth, invasion, metastasis and patients' prognosis, highlighting its potential as a biomarker."
          },
          "object": {
            "entity_id": "ent:87b358ffeadb",
            "entity_type": "MECHANISM",
            "name": "tumour growth",
            "normalized_id": "N/A",
            "aliases": [],
            "description": "A process positively correlated with STC2 overexpression."
          },
          "time_info": null
        },
        {
          "head": "Stanniocalcin 2",
          "relation": "correlate with",
          "tail": "invasion",
          "relation_type": "UNKNOWN",
          "confidence": [
            0.75,
            0.1
          ],
          "evidence": [
            "Therefore, the overexpression of STC2 is positively correlated with tumour growth, invasion, metastasis and patients' prognosis, highlighting its potential as a biomarker and a therapeutic target."
          ],
          "mechanism": "unknown",
          "source": "ocr_result_2_0",
          "subject": {
            "entity_id": "ent:f79164325c1c",
            "entity_type": "BIOMARKER",
            "name": "Stanniocalcin 2",
            "normalized_id": "N/A",
            "aliases": [
              "STC2"
            ],
            "description": "A glycoprotein expressed in a broad spectrum of tumour cells and tissues, with overexpression positively correlated with tumour growth, invasion, metastasis and patients' prognosis, highlighting its potential as a biomarker."
          },
          "object": {
            "entity_id": "ent:d2eaca1cd087",
            "entity_type": "MECHANISM",
            "name": "invasion",
            "normalized_id": "N/A",
            "aliases": [],
            "description": "A process positively correlated with STC2 overexpression."
          },
          "time_info": null
        },
        {
          "head": "Stanniocalcin 2",
          "relation": "correlate with",
          "tail": "metastasis",
          "relation_type": "UNKNOWN",
          "confidence": [
            0.75,
            0.1
          ],
          "evidence": [
            "Therefore, the overexpression of STC2 is positively correlated with tumour growth, invasion, metastasis and patients' prognosis, highlighting its potential as a biomarker and a therapeutic target."
          ],
          "mechanism": "unknown",
          "source": "ocr_result_2_0",
          "subject": {
            "entity_id": "ent:f79164325c1c",
            "entity_type": "BIOMARKER",
            "name": "Stanniocalcin 2",
            "normalized_id": "N/A",
            "aliases": [
              "STC2"
            ],
            "description": "A glycoprotein expressed in a broad spectrum of tumour cells and tissues, with overexpression positively correlated with tumour growth, invasion, metastasis and patients' prognosis, highlighting its potential as a biomarker."
          },
          "object": {
            "entity_id": "ent:b9b750868a17",
            "entity_type": "MECHANISM",
            "name": "metastasis",
            "normalized_id": "N/A",
            "aliases": [],
            "description": "A process positively correlated with STC2 overexpression."
          },
          "time_info": null
        }
      ]
    },
    "ocr_result_2_1": {
      "id": "ocr_result_2_1",
      "name": "",
      "meta": {
        "text": "Importantly, STC2 is broadly upregulated in human tumours including breast cancer [29-32], colorectal cancer [33], gastric cancer [34], esophageal squamous cell carcinoma (ESCC) [35], prostate cancer [36], renal cell carcinoma (RCC) [37], nasopharyngeal carcinoma [38], head and neck squamous cell carcinoma (HNSCC) [39],\n\nhepatocellular carcinoma (HCC) [40], osteosarcoma [41], ovarian cancer [42], lung cancer [43], pancreatic cancer [44], endometrial cancer [45], cervical cancer [46], neuroblastoma [47], gallbladder cancer [48], cholangiocarcinoma [49], and so forth. Clinicopathological investigations indicate the expression of STC2 is correlated with tumour development, tumour progression and patients' prognosis (Table 1).\n\nGene expression profiling and interactive analysis (GEPIA 2) [77] bioinformatic analyses further support\n\nQie and Sang J Exp Clin Cancer Res (2022) 41:161\n\n![img-1.jpeg](img-1.jpeg)\n\n![img-2.jpeg](img-2.jpeg)\nFig. 2 The mRNA expression of STC2 in human normal tissues. The panels A &amp; B were generated using online tool: The Protein Atlas (https://www.proteinatlas.org/)\n\nthe upregulation of STC2 in various human tumours compared to corresponding normal tissues, except for acute myeloid leukemia and skin cutaneous melanoma where STC2 expression is lower than their normal counterparts (Fig. 3). GEPIA 2 analysis indicates insignificant increase of STC2 expression in breast cancer comparing with their normal counterparts, showing inconsistency with the published wet-bench studies, which directly compared the expression of STC2 proteins in this tumour [50, 51]. Since the GEPIA2 bioinformatic analysis is\n\ngenerally based on mRNA levels, this inconsistency suggests the existence of complicated mechanisms to regulate STC2 expression at multiple levels.\n\nIndeed, the expression of STC2 is regulated at both transcriptional and post-transcriptional levels. Interestingly, STC2 levels are induced under various stress conditions like endoplasmic reticulum (ER) stress, hypoxia and nutrient deprivation [78, 79]. Accordingly, STC2 can facilitate cells dealing with stress conditions and preventing cells from apoptosis. Functionally, STC2 has been\n\nQie and Sang J Exp Clin Cancer Res (2022) 41:161\n\nTable 1 The clinical importance of STC2 in human cancers",
        "source": "ocr_result_2"
      },
      "entities": [
        {
          "entity_id": "ent:9d3d04e7a934",
          "entity_type": "GENE",
          "name": "STC2",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Gene described as broadly upregulated in human tumours including breast cancer, colorectal cancer, gastric cancer, and others, with expression correlated with tumour development and progression."
        },
        {
          "entity_id": "ent:cfd769a3fd9f",
          "entity_type": "MECHANISM",
          "name": "apoptosis",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A process that STC2 helps prevent cells from undergoing, as mentioned in the context of stress conditions."
        },
        {
          "entity_id": "ent:7fe021eefd62",
          "entity_type": "DISEASE",
          "name": "breast cancer",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A human tumour where STC2 is broadly upregulated according to the text."
        },
        {
          "entity_id": "ent:a79ea905f7fe",
          "entity_type": "DISEASE",
          "name": "colorectal cancer",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A human tumour where STC2 is broadly upregulated according to the text."
        },
        {
          "entity_id": "ent:d129c9df8964",
          "entity_type": "DISEASE",
          "name": "gastric cancer",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A human tumour where STC2 is broadly upregulated according to the text."
        },
        {
          "entity_id": "ent:c961d67ae6c8",
          "entity_type": "DISEASE",
          "name": "esophageal squamous cell carcinoma",
          "normalized_id": "N/A",
          "aliases": [
            "ESCC"
          ],
          "description": "A human tumour where STC2 is broadly upregulated according to the text."
        },
        {
          "entity_id": "ent:a489e4a5ffbf",
          "entity_type": "DISEASE",
          "name": "prostate cancer",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A human tumour where STC2 is broadly upregulated according to the text."
        },
        {
          "entity_id": "ent:c19fcfb36759",
          "entity_type": "DISEASE",
          "name": "renal cell carcinoma",
          "normalized_id": "N/A",
          "aliases": [
            "RCC"
          ],
          "description": "A human tumour where STC2 is broadly upregulated according to the text."
        },
        {
          "entity_id": "ent:ae558c8e72ad",
          "entity_type": "DISEASE",
          "name": "nasopharyngeal carcinoma",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A human tumour where STC2 is broadly upregulated according to the text."
        },
        {
          "entity_id": "ent:e4e29bf8cb45",
          "entity_type": "DISEASE",
          "name": "head and neck squamous cell carcinoma",
          "normalized_id": "N/A",
          "aliases": [
            "HNSCC"
          ],
          "description": "A human tumour where STC2 is broadly upregulated according to the text."
        },
        {
          "entity_id": "ent:c0d0c3009cf8",
          "entity_type": "DISEASE",
          "name": "hepatocellular carcinoma",
          "normalized_id": "N/A",
          "aliases": [
            "HCC"
          ],
          "description": "A human tumour where STC2 is broadly upregulated according to the text."
        },
        {
          "entity_id": "ent:391891418118",
          "entity_type": "DISEASE",
          "name": "osteosarcoma",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A human tumour where STC2 is broadly upregulated according to the text."
        },
        {
          "entity_id": "ent:1d6653d621f7",
          "entity_type": "DISEASE",
          "name": "ovarian cancer",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A human tumour where STC2 is broadly upregulated according to the text."
        },
        {
          "entity_id": "ent:d560a3c33430",
          "entity_type": "DISEASE",
          "name": "lung cancer",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A human tumour where STC2 is broadly upregulated according to the text."
        },
        {
          "entity_id": "ent:f16de28df58d",
          "entity_type": "DISEASE",
          "name": "pancreatic cancer",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A human tumour where STC2 is broadly upregulated according to the text."
        },
        {
          "entity_id": "ent:d21279974793",
          "entity_type": "DISEASE",
          "name": "endometrial cancer",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A human tumour where STC2 is broadly upregulated according to the text."
        },
        {
          "entity_id": "ent:b6b6405b95e8",
          "entity_type": "DISEASE",
          "name": "cervical cancer",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A human tumour where STC2 is broadly upregulated according to the text."
        },
        {
          "entity_id": "ent:93883eefe477",
          "entity_type": "DISEASE",
          "name": "neuroblastoma",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A human tumour where STC2 is broadly upregulated according to the text."
        },
        {
          "entity_id": "ent:46515d3ea92c",
          "entity_type": "DISEASE",
          "name": "gallbladder cancer",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A human tumour where STC2 is broadly upregulated according to the text."
        },
        {
          "entity_id": "ent:54f8a62a7802",
          "entity_type": "DISEASE",
          "name": "cholangiocarcinoma",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A human tumour where STC2 is broadly upregulated according to the text."
        },
        {
          "entity_id": "ent:edae8e02dc7b",
          "entity_type": "DISEASE",
          "name": "acute myeloid leukemia",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A human tumour where STC2 expression is lower than in normal counterparts according to the text."
        },
        {
          "entity_id": "ent:1618babae48f",
          "entity_type": "DISEASE",
          "name": "skin cutaneous melanoma",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A human tumour where STC2 expression is lower than in normal counterparts according to the text."
        }
      ],
      "relations": []
    },
    "ocr_result_2_2": {
      "id": "ocr_result_2_2",
      "name": "",
      "meta": {
        "text": "|  Tumours | Patient Numbers | Detection Methods | Clinical Importance  |\n| --- | --- | --- | --- |\n|  Breast cancer | 110 | qRT-PCR | Elevated STC2 mRNA levels are correlated with higher DFS rates [50]  |\n|   |  245 | FISH | STC2 expression is associated with improved DFS rates [51]  |\n|   |  110 | IHC | No relationship with progression free survival is demonstrated [52]  |\n|   |  985 + 979 | Microarray | STC2 levels are correlated with good prognosis [53]  |\n|   |  699 | IHC | No correlation is revealed between STC2 levels and tumour recurrence [54]  |\n|   |  477 | IHC | STC2 is associated with favorable outcome in male breast cancer patients [55]  |\n|  Colorectal cancer | 139 | qRT-PCR | High STC2 levels are correlated with poor prognosis [33]  |\n|   |  47 | qRT-PCR | STC2 expression is associated with tumour size [56]  |\n|   |  77 | IHC | STC2 levels are correlated with tumour stage and patients' survival [57]  |\n|   |  383 | Microarray | STC2 expression is associated with tumour stages [58]  |\n|   |  115 | IHC | STC2 levels are correlated with tumour metastasis and disease stages [59]  |\n|   |  379 | RNA-Seq | Elevated STC2 expression is associated with poor prognosis [60]  |\n|   |  202 | qRT-PCR | High STC2 mRNA expression is correlated with poor postoperative survival [61]  |\n|  Gastric cancer | 108 | qRT-PCR | STC2 mRNA levels are higher in cancer than those in normal gastric mucosa, and associated with tumour progression and poor prognosis [62]  |\n|   |  93 | qRT-PCR | Blood STC2 levels are correlated with tumour progression and poor prognosis [63]  |\n|  ESCC | 70 | qRT-PCR | Elevated STC2 mRNA levels are associated with lymph node metastasis and poor prognosis [35]  |\n|  Prostate cancer | 53 | IHC | STC2 IHC staining score is correlated with high Gleason scores [36]  |\n|  RCC | 108 | IHC | For all RCC, clear cell RCC, papillary RCC, patients with high cytosolic STC2 staining have a poor prognosis than those with low expression [37]  |\n|  Nasopharyngeal carcinoma | 94 | IHC | Overall survival rate of patients with high STC2 levels is significantly lower than those with low STC2 expression [38]  |\n|   |  62 | IHC | STC2 is a valuable prognostic marker for poor outcome [64]  |\n|   |  81 | IHC | STC2 positive patients show poor outcome [65]  |\n|   |  111 | RNA-Seq | STC2 is regarded as a biomarker for evaluating patients' prognosis [66]  |\n|   |  68 | IHC | STC2 expression is associated with poor progression [67]  |\n|   |  111 | RNA-Seq | STC2 can be applied to predict the overall survival rates of patients [68]  |\n|  HNSCC | 298 | IHC | Elevated STC2 expression is correlated with poor outcome [39]  |\n|   |  119 | IHC | High STC2 expression is significantly associated with poor survival [69]  |\n|   |  498 | RNA-Seq | High STC2 levels are correlated with poor prognosis [70]  |\n|  HCC | 240 | IHC | STC2 expression is associated with poor survival [40]  |\n|   |  200 | IHC | High STC2 is correlated with poor prognosis [71]  |\n|   |  258 | IHC | High STC2 expression can be utilized to predict overall survival [72]  |\n|   |  364 | RNA-Seq | STC2 expression is associated with poor prognosis of HCC [73]  |\n|  Osteosarcoma | 88 | RNA-Seq | STC2 has an important influence on the survival of patients [41]  |\n|   |  88 | RNA-Seq | STC2 is correlated with the patients' prognosis and metastasis [74]  |\n|   |  87 | RNA-Seq | Elevated STC2 levels are associated with poor prognosis [75]  |\n|  Ovarian cancer | 46 | qRT-PCR | Overexpression of STC2 by vascular cells in ovarian cancer is correlated with decreased disease-free interval [42]  |\n|   |  278 | IHC | STC2 is associated with tumour grade, tumour histotype and poor overall survival [76]  |\n|  Lung cancer | 115 | IHC | STC2 mediates the resistance to EGFR tyrosine kinase inhibitors [43]  |\n|  Pancreatic Cancer | 98 | qRT-PCR | STC2 expression is correlated with clinicopathological factors and patients' prognosis [44]  |\n|  Endometrial cancer | 49 | IHC | High STC2 expression is associated with poor relapse-free survival [45]  |\n|  Cervical cancer | 92 | IHC | STC2 expression is correlated with shorter survival [46]  |\n|  Neuroblastoma | 50 | qRT-PCR | STC2 mRNA levels are associated with higher clinical stages [47]  |\n|  Gallbladder cancer | 46 + 80 | IHC | STC2 expression is correlated with clinical, pathological, and biological behaviors as well as poor prognosis of gallbladder cancer [48]  |\n|  Cholangiocarcinoma | 100 | IHC | Positive expression of STC2 is associated with progression and poor clinical outcomes [49]  |",
        "source": "ocr_result_2"
      },
      "entities": [
        {
          "entity_id": "ent:431af086923e",
          "entity_type": "OTHER",
          "name": "Detection Methods",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Column header in a table listing various methods used to detect or measure biological markers in tumor studies."
        },
        {
          "entity_id": "ent:3c11092db0c7",
          "entity_type": "OTHER",
          "name": "Clinical Importance",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Column header in a table describing the clinical significance or relevance of findings from tumor studies."
        },
        {
          "entity_id": "ent:e8abbc3a91f7",
          "entity_type": "OTHER",
          "name": "qRT-PCR",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A detection method used to measure mRNA levels, as indicated in studies of breast cancer and other tumors."
        },
        {
          "entity_id": "ent:a17c4e575cc2",
          "entity_type": "OTHER",
          "name": "FISH",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A detection method used to assess STC2 expression in breast cancer studies."
        },
        {
          "entity_id": "ent:d199db24cf15",
          "entity_type": "OTHER",
          "name": "IHC",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A detection method used to evaluate STC2 expression and its relationship with survival outcomes in various cancers."
        },
        {
          "entity_id": "ent:d0f09e4d5010",
          "entity_type": "OTHER",
          "name": "Microarray",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A detection method used to measure STC2 levels in breast cancer studies, correlating with prognosis."
        },
        {
          "entity_id": "ent:460b827a70bc",
          "entity_type": "OTHER",
          "name": "RNA-Seq",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A detection method used to assess STC2 expression levels and their association with prognosis in various cancers."
        },
        {
          "entity_id": "ent:cea06fcc553d",
          "entity_type": "BIOMARKER",
          "name": "STC2 IHC staining score",
          "normalized_id": "N/A",
          "aliases": [
            "Blood STC2 levels",
            "cytosolic STC2 staining",
            "STC2",
            "STC2 expression",
            "STC2 levels",
            "STC2 mRNA",
            "STC2 mRNA expression",
            "STC2 mRNA levels",
            "STC2 staining"
          ],
          "description": "STC2 IHC staining score is correlated with high Gleason scores in prostate cancer as stated in the text."
        },
        {
          "entity_id": "ent:b48f4a08ae0a",
          "entity_type": "DISEASE",
          "name": "Breast cancer",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Tumour type studied in patients where STC2 mRNA levels are correlated with DFS rates and STC2 expression is associated with improved DFS rates."
        },
        {
          "entity_id": "ent:f56440ae1dc5",
          "entity_type": "DISEASE",
          "name": "Colorectal cancer",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Tumour type where high STC2 levels are correlated with poor prognosis, tumour size, stage, metastasis, and poor postoperative survival."
        },
        {
          "entity_id": "ent:0fd0bcf83e6d",
          "entity_type": "DISEASE",
          "name": "Gastric cancer",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Cancer type where STC2 mRNA levels are higher in cancer than normal gastric mucosa and associated with tumour progression and poor prognosis."
        },
        {
          "entity_id": "ent:accb8ff78d65",
          "entity_type": "DISEASE",
          "name": "ESCC",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Condition where elevated STC2 mRNA levels are associated with lymph node metastasis and poor prognosis."
        },
        {
          "entity_id": "ent:5f2a88dfd613",
          "entity_type": "DISEASE",
          "name": "Prostate cancer",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Tumour type where STC2 IHC staining score is correlated with high Gleason scores."
        },
        {
          "entity_id": "ent:e0014930bd8a",
          "entity_type": "DISEASE",
          "name": "clear cell RCC",
          "normalized_id": "N/A",
          "aliases": [
            "papillary RCC",
            "RCC"
          ],
          "description": "Type of RCC where patients with high cytosolic STC2 staining have poor prognosis compared to those with low expression."
        },
        {
          "entity_id": "ent:ff899700ac06",
          "entity_type": "DISEASE",
          "name": "Nasopharyngeal carcinoma",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Carcinoma where overall survival rate of patients with high STC2 levels is significantly lower than those with low STC2 expression."
        },
        {
          "entity_id": "ent:bf2b5de62b0a",
          "entity_type": "DISEASE",
          "name": "HNSCC",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Condition where elevated STC2 expression is correlated with poor outcome and high STC2 expression is significantly associated with poor survival."
        },
        {
          "entity_id": "ent:9fe1d405e84e",
          "entity_type": "DISEASE",
          "name": "HCC",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Cancer where STC2 expression is associated with poor survival, correlated with poor prognosis, and can predict overall survival."
        },
        {
          "entity_id": "ent:4393b2a63c81",
          "entity_type": "DISEASE",
          "name": "Osteosarcoma",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Tumour where STC2 has important influence on patient survival, is correlated with prognosis and metastasis, and elevated levels are associated with poor prognosis."
        },
        {
          "entity_id": "ent:6172e762aa01",
          "entity_type": "DISEASE",
          "name": "Ovarian cancer",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Cancer where overexpression of STC2 by vascular cells is correlated with decreased disease-free interval and associated with tumour grade, histotype and poor overall survival."
        },
        {
          "entity_id": "ent:6ef72bc2ab1b",
          "entity_type": "DISEASE",
          "name": "Lung cancer",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Cancer where STC2 mediates resistance to EGFR tyrosine kinase inhibitors."
        },
        {
          "entity_id": "ent:82fed8d772b5",
          "entity_type": "DISEASE",
          "name": "Pancreatic Cancer",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Cancer where STC2 expression is correlated with clinicopathological factors and patients' prognosis."
        },
        {
          "entity_id": "ent:257fbe309001",
          "entity_type": "DISEASE",
          "name": "Endometrial cancer",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Cancer where high STC2 expression is associated with poor relapse-free survival."
        },
        {
          "entity_id": "ent:429203692134",
          "entity_type": "DISEASE",
          "name": "Cervical cancer",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Cancer where STC2 expression is correlated with shorter survival."
        },
        {
          "entity_id": "ent:03cbf0624f20",
          "entity_type": "DISEASE",
          "name": "Neuroblastoma",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Condition where STC2 mRNA levels are associated with higher clinical stages."
        },
        {
          "entity_id": "ent:8a5db17cffdc",
          "entity_type": "DISEASE",
          "name": "Gallbladder cancer",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Cancer where STC2 expression is correlated with clinical, pathological, and biological behaviors as well as poor prognosis."
        },
        {
          "entity_id": "ent:760f32ea3f04",
          "entity_type": "DISEASE",
          "name": "Cholangiocarcinoma",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Cancer where positive expression of STC2 is associated with progression and poor clinical outcomes."
        }
      ],
      "relations": []
    },
    "ocr_result_2_3": {
      "id": "ocr_result_2_3",
      "name": "",
      "meta": {
        "text": "Qie and Sang J Exp Clin Cancer Res (2022) 41:161\n\n![img-3.jpeg](img-3.jpeg)\nA\n\n![img-4.jpeg](img-4.jpeg)\nB\n\n![img-5.jpeg](img-5.jpeg)\nC\n\n![img-6.jpeg](img-6.jpeg)\nD\nFig. 3 The comparison of STC2 expression between human tumours and their relative normal counterparts using the online tool (http://gepia2.cancer-pku.cn/). Panel A: CHOL, cholangiocarcinoma; COAD, colon adenocarcinoma; ESCA, esophageal carcinoma; GBM, glioblastoma multiforme; HNSC, head and neck squamous cell carcinoma; KIRC, kidney renal clear cell carcinoma; LGG, brain lower grade glioma; OV, ovarian serous cystadenocarcinoma; READ, rectum adenocarcinoma; UCEC, uterine corpus endometrial carcinoma; UCS, uterine carcinosarcoma. Panel B: LAML, acute Myeloid Leukemia; SKCM, skin cutaneous melanoma. Panel C: ACC, Adrenocortical carcinoma; CESC, Cervical squamous cell carcinoma and endocervical adenocarcinoma; DLBC, Lymphoid Neoplasm Diffuse Large B-cell Lymphoma; KICH, Kidney Chromophobe; LIHC, Liver hepatocellular carcinoma; LUSC, Lung squamous cell carcinoma; PCPG, Pheochromocytoma and Paraganglioma; SARC, Sarcoma; STAD, Stomach adenocarcinoma; TGCT, Testicular Germ Cell Tumours; THYM, Thymoma. Panel D: BLCA, Bladder Urothelial Carcinoma; BRCA, Breast invasive carcinoma; KIRP, Kidney renal papillary cell carcinoma; LUAD, Lung adenocarcinoma; PAAD, Pancreatic adenocarcinoma; PRAD, Prostate adenocarcinoma; THCA, Thyroid carcinoma. Red bar: tumour tissues; Gray bar: normal tissues. Red star indicates p values less than 0.05\n\nreported to control a variety of cellular processes such as proliferation, migration and immune response. As such, it is hypothesized that STC2 is a critical contributor for the development of acquired resistance to chemo- and radio- therapies, thus holding the promise to be a universal therapeutic target for multiple types of cancers. This review focuses on discussing the regulation, biological importance and particularly, the potential clinical utilization of STC2 in the field of human cancers.\n\n# STC2 is overexpressed in multiple types of human tumours Breast cancer\n\nBreast cancer, the second common cause of death for women, accounts for  $\\sim 26\\%$  of all cancers diagnosed for women [80]. Most breast cancers ( $\\sim 70\\%$ ) are positive for estrogen receptor (Er), a receptor interacting with circulatory estrogens. The constitutive activation of Er signaling leads to hyper-activation of downstream survival signaling that promotes cell growth and inhibits apoptosis. As such, anti-estrogen therapy becomes a\n\nstandard treatment for patients with Er-positive breast cancers. Approximately 15--20% breast cancer patients demonstrate the amplification and/or overexpression of human epidermal growth factor receptor 2 (ErbB2) [81]. ErbB2 can form homodimers or heterodimers with other ErbB family members to activate downstream signaling that enhances the survival and proliferation of oncogenic cells; therefore, overexpression of ErbB2 is associated with poor prognosis in patients with breast cancer [82].\n\nSTC2 is co-expressed with Er in breast cancer cell lines and samples [29, 32, 50, 83, 84]. cDNA microarray revealed a threefold induction of STC2 mRNA upon estrogen treatment in breast cancer cells. Clinically, STC2 mRNA and protein levels are positively correlated with Er expression in human breast cancer specimens [29, 32, 84]. Although STC2 promoter contains canonical DNA-binding sites for Er, STC2 expression is indirectly controlled by Er signaling at the transcriptional level, which is mediated by other intermediary transcriptional factors [84]. Taken all analyzed breast cancer cohort into account, data show that patients with elevated STC2 levels have a better disease-free survival (DFS) rates [50, 51]. Interestingly, when it comes to hormone receptor-negative patients, STC2 levels are not associated with DSF rates [50]. These findings are supported by independent studies involving both woman and male breast cancer patients [53, 55]. It should be noted that the findings from another two studies don't support the notion that STC2 could be applied to evaluate the prognosis of breast cancer patients [52, 54]. Therefore, the value and application of STC2 expression in the prognosis of breast cancers should be further evaluated based on the subtypes and other molecular characteristics.\n\n### Colorectal cancer\n\nBoth mRNA and protein levels of STC2 are elevated in human colorectal cancer tissues comparing to the noncancerous counterparts [33, 56]. The genome-wise studies revealed higher STC2 mRNA levels in colorectal cancer than normal tissues [58, 59]. Clinically, increased STC2 expression is correlated with local invasion, lymphatic metastasis, tumour size and advanced disease stages. Patients with high STC2 expression showed poor prognosis comparing to those with low STC2 expression [33, 56]. Another study revealed STC2 can be induced in human colon cancer cells upon selenomethionine treatment, which is supposed to deprive intracellular cysteine or sulfhydryl sources [85]. While the biological roles of STC2 under this condition require further investigation, it is generally believed high level of STC2 expression predicts poor prognosis of colorectal cancer patients.\n\n### Gastric cancer",
        "source": "ocr_result_2"
      },
      "entities": [
        {
          "entity_id": "ent:3212e6484980",
          "entity_type": "TREATMENT",
          "name": "chemo- and radio- therapies",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Therapies mentioned in the context of STC2 contributing to acquired resistance to them, holding promise as a universal therapeutic target for multiple cancers."
        },
        {
          "entity_id": "ent:295dc006bd13",
          "entity_type": "TREATMENT",
          "name": "anti-estrogen therapy",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Described as a standard treatment for patients with estrogen receptor-positive breast cancers."
        },
        {
          "entity_id": "ent:881a354119f2",
          "entity_type": "GENE",
          "name": "STC2",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A gene whose expression is compared between human tumours and normal tissues, and is hypothesized to be a critical contributor for the development of acquired resistance to therapies."
        },
        {
          "entity_id": "ent:94ca8a6bf403",
          "entity_type": "PROTEIN",
          "name": "estrogen receptor",
          "normalized_id": "N/A",
          "aliases": [
            "Er"
          ],
          "description": "Receptor described as positive in most breast cancers and interacting with circulatory estrogens, with its constitutive activation leading to hyper-activation of downstream survival signaling."
        },
        {
          "entity_id": "ent:3720d7643fa3",
          "entity_type": "PROTEIN",
          "name": "human epidermal growth factor receptor 2",
          "normalized_id": "N/A",
          "aliases": [
            "ErbB2"
          ],
          "description": "Receptor described as demonstrating amplification and/or overexpression in approximately 15-20% breast cancer patients, which can form homodimers or heterodimers with other ErbB family members."
        },
        {
          "entity_id": "ent:42ecc34db6db",
          "entity_type": "MECHANISM",
          "name": "proliferation",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A cellular process that STC2 is reported to control, along with migration and immune response."
        },
        {
          "entity_id": "ent:20ed38fc8546",
          "entity_type": "MECHANISM",
          "name": "migration",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A cellular process that STC2 is reported to control, along with proliferation and immune response."
        },
        {
          "entity_id": "ent:8579404a2d79",
          "entity_type": "MECHANISM",
          "name": "immune response",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A cellular process that STC2 is reported to control, along with proliferation and migration."
        },
        {
          "entity_id": "ent:a0fead2a4b6b",
          "entity_type": "MECHANISM",
          "name": "activation",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Constitutive activation of Er signaling leads to hyper-activation of downstream survival signaling."
        },
        {
          "entity_id": "ent:1e17cc9cb474",
          "entity_type": "MECHANISM",
          "name": "signaling",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Er signaling, when constitutively activated, leads to hyper-activation of downstream survival signaling."
        },
        {
          "entity_id": "ent:cabb8f2f55e6",
          "entity_type": "MECHANISM",
          "name": "cell growth",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Downstream survival signaling promoted by constitutive Er activation promotes cell growth and inhibits apoptosis."
        },
        {
          "entity_id": "ent:74ba0385e676",
          "entity_type": "MECHANISM",
          "name": "apoptosis",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A process inhibited by the downstream survival signaling promoted by constitutive Er activation."
        },
        {
          "entity_id": "ent:4bae7a3731b5",
          "entity_type": "MECHANISM",
          "name": "survival",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Downstream signaling activated by ErbB2 enhances survival and proliferation of oncogenic cells."
        },
        {
          "entity_id": "ent:5d24d5d02c66",
          "entity_type": "DISEASE",
          "name": "cholangiocarcinoma",
          "normalized_id": "N/A",
          "aliases": [
            "CHOL"
          ],
          "description": "A type of human tumour mentioned in the comparison of STC2 expression between tumours and normal tissues."
        },
        {
          "entity_id": "ent:76fc7de47388",
          "entity_type": "DISEASE",
          "name": "colon adenocarcinoma",
          "normalized_id": "N/A",
          "aliases": [
            "COAD"
          ],
          "description": "A type of human tumour mentioned in the comparison of STC2 expression between tumours and normal tissues."
        },
        {
          "entity_id": "ent:86b156b0dfef",
          "entity_type": "DISEASE",
          "name": "esophageal carcinoma",
          "normalized_id": "N/A",
          "aliases": [
            "ESCA"
          ],
          "description": "A type of human tumour mentioned in the comparison of STC2 expression between tumours and normal tissues."
        },
        {
          "entity_id": "ent:188f294c3836",
          "entity_type": "DISEASE",
          "name": "glioblastoma multiforme",
          "normalized_id": "N/A",
          "aliases": [
            "GBM"
          ],
          "description": "A type of human tumour mentioned in the comparison of STC2 expression between tumours and normal tissues."
        },
        {
          "entity_id": "ent:e9383eba571e",
          "entity_type": "DISEASE",
          "name": "head and neck squamous cell carcinoma",
          "normalized_id": "N/A",
          "aliases": [
            "HNSC"
          ],
          "description": "A type of human tumour mentioned in the comparison of STC2 expression between tumours and normal tissues."
        },
        {
          "entity_id": "ent:5d8a5f864e14",
          "entity_type": "DISEASE",
          "name": "kidney renal clear cell carcinoma",
          "normalized_id": "N/A",
          "aliases": [
            "KIRC"
          ],
          "description": "A type of human tumour mentioned in the comparison of STC2 expression between tumours and normal tissues."
        },
        {
          "entity_id": "ent:15414e762b73",
          "entity_type": "DISEASE",
          "name": "brain lower grade glioma",
          "normalized_id": "N/A",
          "aliases": [
            "LGG"
          ],
          "description": "A type of human tumour mentioned in the comparison of STC2 expression between tumours and normal tissues."
        },
        {
          "entity_id": "ent:b79bfc04a42e",
          "entity_type": "DISEASE",
          "name": "ovarian serous cystadenocarcinoma",
          "normalized_id": "N/A",
          "aliases": [
            "OV"
          ],
          "description": "A type of human tumour mentioned in the comparison of STC2 expression between tumours and normal tissues."
        },
        {
          "entity_id": "ent:e29521c9d171",
          "entity_type": "DISEASE",
          "name": "rectum adenocarcinoma",
          "normalized_id": "N/A",
          "aliases": [
            "READ"
          ],
          "description": "A type of human tumour mentioned in the comparison of STC2 expression between tumours and normal tissues."
        },
        {
          "entity_id": "ent:085989a500f2",
          "entity_type": "DISEASE",
          "name": "uterine corpus endometrial carcinoma",
          "normalized_id": "N/A",
          "aliases": [
            "UCEC"
          ],
          "description": "A type of human tumour mentioned in the comparison of STC2 expression between tumours and normal tissues."
        },
        {
          "entity_id": "ent:e8db18b15143",
          "entity_type": "DISEASE",
          "name": "uterine carcinosarcoma",
          "normalized_id": "N/A",
          "aliases": [
            "UCS"
          ],
          "description": "A type of human tumour mentioned in the comparison of STC2 expression between tumours and normal tissues."
        },
        {
          "entity_id": "ent:4d5b4b8a697d",
          "entity_type": "DISEASE",
          "name": "acute Myeloid Leukemia",
          "normalized_id": "N/A",
          "aliases": [
            "LAML"
          ],
          "description": "A type of human tumour mentioned in the comparison of STC2 expression between tumours and normal tissues."
        },
        {
          "entity_id": "ent:3e3accfb14ba",
          "entity_type": "DISEASE",
          "name": "skin cutaneous melanoma",
          "normalized_id": "N/A",
          "aliases": [
            "SKCM"
          ],
          "description": "A type of human tumour mentioned in the comparison of STC2 expression between tumours and normal tissues."
        },
        {
          "entity_id": "ent:54a59e804fb2",
          "entity_type": "DISEASE",
          "name": "Adrenocortical carcinoma",
          "normalized_id": "N/A",
          "aliases": [
            "ACC"
          ],
          "description": "A type of human tumour mentioned in the comparison of STC2 expression between tumours and normal tissues."
        },
        {
          "entity_id": "ent:ac3aa0575741",
          "entity_type": "DISEASE",
          "name": "Cervical squamous cell carcinoma and endocervical adenocarcinoma",
          "normalized_id": "N/A",
          "aliases": [
            "CESC"
          ],
          "description": "A type of human tumour mentioned in the comparison of STC2 expression between tumours and normal tissues."
        },
        {
          "entity_id": "ent:d3f263a1a590",
          "entity_type": "DISEASE",
          "name": "Lymphoid Neoplasm Diffuse Large B-cell Lymphoma",
          "normalized_id": "N/A",
          "aliases": [
            "DLBC"
          ],
          "description": "A type of human tumour mentioned in the comparison of STC2 expression between tumours and normal tissues."
        },
        {
          "entity_id": "ent:95c64cf7d318",
          "entity_type": "DISEASE",
          "name": "Kidney Chromophobe",
          "normalized_id": "N/A",
          "aliases": [
            "KICH"
          ],
          "description": "A type of human tumour mentioned in the comparison of STC2 expression between tumours and normal tissues."
        },
        {
          "entity_id": "ent:85d0edc43168",
          "entity_type": "DISEASE",
          "name": "Liver hepatocellular carcinoma",
          "normalized_id": "N/A",
          "aliases": [
            "LIHC"
          ],
          "description": "A type of human tumour mentioned in the comparison of STC2 expression between tumours and normal tissues."
        },
        {
          "entity_id": "ent:a1d3ded196e7",
          "entity_type": "DISEASE",
          "name": "Lung squamous cell carcinoma",
          "normalized_id": "N/A",
          "aliases": [
            "LUSC"
          ],
          "description": "A type of human tumour mentioned in the comparison of STC2 expression between tumours and normal tissues."
        },
        {
          "entity_id": "ent:1b60680cecba",
          "entity_type": "DISEASE",
          "name": "Pheochromocytoma and Paraganglioma",
          "normalized_id": "N/A",
          "aliases": [
            "PCPG"
          ],
          "description": "A type of human tumour mentioned in the comparison of STC2 expression between tumours and normal tissues."
        },
        {
          "entity_id": "ent:3e5237d8eb70",
          "entity_type": "DISEASE",
          "name": "Sarcoma",
          "normalized_id": "N/A",
          "aliases": [
            "SARC"
          ],
          "description": "A type of human tumour mentioned in the comparison of STC2 expression between tumours and normal tissues."
        },
        {
          "entity_id": "ent:92a0df0c8c92",
          "entity_type": "DISEASE",
          "name": "Stomach adenocarcinoma",
          "normalized_id": "N/A",
          "aliases": [
            "STAD"
          ],
          "description": "A type of human tumour mentioned in the comparison of STC2 expression between tumours and normal tissues."
        },
        {
          "entity_id": "ent:82539f3ca367",
          "entity_type": "DISEASE",
          "name": "Testicular Germ Cell Tumours",
          "normalized_id": "N/A",
          "aliases": [
            "TGCT"
          ],
          "description": "A type of human tumour mentioned in the comparison of STC2 expression between tumours and normal tissues."
        },
        {
          "entity_id": "ent:8d608d53f863",
          "entity_type": "DISEASE",
          "name": "Thymoma",
          "normalized_id": "N/A",
          "aliases": [
            "THYM"
          ],
          "description": "A type of human tumour mentioned in the comparison of STC2 expression between tumours and normal tissues."
        },
        {
          "entity_id": "ent:7fbae7d57a30",
          "entity_type": "DISEASE",
          "name": "Bladder Urothelial Carcinoma",
          "normalized_id": "N/A",
          "aliases": [
            "BLCA"
          ],
          "description": "A type of human tumour mentioned in the comparison of STC2 expression between tumours and normal tissues."
        },
        {
          "entity_id": "ent:698f8bca871c",
          "entity_type": "DISEASE",
          "name": "Breast invasive carcinoma",
          "normalized_id": "N/A",
          "aliases": [
            "BRCA"
          ],
          "description": "A type of human tumour mentioned in the comparison of STC2 expression between tumours and normal tissues."
        },
        {
          "entity_id": "ent:44489d8921a1",
          "entity_type": "DISEASE",
          "name": "Kidney renal papillary cell carcinoma",
          "normalized_id": "N/A",
          "aliases": [
            "KIRP"
          ],
          "description": "A type of human tumour mentioned in the comparison of STC2 expression between tumours and normal tissues."
        },
        {
          "entity_id": "ent:2d9bbebf01e5",
          "entity_type": "DISEASE",
          "name": "Lung adenocarcinoma",
          "normalized_id": "N/A",
          "aliases": [
            "LUAD"
          ],
          "description": "A type of human tumour mentioned in the comparison of STC2 expression between tumours and normal tissues."
        },
        {
          "entity_id": "ent:a4f3098e0316",
          "entity_type": "DISEASE",
          "name": "Pancreatic adenocarcinoma",
          "normalized_id": "N/A",
          "aliases": [
            "PAAD"
          ],
          "description": "A type of human tumour mentioned in the comparison of STC2 expression between tumours and normal tissues."
        },
        {
          "entity_id": "ent:2d17b3b786b9",
          "entity_type": "DISEASE",
          "name": "Prostate adenocarcinoma",
          "normalized_id": "N/A",
          "aliases": [
            "PRAD"
          ],
          "description": "A type of human tumour mentioned in the comparison of STC2 expression between tumours and normal tissues."
        },
        {
          "entity_id": "ent:ad83613760cf",
          "entity_type": "DISEASE",
          "name": "Thyroid carcinoma",
          "normalized_id": "N/A",
          "aliases": [
            "THCA"
          ],
          "description": "A type of human tumour mentioned in the comparison of STC2 expression between tumours and normal tissues."
        },
        {
          "entity_id": "ent:243b0190651f",
          "entity_type": "DISEASE",
          "name": "cancers",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Multiple types are mentioned as having STC2 as a potential universal therapeutic target."
        },
        {
          "entity_id": "ent:9ac036931c2f",
          "entity_type": "DISEASE",
          "name": "Breast cancer",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Described as the second common cause of death for women, accounting for about 26% of all cancers diagnosed for women."
        },
        {
          "entity_id": "ent:6e82daffe5a9",
          "entity_type": "DISEASE",
          "name": "breast cancers",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Most (~70%) are positive for estrogen receptor (Er), and anti-estrogen therapy is a standard treatment for patients with Er-positive breast cancers."
        },
        {
          "entity_id": "ent:206ce5fab45f",
          "entity_type": "DISEASE",
          "name": "Colorectal cancer",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Both mRNA and protein levels of STC2 are elevated in human tissues of this condition compared to noncancerous counterparts."
        },
        {
          "entity_id": "ent:097ce5f9950f",
          "entity_type": "DISEASE",
          "name": "Gastric cancer",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "N/A"
        }
      ],
      "relations": []
    },
    "ocr_result_2_4": {
      "id": "ocr_result_2_4",
      "name": "",
      "meta": {
        "text": "Although its incidence is decreasing, gastric cancer remains one of the most common cancers worldwide. The gastric cancer screening is not a broadly-used routine test; thus, it is not uncommon that the majority of patients made their first visit with an advanced stage gastric cancer [86]. Postoperative adjuvant chemotherapy assists the improvement of patients' prognosis with advanced stage tumours; therefore, it's beneficial to identify novel biomarkers of gastric cancer to assess the necessity to take adjuvant therapy [62]. cDNA microarray revealed elevated STC2 levels in gastric cancer comparing to normal tissues. Consistently, STC2 levels are higher in gastric cancer tissues than those in normal mucosa; elevated STC2 expression is correlated with tumour invasion, lymphatic metastasis and poor prognosis [62, 63]. Furthermore, blood STC2 levels have been shown to be a useful biomarker to screen and evaluate the prognosis of patients with gastric cancer [87, 88].\n\n### Esophageal squamous cell carcinoma (ESCC)\n\nIn a study looking for genes related to ESCC progression, STC2 is illustrated to be upregulated in ESCC comparing to normal tissues [35]. Ectopic expression of STC2 enhances the proliferation and invasiveness of ESCC cells; while knockdown of STC2 compromises the proliferation of ESCC cells with high STC2 levels [35]. Further clinicopathological analyses demonstrated STC2 levels are correlated with lymphatic invasion, lymph node metastasis, and poor prognosis in ESCC patients, suggesting STC2 is a potential biomarker and a therapeutic target for ESCC.\n\n### Prostate cancer\n\nProstate cancer is one of the major public health problems and the second leading cause of cancer-related death for men. In 2021, the estimated incidence will be 248,530 cases and 34,130 men will probably die of prostate cancer [89]. Currently, surgery and radiotherapy remain the most effective treatment for patients with local tumours; however, approximately 30 percent of patients suffer from relapse even after treatment [90]. The majority of relapsed patients still demonstrate acceptable response to medical androgen ablation or castration. Unfortunately, the tumours will finally become castration-resistant and more aggressive. Therefore, it's with great importance to search for new therapeutic candidates in order to treat patients with castration-resistant prostate cancer (CRPC) [36].\n\nCRPC cells show increased STC2 mRNA levels relative to those from castration-nave prostate cancer cells. Clinically, the expression of STC2 is correlated with high\n\nQie and Sang J Exp Clin Cancer Res (2022) 41:161\n\nGleason scores [36]. Knockdown of STC2 compromises the colony formation; while ectopic expression of STC2 promotes cell proliferation [36], indicating STC2 may serve as a novel diagnostic biomarker for aggressive prostate cancer and a new therapeutic target for CRPC. In fact, STC2 is among the most upregulated genes in hormone insensitive prostate cancer cells treated with pigment epithelium-derived factor, but the roles of STC2 in CRPC and its potential as a therapeutic target remain unclear and require further investigation [91].\n\n# Renal cell carcinoma (RCC)\n\nRCC represents the most common kidney tumours in adults. Approximately  $30\\%$  RCC patients are diagnosed with metastatic lesions at first visit; some patients will finally develop metastasis even with the removal of local tumours [92]. There remains no effective treatment for patients with metastatic RCC; therefore, it's critical to search for novel therapeutic targets. Two independent whole genome-wise studies identified STC2 as one of the most upregulated genes in RCC tumour tissues relative to adjacent normal kidney [93, 94]. Immunohistochemical (IHC) staining demonstrated that STC2 is mainly expressed in distal tubuli and glomeruli in normal kidney tissues with both cytoplasmic and membranous signals detected in RCC tumours. Both mRNA and protein levels of STC2 are higher in RCC than in non-tumorous adjacent tissues [37]. The expression of STC2 is correlated with the aggressiveness of primary RCC and the survival rates post radical nephrectomy [37]. Since STC2 is a secreted protein, its serum levels can be applied as a biomarker to evaluate the progression of RCC, but further investigations are required to clarify this probability.\n\n# Other tumours\n\nIn addition to the above-mentioned tumours, STC2 is also upregulated in other tumours like nasopharyngeal carcinoma, HNSCC, HCC, osteosarcoma, ovarian cancer, lung cancer, pancreatic cancer, endometrial cancer, cervical cancer, neuroblastoma, gallbladder cancer and cholangiocarcinoma as listed in Table 1. In brief, elevated STC2 levels are correlated with tumour progression, disease stage and patients' prognosis. STC2 is detected as a secreted protein in the extracellular proteome of HCC cells [95]; in the absence of cysteine, STC2 is upregulated, highlighting that as a stress response factor STC2 may reduce cell proliferation when nutrient is limited [96]. The expression of STC2 in vascular cells is correlated with decreased DFS in ovarian cancer [42]. STC2 is identified as a screening marker for endometrial cancer in combination with CRELD1, GRK5 and SLC25A27 [97]. In human neuroblastoma, the expression of STC2 is",
        "source": "ocr_result_2"
      },
      "entities": [
        {
          "entity_id": "ent:5e63dd9a6c2e",
          "entity_type": "GENE",
          "name": "STC2",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Gene with elevated levels in gastric cancer compared to normal tissues, correlated with tumour invasion, lymphatic metastasis and poor prognosis."
        },
        {
          "entity_id": "ent:69d065740be7",
          "entity_type": "MECHANISM",
          "name": "stress response factor",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "STC2 is described as a stress response factor that may reduce cell proliferation when nutrient is limited."
        },
        {
          "entity_id": "ent:b18be7108c70",
          "entity_type": "TREATMENT",
          "name": "adjuvant chemotherapy",
          "normalized_id": "N/A",
          "aliases": [
            "adjuvant therapy"
          ],
          "description": "Postoperative treatment described as assisting the improvement of patients' prognosis with advanced stage gastric cancer."
        },
        {
          "entity_id": "ent:6071f6e3d2ba",
          "entity_type": "TREATMENT",
          "name": "surgery",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Treatment mentioned as remaining one of the most effective treatments for patients with local prostate cancer tumours."
        },
        {
          "entity_id": "ent:77f4a4c87d3c",
          "entity_type": "TREATMENT",
          "name": "radiotherapy",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Treatment mentioned as remaining one of the most effective treatments for patients with local prostate cancer tumours."
        },
        {
          "entity_id": "ent:137526ef1467",
          "entity_type": "TREATMENT",
          "name": "medical androgen ablation",
          "normalized_id": "N/A",
          "aliases": [
            "castration"
          ],
          "description": "Treatment mentioned as something the majority of relapsed prostate cancer patients still demonstrate acceptable response to."
        },
        {
          "entity_id": "ent:119565b494da",
          "entity_type": "TREATMENT",
          "name": "radical nephrectomy",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Surgical procedure mentioned in relation to survival rates for renal cell carcinoma patients."
        },
        {
          "entity_id": "ent:e330b9fbd208",
          "entity_type": "DISEASE",
          "name": "gastric cancer",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A cancer described as having decreasing incidence but remaining common worldwide, with elevated STC2 levels correlated with tumour invasion, lymphatic metastasis, and poor prognosis."
        },
        {
          "entity_id": "ent:39b2b81297cc",
          "entity_type": "DISEASE",
          "name": "cancers",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "N/A"
        },
        {
          "entity_id": "ent:8242dcd1f72b",
          "entity_type": "DISEASE",
          "name": "advanced stage gastric cancer",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A condition where patients often first visit with an advanced stage, and postoperative adjuvant chemotherapy assists prognosis improvement."
        },
        {
          "entity_id": "ent:7f09222afd3a",
          "entity_type": "DISEASE",
          "name": "tumours",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "N/A"
        },
        {
          "entity_id": "ent:87104b8ab0db",
          "entity_type": "DISEASE",
          "name": "tumour invasion",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A factor correlated with elevated STC2 expression in gastric cancer."
        },
        {
          "entity_id": "ent:dadb6b243aee",
          "entity_type": "DISEASE",
          "name": "lymphatic metastasis",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A factor correlated with elevated STC2 expression in gastric cancer."
        },
        {
          "entity_id": "ent:c749d5928de1",
          "entity_type": "DISEASE",
          "name": "poor prognosis",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A condition correlated with elevated STC2 expression in gastric cancer and ESCC."
        },
        {
          "entity_id": "ent:e4db7f1e6347",
          "entity_type": "DISEASE",
          "name": "Esophageal squamous cell carcinoma",
          "normalized_id": "N/A",
          "aliases": [
            "ESCC"
          ],
          "description": "A cancer where STC2 is upregulated compared to normal tissues, with levels correlated with lymphatic invasion, lymph node metastasis, and poor prognosis."
        },
        {
          "entity_id": "ent:e7a62beb4625",
          "entity_type": "DISEASE",
          "name": "lymphatic invasion",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A factor correlated with STC2 levels in ESCC patients."
        },
        {
          "entity_id": "ent:208e30c64018",
          "entity_type": "DISEASE",
          "name": "lymph node metastasis",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A factor correlated with STC2 levels in ESCC patients."
        },
        {
          "entity_id": "ent:7e8b2f87269e",
          "entity_type": "DISEASE",
          "name": "Prostate cancer",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A major public health problem and the second leading cause of cancer-related death for men, with estimated high incidence and mortality."
        },
        {
          "entity_id": "ent:7ba5b5b42051",
          "entity_type": "DISEASE",
          "name": "cancer-related death",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "N/A"
        },
        {
          "entity_id": "ent:ba2546f2e769",
          "entity_type": "DISEASE",
          "name": "relapse",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A condition affecting approximately 30 percent of prostate cancer patients even after surgery or radiotherapy treatment."
        },
        {
          "entity_id": "ent:52a8afde0771",
          "entity_type": "DISEASE",
          "name": "castration-resistant prostate cancer",
          "normalized_id": "N/A",
          "aliases": [
            "CRPC"
          ],
          "description": "A condition where tumours become castration-resistant and more aggressive, with increased STC2 mRNA levels in cells."
        },
        {
          "entity_id": "ent:5fdc60be47f6",
          "entity_type": "DISEASE",
          "name": "aggressive prostate cancer",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A condition for which STC2 may serve as a novel diagnostic biomarker."
        },
        {
          "entity_id": "ent:6c36dc707c3e",
          "entity_type": "DISEASE",
          "name": "Renal cell carcinoma",
          "normalized_id": "N/A",
          "aliases": [
            "RCC"
          ],
          "description": "The most common kidney tumours in adults, with STC2 upregulated in tumour tissues and expression correlated with aggressiveness and survival rates."
        },
        {
          "entity_id": "ent:26878e67bc3a",
          "entity_type": "DISEASE",
          "name": "kidney tumours",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "N/A"
        },
        {
          "entity_id": "ent:beca9868629d",
          "entity_type": "DISEASE",
          "name": "metastatic lesions",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Conditions diagnosed in approximately 30% of RCC patients at first visit."
        },
        {
          "entity_id": "ent:559ef91937c9",
          "entity_type": "DISEASE",
          "name": "metastasis",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A condition some RCC patients develop even after removal of local tumours."
        },
        {
          "entity_id": "ent:8c561d09c2eb",
          "entity_type": "DISEASE",
          "name": "metastatic RCC",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A condition for which there is no effective treatment, making search for novel therapeutic targets critical."
        },
        {
          "entity_id": "ent:9a179f23dc87",
          "entity_type": "DISEASE",
          "name": "nasopharyngeal carcinoma",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A tumour where STC2 is upregulated, with elevated levels correlated with tumour progression, disease stage, and prognosis."
        },
        {
          "entity_id": "ent:7d3ad7243df1",
          "entity_type": "DISEASE",
          "name": "HNSCC",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A tumour where STC2 is upregulated, with elevated levels correlated with tumour progression, disease stage, and prognosis."
        },
        {
          "entity_id": "ent:82d22e9ae6ae",
          "entity_type": "DISEASE",
          "name": "HCC",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A tumour where STC2 is upregulated, with elevated levels correlated with tumour progression, disease stage, and prognosis."
        },
        {
          "entity_id": "ent:52083a1253f5",
          "entity_type": "DISEASE",
          "name": "osteosarcoma",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A tumour where STC2 is upregulated, with elevated levels correlated with tumour progression, disease stage, and prognosis."
        },
        {
          "entity_id": "ent:d6ba3f26a20d",
          "entity_type": "DISEASE",
          "name": "ovarian cancer",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A tumour where STC2 is upregulated, with elevated levels correlated with tumour progression, disease stage, and prognosis."
        },
        {
          "entity_id": "ent:a06e893017fd",
          "entity_type": "DISEASE",
          "name": "lung cancer",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A tumour where STC2 is upregulated, with elevated levels correlated with tumour progression, disease stage, and prognosis."
        },
        {
          "entity_id": "ent:66c28c1a402c",
          "entity_type": "DISEASE",
          "name": "pancreatic cancer",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A tumour where STC2 is upregulated, with elevated levels correlated with tumour progression, disease stage, and prognosis."
        },
        {
          "entity_id": "ent:fbb1c59776d6",
          "entity_type": "DISEASE",
          "name": "endometrial cancer",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A tumour where STC2 is identified as a screening marker in combination with other genes."
        },
        {
          "entity_id": "ent:663267b6fcc3",
          "entity_type": "DISEASE",
          "name": "cervical cancer",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A tumour where STC2 is upregulated, with elevated levels correlated with tumour progression, disease stage, and prognosis."
        },
        {
          "entity_id": "ent:a8efbd059f73",
          "entity_type": "DISEASE",
          "name": "neuroblastoma",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A tumour where STC2 is upregulated, with elevated levels correlated with tumour progression, disease stage, and prognosis."
        },
        {
          "entity_id": "ent:2ce91abfd37a",
          "entity_type": "DISEASE",
          "name": "gallbladder cancer",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A tumour where STC2 is upregulated, with elevated levels correlated with tumour progression, disease stage, and prognosis."
        },
        {
          "entity_id": "ent:f1653d8eea49",
          "entity_type": "DISEASE",
          "name": "cholangiocarcinoma",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A tumour where STC2 is upregulated, with elevated levels correlated with tumour progression, disease stage, and prognosis."
        },
        {
          "entity_id": "ent:a51eea0f5716",
          "entity_type": "DISEASE",
          "name": "tumour progression",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A condition correlated with elevated STC2 levels in various tumours."
        },
        {
          "entity_id": "ent:980d1f6d7b67",
          "entity_type": "DISEASE",
          "name": "disease stage",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A condition correlated with elevated STC2 levels in various tumours."
        }
      ],
      "relations": [
        {
          "head": "STC2",
          "relation": "correlate with",
          "tail": "tumour invasion",
          "relation_type": "UNKNOWN",
          "confidence": [
            0.85,
            0.15
          ],
          "evidence": [
            "elevated STC2 expression is correlated with tumour invasion, lymphatic metastasis and poor prognosis [62, 63]."
          ],
          "mechanism": "unknown",
          "source": "ocr_result_2_4",
          "subject": {
            "entity_id": "ent:5e63dd9a6c2e",
            "entity_type": "GENE",
            "name": "STC2",
            "normalized_id": "N/A",
            "aliases": [],
            "description": "Gene with elevated levels in gastric cancer compared to normal tissues, correlated with tumour invasion, lymphatic metastasis and poor prognosis."
          },
          "object": {
            "entity_id": "ent:87104b8ab0db",
            "entity_type": "DISEASE",
            "name": "tumour invasion",
            "normalized_id": "N/A",
            "aliases": [],
            "description": "A factor correlated with elevated STC2 expression in gastric cancer."
          },
          "time_info": null
        },
        {
          "head": "STC2",
          "relation": "correlate with",
          "tail": "lymphatic metastasis",
          "relation_type": "UNKNOWN",
          "confidence": [
            0.85,
            0.15
          ],
          "evidence": [
            "elevated STC2 expression is correlated with tumour invasion, lymphatic metastasis and poor prognosis [62, 63].",
            "Further clinicopathological analyses demonstrated STC2 levels are correlated with lymphatic invasion, lymph node metastasis, and poor prognosis in ESCC patients"
          ],
          "mechanism": "unknown",
          "source": "ocr_result_2_4",
          "subject": {
            "entity_id": "ent:5e63dd9a6c2e",
            "entity_type": "GENE",
            "name": "STC2",
            "normalized_id": "N/A",
            "aliases": [],
            "description": "Gene with elevated levels in gastric cancer compared to normal tissues, correlated with tumour invasion, lymphatic metastasis and poor prognosis."
          },
          "object": {
            "entity_id": "ent:559ef91937c9",
            "entity_type": "DISEASE",
            "name": "metastasis",
            "normalized_id": "N/A",
            "aliases": [],
            "description": "A condition some RCC patients develop even after removal of local tumours."
          },
          "time_info": null
        },
        {
          "head": "STC2",
          "relation": "correlate with",
          "tail": "poor prognosis",
          "relation_type": "UNKNOWN",
          "confidence": [
            0.88,
            0.1
          ],
          "evidence": [
            "elevated STC2 expression is correlated with tumour invasion, lymphatic metastasis and poor prognosis [62, 63].",
            "Further clinicopathological analyses demonstrated STC2 levels are correlated with lymphatic invasion, lymph node metastasis, and poor prognosis in ESCC patients",
            "The expression of STC2 is correlated with the aggressiveness of primary RCC and the survival rates post radical nephrectomy [37]."
          ],
          "mechanism": "unknown",
          "source": "ocr_result_2_4",
          "subject": {
            "entity_id": "ent:5e63dd9a6c2e",
            "entity_type": "GENE",
            "name": "STC2",
            "normalized_id": "N/A",
            "aliases": [],
            "description": "Gene with elevated levels in gastric cancer compared to normal tissues, correlated with tumour invasion, lymphatic metastasis and poor prognosis."
          },
          "object": {
            "entity_id": "ent:c749d5928de1",
            "entity_type": "DISEASE",
            "name": "poor prognosis",
            "normalized_id": "N/A",
            "aliases": [],
            "description": "A condition correlated with elevated STC2 expression in gastric cancer and ESCC."
          },
          "time_info": null
        },
        {
          "head": "STC2",
          "relation": "correlate with",
          "tail": "lymphatic invasion",
          "relation_type": "UNKNOWN",
          "confidence": [
            0.82,
            0.15
          ],
          "evidence": [
            "Further clinicopathological analyses demonstrated STC2 levels are correlated with lymphatic invasion, lymph node metastasis, and poor prognosis in ESCC patients"
          ],
          "mechanism": "unknown",
          "source": "ocr_result_2_4",
          "subject": {
            "entity_id": "ent:5e63dd9a6c2e",
            "entity_type": "GENE",
            "name": "STC2",
            "normalized_id": "N/A",
            "aliases": [],
            "description": "Gene with elevated levels in gastric cancer compared to normal tissues, correlated with tumour invasion, lymphatic metastasis and poor prognosis."
          },
          "object": {
            "entity_id": "ent:e7a62beb4625",
            "entity_type": "DISEASE",
            "name": "lymphatic invasion",
            "normalized_id": "N/A",
            "aliases": [],
            "description": "A factor correlated with STC2 levels in ESCC patients."
          },
          "time_info": null
        },
        {
          "head": "STC2",
          "relation": "correlate with",
          "tail": "lymph node metastasis",
          "relation_type": "UNKNOWN",
          "confidence": [
            0.85,
            0.15
          ],
          "evidence": [
            "Further clinicopathological analyses demonstrated STC2 levels are correlated with lymphatic invasion, lymph node metastasis, and poor prognosis in ESCC patients"
          ],
          "mechanism": "unknown",
          "source": "ocr_result_2_4",
          "subject": {
            "entity_id": "ent:5e63dd9a6c2e",
            "entity_type": "GENE",
            "name": "STC2",
            "normalized_id": "N/A",
            "aliases": [],
            "description": "Gene with elevated levels in gastric cancer compared to normal tissues, correlated with tumour invasion, lymphatic metastasis and poor prognosis."
          },
          "object": {
            "entity_id": "ent:559ef91937c9",
            "entity_type": "DISEASE",
            "name": "metastasis",
            "normalized_id": "N/A",
            "aliases": [],
            "description": "A condition some RCC patients develop even after removal of local tumours."
          },
          "time_info": null
        },
        {
          "head": "STC2",
          "relation": "correlate with",
          "tail": "aggressiveness of primary RCC",
          "relation_type": "UNKNOWN",
          "confidence": [
            0.8,
            0.15
          ],
          "evidence": [
            "The expression of STC2 is correlated with the aggressiveness of primary RCC and the survival rates post radical nephrectomy [37]."
          ],
          "mechanism": "unknown",
          "source": "ocr_result_2_4",
          "subject": {
            "entity_id": "ent:5e63dd9a6c2e",
            "entity_type": "GENE",
            "name": "STC2",
            "normalized_id": "N/A",
            "aliases": [],
            "description": "Gene with elevated levels in gastric cancer compared to normal tissues, correlated with tumour invasion, lymphatic metastasis and poor prognosis."
          },
          "object": {
            "entity_id": "ent:6c36dc707c3e",
            "entity_type": "DISEASE",
            "name": "Renal cell carcinoma",
            "normalized_id": "N/A",
            "aliases": [
              "RCC"
            ],
            "description": "The most common kidney tumours in adults, with STC2 upregulated in tumour tissues and expression correlated with aggressiveness and survival rates."
          },
          "time_info": null
        },
        {
          "head": "STC2",
          "relation": "correlate with",
          "tail": "survival rates post radical nephrectomy",
          "relation_type": "UNKNOWN",
          "confidence": [
            0.78,
            0.1
          ],
          "evidence": [
            "The expression of STC2 is correlated with the aggressiveness of primary RCC and the survival rates post radical nephrectomy [37]."
          ],
          "mechanism": "unknown",
          "source": "ocr_result_2_4",
          "subject": {
            "entity_id": "ent:5e63dd9a6c2e",
            "entity_type": "GENE",
            "name": "STC2",
            "normalized_id": "N/A",
            "aliases": [],
            "description": "Gene with elevated levels in gastric cancer compared to normal tissues, correlated with tumour invasion, lymphatic metastasis and poor prognosis."
          },
          "object": {
            "entity_id": "ent:119565b494da",
            "entity_type": "TREATMENT",
            "name": "radical nephrectomy",
            "normalized_id": "N/A",
            "aliases": [],
            "description": "Surgical procedure mentioned in relation to survival rates for renal cell carcinoma patients."
          },
          "time_info": null
        },
        {
          "head": "STC2",
          "relation": "correlate with",
          "tail": "tumour progression",
          "relation_type": "UNKNOWN",
          "confidence": [
            0.75,
            0.15
          ],
          "evidence": [
            "In brief, elevated STC2 levels are correlated with tumour progression, disease stage and patients' prognosis."
          ],
          "mechanism": "unknown",
          "source": "ocr_result_2_4",
          "subject": {
            "entity_id": "ent:5e63dd9a6c2e",
            "entity_type": "GENE",
            "name": "STC2",
            "normalized_id": "N/A",
            "aliases": [],
            "description": "Gene with elevated levels in gastric cancer compared to normal tissues, correlated with tumour invasion, lymphatic metastasis and poor prognosis."
          },
          "object": {
            "entity_id": "ent:a51eea0f5716",
            "entity_type": "DISEASE",
            "name": "tumour progression",
            "normalized_id": "N/A",
            "aliases": [],
            "description": "A condition correlated with elevated STC2 levels in various tumours."
          },
          "time_info": null
        },
        {
          "head": "STC2",
          "relation": "correlate with",
          "tail": "disease stage",
          "relation_type": "UNKNOWN",
          "confidence": [
            0.75,
            0.15
          ],
          "evidence": [
            "In brief, elevated STC2 levels are correlated with tumour progression, disease stage and patients' prognosis."
          ],
          "mechanism": "unknown",
          "source": "ocr_result_2_4",
          "subject": {
            "entity_id": "ent:5e63dd9a6c2e",
            "entity_type": "GENE",
            "name": "STC2",
            "normalized_id": "N/A",
            "aliases": [],
            "description": "Gene with elevated levels in gastric cancer compared to normal tissues, correlated with tumour invasion, lymphatic metastasis and poor prognosis."
          },
          "object": {
            "entity_id": "ent:980d1f6d7b67",
            "entity_type": "DISEASE",
            "name": "disease stage",
            "normalized_id": "N/A",
            "aliases": [],
            "description": "A condition correlated with elevated STC2 levels in various tumours."
          },
          "time_info": null
        },
        {
          "head": "STC2",
          "relation": "correlate with",
          "tail": "decreased DFS in ovarian cancer",
          "relation_type": "UNKNOWN",
          "confidence": [
            0.7,
            0.15
          ],
          "evidence": [
            "The expression of STC2 in vascular cells is correlated with decreased DFS in ovarian cancer [42]."
          ],
          "mechanism": "unknown",
          "source": "ocr_result_2_4",
          "subject": {
            "entity_id": "ent:5e63dd9a6c2e",
            "entity_type": "GENE",
            "name": "STC2",
            "normalized_id": "N/A",
            "aliases": [],
            "description": "Gene with elevated levels in gastric cancer compared to normal tissues, correlated with tumour invasion, lymphatic metastasis and poor prognosis."
          },
          "object": {
            "entity_id": "ent:d6ba3f26a20d",
            "entity_type": "DISEASE",
            "name": "ovarian cancer",
            "normalized_id": "N/A",
            "aliases": [],
            "description": "A tumour where STC2 is upregulated, with elevated levels correlated with tumour progression, disease stage, and prognosis."
          },
          "time_info": null
        },
        {
          "head": "STC2",
          "relation": "enhance",
          "tail": "invasiveness",
          "relation_type": "UNKNOWN",
          "confidence": [
            0.65,
            0.1
          ],
          "evidence": [
            "Ectopic expression of STC2 enhances the proliferation and invasiveness of ESCC cells; while knockdown of STC2 compromises the proliferation of ESCC cells with high STC2 levels [35]."
          ],
          "mechanism": "unknown",
          "source": "ocr_result_2_4",
          "subject": {
            "entity_id": "ent:5e63dd9a6c2e",
            "entity_type": "GENE",
            "name": "STC2",
            "normalized_id": "N/A",
            "aliases": [],
            "description": "Gene with elevated levels in gastric cancer compared to normal tissues, correlated with tumour invasion, lymphatic metastasis and poor prognosis."
          },
          "object": {
            "entity_id": "ent:87104b8ab0db",
            "entity_type": "DISEASE",
            "name": "tumour invasion",
            "normalized_id": "N/A",
            "aliases": [],
            "description": "A factor correlated with elevated STC2 expression in gastric cancer."
          },
          "time_info": null
        }
      ]
    },
    "ocr_result_2_5": {
      "id": "ocr_result_2_5",
      "name": "",
      "meta": {
        "text": "![img-7.jpeg](img-7.jpeg)\nFig. 4 STC2 modulates the severity of ER stress response, promotes cell survival and prevents apoptosis. Hypoxia, nutrient depletion associated ATP depletion, and oxidative stress trigger ER stress. Similarly, therapeutic treatment and some compounds disrupting ER functions also trigger ER stress. Under such conditions, BiP, the negative regulator of ATF6, PERK and IRE1, is sequestrated by misfolded proteins accumulated in the ER lumen. The activation of ATF6 (tATF6, truncated and activated form), ATF4 and XBP1 leads to transcriptional upregulation of genes involved in ER homeostasis, ER biogenesis, inflammatory response, protein folding and degradation. Severe and prolonged ER stress leads to the activation of JNK/NF-  $\\kappa \\mathrm{B}$  and CHOP pathways which promote apoptosis. Under moderate stress conditions, the p-eIF2a-ATF4 axis serves as a modulator of the severity of ER stress response by activating three down stress genes: 1) as the negative regulator of ER stress, BiP upregulation facilitates restoring ER homeostasis; 2) GADD34, a phosphoprotein phosphatase, directly dephosphorylates eIF2a to attenuate ATF4-mediated stress response; and 3) importantly, STC2 performs its function through affecting ATF4 or calcineurin, a calcium and calmodulin dependent serine/threonine protein phosphatase that is evidenced by the report showing aluminium toxicity causes ER stress, which activates IRE1 $\\beta$ , but not ATF4, finally leading to apoptosis\n\nassociated with clinical stages [47]. Moreover, in human fibrosarcoma cells, STC2 has been reported to be phosphorylated between Serine-285 and Serine-298 in the C-terminal region by casein kinase [98].\n\nTaken together, the above findings show that increased expression of STC2 is negatively correlated with patients' prognosis for most human cancers except breast cancer [29, 32, 84], which might be a result of different tissue origins and specific genetic context, such as the existence of complicated hormone-related mechanisms. As a secreted glycoprotein, STC2 has been detected in the sera of patients with colorectal cancer [33], gastric cancer\n\n[87], and laryngeal cancer [64]. In accordance, STC2 is also detected in the culture medium of tumour cell lines derived from glioma and fibrosarcoma [98]. Therefore, it is promising to systematically investigate the clinicopathological importance of serum STC2 levels in tumor diagnosis and in evaluating patients' prognosis for multiple types of human cancers.\n\n### Transcription factors involved in STC2 regulation\n\n### Activating transcription factor 4 (ATF4)\n\nATF4 plays a critical role in mediating integrated stress response (IRS), and ATF4 is correlated with STC2 expression. Tumour microenvironment is characterized by uneven oxygen levels, insufficient nutrient supply and low pH [99]; these stress conditions lead to ER stress that disrupts protein maturation, accumulates unfolded or misfolded proteins, and ultimately activates the evolutionarily conserved response, unfold protein response (UPR) [100]. Several factors, such as PKR-like ER kinase (PERK), inositol-requiring protein 1 (IRE1) and activating transcription factor 6 (ATF6) can be activated through the loss of interaction with Bip and/or the direct binding with unfolded or misfolded proteins [101]. UPR regulates apoptosis and several other pathways to control cell survival [102]. Besides the well-characterized UPR genes, factors involved in cellular Ca^{2+} homeostasis, such as Nucleobindin 2, sarco- (endo-) plasmic reticulum Ca^{2+}-ATPase 2, calcitonin gene-related peptide 2 and STC2 can be induced upon the treatment with either tunicamycin (an inhibitor of N-linked glycosylation) or thapsigargin (an inhibitor of sarco- (endo-) plasmic reticulum Ca^{2+}-ATPase) (Fig. 4) [103]. Both tunicamycin and thapsigargin have been shown to upregulate the expression and secretion of STC2 in a time-dependent manner. The expression of STC2 is enhanced by ER stress inducers like dithiothreitol, methyl methanesulfonate, hydrogen peroxide (H_{2}O_{2}) and hypoxia but not by non-ER stress inducers such as high extracellular Ca^{2+} levels, high osmolarity, ultraviolet radiation, staurosporine or heat shock [103], suggesting that STC2 is likely a direct downstream target of UPR or ER stress. Mechanistically, ER stress-induced STC2 expression depends on ATF4 pathway but not XBP-1 and ATF6.",
        "source": "ocr_result_2"
      },
      "entities": [
        {
          "entity_id": "ent:f9240c9d04c1",
          "entity_type": "BIOMARKER",
          "name": "STC2",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A secreted glycoprotein detected in the sera of patients with colorectal cancer, gastric cancer, and laryngeal cancer, and in the culture medium of tumour cell lines, with serum levels promising for tumor diagnosis and prognosis evaluation."
        },
        {
          "entity_id": "ent:3de5e029fa91",
          "entity_type": "TREATMENT",
          "name": "therapeutic treatment",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "The text mentions therapeutic treatment as something that, along with some compounds, can trigger ER stress."
        },
        {
          "entity_id": "ent:ff6ad849d6a9",
          "entity_type": "TREATMENT",
          "name": "tunicamycin",
          "normalized_id": "N/A",
          "aliases": [
            "an inhibitor of N-linked glycosylation"
          ],
          "description": "Described as an inhibitor of N-linked glycosylation used in treatment to induce the expression of factors like STC2."
        },
        {
          "entity_id": "ent:a65442c0bf39",
          "entity_type": "TREATMENT",
          "name": "thapsigargin",
          "normalized_id": "N/A",
          "aliases": [
            "an inhibitor of sarco- (endo-) plasmic reticulum Ca^{2+}-ATPase"
          ],
          "description": "Described as an inhibitor of sarco-(endo-)plasmic reticulum Ca^{2+}-ATPase used in treatment to induce the expression of factors like STC2."
        },
        {
          "entity_id": "ent:dc46e2a86a32",
          "entity_type": "PATHWAY",
          "name": "ER stress response",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A response triggered by hypoxia, nutrient depletion, ATP depletion, oxidative stress, or compounds disrupting ER functions, leading to the sequestration of BiP and activation of transcription factors."
        },
        {
          "entity_id": "ent:7dd4ef607d8d",
          "entity_type": "PATHWAY",
          "name": "JNK/NF-B and CHOP pathways",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Pathways activated by severe and prolonged ER stress that promote apoptosis."
        },
        {
          "entity_id": "ent:cc17b62c1547",
          "entity_type": "PATHWAY",
          "name": "p-eIF2a-ATF4 axis",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Serves as a modulator of the severity of ER stress response by activating three downstream stress genes under moderate stress conditions."
        },
        {
          "entity_id": "ent:4cc61af57cf7",
          "entity_type": "PATHWAY",
          "name": "integrated stress response (IRS)",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A critical role mediated by ATF4, activated by stress conditions in the tumor microenvironment like uneven oxygen levels and insufficient nutrient supply."
        },
        {
          "entity_id": "ent:009efef95270",
          "entity_type": "PATHWAY",
          "name": "unfold protein response (UPR)",
          "normalized_id": "N/A",
          "aliases": [
            "ER stress",
            "unfold protein response",
            "UPR"
          ],
          "description": "An evolutionarily conserved response activated by ER stress that disrupts protein maturation and accumulates unfolded or misfolded proteins."
        },
        {
          "entity_id": "ent:876d40feec0c",
          "entity_type": "PATHWAY",
          "name": "ATF4 pathway",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A pathway on which ER stress-induced STC2 expression depends, but not on XBP-1 and ATF6."
        },
        {
          "entity_id": "ent:5fd6a054510f",
          "entity_type": "MECHANISM",
          "name": "apoptosis",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A process that severe and prolonged ER stress leads to through activation of JNK/NF-B and CHOP pathways, and is prevented by STC2."
        },
        {
          "entity_id": "ent:682f83dafce1",
          "entity_type": "MECHANISM",
          "name": "oxidative stress",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A condition that, along with hypoxia and nutrient depletion, triggers ER stress."
        },
        {
          "entity_id": "ent:4fe8a3927ba3",
          "entity_type": "MECHANISM",
          "name": "inflammatory response",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A process whose involved genes are transcriptionally upregulated by activation of ATF6, ATF4 and XBP1 under ER stress conditions."
        },
        {
          "entity_id": "ent:998cc29ecf71",
          "entity_type": "MECHANISM",
          "name": "protein folding",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A process whose involved genes are transcriptionally upregulated by activation of ATF6, ATF4 and XBP1 under ER stress conditions."
        },
        {
          "entity_id": "ent:875044533c9c",
          "entity_type": "MECHANISM",
          "name": "degradation",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A process whose involved genes are transcriptionally upregulated by activation of ATF6, ATF4 and XBP1 under ER stress conditions."
        },
        {
          "entity_id": "ent:8de4024a2282",
          "entity_type": "MECHANISM",
          "name": "cell survival",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A process promoted by STC2 modulation of ER stress response severity under moderate stress conditions."
        },
        {
          "entity_id": "ent:62488071a005",
          "entity_type": "MECHANISM",
          "name": "signal transduction",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "N/A"
        },
        {
          "entity_id": "ent:4099f3c855f8",
          "entity_type": "MECHANISM",
          "name": "receptor binding",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "N/A"
        },
        {
          "entity_id": "ent:d9dd55e27f63",
          "entity_type": "MECHANISM",
          "name": "dephosphorylation",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "N/A"
        },
        {
          "entity_id": "ent:f90f4aec4786",
          "entity_type": "DISEASE",
          "name": "cancers",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Human conditions where increased expression of STC2 is negatively correlated with patients' prognosis for most types except breast cancer."
        },
        {
          "entity_id": "ent:fa922888d10d",
          "entity_type": "DISEASE",
          "name": "breast cancer",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A type of human cancer where increased expression of STC2 is not negatively correlated with patients' prognosis, possibly due to different tissue origins and specific genetic context."
        },
        {
          "entity_id": "ent:a1c838119974",
          "entity_type": "DISEASE",
          "name": "colorectal cancer",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A condition where STC2 has been detected in the sera of patients."
        },
        {
          "entity_id": "ent:709be2b0109e",
          "entity_type": "DISEASE",
          "name": "gastric cancer",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A condition where STC2 has been detected in the sera of patients."
        },
        {
          "entity_id": "ent:4177fb750e73",
          "entity_type": "DISEASE",
          "name": "laryngeal cancer",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A condition where STC2 has been detected in the sera of patients."
        },
        {
          "entity_id": "ent:3a7764293040",
          "entity_type": "DISEASE",
          "name": "glioma",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A tumor type from which STC2 is detected in the culture medium of derived cell lines."
        },
        {
          "entity_id": "ent:0f53ccde09d1",
          "entity_type": "DISEASE",
          "name": "fibrosarcoma",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A tumor type from which STC2 is detected in the culture medium of derived cell lines and where STC2 has been reported to be phosphorylated in human cells."
        },
        {
          "entity_id": "ent:74b2ab612e5f",
          "entity_type": "DISEASE",
          "name": "tumor",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A condition where it is promising to investigate the clinicopathological importance of serum STC2 levels in diagnosis and evaluating patients' prognosis."
        },
        {
          "entity_id": "ent:002def07f987",
          "entity_type": "GENE",
          "name": "ATF6",
          "normalized_id": "N/A",
          "aliases": [
            "activating transcription factor 6"
          ],
          "description": "A negative regulator of ER stress whose activation leads to transcriptional upregulation of genes involved in ER homeostasis and other processes."
        },
        {
          "entity_id": "ent:0063bf212eb4",
          "entity_type": "GENE",
          "name": "PERK",
          "normalized_id": "N/A",
          "aliases": [
            "PKR-like ER kinase"
          ],
          "description": "A factor that can be activated through the loss of interaction with Bip and/or direct binding with unfolded or misfolded proteins during ER stress."
        },
        {
          "entity_id": "ent:058dc3bed341",
          "entity_type": "GENE",
          "name": "IRE1",
          "normalized_id": "N/A",
          "aliases": [
            "inositol-requiring protein 1"
          ],
          "description": "A factor that can be activated through the loss of interaction with Bip and/or direct binding with unfolded or misfolded proteins during ER stress."
        },
        {
          "entity_id": "ent:61bb6603da92",
          "entity_type": "GENE",
          "name": "ATF4",
          "normalized_id": "N/A",
          "aliases": [
            "activating transcription factor 4"
          ],
          "description": "A transcription factor whose activation leads to transcriptional upregulation of genes, and ER stress-induced STC2 expression depends on its pathway."
        },
        {
          "entity_id": "ent:d533c0cdfd73",
          "entity_type": "GENE",
          "name": "XBP1",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A gene whose activation leads to transcriptional upregulation of genes involved in ER homeostasis and other processes."
        },
        {
          "entity_id": "ent:8556a71c69b2",
          "entity_type": "GENE",
          "name": "JNK",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Part of a pathway (JNK/NF-B) that is activated by severe and prolonged ER stress and promotes apoptosis."
        },
        {
          "entity_id": "ent:1950ea5ff242",
          "entity_type": "GENE",
          "name": "NF-B",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Part of a pathway (JNK/NF-B) that is activated by severe and prolonged ER stress and promotes apoptosis."
        },
        {
          "entity_id": "ent:8e209c3cea3f",
          "entity_type": "GENE",
          "name": "eIF2a",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A factor dephosphorylated by GADD34 to attenuate ATF4-mediated stress response under moderate ER stress conditions."
        },
        {
          "entity_id": "ent:8a233d3ab0bc",
          "entity_type": "GENE",
          "name": "GADD34",
          "normalized_id": "N/A",
          "aliases": [
            "CHOP"
          ],
          "description": "A phosphoprotein phosphatase that directly dephosphorylates eIF2a to attenuate ATF4-mediated stress response under moderate ER stress."
        },
        {
          "entity_id": "ent:48f8fb0bf3e0",
          "entity_type": "GENE",
          "name": "IRE1",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Activated by aluminium toxicity-induced ER stress, leading to apoptosis associated with clinical stages."
        },
        {
          "entity_id": "ent:feafe594826c",
          "entity_type": "GENE",
          "name": "XBP-1",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A pathway on which ER stress-induced STC2 expression does not depend, according to the document."
        },
        {
          "entity_id": "ent:4f1b5e9ecd26",
          "entity_type": "PROTEIN",
          "name": "BiP",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Negative regulator of ATF6, PERK and IRE1 that is sequestrated by misfolded proteins accumulated in the ER lumen during ER stress."
        },
        {
          "entity_id": "ent:dae8d18dbc4d",
          "entity_type": "PROTEIN",
          "name": "p-eIF2a",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Part of the p-eIF2a-ATF4 axis that serves as a modulator of the severity of ER stress response under moderate stress conditions."
        },
        {
          "entity_id": "ent:e21081e686e8",
          "entity_type": "PROTEIN",
          "name": "calcineurin",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Calcium and calmodulin dependent serine/threonine protein phosphatase that STC2 performs its function through affecting."
        },
        {
          "entity_id": "ent:49ae5b4a933b",
          "entity_type": "PROTEIN",
          "name": "casein kinase",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Phosphorylates STC2 between Serine-285 and Serine-298 in the C-terminal region in human fibrosarcoma cells."
        }
      ],
      "relations": []
    },
    "ocr_result_2_6": {
      "id": "ocr_result_2_6",
      "name": "",
      "meta": {
        "text": "On the other hand, STC2 can also modulate ATF4 activity and function as an inhibitor of apoptosis. The conserved response upon moderate ER stress facilitates cellular adaptation to enhance survival, for example, induction of ATF4 and its downstream genes, BiP and GADD34, specifically ameliorates and limits the severity of ER stress. Upon persisting and severe ER stress, the three ER stress-triggered responsive arms ATF4, ATF6 and IRE1 may cooperatively trigger apoptosis via CHOP and JNK/NF-B pathways. As a cytotoxic reagent, aluminium induces apoptosis through activating ER stress. Unlike tunicamycin, aluminium glycinate induces the expression of IRE1 instead of IRE1, and it suppresses the transcription of other UPR genes like molecular chaperone BiP/Grp78, Ca^{2+}-binding chaperones (calnexin and calreticulin) and STC2 (Fig. 4) [104]. In addition, STC2 compromises calcineurin expression and calcineurin-dependent PERK phosphorylation in cerulein-induced pancreatitis mouse model [105]. Although PERK activity is suppressed, ATF4 expression is upregulated in STC2 transgenic mice, suggesting a feed-forward model of STC2 in regulating ATF4-dependent adaptive pathway through unknown mechanisms. In ischemic rat brain, subsequent reperfusion induces STC2 expression in brain tissues previously exposed to hypoxia. Functionally, STC2 enhances cell survival upon exposure to reperfusion associated oxidative stress, which is a common cause of ER stress as well. Therefore, STC2 demonstrates protective effects through limiting the severity of ER stress via modulating ATF4 signaling.\n\nBesides PERK, there are three other stress-activated kinases GCN2, PKR and HRI, that can activate the eIF2-ATF4 axis and facilitate cellular homeostasis and adaptation to stress conditions such as proteotoxicity, nutrient withdrawal, oxidative stress and viral infection [106--108]. Under such conditions, phosphorylated eIF2 inhibits global protein translation, but selectively promotes the translation of proteins such as ATF4 that are critical for stress response and cell survival. Interestingly, previous cDNA microarray screening identified STC2 is also upregulated upon either glutamine- or glucose-deprivation, both conditions can trigger ER stress via different mechanisms [78, 109]. For example, glutamine deprivation promotes the phosphorylation of eIF2 through amino acids deprivation triggered GCN2 activation. Glucose deprivation triggers ER stress through the following mechanisms: 1) glucose deprivation impairs ATP production; 2) inhibited pentose pathway causes intracellular redox imbalance, leading to oxidative stress; and 3) low glucose also suppresses protein glycosylation, resulting in protein unfolding/misfolding. Further studies are required to dissect how STC2 expression is controlled in cells under various stress conditions, and how it regulates biological processes in stressed cells. Nevertheless, ATF4-dependent induction of STC2 expression establishes the principle that STC2 is a general stress-responsive factor mediating the adaptation of cells to various types of stresses.\n\n### Hypoxia-inducible factor-1 (HIF-1)\n\nMammalian cells require sufficient and constitutive oxygen supply for a variety of metabolic processes\n\nQie and Sang J Exp Clin Cancer Res (2022) 41:161\n\n![img-8.jpeg](img-8.jpeg)\nFig. 5 The biological functions of STC2 under hypoxic conditions. STC2 promoter contains hypoxia response elements (HREs) and amino acid response elements (AAREs). Under hypoxic conditions, HIF-1 $\\alpha$  is stabilized, and forms the HIF-1 heterodimer through interacting with HIF-1 $\\beta$ . Then, HIF-1 is translocated into the nucleus where it binds to CBP/p300 and form a transcription complex to induce the expression of STC2. In addition, hypoxia also induces the expression of ATF4 through increased gene transcription, protein translation and protein stabilization. Thereafter, ATF4 is translocated into nucleus and form a transcriptional complex with co-factors to enhance the expression of downstream genes; however, it remains elusive whether ATF4 also contributes to STC2 upregulation under hypoxic conditions. Functionally, STC2 promotes cell cycle progression through enhancing cyclin D expression and Rb phosphorylation; STC2 induces epithelial-mesenchymal transition (EMT) through upregulating mesenchymal markers (N-cadherin and vimentin) and downregulating E-cadherin; in addition, STC2 can drive cell migration and invasion through the upregulation of matrix metalloproteinase (MMP)-2 and -9\n\n[110-112]. Hypoxia is a common phenomenon in solid tumours, under which the proliferation of tumour cells usually outgrows the growth of vascular vessels, leading to insufficient oxygen supply [100]. Under hypoxic conditions, tumour cells activate the evolutionarily conserved hypoxic response through stabilizing HIF-1 $\\alpha$  that forms a HIF-1 heterodimer through interacting with HIF-1 $\\beta$  [113]. Then, HIF-1 binds to hypoxia-response element (HRE) to enhance the expression of angiogenic, glycolytic and other relevant genes that mediate the adaptive response [114].",
        "source": "ocr_result_2"
      },
      "entities": [
        {
          "entity_id": "ent:fd46ba4110da",
          "entity_type": "PATHWAY",
          "name": "CHOP and JNK/NF-B pathways",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Pathways described as being cooperatively triggered by ER stress-responsive arms ATF4, ATF6 and IRE1 to induce apoptosis."
        },
        {
          "entity_id": "ent:952c9513f374",
          "entity_type": "PATHWAY",
          "name": "ATF4-dependent adaptive pathway",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Pathway described as being regulated by STC2 through unknown mechanisms, with ATF4 expression upregulated despite PERK suppression."
        },
        {
          "entity_id": "ent:52e37d9df8d8",
          "entity_type": "PATHWAY",
          "name": "ATF4 signaling",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Signaling described as being modulated by STC2 to limit the severity of ER stress, demonstrating protective effects."
        },
        {
          "entity_id": "ent:9e103d80e9f4",
          "entity_type": "PATHWAY",
          "name": "eIF2-ATF4 axis",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Axis described as being activated by stress-activated kinases GCN2, PKR and HRI to facilitate cellular homeostasis and adaptation to stress conditions."
        },
        {
          "entity_id": "ent:ddcdefdeb291",
          "entity_type": "PATHWAY",
          "name": "pentose pathway",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Pathway described as being inhibited during glucose deprivation, causing intracellular redox imbalance and leading to oxidative stress."
        },
        {
          "entity_id": "ent:2f320cdbdb79",
          "entity_type": "PATHWAY",
          "name": "hypoxic response",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Response described as evolutionarily conserved and activated by tumour cells under hypoxic conditions through stabilizing HIF-1."
        },
        {
          "entity_id": "ent:4aecb049e53e",
          "entity_type": "GENE",
          "name": "STC2",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "STC2 can modulate ATF4 activity and function as an inhibitor of apoptosis, and its expression is induced under various stress conditions."
        },
        {
          "entity_id": "ent:00843792d392",
          "entity_type": "GENE",
          "name": "ATF4",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "ATF4 is induced upon moderate ER stress, and its downstream genes include BiP and GADD34; it is involved in stress response pathways."
        },
        {
          "entity_id": "ent:ee666c4dd8ed",
          "entity_type": "GENE",
          "name": "GADD34",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "GADD34 is mentioned as a downstream gene of ATF4 in the context of ER stress response."
        },
        {
          "entity_id": "ent:98c6aa01e22c",
          "entity_type": "GENE",
          "name": "ATF6",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "ATF6 is one of the three ER stress-triggered responsive arms that may cooperatively trigger apoptosis."
        },
        {
          "entity_id": "ent:21de92cd2c20",
          "entity_type": "GENE",
          "name": "CHOP",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "CHOP is involved in apoptosis pathways triggered by ER stress along with JNK/NF-B."
        },
        {
          "entity_id": "ent:9014914a426b",
          "entity_type": "GENE",
          "name": "JNK",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "JNK is part of the pathway through which ER stress may trigger apoptosis, mentioned alongside NF-B."
        },
        {
          "entity_id": "ent:baf886dbc869",
          "entity_type": "GENE",
          "name": "NF-B",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "NF-B is part of the pathway through which ER stress may trigger apoptosis, mentioned alongside JNK."
        },
        {
          "entity_id": "ent:b6b57a172380",
          "entity_type": "GENE",
          "name": "IRE1",
          "normalized_id": "N/A",
          "aliases": [
            "IRE1",
            "IRE1"
          ],
          "description": "IRE1 is induced by aluminium glycinate instead of IRE1, as mentioned in the context of ER stress."
        },
        {
          "entity_id": "ent:1f5b1dfdda73",
          "entity_type": "GENE",
          "name": "calnexin",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Calnexin is mentioned as a Ca^{2+}-binding chaperone, part of the UPR genes whose transcription is suppressed."
        },
        {
          "entity_id": "ent:352b6f6f65e4",
          "entity_type": "GENE",
          "name": "calreticulin",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Calreticulin is mentioned as a Ca^{2+}-binding chaperone, part of the UPR genes whose transcription is suppressed."
        },
        {
          "entity_id": "ent:015c761b741b",
          "entity_type": "GENE",
          "name": "PERK",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "PERK activity is suppressed in STC2 transgenic mice, and its phosphorylation is calcineurin-dependent."
        },
        {
          "entity_id": "ent:13d054d8e88f",
          "entity_type": "GENE",
          "name": "GCN2",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "GCN2 is a stress-activated kinase that can activate the eIF2-ATF4 axis under conditions like amino acid deprivation."
        },
        {
          "entity_id": "ent:1b288fbeae2d",
          "entity_type": "GENE",
          "name": "PKR",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "PKR is a stress-activated kinase that can activate the eIF2-ATF4 axis under stress conditions such as viral infection."
        },
        {
          "entity_id": "ent:b3bf733a4eeb",
          "entity_type": "GENE",
          "name": "HRI",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "HRI is a stress-activated kinase that can activate the eIF2-ATF4 axis under various stress conditions."
        },
        {
          "entity_id": "ent:24ebdfd9dd2d",
          "entity_type": "GENE",
          "name": "eIF2",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "eIF2 is part of the eIF2-ATF4 axis; its phosphorylation inhibits global translation but promotes ATF4 translation."
        },
        {
          "entity_id": "ent:b010560af789",
          "entity_type": "GENE",
          "name": "HIF-1",
          "normalized_id": "N/A",
          "aliases": [
            "HIF-1 heterodimer"
          ],
          "description": "HIF-1 is a hypoxia-inducible factor; under hypoxia, HIF-1 stabilizes and forms a heterodimer with HIF-1."
        },
        {
          "entity_id": "ent:68cf848b8542",
          "entity_type": "GENE",
          "name": "HIF-1",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "HIF-1 is stabilized under hypoxic conditions and interacts with HIF-1 to form the HIF-1 heterodimer."
        },
        {
          "entity_id": "ent:9cd78444ae6c",
          "entity_type": "GENE",
          "name": "HIF-1",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "HIF-1 interacts with HIF-1 to form the HIF-1 heterodimer under hypoxic conditions."
        },
        {
          "entity_id": "ent:090d0fdfa166",
          "entity_type": "GENE",
          "name": "CBP",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "CBP is mentioned as binding with HIF-1 in the nucleus to form a transcription complex that induces STC2 expression."
        },
        {
          "entity_id": "ent:b8029461aeb1",
          "entity_type": "GENE",
          "name": "N-cadherin",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "N-cadherin is upregulated by STC2 as a mesenchymal marker during epithelial-mesenchymal transition (EMT)."
        },
        {
          "entity_id": "ent:08d5324bdfba",
          "entity_type": "GENE",
          "name": "vimentin",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Vimentin is upregulated by STC2 as a mesenchymal marker during epithelial-mesenchymal transition (EMT)."
        },
        {
          "entity_id": "ent:d932c6e48f40",
          "entity_type": "GENE",
          "name": "E-cadherin",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "E-cadherin is downregulated by STC2 during epithelial-mesenchymal transition (EMT)."
        },
        {
          "entity_id": "ent:84d8082e155f",
          "entity_type": "GENE",
          "name": "MMP",
          "normalized_id": "N/A",
          "aliases": [
            "matrix metalloproteinase"
          ],
          "description": "MMP, specifically MMP-2 and -9, is upregulated by STC2 to drive cell migration and invasion."
        },
        {
          "entity_id": "ent:556b471b9ca4",
          "entity_type": "MECHANISM",
          "name": "apoptosis",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A process that can be inhibited by STC2 or triggered by ER stress via CHOP and JNK/NF-B pathways."
        },
        {
          "entity_id": "ent:f411f8d5beaf",
          "entity_type": "MECHANISM",
          "name": "ER stress",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A stress condition that can be moderate, persisting, or severe, and facilitates cellular adaptation or triggers apoptosis."
        },
        {
          "entity_id": "ent:85419b89736e",
          "entity_type": "MECHANISM",
          "name": "cellular adaptation",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A process facilitated by the conserved response upon moderate ER stress to enhance survival."
        },
        {
          "entity_id": "ent:4a89f1e04e61",
          "entity_type": "MECHANISM",
          "name": "activating ER stress",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A mechanism by which aluminium induces apoptosis as a cytotoxic reagent."
        },
        {
          "entity_id": "ent:4b1a879aca6c",
          "entity_type": "MECHANISM",
          "name": "oxidative stress",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A common cause of ER stress that STC2 enhances cell survival upon exposure to during reperfusion."
        },
        {
          "entity_id": "ent:355fab9bf0a2",
          "entity_type": "MECHANISM",
          "name": "cellular homeostasis",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A state facilitated by stress-activated kinases activating the eIF2-ATF4 axis under stress conditions."
        },
        {
          "entity_id": "ent:f130025fbf9b",
          "entity_type": "MECHANISM",
          "name": "adaptation to stress conditions",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A process facilitated by stress-activated kinases activating the eIF2-ATF4 axis under conditions like proteotoxicity and nutrient withdrawal."
        },
        {
          "entity_id": "ent:622e49e7997f",
          "entity_type": "MECHANISM",
          "name": "proteotoxicity",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A stress condition under which stress-activated kinases can activate the eIF2-ATF4 axis."
        },
        {
          "entity_id": "ent:b02cbe48053b",
          "entity_type": "MECHANISM",
          "name": "nutrient withdrawal",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A stress condition under which stress-activated kinases can activate the eIF2-ATF4 axis."
        },
        {
          "entity_id": "ent:973ec7aefed9",
          "entity_type": "MECHANISM",
          "name": "viral infection",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A stress condition under which stress-activated kinases can activate the eIF2-ATF4 axis."
        },
        {
          "entity_id": "ent:2b9d2d4f6cdf",
          "entity_type": "MECHANISM",
          "name": "phosphorylated eIF2 inhibits global protein translation",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A mechanism under stress conditions where phosphorylated eIF2 inhibits global protein translation but selectively promotes translation of proteins like ATF4."
        },
        {
          "entity_id": "ent:e179fc25613b",
          "entity_type": "MECHANISM",
          "name": "stress response",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A critical function for cell survival where proteins like ATF4 are selectively translated under stress conditions."
        },
        {
          "entity_id": "ent:b169a24155d8",
          "entity_type": "MECHANISM",
          "name": "cell survival",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A state where proteins like ATF4, critical for stress response, are selectively translated under stress conditions."
        },
        {
          "entity_id": "ent:3de18763b180",
          "entity_type": "MECHANISM",
          "name": "phosphorylation of eIF2",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A process promoted by glutamine deprivation through amino acids deprivation triggered GCN2 activation."
        },
        {
          "entity_id": "ent:a9e24b4c312d",
          "entity_type": "MECHANISM",
          "name": "GCN2 activation",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "An activation triggered by amino acids deprivation that promotes phosphorylation of eIF2 during glutamine deprivation."
        },
        {
          "entity_id": "ent:efcda326f73e",
          "entity_type": "MECHANISM",
          "name": "glucose deprivation impairs ATP production",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A mechanism by which glucose deprivation triggers ER stress."
        },
        {
          "entity_id": "ent:2f403ca10783",
          "entity_type": "MECHANISM",
          "name": "inhibited pentose pathway causes intracellular redox imbalance",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A mechanism leading to oxidative stress during glucose deprivation, which triggers ER stress."
        },
        {
          "entity_id": "ent:a3cccb82c90a",
          "entity_type": "MECHANISM",
          "name": "low glucose also suppresses protein glycosylation",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A mechanism during glucose deprivation that results in protein unfolding/misfolding, triggering ER stress."
        },
        {
          "entity_id": "ent:a640abcb3aee",
          "entity_type": "MECHANISM",
          "name": "protein unfolding/misfolding",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A result of suppressed protein glycosylation due to low glucose, which triggers ER stress."
        },
        {
          "entity_id": "ent:c239168c0280",
          "entity_type": "MECHANISM",
          "name": "adaptation of cells to various types of stresses",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A process mediated by STC2 as a general stress-responsive factor through ATF4-dependent induction."
        },
        {
          "entity_id": "ent:3134da31e01f",
          "entity_type": "MECHANISM",
          "name": "cell cycle progression",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A process promoted by STC2 under hypoxic conditions through enhancing cyclin D expression and Rb phosphorylation."
        },
        {
          "entity_id": "ent:1a09ff5cd015",
          "entity_type": "MECHANISM",
          "name": "epithelial-mesenchymal transition (EMT)",
          "normalized_id": "N/A",
          "aliases": [
            "EMT"
          ],
          "description": "A process induced by STC2 under hypoxic conditions through upregulating mesenchymal markers and downregulating E-cadherin."
        },
        {
          "entity_id": "ent:893ef71151e8",
          "entity_type": "MECHANISM",
          "name": "cell migration and invasion",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Processes driven by STC2 under hypoxic conditions through the upregulation of matrix metalloproteinase (MMP)-2 and -9."
        },
        {
          "entity_id": "ent:c9c6ab528336",
          "entity_type": "MECHANISM",
          "name": "adaptive response",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A response mediated by genes whose expression is enhanced by HIF-1 binding to HRE under hypoxic conditions."
        },
        {
          "entity_id": "ent:55b4334733c3",
          "entity_type": "PROTEIN",
          "name": "JNK/NF-B",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A pathway via which the three ER stress-triggered responsive arms ATF4, ATF6 and IRE1 may cooperatively trigger apoptosis upon persisting and severe ER stress."
        },
        {
          "entity_id": "ent:02d0e0ce63eb",
          "entity_type": "PROTEIN",
          "name": "BiP/Grp78",
          "normalized_id": "N/A",
          "aliases": [
            "BiP",
            "Grp78"
          ],
          "description": "A molecular chaperone and UPR gene whose transcription is suppressed by aluminium glycinate."
        },
        {
          "entity_id": "ent:89a901f2c625",
          "entity_type": "PROTEIN",
          "name": "calcineurin",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A protein whose expression is compromised by STC2 in a cerulein-induced pancreatitis mouse model."
        },
        {
          "entity_id": "ent:f94930b45445",
          "entity_type": "PROTEIN",
          "name": "CBP/p300",
          "normalized_id": "N/A",
          "aliases": [
            "p300"
          ],
          "description": "A transcription complex component that HIF-1 binds to in the nucleus to induce the expression of STC2 under hypoxic conditions."
        },
        {
          "entity_id": "ent:0849c8d3d368",
          "entity_type": "PROTEIN",
          "name": "cyclin D",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A protein whose expression is enhanced by STC2 to promote cell cycle progression under hypoxic conditions."
        },
        {
          "entity_id": "ent:ebef1212a8af",
          "entity_type": "PROTEIN",
          "name": "Rb",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A protein whose phosphorylation is enhanced by STC2 to promote cell cycle progression under hypoxic conditions."
        },
        {
          "entity_id": "ent:6553ac70e722",
          "entity_type": "PROTEIN",
          "name": "matrix metalloproteinase (MMP)-2",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A protein upregulated by STC2 to drive cell migration and invasion under hypoxic conditions."
        },
        {
          "entity_id": "ent:e386330f3c5d",
          "entity_type": "PROTEIN",
          "name": "matrix metalloproteinase (MMP)-9",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A protein upregulated by STC2 to drive cell migration and invasion under hypoxic conditions."
        }
      ],
      "relations": []
    },
    "ocr_result_2_7": {
      "id": "ocr_result_2_7",
      "name": "",
      "meta": {
        "text": "cDNA microarray analysis demonstrated hypoxia induces the expression of STC2 in proximal tubular epithelial cells; the longer the cells expose to hypoxia, the higher STC2 mRNA levels are detected [115]. Bioinformatic analysis reveals STC2 promoter contains conserved putative HRE binding motifs; consistently, electrophoretic mobility shift assay demonstrates HIF-1 directly binds to those motifs (Fig. 5), and the constitutively active form of HIF-1 $\\alpha$  (AdCA5) also upregulates STC2 expression at both mRNA and protein levels. There are several CpG islands in the  $5^{\\prime}$ -flanking region of the upstream sequence relative to STC2 translation start site; the methylation of these CpG islands compromises STC2 expression in cells derived from human ovarian cancer, pancreatic cancer, colon adenoma and leukemia, but not in normal epithelial cells [116]; furthermore, 5-aza- $2^{\\prime}$ -deoxycytidine, a DNA methylation inhibitor successfully induces STC2 expression [116]. In addition, chetomin, a p300 inhibitor, also reverses hypoxia-induced STC2\n\nexpression [117], highlighting CBP/p300 are indispensable co-activators of HIF-1 for STC2 upregulation. As a direct target of HIF-1, STC2 is proposed to facilitate cell survival, proliferation and migration when exposed to low oxygen conditions [103, 116-118].\n\n# High-mobility gene group A2 (HMGA2)\n\nHigh Mobility Group A (HMGA) proteins belong to the family of non-histone chromatin factors that possess transcriptional activities [119]. HMGA family has three members: HMGA1a, HMGA1b and HMGA2, all three contain a highly conserved DNA binding domain and a negative charged c-terminal tail. HMGA2 regulates cell growth, differentiation and migration [120]. HMGA2 is expressed in embryonic tissues and certain malignant tumours like ovarian cancer but not normal adult tissues. In a study aiming to understand the role of HMGA2 in regulating tumour development and progression, cDNA microarray was applied to investigate the mRNA expression profile of ovarian surface epithelial cells with various levels of HMGA2. Among thirty-six upregulated genes, STC2 is identified [121], suggesting the regulation of STC2 by HMGA2. Another independent study further illustrated the correlation between HMGA2 and STC2 in human high-grade serous cancer samples. Bioinformatic analysis demonstrated putative HMGA2 binding sites in the  $5^{\\prime}$  transcription start site of STC2 promoter; moreover, luciferase reporter assay identified ectopic HMGA2 expression can enhance the luciferase activity mediated\n\nby STC2 promoter in a dose-dependent manner, suggesting STC2 is transcriptionally induced by HMGA2 [76]. Consistently, a positive correlation between HMGA2 and STC2 IHC staining score is also revealed in human epithelial ovarian cancer samples. These findings provide evidence that HMGA2, as an oncofetal protein, can transcriptionally upregulate STC2 during fetal development and oncogenesis, suggesting that STC2 plays important roles in those processes.\n\n### Aryl hydrocarbon receptor (AhR)\n\nAhR, a transcription factor with multiple functions, works as an environmental sensor that facilitates the integration of different signaling pathways. Under physiological conditions, AhR involves in many processes like defending chemicals and pathogens, development, immune response and reproduction, thus facilitating cell adaptation to environmental stresses. cDNA microarray found STC2 as a putative downstream target of AhR in primary human hepatocytes and HepaRG cells [122, 123]. Bioinformatic analysis demonstrated AhR can be recruited to the potential xenobiotic response elements in STC2 promoter that is evidenced by chromatin immunoprecipitation; moreover, AhR agonists effectively block STC2 expression, indicating STC2 is an AhR-dependent gene. Mechanistically, upon the treatment of cinnabarinic acid (the AhR agonist), metastasis-associated protein 2 is recruited to the STC2 promoter, leading to the acetylation of lysine residue in histone H4 and the transcription of STC2 gene [124]. Biologically, STC2 protects cells from various stress conditions like ER stress induced by H_{2}O_{2}, thapsigargin and ethanol [124, 125]. The induction of STC2 by AhR indicates a role of STC2 in cellular response to environmental hazardous agents.\n\n### Specificity protein 1 (Sp1)\n\nSp1, a transactivation molecule, belongs to Sp or Krppel-like factor protein family [126]. Sp1 functions to promote the activities of oncogenes for cell survival, tumour progression and metastasis. Structurally, Sp1 contains N-terminal inhibitory domain, Transactivating domain, A highly charged group of 69 residues, DNA binding domain and C-terminal domain for synergistic transactivation. Sp1 is upregulated in several human cancers like colorectal cancer, and the expression of Sp1 is correlated with poor prognosis [127]. Bioinformatic analyses revealed potential Sp1 binding sites in STC2 promoter. In accordance, luciferase assay demonstrated genetic manipulation of Sp1 alters STC2 promoter-mediated luciferase activity in a dose-dependent manner in colorectal cancer cells. Either ectopic expression or knockdown of Sp1 can alter STC2 protein levels [128], further denoting the direct regulation of STC2 by Sp1. Considering Sp1 as a general transcription factor commonly involved in the basal level expression of many genes, it is likely a necessary but insufficient transcription factor for stress-induced STC2 transcription.\n\n### Non-coding RNAs-mediated post-transcriptional regulation",
        "source": "ocr_result_2"
      },
      "entities": [
        {
          "entity_id": "ent:87356fb7794a",
          "entity_type": "BIOMARKER",
          "name": "STC2 mRNA",
          "normalized_id": "N/A",
          "aliases": [
            "STC2"
          ],
          "description": "N/A"
        },
        {
          "entity_id": "ent:e81b827cd396",
          "entity_type": "PROTEIN",
          "name": "HIF-1",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A transcription factor that directly binds to HRE motifs in the STC2 promoter and upregulates STC2 expression, with CBP/p300 as indispensable co-activators for this upregulation."
        },
        {
          "entity_id": "ent:6aba697933bf",
          "entity_type": "PROTEIN",
          "name": "CBP/p300",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Proteins described as indispensable co-activators of HIF-1 for the upregulation of STC2 expression."
        },
        {
          "entity_id": "ent:326b2bade65f",
          "entity_type": "PROTEIN",
          "name": "HMGA2",
          "normalized_id": "N/A",
          "aliases": [
            "High-mobility gene group A2"
          ],
          "description": "A non-histone chromatin factor and oncofetal protein that regulates cell growth, differentiation, and migration, and can transcriptionally upregulate STC2 during fetal development and oncogenesis."
        },
        {
          "entity_id": "ent:5f2fd9c8f957",
          "entity_type": "PROTEIN",
          "name": "HMGA",
          "normalized_id": "N/A",
          "aliases": [
            "High Mobility Group A"
          ],
          "description": "A family of non-histone chromatin factors that possess transcriptional activities, with three members: HMGA1a, HMGA1b, and HMGA2."
        },
        {
          "entity_id": "ent:56a37b81ee16",
          "entity_type": "PROTEIN",
          "name": "AhR",
          "normalized_id": "N/A",
          "aliases": [
            "Aryl hydrocarbon receptor"
          ],
          "description": "A transcription factor that acts as an environmental sensor, with STC2 identified as a putative downstream target in hepatocytes, and its agonists can block STC2 expression."
        },
        {
          "entity_id": "ent:75d8ba95fee7",
          "entity_type": "PROTEIN",
          "name": "Sp1",
          "normalized_id": "N/A",
          "aliases": [
            "Specificity protein 1"
          ],
          "description": "A transactivation molecule that belongs to the Sp or Krppel-like factor protein family, promotes oncogene activities, and directly regulates STC2 by altering its promoter activity and protein levels."
        },
        {
          "entity_id": "ent:619cd635d28a",
          "entity_type": "GENE",
          "name": "HIF-1 ",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "The constitutively active form (AdCA5) of this protein upregulates STC2 expression at mRNA and protein levels."
        },
        {
          "entity_id": "ent:8378f6102422",
          "entity_type": "GENE",
          "name": "HMGA1a",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A member of the HMGA protein family, which are non-histone chromatin factors with transcriptional activities."
        },
        {
          "entity_id": "ent:5a3150d8f623",
          "entity_type": "GENE",
          "name": "HMGA1b",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A member of the HMGA protein family, which are non-histone chromatin factors with transcriptional activities."
        },
        {
          "entity_id": "ent:dd3f271c81b8",
          "entity_type": "MECHANISM",
          "name": "hypoxia induces the expression of STC2",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Hypoxia induces STC2 expression in proximal tubular epithelial cells, with longer exposure leading to higher mRNA levels."
        },
        {
          "entity_id": "ent:cd8921d869f6",
          "entity_type": "MECHANISM",
          "name": "HIF-1 directly binds to HRE binding motifs",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "HIF-1 directly binds to conserved HRE binding motifs in the STC2 promoter, as shown by electrophoretic mobility shift assay."
        },
        {
          "entity_id": "ent:c0c628def921",
          "entity_type": "MECHANISM",
          "name": "methylation of CpG islands compromises STC2 expression",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Methylation of CpG islands in the STC2 promoter region compromises STC2 expression in cancer cells but not normal epithelial cells."
        },
        {
          "entity_id": "ent:c1a19150bf6f",
          "entity_type": "MECHANISM",
          "name": "5-aza-2-deoxycytidine induces STC2 expression",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "DNA methylation inhibitor 5-aza-2'-deoxycytidine induces STC2 expression by inhibiting methylation."
        },
        {
          "entity_id": "ent:65ea50798201",
          "entity_type": "MECHANISM",
          "name": "chetomin reverses hypoxia-induced STC2 expression",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Chetomin, a p300 inhibitor, reverses hypoxia-induced STC2 expression, highlighting CBP/p300 as co-activators of HIF-1."
        },
        {
          "entity_id": "ent:afae3885c76a",
          "entity_type": "MECHANISM",
          "name": "CBP/p300 are indispensable co-activators of HIF-1 for STC2 upregulation",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "CBP/p300 are described as indispensable co-activators of HIF-1 for STC2 upregulation during hypoxia."
        },
        {
          "entity_id": "ent:bd84af73c6d1",
          "entity_type": "MECHANISM",
          "name": "STC2 facilitates cell survival, proliferation and migration",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "STC2 facilitates cell survival, proliferation and migration under low oxygen conditions as a direct HIF-1 target."
        },
        {
          "entity_id": "ent:46ee67c0a731",
          "entity_type": "MECHANISM",
          "name": "HMGA2 regulates cell growth, differentiation and migration",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "HMGA2 regulates cell growth, differentiation and migration according to the text."
        },
        {
          "entity_id": "ent:4704c77687c6",
          "entity_type": "MECHANISM",
          "name": "ectopic HMGA2 expression enhances luciferase activity mediated by STC2 promoter",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Ectopic HMGA2 expression enhances STC2 promoter-mediated luciferase activity dose-dependently, suggesting transcriptional induction."
        },
        {
          "entity_id": "ent:5e117502ace8",
          "entity_type": "MECHANISM",
          "name": "HMGA2 upregulates STC2",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "HMGA2 transcriptionally upregulates STC2 during fetal development and oncogenesis as an oncofetal protein."
        },
        {
          "entity_id": "ent:21d23d1f9219",
          "entity_type": "MECHANISM",
          "name": "AhR agonists block STC2 expression",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "AhR agonists block STC2 expression, indicating STC2 is an AhR-dependent gene."
        },
        {
          "entity_id": "ent:b85f47d064fc",
          "entity_type": "MECHANISM",
          "name": "cinnabarinic acid leads to acetylation of lysine residue in histone H4 and transcription of STC2 gene",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Metastasis-associated protein 2 recruitment to STC2 promoter leads to histone H4 acetylation and STC2 transcription upon cinnabarinic acid treatment."
        },
        {
          "entity_id": "ent:929005127012",
          "entity_type": "MECHANISM",
          "name": "STC2 protects cells from various stress conditions",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "STC2 protects cells from stress conditions including ER stress induced by H2O2, thapsigargin and ethanol."
        },
        {
          "entity_id": "ent:9dfd82294327",
          "entity_type": "MECHANISM",
          "name": "Sp1 functions to promote the activities of oncogenes for cell survival, tumour progression and metastasis",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Sp1 promotes oncogene activities for cell survival, tumour progression and metastasis according to the text."
        },
        {
          "entity_id": "ent:d336e03285c8",
          "entity_type": "MECHANISM",
          "name": "genetic manipulation of Sp1 alters STC2 promoter-mediated luciferase activity",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Genetic manipulation of Sp1 alters STC2 promoter-mediated luciferase activity dose-dependently in colorectal cancer cells."
        },
        {
          "entity_id": "ent:7355c1b198f5",
          "entity_type": "MECHANISM",
          "name": "ectopic expression or knockdown of Sp1 alters STC2 protein levels",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Ectopic expression or knockdown of Sp1 alters STC2 protein levels, indicating direct regulation."
        }
      ],
      "relations": []
    },
    "ocr_result_2_8": {
      "id": "ocr_result_2_8",
      "name": "",
      "meta": {
        "text": "The non-coding RNAs (ncRNAs) define a group of RNAs that are not translated into proteins [129]. The ncRNAs can be classified into two major groups according to their sizes: those with length shorter than 200 nt including microRNA (miRNA), small interfering RNA (siRNA), small nuclear RNA (snRNA), and piwi-interacting RNA (piRNA); and those with length longer than 200 nt, such as long non-coding RNAs (lncRNAs) [130]. miRNAs are small, single-stranded, and about 22 nucleotides in length [131, 132]. The sequences encoding miRNAs are mainly located within protein-coding genes, and they share the promoters with protein-coding genes; in other conditions, miRNAs are located in the intergenic regions [131]. Mechanistically, miRNAs recognize and bind to their targets through the complementary sequence within the targeted mRNAs. In general, a specific miRNA can target more than one mRNA, and a specific mRNA can be targeted by several different miRNAs. Biologically, miRNAs mediate the post-transcriptional gene repression or mRNA degradation [132], and they can regulate cell differentiation, maturation, proliferation, survival and immune response that are related to tumorigenesis, tumour metastasis and progression [133]. Functionally, lncRNAs perform their functions through transcriptional regulation in either cis or trans manner. In addition, lncRNAs can function as molecular scaffolds that facilitate the interaction between mRNAs, miRNAs, DNAs and their relevant proteins like transcription factors, RNA-binding proteins and chromatin modifying complexes [134]. Therefore, lncRNAs are essential for various biological processes, and the dysregulation of lncRNAs presents in many pathological conditions, particularly, cancers [135]. The following are some examples of miRNAs and lncRNAs reported to regulate STC2 expression.\n\n### miR-206 regulates STC2 in gastric cancer and HNSCC\n\nThe miR-206 is located in the human chromosome 6p12.2. It is highly expressed in muscle tissues and controls the process of myogenesis. miR-206 demonstrates tumour-suppressor activities during tumour development and progression in breast cancer, lung cancer and rhabdomyosarcoma [136]. In gastric cancer, increased miR-206 levels are inversely correlated with tumour invasion, metastasis and disease stage. Bioinformatic analysis\n\nTable 2: Reported biological functions of STC2 in human cancers\n\nplus overexpression experiments revealed STC2 is a potential target of miR-206 [137]. In accordance, miR-206 expression is negatively associated with tumour stage in HNSCC. On the other hand, increased LINC00460 can effectively antagonize miR-206 function and upregulate the expression of STC2, which inhibits autophagy through downregulating Beclin-1 and suppresses apoptosis by activating Erk and Akt signaling [138]. Moreover, another long non-coding RNA, HOTAIR, also functions as a sponge to antagonize miR-206 activity, therefore, inducing STC2 expression to enhance cell proliferation, migration and invasion through activating PI3K-Akt signaling in HNSCC [139].\n\n### Other microRNAs\n\nOther microRNAs are also found to regulate STC2 expression in human cancers. miR-485-5p is significantly downregulated in human HCC samples when comparing to normal liver tissues, and its expression is correlated with tumour size and tumour number. Bioinformatic algorithm prediction suggests STC2 is a target of miR-485-5p. Genetic manipulation of miR-485-5p alters luciferase reporter activity-mediated by the 3'-untranslated region (UTR) of STC2 mRNA and STC2 protein levels in HCC cells [140]. Another study illustrated a reverse correlation between miR-184 and STC2 mRNA levels in human glioblastoma tissues. A complimentary sequence of miR-184 was identified in the 3'-UTR of STC2 mRNA. Further analyses demonstrated that miR-184 can downregulate STC2 expression through a direct interaction with the 3'-UTR of STC2 [141]. Functionally, miR-184 suppresses the proliferation, invasion and migration of glioblastoma cells in an STC2-dependent manner. A binding sequence of miR-190 was found in the 3'-UTR of STC2 mRNA and the luciferase reporter assay showed a direct regulation of STC2 by miR-190 [142]. miR-190 regulates epithelial-mesenchymal transition (EMT) and angiogenesis through altering the activity of Erk and Akt signaling in an STC2-dependent manner in breast cancer cells. Furthermore, miR-381 inhibits cell proliferation, migration and invasion in HNSCC cells. Bioinformatic analysis and dual luciferase reporter assay highlight STC2 as a direct target of miR-381 [143]. Importantly, ectopic expression of STC2 antagonizes the inhibiting activity of miR-381 in HNSCC cells through regulating the FAK-PI3K-Akt-mTOR signaling pathway.\n\n### LncRNAs",
        "source": "ocr_result_2"
      },
      "entities": [
        {
          "entity_id": "ent:6576354839ae",
          "entity_type": "PATHWAY",
          "name": "PI3K-Akt signaling",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A signaling pathway activated by HOTAIR to induce STC2 expression, enhancing cell proliferation, migration and invasion in HNSCC."
        },
        {
          "entity_id": "ent:1495ed795b05",
          "entity_type": "PATHWAY",
          "name": "FAK-PI3K-Akt-mTOR signaling pathway",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A signaling pathway regulated by STC2 to antagonize the inhibiting activity of miR-381 in HNSCC cells."
        },
        {
          "entity_id": "ent:a579e21a3c89",
          "entity_type": "GENE",
          "name": "miR-206",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A microRNA located on human chromosome 6p12.2 that demonstrates tumour-suppressor activities and regulates STC2 expression in gastric cancer and HNSCC."
        },
        {
          "entity_id": "ent:c2955c96a855",
          "entity_type": "GENE",
          "name": "STC2",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A gene identified as a potential target of miR-206 through bioinformatic analysis and overexpression experiments in gastric cancer."
        },
        {
          "entity_id": "ent:bef9a83eb617",
          "entity_type": "GENE",
          "name": "LINC00460",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A long non-coding RNA that can antagonize miR-206 function and upregulate STC2 expression, inhibiting autophagy and suppressing apoptosis."
        },
        {
          "entity_id": "ent:e4fff95dc1d0",
          "entity_type": "GENE",
          "name": "HOTAIR",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A long non-coding RNA that functions as a sponge to antagonize miR-206 activity, inducing STC2 expression to enhance cell proliferation, migration and invasion."
        },
        {
          "entity_id": "ent:026c68fb5edb",
          "entity_type": "GENE",
          "name": "miR-485-5p",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A microRNA significantly downregulated in human HCC samples, with bioinformatic prediction suggesting STC2 is its target."
        },
        {
          "entity_id": "ent:3629e9a833da",
          "entity_type": "GENE",
          "name": "miR-184",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A microRNA with levels reversely correlated with STC2 mRNA in glioblastoma tissues, shown to downregulate STC2 through direct interaction with its 3'-UTR."
        },
        {
          "entity_id": "ent:cc6bc0cc33d9",
          "entity_type": "GENE",
          "name": "miR-190",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A microRNA with a binding sequence in the 3'-UTR of STC2 mRNA, directly regulating STC2 and affecting EMT and angiogenesis in breast cancer cells."
        },
        {
          "entity_id": "ent:50c714949759",
          "entity_type": "GENE",
          "name": "miR-381",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A microRNA that inhibits cell proliferation, migration and invasion in HNSCC cells, with STC2 identified as its direct target through bioinformatic analysis and luciferase assays."
        },
        {
          "entity_id": "ent:346a67328665",
          "entity_type": "BIOMARKER",
          "name": "miRNA",
          "normalized_id": "N/A",
          "aliases": [
            "microRNA"
          ],
          "description": "Small, single-stranded non-coding RNA about 22 nucleotides in length that mediates post-transcriptional gene repression or mRNA degradation."
        },
        {
          "entity_id": "ent:e30c4d1db090",
          "entity_type": "BIOMARKER",
          "name": "lncRNAs",
          "normalized_id": "N/A",
          "aliases": [
            "long non-coding RNAs"
          ],
          "description": "Long non-coding RNAs that perform functions through transcriptional regulation and act as molecular scaffolds for interactions between mRNAs, miRNAs, DNAs, and proteins."
        },
        {
          "entity_id": "ent:e261b71bee5c",
          "entity_type": "MECHANISM",
          "name": "post-transcriptional gene repression",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A biological process mediated by miRNAs that involves repression of genes after transcription."
        },
        {
          "entity_id": "ent:ac9e8aa48f65",
          "entity_type": "MECHANISM",
          "name": "mRNA degradation",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A process mediated by miRNAs that involves breaking down messenger RNA molecules."
        },
        {
          "entity_id": "ent:c21a62efd2cf",
          "entity_type": "MECHANISM",
          "name": "transcriptional regulation",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A functional mechanism through which lncRNAs perform their functions, either in cis or trans manner."
        },
        {
          "entity_id": "ent:10f28c14a3cd",
          "entity_type": "MECHANISM",
          "name": "molecular scaffolds",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A functional role of lncRNAs that facilitates interactions between mRNAs, miRNAs, DNAs and relevant proteins."
        },
        {
          "entity_id": "ent:ee010af53a0d",
          "entity_type": "MECHANISM",
          "name": "inhibits autophagy",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A process where STC2 expression suppresses autophagy through downregulating Beclin-1."
        },
        {
          "entity_id": "ent:ba7e1093e991",
          "entity_type": "MECHANISM",
          "name": "suppresses apoptosis",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A process where STC2 expression inhibits apoptosis by activating Erk and Akt signaling."
        },
        {
          "entity_id": "ent:3db26cd512ad",
          "entity_type": "MECHANISM",
          "name": "activating Erk and Akt signaling",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A signaling mechanism activated by STC2 expression that suppresses apoptosis."
        },
        {
          "entity_id": "ent:641f36142a80",
          "entity_type": "MECHANISM",
          "name": "functions as a sponge",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A mechanism where HOTAIR antagonizes miR-206 activity by acting as a molecular sponge."
        },
        {
          "entity_id": "ent:a8ba18e76940",
          "entity_type": "MECHANISM",
          "name": "activating PI3K-Akt signaling",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A signaling pathway activated by STC2 expression to enhance cell proliferation, migration and invasion."
        },
        {
          "entity_id": "ent:112f05a20cbc",
          "entity_type": "MECHANISM",
          "name": "direct interaction",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A mechanism where miR-184 downregulates STC2 expression through binding to the 3'-UTR of STC2 mRNA."
        },
        {
          "entity_id": "ent:422b0bbd718e",
          "entity_type": "MECHANISM",
          "name": "direct regulation",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A mechanism where miR-190 directly regulates STC2, as shown by luciferase reporter assay."
        },
        {
          "entity_id": "ent:89120d4d831d",
          "entity_type": "MECHANISM",
          "name": "regulates epithelial-mesenchymal transition (EMT)",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A process where miR-190 regulates EMT through altering Erk and Akt signaling in an STC2-dependent manner."
        },
        {
          "entity_id": "ent:634e2687539f",
          "entity_type": "MECHANISM",
          "name": "regulating the FAK-PI3K-Akt-mTOR signaling pathway",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A mechanism where STC2 antagonizes miR-381's inhibiting activity in HNSCC cells through pathway regulation."
        },
        {
          "entity_id": "ent:614592231a2b",
          "entity_type": "DISEASE",
          "name": "tumorigenesis",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A biological process related to miRNAs regulating cell differentiation, maturation, proliferation, survival and immune response."
        },
        {
          "entity_id": "ent:c691685dcd1a",
          "entity_type": "DISEASE",
          "name": "tumour metastasis",
          "normalized_id": "N/A",
          "aliases": [
            "metastasis"
          ],
          "description": "A process related to tumour progression that miRNAs can regulate through cell differentiation, maturation, proliferation, survival and immune response."
        },
        {
          "entity_id": "ent:a508aa27eec5",
          "entity_type": "DISEASE",
          "name": "gastric cancer",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A cancer type where miR-206 regulates STC2 and increased miR-206 levels are inversely correlated with tumour invasion, metastasis and disease stage."
        },
        {
          "entity_id": "ent:8e9f96670457",
          "entity_type": "DISEASE",
          "name": "HNSCC",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A cancer type where miR-206 regulates STC2 and miR-206 expression is negatively associated with tumour stage."
        },
        {
          "entity_id": "ent:baa25929260a",
          "entity_type": "DISEASE",
          "name": "tumour invasion",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A condition in gastric cancer that is inversely correlated with increased miR-206 levels."
        },
        {
          "entity_id": "ent:8d406289529d",
          "entity_type": "DISEASE",
          "name": "disease stage",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A condition in gastric cancer that is inversely correlated with increased miR-206 levels."
        },
        {
          "entity_id": "ent:b35fe6cd8c86",
          "entity_type": "DISEASE",
          "name": "tumour stage",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A condition in HNSCC that is negatively associated with miR-206 expression."
        },
        {
          "entity_id": "ent:7984e8cad0f3",
          "entity_type": "DISEASE",
          "name": "autophagy",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A process inhibited by STC2 upregulation through downregulating Beclin-1."
        },
        {
          "entity_id": "ent:50d81c6ef563",
          "entity_type": "DISEASE",
          "name": "apoptosis",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A process suppressed by STC2 upregulation through activating Erk and Akt signaling."
        },
        {
          "entity_id": "ent:b528f258ee3a",
          "entity_type": "DISEASE",
          "name": "human cancers",
          "normalized_id": "N/A",
          "aliases": [
            "cancers"
          ],
          "description": "Conditions where other microRNAs are found to regulate STC2 expression."
        },
        {
          "entity_id": "ent:0bd90fb2f014",
          "entity_type": "DISEASE",
          "name": "HCC",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A condition where miR-485-5p is significantly downregulated in human samples compared to normal liver tissues."
        },
        {
          "entity_id": "ent:c164ec0dd6f9",
          "entity_type": "DISEASE",
          "name": "glioblastoma",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A condition where a reverse correlation between miR-184 and STC2 mRNA levels was illustrated in human tissues."
        },
        {
          "entity_id": "ent:f3292c0db02b",
          "entity_type": "DISEASE",
          "name": "breast cancer",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A condition where miR-190 regulates epithelial-mesenchymal transition (EMT) and angiogenesis through altering Erk and Akt signaling in an STC2-dependent manner in cells."
        }
      ],
      "relations": []
    },
    "ocr_result_2_9": {
      "id": "ocr_result_2_9",
      "name": "",
      "meta": {
        "text": "LINC00460 stands for the long intergenic nonprotein coding RNA 460 that is located in Chromosome 13q33.2 region with a length of 935 nt [144]. LINC00460 is upregulated in a variety of human cancers and demonstrates oncogenic properties. Particularly, LINC00460 is upregulated to drive the development of HNSCC, colorectal cancer, RCC, HCC, lung cancer, thyroid cancer, glioma, meningioma, etc. [145]. Clinically, the expression of LINC00460 is correlated with lymph node metastasis, EMT and patients' prognosis [146]. There is elevated expression of LINC00460 and STC2 in human HNSCC while with a clear reduction of miR-206 levels [138]. Mechanistically, LINC00460 works as a sponge to compromise miR-206 function, leading to the upregulation of STC2 at both mRNA and protein levels, and finally the activation of Akt signaling that suppresses apoptosis and autophagy [138]. Consistently, lncRNA homeobox transcript antisense RNA (HOTAIR) is overexpressed in human HNSCC samples, and it can also promote STC2 expression through functioning as a sponge of miR-206 [147]. In addition, other two lncRNAs are reported to regulate STC2 expression, for example, ROR1-AS1 functions to sponge miR-670-3p that suppresses STC2 expression in cervical cancer [148]; SNHG17 promotes\n\nThe discovery of non-coding RNA-mediated regulation of STC2 expression provides new insights into the regulation of STC2, and opens new doors for therapeutical approaches to target STC2.\n\n### The biological roles of STC2 in human cancers\n\n### STC2 promotes tumour cell survival and tumour growth\n\nTumour growth depends on the proliferation of tumour cells and the ability of tumour cells resisting cell death. In general, STC2 drives cell proliferation and maintains cell survival in a plethora of tumour cells, particularly for those under stress conditions [33, 35, 36, 47, 62, 84, 116--118]. Knockdown of STC2 leads to apoptosis upon treatment with thapsigargin but not tunicamycin or staurosporine; on another hand, overexpression of STC2 successfully inhibits apoptosis-induced by thapsigargin [103]. In transgenic mice, STC2 protects cells from necrosis and apoptosis in a pancreatitis model-induced by cerulein [105]. Under hypoxic conditions, STC2 is upregulated in SKOV3 and MCF-7 cells, leading to cyclin D induction and Rb hyper-phosphorylation, finally driving cell proliferation (Table 2) [117]. In accordance, knockdown of STC2 compromises colony formation of PC-3 cells; while overexpression of STC2 promotes 22Rv1 cell proliferation [36]. Moreover, STC2 also promotes the proliferation of tumour cells derived from ESCC [35], gastric cancer [62], colorectal cancer [33], nasopharyngeal carcinoma [79], etc.. Elevated STC2 levels are correlated with tumour size in colorectal cancer [33]; chorioallantoic membrane of chicken embryo assay revealed ectopic expression of STC2 enhances the growth of tumour xenografts, resulting in tumours with bigger size than control group [47]. However, overexpression of STC2 compromises cell proliferation as well as colony formation in breast cancer cells [84], suggesting STC2 possesses tumour suppressor-like activities in breast cancer. These findings indicate STC2 performs its roles in a context-dependent manner. Further studies are required to dissect the detailed molecular mechanisms in order to develop new therapies.\n\n### STC2 facilitates tumour metastasis\n\nTumour metastasis involves four major steps: 1) acquisition of a metastatic phenotype, tumour cells undergo EMT through downregulating epithelial markers and upregulating mesenchymal markers, leading to reduced cell--cell adhesion, apical-basolateral polarity and increased motility [153]; 2) breakdown of the extracellular matrix (ECM) by matrix metalloproteinase (MMP) -2 and -9 secreted by tumour cells [154]; 3) intravasation, tumour cells migrate through the perivascular tissue, penetrate the blood vessel walls and become circulating tumour cells (CTCs) [155]; 4) extravasation and formation of metastatic tumours, CTCs invade through the blood vessel walls and reside in distal tissues or organs and finally form a metastatic tumour [156]. STC2 enhances tumour metastasis through promoting EMT and upregulating MMP -2 and -9 [47, 118]. Under hypoxic conditions, HIF-1 promotes the expression of STC2 to upregulate mesenchymal markers like N-cadherin and vimentin while to suppress the expression of E-cadherin, an epithelial marker; moreover, ectopic expression of STC2 upregulate MMP-2 and -9 that facilitate the degradation of ECM (Table 2) [118]. Transwell assay revealed overexpression of STC2 enhances the invasion of ovarian cancer cells through matrigel or HUVEC -coated wells [118]; in accordance, overexpression of STC2 upregulates MMP-2 expression and enhances the invasive ability of neuroblastoma cells [47]. Furthermore, elevated STC2 levels are associated with invasiveness and metastasis in human tumours like ESCC [35], gastric cancer [62], colorectal cancer [33], RCC [37] and neuroblastoma [47].\n\n### STC2 regulates cellular response to nutrient-deprivation",
        "source": "ocr_result_2"
      },
      "entities": [
        {
          "entity_id": "ent:553a46a0ea5b",
          "entity_type": "PATHWAY",
          "name": "Akt signaling",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A signaling pathway described as being activated, leading to the suppression of apoptosis and autophagy."
        },
        {
          "entity_id": "ent:b6f9cdf1f5bf",
          "entity_type": "PATHWAY",
          "name": "EMT",
          "normalized_id": "N/A",
          "aliases": [
            "epithelial-mesenchymal transition"
          ],
          "description": "A process correlated with LINC00460 expression and described as involving downregulation of epithelial markers and upregulation of mesenchymal markers to increase cell motility."
        },
        {
          "entity_id": "ent:f264bd8b5379",
          "entity_type": "GENE",
          "name": "LINC00460",
          "normalized_id": "N/A",
          "aliases": [
            "long intergenic nonprotein coding RNA 460"
          ],
          "description": "A long intergenic nonprotein coding RNA located in Chromosome 13q33.2 region, upregulated in various human cancers and demonstrates oncogenic properties."
        },
        {
          "entity_id": "ent:cca9b8b2021a",
          "entity_type": "GENE",
          "name": "Chromosome 13q33.2",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A chromosomal region where LINC00460 is located."
        },
        {
          "entity_id": "ent:f42c99f95754",
          "entity_type": "GENE",
          "name": "miR-206",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A microRNA with reduced levels in human HNSCC, whose function is compromised by LINC00460 acting as a sponge."
        },
        {
          "entity_id": "ent:1ee7918f3876",
          "entity_type": "GENE",
          "name": "STC2",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A gene upregulated at both mRNA and protein levels due to LINC00460 compromising miR-206 function, leading to activation of Akt signaling."
        },
        {
          "entity_id": "ent:bcaa2300ab71",
          "entity_type": "GENE",
          "name": "HOTAIR",
          "normalized_id": "N/A",
          "aliases": [
            "homeobox transcript antisense RNA"
          ],
          "description": "A lncRNA overexpressed in human HNSCC samples that promotes STC2 expression by functioning as a sponge of miR-206."
        },
        {
          "entity_id": "ent:b97e237451e7",
          "entity_type": "GENE",
          "name": "ROR1-AS1",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A lncRNA reported to regulate STC2 expression by sponging miR-670-3p that suppresses STC2 expression in cervical cancer."
        },
        {
          "entity_id": "ent:a608ba65ef60",
          "entity_type": "GENE",
          "name": "miR-670-3p",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A microRNA that suppresses STC2 expression and is sponged by ROR1-AS1 in cervical cancer."
        },
        {
          "entity_id": "ent:8198a8416c3b",
          "entity_type": "GENE",
          "name": "SNHG17",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A lncRNA reported to regulate STC2 expression."
        },
        {
          "entity_id": "ent:2cfaa1738dba",
          "entity_type": "PROTEIN",
          "name": "Akt",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Signaling protein described as being activated by STC2 upregulation, which suppresses apoptosis and autophagy."
        },
        {
          "entity_id": "ent:6448a6375b9a",
          "entity_type": "PROTEIN",
          "name": "HIF-1",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Protein described as promoting the expression of STC2 under hypoxic conditions to upregulate mesenchymal markers and suppress epithelial markers."
        },
        {
          "entity_id": "ent:f254453ee920",
          "entity_type": "MECHANISM",
          "name": "oncogenic properties",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Properties described as being demonstrated by LINC00460 when upregulated in human cancers."
        },
        {
          "entity_id": "ent:f91aa7f1971b",
          "entity_type": "MECHANISM",
          "name": "sponge",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Mechanism described where LINC00460 works to compromise miR-206 function."
        },
        {
          "entity_id": "ent:c8a61dfc51ad",
          "entity_type": "MECHANISM",
          "name": "activation of Akt signaling",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Process described as being activated, leading to the suppression of apoptosis and autophagy."
        },
        {
          "entity_id": "ent:8707b315071b",
          "entity_type": "MECHANISM",
          "name": "suppresses apoptosis and autophagy",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Action described as a result of Akt signaling activation."
        },
        {
          "entity_id": "ent:0400a51fb086",
          "entity_type": "MECHANISM",
          "name": "functioning as a sponge",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Mechanism described for HOTAIR to promote STC2 expression by sponging miR-206."
        },
        {
          "entity_id": "ent:9b0e2a1a8cf0",
          "entity_type": "MECHANISM",
          "name": "proliferation",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Process described as being driven by STC2 in tumour cells."
        },
        {
          "entity_id": "ent:a3a7de082e4f",
          "entity_type": "MECHANISM",
          "name": "cell survival",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "State described as being maintained by STC2 in tumour cells."
        },
        {
          "entity_id": "ent:ab300c209c84",
          "entity_type": "MECHANISM",
          "name": "apoptosis",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Process described as being induced upon thapsigargin treatment after STC2 knockdown."
        },
        {
          "entity_id": "ent:ee4168c2bc8a",
          "entity_type": "MECHANISM",
          "name": "inhibits apoptosis",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Action described for STC2 overexpression in response to thapsigargin."
        },
        {
          "entity_id": "ent:fd463577d3f0",
          "entity_type": "MECHANISM",
          "name": "protects cells from necrosis and apoptosis",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Action described for STC2 in a cerulein-induced pancreatitis model in transgenic mice."
        },
        {
          "entity_id": "ent:bf54e985ff07",
          "entity_type": "MECHANISM",
          "name": "driving cell proliferation",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Result described from STC2 upregulation under hypoxia, leading to cyclin D induction and Rb hyper-phosphorylation."
        },
        {
          "entity_id": "ent:db6f0de18502",
          "entity_type": "MECHANISM",
          "name": "promotes tumour metastasis",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Action described for STC2 through promoting EMT and upregulating MMP-2 and -9."
        },
        {
          "entity_id": "ent:379a67b49304",
          "entity_type": "MECHANISM",
          "name": "promoting EMT",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Mechanism described for how STC2 enhances tumour metastasis."
        },
        {
          "entity_id": "ent:7d4bc2e122c9",
          "entity_type": "MECHANISM",
          "name": "upregulating MMP -2 and -9",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Mechanism described for how STC2 enhances tumour metastasis."
        },
        {
          "entity_id": "ent:41f45c615433",
          "entity_type": "MECHANISM",
          "name": "facilitate the degradation of ECM",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Action described for MMP-2 and -9 when upregulated by ectopic STC2 expression."
        },
        {
          "entity_id": "ent:afb6ea5f0d6a",
          "entity_type": "MECHANISM",
          "name": "enhances the invasive ability",
          "normalized_id": "N/A",
          "aliases": [
            "enhances the invasion"
          ],
          "description": "Action described for STC2 overexpression in neuroblastoma cells, associated with upregulating MMP-2 expression."
        },
        {
          "entity_id": "ent:63f60a66e261",
          "entity_type": "DISEASE",
          "name": "HNSCC",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Described as a cancer where LINC00460 is upregulated to drive development, with elevated expression of LINC00460 and STC2 in human HNSCC."
        },
        {
          "entity_id": "ent:11fd28c4b14d",
          "entity_type": "DISEASE",
          "name": "colorectal cancer",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Described as a cancer where LINC00460 is upregulated to drive development, and where STC2 promotes proliferation of tumour cells."
        },
        {
          "entity_id": "ent:ac97c8049f74",
          "entity_type": "DISEASE",
          "name": "RCC",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Described as a cancer where LINC00460 is upregulated to drive development, and where elevated STC2 levels are associated with invasiveness and metastasis."
        },
        {
          "entity_id": "ent:06fc06f9657c",
          "entity_type": "DISEASE",
          "name": "HCC",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Described as a cancer where LINC00460 is upregulated to drive development."
        },
        {
          "entity_id": "ent:134044553e42",
          "entity_type": "DISEASE",
          "name": "lung cancer",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Described as a cancer where LINC00460 is upregulated to drive development."
        },
        {
          "entity_id": "ent:362eb23e7fe9",
          "entity_type": "DISEASE",
          "name": "thyroid cancer",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Described as a cancer where LINC00460 is upregulated to drive development."
        },
        {
          "entity_id": "ent:0434618cef54",
          "entity_type": "DISEASE",
          "name": "glioma",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Described as a cancer where LINC00460 is upregulated to drive development."
        },
        {
          "entity_id": "ent:e5c5112975f8",
          "entity_type": "DISEASE",
          "name": "meningioma",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Described as a cancer where LINC00460 is upregulated to drive development."
        },
        {
          "entity_id": "ent:dc2fc59594f7",
          "entity_type": "DISEASE",
          "name": "cervical cancer",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Described as a cancer where ROR1-AS1 functions to sponge miR-670-3p that suppresses STC2 expression."
        },
        {
          "entity_id": "ent:055265745c0a",
          "entity_type": "DISEASE",
          "name": "human cancers",
          "normalized_id": "N/A",
          "aliases": [
            "cancers"
          ],
          "description": "Described in the context of the biological roles of STC2 in human cancers, including promoting tumour cell survival and growth."
        },
        {
          "entity_id": "ent:ff9d185a797a",
          "entity_type": "DISEASE",
          "name": "necrosis",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Described as being protected against by STC2 in a pancreatitis model-induced by cerulein in transgenic mice."
        },
        {
          "entity_id": "ent:3f25479b98e7",
          "entity_type": "DISEASE",
          "name": "pancreatitis",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Described as a model induced by cerulein in transgenic mice where STC2 protects cells from necrosis and apoptosis."
        },
        {
          "entity_id": "ent:228d6df67288",
          "entity_type": "DISEASE",
          "name": "ESCC",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Described as a cancer where STC2 promotes the proliferation of tumour cells derived from ESCC, and where elevated STC2 levels are associated with invasiveness and metastasis."
        },
        {
          "entity_id": "ent:063eb6e600c1",
          "entity_type": "DISEASE",
          "name": "gastric cancer",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Described as a cancer where STC2 promotes the proliferation of tumour cells, and where elevated STC2 levels are associated with invasiveness and metastasis."
        },
        {
          "entity_id": "ent:13649c067d84",
          "entity_type": "DISEASE",
          "name": "nasopharyngeal carcinoma",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Described as a cancer where STC2 promotes the proliferation of tumour cells."
        },
        {
          "entity_id": "ent:3b87cabe820b",
          "entity_type": "DISEASE",
          "name": "breast cancer",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Described as a cancer where overexpression of STC2 compromises cell proliferation and colony formation, suggesting tumour suppressor-like activities."
        },
        {
          "entity_id": "ent:1055dc76d2d5",
          "entity_type": "DISEASE",
          "name": "tumour metastasis",
          "normalized_id": "N/A",
          "aliases": [
            "metastasis"
          ],
          "description": "Described as involving four major steps including EMT, ECM breakdown, intravasation, and extravasation, and enhanced by STC2 through promoting EMT and upregulating MMP-2 and -9."
        },
        {
          "entity_id": "ent:a16a23d076e3",
          "entity_type": "DISEASE",
          "name": "neuroblastoma",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Described as a cancer where overexpression of STC2 upregulates MMP-2 expression and enhances invasive ability, and where elevated STC2 levels are associated with invasiveness and metastasis."
        },
        {
          "entity_id": "ent:6d58dae4ad06",
          "entity_type": "OTHER",
          "name": "lymph node metastasis",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A clinical factor correlated with the expression of LINC00460."
        },
        {
          "entity_id": "ent:f9655ef5aecc",
          "entity_type": "OTHER",
          "name": "patients' prognosis",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A clinical factor correlated with the expression of LINC00460."
        },
        {
          "entity_id": "ent:a0c1bb0a83f4",
          "entity_type": "OTHER",
          "name": "therapeutical approaches",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "New doors opened for targeting STC2, as per the discovery of non-coding RNA-mediated regulation."
        },
        {
          "entity_id": "ent:5770daf7341d",
          "entity_type": "OTHER",
          "name": "biological roles",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Described roles of STC2 in human cancers, as indicated by the section heading."
        },
        {
          "entity_id": "ent:e9f1839a0b64",
          "entity_type": "OTHER",
          "name": "tumour cell survival",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A role of STC2, as indicated by the section heading 'STC2 promotes tumour cell survival and tumour growth'."
        },
        {
          "entity_id": "ent:f4f78b43fab6",
          "entity_type": "OTHER",
          "name": "tumour growth",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A role promoted by STC2, as indicated by the section heading."
        },
        {
          "entity_id": "ent:63dd648c5c75",
          "entity_type": "OTHER",
          "name": "stress conditions",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Conditions under which STC2 drives cell proliferation and maintains cell survival in tumour cells."
        },
        {
          "entity_id": "ent:67759e26b2ed",
          "entity_type": "OTHER",
          "name": "hypoxic conditions",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Conditions under which STC2 is upregulated in SKOV3 and MCF-7 cells, leading to cyclin D induction and Rb hyper-phosphorylation."
        },
        {
          "entity_id": "ent:77c2fc4869e5",
          "entity_type": "OTHER",
          "name": "colony formation",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A cellular process compromised by knockdown of STC2 in PC-3 cells and also compromised by overexpression of STC2 in breast cancer cells."
        },
        {
          "entity_id": "ent:af3ac5b97578",
          "entity_type": "OTHER",
          "name": "tumour size",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Correlated with elevated STC2 levels in colorectal cancer."
        },
        {
          "entity_id": "ent:702bc87c3dde",
          "entity_type": "OTHER",
          "name": "chorioallantoic membrane of chicken embryo assay",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "An assay that revealed ectopic expression of STC2 enhances the growth of tumour xenografts."
        },
        {
          "entity_id": "ent:383c17395841",
          "entity_type": "OTHER",
          "name": "tumour xenografts",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "The growth of which is enhanced by ectopic expression of STC2, as revealed by an assay."
        },
        {
          "entity_id": "ent:b6214242ad99",
          "entity_type": "OTHER",
          "name": "tumour suppressor-like activities",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Activities possessed by STC2 in breast cancer, where its overexpression compromises cell proliferation and colony formation."
        },
        {
          "entity_id": "ent:50b8013de974",
          "entity_type": "OTHER",
          "name": "context-dependent manner",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "The manner in which STC2 performs its roles, as indicated by findings showing both promoting and compromising effects on proliferation."
        },
        {
          "entity_id": "ent:700e2d3977a4",
          "entity_type": "OTHER",
          "name": "metastatic phenotype",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Acquired by tumour cells as the first major step in tumour metastasis."
        },
        {
          "entity_id": "ent:1c84e4efcdce",
          "entity_type": "OTHER",
          "name": "cell--cell adhesion",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Reduced in tumour cells undergoing EMT as part of acquiring a metastatic phenotype."
        },
        {
          "entity_id": "ent:687d2a7371d0",
          "entity_type": "OTHER",
          "name": "apical-basolateral polarity",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Reduced in tumour cells undergoing EMT as part of acquiring a metastatic phenotype."
        },
        {
          "entity_id": "ent:2d2ff2feb1c5",
          "entity_type": "OTHER",
          "name": "increased motility",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Occurs in tumour cells undergoing EMT as part of acquiring a metastatic phenotype."
        },
        {
          "entity_id": "ent:de5c08341792",
          "entity_type": "OTHER",
          "name": "intravasation",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "The third major step in tumour metastasis, where tumour cells migrate, penetrate blood vessel walls, and become circulating tumour cells."
        },
        {
          "entity_id": "ent:bf85faa9d7a1",
          "entity_type": "OTHER",
          "name": "extravasation",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Part of the fourth major step in tumour metastasis, where circulating tumour cells invade through blood vessel walls."
        },
        {
          "entity_id": "ent:4fc4fa9a79f5",
          "entity_type": "OTHER",
          "name": "metastatic tumours",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Formed in the fourth major step of tumour metastasis after extravasation and residing in distal tissues or organs."
        },
        {
          "entity_id": "ent:f98257d6236c",
          "entity_type": "OTHER",
          "name": "Transwell assay",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "An assay that revealed overexpression of STC2 enhances the invasion of ovarian cancer cells through matrigel or HUVEC-coated wells."
        },
        {
          "entity_id": "ent:d7bf63da8bc8",
          "entity_type": "OTHER",
          "name": "invasive ability",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Enhanced by overexpression of STC2 in neuroblastoma cells, which also upregulates MMP-2 expression."
        },
        {
          "entity_id": "ent:f5e8eb88424e",
          "entity_type": "OTHER",
          "name": "invasiveness",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Associated with elevated STC2 levels in human tumours like ESCC, gastric cancer, colorectal cancer, RCC, and neuroblastoma."
        },
        {
          "entity_id": "ent:d21e627e46b0",
          "entity_type": "OTHER",
          "name": "cellular response to nutrient-deprivation",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A process regulated by STC2, as indicated by the section heading."
        }
      ],
      "relations": []
    },
    "ocr_result_2_10": {
      "id": "ocr_result_2_10",
      "name": "",
      "meta": {
        "text": "Metabolic reprogramming is regarded as an emerging hallmark of human cancers [157]. Generally, there are two major characteristics of cancer metabolism: Warburg effect and active glutaminolysis [110, 111, 158], which define the unique metabolism of glucose and glutamine, respectively. Warburg effect emphasizes tumour cells can utilize glucose through glycolysis even in the presence of oxygen, and glutaminolysis indicates the conversion of glutamine to glutamate that is catalyzed by glutaminase [159]. Glucose and glutamine can not only provide energy for tumour cells, but also can be employed to produce building blocks for proliferating cells and factors to resist damages under stress conditions; therefore, it is important and useful to dissect the molecular scenario how tumour cells response to nutrient-deprived stresses and maintain cellular homeostasis in order to search for potential therapeutic candidates [78]. According to this hypothesis, we performed cDNA microarray analysis to investigate the gene expression of Hep3B cells upon glucose- or glutamine- deprivation relative to that of Hep3B cells in complete medium [120]. Importantly, STC2 is identified as one of the most upregulated genes upon either glucose- or glutamine- deprivation. In another study of our laboratory, we found glucose-deprivation can induce STC2 at protein levels in CNE2 nasopharyngeal carcinoma cells [79]. Additionally, other independent studies also found the induction of STC2 upon cysteine-deprivation or selenomethionine treatment that deprives intracellular sulfhydryl groups hence triggering oxidative\n\nTable 3: STC2 mediates tumour cells' resistance to therapies\n\nstress [85, 96]. Taken together, these studies reveal that STC2 is a common responding factor that is induced by nutrient deprivation (Table 2).\n\nRecently, a study with bioinformatic analysis found STC2 can be grouped with glycolytic genes to assess the prognosis of patients with osteosarcoma [41]. Mechanistically, STC2 promotes glucose utilization though inducing the expression of glycolytic genes including Glucose Transporter 1 and Lactate Dehydrogenase A [41]. Currently, our laboratory is working on the detailed molecular mechanisms of how STC2 is induced upon glutamine-deprivation and its biological functions in metabolic reprogramming during tumorigenesis and tumour progression.\n\n### STC2 promotes tumour immune avoidance\n\nMany studies demonstrate it is promising to evaluate the therapeutic efficacy of adjuvant chemotherapy through detecting the presence of pre-existing or treatment-induced antitumor immune response, as the immune response will facilitate the development of therapeutic vaccines by directly converting tumour tissues to antigens if the chemotherapies induce immunogenic cell death. Mechanistically, immunogenic cell death is characterized by ER stress and autophagy that regulates the expression of metagenes (the immune-relevant transcripts or gene sets). STC2, overexpressed in T cells with a Th2 response, is identified as a metagene that demonstrates negative correlation with immune-associated metagenes in breast cancer [52]. Moreover, STC2 can modulate the immunomodulatory properties of mesenchymal stem cells, which compromise the activity of IFN--producing CD8^{+} Tc1 cells through interacting and altering the activity of heme oxygenase 1 (Table 2) [152]. The plasma-protein histidine-rich glycoprotein (HRG), a cation- and heparin- binding plasma glycoprotein, controls the phenotypic switching of macrophages through enhancing cytokine production and phagocytotic activity in tumours, resulting in the vessel normalization and antitumor immune responses. Unbiased analysis identified as a binding partner of HRG, STC2 can modulate the immune response of inflammatory cells [160]; however, the in vivo biological importance of STC2-HRG complex remains to be further dissected.\n\n### Roles of STC2 in mediating tumour resistance to therapies\n\n### STC2-mediated resistance to chemotherapy\n\nSTC2 is upregulated upon exposure to several chemotherapeutic treatments, such as, anti-vascular endothelial growth factor (VEGF) antibody, cisplatin, oxaliplatin and tyrosine kinase inhibitors (TKIs), highlighting its potential in mediating the development of acquired resistance to chemotherapies (Table 3).\n\nThe application of bevacizumab, the anti-VEGF antibody, successfully inhibits the growth of human colon cancer xenografts through blocking cell cycle progression at early stage and inducing apoptosis at late stage. cDNA microarray revealed bevacizumab induces STC2 expression through activating HIF-1 signaling in orthotopic human colon cancer xenografts [161]. Since STC2 drives cell proliferation and migration under hypoxic conditions; it is not surprised that STC2 is overexpressed in liver metastatic tumours of human colorectal carcinoma treated with bevacizumab relative to those without treatment, indicating STC2 may contribute to the development of acquired resistance to anti-VEGF treatment.\n\nCisplatin-resistant cervical cancer cells demonstrate increased STC2 mRNA and protein levels, while knockdown of STC2 effectively compromise cell proliferation and induce apoptosis in resistant cells [150], indicating",
        "source": "ocr_result_2"
      },
      "entities": [
        {
          "entity_id": "ent:7189291d600f",
          "entity_type": "PATHWAY",
          "name": "glycolysis",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A process where tumour cells utilize glucose, even in the presence of oxygen, as part of the Warburg effect in cancer metabolism."
        },
        {
          "entity_id": "ent:8a3ccc0db6b5",
          "entity_type": "PATHWAY",
          "name": "Warburg effect",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A characteristic of cancer metabolism where tumour cells utilize glucose through glycolysis even in the presence of oxygen."
        },
        {
          "entity_id": "ent:c81d07d3c6f9",
          "entity_type": "PATHWAY",
          "name": "glutaminolysis",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A characteristic of cancer metabolism involving the conversion of glutamine to glutamate, catalyzed by glutaminase."
        },
        {
          "entity_id": "ent:cf70b34d31de",
          "entity_type": "PATHWAY",
          "name": "glycolytic genes",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Genes associated with glycolysis, used with STC2 to assess prognosis in osteosarcoma patients and whose expression is induced by STC2."
        },
        {
          "entity_id": "ent:748657749307",
          "entity_type": "PATHWAY",
          "name": "HIF-1 signaling",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A signaling pathway activated by bevacizumab that induces STC2 expression in orthotopic human colon cancer xenografts."
        },
        {
          "entity_id": "ent:97f4f08c27a4",
          "entity_type": "PATHWAY",
          "name": "cell cycle progression",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A process blocked at an early stage by bevacizumab application to inhibit the growth of human colon cancer xenografts."
        },
        {
          "entity_id": "ent:3b2bf3d570cb",
          "entity_type": "GENE",
          "name": "STC2",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Identified as one of the most upregulated genes upon either glucose- or glutamine-deprivation in Hep3B cells, and found induced at protein levels in CNE2 cells upon glucose-deprivation."
        },
        {
          "entity_id": "ent:3cccafad3795",
          "entity_type": "GENE",
          "name": "Glucose Transporter 1",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A glycolytic gene whose expression is induced by STC2 to promote glucose utilization in tumour cells."
        },
        {
          "entity_id": "ent:4692f2dd7750",
          "entity_type": "GENE",
          "name": "Lactate Dehydrogenase A",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A glycolytic gene whose expression is induced by STC2 to promote glucose utilization in tumour cells."
        },
        {
          "entity_id": "ent:f92354d06968",
          "entity_type": "GENE",
          "name": "VEGF",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Vascular endothelial growth factor, targeted by the anti-VEGF antibody bevacizumab in chemotherapeutic treatments."
        },
        {
          "entity_id": "ent:a5433cd90f3a",
          "entity_type": "GENE",
          "name": "HIF-1",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A signaling pathway activated by bevacizumab to induce STC2 expression in orthotopic human colon cancer xenografts."
        },
        {
          "entity_id": "ent:ec15789de96d",
          "entity_type": "TREATMENT",
          "name": "adjuvant chemotherapy",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A therapy mentioned as having its therapeutic efficacy evaluated by detecting antitumor immune response."
        },
        {
          "entity_id": "ent:a77afffab48b",
          "entity_type": "TREATMENT",
          "name": "chemotherapies",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Treatments mentioned in the context of inducing immunogenic cell death to facilitate therapeutic vaccine development."
        },
        {
          "entity_id": "ent:8c1ae83ad43d",
          "entity_type": "TREATMENT",
          "name": "anti-vascular endothelial growth factor (VEGF) antibody",
          "normalized_id": "N/A",
          "aliases": [
            "anti-VEGF antibody"
          ],
          "description": "A chemotherapeutic treatment exposure that upregulates STC2, as mentioned in the text."
        },
        {
          "entity_id": "ent:e25b62237427",
          "entity_type": "TREATMENT",
          "name": "cisplatin",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A chemotherapeutic treatment exposure that upregulates STC2, as mentioned in the text."
        },
        {
          "entity_id": "ent:e3dbd614fc44",
          "entity_type": "TREATMENT",
          "name": "oxaliplatin",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A chemotherapeutic treatment exposure that upregulates STC2, as mentioned in the text."
        },
        {
          "entity_id": "ent:986a5944fd54",
          "entity_type": "TREATMENT",
          "name": "tyrosine kinase inhibitors (TKIs)",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A chemotherapeutic treatment exposure that upregulates STC2, as mentioned in the text."
        },
        {
          "entity_id": "ent:ab62f6c518c4",
          "entity_type": "TREATMENT",
          "name": "bevacizumab",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Described as an anti-VEGF antibody application that inhibits tumor growth and induces STC2 expression."
        },
        {
          "entity_id": "ent:6550e8f91ecc",
          "entity_type": "TREATMENT",
          "name": "anti-VEGF treatment",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A treatment to which STC2 may contribute to the development of acquired resistance."
        },
        {
          "entity_id": "ent:b3d8ff3bd9d1",
          "entity_type": "BIOMARKER",
          "name": "metagenes",
          "normalized_id": "N/A",
          "aliases": [
            "immune-relevant transcripts or gene sets"
          ],
          "description": "Immune-relevant transcripts or gene sets that characterize immunogenic cell death, with STC2 identified as one demonstrating negative correlation with immune-associated metagenes in breast cancer."
        },
        {
          "entity_id": "ent:1bf694bc14dc",
          "entity_type": "BIOMARKER",
          "name": "heme oxygenase 1",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "An enzyme whose activity is altered by STC2 interaction, compromising the activity of IFN--producing CD8+ Tc1 cells."
        },
        {
          "entity_id": "ent:39b092bcf52a",
          "entity_type": "BIOMARKER",
          "name": "histidine-rich glycoprotein",
          "normalized_id": "N/A",
          "aliases": [
            "HRG"
          ],
          "description": "A plasma glycoprotein that controls macrophage phenotypic switching, with STC2 identified as its binding partner to modulate immune response."
        },
        {
          "entity_id": "ent:7f1142971514",
          "entity_type": "BIOMARKER",
          "name": "STC2-HRG complex",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A complex formed between STC2 and HRG that modulates the immune response of inflammatory cells, though its in vivo importance requires further study."
        },
        {
          "entity_id": "ent:10d1138388e9",
          "entity_type": "MECHANISM",
          "name": "Metabolic reprogramming",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Described as an emerging hallmark of human cancers, involving unique metabolism of glucose and glutamine."
        },
        {
          "entity_id": "ent:2bec8a3a9cd4",
          "entity_type": "MECHANISM",
          "name": "oxidative stress",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Triggered by treatments that deprive intracellular sulfhydryl groups, such as selenomethionine treatment."
        },
        {
          "entity_id": "ent:ef9d2e340da4",
          "entity_type": "MECHANISM",
          "name": "immunogenic cell death",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Characterized by ER stress and autophagy that regulates the expression of immune-relevant metagenes, induced by chemotherapies."
        },
        {
          "entity_id": "ent:1025eae4a613",
          "entity_type": "MECHANISM",
          "name": "ER stress",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A characteristic of immunogenic cell death, which regulates the expression of immune-relevant metagenes."
        },
        {
          "entity_id": "ent:3a1982d09342",
          "entity_type": "MECHANISM",
          "name": "autophagy",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A characteristic of immunogenic cell death, which regulates the expression of immune-relevant metagenes."
        },
        {
          "entity_id": "ent:9eb786a8c031",
          "entity_type": "MECHANISM",
          "name": "apoptosis",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Induced at late stage by bevacizumab treatment, which inhibits growth of human colon cancer xenografts."
        },
        {
          "entity_id": "ent:7d6cf90de152",
          "entity_type": "PROTEIN",
          "name": "glutaminase",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Enzyme described as catalyzing the conversion of glutamine to glutamate in the process of glutaminolysis."
        },
        {
          "entity_id": "ent:fb8a0bd08861",
          "entity_type": "DISEASE",
          "name": "human cancers",
          "normalized_id": "N/A",
          "aliases": [
            "cancer",
            "carcinoma",
            "tumour",
            "tumours"
          ],
          "description": "Described as having metabolic reprogramming as an emerging hallmark, with characteristics including Warburg effect and active glutaminolysis."
        },
        {
          "entity_id": "ent:465452c4c131",
          "entity_type": "DISEASE",
          "name": "nasopharyngeal carcinoma",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Described in CNE2 cells where glucose-deprivation can induce STC2 at protein levels."
        },
        {
          "entity_id": "ent:ad99f40ea09e",
          "entity_type": "DISEASE",
          "name": "osteosarcoma",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Described in patients where STC2 can be grouped with glycolytic genes to assess prognosis."
        },
        {
          "entity_id": "ent:09127ef0d11e",
          "entity_type": "DISEASE",
          "name": "tumorigenesis",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Described as a process during which STC2 has biological functions in metabolic reprogramming."
        },
        {
          "entity_id": "ent:1d966607df58",
          "entity_type": "DISEASE",
          "name": "tumour progression",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Described as a process during which STC2 has biological functions in metabolic reprogramming."
        },
        {
          "entity_id": "ent:3f2e536c3e91",
          "entity_type": "DISEASE",
          "name": "breast cancer",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Described as having STC2 identified as a metagene that demonstrates negative correlation with immune-associated metagenes."
        },
        {
          "entity_id": "ent:98e616746627",
          "entity_type": "DISEASE",
          "name": "colon cancer",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Described in human xenografts where bevacizumab application successfully inhibits growth through blocking cell cycle and inducing apoptosis."
        },
        {
          "entity_id": "ent:88f91827c69b",
          "entity_type": "DISEASE",
          "name": "colorectal carcinoma",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Described in human liver metastatic tumours where STC2 is overexpressed in those treated with bevacizumab."
        },
        {
          "entity_id": "ent:b68c4a9dcc81",
          "entity_type": "DISEASE",
          "name": "cervical cancer",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Described in cisplatin-resistant cells that demonstrate increased STC2 mRNA and protein levels."
        }
      ],
      "relations": [
        {
          "head": "STC2",
          "relation": "induce",
          "tail": "expression of glycolytic genes",
          "relation_type": "UNKNOWN",
          "confidence": [
            0.75,
            0.05
          ],
          "evidence": [
            "Mechanistically, STC2 promotes glucose utilization though inducing the expression of glycolytic genes including Glucose Transporter 1 and Lactate Dehydrogenase A [41]."
          ],
          "mechanism": "unknown",
          "source": "ocr_result_2_10",
          "subject": {
            "entity_id": "ent:7f1142971514",
            "entity_type": "BIOMARKER",
            "name": "STC2-HRG complex",
            "normalized_id": "N/A",
            "aliases": [],
            "description": "A complex formed between STC2 and HRG that modulates the immune response of inflammatory cells, though its in vivo importance requires further study."
          },
          "object": {
            "entity_id": "ent:cf70b34d31de",
            "entity_type": "PATHWAY",
            "name": "glycolytic genes",
            "normalized_id": "N/A",
            "aliases": [],
            "description": "Genes associated with glycolysis, used with STC2 to assess prognosis in osteosarcoma patients and whose expression is induced by STC2."
          },
          "time_info": null
        },
        {
          "head": "bevacizumab",
          "relation": "induce",
          "tail": "STC2 expression",
          "relation_type": "UNKNOWN",
          "confidence": [
            0.82,
            0.05
          ],
          "evidence": [
            "cDNA microarray revealed bevacizumab induces STC2 expression through activating HIF-1 signaling in orthotopic human colon cancer xenografts [161].",
            "STC2 is upregulated upon exposure to several chemotherapeutic treatments, such as, anti-vascular endothelial growth factor (VEGF) antibody, cisplatin, oxaliplatin and tyrosine kinase inhibitors (TKIs), highlighting its potential in mediating the development of acquired resistance to chemotherapies (Table 3)."
          ],
          "mechanism": "unknown",
          "source": "ocr_result_2_10",
          "subject": {
            "entity_id": "ent:ab62f6c518c4",
            "entity_type": "TREATMENT",
            "name": "bevacizumab",
            "normalized_id": "N/A",
            "aliases": [],
            "description": "Described as an anti-VEGF antibody application that inhibits tumor growth and induces STC2 expression."
          },
          "object": {
            "entity_id": "ent:3b2bf3d570cb",
            "entity_type": "GENE",
            "name": "STC2",
            "normalized_id": "N/A",
            "aliases": [],
            "description": "Identified as one of the most upregulated genes upon either glucose- or glutamine-deprivation in Hep3B cells, and found induced at protein levels in CNE2 cells upon glucose-deprivation."
          },
          "time_info": null
        },
        {
          "head": "bevacizumab",
          "relation": "activate",
          "tail": "HIF-1 signaling",
          "relation_type": "UNKNOWN",
          "confidence": [
            0.78,
            0.05
          ],
          "evidence": [
            "cDNA microarray revealed bevacizumab induces STC2 expression through activating HIF-1 signaling in orthotopic human colon cancer xenografts [161]."
          ],
          "mechanism": "unknown",
          "source": "ocr_result_2_10",
          "subject": {
            "entity_id": "ent:ab62f6c518c4",
            "entity_type": "TREATMENT",
            "name": "bevacizumab",
            "normalized_id": "N/A",
            "aliases": [],
            "description": "Described as an anti-VEGF antibody application that inhibits tumor growth and induces STC2 expression."
          },
          "object": {
            "entity_id": "ent:a5433cd90f3a",
            "entity_type": "GENE",
            "name": "HIF-1",
            "normalized_id": "N/A",
            "aliases": [],
            "description": "A signaling pathway activated by bevacizumab to induce STC2 expression in orthotopic human colon cancer xenografts."
          },
          "time_info": null
        },
        {
          "head": "STC2",
          "relation": "drive",
          "tail": "cell proliferation",
          "relation_type": "UNKNOWN",
          "confidence": [
            0.7,
            0.1
          ],
          "evidence": [
            "Since STC2 drives cell proliferation and migration under hypoxic conditions; it is not surprised that STC2 is overexpressed in liver metastatic tumours of human colorectal carcinoma treated with bevacizumab relative to those without treatment, indicating STC2 may contribute to the development of acquired resistance to anti-VEGF treatment."
          ],
          "mechanism": "unknown",
          "source": "ocr_result_2_10",
          "subject": {
            "entity_id": "ent:3b2bf3d570cb",
            "entity_type": "GENE",
            "name": "STC2",
            "normalized_id": "N/A",
            "aliases": [],
            "description": "Identified as one of the most upregulated genes upon either glucose- or glutamine-deprivation in Hep3B cells, and found induced at protein levels in CNE2 cells upon glucose-deprivation."
          },
          "object": {
            "entity_id": "ent:97f4f08c27a4",
            "entity_type": "PATHWAY",
            "name": "cell cycle progression",
            "normalized_id": "N/A",
            "aliases": [],
            "description": "A process blocked at an early stage by bevacizumab application to inhibit the growth of human colon cancer xenografts."
          },
          "time_info": null
        },
        {
          "head": "knockdown of STC2",
          "relation": "compromise",
          "tail": "cell proliferation",
          "relation_type": "UNKNOWN",
          "confidence": [
            0.85,
            0.05
          ],
          "evidence": [
            "Cisplatin-resistant cervical cancer cells demonstrate increased STC2 mRNA and protein levels, while knockdown of STC2 effectively compromise cell proliferation and induce apoptosis in resistant cells [150], indicating"
          ],
          "mechanism": "unknown",
          "source": "ocr_result_2_10",
          "subject": {
            "entity_id": "ent:3b2bf3d570cb",
            "entity_type": "GENE",
            "name": "STC2",
            "normalized_id": "N/A",
            "aliases": [],
            "description": "Identified as one of the most upregulated genes upon either glucose- or glutamine-deprivation in Hep3B cells, and found induced at protein levels in CNE2 cells upon glucose-deprivation."
          },
          "object": {
            "entity_id": "ent:97f4f08c27a4",
            "entity_type": "PATHWAY",
            "name": "cell cycle progression",
            "normalized_id": "N/A",
            "aliases": [],
            "description": "A process blocked at an early stage by bevacizumab application to inhibit the growth of human colon cancer xenografts."
          },
          "time_info": null
        },
        {
          "head": "knockdown of STC2",
          "relation": "induce",
          "tail": "apoptosis",
          "relation_type": "UNKNOWN",
          "confidence": [
            0.85,
            0.05
          ],
          "evidence": [
            "Cisplatin-resistant cervical cancer cells demonstrate increased STC2 mRNA and protein levels, while knockdown of STC2 effectively compromise cell proliferation and induce apoptosis in resistant cells [150], indicating"
          ],
          "mechanism": "unknown",
          "source": "ocr_result_2_10",
          "subject": {
            "entity_id": "ent:3b2bf3d570cb",
            "entity_type": "GENE",
            "name": "STC2",
            "normalized_id": "N/A",
            "aliases": [],
            "description": "Identified as one of the most upregulated genes upon either glucose- or glutamine-deprivation in Hep3B cells, and found induced at protein levels in CNE2 cells upon glucose-deprivation."
          },
          "object": {
            "entity_id": "ent:9eb786a8c031",
            "entity_type": "MECHANISM",
            "name": "apoptosis",
            "normalized_id": "N/A",
            "aliases": [],
            "description": "Induced at late stage by bevacizumab treatment, which inhibits growth of human colon cancer xenografts."
          },
          "time_info": null
        },
        {
          "head": "STC2",
          "relation": "interact",
          "tail": "heme oxygenase 1",
          "relation_type": "UNKNOWN",
          "confidence": [
            0.65,
            0.6
          ],
          "evidence": [
            "Moreover, STC2 can modulate the immunomodulatory properties of mesenchymal stem cells, which compromise the activity of IFN--producing CD8^{+} Tc1 cells through interacting and altering the activity of heme oxygenase 1 (Table 2) [152]."
          ],
          "mechanism": "unknown",
          "source": "ocr_result_2_10",
          "subject": {
            "entity_id": "ent:7f1142971514",
            "entity_type": "BIOMARKER",
            "name": "STC2-HRG complex",
            "normalized_id": "N/A",
            "aliases": [],
            "description": "A complex formed between STC2 and HRG that modulates the immune response of inflammatory cells, though its in vivo importance requires further study."
          },
          "object": {
            "entity_id": "ent:1bf694bc14dc",
            "entity_type": "BIOMARKER",
            "name": "heme oxygenase 1",
            "normalized_id": "N/A",
            "aliases": [],
            "description": "An enzyme whose activity is altered by STC2 interaction, compromising the activity of IFN--producing CD8+ Tc1 cells."
          },
          "time_info": null
        },
        {
          "head": "STC2",
          "relation": "bind",
          "tail": "HRG",
          "relation_type": "UNKNOWN",
          "confidence": [
            0.6,
            0.6
          ],
          "evidence": [
            "Unbiased analysis identified as a binding partner of HRG, STC2 can modulate the immune response of inflammatory cells [160]; however, the in vivo biological importance of STC2-HRG complex remains to be further dissected."
          ],
          "mechanism": "unknown",
          "source": "ocr_result_2_10",
          "subject": {
            "entity_id": "ent:7f1142971514",
            "entity_type": "BIOMARKER",
            "name": "STC2-HRG complex",
            "normalized_id": "N/A",
            "aliases": [],
            "description": "A complex formed between STC2 and HRG that modulates the immune response of inflammatory cells, though its in vivo importance requires further study."
          },
          "object": {
            "entity_id": "ent:7f1142971514",
            "entity_type": "BIOMARKER",
            "name": "STC2-HRG complex",
            "normalized_id": "N/A",
            "aliases": [],
            "description": "A complex formed between STC2 and HRG that modulates the immune response of inflammatory cells, though its in vivo importance requires further study."
          },
          "time_info": null
        },
        {
          "head": "bevacizumab",
          "relation": "inhibit",
          "tail": "growth",
          "relation_type": "UNKNOWN",
          "confidence": [
            0.88,
            0.05
          ],
          "evidence": [
            "The application of bevacizumab, the anti-VEGF antibody, successfully inhibits the growth of human colon cancer xenografts through blocking cell cycle progression at early stage and inducing apoptosis at late stage."
          ],
          "mechanism": "unknown",
          "source": "ocr_result_2_10",
          "subject": {
            "entity_id": "ent:ab62f6c518c4",
            "entity_type": "TREATMENT",
            "name": "bevacizumab",
            "normalized_id": "N/A",
            "aliases": [],
            "description": "Described as an anti-VEGF antibody application that inhibits tumor growth and induces STC2 expression."
          },
          "object": {
            "entity_id": "ent:8c1ae83ad43d",
            "entity_type": "TREATMENT",
            "name": "anti-vascular endothelial growth factor (VEGF) antibody",
            "normalized_id": "N/A",
            "aliases": [
              "anti-VEGF antibody"
            ],
            "description": "A chemotherapeutic treatment exposure that upregulates STC2, as mentioned in the text."
          },
          "time_info": null
        },
        {
          "head": "bevacizumab",
          "relation": "block",
          "tail": "cell cycle progression",
          "relation_type": "UNKNOWN",
          "confidence": [
            0.8,
            0.05
          ],
          "evidence": [
            "The application of bevacizumab, the anti-VEGF antibody, successfully inhibits the growth of human colon cancer xenografts through blocking cell cycle progression at early stage and inducing apoptosis at late stage."
          ],
          "mechanism": "unknown",
          "source": "ocr_result_2_10",
          "subject": {
            "entity_id": "ent:ab62f6c518c4",
            "entity_type": "TREATMENT",
            "name": "bevacizumab",
            "normalized_id": "N/A",
            "aliases": [],
            "description": "Described as an anti-VEGF antibody application that inhibits tumor growth and induces STC2 expression."
          },
          "object": {
            "entity_id": "ent:97f4f08c27a4",
            "entity_type": "PATHWAY",
            "name": "cell cycle progression",
            "normalized_id": "N/A",
            "aliases": [],
            "description": "A process blocked at an early stage by bevacizumab application to inhibit the growth of human colon cancer xenografts."
          },
          "time_info": null
        }
      ]
    },
    "ocr_result_2_11": {
      "id": "ocr_result_2_11",
      "name": "",
      "meta": {
        "text": "STC2 as a mediator of tumour cells' adaptation to cisplatin and it can be targeted to overcome the acquired resistance. Mechanistically, resistant cells demonstrate increased phosphorylation of Erk, JNK and p38, which can be reversed by STC2 knockdown. In accordance, STC2 is upregulated in human colorectal cancer cells with resistance to oxaliplatin relative to their parental counterparts. Moreover, increased STC2 protein levels were observed in the culture medium from resistant cells. Therapeutically, knockdown of STC2 effectively re-sensitizes resistant cells to oxaliplatin, and exposure of cells to recombinant STC2 protein is sufficient to compromise apoptosis induced by oxaliplatin in parental colorectal cancer cells [151], demonstrating STC2 performs its biological functions at least partially through a paracrine mechanism. Mechanistic analyses indicate that STC2 can promote the activation of PI3K-Akt signaling to induce the expression of P-glycoprotein, which involves in the absorption, distribution and excretion of chemical compounds and is regarded as a primary factor to induce acquired resistance to oxaliplatin [151].\n\nIn human HCC cells, ectopic expression of STC2 compromises paclitaxel-induced apoptosis through upregulating P-glycoprotein and Bcl2. Amphiphilic cationic PHB-PDMAEMA polyester has been synthesized and applied as a delivery carrier for paclitaxel to overcome P-glycoprotein-mediated resistant effects [162]; cell culture analysis demonstrated that this treatment partially overcomes STC2-P-glycoprotien-mediated drug resistance, providing a new way to more efficiently treat human cancers.\n\nHyperactivation of epidermal growth factor receptor (EGFR) signaling is a critical contributor for the development and progression of lung cancer [163]; therefore, TKIs are widely applied to treat non-small cell lung cancer (NSCLC) with the hyperactivation of EGFR signaling; however, some tumours will finally develop acquired resistance to TKIs. cDNA microarray analysis demonstrated the upregulation of STC2 in resistant tumour cells comparing to their parental counterparts, and STC2 is upregulated in several other cell lines exposed to TKIs, indicating that STC2 upregulation is a common phenomenon in resistant tumour cells [43]. Importantly, elevated STC2 levels are correlated with poor prognosis in patients with lung cancer. Moreover, ectopic expression of STC2 drives acquired resistance, while knockdown of STC2 successfully re-sensitizes resistant cells to TKIs. Mechanistically, STC2 enhances the activation of c-Jun singling, the transcription of AXL and the activation of Erk pathway [95]. Consistently, knockdown or chemical inhibitors targeting either AXL or Erk can facilitate overcoming TKI resistance-mediated by STC2 overexpression.\n\n### STC2-mediated resistance to radiotherapy\n\nRadiotherapy or radiation therapy is an approach to treat tumours through exposing them to high dosages of radiation. Mechanistically, radiation causes DNA damage-induced cell death, and finally suppresses tumour growth. Radiation therapy includes external beam, internal beam and systemic radiation like radioactive iodine for thyroid cancer, and molecular radiotherapy for advanced prostate cancer and gastroenteropancreatic neuroendocrine tumour. External beam radiotherapy is widely applied to treat many different tumours including breast cancer, colorectal cancer, esophageal cancer, HNSCC, NSCLC, skin squamous cell carcinoma, prostate cancer, brain tumours; while internal beam therapy is normally used to treat HNSCC, breast cancer, cervical cancer, prostate cancer and tumours from the eye. Although they are sensitive to radiotherapy initially, tumour cells will finally develop acquired resistance to radiotherapy. Therefore, it is critical to identify new molecular mechanisms of how tumour cells develop acquired resistance. As a stress response factor, STC2 is upregulated upon irradiation treatment [164, 165]. In a study with human nasopharyngeal carcinomas, after intensity-modulated radiotherapy, the incidence rate of residual tumours is 54.8% for patients with STC2 positive tumours, while it's only 17.4% for those with STC2 negative ones, suggesting STC2 levels are correlated with the response of tumours to radiation therapy [38]. Consistently, these findings are also revealed in patients with cervical cancer [46]. Another study utilized human CNE2 nasopharyngeal carcinoma cells to investigate the mechanism of how STC2 mediates the development of acquired resistance to radiation. STC2 knockout compromises colony formation induced by radiation regardless of oxygen levels because of increased apoptosis and reduced cell proliferation [79]. Further analysis indicates STC2 knockout not only promotes cell cycle arrest in G_{2}-M phase, but also suppresses cell migration and invasion. Therefore, STC2 is an indispensable factor to control post-radiation proliferation, survival and migration; and STC2 is a promising target for developing a novel therapy to overcome radiation resistance in human cancers.\n\n### Conclusions and future perspectives\n\nSTC2 is upregulated in most types of human cancers. Elevated STC2 levels are associated with tumour size, invasiveness, metastasis and poor prognosis in most tumours other than some breast cancers. In addition, overexpression of STC2 is controlled by diverse mechanisms that will fit STC2 into different signaling networks in order to facilitate cell survival. Further analyses are required to dissect these mechanisms in a context-dependent manner.\n\nQie and Sang J Exp Clin Cancer Res (2022) 41:161",
        "source": "ocr_result_2"
      },
      "entities": [
        {
          "entity_id": "ent:5325cd40e1a0",
          "entity_type": "PATHWAY",
          "name": "PI3K-Akt signaling",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "STC2 can promote the activation of PI3K-Akt signaling to induce the expression of P-glycoprotein."
        },
        {
          "entity_id": "ent:44bced2d3fbd",
          "entity_type": "PATHWAY",
          "name": "c-Jun signaling",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "STC2 enhances the activation of c-Jun singling, the transcription of AXL and the activation of Erk pathway."
        },
        {
          "entity_id": "ent:ec8865bdbf50",
          "entity_type": "PATHWAY",
          "name": "Erk pathway",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "STC2 enhances the activation of c-Jun singling, the transcription of AXL and the activation of Erk pathway."
        },
        {
          "entity_id": "ent:2487512e28f6",
          "entity_type": "BIOMARKER",
          "name": "STC2",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A protein upregulated in human colorectal cancer cells with resistance to oxaliplatin and correlated with poor prognosis in lung cancer patients."
        },
        {
          "entity_id": "ent:eab86b4ca0a9",
          "entity_type": "BIOMARKER",
          "name": "Erk",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A signaling molecule whose phosphorylation is increased in resistant cells and can be reversed by STC2 knockdown."
        },
        {
          "entity_id": "ent:48eed59fc476",
          "entity_type": "BIOMARKER",
          "name": "JNK",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A signaling molecule whose phosphorylation is increased in resistant cells and can be reversed by STC2 knockdown."
        },
        {
          "entity_id": "ent:0ffafe875514",
          "entity_type": "BIOMARKER",
          "name": "p38",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A signaling molecule whose phosphorylation is increased in resistant cells and can be reversed by STC2 knockdown."
        },
        {
          "entity_id": "ent:eb088a81692c",
          "entity_type": "BIOMARKER",
          "name": "PI3K-Akt",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A signaling pathway that STC2 can promote the activation of to induce P-glycoprotein expression."
        },
        {
          "entity_id": "ent:ecce9106e732",
          "entity_type": "BIOMARKER",
          "name": "P-glycoprotein",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A protein induced by STC2 via PI3K-Akt signaling, involved in chemical compound handling and regarded as a primary factor for acquired resistance to oxaliplatin."
        },
        {
          "entity_id": "ent:0f3c9072d450",
          "entity_type": "BIOMARKER",
          "name": "Bcl2",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A protein upregulated by STC2 to compromise paclitaxel-induced apoptosis in human HCC cells."
        },
        {
          "entity_id": "ent:3ec2bbf373ac",
          "entity_type": "BIOMARKER",
          "name": "AXL",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A gene whose transcription is enhanced by STC2 to mediate TKI resistance in lung cancer."
        },
        {
          "entity_id": "ent:7113599bc0d4",
          "entity_type": "GENE",
          "name": "PI3K",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Part of the PI3K-Akt signaling pathway that STC2 can promote the activation of to induce P-glycoprotein expression."
        },
        {
          "entity_id": "ent:5613edde45e0",
          "entity_type": "GENE",
          "name": "Akt",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Part of the PI3K-Akt signaling pathway that STC2 can promote the activation of to induce P-glycoprotein expression."
        },
        {
          "entity_id": "ent:b5bb74260b2d",
          "entity_type": "GENE",
          "name": "c-Jun",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "STC2 enhances the activation of c-Jun signaling, which is part of the mechanism in TKI resistance according to the document."
        },
        {
          "entity_id": "ent:2b1ee14f4dc3",
          "entity_type": "PROTEIN",
          "name": "epidermal growth factor receptor",
          "normalized_id": "N/A",
          "aliases": [
            "EGFR"
          ],
          "description": "Hyperactivation of its signaling is a critical contributor to lung cancer development and progression."
        },
        {
          "entity_id": "ent:48fec0c7d3d1",
          "entity_type": "TREATMENT",
          "name": "cisplatin",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A drug to which tumour cells adapt, and STC2 mediates this adaptation, with acquired resistance being a focus of study."
        },
        {
          "entity_id": "ent:9ffb4e1df527",
          "entity_type": "TREATMENT",
          "name": "oxaliplatin",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A drug to which human colorectal cancer cells develop resistance, and STC2 knockdown can re-sensitize resistant cells to it."
        },
        {
          "entity_id": "ent:8340a43eb500",
          "entity_type": "TREATMENT",
          "name": "paclitaxel",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A drug whose induced apoptosis is compromised by ectopic STC2 expression in human HCC cells through upregulation of P-glycoprotein and Bcl2."
        },
        {
          "entity_id": "ent:7280b91ec0f2",
          "entity_type": "TREATMENT",
          "name": "TKIs",
          "normalized_id": "N/A",
          "aliases": [
            "TKI"
          ],
          "description": "Tyrosine kinase inhibitors widely applied to treat non-small cell lung cancer with hyperactivated EGFR signaling, though some tumours develop acquired resistance."
        },
        {
          "entity_id": "ent:6029ccf719bf",
          "entity_type": "TREATMENT",
          "name": "radiation therapy",
          "normalized_id": "N/A",
          "aliases": [
            "radiotherapy",
            "Radiotherapy"
          ],
          "description": "Includes external beam, internal beam and systemic radiation like radioactive iodine for thyroid cancer, and molecular radiotherapy for advanced prostate cancer and gastroenteropancreatic neuroendocrine tumour."
        },
        {
          "entity_id": "ent:569a305a53e2",
          "entity_type": "TREATMENT",
          "name": "external beam radiotherapy",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Widely applied to treat many different tumours including breast cancer, colorectal cancer, esophageal cancer, HNSCC, NSCLC, skin squamous cell carcinoma, prostate cancer, and brain tumours."
        },
        {
          "entity_id": "ent:a57b7f881d4e",
          "entity_type": "TREATMENT",
          "name": "internal beam therapy",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Normally used to treat HNSCC, breast cancer, cervical cancer, prostate cancer and tumours from the eye."
        },
        {
          "entity_id": "ent:499ddc0e7af2",
          "entity_type": "TREATMENT",
          "name": "intensity-modulated radiotherapy",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A treatment given to patients with human nasopharyngeal carcinomas, after which STC2 levels are correlated with tumour response."
        },
        {
          "entity_id": "ent:46e84752c118",
          "entity_type": "TREATMENT",
          "name": "radiation",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A treatment that induces colony formation in human CNE2 nasopharyngeal carcinoma cells, an effect compromised by STC2 knockout."
        },
        {
          "entity_id": "ent:b888208873ce",
          "entity_type": "DISEASE",
          "name": "colorectal cancer",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A type of human cancer mentioned in the context of cells developing resistance to oxaliplatin."
        },
        {
          "entity_id": "ent:4ce4a5ccbdee",
          "entity_type": "DISEASE",
          "name": "HCC",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A type of human cancer cell mentioned where ectopic expression of STC2 compromises paclitaxel-induced apoptosis."
        },
        {
          "entity_id": "ent:adf1ddf346b8",
          "entity_type": "DISEASE",
          "name": "lung cancer",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A cancer type where hyperactivation of EGFR signaling contributes to development and progression."
        },
        {
          "entity_id": "ent:708010092575",
          "entity_type": "DISEASE",
          "name": "non-small cell lung cancer",
          "normalized_id": "N/A",
          "aliases": [
            "NSCLC"
          ],
          "description": "A type of lung cancer treated with TKIs, where some tumors develop acquired resistance."
        },
        {
          "entity_id": "ent:1c5b401efcfb",
          "entity_type": "DISEASE",
          "name": "thyroid cancer",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A cancer type mentioned as an example where systemic radiation like radioactive iodine is used."
        },
        {
          "entity_id": "ent:871a40566879",
          "entity_type": "DISEASE",
          "name": "prostate cancer",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A cancer type mentioned in the context of molecular radiotherapy for advanced cases."
        },
        {
          "entity_id": "ent:4880595796b9",
          "entity_type": "DISEASE",
          "name": "gastroenteropancreatic neuroendocrine tumour",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A tumour type mentioned as an example where molecular radiotherapy is applied."
        },
        {
          "entity_id": "ent:40c3975aa8df",
          "entity_type": "DISEASE",
          "name": "esophageal cancer",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A tumour type mentioned as being widely treated with external beam radiotherapy."
        },
        {
          "entity_id": "ent:fa3e4c94c92a",
          "entity_type": "DISEASE",
          "name": "HNSCC",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A tumour type mentioned as being widely treated with external beam radiotherapy."
        },
        {
          "entity_id": "ent:6f6bd7a190e2",
          "entity_type": "DISEASE",
          "name": "skin squamous cell carcinoma",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A tumour type mentioned as being widely treated with external beam radiotherapy."
        },
        {
          "entity_id": "ent:32baacc2e53a",
          "entity_type": "DISEASE",
          "name": "brain tumours",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Tumour type mentioned as being widely treated with external beam radiotherapy."
        },
        {
          "entity_id": "ent:388aa6f38e8a",
          "entity_type": "DISEASE",
          "name": "cervical cancer",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "A cancer type mentioned as normally treated with internal beam therapy."
        },
        {
          "entity_id": "ent:36e4519b9c4c",
          "entity_type": "DISEASE",
          "name": "tumours",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Mentioned in the context of being treated with internal beam therapy for those from the eye."
        },
        {
          "entity_id": "ent:61d57c091677",
          "entity_type": "DISEASE",
          "name": "nasopharyngeal carcinomas",
          "normalized_id": "N/A",
          "aliases": [
            "nasopharyngeal carcinoma"
          ],
          "description": "A type of human cancer studied in relation to STC2 levels and response to intensity-modulated radiotherapy."
        },
        {
          "entity_id": "ent:3be8a5d85639",
          "entity_type": "DISEASE",
          "name": "human cancers",
          "normalized_id": "N/A",
          "aliases": [
            "cancers"
          ],
          "description": "Mentioned as contexts where STC2 is a promising target for developing novel therapies to overcome radiation resistance."
        },
        {
          "entity_id": "ent:56b4ac6b7c45",
          "entity_type": "DISEASE",
          "name": "breast cancers",
          "normalized_id": "N/A",
          "aliases": [
            "breast cancer"
          ],
          "description": "Mentioned as an exception where elevated STC2 levels are not associated with poor prognosis in some cases."
        },
        {
          "entity_id": "ent:1050e35291da",
          "entity_type": "MECHANISM",
          "name": "phosphorylation",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Increased phosphorylation of Erk, JNK and p38 is demonstrated in resistant cells and can be reversed by STC2 knockdown."
        },
        {
          "entity_id": "ent:c4746caf2cfe",
          "entity_type": "MECHANISM",
          "name": "apoptosis",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Exposure of cells to recombinant STC2 protein is sufficient to compromise apoptosis induced by oxaliplatin in parental colorectal cancer cells."
        },
        {
          "entity_id": "ent:c2b569458404",
          "entity_type": "MECHANISM",
          "name": "paracrine mechanism",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "STC2 performs its biological functions at least partially through a paracrine mechanism."
        },
        {
          "entity_id": "ent:e7dd72587625",
          "entity_type": "MECHANISM",
          "name": "activation",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "STC2 can promote the activation of PI3K-Akt signaling to induce the expression of P-glycoprotein."
        },
        {
          "entity_id": "ent:788abec578bc",
          "entity_type": "MECHANISM",
          "name": "expression",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "STC2 can promote the activation of PI3K-Akt signaling to induce the expression of P-glycoprotein."
        },
        {
          "entity_id": "ent:60ff5213c1b4",
          "entity_type": "MECHANISM",
          "name": "absorption",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "P-glycoprotein involves in the absorption, distribution and excretion of chemical compounds."
        },
        {
          "entity_id": "ent:9d32bbc27637",
          "entity_type": "MECHANISM",
          "name": "distribution",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "P-glycoprotein involves in the absorption, distribution and excretion of chemical compounds."
        },
        {
          "entity_id": "ent:e6d2a007acb4",
          "entity_type": "MECHANISM",
          "name": "excretion",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "P-glycoprotein involves in the absorption, distribution and excretion of chemical compounds."
        },
        {
          "entity_id": "ent:88e7aa5dceec",
          "entity_type": "MECHANISM",
          "name": "upregulating",
          "normalized_id": "N/A",
          "aliases": [
            "upregulation"
          ],
          "description": "Ectopic expression of STC2 compromises paclitaxel-induced apoptosis through upregulating P-glycoprotein and Bcl2."
        },
        {
          "entity_id": "ent:952b41bc6487",
          "entity_type": "MECHANISM",
          "name": "Hyperactivation",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Hyperactivation of epidermal growth factor receptor (EGFR) signaling is a critical contributor for the development and progression of lung cancer."
        },
        {
          "entity_id": "ent:4e0ddf6c3ac1",
          "entity_type": "MECHANISM",
          "name": "transcription",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "STC2 enhances the activation of c-Jun singling, the transcription of AXL and the activation of Erk pathway."
        },
        {
          "entity_id": "ent:bbf5a6d5e330",
          "entity_type": "MECHANISM",
          "name": "DNA damage-induced cell death",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Mechanistically, radiation causes DNA damage-induced cell death, and finally suppresses tumour growth."
        },
        {
          "entity_id": "ent:387a9086d699",
          "entity_type": "MECHANISM",
          "name": "stress response",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "As a stress response factor, STC2 is upregulated upon irradiation treatment."
        },
        {
          "entity_id": "ent:c5c9bb51a2c4",
          "entity_type": "MECHANISM",
          "name": "cell proliferation",
          "normalized_id": "N/A",
          "aliases": [
            "proliferation"
          ],
          "description": "STC2 knockout compromises colony formation induced by radiation because of increased apoptosis and reduced cell proliferation."
        },
        {
          "entity_id": "ent:12b82abbe582",
          "entity_type": "MECHANISM",
          "name": "cell cycle arrest",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "STC2 knockout not only promotes cell cycle arrest in G_{2}-M phase, but also suppresses cell migration and invasion."
        },
        {
          "entity_id": "ent:dc5e8c3f5440",
          "entity_type": "MECHANISM",
          "name": "cell migration",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "STC2 knockout not only promotes cell cycle arrest in G_{2}-M phase, but also suppresses cell migration and invasion."
        },
        {
          "entity_id": "ent:231751ce44ff",
          "entity_type": "MECHANISM",
          "name": "invasion",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "STC2 knockout not only promotes cell cycle arrest in G_{2}-M phase, but also suppresses cell migration and invasion."
        },
        {
          "entity_id": "ent:ac8ce1bc73c6",
          "entity_type": "MECHANISM",
          "name": "survival",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "STC2 is an indispensable factor to control post-radiation proliferation, survival and migration."
        },
        {
          "entity_id": "ent:3e1514ff888c",
          "entity_type": "MECHANISM",
          "name": "migration",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "STC2 is an indispensable factor to control post-radiation proliferation, survival and migration."
        },
        {
          "entity_id": "ent:db0739956f2f",
          "entity_type": "MECHANISM",
          "name": "cell survival",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Overexpression of STC2 is controlled by diverse mechanisms that will fit STC2 into different signaling networks in order to facilitate cell survival."
        }
      ],
      "relations": []
    },
    "ocr_result_2_12": {
      "id": "ocr_result_2_12",
      "name": "",
      "meta": {
        "text": "As a secreted glycoprotein hormone, serum STC2 levels can be easily monitored, thus it is promising to investigate whether serum STC2 levels can be utilized as a practical biomarker to assess prognosis or recurrence in patients with various types of cancers. STC2 regulates various aspects of tumour biology like cell proliferation, invasion and metastasis that are associated with tumour phenotypes and disease stages. Solid tumour cells commonly encounter stress conditions which selectively activate corresponding signaling pathways to reprogram metabolism, adjust tumour cell survival, proliferation, invasion and migration. STC2 is upregulated in many tumour cells under multiple stress conditions which activate ATF4, HIF-1 or both, strongly suggesting that STC2 participates in the evolutionarily conserved response under stress conditions.\n\nSTC2 is a glycosylated and secreted protein; hence, it is hypothesized to function in an autocrine or paracrine manner, but its potential receptor remains unclear [166]. The primary and most critical question is to identify STC2 receptor in order to better understand its signal transduction pathway and mechanisms of action. In addition, intracellular functions of STC2 prior to secretion also warrant further investigation.\n\nIn summary, STC2 is a promising biomarker to evaluate patients' prognosis and a potential candidate for developing targeted therapies, particularly for patients with late-stage diseases that usually require combined therapies. Further investigation into its mechanism of action may facilitate its clinical utilization as a biomarker and a novel therapeutic target.\n\n## Abbreviations\n\nAhR: Aryl hydrocarbon receptor; ATF: Activating transcription factor; CRPC: Castration-resistant prostate cancer; CTC: Circulating tumour cells; DFS: Disease-free survival; ECM: Extracellular matrix; EGFR: Epidermal growth factor receptor; EMT: Epithelial-mesenchymal transition; Er: Estrogen receptor; ER stress: Endoplasmic reticulum stress; ErbB: Epidermal growth factor receptor; ESCC: Esophageal squamous cell carcinoma; FISH: Fluorescence in situ hybridization; GCN2: General control nonderepressible 2; HCC: Hepatocellular carcinoma; HDAC: Histone deacetylase; HIF: Hypoxia-inducible factor; HMGA2: High-mobility gene group A2; HNSCC: Head and neck squamous cell carcinoma; HRE: Hypoxia-response element; HRG: Histidine-rich glycoprotein; HRI: Heme-Regulated Inhibitor (=Eukaryotic Translation Initiation Factor 2 Alpha Kinase 1); IHC: Immunohistochemical; IRE1: Inositol-requiring protein 1; IncRNA: Long non-coding RNA; miRNA: MicroRNAs; MMP: Matrix metalloproteinase; NSCLC: Non-small cell lung cancer; PERK: PKR-like ER kinase; PKR: Protein R kinase (=Eukaryotic Translation Initiation Factor 2 Alpha Kinase 2); qRT-PCR: Quantitative Real-Time Polymerase Chain Reaction; RCC: Renal cell carcinoma; Sp1: Specificity protein 1; STC: Stanniocalcin; TKI: Tyrosine kinase inhibitor; UPR: Unfold protein response; UTR: Untranslated region; VEGF: Vascular endothelial growth factor.\n\n## Acknowledgements\n\nThe authors appreciate the Start-up funding awarded to S.Q. from the Tianjin Medical University Cancer Institute and Hospital.\n\n## Authors' Contributions\n\nS.Q. and N.S. proposed, wrote and edited the manuscript. S.Q. and N.S. prepared and composed the tables and figures demonstrated in this manuscript. All authors read and approved the final manuscript.\n\n## Funding\n\nThis study is supported by the Start-up funding awarded to S.Q. from the Tianjin Medical University Cancer Institute and Hospital (No.: 2021-1-7) and 2021 Tianjin Medical University Cancer Institute and Hospital Talent Program and Start-up Grant for Doctors awarded to S.Q. (No.: B2102). The research in N.S. laboratory is supported by a Research Contract Award from Lipogen Inc, (New Jersey, USA). Tianjin Medical University Cancer Institute and Hospital, 2021-1-7, Shuo Qie, 2021 Tianjin Medical University Cancer Institute and Hospital Talent Program and Start-up Grant for Doctors, B2102, Shuo Qie, The Research Contract Award from Lipogen Inc, (New Jersey, USA)\n\n## Availability of data and materials\n\nNot applicable.\n\n## Declarations\n\n### Ethics approval and consent to participate\n\nNot applicable.\n\n### Consent for publication\n\nAll authors have agreed on the contents of the manuscript.\n\n### Competing interests\n\nThe authors declare that they have no competing interests.\n\n## Author details\n\n$^{1}$ Department of Pathology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China. $^{2}$ National Clinical Research Center for Cancer, Tianjin, China. $^{3}$ Key Laboratory of Cancer Prevention and Therapy (Tianjin), Tianjin, China. $^{4}$ Tianjin's Clinical Research Center for Cancer, Tianjin, China. $^{5}$ Department of Biology, Drexel University, PA, Philadelphia, USA.\n\nReceived: 8 February 2022 Accepted: 19 April 2022\n\nPublished online: 02 May 2022",
        "source": "ocr_result_2"
      },
      "entities": [
        {
          "entity_id": "ent:cac3ab2c4b97",
          "entity_type": "BIOMARKER",
          "name": "STC2",
          "normalized_id": "N/A",
          "aliases": [
            "Stanniocalcin",
            "Stanniocalcin 2"
          ],
          "description": "A secreted glycoprotein hormone whose serum levels are monitored and investigated as a practical biomarker to assess prognosis or recurrence in patients with various types of cancers."
        },
        {
          "entity_id": "ent:ddea23518122",
          "entity_type": "BIOMARKER",
          "name": "serum STC2 levels",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Levels of STC2 in serum that can be easily monitored and are investigated as a practical biomarker for assessing prognosis or recurrence in cancer patients."
        },
        {
          "entity_id": "ent:9243921308c6",
          "entity_type": "MECHANISM",
          "name": "cell proliferation",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Aspect of tumour biology regulated by STC2, associated with tumour phenotypes and disease stages."
        },
        {
          "entity_id": "ent:79193be1d7c1",
          "entity_type": "MECHANISM",
          "name": "invasion",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Aspect of tumour biology regulated by STC2, associated with tumour phenotypes and disease stages."
        },
        {
          "entity_id": "ent:2683098401ae",
          "entity_type": "MECHANISM",
          "name": "metastasis",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Aspect of tumour biology regulated by STC2, associated with tumour phenotypes and disease stages."
        },
        {
          "entity_id": "ent:5e9c370f8c28",
          "entity_type": "MECHANISM",
          "name": "signal transduction pathway",
          "normalized_id": "N/A",
          "aliases": [
            "signaling pathways"
          ],
          "description": "Pathway associated with STC2 that requires identification of its receptor to be better understood."
        },
        {
          "entity_id": "ent:fafa10522ab3",
          "entity_type": "MECHANISM",
          "name": "mechanisms of action",
          "normalized_id": "N/A",
          "aliases": [
            "mechanism of action",
            "MOA"
          ],
          "description": "Associated with STC2's signal transduction pathway, requiring better understanding through receptor identification."
        },
        {
          "entity_id": "ent:c451b5e44f28",
          "entity_type": "OTHER",
          "name": "biomarker",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Serum STC2 levels are described as potentially being utilized as a practical biomarker to assess prognosis or recurrence in patients with various types of cancers."
        },
        {
          "entity_id": "ent:1fcb3b5bf10c",
          "entity_type": "OTHER",
          "name": "prognosis",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Serum STC2 levels are described as potentially being utilized to assess prognosis in patients with various types of cancers."
        },
        {
          "entity_id": "ent:8a5ffa3628a5",
          "entity_type": "OTHER",
          "name": "recurrence",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Serum STC2 levels are described as potentially being utilized to assess recurrence in patients with various types of cancers."
        },
        {
          "entity_id": "ent:ea39bd9d4cfb",
          "entity_type": "OTHER",
          "name": "tumour phenotypes",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Cell proliferation, invasion and metastasis regulated by STC2 are described as being associated with tumour phenotypes."
        },
        {
          "entity_id": "ent:4af61ca32915",
          "entity_type": "OTHER",
          "name": "disease stages",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Cell proliferation, invasion and metastasis regulated by STC2 are described as being associated with disease stages."
        },
        {
          "entity_id": "ent:9e659bafb526",
          "entity_type": "OTHER",
          "name": "stress conditions",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Solid tumour cells are described as commonly encountering stress conditions which selectively activate corresponding signaling pathways."
        },
        {
          "entity_id": "ent:bd4b8f01721e",
          "entity_type": "OTHER",
          "name": "targeted therapies",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "STC2 is described as a potential candidate for developing targeted therapies, particularly for patients with late-stage diseases."
        },
        {
          "entity_id": "ent:385d57ec839f",
          "entity_type": "OTHER",
          "name": "combined therapies",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Late-stage diseases are described as usually requiring combined therapies."
        },
        {
          "entity_id": "ent:b706dd538ca8",
          "entity_type": "OTHER",
          "name": "therapeutic target",
          "normalized_id": "N/A",
          "aliases": [],
          "description": "Further investigation into STC2's mechanism of action may facilitate its clinical utilization as a novel therapeutic target."
        },
        {
          "entity_id": "ent:6c0754c67cd1",
          "entity_type": "PROTEIN",
          "name": "ATF4",
          "normalized_id": "N/A",
          "aliases": [
            "Activating transcription factor",
            "ATF"
          ],
          "description": "A factor activated under stress conditions that upregulates STC2 in tumour cells."
        },
        {
          "entity_id": "ent:51d086909fe2",
          "entity_type": "PROTEIN",
          "name": "HIF-1",
          "normalized_id": "N/A",
          "aliases": [
            "HIF",
            "Hypoxia-inducible factor"
          ],
          "description": "A factor activated under stress conditions that upregulates STC2 in tumour cells."
        },
        {
          "entity_id": "ent:ec317e39479a",
          "entity_type": "PROTEIN",
          "name": "AhR",
          "normalized_id": "N/A",
          "aliases": [
            "Aryl hydrocarbon receptor"
          ],
          "description": "Aryl hydrocarbon receptor, listed in the abbreviations section."
        },
        {
          "entity_id": "ent:8cd97310c449",
          "entity_type": "PROTEIN",
          "name": "EGFR",
          "normalized_id": "N/A",
          "aliases": [
            "Epidermal growth factor receptor",
            "ErbB"
          ],
          "description": "Epidermal growth factor receptor, listed in the abbreviations section."
        },
        {
          "entity_id": "ent:e964c12901aa",
          "entity_type": "PROTEIN",
          "name": "GCN2",
          "normalized_id": "N/A",
          "aliases": [
            "General control nonderepressible 2"
          ],
          "description": "General control nonderepressible 2, listed in the abbreviations section."
        },
        {
          "entity_id": "ent:ad94c27da775",
          "entity_type": "PROTEIN",
          "name": "HDAC",
          "normalized_id": "N/A",
          "aliases": [
            "Histone deacetylase"
          ],
          "description": "Histone deacetylase, listed in the abbreviations section."
        },
        {
          "entity_id": "ent:5c3658467b39",
          "entity_type": "PROTEIN",
          "name": "HMGA2",
          "normalized_id": "N/A",
          "aliases": [
            "High-mobility gene group A2"
          ],
          "description": "High-mobility gene group A2, listed in the abbreviations section."
        },
        {
          "entity_id": "ent:7e4489e7f36e",
          "entity_type": "PROTEIN",
          "name": "HRG",
          "normalized_id": "N/A",
          "aliases": [
            "Histidine-rich glycoprotein"
          ],
          "description": "Histidine-rich glycoprotein, listed in the abbreviations section."
        },
        {
          "entity_id": "ent:2c5cf203a250",
          "entity_type": "PROTEIN",
          "name": "HRI",
          "normalized_id": "N/A",
          "aliases": [
            "Heme-Regulated Inhibitor (=Eukaryotic Translation Initiation Factor 2 Alpha Kinase 1)"
          ],
          "description": "Heme-Regulated Inhibitor, also known as Eukaryotic Translation Initiation Factor 2 Alpha Kinase 1, listed in the abbreviations section."
        },
        {
          "entity_id": "ent:6b269e281f5d",
          "entity_type": "PROTEIN",
          "name": "IRE1",
          "normalized_id": "N/A",
          "aliases": [
            "Inositol-requiring protein 1"
          ],
          "description": "Inositol-requiring protein 1, listed in the abbreviations section."
        },
        {
          "entity_id": "ent:8b71f02458c6",
          "entity_type": "PROTEIN",
          "name": "MMP",
          "normalized_id": "N/A",
          "aliases": [
            "Matrix metalloproteinase"
          ],
          "description": "Matrix metalloproteinase, listed in the abbreviations section."
        },
        {
          "entity_id": "ent:16044f65391c",
          "entity_type": "PROTEIN",
          "name": "PERK",
          "normalized_id": "N/A",
          "aliases": [
            "PKR-like ER kinase"
          ],
          "description": "PKR-like ER kinase, listed in the abbreviations section."
        },
        {
          "entity_id": "ent:2b965eb3d8d2",
          "entity_type": "PROTEIN",
          "name": "PKR",
          "normalized_id": "N/A",
          "aliases": [
            "Protein R kinase (=Eukaryotic Translation Initiation Factor 2 Alpha Kinase 2)"
          ],
          "description": "Protein R kinase, also known as Eukaryotic Translation Initiation Factor 2 Alpha Kinase 2, listed in the abbreviations section."
        },
        {
          "entity_id": "ent:3f909f0d1ae5",
          "entity_type": "PROTEIN",
          "name": "Sp1",
          "normalized_id": "N/A",
          "aliases": [
            "Specificity protein 1"
          ],
          "description": "Specificity protein 1, listed in the abbreviations section."
        },
        {
          "entity_id": "ent:2ba7c9dd199a",
          "entity_type": "PROTEIN",
          "name": "STC",
          "normalized_id": "N/A",
          "aliases": [
            "Stanniocalcin"
          ],
          "description": "Stanniocalcin, listed in the abbreviations section."
        },
        {
          "entity_id": "ent:313009687382",
          "entity_type": "PROTEIN",
          "name": "VEGF",
          "normalized_id": "N/A",
          "aliases": [
            "Vascular endothelial growth factor"
          ],
          "description": "Vascular endothelial growth factor, listed in the abbreviations section."
        }
      ],
      "relations": [
        {
          "head": "STC2",
          "relation": "regulate",
          "tail": "cell proliferation",
          "relation_type": "UNKNOWN",
          "confidence": [
            0.75,
            0.15
          ],
          "evidence": [
            "STC2 regulates various aspects of tumour biology like cell proliferation, invasion and metastasis that are associated with tumour phenotypes and disease stages."
          ],
          "mechanism": "unknown",
          "source": "ocr_result_2_12",
          "subject": {
            "entity_id": "ent:2ba7c9dd199a",
            "entity_type": "PROTEIN",
            "name": "STC",
            "normalized_id": "N/A",
            "aliases": [
              "Stanniocalcin"
            ],
            "description": "Stanniocalcin, listed in the abbreviations section."
          },
          "object": {
            "entity_id": "ent:9243921308c6",
            "entity_type": "MECHANISM",
            "name": "cell proliferation",
            "normalized_id": "N/A",
            "aliases": [],
            "description": "Aspect of tumour biology regulated by STC2, associated with tumour phenotypes and disease stages."
          },
          "time_info": null
        },
        {
          "head": "STC2",
          "relation": "regulate",
          "tail": "invasion",
          "relation_type": "UNKNOWN",
          "confidence": [
            0.75,
            0.15
          ],
          "evidence": [
            "STC2 regulates various aspects of tumour biology like cell proliferation, invasion and metastasis that are associated with tumour phenotypes and disease stages."
          ],
          "mechanism": "unknown",
          "source": "ocr_result_2_12",
          "subject": {
            "entity_id": "ent:2ba7c9dd199a",
            "entity_type": "PROTEIN",
            "name": "STC",
            "normalized_id": "N/A",
            "aliases": [
              "Stanniocalcin"
            ],
            "description": "Stanniocalcin, listed in the abbreviations section."
          },
          "object": {
            "entity_id": "ent:79193be1d7c1",
            "entity_type": "MECHANISM",
            "name": "invasion",
            "normalized_id": "N/A",
            "aliases": [],
            "description": "Aspect of tumour biology regulated by STC2, associated with tumour phenotypes and disease stages."
          },
          "time_info": null
        },
        {
          "head": "STC2",
          "relation": "regulate",
          "tail": "metastasis",
          "relation_type": "UNKNOWN",
          "confidence": [
            0.75,
            0.15
          ],
          "evidence": [
            "STC2 regulates various aspects of tumour biology like cell proliferation, invasion and metastasis that are associated with tumour phenotypes and disease stages."
          ],
          "mechanism": "unknown",
          "source": "ocr_result_2_12",
          "subject": {
            "entity_id": "ent:2ba7c9dd199a",
            "entity_type": "PROTEIN",
            "name": "STC",
            "normalized_id": "N/A",
            "aliases": [
              "Stanniocalcin"
            ],
            "description": "Stanniocalcin, listed in the abbreviations section."
          },
          "object": {
            "entity_id": "ent:2683098401ae",
            "entity_type": "MECHANISM",
            "name": "metastasis",
            "normalized_id": "N/A",
            "aliases": [],
            "description": "Aspect of tumour biology regulated by STC2, associated with tumour phenotypes and disease stages."
          },
          "time_info": null
        },
        {
          "head": "stress conditions",
          "relation": "activate",
          "tail": "signal transduction pathway",
          "relation_type": "UNKNOWN",
          "confidence": [
            0.85,
            0.05
          ],
          "evidence": [
            "Solid tumour cells commonly encounter stress conditions which selectively activate corresponding signaling pathways to reprogram metabolism, adjust tumour cell survival, proliferation, invasion and migration."
          ],
          "mechanism": "unknown",
          "source": "ocr_result_2_12",
          "subject": {
            "entity_id": "ent:9e659bafb526",
            "entity_type": "OTHER",
            "name": "stress conditions",
            "normalized_id": "N/A",
            "aliases": [],
            "description": "Solid tumour cells are described as commonly encountering stress conditions which selectively activate corresponding signaling pathways."
          },
          "object": {
            "entity_id": "ent:5e9c370f8c28",
            "entity_type": "MECHANISM",
            "name": "signal transduction pathway",
            "normalized_id": "N/A",
            "aliases": [
              "signaling pathways"
            ],
            "description": "Pathway associated with STC2 that requires identification of its receptor to be better understood."
          },
          "time_info": null
        },
        {
          "head": "stress conditions",
          "relation": "upregulate",
          "tail": "STC2",
          "relation_type": "UNKNOWN",
          "confidence": [
            0.8,
            0.1
          ],
          "evidence": [
            "STC2 is upregulated in many tumour cells under multiple stress conditions which activate ATF4, HIF-1 or both, strongly suggesting that STC2 participates in the evolutionarily conserved response under stress conditions."
          ],
          "mechanism": "unknown",
          "source": "ocr_result_2_12",
          "subject": {
            "entity_id": "ent:9e659bafb526",
            "entity_type": "OTHER",
            "name": "stress conditions",
            "normalized_id": "N/A",
            "aliases": [],
            "description": "Solid tumour cells are described as commonly encountering stress conditions which selectively activate corresponding signaling pathways."
          },
          "object": {
            "entity_id": "ent:2ba7c9dd199a",
            "entity_type": "PROTEIN",
            "name": "STC",
            "normalized_id": "N/A",
            "aliases": [
              "Stanniocalcin"
            ],
            "description": "Stanniocalcin, listed in the abbreviations section."
          },
          "time_info": null
        },
        {
          "head": "stress conditions",
          "relation": "activate",
          "tail": "ATF4",
          "relation_type": "UNKNOWN",
          "confidence": [
            0.7,
            0.1
          ],
          "evidence": [
            "STC2 is upregulated in many tumour cells under multiple stress conditions which activate ATF4, HIF-1 or both, strongly suggesting that STC2 participates in the evolutionarily conserved response under stress conditions."
          ],
          "mechanism": "unknown",
          "source": "ocr_result_2_12",
          "subject": {
            "entity_id": "ent:9e659bafb526",
            "entity_type": "OTHER",
            "name": "stress conditions",
            "normalized_id": "N/A",
            "aliases": [],
            "description": "Solid tumour cells are described as commonly encountering stress conditions which selectively activate corresponding signaling pathways."
          },
          "object": {
            "entity_id": "ent:6c0754c67cd1",
            "entity_type": "PROTEIN",
            "name": "ATF4",
            "normalized_id": "N/A",
            "aliases": [
              "Activating transcription factor",
              "ATF"
            ],
            "description": "A factor activated under stress conditions that upregulates STC2 in tumour cells."
          },
          "time_info": null
        },
        {
          "head": "stress conditions",
          "relation": "activate",
          "tail": "HIF-1",
          "relation_type": "UNKNOWN",
          "confidence": [
            0.7,
            0.1
          ],
          "evidence": [
            "STC2 is upregulated in many tumour cells under multiple stress conditions which activate ATF4, HIF-1 or both, strongly suggesting that STC2 participates in the evolutionarily conserved response under stress conditions."
          ],
          "mechanism": "unknown",
          "source": "ocr_result_2_12",
          "subject": {
            "entity_id": "ent:9e659bafb526",
            "entity_type": "OTHER",
            "name": "stress conditions",
            "normalized_id": "N/A",
            "aliases": [],
            "description": "Solid tumour cells are described as commonly encountering stress conditions which selectively activate corresponding signaling pathways."
          },
          "object": {
            "entity_id": "ent:51d086909fe2",
            "entity_type": "PROTEIN",
            "name": "HIF-1",
            "normalized_id": "N/A",
            "aliases": [
              "HIF",
              "Hypoxia-inducible factor"
            ],
            "description": "A factor activated under stress conditions that upregulates STC2 in tumour cells."
          },
          "time_info": null
        },
        {
          "head": "STC2",
          "relation": "participate in",
          "tail": "response under stress conditions",
          "relation_type": "UNKNOWN",
          "confidence": [
            0.8,
            0.05
          ],
          "evidence": [
            "STC2 is upregulated in many tumour cells under multiple stress conditions which activate ATF4, HIF-1 or both, strongly suggesting that STC2 participates in the evolutionarily conserved response under stress conditions."
          ],
          "mechanism": "unknown",
          "source": "ocr_result_2_12",
          "subject": {
            "entity_id": "ent:2ba7c9dd199a",
            "entity_type": "PROTEIN",
            "name": "STC",
            "normalized_id": "N/A",
            "aliases": [
              "Stanniocalcin"
            ],
            "description": "Stanniocalcin, listed in the abbreviations section."
          },
          "object": {
            "entity_id": "ent:9e659bafb526",
            "entity_type": "OTHER",
            "name": "stress conditions",
            "normalized_id": "N/A",
            "aliases": [],
            "description": "Solid tumour cells are described as commonly encountering stress conditions which selectively activate corresponding signaling pathways."
          },
          "time_info": null
        }
      ]
    }
  },
  "alignments": [
    {
      "src_subgraph": "ocr_result_1_0",
      "src_entity": "ent:17e8a4ffd9ec",
      "tgt_subgraph": "ocr_result_1_1",
      "tgt_entity": "ent:eb3f3e38d77d"
    },
    {
      "src_subgraph": "ocr_result_1_0",
      "src_entity": "ent:b9c77630ce9d",
      "tgt_subgraph": "ocr_result_1_1",
      "tgt_entity": "ent:4ecb24b2e330"
    },
    {
      "src_subgraph": "ocr_result_1_0",
      "src_entity": "ent:0da0981b2564",
      "tgt_subgraph": "ocr_result_1_1",
      "tgt_entity": "ent:cd96e2edb784"
    },
    {
      "src_subgraph": "ocr_result_1_0",
      "src_entity": "ent:b5725f0f5a69",
      "tgt_subgraph": "ocr_result_1_1",
      "tgt_entity": "ent:1b18fa08fa0e"
    },
    {
      "src_subgraph": "ocr_result_1_0",
      "src_entity": "ent:b0d44ea5de70",
      "tgt_subgraph": "ocr_result_1_1",
      "tgt_entity": "ent:6b62c000294a"
    },
    {
      "src_subgraph": "ocr_result_1_0",
      "src_entity": "ent:1706e10b3438",
      "tgt_subgraph": "ocr_result_1_1",
      "tgt_entity": "ent:8a56f8d1077b"
    },
    {
      "src_subgraph": "ocr_result_1_0",
      "src_entity": "ent:1706e10b3438",
      "tgt_subgraph": "ocr_result_1_1",
      "tgt_entity": "ent:9d29d3782591"
    },
    {
      "src_subgraph": "ocr_result_1_0",
      "src_entity": "ent:1706e10b3438",
      "tgt_subgraph": "ocr_result_1_1",
      "tgt_entity": "ent:9d6f7764d7f7"
    },
    {
      "src_subgraph": "ocr_result_1_0",
      "src_entity": "ent:d7933eae15a6",
      "tgt_subgraph": "ocr_result_1_1",
      "tgt_entity": "ent:9ade75d3a354"
    },
    {
      "src_subgraph": "ocr_result_1_0",
      "src_entity": "ent:d7933eae15a6",
      "tgt_subgraph": "ocr_result_1_1",
      "tgt_entity": "ent:1b18fa08fa0e"
    },
    {
      "src_subgraph": "ocr_result_1_0",
      "src_entity": "ent:102fb1dfef68",
      "tgt_subgraph": "ocr_result_1_1",
      "tgt_entity": "ent:d8069daedbe7"
    },
    {
      "src_subgraph": "ocr_result_1_0",
      "src_entity": "ent:49d941816dbd",
      "tgt_subgraph": "ocr_result_1_1",
      "tgt_entity": "ent:0d5a025daa33"
    },
    {
      "src_subgraph": "ocr_result_1_0",
      "src_entity": "ent:59567678c41b",
      "tgt_subgraph": "ocr_result_1_1",
      "tgt_entity": "ent:4dccca3c35de"
    },
    {
      "src_subgraph": "ocr_result_1_0",
      "src_entity": "ent:59567678c41b",
      "tgt_subgraph": "ocr_result_1_1",
      "tgt_entity": "ent:6f8a67888b27"
    },
    {
      "src_subgraph": "ocr_result_1_0",
      "src_entity": "ent:59567678c41b",
      "tgt_subgraph": "ocr_result_1_1",
      "tgt_entity": "ent:cd96e2edb784"
    },
    {
      "src_subgraph": "ocr_result_1_3",
      "src_entity": "ent:278c211767cd",
      "tgt_subgraph": "ocr_result_1_1",
      "tgt_entity": "ent:4683f251fbed"
    },
    {
      "src_subgraph": "ocr_result_1_3",
      "src_entity": "ent:e6a70fe46bd0",
      "tgt_subgraph": "ocr_result_1_1",
      "tgt_entity": "ent:82fb4cdbc0f1"
    },
    {
      "src_subgraph": "ocr_result_1_3",
      "src_entity": "ent:1b34d319268f",
      "tgt_subgraph": "ocr_result_1_0",
      "tgt_entity": "ent:b9c77630ce9d"
    },
    {
      "src_subgraph": "ocr_result_1_3",
      "src_entity": "ent:7b050232663a",
      "tgt_subgraph": "ocr_result_1_0",
      "tgt_entity": "ent:17e8a4ffd9ec"
    },
    {
      "src_subgraph": "ocr_result_1_3",
      "src_entity": "ent:7b050232663a",
      "tgt_subgraph": "ocr_result_1_1",
      "tgt_entity": "ent:eb3f3e38d77d"
    },
    {
      "src_subgraph": "ocr_result_1_3",
      "src_entity": "ent:d62f37a1635f",
      "tgt_subgraph": "ocr_result_1_0",
      "tgt_entity": "ent:0da0981b2564"
    },
    {
      "src_subgraph": "ocr_result_1_3",
      "src_entity": "ent:d62f37a1635f",
      "tgt_subgraph": "ocr_result_1_1",
      "tgt_entity": "ent:cd96e2edb784"
    },
    {
      "src_subgraph": "ocr_result_1_3",
      "src_entity": "ent:0402bc63bf6f",
      "tgt_subgraph": "ocr_result_1_1",
      "tgt_entity": "ent:92bded174bee"
    },
    {
      "src_subgraph": "ocr_result_1_3",
      "src_entity": "ent:0402bc63bf6f",
      "tgt_subgraph": "ocr_result_1_1",
      "tgt_entity": "ent:8a56f8d1077b"
    },
    {
      "src_subgraph": "ocr_result_1_3",
      "src_entity": "ent:89fda2b6831c",
      "tgt_subgraph": "ocr_result_1_1",
      "tgt_entity": "ent:e23b214a9f4e"
    },
    {
      "src_subgraph": "ocr_result_1_3",
      "src_entity": "ent:f1e37c2e4678",
      "tgt_subgraph": "ocr_result_1_1",
      "tgt_entity": "ent:8a56f8d1077b"
    },
    {
      "src_subgraph": "ocr_result_1_3",
      "src_entity": "ent:f1e37c2e4678",
      "tgt_subgraph": "ocr_result_1_1",
      "tgt_entity": "ent:9d6f7764d7f7"
    },
    {
      "src_subgraph": "ocr_result_1_3",
      "src_entity": "ent:f1e37c2e4678",
      "tgt_subgraph": "ocr_result_1_1",
      "tgt_entity": "ent:9d29d3782591"
    },
    {
      "src_subgraph": "ocr_result_1_3",
      "src_entity": "ent:6251b566bcc9",
      "tgt_subgraph": "ocr_result_1_1",
      "tgt_entity": "ent:d8069daedbe7"
    },
    {
      "src_subgraph": "ocr_result_1_3",
      "src_entity": "ent:6251b566bcc9",
      "tgt_subgraph": "ocr_result_1_0",
      "tgt_entity": "ent:102fb1dfef68"
    },
    {
      "src_subgraph": "ocr_result_1_3",
      "src_entity": "ent:6251b566bcc9",
      "tgt_subgraph": "ocr_result_1_1",
      "tgt_entity": "ent:9d29d3782591"
    },
    {
      "src_subgraph": "ocr_result_1_3",
      "src_entity": "ent:674c5ee16cc2",
      "tgt_subgraph": "ocr_result_1_0",
      "tgt_entity": "ent:b0d44ea5de70"
    },
    {
      "src_subgraph": "ocr_result_1_3",
      "src_entity": "ent:674c5ee16cc2",
      "tgt_subgraph": "ocr_result_1_1",
      "tgt_entity": "ent:6b62c000294a"
    },
    {
      "src_subgraph": "ocr_result_1_3",
      "src_entity": "ent:0944d9619277",
      "tgt_subgraph": "ocr_result_1_0",
      "tgt_entity": "ent:b5725f0f5a69"
    },
    {
      "src_subgraph": "ocr_result_1_3",
      "src_entity": "ent:19d56a8ea9b0",
      "tgt_subgraph": "ocr_result_1_0",
      "tgt_entity": "ent:b0d44ea5de70"
    },
    {
      "src_subgraph": "ocr_result_1_3",
      "src_entity": "ent:19d56a8ea9b0",
      "tgt_subgraph": "ocr_result_1_0",
      "tgt_entity": "ent:4d574fb64211"
    },
    {
      "src_subgraph": "ocr_result_1_3",
      "src_entity": "ent:bdd05ac4eac7",
      "tgt_subgraph": "ocr_result_1_1",
      "tgt_entity": "ent:9ade75d3a354"
    },
    {
      "src_subgraph": "ocr_result_1_3",
      "src_entity": "ent:bdd05ac4eac7",
      "tgt_subgraph": "ocr_result_1_1",
      "tgt_entity": "ent:1b18fa08fa0e"
    },
    {
      "src_subgraph": "ocr_result_1_3",
      "src_entity": "ent:bdd05ac4eac7",
      "tgt_subgraph": "ocr_result_1_0",
      "tgt_entity": "ent:d7933eae15a6"
    },
    {
      "src_subgraph": "ocr_result_1_7",
      "src_entity": "ent:462e0511509f",
      "tgt_subgraph": "ocr_result_1_1",
      "tgt_entity": "ent:868f31807433"
    },
    {
      "src_subgraph": "ocr_result_1_7",
      "src_entity": "ent:2e4e9b8bab05",
      "tgt_subgraph": "ocr_result_1_0",
      "tgt_entity": "ent:c2f76a150273"
    },
    {
      "src_subgraph": "ocr_result_1_7",
      "src_entity": "ent:e1fbbd878a1d",
      "tgt_subgraph": "ocr_result_1_1",
      "tgt_entity": "ent:6f8a67888b27"
    },
    {
      "src_subgraph": "ocr_result_1_7",
      "src_entity": "ent:0856e782c875",
      "tgt_subgraph": "ocr_result_1_1",
      "tgt_entity": "ent:82fb4cdbc0f1"
    },
    {
      "src_subgraph": "ocr_result_1_7",
      "src_entity": "ent:0856e782c875",
      "tgt_subgraph": "ocr_result_1_3",
      "tgt_entity": "ent:e6a70fe46bd0"
    },
    {
      "src_subgraph": "ocr_result_1_7",
      "src_entity": "ent:1338729ecfde",
      "tgt_subgraph": "ocr_result_1_0",
      "tgt_entity": "ent:c2f76a150273"
    },
    {
      "src_subgraph": "ocr_result_1_7",
      "src_entity": "ent:d48e5d5ce7a9",
      "tgt_subgraph": "ocr_result_1_0",
      "tgt_entity": "ent:0da0981b2564"
    },
    {
      "src_subgraph": "ocr_result_1_7",
      "src_entity": "ent:d48e5d5ce7a9",
      "tgt_subgraph": "ocr_result_1_1",
      "tgt_entity": "ent:cd96e2edb784"
    },
    {
      "src_subgraph": "ocr_result_1_7",
      "src_entity": "ent:8d2e0b3b2eaa",
      "tgt_subgraph": "ocr_result_1_1",
      "tgt_entity": "ent:4ecb24b2e330"
    },
    {
      "src_subgraph": "ocr_result_1_7",
      "src_entity": "ent:9ec073085dfc",
      "tgt_subgraph": "ocr_result_1_0",
      "tgt_entity": "ent:0da0981b2564"
    },
    {
      "src_subgraph": "ocr_result_1_7",
      "src_entity": "ent:9ec073085dfc",
      "tgt_subgraph": "ocr_result_1_1",
      "tgt_entity": "ent:cd96e2edb784"
    },
    {
      "src_subgraph": "ocr_result_1_7",
      "src_entity": "ent:c377f9041217",
      "tgt_subgraph": "ocr_result_1_0",
      "tgt_entity": "ent:58b22f5d611d"
    },
    {
      "src_subgraph": "ocr_result_1_7",
      "src_entity": "ent:c377f9041217",
      "tgt_subgraph": "ocr_result_1_0",
      "tgt_entity": "ent:bdb75e153017"
    },
    {
      "src_subgraph": "ocr_result_1_7",
      "src_entity": "ent:f4f6d8dd583f",
      "tgt_subgraph": "ocr_result_1_0",
      "tgt_entity": "ent:58b22f5d611d"
    },
    {
      "src_subgraph": "ocr_result_1_7",
      "src_entity": "ent:f4f6d8dd583f",
      "tgt_subgraph": "ocr_result_1_0",
      "tgt_entity": "ent:b9c77630ce9d"
    },
    {
      "src_subgraph": "ocr_result_1_8",
      "src_entity": "ent:648bfbd70daf",
      "tgt_subgraph": "ocr_result_1_0",
      "tgt_entity": "ent:ede5fce3b5af"
    },
    {
      "src_subgraph": "ocr_result_1_8",
      "src_entity": "ent:353654a4ddf7",
      "tgt_subgraph": "ocr_result_1_7",
      "tgt_entity": "ent:0856e782c875"
    },
    {
      "src_subgraph": "ocr_result_1_8",
      "src_entity": "ent:353654a4ddf7",
      "tgt_subgraph": "ocr_result_1_1",
      "tgt_entity": "ent:82fb4cdbc0f1"
    },
    {
      "src_subgraph": "ocr_result_1_8",
      "src_entity": "ent:c82775eda705",
      "tgt_subgraph": "ocr_result_1_0",
      "tgt_entity": "ent:0da0981b2564"
    },
    {
      "src_subgraph": "ocr_result_1_8",
      "src_entity": "ent:c82775eda705",
      "tgt_subgraph": "ocr_result_1_7",
      "tgt_entity": "ent:9ec073085dfc"
    },
    {
      "src_subgraph": "ocr_result_1_8",
      "src_entity": "ent:c82775eda705",
      "tgt_subgraph": "ocr_result_1_7",
      "tgt_entity": "ent:d48e5d5ce7a9"
    },
    {
      "src_subgraph": "ocr_result_1_8",
      "src_entity": "ent:8fce394d7761",
      "tgt_subgraph": "ocr_result_1_7",
      "tgt_entity": "ent:d48e5d5ce7a9"
    },
    {
      "src_subgraph": "ocr_result_1_8",
      "src_entity": "ent:8fce394d7761",
      "tgt_subgraph": "ocr_result_1_0",
      "tgt_entity": "ent:0da0981b2564"
    },
    {
      "src_subgraph": "ocr_result_1_8",
      "src_entity": "ent:ba6e7c6fe9c9",
      "tgt_subgraph": "ocr_result_1_3",
      "tgt_entity": "ent:674c5ee16cc2"
    },
    {
      "src_subgraph": "ocr_result_1_8",
      "src_entity": "ent:ba6e7c6fe9c9",
      "tgt_subgraph": "ocr_result_1_0",
      "tgt_entity": "ent:b0d44ea5de70"
    },
    {
      "src_subgraph": "ocr_result_1_8",
      "src_entity": "ent:ba6e7c6fe9c9",
      "tgt_subgraph": "ocr_result_1_1",
      "tgt_entity": "ent:6b62c000294a"
    },
    {
      "src_subgraph": "ocr_result_1_8",
      "src_entity": "ent:b51fbcce41f8",
      "tgt_subgraph": "ocr_result_1_0",
      "tgt_entity": "ent:2ba0cafc389b"
    },
    {
      "src_subgraph": "ocr_result_1_8",
      "src_entity": "ent:279100aadc9a",
      "tgt_subgraph": "ocr_result_1_1",
      "tgt_entity": "ent:9ade75d3a354"
    },
    {
      "src_subgraph": "ocr_result_1_8",
      "src_entity": "ent:279100aadc9a",
      "tgt_subgraph": "ocr_result_1_3",
      "tgt_entity": "ent:bdd05ac4eac7"
    },
    {
      "src_subgraph": "ocr_result_1_8",
      "src_entity": "ent:279100aadc9a",
      "tgt_subgraph": "ocr_result_1_1",
      "tgt_entity": "ent:1b18fa08fa0e"
    },
    {
      "src_subgraph": "ocr_result_1_8",
      "src_entity": "ent:279100aadc9a",
      "tgt_subgraph": "ocr_result_1_0",
      "tgt_entity": "ent:d7933eae15a6"
    },
    {
      "src_subgraph": "ocr_result_1_8",
      "src_entity": "ent:1480e309f2c2",
      "tgt_subgraph": "ocr_result_1_1",
      "tgt_entity": "ent:d8069daedbe7"
    },
    {
      "src_subgraph": "ocr_result_1_8",
      "src_entity": "ent:1480e309f2c2",
      "tgt_subgraph": "ocr_result_1_3",
      "tgt_entity": "ent:6251b566bcc9"
    },
    {
      "src_subgraph": "ocr_result_1_8",
      "src_entity": "ent:1480e309f2c2",
      "tgt_subgraph": "ocr_result_1_1",
      "tgt_entity": "ent:9d29d3782591"
    },
    {
      "src_subgraph": "ocr_result_1_8",
      "src_entity": "ent:1480e309f2c2",
      "tgt_subgraph": "ocr_result_1_0",
      "tgt_entity": "ent:102fb1dfef68"
    },
    {
      "src_subgraph": "ocr_result_1_8",
      "src_entity": "ent:1b28af4fb0bf",
      "tgt_subgraph": "ocr_result_1_1",
      "tgt_entity": "ent:212605757955"
    },
    {
      "src_subgraph": "ocr_result_1_8",
      "src_entity": "ent:1ca7b1bf6d46",
      "tgt_subgraph": "ocr_result_1_1",
      "tgt_entity": "ent:9d29d3782591"
    },
    {
      "src_subgraph": "ocr_result_1_8",
      "src_entity": "ent:1ca7b1bf6d46",
      "tgt_subgraph": "ocr_result_1_1",
      "tgt_entity": "ent:8a56f8d1077b"
    },
    {
      "src_subgraph": "ocr_result_1_8",
      "src_entity": "ent:1ca7b1bf6d46",
      "tgt_subgraph": "ocr_result_1_3",
      "tgt_entity": "ent:f1e37c2e4678"
    },
    {
      "src_subgraph": "ocr_result_1_8",
      "src_entity": "ent:db89a628f80b",
      "tgt_subgraph": "ocr_result_1_1",
      "tgt_entity": "ent:212605757955"
    },
    {
      "src_subgraph": "ocr_result_1_8",
      "src_entity": "ent:db89a628f80b",
      "tgt_subgraph": "ocr_result_1_1",
      "tgt_entity": "ent:8c0ad29aae85"
    },
    {
      "src_subgraph": "ocr_result_1_8",
      "src_entity": "ent:54d2bebc226d",
      "tgt_subgraph": "ocr_result_1_0",
      "tgt_entity": "ent:17e8a4ffd9ec"
    },
    {
      "src_subgraph": "ocr_result_1_8",
      "src_entity": "ent:8fde78fdafaf",
      "tgt_subgraph": "ocr_result_1_0",
      "tgt_entity": "ent:58b22f5d611d"
    },
    {
      "src_subgraph": "ocr_result_1_8",
      "src_entity": "ent:8fde78fdafaf",
      "tgt_subgraph": "ocr_result_1_7",
      "tgt_entity": "ent:c377f9041217"
    },
    {
      "src_subgraph": "ocr_result_1_8",
      "src_entity": "ent:8fde78fdafaf",
      "tgt_subgraph": "ocr_result_1_0",
      "tgt_entity": "ent:bdb75e153017"
    },
    {
      "src_subgraph": "ocr_result_1_8",
      "src_entity": "ent:e44f671ea1c6",
      "tgt_subgraph": "ocr_result_1_3",
      "tgt_entity": "ent:1b34d319268f"
    },
    {
      "src_subgraph": "ocr_result_1_8",
      "src_entity": "ent:e44f671ea1c6",
      "tgt_subgraph": "ocr_result_1_0",
      "tgt_entity": "ent:b9c77630ce9d"
    },
    {
      "src_subgraph": "ocr_result_1_8",
      "src_entity": "ent:86ad740427f6",
      "tgt_subgraph": "ocr_result_1_0",
      "tgt_entity": "ent:58b22f5d611d"
    },
    {
      "src_subgraph": "ocr_result_1_8",
      "src_entity": "ent:86ad740427f6",
      "tgt_subgraph": "ocr_result_1_7",
      "tgt_entity": "ent:c377f9041217"
    },
    {
      "src_subgraph": "ocr_result_1_8",
      "src_entity": "ent:86ad740427f6",
      "tgt_subgraph": "ocr_result_1_7",
      "tgt_entity": "ent:f4f6d8dd583f"
    },
    {
      "src_subgraph": "ocr_result_1_8",
      "src_entity": "ent:86ad740427f6",
      "tgt_subgraph": "ocr_result_1_0",
      "tgt_entity": "ent:bdb75e153017"
    },
    {
      "src_subgraph": "ocr_result_1_8",
      "src_entity": "ent:86ad740427f6",
      "tgt_subgraph": "ocr_result_1_0",
      "tgt_entity": "ent:49d941816dbd"
    },
    {
      "src_subgraph": "ocr_result_1_9",
      "src_entity": "ent:5e647d1b5c27",
      "tgt_subgraph": "ocr_result_1_8",
      "tgt_entity": "ent:2ac7a4576b87"
    },
    {
      "src_subgraph": "ocr_result_1_9",
      "src_entity": "ent:bff39a19a8e8",
      "tgt_subgraph": "ocr_result_1_8",
      "tgt_entity": "ent:e44f671ea1c6"
    },
    {
      "src_subgraph": "ocr_result_1_9",
      "src_entity": "ent:e9b94210cd3f",
      "tgt_subgraph": "ocr_result_1_8",
      "tgt_entity": "ent:54d2bebc226d"
    },
    {
      "src_subgraph": "ocr_result_1_9",
      "src_entity": "ent:e9b94210cd3f",
      "tgt_subgraph": "ocr_result_1_1",
      "tgt_entity": "ent:eb3f3e38d77d"
    },
    {
      "src_subgraph": "ocr_result_1_9",
      "src_entity": "ent:aa7e5c0341c6",
      "tgt_subgraph": "ocr_result_1_0",
      "tgt_entity": "ent:58b22f5d611d"
    },
    {
      "src_subgraph": "ocr_result_1_9",
      "src_entity": "ent:aa7e5c0341c6",
      "tgt_subgraph": "ocr_result_1_7",
      "tgt_entity": "ent:c377f9041217"
    },
    {
      "src_subgraph": "ocr_result_1_9",
      "src_entity": "ent:aa7e5c0341c6",
      "tgt_subgraph": "ocr_result_1_8",
      "tgt_entity": "ent:86ad740427f6"
    },
    {
      "src_subgraph": "ocr_result_1_9",
      "src_entity": "ent:7034bc4157ba",
      "tgt_subgraph": "ocr_result_1_0",
      "tgt_entity": "ent:0da0981b2564"
    },
    {
      "src_subgraph": "ocr_result_1_9",
      "src_entity": "ent:7034bc4157ba",
      "tgt_subgraph": "ocr_result_1_7",
      "tgt_entity": "ent:d48e5d5ce7a9"
    },
    {
      "src_subgraph": "ocr_result_1_9",
      "src_entity": "ent:2cb0e97f3d2e",
      "tgt_subgraph": "ocr_result_1_8",
      "tgt_entity": "ent:e44f671ea1c6"
    },
    {
      "src_subgraph": "ocr_result_1_9",
      "src_entity": "ent:ee709b4c0aa7",
      "tgt_subgraph": "ocr_result_1_0",
      "tgt_entity": "ent:c2f76a150273"
    },
    {
      "src_subgraph": "ocr_result_1_9",
      "src_entity": "ent:ee709b4c0aa7",
      "tgt_subgraph": "ocr_result_1_7",
      "tgt_entity": "ent:1338729ecfde"
    },
    {
      "src_subgraph": "ocr_result_1_9",
      "src_entity": "ent:ee709b4c0aa7",
      "tgt_subgraph": "ocr_result_1_7",
      "tgt_entity": "ent:2e4e9b8bab05"
    },
    {
      "src_subgraph": "ocr_result_1_9",
      "src_entity": "ent:6915408f8e55",
      "tgt_subgraph": "ocr_result_1_0",
      "tgt_entity": "ent:2ba0cafc389b"
    },
    {
      "src_subgraph": "ocr_result_1_9",
      "src_entity": "ent:6915408f8e55",
      "tgt_subgraph": "ocr_result_1_8",
      "tgt_entity": "ent:b51fbcce41f8"
    },
    {
      "src_subgraph": "ocr_result_1_9",
      "src_entity": "ent:6915408f8e55",
      "tgt_subgraph": "ocr_result_1_8",
      "tgt_entity": "ent:b43e480dc6e3"
    },
    {
      "src_subgraph": "ocr_result_1_9",
      "src_entity": "ent:6915408f8e55",
      "tgt_subgraph": "ocr_result_1_0",
      "tgt_entity": "ent:1706e10b3438"
    },
    {
      "src_subgraph": "ocr_result_1_9",
      "src_entity": "ent:d9247696c877",
      "tgt_subgraph": "ocr_result_1_8",
      "tgt_entity": "ent:b43e480dc6e3"
    },
    {
      "src_subgraph": "ocr_result_1_9",
      "src_entity": "ent:d9247696c877",
      "tgt_subgraph": "ocr_result_1_8",
      "tgt_entity": "ent:648bfbd70daf"
    },
    {
      "src_subgraph": "ocr_result_1_9",
      "src_entity": "ent:eaee2392f832",
      "tgt_subgraph": "ocr_result_1_8",
      "tgt_entity": "ent:c82775eda705"
    },
    {
      "src_subgraph": "ocr_result_1_9",
      "src_entity": "ent:eaee2392f832",
      "tgt_subgraph": "ocr_result_1_0",
      "tgt_entity": "ent:0da0981b2564"
    },
    {
      "src_subgraph": "ocr_result_1_9",
      "src_entity": "ent:eaee2392f832",
      "tgt_subgraph": "ocr_result_1_7",
      "tgt_entity": "ent:9ec073085dfc"
    },
    {
      "src_subgraph": "ocr_result_1_9",
      "src_entity": "ent:eaee2392f832",
      "tgt_subgraph": "ocr_result_1_7",
      "tgt_entity": "ent:d48e5d5ce7a9"
    },
    {
      "src_subgraph": "ocr_result_1_9",
      "src_entity": "ent:c9907d238b42",
      "tgt_subgraph": "ocr_result_1_0",
      "tgt_entity": "ent:b0d44ea5de70"
    },
    {
      "src_subgraph": "ocr_result_1_9",
      "src_entity": "ent:8b82e4f8bdcd",
      "tgt_subgraph": "ocr_result_1_8",
      "tgt_entity": "ent:e44f671ea1c6"
    },
    {
      "src_subgraph": "ocr_result_1_9",
      "src_entity": "ent:f0f7b2500bf1",
      "tgt_subgraph": "ocr_result_1_7",
      "tgt_entity": "ent:8d2e0b3b2eaa"
    },
    {
      "src_subgraph": "ocr_result_1_9",
      "src_entity": "ent:f0f7b2500bf1",
      "tgt_subgraph": "ocr_result_1_1",
      "tgt_entity": "ent:eb3f3e38d77d"
    },
    {
      "src_subgraph": "ocr_result_1_9",
      "src_entity": "ent:b90180e99bfc",
      "tgt_subgraph": "ocr_result_1_7",
      "tgt_entity": "ent:0856e782c875"
    },
    {
      "src_subgraph": "ocr_result_1_9",
      "src_entity": "ent:b90180e99bfc",
      "tgt_subgraph": "ocr_result_1_1",
      "tgt_entity": "ent:82fb4cdbc0f1"
    },
    {
      "src_subgraph": "ocr_result_1_10",
      "src_entity": "ent:7eec4c2bdf1c",
      "tgt_subgraph": "ocr_result_1_7",
      "tgt_entity": "ent:8d2e0b3b2eaa"
    },
    {
      "src_subgraph": "ocr_result_1_10",
      "src_entity": "ent:9eb46c4092e9",
      "tgt_subgraph": "ocr_result_1_9",
      "tgt_entity": "ent:e9b94210cd3f"
    },
    {
      "src_subgraph": "ocr_result_1_10",
      "src_entity": "ent:9eb46c4092e9",
      "tgt_subgraph": "ocr_result_1_8",
      "tgt_entity": "ent:54d2bebc226d"
    },
    {
      "src_subgraph": "ocr_result_1_10",
      "src_entity": "ent:f6c4f83730a0",
      "tgt_subgraph": "ocr_result_1_9",
      "tgt_entity": "ent:7034bc4157ba"
    },
    {
      "src_subgraph": "ocr_result_1_10",
      "src_entity": "ent:f6c4f83730a0",
      "tgt_subgraph": "ocr_result_1_0",
      "tgt_entity": "ent:0da0981b2564"
    },
    {
      "src_subgraph": "ocr_result_1_10",
      "src_entity": "ent:f6c4f83730a0",
      "tgt_subgraph": "ocr_result_1_7",
      "tgt_entity": "ent:d48e5d5ce7a9"
    },
    {
      "src_subgraph": "ocr_result_1_10",
      "src_entity": "ent:2dce450b9171",
      "tgt_subgraph": "ocr_result_1_8",
      "tgt_entity": "ent:c745d0183f70"
    },
    {
      "src_subgraph": "ocr_result_1_10",
      "src_entity": "ent:2dce450b9171",
      "tgt_subgraph": "ocr_result_1_9",
      "tgt_entity": "ent:1618d04b838c"
    },
    {
      "src_subgraph": "ocr_result_1_10",
      "src_entity": "ent:42f388b4924a",
      "tgt_subgraph": "ocr_result_1_1",
      "tgt_entity": "ent:82fb4cdbc0f1"
    },
    {
      "src_subgraph": "ocr_result_1_10",
      "src_entity": "ent:42f388b4924a",
      "tgt_subgraph": "ocr_result_1_7",
      "tgt_entity": "ent:0856e782c875"
    },
    {
      "src_subgraph": "ocr_result_1_10",
      "src_entity": "ent:42f388b4924a",
      "tgt_subgraph": "ocr_result_1_8",
      "tgt_entity": "ent:353654a4ddf7"
    },
    {
      "src_subgraph": "ocr_result_1_10",
      "src_entity": "ent:61b6bd4b4a41",
      "tgt_subgraph": "ocr_result_1_8",
      "tgt_entity": "ent:353654a4ddf7"
    },
    {
      "src_subgraph": "ocr_result_1_10",
      "src_entity": "ent:61b6bd4b4a41",
      "tgt_subgraph": "ocr_result_1_7",
      "tgt_entity": "ent:0856e782c875"
    },
    {
      "src_subgraph": "ocr_result_1_10",
      "src_entity": "ent:61b6bd4b4a41",
      "tgt_subgraph": "ocr_result_1_1",
      "tgt_entity": "ent:82fb4cdbc0f1"
    },
    {
      "src_subgraph": "ocr_result_1_10",
      "src_entity": "ent:fffabe1f29a9",
      "tgt_subgraph": "ocr_result_1_1",
      "tgt_entity": "ent:a48a954a3c52"
    },
    {
      "src_subgraph": "ocr_result_2_0",
      "src_entity": "ent:8d327767b802",
      "tgt_subgraph": "ocr_result_1_10",
      "tgt_entity": "ent:31268a57fd65"
    },
    {
      "src_subgraph": "ocr_result_2_4",
      "src_entity": "ent:77f4a4c87d3c",
      "tgt_subgraph": "ocr_result_1_9",
      "tgt_entity": "ent:cfcd54cd829c"
    },
    {
      "src_subgraph": "ocr_result_2_4",
      "src_entity": "ent:5e63dd9a6c2e",
      "tgt_subgraph": "ocr_result_2_0",
      "tgt_entity": "ent:f79164325c1c"
    },
    {
      "src_subgraph": "ocr_result_2_4",
      "src_entity": "ent:39b2b81297cc",
      "tgt_subgraph": "ocr_result_2_0",
      "tgt_entity": "ent:09c62a5bec9c"
    },
    {
      "src_subgraph": "ocr_result_2_4",
      "src_entity": "ent:dadb6b243aee",
      "tgt_subgraph": "ocr_result_2_0",
      "tgt_entity": "ent:b9b750868a17"
    },
    {
      "src_subgraph": "ocr_result_2_4",
      "src_entity": "ent:7f09222afd3a",
      "tgt_subgraph": "ocr_result_2_0",
      "tgt_entity": "ent:b8f43b436b78"
    },
    {
      "src_subgraph": "ocr_result_2_4",
      "src_entity": "ent:7f09222afd3a",
      "tgt_subgraph": "ocr_result_2_0",
      "tgt_entity": "ent:09c62a5bec9c"
    },
    {
      "src_subgraph": "ocr_result_2_4",
      "src_entity": "ent:beca9868629d",
      "tgt_subgraph": "ocr_result_2_0",
      "tgt_entity": "ent:b9b750868a17"
    },
    {
      "src_subgraph": "ocr_result_2_4",
      "src_entity": "ent:559ef91937c9",
      "tgt_subgraph": "ocr_result_2_0",
      "tgt_entity": "ent:b9b750868a17"
    },
    {
      "src_subgraph": "ocr_result_2_10",
      "src_entity": "ent:ec15789de96d",
      "tgt_subgraph": "ocr_result_2_4",
      "tgt_entity": "ent:b18be7108c70"
    },
    {
      "src_subgraph": "ocr_result_2_10",
      "src_entity": "ent:a5433cd90f3a",
      "tgt_subgraph": "ocr_result_1_7",
      "tgt_entity": "ent:8d2e0b3b2eaa"
    },
    {
      "src_subgraph": "ocr_result_2_10",
      "src_entity": "ent:a77afffab48b",
      "tgt_subgraph": "ocr_result_2_0",
      "tgt_entity": "ent:2dbb68fbc092"
    },
    {
      "src_subgraph": "ocr_result_2_10",
      "src_entity": "ent:a77afffab48b",
      "tgt_subgraph": "ocr_result_2_0",
      "tgt_entity": "ent:ba8e328de0ee"
    },
    {
      "src_subgraph": "ocr_result_2_10",
      "src_entity": "ent:a77afffab48b",
      "tgt_subgraph": "ocr_result_1_9",
      "tgt_entity": "ent:cfcd54cd829c"
    },
    {
      "src_subgraph": "ocr_result_2_10",
      "src_entity": "ent:1025eae4a613",
      "tgt_subgraph": "ocr_result_2_0",
      "tgt_entity": "ent:729959de711f"
    },
    {
      "src_subgraph": "ocr_result_2_10",
      "src_entity": "ent:9eb786a8c031",
      "tgt_subgraph": "ocr_result_2_0",
      "tgt_entity": "ent:8d327767b802"
    },
    {
      "src_subgraph": "ocr_result_2_10",
      "src_entity": "ent:9eb786a8c031",
      "tgt_subgraph": "ocr_result_1_10",
      "tgt_entity": "ent:31268a57fd65"
    },
    {
      "src_subgraph": "ocr_result_2_10",
      "src_entity": "ent:ad99f40ea09e",
      "tgt_subgraph": "ocr_result_2_4",
      "tgt_entity": "ent:52083a1253f5"
    },
    {
      "src_subgraph": "ocr_result_2_10",
      "src_entity": "ent:465452c4c131",
      "tgt_subgraph": "ocr_result_2_4",
      "tgt_entity": "ent:9a179f23dc87"
    },
    {
      "src_subgraph": "ocr_result_2_10",
      "src_entity": "ent:1d966607df58",
      "tgt_subgraph": "ocr_result_2_4",
      "tgt_entity": "ent:a51eea0f5716"
    },
    {
      "src_subgraph": "ocr_result_2_10",
      "src_entity": "ent:fb8a0bd08861",
      "tgt_subgraph": "ocr_result_2_0",
      "tgt_entity": "ent:09c62a5bec9c"
    },
    {
      "src_subgraph": "ocr_result_2_10",
      "src_entity": "ent:fb8a0bd08861",
      "tgt_subgraph": "ocr_result_2_4",
      "tgt_entity": "ent:39b2b81297cc"
    },
    {
      "src_subgraph": "ocr_result_2_10",
      "src_entity": "ent:fb8a0bd08861",
      "tgt_subgraph": "ocr_result_2_4",
      "tgt_entity": "ent:7f09222afd3a"
    },
    {
      "src_subgraph": "ocr_result_2_10",
      "src_entity": "ent:fb8a0bd08861",
      "tgt_subgraph": "ocr_result_2_0",
      "tgt_entity": "ent:b8f43b436b78"
    },
    {
      "src_subgraph": "ocr_result_2_10",
      "src_entity": "ent:b68c4a9dcc81",
      "tgt_subgraph": "ocr_result_2_4",
      "tgt_entity": "ent:663267b6fcc3"
    },
    {
      "src_subgraph": "ocr_result_2_12",
      "src_entity": "ent:79193be1d7c1",
      "tgt_subgraph": "ocr_result_2_0",
      "tgt_entity": "ent:d2eaca1cd087"
    },
    {
      "src_subgraph": "ocr_result_2_12",
      "src_entity": "ent:9243921308c6",
      "tgt_subgraph": "ocr_result_2_0",
      "tgt_entity": "ent:64b41bedef19"
    },
    {
      "src_subgraph": "ocr_result_2_12",
      "src_entity": "ent:2683098401ae",
      "tgt_subgraph": "ocr_result_2_0",
      "tgt_entity": "ent:b9b750868a17"
    },
    {
      "src_subgraph": "ocr_result_2_12",
      "src_entity": "ent:2683098401ae",
      "tgt_subgraph": "ocr_result_2_4",
      "tgt_entity": "ent:559ef91937c9"
    },
    {
      "src_subgraph": "ocr_result_2_12",
      "src_entity": "ent:2683098401ae",
      "tgt_subgraph": "ocr_result_2_0",
      "tgt_entity": "ent:d2eaca1cd087"
    },
    {
      "src_subgraph": "ocr_result_2_12",
      "src_entity": "ent:9e659bafb526",
      "tgt_subgraph": "ocr_result_2_0",
      "tgt_entity": "ent:8e94b217755d"
    },
    {
      "src_subgraph": "ocr_result_2_12",
      "src_entity": "ent:8a5ffa3628a5",
      "tgt_subgraph": "ocr_result_2_4",
      "tgt_entity": "ent:ba2546f2e769"
    },
    {
      "src_subgraph": "ocr_result_2_12",
      "src_entity": "ent:4af61ca32915",
      "tgt_subgraph": "ocr_result_2_4",
      "tgt_entity": "ent:980d1f6d7b67"
    },
    {
      "src_subgraph": "ocr_result_2_12",
      "src_entity": "ent:51d086909fe2",
      "tgt_subgraph": "ocr_result_2_10",
      "tgt_entity": "ent:a5433cd90f3a"
    },
    {
      "src_subgraph": "ocr_result_2_12",
      "src_entity": "ent:e964c12901aa",
      "tgt_subgraph": "ocr_result_1_1",
      "tgt_entity": "ent:4ecb24b2e330"
    },
    {
      "src_subgraph": "ocr_result_2_12",
      "src_entity": "ent:2b965eb3d8d2",
      "tgt_subgraph": "ocr_result_1_1",
      "tgt_entity": "ent:e6e8799f2979"
    }
  ],
  "key_entities": [
    {
      "entity_id": "ent:f82f40b55d07",
      "entity_type": "PROTEIN",
      "name": "MAO-B",
      "normalized_id": "N/A",
      "aliases": [
        "MAO-B",
        "MAOB"
      ],
      "description": "Enzyme demonstrated in brain astrocytes and serotonergic neurons, showing differential age-related changes in mouse brain and peripheral organs, with age-related increases in human brain."
    },
    {
      "entity_id": "ent:9ad1f6609c5c",
      "entity_type": "PROTEIN",
      "name": "monoamine oxidase type B",
      "normalized_id": "N/A",
      "aliases": [
        "MAO-B",
        "monoamine oxidase B",
        "monoamine oxidase-B"
      ],
      "description": "An enzyme questioned for its role in dopaminergic nerve cell death in Parkinson's disease according to the document."
    },
    {
      "entity_id": "ent:b3040f3e67f7",
      "entity_type": "PROTEIN",
      "name": "MAOB",
      "normalized_id": "N/A",
      "aliases": [
        "MAOB",
        "Monoamine oxidase B",
        "Monoamine oxidase-B"
      ],
      "description": "Monoamine oxidase-B (MAOB) is described as an enzyme that mediates the aberrant synthesis of GABA and hydrogen peroxide in reactive astrocytes of Parkinson's disease, and its expression increases with aging and in neurodegenerative conditions."
    },
    {
      "entity_id": "ent:4cb806fad36b",
      "entity_type": "GENE",
      "name": "Stanniocalcin 2",
      "normalized_id": "N/A",
      "aliases": [
        "Stanniocalcin",
        "Stanniocalcin 2",
        "STC2"
      ],
      "description": "Gene with elevated levels in gastric cancer compared to normal tissues, correlated with tumour invasion, lymphatic metastasis and poor prognosis."
    },
    {
      "entity_id": "ent:ceb73a8e75a9",
      "entity_type": "PROTEIN",
      "name": "STC",
      "normalized_id": "N/A",
      "aliases": [
        "Stanniocalcin"
      ],
      "description": "Stanniocalcin, listed in the abbreviations section."
    },
    {
      "entity_id": "ent:ec5780b581ff",
      "entity_type": "BIOMARKER",
      "name": "STC2-HRG complex",
      "normalized_id": "N/A",
      "aliases": [],
      "description": "A complex formed between STC2 and HRG that modulates the immune response of inflammatory cells, though its in vivo importance requires further study."
    }
  ],
  "keyword_entity_map": {
    "MAO-B": [
      {
        "entity_id": "ent:f82f40b55d07",
        "entity_type": "PROTEIN",
        "name": "MAO-B",
        "normalized_id": "N/A",
        "aliases": [
          "MAO-B",
          "MAOB"
        ],
        "description": "Enzyme demonstrated in brain astrocytes and serotonergic neurons, showing differential age-related changes in mouse brain and peripheral organs, with age-related increases in human brain."
      },
      {
        "entity_id": "ent:9ad1f6609c5c",
        "entity_type": "PROTEIN",
        "name": "monoamine oxidase type B",
        "normalized_id": "N/A",
        "aliases": [
          "MAO-B",
          "monoamine oxidase B",
          "monoamine oxidase-B"
        ],
        "description": "An enzyme questioned for its role in dopaminergic nerve cell death in Parkinson's disease according to the document."
      },
      {
        "entity_id": "ent:b3040f3e67f7",
        "entity_type": "PROTEIN",
        "name": "MAOB",
        "normalized_id": "N/A",
        "aliases": [
          "MAOB",
          "Monoamine oxidase B",
          "Monoamine oxidase-B"
        ],
        "description": "Monoamine oxidase-B (MAOB) is described as an enzyme that mediates the aberrant synthesis of GABA and hydrogen peroxide in reactive astrocytes of Parkinson's disease, and its expression increases with aging and in neurodegenerative conditions."
      }
    ],
    "STC2": [
      {
        "entity_id": "ent:4cb806fad36b",
        "entity_type": "GENE",
        "name": "Stanniocalcin 2",
        "normalized_id": "N/A",
        "aliases": [
          "Stanniocalcin",
          "Stanniocalcin 2",
          "STC2"
        ],
        "description": "Gene with elevated levels in gastric cancer compared to normal tissues, correlated with tumour invasion, lymphatic metastasis and poor prognosis."
      },
      {
        "entity_id": "ent:ceb73a8e75a9",
        "entity_type": "PROTEIN",
        "name": "STC",
        "normalized_id": "N/A",
        "aliases": [
          "Stanniocalcin"
        ],
        "description": "Stanniocalcin, listed in the abbreviations section."
      },
      {
        "entity_id": "ent:ec5780b581ff",
        "entity_type": "BIOMARKER",
        "name": "STC2-HRG complex",
        "normalized_id": "N/A",
        "aliases": [],
        "description": "A complex formed between STC2 and HRG that modulates the immune response of inflammatory cells, though its in vivo importance requires further study."
      }
    ]
  },
  "meta": {
    "generated_at": "20260103-195134",
    "entity_id_mapping_path": "cache/entity_id_mapping_20260103-194400.pkl"
  },
  "paths": {
    "MAO-B": [
      {
        "nodes": [
          {
            "entity_id": "ent:f82f40b55d07",
            "entity_type": "PROTEIN",
            "name": "MAO-B",
            "normalized_id": "N/A",
            "aliases": [
              "MAO-B",
              "MAOB"
            ],
            "description": "Enzyme demonstrated in brain astrocytes and serotonergic neurons, showing differential age-related changes in mouse brain and peripheral organs, with age-related increases in human brain."
          },
          {
            "entity_id": "ent:434e480a4a35",
            "entity_type": "TREATMENT",
            "name": "irreversible MAOB inhibitors",
            "normalized_id": "N/A",
            "aliases": [
              "irreversible inhibitors",
              "irreversible MAOB inhibitors",
              "MAOB inhibitors"
            ],
            "description": "Inhibitors of monoamine oxidase B that are described as having shortcomings in the context of Alzheimer's disease treatment."
          },
          {
            "entity_id": "ent:70547b872a76",
            "entity_type": "MECHANISM",
            "name": "blockade of the excessive astrocytic GABA synthesis",
            "normalized_id": "N/A",
            "aliases": [],
            "description": "The therapeutic efficacy of MAOB inhibitors for PD is attributed to a blockade of the excessive astrocytic GABA synthesis."
          }
        ],
        "edges": [
          {
            "head": "MAO-B",
            "relation": "circumvent",
            "tail": "irreversible MAOB inhibitors",
            "relation_type": null,
            "confidence": [
              0.85,
              0.1
            ],
            "evidence": [
              "Newly developed reversible MAO-B inhibitor circumvents the shortcomings of irreversible inhibitors in Alzheimer's disease."
            ],
            "mechanism": "unknown",
            "source": "ocr_result_1_7",
            "subject": {
              "entity_id": "ent:f82f40b55d07",
              "entity_type": "PROTEIN",
              "name": "MAO-B",
              "normalized_id": "N/A",
              "aliases": [
                "MAO-B",
                "MAOB"
              ],
              "description": "Enzyme demonstrated in brain astrocytes and serotonergic neurons, showing differential age-related changes in mouse brain and peripheral organs, with age-related increases in human brain."
            },
            "object": {
              "entity_id": "ent:434e480a4a35",
              "entity_type": "TREATMENT",
              "name": "irreversible MAOB inhibitors",
              "normalized_id": "N/A",
              "aliases": [
                "irreversible inhibitors",
                "irreversible MAOB inhibitors",
                "MAOB inhibitors"
              ],
              "description": "Inhibitors of monoamine oxidase B that are described as having shortcomings in the context of Alzheimer's disease treatment."
            },
            "time_info": null
          },
          {
            "head": "irreversible MAOB inhibitors",
            "relation": "block",
            "tail": "blockade of the excessive astrocytic GABA synthesis",
            "relation_type": null,
            "confidence": [
              0.8,
              0.05
            ],
            "evidence": [
              "The therapeutic efficacy of MAOB inhibitors for PD is not attributed to a blockade of DA degradation. Instead, it is attributed to a blockade of the excessive astrocytic GABA synthesis and the aberrant tonic inhibition of DAergic neurons in the SNpc."
            ],
            "mechanism": "unknown",
            "source": "ocr_result_1_1",
            "subject": {
              "entity_id": "ent:434e480a4a35",
              "entity_type": "TREATMENT",
              "name": "irreversible MAOB inhibitors",
              "normalized_id": "N/A",
              "aliases": [
                "irreversible inhibitors",
                "irreversible MAOB inhibitors",
                "MAOB inhibitors"
              ],
              "description": "Inhibitors of monoamine oxidase B that are described as having shortcomings in the context of Alzheimer's disease treatment."
            },
            "object": {
              "entity_id": "ent:70547b872a76",
              "entity_type": "MECHANISM",
              "name": "blockade of the excessive astrocytic GABA synthesis",
              "normalized_id": "N/A",
              "aliases": [],
              "description": "The therapeutic efficacy of MAOB inhibitors for PD is attributed to a blockade of the excessive astrocytic GABA synthesis."
            },
            "time_info": null
          }
        ]
      }
    ],
    "STC2": [
      {
        "nodes": [
          {
            "entity_id": "ent:4cb806fad36b",
            "entity_type": "GENE",
            "name": "Stanniocalcin 2",
            "normalized_id": "N/A",
            "aliases": [
              "Stanniocalcin",
              "Stanniocalcin 2",
              "STC2"
            ],
            "description": "Gene with elevated levels in gastric cancer compared to normal tissues, correlated with tumour invasion, lymphatic metastasis and poor prognosis."
          },
          {
            "entity_id": "ent:b26ae4f28d7a",
            "entity_type": "OTHER",
            "name": "stress conditions",
            "normalized_id": "N/A",
            "aliases": [
              "stress conditions"
            ],
            "description": "Solid tumour cells are described as commonly encountering stress conditions which selectively activate corresponding signaling pathways."
          },
          {
            "entity_id": "ent:ceb73a8e75a9",
            "entity_type": "PROTEIN",
            "name": "STC",
            "normalized_id": "N/A",
            "aliases": [
              "Stanniocalcin"
            ],
            "description": "Stanniocalcin, listed in the abbreviations section."
          },
          {
            "entity_id": "ent:fc370882bdd3",
            "entity_type": "MECHANISM",
            "name": "invasion",
            "normalized_id": "N/A",
            "aliases": [
              "invasion"
            ],
            "description": "Aspect of tumour biology regulated by STC2, associated with tumour phenotypes and disease stages."
          }
        ],
        "edges": [
          {
            "head": "Stanniocalcin 2",
            "relation": "facilitate",
            "tail": "stress conditions",
            "relation_type": null,
            "confidence": [
              0.75,
              0.1
            ],
            "evidence": [
              "Biologically, STC2 facilitates cells dealing with stress conditions and prevents apoptosis."
            ],
            "mechanism": "unknown",
            "source": "ocr_result_2_0",
            "subject": {
              "entity_id": "ent:4cb806fad36b",
              "entity_type": "GENE",
              "name": "Stanniocalcin 2",
              "normalized_id": "N/A",
              "aliases": [
                "Stanniocalcin",
                "Stanniocalcin 2",
                "STC2"
              ],
              "description": "Gene with elevated levels in gastric cancer compared to normal tissues, correlated with tumour invasion, lymphatic metastasis and poor prognosis."
            },
            "object": {
              "entity_id": "ent:b26ae4f28d7a",
              "entity_type": "OTHER",
              "name": "stress conditions",
              "normalized_id": "N/A",
              "aliases": [
                "stress conditions"
              ],
              "description": "Solid tumour cells are described as commonly encountering stress conditions which selectively activate corresponding signaling pathways."
            },
            "time_info": null
          },
          {
            "head": "stress conditions",
            "relation": "upregulate",
            "tail": "STC",
            "relation_type": null,
            "confidence": [
              0.8,
              0.1
            ],
            "evidence": [
              "STC2 is upregulated in many tumour cells under multiple stress conditions which activate ATF4, HIF-1 or both, strongly suggesting that STC2 participates in the evolutionarily conserved response under stress conditions."
            ],
            "mechanism": "unknown",
            "source": "ocr_result_2_12",
            "subject": {
              "entity_id": "ent:b26ae4f28d7a",
              "entity_type": "OTHER",
              "name": "stress conditions",
              "normalized_id": "N/A",
              "aliases": [
                "stress conditions"
              ],
              "description": "Solid tumour cells are described as commonly encountering stress conditions which selectively activate corresponding signaling pathways."
            },
            "object": {
              "entity_id": "ent:ceb73a8e75a9",
              "entity_type": "PROTEIN",
              "name": "STC",
              "normalized_id": "N/A",
              "aliases": [
                "Stanniocalcin"
              ],
              "description": "Stanniocalcin, listed in the abbreviations section."
            },
            "time_info": null
          },
          {
            "head": "STC",
            "relation": "regulate",
            "tail": "invasion",
            "relation_type": null,
            "confidence": [
              0.75,
              0.15
            ],
            "evidence": [
              "STC2 regulates various aspects of tumour biology like cell proliferation, invasion and metastasis that are associated with tumour phenotypes and disease stages."
            ],
            "mechanism": "unknown",
            "source": "ocr_result_2_12",
            "subject": {
              "entity_id": "ent:ceb73a8e75a9",
              "entity_type": "PROTEIN",
              "name": "STC",
              "normalized_id": "N/A",
              "aliases": [
                "Stanniocalcin"
              ],
              "description": "Stanniocalcin, listed in the abbreviations section."
            },
            "object": {
              "entity_id": "ent:fc370882bdd3",
              "entity_type": "MECHANISM",
              "name": "invasion",
              "normalized_id": "N/A",
              "aliases": [
                "invasion"
              ],
              "description": "Aspect of tumour biology regulated by STC2, associated with tumour phenotypes and disease stages."
            },
            "time_info": null
          }
        ]
      }
    ]
  },
  "hypothesesdir": ""
}